<SEC-DOCUMENT>0000950170-21-000935.txt : 20210805
<SEC-HEADER>0000950170-21-000935.hdr.sgml : 20210805
<ACCEPTANCE-DATETIME>20210805161619
ACCESSION NUMBER:		0000950170-21-000935
CONFORMED SUBMISSION TYPE:	10-Q
PUBLIC DOCUMENT COUNT:		67
CONFORMED PERIOD OF REPORT:	20210630
FILED AS OF DATE:		20210805
DATE AS OF CHANGE:		20210805

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Vir Biotechnology, Inc.
		CENTRAL INDEX KEY:			0001706431
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				812730369
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-Q
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39083
		FILM NUMBER:		211148399

	BUSINESS ADDRESS:	
		STREET 1:		499 ILLINOIS STREET
		STREET 2:		SUITE 500
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
		BUSINESS PHONE:		415-906-4324

	MAIL ADDRESS:	
		STREET 1:		499 ILLINOIS STREET
		STREET 2:		SUITE 500
		CITY:			SAN FRANCISCO
		STATE:			CA
		ZIP:			94158
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-Q
<SEQUENCE>1
<FILENAME>vir-20210630.htm
<DESCRIPTION>10-Q
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-08-05T15:34:51.8110+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:vir="http://www.vir.bio/20210630" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-Q</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric id="F_1b048b11-a161-4358-a429-9cf7cce4559b" name="dei:AmendmentFlag" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398">false</ix:nonNumeric><ix:nonNumeric id="F_aef41f24-e203-4eae-9d46-eb6b4157b2f3" name="dei:EntityCentralIndexKey" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398">0001706431</ix:nonNumeric><ix:nonNumeric id="F_89b36744-6825-4405-8082-31787f74cb3c" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f">us-gaap:AccruedLiabilitiesAndOtherLiabilities</ix:nonNumeric><ix:nonNumeric id="F_580369ee-3852-4e0f-9dd1-a3ca48903cb6" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228">us-gaap:AccruedLiabilitiesAndOtherLiabilities</ix:nonNumeric><ix:nonFraction id="F_6e3929ca-6385-4783-8f59-917256874890" name="us-gaap:LongTermInvestments" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_68e96f79-a508-48f1-bc17-ed7aec35b970" name="us-gaap:LesseeOperatingLeaseRenewalTerm" contextRef="C_1e87793a-cf2d-4040-b332-0a1245e6d6f5">P1Y</ix:nonNumeric><ix:nonNumeric id="F_d37f8ac9-179a-4133-8028-433301ccfa33" name="dei:DocumentFiscalPeriodFocus" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398">Q2</ix:nonNumeric><ix:nonFraction id="F_1c9962ee-a190-465d-aa07-6d3629acaf80" name="us-gaap:PreferredStockValue" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_cca64ea2-fd50-4e06-8f49-480df4e815bb" name="us-gaap:PreferredStockValue" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_97d90c09-330b-4395-957c-d835eae45d99" name="us-gaap:CommitmentsAndContingencies" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_c18ffe7d-7fee-436a-8b7b-480a5133bb74" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398">true</ix:nonNumeric><ix:nonNumeric id="F_bb06e195-126d-4785-a160-62ee3e70bc39" name="dei:CurrentFiscalYearEndDate" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398">--12-31</ix:nonNumeric><ix:nonFraction id="F_4f731a02-7364-48b7-9bec-4e3793c9b91b" name="us-gaap:CommitmentsAndContingencies" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" unitRef="U_USD" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="vir-20210630.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_eb4adf6c-364c-4b79-92fd-28aa9a50e441"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fd53f66c-e257-4732-8340-be571f9ac325"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cc499f93-896e-4bdf-be24-28ce2921af3f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_97dded0d-16f2-4d7e-ae2b-6fc06ecdfde2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-08-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ef15310-89d7-4a2b-81fa-497de643a6d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b171620-e654-43aa-be16-06e50f0a2698"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-14</xbrli:startDate><xbrli:endDate>2021-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_393392b3-d188-48ce-8ebf-843e5e51a678"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-06-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d18e2209-527e-424f-914a-da611d338ba7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:MedImmuneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:MedImmuneLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8780a7ad-2026-45bc-835f-43e7a4f6e155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HBVProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_09789d61-addd-4c37-ab93-6605597b8a60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f1864eb6-8023-4cef-ad5b-04b72b08c0df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_33c31548-53fa-4da7-9d3c-4b3f3239fd4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_502695ad-a686-4d7f-9e55-303eb9e384b6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyOneStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-14</xbrli:startDate><xbrli:endDate>2021-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f01da11-0303-4186-9f77-73befdf1a6bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2ff7bfd4-ce79-493b-87b6-550ee9f49df4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de475ddf-8c37-4d7a-ad85-a7698299ec12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-29</xbrli:startDate><xbrli:endDate>2020-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a4e86e58-4404-4536-961e-ac48e8ff6e70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vir:ContingentlyIssuableSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c50def4f-f04d-4b74-a20a-53c116d0b11f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-23</xbrli:startDate><xbrli:endDate>2021-03-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_20e142d1-b753-47f7-9ab1-dd536e70a74d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9d811492-0ef4-42f2-b9e1-20840319d292"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_503f5c65-589f-45e0-a4cb-0b480e0d8198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_037841ec-b5b1-4809-aef7-1a37b14ddff9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_492c3181-e320-4bbf-9047-04048449d863"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_943aaa7d-bd8e-4ac3-a401-aaa53e6c2044"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7ac0807c-bde4-490e-afcd-dd874265ab98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:MedImmuneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfluenzaAAndInfluenzaBMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:MedImmuneLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_02f60d12-f390-4dfe-ac4c-a065441e738a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d0832ce6-8218-4bd2-a0a0-9ac172d5777a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ff3535ee-1915-4fab-bcf7-801568ea00ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HepatitisBVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_914881ac-2ab5-47f4-8eed-c4210e53dc3a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a2dda4ba-cdd3-4a25-95df-9f71c39ebfdf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cd460f41-06b3-4477-9de5-9e78e41bc13e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8e7bbb2c-772e-4f93-ba28-8ef8fd39ba8a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:FirstInfectiousDiseaseProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_329ccbc8-94c6-4565-9ecf-7b34632b826e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ac8bcb94-38bb-498a-a74f-16bc3f88cf85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ea616198-c6e1-442a-bb05-ddf05a1b5bc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b52dd29-86c0-42a1-9b29-10e07e25991f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_86f05426-07f5-4481-b708-0d76a9b442e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0f91c4ca-040c-431f-8606-3532fe5467a6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e28f1ecf-80aa-4b09-b8ff-8c09db69a316"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e2de7da2-b046-4ec0-ad5e-5f3b001ed026"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_11d39f80-330e-4128-989f-4084388ad346"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:FirstSiRNAProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f41bf82e-773a-4ae8-995a-1851961c2803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_28568052-9082-41a4-83b2-60aaae0ee1be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2016-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a6dafe0c-9e29-491e-9182-9ea032ca7de7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b6d51956-3a22-4bd6-95a5-dad4c1d17f90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_45bc5026-51b3-4f16-b7d4-61e29f251c4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aa261db7-a4b4-4b7f-9010-cd5b869abb50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">vir:SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_78a42173-a11f-4d19-985c-306f3564ed73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f678eb79-9e2a-44ae-9e54-e1a433974f29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2aa1b8d8-ce49-419f-80ad-d249064f51e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f7225c3a-02c3-4844-a759-8800e4846129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6f7a01e9-125b-4678-81a3-a6efb1b4d77e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0b1f8126-42c0-40fe-81c1-24cbdc0b2ccc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_522751c2-1d6d-4f23-b1b2-c7eaa1905197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bc5714bf-f943-475e-bcd8-0aa08e910f85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1f9878a0-4b15-4465-8e06-ac38077a8fcc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b6795825-d2b1-4664-92a7-7f4efb4ea7bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c73e700-bcbb-487f-bdf6-77164c1deeaf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cc9ec168-d4bd-41fa-97ec-80d1e7eac7e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d67bc640-0ce6-494e-ad6f-32b76b35dc04"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17fb449e-4cf8-4a5c-b8a6-4e7113c7b17e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:MedImmuneAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:MedImmuneLimitedLiabilityCompanyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cce66117-e613-4efa-aee1-873b41ff2cc8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_656e7f8d-dcdb-4596-bc50-c6a3693b2cf4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_61924055-2acd-43c4-9155-681af2ed1b88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vir:RestrictedStockAwardsRSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7fcc913c-909b-4375-aabd-561f445a0b0f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d8c8927a-29a9-44cd-b032-581051ff30bf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HepatitisBVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7b946c14-81b3-4ee4-9cc6-59aca5e74078"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eae8bb82-8872-4a24-ae26-c2e4d2dfb653"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d5790db-7c09-460a-9153-c6331074affd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_355e350c-6186-4712-9d71-af22d0b9a120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b863aacc-f9e9-437e-93af-f43803e428c1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4df49172-31b6-455e-a6d9-ebce7871f7da"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:AgenovirCorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HepatitisBVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_be538fc0-b3da-4933-b596-db6f96112f97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b9591672-a7df-4119-8763-beff32620126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_06a67e5e-7cd4-4262-8c8f-9cc28e2a7ddf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_416eb633-0ce4-467f-ad2a-37987bfe677b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:DevelopmentAndManufacturingCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:WuXiBiologicsLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_42a0066f-bcc3-4b1a-a379-4a993e12dcb9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_782d1920-e03d-4185-85d4-a0abdc3fe2bc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab45b547-9dd6-4076-8bde-04eaac698732"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HBVResearchProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39a5ff4f-90c0-4385-8a23-486f8b46bf9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec6ee7cb-4c4f-4392-b06d-b2cc4c6ba486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a7eab319-293e-4b73-85e4-92da414f023c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:AgenovirCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ec0ee7d1-1e16-4d9f-82e9-4d32b4f67282"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a2ea91d2-7c4a-4260-9f6d-7c6a185c065b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vir:EstimatedSharesIssuableUnderTheESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f8e1feaf-38cf-4eb8-be71-a6d9ca4cc72d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputExpectedRevenueVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66bfb7f9-fc0b-4e62-b6fc-4e629327a410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b4f1dc34-56da-4847-88c1-d9bfde49f709"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60e33361-8e0c-4167-99a3-8c9f96e030ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vir:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61ac6d35-003c-4932-8b7f-75b0994fe73e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ad365c4d-bc8d-4cfb-9e07-53dd946f68e3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6b3098b0-fc6d-48cf-bf55-bfa1dcc811a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfluenzaAResearchProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_440aee8c-e7b5-48d3-90f4-51f9d0631f45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_69fba054-c419-4e8e-b49f-667d17bf850d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7d59a58f-5636-44a9-b169-b1a6c7e3176b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23d80066-9c6a-4bf0-aa4b-f95964ef06dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8078c547-b260-434d-8ab2-1b0f12cd0d5f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-14</xbrli:startDate><xbrli:endDate>2021-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cca64f01-43cb-4521-a7c0-b8c072d00e2a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-03-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_33d141a8-0bd8-4ec8-aaaf-e21290176a35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c6864edf-79da-4827-8feb-994154b4369a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_64416581-7d0b-4707-ab43-2587ae9cbcd4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_24a7634d-6a60-4a00-b501-5473727d2f4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_da489d47-65d8-4ebf-bb93-4ab4e0d479cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8482726a-4650-4001-aa57-337a908bb4ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputExpectedRevenueVolatilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_17da886f-2297-41d5-a984-97218fc86f75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d42ac1db-ea33-4759-bbf7-4fa64295c694"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c3b4e715-3396-4fc0-a8e8-1b7c2ed5260b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d0b20436-58e4-46d4-92e4-fe201bcf47c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_918fa4e1-d7cd-4bf6-82cc-f13652a23ef9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e33744e-999f-4346-9f7e-415731786c7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_31d70583-f863-4f52-9c17-5d19f672cbae"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_61e10aad-3a2a-4489-b640-a9768ebb4c27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_324b7022-f782-4c4b-a128-564a104bd122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vir:ContingentlyIssuableSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_be6f5270-fc80-45c9-a95c-b5ef6403279b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HBVResearchProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7c63340d-0674-48e2-b11f-13fdad617a64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eca11749-bb55-4f33-bd21-2d25c913415b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_01c272b4-05c2-41fb-90b2-afebf3595d73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0db18e03-f55e-4678-9eaa-949bdcc27a33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vir:FollowOnOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-07-10</xbrli:startDate><xbrli:endDate>2020-07-10</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b435674c-7a19-45d9-b704-d50d4dea4823"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7b508c4b-45d1-41c3-816a-cd29050692e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_59766912-8729-44fa-8223-2711163a2f37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vir:ClinicalDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7e3f6ce0-b70a-4697-a4fb-c60b7c239059"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4830ca2a-0ad5-4a32-b98f-bae2d1970486"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d8427988-1d9b-42d6-a158-ce5e24c17b41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c99a0b18-718d-4edc-baf8-ddcb6d2b2cee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-01</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_befad2fc-309f-4f88-99dc-baaef6380944"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7828555d-b746-4f30-8bb5-ef260d0b147b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9f0a8c2d-23ab-4ba5-9c8d-ca28574c8b2c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a2db8718-9aa3-44fb-bd21-a5914cb932c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1e5484c7-876b-4630-8566-d2b6146b4e47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HepatitisBVirusProductMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3edca66f-50fb-4438-8b85-01c89b9c1b0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_93449051-f049-49fc-bbdb-95aeef0d2e9a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d2c8c218-592c-4345-a42f-8c7f3cefb5aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AnotherProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2aa44c95-3aa8-4eec-9de8-8fa66be5bfc1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:BiologicalMaterialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b64fcbdc-5a21-4b8c-8ac7-983b9bfe2eb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e1b6477-b8d1-4ae0-89fa-0e4e1af40ea7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8162e8b4-3609-4bdc-ba16-5e1d76bb3c6b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d82c1375-fe52-423c-8c26-277c32efef51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3dda4289-3d1f-4bc7-9199-58bb203939aa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1ff555c9-cb2a-45df-8631-74d23812f12b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6d87011b-3e4c-46db-bad8-0f23e0dcc637"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-03-16</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e39462a8-8050-424d-a953-9a65943f5705"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e7b02693-c6da-4de6-a120-f9ea9345d4d8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AntibodyProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_02faa5a7-4825-491e-950b-34ee5ddb4d0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">vir:SalesAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_66892b6e-71bf-4e32-a6ae-3770380bc675"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3e223018-5e3f-452c-824b-e2e4d71405b7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_78af002d-b722-4eae-8f4a-2d0c76fa8ae0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1e87793a-cf2d-4040-b332-0a1245e6d6f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_44f8d63c-2efc-4376-972c-8a2d8299bc16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f9d182b-02f1-4140-983b-012691d8ce35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7a088139-2add-4c37-8158-c3dc9538d2fe"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bbedea33-e0d1-40dc-8d3b-acfc0f01d81c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:SARSCoV2ProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_19b8ac7c-1cc1-4683-98aa-a394a77dd75f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfluenzaAAndHBVResearchProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-08-01</xbrli:startDate><xbrli:endDate>2019-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_27542471-f913-4a68-8616-f01ea8e68d78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b26811f-118d-4a95-ad64-0f8108301f7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AntibodyProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-29</xbrli:startDate><xbrli:endDate>2020-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4ba8283a-0045-486b-80d8-2e80d28e4574"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b213ca27-309b-4229-b799-81e86bb50576"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:BiologicalMaterialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b68e43f8-fa5f-4941-a772-ac4ca77f6039"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b16f4229-15e5-4b92-a679-7c593814f6cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_53ccc202-bb29-4485-bc6c-689015df256e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a548882f-b462-4623-9763-e036f6ae6cce"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dc5358a1-e8cd-4f63-a453-32242603a269"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-05-31</xbrli:startDate><xbrli:endDate>2018-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_580342cb-5db5-408f-ae9b-48fd57cdb017"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_237f8a0b-7ccb-4bfe-9900-7d13c307285b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fa28c391-ecec-4c12-bcfb-f369058e9862"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e5e16aa4-a601-484e-b470-db2c156ea530"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyOneStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e403ff64-40f3-494a-998d-769d7e8bb228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6a378198-8973-420d-8130-5f606a6b57c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a63cca2-9347-45c4-8512-1e97604d2422"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f34e6246-fbef-4861-a312-c896b3da8b57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e9e35c31-e697-4c7a-a5b4-23131aea2dca"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce595069-e39b-49ee-a1e2-8dcfaf1fc58f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f54bf625-9153-4033-9112-6b27a3bd3803"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b3b3b775-48e3-4d0e-8077-eeeff976fb8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_436fb49f-f2d5-49a1-83a3-3a3e54fd290d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyXencorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a8995a77-2e40-4bdd-a7bd-5c2389acc76c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_704b0f66-c02a-4e7b-91c5-906e38831293"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd77d5c8-3f48-412e-8a01-2400a5a99d89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_222e97e5-5f11-45bd-9409-870b0ab08dec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HBVProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_33123595-07a6-4f85-a3a1-bc8546d832b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e1c1ce3e-6936-4e79-8e73-e9a37f058e7c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vir:FollowOnOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-07-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_26c131f2-0874-4ae2-9e57-8f39b5db6f09"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3943c51c-7e55-4e41-b9e4-df3e298c1f39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8f7f9c58-f98b-4a8f-95b9-e5182870c64d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:DefinitiveCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ed8a63f-0dfd-42e1-84e0-c0de8453fb41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vir:RestrictedStockAwardsRSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_63fb600b-266b-4936-b5f6-f0acd37a0f30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vir:EstimatedSharesIssuableUnderTheESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e1137d24-689b-45da-9ecd-65f97451d124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8e671199-2ede-4d79-bb43-b621397a4811"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2a630976-9689-4329-bdef-af492a67b7b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AntibodyProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:GlaxoSmithKlineTradingServiceLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-08-01</xbrli:startDate><xbrli:endDate>2020-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d09734ea-ce01-4393-81cd-a61fc90f7e98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e1a0849-5b76-49b5-9f9a-4c78c1961b02"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_51cc81ca-5eda-4a6a-a5dd-56c6a7083323"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9b5a18c-ba78-4c5f-bb0f-40e2ed6661d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:EachInfectiousDiseaseSiRNAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-10-01</xbrli:startDate><xbrli:endDate>2017-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e18bb3c-4c77-45f7-a376-3d3aa6ea7b8b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0edc973f-cc4f-4eea-b393-2ad3dc16ecf5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a23df604-43e8-477f-95be-d67c4d36ef27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7073499b-8aca-4a83-ae2c-8686d7874fe9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd7a1755-2831-46df-a378-33b1c1bbe888"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-02-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95a77a5d-c658-44c7-bb81-77f5350143bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a5f22e22-a17d-48d9-87ec-0cc77e37762d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cc967922-0ffb-4e42-9643-902ddc2a4a56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CommercializationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-07-01</xbrli:startDate><xbrli:endDate>2018-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_08207110-60df-4348-8106-e824e9e44ab8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_89d302b2-5e08-4283-8a49-1c1dc6be912e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vir:AccruedLiabilitiesAndOtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8bc5a624-6688-41fd-9d8d-c6c0f2147de0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_669328e0-ec12-4a46-9f8e-7642c8e0853a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_65199b01-efc8-4ecd-92f0-3fdb4dbb14b2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c37af972-2bf8-4eff-9bc7-4763e2ab45d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2063058a-a5a7-4574-92c4-5fad668297f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AntibodyProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5cba9a1a-7684-4b5b-9e26-eb24c2aeb651"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4b592749-62ec-4fae-9b15-04061affca47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:LicensedProductByLicensedProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d438ee24-58b2-47f8-b7c8-f3890a19f797"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_96589541-95bc-4aef-a913-79c4b0b517f0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c4e13756-0547-45df-9116-975dfa1cdf28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-03-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6fc26d34-68e7-4c09-8e67-4e2b004cdc10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-09-01</xbrli:startDate><xbrli:endDate>2016-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_425979e0-416e-4c32-9ffb-95870c96d614"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">vir:SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75ead0cb-5540-4c8d-9421-64e16f11ecda"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a077a0ad-b848-485c-96a1-3489ae549b2f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f9ac6857-461c-4a04-bd24-2ecc9ae4c36c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:VaccineProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-29</xbrli:startDate><xbrli:endDate>2020-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_04fdbfd3-0666-4745-bebd-01d2061c67e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vir:ContingentlyIssuableSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9fb0d2a0-3667-49a0-9e2e-0eb6e51eb0f2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-29</xbrli:startDate><xbrli:endDate>2020-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d26edc6-7745-4758-988b-eb4ba800efed"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6d69c128-4e88-4988-9333-0cfb938c1233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0967f1dd-e649-43d3-b4d5-8e34df7fb432"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyXencorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_99cf4f8f-4dae-413b-b3e0-c9a5646a7659"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a445d18b-0608-4e5b-93b9-215040fa78ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vir:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cff84f6a-b57e-47a0-a02b-dcac6185a725"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-14</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9ae22d18-4ca6-4836-bd15-1b10932c9c7f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vir:AccruedLiabilitiesAndOtherLiabilitiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f57d1eff-a8c4-4b5c-8802-9f372ef5f371"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_10f77595-19f0-40f3-8510-ff21caa1970b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_33a88677-9ecc-4f3d-aca3-76408bf827c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0e63f2d6-4f5f-4686-b5df-65f256ff2672"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-29</xbrli:startDate><xbrli:endDate>2020-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1f8aa1e7-f35e-48bb-afdc-73dd30c26626"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a83f3768-0952-4ecd-91fb-ac4523a646de"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKCollaborationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-12</xbrli:startDate><xbrli:endDate>2021-02-14</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2780ba97-f35b-4286-8d16-f6c692bbc074"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_991c9783-f1f0-4095-b9b0-9d1076bde40f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a4c9273d-ad95-4c98-a7c8-805e95b768b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-30</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9e86b99a-0581-4171-849d-e82b23f80034"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HBVProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_24d34ab3-57a3-4b9e-8de9-5279d44dd035"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_267658dc-f7db-4ab6-94bc-b9662b0d993d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-10-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0593f237-da08-4238-8805-6911cc8c2af4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4504c120-b2bc-4009-8fb3-837091fb0248"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_97110788-5408-406c-be78-a9a445a7d443"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eb7ebaf7-00e9-4b11-8346-81d73478b9fa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfluenzaAResearchProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-09-01</xbrli:startDate><xbrli:endDate>2019-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b649d3cd-def2-4c81-bc48-8799c56de0c7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_766775c9-df87-46ac-a6ca-0995a7c65d87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CollaborationRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8f037847-06a9-43f3-aee1-9f0d4957157f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-27</xbrli:startDate><xbrli:endDate>2020-04-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b570c7a7-2e4b-4988-8066-7fc9aded3533"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eda1b75d-a4eb-47cf-a94a-90d8ad6a84c9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_eeb1528b-b730-41f5-8477-0b25922ee91b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vir:ContingentlyIssuableSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_69fd0161-00a7-47b8-8f7e-c649aad213a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2961edff-bc89-457f-97d0-23460c2e7059"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_52d2443e-0fd8-42f6-9e80-a3310414715c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-03-25</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e8581c5a-3e43-44a2-8670-9db42cd8f49a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f7017d66-420f-462d-adcf-f3fb86e73c23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3c3d0c98-1fee-4858-be8f-d493a8a73e1e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f55782eb-212f-4f4e-9bf4-65f42e20a89a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_30c20ac0-452b-41d8-aabf-b6962ca7e754"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HBVProgramMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0df1d4d3-33f9-423e-ba29-51df45853b5a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ae3adcd-4938-4c7c-921a-6d25c5205981"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:LicensedProductByLicensedProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0546abb1-16aa-4fcd-a7d6-0e80f088c135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vir:EstimatedSharesIssuableUnderTheESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de3d836a-48cf-4d4f-8714-440719392b2e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c85ee215-3e1c-44fb-b984-1097930c5e13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vir:EstimatedSharesIssuableUnderTheESPPMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_69917036-35e4-4dc8-8976-064800b680f9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ef16289-589c-49ff-b97d-b1ade8c4d8c4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_50d30b84-60dd-41c6-9dc3-a2fcb990166c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ef0ac41-102d-42f3-9751-1d32659fb4a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vir:RestrictedStockAwardsRSAMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_325ad0aa-a95c-4661-a917-fc337e70902e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee4e07f2-7234-48ee-b89e-21a8a39c2507"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c95fa8bf-5f9a-4eec-9c84-72c03b21861f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1978c92a-9f5f-463a-83b8-88d2ffb3548f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_20097cda-ecaf-4c10-976d-a846aa4a6d9b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:AgenovirCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8a64e883-900d-492a-b0a8-528b6645aa64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_565a5874-4857-48d4-82b7-a9f3af6c43c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_abdc6453-b0c7-4eaa-a85e-f7e083980647"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_93f053bf-00d2-4957-b2e8-a0580ba1a1ee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-01</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9b221d24-b45a-4cc0-b6cb-8320c56dc6fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b639fc9-2f14-4483-9c0f-de032ca38766"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c55af785-6145-4ede-ac28-0f3933e1634e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2be4dcd-5221-4917-9b4b-42643238614b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_51eb1ee6-e4e4-42a9-b6e3-135a3e77a4ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e877910e-22cc-4649-a193-5d784dba152c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001706431</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_Unit"><xbrli:measure>vir:Unit</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Milestone"><xbrli:measure>vir:Milestone</xbrli:measure></xbrli:unit><xbrli:unit id="U_Program"><xbrli:measure>vir:Program</xbrli:measure></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="U_USDollarShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_d3053df8-07d3-47e7-a42a-fa71bc831f41" fromRefs="F_56109b05-5ebc-4f11-b821-ed99759c2371 F_6773aded-723c-495c-83b9-6854a1396b26"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_d9b30841-09a6-45ce-abe3-d841782efe16" fromRefs="F_bd6a27fd-8bca-4f9b-b2b4-7aca9663363e F_27166cde-7091-4715-bef5-9da941265164 F_bbaff870-ba24-4b6f-84f4-7aa037d1f56c F_e1d45d63-d79c-4ab1-8c89-4be796dbbcd7"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_e1cbc8b4-2fd4-49ea-849b-b5db014aa101" fromRefs="F_5b0ce1b2-dad8-4280-9da4-923155a0d87d F_a30731d5-b26d-4d84-aaf8-d60f6fae99ba"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_29cb2c38-3c6e-43b9-9519-fa69c33f0bf5" fromRefs="F_bb4b78ac-feb8-4c7b-915d-f82d5be6e70c F_00c871dd-ddfa-4fa3-8f32-e1ee2e31543e F_dfeb5c11-f6ec-465e-a911-219ce65c2da1 F_eedf6555-c570-477d-8f16-8cdd93f9b39b F_9c009c67-e6f6-4098-8951-601312e1939e F_a0a30f24-aca0-4941-9090-570e22369935"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_58e4891f-39b5-45d1-8dc4-f916fec2ed20" fromRefs="F_860b67b2-83e8-45e4-a820-8df4f2b81016 F_3fc0effe-077a-457b-be78-cd81563ae0e9 F_a9ff057e-0024-4020-9739-bf0e4099abee F_daff6193-bbf4-476a-9d8a-157d74ee8503 F_3584cc21-6d37-4ef6-87ac-6540b38c433d"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_975f8be1-254b-40dd-96db-8cb78836fecf" fromRefs="F_0e373577-f4ac-45f8-9fe7-66848eeef012 F_e80ccab1-add9-4c97-91bd-79f96dd448ef F_18a16493-faf3-428a-b4fb-7c6f1cc4f093 F_27fda7ed-591d-4518-af47-9f573ab1e5ce"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_af2a8f75-e140-4119-9483-1f845d2145ab" fromRefs="F_3d6a3aee-cb76-466b-916d-4d85ca0061f4 F_621ac5dc-b959-41b4-a949-bfa6ead3db85"></ix:relationship></ix:resources></ix:header></div>
  <p style="border-top:2.250pt double;padding-top:1.0pt;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">SECURITIES AND EXCHANGE COMMISSION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">WASHINGTON, DC 20549</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">FORM </span><span style="font-size:18.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c17d272b-0384-4c5b-aa45-b3a63197fa45" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="dei:DocumentType"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:18.0pt;font-family:Times New Roman;">10-Q</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(Mark One)</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e52c80d7-6d31-47cd-b3a8-b5263ef32111" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="dei:DocumentQuarterlyReport" format="ixt-sec:boolballotbox"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">For the quarterly period ended </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0d9d628d-bb84-4ef0-b69d-f11491446c1d" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">June 30, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8587c59c-e8fc-4544-b6e5-3c58030c0430" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="dei:DocumentFiscalYearFocus"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:Times New Roman;"></span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">OR</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_23ad3275-a838-476a-aeed-156778510dba" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:4.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">For the transition period from </span><span style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Commission File Number: </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_67d2b434-8991-4bc1-ab36-85defd45e5c5" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="dei:EntityFileNumber"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">001-39083</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:4.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:24.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a8dd6d3d-bdd9-4292-a1be-bafac289c717" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="dei:EntityRegistrantName"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:24.0pt;font-family:Times New Roman;">Vir Biotechnology, Inc.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:24.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(Exact name of registrant as specified in its charter)</span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_59e17f76-f5d0-4bda-a452-f74067014a69" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_73ea5cbd-a651-48ef-8528-4717eabe3d7c" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="dei:EntityTaxIdentificationNumber"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">81-2730369</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Identification No.)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.75pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_88f958ce-3eab-4489-83ca-b527f6c66543" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="dei:EntityAddressAddressLine1"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">499 Illinois Street, Suite 500</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c42f376a-49ce-4e6d-9cf6-01ce3b8108dc" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="dei:EntityAddressCityOrTown"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">San Francisco</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_01ae5a1f-8d07-447a-a5be-2a8003ef9811" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">California</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4c222883-a93a-481a-89ee-d8f8e46c066a" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="dei:EntityAddressPostalZipCode"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">94158</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Address of principal executive offices)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Zip Code)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Registrant&#x2019;s telephone number, including area code: (</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b0a84a5f-3219-4d65-9386-e3c021e8b583" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="dei:CityAreaCode"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">415</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">) </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_af233e57-f938-4c4b-8df2-3ad47f07ef67" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="dei:LocalPhoneNumber"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">906-4324</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Securities registered pursuant to Section&#160;12(b) of the Act:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:18.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:40.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Title of each class</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Trading</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Symbol(s)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1fc6f078-8b14-486c-a775-490aecd6ebb2" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="dei:Security12bTitle"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e1c3a8d4-76e5-4a85-8ed8-ad16128d0625" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="dei:TradingSymbol"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fa7ee57a-51c2-40e5-9874-7acdc084cccc" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nasdaq Global Select Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. &#160;&#160;&#160;&#160;</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d6ab0cfc-def3-4c32-a1fb-e8a3f4df2d4f" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="dei:EntityCurrentReportingStatus"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). &#160;&#160;&#160;&#160;</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4983a0ac-f54c-47e7-aaa7-8f15b3685ee9" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="dei:EntityInteractiveDataCurrent"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#9746;&#160;&#160;&#160;&#160;No&#160;&#160;&#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:21.88%;"></td>
    <td style="width:0.88%;"></td>
    <td style="width:49.88%;"></td>
    <td style="width:0.944%;"></td>
    <td style="width:21.898%;"></td>
    <td style="width:0.88%;"></td>
    <td style="width:3.639%;"></td>
   </tr>
   <tr style="height:10.8pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_46c608ae-2a9f-4178-a704-b47a942a1650" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Large&#160;accelerated&#160;filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accelerated&#160;filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
   </tr>
   <tr style="height:3.6pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Non-accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;&#160;&#160;&#160;&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Smaller&#160;reporting&#160;company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_819aee21-d7fe-4535-9e4e-8c8305df6ca1" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:2.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aaa5b50f-2fa0-49eb-91b4-331816674020" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;&#9744;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). &#160;&#160;&#160;&#160;Yes&#160;</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0b544c9a-09e4-4480-896c-889905137da8" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="dei:EntityShellCompany" format="ixt-sec:boolballotbox"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;No&#160;&#9746;&#160;&#160;&#160;&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:4.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of August 2, 2021, the registrant had </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b5f1c57e-f242-4f84-9391-38b69ec4991a" contextRef="C_97dded0d-16f2-4d7e-ae2b-6fc06ecdfde2" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">130,611,795</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock, $0.0001 par value per share, outstanding.</span></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:2.250pt double;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Table of Contents</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.083%;"></td>
    <td style="width:82.926%;"></td>
    <td style="width:6.991%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART I.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_ifinancial_information"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">FINANCIAL INFORMATION</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_financial_statements"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Financial Statements (unaudited)</span><span style="color:rgba(5,99,193,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#condensed_consolidated_balance_sheets"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Condensed Consolidated Balance Sheets as of June 30, 2021 (unaudited) and December 31, 2020</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:7.2pt;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#condensed_consolidated_statements_operat"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2021 and 2020 (unaudited)</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:7.2pt;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#condensed_consolidated_statements_compre"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Condensed Consolidated Statements of Comprehensive Income (Loss) for the Three and Six Months Ended June 30, 2021 and 2020 (unaudited)</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:7.2pt;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#condensed_consolidated_statements_stockh"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Condensed Consolidated Statements of Stockholders&#x2019; Equity for the Three and Six Months Ended June 30, 2021 and 2020 (unaudited)</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:7.2pt;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:-7.2pt;padding-left:7.2pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#condensed_consolidated_statements_cash_f"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2021 and 2020 (unaudited)</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;text-indent:6.85pt;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="margin-left:6.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_unaudited_condensed_consolidate"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notes to Unaudited Condensed Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_managements_discussion_analysis_f"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_quantitative_qualitative_disclosu"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_controls_and_procedures"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART II.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iior_information"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">OTHER INFORMATION</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_legal_proceedings"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1A.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1a_risk_factors"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 2.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_unregistered_sales_equity_securit"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Unregistered Sales of Equity Securities and Use of Proceeds</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 3.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_defaults_upon_senior_securities"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Defaults Upon Senior Securities</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 4.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 5.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_or_information"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Other Information</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 6.</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6_exhibits"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibits</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#signatures"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Signatures</span></a></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Quarterly Report on Form 10-Q contains forward-looking statements about us and our industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future financial condition, future operations, research and development, planned clinical trials and preclinical studies, technology platforms, the timing and likelihood of regulatory filings and approvals for our product candidates, our ability to commercialize our product candidates, the potential benefits of collaborations, projected costs, prospects, plans, objectives of management and expected market growth, are forward-looking statements. In some cases, you can identify forward-looking statements by terminology such as &#x201c;aim,&#x201d; &#x201c;anticipate,&#x201d; &#x201c;assume,&#x201d; &#x201c;believe,&#x201d; &#x201c;contemplate,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;design,&#x201d; &#x201c;due,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;goal,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;objective,&#x201d; &#x201c;plan,&#x201d; &#x201c;positioned,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;seek,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;will,&#x201d; &#x201c;would&#x201d; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. These forward-looking statements are subject to a number of known and unknown risks, uncertainties and assumptions described in the sections titled &#x201c;Risk Factors&#x201d; and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations&#x201d; and elsewhere in this report. Other sections of this report may include additional factors that could harm our business and financial performance. Moreover, we operate in a very competitive and rapidly changing environment. New risk factors emerge from time to time, and it is not possible for our management to predict all risk factors nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in, or implied by, any forward-looking statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In light of the significant uncertainties in these forward-looking statements, you should not rely upon forward-looking statements as predictions of future events. Although we believe that we have a reasonable basis for each forward-looking statement contained in this report, we cannot guarantee that the future results, levels of activity, performance or events and circumstances reflected in the forward-looking statements will be achieved or occur at all. You should refer to the section titled &#x201c;Risk Factors&#x201d; for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. Except as required by law, we undertake no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RISK FACTOR SUMMARY</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.56;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investing in our securities involves a high degree of risk. Below is a summary of material factors that make an investment in our securities speculative or risky. Importantly, this summary does not address all of the risks that we face. Additional discussion of the risks summarized in this risk factor summary, as well as other risks that we face, can be found under the heading &#x201c;Risk Factors&#x201d; in Part II of this Quarterly Report on Form 10-Q.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business is subject to a number of risks of which you should be aware before making a decision to invest in our common stock. These risks include, among others, the following:</span></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred significant net losses since inception and anticipate that we will continue to incur substantial net losses for the foreseeable future and may never achieve or maintain profitability.</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will require substantial additional funding to finance our operations. If we are unable to raise capital when needed, we could be forced to delay, reduce or terminate certain of our development programs or other operations.</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are committing substantial financial resources and personnel and making substantial capital commitments with third parties in furtherance of our pursuit of a potential therapy for&#160;COVID-19,&#160;the disease caused by the virus&#160;SARS-CoV-2,&#160;and we may be unable to secure sufficient capital, market demand or manufacturing capacity to successfully develop and commercialize a therapy that treats the virus in a timely manner, if at all.</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future success is substantially dependent on the successful clinical development, regulatory approval and commercialization of EUA product(s) and our product candidates in a timely manner. If we are not able to obtain required regulatory approvals and marketing authorizations, we will not be able to commercialize our product candidates and our ability to generate product revenue will be adversely affected.</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a party to strategic collaboration and license agreements pursuant to which we are obligated to make substantial payments upon achievement of milestone events and, in certain cases, have relinquished important rights over the development and commercialization of certain current and future product candidates. We also intend to explore additional strategic collaborations, which may never materialize or may require that we relinquish rights to and control over the development and commercialization of our product candidates.</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials and we cannot assure you that any ongoing, planned or future clinical trials will lead to results sufficient for the necessary regulatory approvals.</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical product development involves a lengthy and expensive process. We may incur additional costs and encounter substantial delays or difficulties in our clinical trials.</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business could be materially adversely affected by the effects of health pandemics or epidemics, including the current COVID-19 pandemic and future outbreaks of the disease.</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The market price of our common stock has been, and in the future, may be, volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We intend to rely on third parties to produce clinical and commercial supplies of our product candidates.</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are unable to obtain and maintain patent protection for our product candidates and technology, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our product candidates and technology may be adversely affected.</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are highly dependent on our key personnel, and if we are not able to retain these members of our management team or recruit and retain additional management, clinical and scientific personnel, our business will be harmed.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_ifinancial_information"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART I&#x2014;FINANCI</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AL INFORMATION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_financial_statements"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1. Financi</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">al Statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="condensed_consolidated_balance_sheets"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Condensed Consolida</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ted Balance Sheets</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(in thousands, except share and per share data)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(unaudited)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.898%;"></td>
    <td style="width:1.62%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:13.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.62%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.861%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">June&#160;30,<br />2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December&#160;31,<br />2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">ASSETS</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">CURRENT ASSETS:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6988bbe6-9b5a-425b-9e22-8909027e2a1a" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">741,951</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f5298bb7-9ad1-49eb-9f72-1eb2fd92ac21" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">436,575</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Short-term investments</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_07a8b252-7113-4f4f-afb2-c8a6768a0ccf" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">84,107</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5711558c-de9e-4753-a400-0db149dc4e5d" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:MarketableSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">300,286</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Restricted cash and cash equivalents, current</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_80b85232-2a97-42d5-b5b4-b21e088a1475" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,004</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cce3f174-0368-4431-a1cd-d121da844f25" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,993</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4fa0ee7c-3cc3-4cde-9030-54e4eea02f22" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,233</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1c21f11d-f955-4d4f-89a7-0ebfad41a7f2" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,511</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_057f86b5-436a-4350-ad84-3aaacedbf02b" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">862,295</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf381f47-3200-45da-a2ef-cec9d4a34dea" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">772,365</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Intangible assets, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bedc34ef-8037-45a1-a27d-0a314bee56e1" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,554</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_27766c45-a4a3-4b21-8460-73d3d5eaaad0" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,820</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Goodwill</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d76ea190-8005-4e52-a812-5f03ecb5d0ff" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,937</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8968be21-57be-49f2-adfb-793e6748fa46" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,937</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Long-term investments</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d50e7cca-7858-4cfc-8681-cd772c3c17c9" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,680</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6e3929ca-6385-4783-8f59-917256874890;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a11d501a-4c85-4da7-9395-028f72a08af4" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,251</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2dda9dc6-16e6-4844-9e22-3c08210f5541" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,946</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating right-of-use assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_99366022-3310-4a99-bede-4dc9c86a6353" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,972</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_549406fb-634c-461b-8b5d-09c642dc916b" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,947</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Restricted cash and cash equivalents, noncurrent</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_522b8900-e2fe-4e0e-ba10-3afe8325888f" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,002</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0b0e61f4-444f-40b2-9de4-c56e43ff3cc6" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,919</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59bd3b10-5a27-40e3-acde-732567558119" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:OtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,890</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_77c9935a-d72b-4726-919c-ac37af3fd1b5" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:OtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,827</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">TOTAL ASSETS</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4272b3f3-5c1d-40a8-8475-eeb119575c59" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,057,581</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_80769845-5e61-48fa-9839-12aae4c97d8d" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">918,761</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">CURRENT LIABILITIES:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accounts payable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5125c50f-4ecf-4e8f-a079-abd5018b68dc" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,032</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_49b036ba-0d3b-4d58-865c-8b321ff60f05" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,077</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accrued and other liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cd0484e2-cc8b-41d5-a208-f3f406157a0d" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64,074</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_90e07ee8-fb02-448e-b185-fd073b2b1ab6" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,936</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Deferred revenue, current portion</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_65beeb24-ac07-415c-b94e-8720349608cc" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,718</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c3caf2a8-1cc7-4d51-80d2-c9c0d4760529" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,451</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Contingent consideration, current portion</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_70007cf2-23bc-4580-8d00-d0117d05c5f6" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26,200</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_60897f55-2f98-4e61-aab6-3a73c9031ea8" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,600</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b25b1135-b856-4a6f-a0ef-51bcfd1162e2" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">146,024</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_07d436da-54b5-4bb0-99c0-41e407ec194d" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">99,064</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Deferred revenue, noncurrent</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6e58135-38c1-4ab3-abd5-2b580ad7955b" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,496</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e60392d8-24df-41ec-b55b-d7e3d6ceb784" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,815</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating lease liabilities, noncurrent</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5091f7c7-d718-4b6a-80b4-dc9e8bed2a08" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68,938</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9ff4b0d7-70f2-49ac-bd62-30ec612fc3fa" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66,556</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Contingent consideration, noncurrent</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fa3dbf68-686d-4476-bbed-c0c6e436c079" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,692</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_00493518-86b6-4564-8605-531f2b6c1555" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">25,374</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Deferred tax liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eafc95a4-7851-4d2f-8216-cf1f81fb6ddf" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,253</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a2edb736-d180-4ec6-a872-45c787b8c281" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,253</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other long-term liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c95aa721-164d-4e28-9428-18348589cce5" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,853</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e2caebd4-cfe8-4d11-bcef-bccd7d8b5df4" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:OtherLiabilitiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,847</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">TOTAL LIABILITIES</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a59100c-604d-45c6-8b55-d9021ecbe716" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">320,256</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_22fa36fc-9d8c-48d5-a5f6-2a4d0447ea32" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">201,909</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Commitments and contingencies (Note 8)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">STOCKHOLDERS&#x2019; EQUITY:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Preferred stock, $</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f1209ce-0356-4ae4-add2-055b0f4c79e4" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF"><ix:nonFraction id="F_cc021883-70c1-4d12-a2a5-3c891a7b5e83" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;par value; </span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2b96796c-6cab-4a62-8b65-1ee887635f26" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_a109a352-b0b5-498c-a550-445605bca080" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;shares authorized as of June 30, 2021 and <br />&#160;&#160;&#160;December 31, 2020; </span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_28ea79b7-9574-4569-ad84-cbf6bd5319b3" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_0ffd6645-a43d-4337-9295-2aa8682d71f2" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_9d596b1e-16df-4b35-9148-063d2e7187b0" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_ed79dc29-48a3-445c-8722-3da45bd431d3" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;shares issued and outstanding as of June 30, 2021 and <br />&#160;&#160;&#160;December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_cca64ea2-fd50-4e06-8f49-480df4e815bb;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1c9962ee-a190-465d-aa07-6d3629acaf80;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Common stock, $</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f5625f1-04b1-43bb-9b3d-46656f75cd96" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF"><ix:nonFraction id="F_846000c0-9054-4f81-ac82-9e648d344522" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF">0.0001</ix:nonFraction></ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;par value; </span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_34dbfb57-0273-4612-a2dd-aa62296087fd" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_8ac8dfbe-f497-4559-921f-b27c71e1ce44" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">300,000,000</ix:nonFraction></ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;shares authorized as of June 30, 2021 and <br />&#160;&#160;&#160;December 31, 2020; </span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1060a573-ee40-40ec-8b0a-9a750c15bb82" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_3cb62ffc-480a-4918-a794-cd80786f1156" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">130,479,975</ix:nonFraction></ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;and </span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b7245e2-c2af-4679-ab0d-52e1deaf7901" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_277bb349-54c1-40f8-b879-20c5d4c67bfd" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">127,416,740</ix:nonFraction></ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;shares issued and outstanding as <br />&#160;&#160;&#160;of June 30, 2021 and December 31, 2020, respectively</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_11b189fc-23ea-4552-b374-1981fbd82297" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f4bbf45f-6c07-4a87-a54b-e8a2bac0b16b" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_16021e03-1412-4e61-97ca-698c0ae12d02" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,512,928</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f6a80554-8bff-44a6-b806-bb2fc3e491cf" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:AdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,385,301</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accumulated other comprehensive loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ed0f8f7-243c-4924-a430-6cde58bf8d40" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,334</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6fd0ef94-3335-4f95-bd4b-d115936951f8" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,278</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5c0a38d1-359e-4915-8f9e-18897ccd7826" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">774,282</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a029a6bb-22fa-41b3-a655-1429dd579668" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">667,184</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">TOTAL STOCKHOLDERS&#x2019; EQUITY</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_10db0ad5-d12c-4ced-b8a6-fad7714a4306" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">737,325</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4bec80df-9a35-4406-bdbf-982b61e02ea4" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">716,852</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">TOTAL LIABILITIES AND STOCKHOLDERS&#x2019; EQUITY</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_68a4b240-6234-48ef-ab5b-e0dc976ecd2c" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,057,581</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dc383a89-a5bf-43bd-a527-8892485876c4" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">918,761</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="condensed_consolidated_statements_operat"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Condensed Consolidated S</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">tatements of Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in thousands, except share and per share data</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(unaudited)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:45.009%;"></td>
    <td style="width:1.333%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.324%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.676%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.324%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.343%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.324%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.343%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:10.324%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Three Months Ended June&#160;30,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Six Months Ended June&#160;30,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Revenue:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Collaboration revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59d64f78-8c37-4dc5-aa82-0fe2604dacde" contextRef="C_8162e8b4-3609-4bdc-ba16-5e1d76bb3c6b" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,333</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ebc51404-5879-4538-8bbe-dc0720ec3b99" contextRef="C_09789d61-addd-4c37-ab93-6605597b8a60" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5d6b5343-c3f6-415e-bb01-0ae5210236be" contextRef="C_766775c9-df87-46ac-a6ca-0995a7c65d87" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,333</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b4570d29-2dcb-4681-990a-da468d7e0d12" contextRef="C_86f05426-07f5-4481-b708-0d76a9b442e3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Contract revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_027914bb-549d-4da1-8ac8-4c1553b069dc" contextRef="C_037841ec-b5b1-4809-aef7-1a37b14ddff9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">168,653</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5bb46ba9-22b9-470a-8a7e-68b0bbcab172" contextRef="C_d438ee24-58b2-47f8-b7c8-f3890a19f797" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43,522</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a216013e-b53e-4586-93b6-fcb25dee7020" contextRef="C_5ef16289-589c-49ff-b97d-b1ade8c4d8c4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">169,266</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8e88873b-f35c-451f-afd6-c279bd42fd56" contextRef="C_4504c120-b2bc-4009-8fb3-837091fb0248" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,009</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Grant revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7b77b554-1849-489a-809b-04dc89d75104" contextRef="C_9b221d24-b45a-4cc0-b6cb-8320c56dc6fc" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,082</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf2f5b1b-1f0b-4e95-abda-2526101cc3a2" contextRef="C_08207110-60df-4348-8106-e824e9e44ab8" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">719</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1441bc52-0a84-451d-bf7c-57692002a221" contextRef="C_eb4adf6c-364c-4b79-92fd-28aa9a50e441" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,453</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a5e13a12-d76c-4132-bfc7-d50cf0a0f918" contextRef="C_1f9d182b-02f1-4140-983b-012691d8ce35" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,950</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">License revenue from a related party</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f9ddcbc-5fc6-4a78-8b3f-5e40efe9a23a" contextRef="C_de3d836a-48cf-4d4f-8714-440719392b2e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b37c0904-8585-4aa0-888e-c5e39c003079" contextRef="C_69917036-35e4-4dc8-8976-064800b680f9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,747</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d2e3e3c8-58ef-4d32-a44b-e9f9cf5e233e" contextRef="C_de3d836a-48cf-4d4f-8714-440719392b2e" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4e70905f-6d51-4dde-9093-0330384d7fbd" contextRef="C_1ff555c9-cb2a-45df-8631-74d23812f12b" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,747</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b1006b24-6abc-4859-b21c-0b42c2acce17" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">177,068</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dcd8d349-919d-43c6-ba4d-af599b1222ea" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66,988</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b09de97d-1c44-44ec-813c-c7e5c5809aa8" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">179,052</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_17dd57b8-331a-4dec-8057-5beef9b44831" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:Revenues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72,706</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cost of revenue</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7f38ff6e-9f50-402a-9ba1-7ef362739c93" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,144</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e30badf5-1e39-4e28-b6ff-811ea469d568" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab7d6943-876e-48f3-84e1-f47d8cfd6b4d" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,152</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_88262048-d8c6-4fc8-81d6-bd921a95ed0d" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:CostOfRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8d49289c-f248-4dd7-8b88-10da9f6bb76e" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">86,126</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1fff5c7c-a5b5-4602-bcf2-909c78f07c12" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">79,653</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4976527f-d869-43de-bdf1-b2c8d01007ee" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">220,996</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9e74061f-ee0a-4859-b307-3808e7f6dd7c" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">144,632</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Selling, general and administrative</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7e31dccb-a7c0-4c20-8141-064dbc8e7126" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">28,781</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cdd5e4ff-b4f6-42ae-a20e-3fd7e03ad76e" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,386</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a4d378b4-b72b-4da5-bbaa-0cef3e581a49" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">54,520</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_83970c4d-393f-4cb9-97d0-e8bf463dcb3f" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:SellingGeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,035</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69938ab2-e08d-4db6-ad01-f19d4790cb78" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">116,051</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e96f63e2-b2d1-463a-b555-e3c8df3d32ff" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">96,039</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cd7bdb4b-db31-4e37-abf0-e34f9ceeabe3" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">276,668</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6cde6a54-6405-41ae-8068-348c57f67518" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">173,667</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Income (loss) from operations</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c1ee6600-5853-4b35-8f14-c5f66a72e334" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,017</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb49efde-4a09-437b-9c94-1700c3f0d04c" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">29,051</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_360aad54-d59c-46ba-afbd-0cb3495c54a1" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">97,616</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_06dcc6d4-8b51-453e-ad41-bd3abf99775f" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">100,961</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Interest income</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_84b34ca1-65f7-4a1d-898c-fc164674169b" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">97</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_29e19332-12c3-4011-9243-9342a37b5521" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">825</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b3af91af-5238-475a-bce3-96065a497401" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">261</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9b94e75e-868e-4c27-95ca-31fe6ec89597" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,580</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other income (expense), net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5d2f3d70-35d7-425c-b749-7c8a106b0975" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">752</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_837f9a4a-b9e4-4460-8a39-a2c004d8fa82" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,895</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0df41ec4-fc64-42f0-9d0f-dd7f9a10d306" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,494</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b797c3a-1649-4f55-829d-38051f2ed0f9" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,964</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total other income (expense)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec6e4828-74b2-414f-bcf4-a976b1bdee31" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">849</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_70e40a95-3a56-41ed-841d-195a1d1add21" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,070</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b27690a3-76be-4854-bcd0-3ee238d82d70" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,233</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c4258e3-97d2-4f07-82e0-8bccf3e053f7" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:NonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">7,384</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Income (loss) before provision for income taxes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_56ff4683-d328-4dc7-bb4f-a06b57cf7b3a" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,866</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_48dd4009-1e24-45e9-a607-48a620b475e4" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">31,121</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_56a17daa-158a-4b20-a5d0-72e168f888c3" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">106,849</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5648483d-01cb-44dd-beb4-235e2c51ccda" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">108,345</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Provision for income taxes</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ef3d854f-7899-421c-8257-3abcf00a7433" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">53</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_93e39219-9cd8-45a0-adca-7d8fc77c7968" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">46</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b017fa04-cdb3-4a8c-9ab1-5cc87518f5a2" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">249</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3802c99d-921c-48cc-be9b-b9353f374f35" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net income (loss)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_65725035-4a19-478b-9296-c556ff67797e" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,813</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_73c4ba26-2695-45ba-8368-9f592be03031" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">31,167</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dc2caf53-a2a0-4267-bdb4-279fb7619d5d" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">107,098</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_660bada9-1c80-4367-869c-b0d02aaa37e4" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">108,407</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net income (loss) per share, basic</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f060d18c-5f42-42c6-a19f-1e5c6b7f9b87" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2">0.48</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_919de847-dcc6-4b4f-a1d3-1e6802b40470" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-">0.27</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a9b7f1d-1ce3-41fa-9b51-53beb48a56a2" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-">0.83</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d9dad893-fe35-4f58-976d-d15289ec9e2f" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-">0.97</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net income (loss) per share, diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0f7c6813-19e5-4024-a28a-4291876670d7" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2">0.46</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bda12359-b715-4fd8-b72c-30c60aa1f364" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-">0.27</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9257cc0d-7844-416f-87f7-4e0a32666fcb" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-">0.83</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f0f890fd-5ffa-4a0b-aad4-28496db6eb7a" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-">0.97</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Weighted-average shares outstanding, basic</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c8349f07-42f6-46ea-8f77-ae9f6e42a59a" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">130,121,943</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0a180304-c711-4a7c-ac1f-a8d179379af2" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">114,980,652</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2b9d7829-6762-4465-b0e0-25922ea23d22" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">128,938,851</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_071cd25e-f97a-4f34-bdc0-2ce5c9e1085d" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">111,684,283</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Weighted-average shares outstanding, diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_df8fbf92-4f42-402d-b8cb-90589a49eee0" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">133,789,977</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2bf7bb9b-4728-48b8-ab3d-86c7767bf861" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">114,980,652</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_400842ff-9c75-4461-8e05-2711a7066486" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">128,938,851</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6c34880e-df2e-4cca-96eb-553c5cce0237" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">111,684,283</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="condensed_consolidated_statements_compre"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Condensed Consolidated Statement</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">s of Comprehensive Income (Loss)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in thousands)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(unaudited)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.343%;"></td>
    <td style="width:1.213%;"></td>
    <td style="width:1.037%;"></td>
    <td style="width:9.157%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.222%;"></td>
    <td style="width:1.037%;"></td>
    <td style="width:9.157%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.222%;"></td>
    <td style="width:1.037%;"></td>
    <td style="width:9.157%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.222%;"></td>
    <td style="width:1.037%;"></td>
    <td style="width:9.157%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Three Months Ended June&#160;30,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Six Months Ended June&#160;30,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab579a8e-48e7-4206-8f14-644e06cb0f3a" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,813</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c682319-507f-43c5-8d59-3b20492bacbb" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">31,167</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_163378d5-3189-424c-9e63-522e13c44e6e" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">107,098</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_303eb488-ddf2-49bf-9f0e-273b86a287b9" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">108,407</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other comprehensive income (loss):</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unrealized gain (loss) on investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_143c1028-9e9f-412b-8703-f146ddedbf6f" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">44</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab0ed29f-c176-4ac4-9c07-7fee5d481a69" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">549</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eab350e8-338f-44ad-a195-7e51b94eaad6" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">84</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e0de3e8a-1429-4f4e-be6f-7f86e4b5b808" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">295</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Amortization of actuarial loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f8beb47-1553-4b27-9ac2-0df0b42daaa6" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">14</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ad625dc-3130-4c8a-999f-c5ad567740f3" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1ff04aaf-ebf3-49cc-bbc2-ae1543251399" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">28</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_caf5eb1e-1adf-4e4e-8381-566cf279fa37" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other comprehensive income (loss)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8bdf9e30-6286-4ef7-8ee5-66ddccd20d38" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">30</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dbc9c5e4-7771-49e4-bb5a-3337d142faae" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">543</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_133bedce-911d-4e4b-b6ff-00c7949737a9" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">56</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_52a36831-a045-41fb-80ad-e66078386842" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">306</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive income (loss)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f6a0782b-18a2-483b-8e6a-b260f0e66d97" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,783</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_20cea3ba-faa7-4db6-ba88-eb887e916aed" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">31,710</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9aa12b1a-2080-4448-8138-5510ef6a2f07" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">107,154</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f9b25390-5ee9-4fb2-83a3-c5c3ae6d98db" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">108,101</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="condensed_consolidated_statements_stockh"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Condensed Consolidated S</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">tatements of Stockholders&#x2019; Equity</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(in thousands, except share amounts)</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(unaudited)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:29.063%;"></td>
    <td style="width:1.208%;"></td>
    <td style="width:1.007%;"></td>
    <td style="width:8.0%;"></td>
    <td style="width:1.007%;"></td>
    <td style="width:1.208%;"></td>
    <td style="width:1.042%;"></td>
    <td style="width:7.611%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.201%;"></td>
    <td style="width:1.042%;"></td>
    <td style="width:9.021%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.201%;"></td>
    <td style="width:1.042%;"></td>
    <td style="width:9.021%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.201%;"></td>
    <td style="width:1.042%;"></td>
    <td style="width:9.021%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.042%;"></td>
    <td style="width:9.021%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Accumulated</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Additional</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Other</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Paid-in</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Comprehensive</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Accumulated</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Stockholders'</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Share</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Income (Loss)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance at March 31, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8e73838e-3ac6-419c-806a-437122e47861" contextRef="C_61ac6d35-003c-4932-8b7f-75b0994fe73e" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">129,891,856</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9c369f08-bf64-4474-9418-5047e040036c" contextRef="C_61ac6d35-003c-4932-8b7f-75b0994fe73e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a4aa7b30-7e1b-4a4d-a2b8-5bf820b9db4b" contextRef="C_914881ac-2ab5-47f4-8eed-c4210e53dc3a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,488,337</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6ecd0b9-c99e-406d-8061-ae515e8907ed" contextRef="C_7c63340d-0674-48e2-b11f-13fdad617a64" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,304</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c3edfd1d-e217-47ea-95a8-6a004051e6a5" contextRef="C_d8427988-1d9b-42d6-a158-ce5e24c17b41" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">836,095</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_45413892-4842-4a3c-a25b-2d8f6d541cba" contextRef="C_3edca66f-50fb-4438-8b85-01c89b9c1b0a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">650,951</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vesting of restricted common stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6de5df55-ba05-4a13-8846-6615d67fd7a6" contextRef="C_a2dda4ba-cdd3-4a25-95df-9f71c39ebfdf" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">34,446</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_05a6fe23-ec2c-4234-a15a-302ffc8aae68" contextRef="C_a2dda4ba-cdd3-4a25-95df-9f71c39ebfdf" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">553,673</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ba46021a-151d-465b-b775-f06d4508b679" contextRef="C_6f7a01e9-125b-4678-81a3-a6efb1b4d77e" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,593</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f6962bf-9fe2-479b-a58a-fe25e564fb38" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,593</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f6e3177-2ef1-4bc5-9b16-5c0dd89dc899" contextRef="C_6f7a01e9-125b-4678-81a3-a6efb1b4d77e" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,998</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_65708f24-03a1-4762-bb9e-f385b959c114" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,998</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e39fd306-c286-4d51-803f-7efc8465f974" contextRef="C_be538fc0-b3da-4933-b596-db6f96112f97" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">30</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_85347c94-96bb-4704-ae9e-93ea2ebddef1" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">30</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3041fc68-b40d-411f-9f5d-add5664401d7" contextRef="C_2ff7bfd4-ce79-493b-87b6-550ee9f49df4" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,813</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9529635b-3877-466f-995e-5540768d929c" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,813</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance at June 30, 2021</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e2e69a9e-5f8a-49bb-8115-08d55b8b2420" contextRef="C_45bc5026-51b3-4f16-b7d4-61e29f251c4a" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">130,479,975</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab6ce2d3-bc1a-4886-a110-9e37f06473de" contextRef="C_45bc5026-51b3-4f16-b7d4-61e29f251c4a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7fa5d680-d1a0-431e-947f-04498daf5361" contextRef="C_befad2fc-309f-4f88-99dc-baaef6380944" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,512,928</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e630a151-4f12-422f-b096-4ac2228dff14" contextRef="C_918fa4e1-d7cd-4bf6-82cc-f13652a23ef9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,334</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2f26ccd4-e978-4ed9-a32f-9681c54afc93" contextRef="C_1978c92a-9f5f-463a-83b8-88d2ffb3548f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">774,282</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b9c0bca-4a6a-4632-a601-0a4ffebdf8f2" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">737,325</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Accumulated</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Additional</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Other</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Paid-in</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Comprehensive</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Accumulated</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Stockholders'</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Share</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Income (Loss)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Equity</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance at March 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_95fd3208-34f9-4b4e-905c-1842ea30cd9c" contextRef="C_355e350c-6186-4712-9d71-af22d0b9a120" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">108,350,368</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_06a86a79-5fb1-4b9b-a80e-93a99c56a452" contextRef="C_355e350c-6186-4712-9d71-af22d0b9a120" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_436bbf04-6eb8-4199-92ca-b2911b0b9773" contextRef="C_b6d51956-3a22-4bd6-95a5-dad4c1d17f90" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">825,833</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ebc03b3f-5247-4475-a4a4-0faedc1b40ce" contextRef="C_a8995a77-2e40-4bdd-a7bd-5c2389acc76c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">248</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2eeb7791-7141-4b63-9407-6657f7d2a925" contextRef="C_1ef15310-89d7-4a2b-81fa-497de643a6d3" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">445,759</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e17369f3-a5d9-4422-a40b-8a8172e465b2" contextRef="C_c4e13756-0547-45df-9116-975dfa1cdf28" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">380,333</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance of common stock in connection with the <br />&#160;&#160;achievement of a milestone</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f91af005-a652-4587-aa67-46c2b19a5402" contextRef="C_fa28c391-ecec-4c12-bcfb-f369058e9862" name="vir:StockIssuedDuringPeriodSharesAchievementOfMilestone" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,111,111</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance of common stock in connection with a<br />&#160;&#160;collaboration agreement</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6f8ec0eb-f47b-4f6c-88c2-463badc63a7e" contextRef="C_fa28c391-ecec-4c12-bcfb-f369058e9862" name="vir:StockIssuedDuringPeriodSharesCollaborationAgreement" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,626,027</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_53104dd9-3156-4c72-828a-7078f9729266" contextRef="C_fa28c391-ecec-4c12-bcfb-f369058e9862" name="vir:StockIssuedDuringPeriodValueCollaborationAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bdde06db-57b6-4119-8415-ab9f8709266a" contextRef="C_cce66117-e613-4efa-aee1-873b41ff2cc8" name="vir:StockIssuedDuringPeriodValueCollaborationAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">206,698</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_854184ae-7b8a-4080-9e8d-ca9176bbfae9" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="vir:StockIssuedDuringPeriodValueCollaborationAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">206,699</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance of common stock for cashless exercise<br />&#160;&#160;of warrant</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fbcf8621-b968-48f4-8de3-b774d4e1264d" contextRef="C_fa28c391-ecec-4c12-bcfb-f369058e9862" name="vir:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">211,774</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vesting of restricted common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4dd7d7b2-7d7a-4075-89bc-7e4c07358cc4" contextRef="C_fa28c391-ecec-4c12-bcfb-f369058e9862" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">612,546</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cb3c8ba8-543e-4085-980c-06c4e4c5284c" contextRef="C_cce66117-e613-4efa-aee1-873b41ff2cc8" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">462</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4c4e4667-2eab-4b21-b7cb-f9c8411ea658" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">462</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_24cf6a24-3582-4500-9bf1-0e00ea160e36" contextRef="C_fa28c391-ecec-4c12-bcfb-f369058e9862" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">815,260</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2679d91c-5c20-48a5-a6bb-814c05a71294" contextRef="C_cce66117-e613-4efa-aee1-873b41ff2cc8" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,245</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bfa84db9-5378-4175-bc27-1657a46564bb" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,245</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89945d7f-dae1-4ddd-9555-2c7e22bcfe03" contextRef="C_cce66117-e613-4efa-aee1-873b41ff2cc8" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,750</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_646a663c-4b19-4488-8156-e63bc668e61f" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,750</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other comprehensive loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_020c8337-8f93-4475-b45b-c909ce21a4a3" contextRef="C_a23df604-43e8-477f-95be-d67c4d36ef27" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">543</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_034a748a-1da6-4d39-b597-7921a475e44d" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">543</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e7d7b44-6d09-44b4-9065-9fa50eff3634" contextRef="C_329ccbc8-94c6-4565-9ecf-7b34632b826e" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">31,167</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f6f1871-fc3d-4951-ae98-52b5a8fef0f1" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">31,167</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance at June 30, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_629c7fab-f72b-48b4-8697-4d2ce50b8f1d" contextRef="C_b6795825-d2b1-4664-92a7-7f4efb4ea7bd" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">117,727,086</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e261d2be-3037-425f-965a-08a59cdb92f9" contextRef="C_b6795825-d2b1-4664-92a7-7f4efb4ea7bd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab1d401c-b548-4b95-b4af-dcc81b71e2fe" contextRef="C_0b1f8126-42c0-40fe-81c1-24cbdc0b2ccc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,040,988</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_556ce8c6-3046-4bd0-9b35-486b1a6bf283" contextRef="C_01c272b4-05c2-41fb-90b2-afebf3595d73" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">295</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b052b4c1-deee-44a7-9b9e-84dcd80105c7" contextRef="C_a2db8718-9aa3-44fb-bd21-a5914cb932c2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">476,926</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_14bb7acc-0679-413d-89f1-0c26dfd7a682" contextRef="C_e28f1ecf-80aa-4b09-b8ff-8c09db69a316" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">563,779</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Condensed Consolidated Statements of Stockholders&#x2019; Equity</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(in thousands, except share amounts)</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(unaudited)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:29.139%;"></td>
    <td style="width:1.208%;"></td>
    <td style="width:1.007%;"></td>
    <td style="width:7.667%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.201%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:7.667%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.201%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.097%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.201%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.097%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.201%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.014%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.201%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:9.097%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Accumulated</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Additional</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Other</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Paid-in</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Comprehensive</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Accumulated</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Stockholders'</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Share</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Income (Loss)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_74e511ac-6592-487d-8613-9217d99a37ef" contextRef="C_3c3d0c98-1fee-4858-be8f-d493a8a73e1e" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">127,416,740</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9c6bd07d-185f-4762-acf4-b54b7638452a" contextRef="C_3c3d0c98-1fee-4858-be8f-d493a8a73e1e" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4aac2db0-97a3-485c-a150-a894391723e3" contextRef="C_9b52dd29-86c0-42a1-9b29-10e07e25991f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,385,301</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_294319b5-8f10-44ec-824e-ed9f6fb4d598" contextRef="C_2a63cca2-9347-45c4-8512-1e97604d2422" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,278</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7fcd96d6-a3dd-4838-9b34-7fb5ffde4d37" contextRef="C_f55782eb-212f-4f4e-9bf4-65f42e20a89a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">667,184</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_808e4739-eb12-4955-9f33-c7877cdf766a" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">716,852</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance of common stock in connection with a<br />&#160;&#160;collaboration agreement</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_acb1c808-9b2f-4812-9b73-12b4150c44f9" contextRef="C_78af002d-b722-4eae-8f4a-2d0c76fa8ae0" name="vir:StockIssuedDuringPeriodSharesCollaborationAgreement" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,924,927</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_72f69b12-ceb7-43a9-8b44-4de9285dab8f" contextRef="C_96589541-95bc-4aef-a913-79c4b0b517f0" name="vir:StockIssuedDuringPeriodValueCollaborationAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">85,213</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_72326b77-0629-4488-801f-433c93c09436" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="vir:StockIssuedDuringPeriodValueCollaborationAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">85,213</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vesting of restricted common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6bce667a-8b27-42e4-b2ae-e8f421f3399d" contextRef="C_78af002d-b722-4eae-8f4a-2d0c76fa8ae0" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">87,409</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7cba796e-6f31-49ad-9150-d2bacd9f869b" contextRef="C_78af002d-b722-4eae-8f4a-2d0c76fa8ae0" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,050,899</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e2515e63-01ab-445f-8b52-e5005494917f" contextRef="C_96589541-95bc-4aef-a913-79c4b0b517f0" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,945</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_55191f36-e3f6-4932-925d-8595e8e0a7c5" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,945</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c1c6d423-b69e-4a48-aded-c08d2ff72990" contextRef="C_96589541-95bc-4aef-a913-79c4b0b517f0" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,469</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c4645d0-e8d7-4e7f-839b-d09eaee92ffb" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,469</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other comprehensive loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_61d31b80-6900-44cd-9bed-ce4a9725efff" contextRef="C_3e223018-5e3f-452c-824b-e2e4d71405b7" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">56</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c9b17ed9-9239-4ba1-9cb4-3474475bf7d9" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">56</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1821dbb-aeb3-410b-98e2-805338304d84" contextRef="C_24d34ab3-57a3-4b9e-8de9-5279d44dd035" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">107,098</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6976c72e-3cc3-4beb-bfae-dd007fa23c1b" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">107,098</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance at June 30, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2077898e-be83-4f10-9459-8b99e2a8864f" contextRef="C_45bc5026-51b3-4f16-b7d4-61e29f251c4a" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">130,479,975</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89c1acbb-25bc-4b50-9bc7-2c86919edaf4" contextRef="C_45bc5026-51b3-4f16-b7d4-61e29f251c4a" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4adee54c-732c-4456-bb7b-8b41def63eec" contextRef="C_befad2fc-309f-4f88-99dc-baaef6380944" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,512,928</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_db4e5228-275e-4802-9621-e31ee0255789" contextRef="C_918fa4e1-d7cd-4bf6-82cc-f13652a23ef9" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,334</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de432f40-0e21-4a04-a292-cc4212fc4e42" contextRef="C_1978c92a-9f5f-463a-83b8-88d2ffb3548f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">774,282</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4ea03af9-725e-4b2d-b387-42a6353de101" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">737,325</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Accumulated</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Additional</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Other</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Common Stock</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Paid-in</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Comprehensive</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Accumulated</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Stockholders'</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Share</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Capital</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Income (Loss)</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Deficit</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Equity</span></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2019</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_532bc040-e9c2-4f7c-91b5-358f3fbe823a" contextRef="C_9d811492-0ef4-42f2-b9e1-20840319d292" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">107,648,925</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a4c9b880-9419-4163-9ee5-bc52afac12f3" contextRef="C_9d811492-0ef4-42f2-b9e1-20840319d292" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e23dcde1-fb60-4cf7-bf70-26470a18cb10" contextRef="C_b9591672-a7df-4119-8763-beff32620126" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">793,051</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d94f5a4-385f-4edd-a4c3-dc66462301d2" contextRef="C_e1137d24-689b-45da-9ecd-65f97451d124" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">601</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_94c210c5-f768-417e-bab1-f4128b372cb3" contextRef="C_b570c7a7-2e4b-4988-8066-7fc9aded3533" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">368,519</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e2181808-c371-4d3b-b6cf-7c543288d716" contextRef="C_2961edff-bc89-457f-97d0-23460c2e7059" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">423,942</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reclassification of derivative liability to additional<br />&#160;&#160;paid-in capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4b2f1989-6784-4b4f-864d-021e72737f27" contextRef="C_b16f4229-15e5-4b92-a679-7c593814f6cd" name="vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,245</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_180136c5-718f-40f6-ad31-db53c37431fa" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,245</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance of common stock in connection with the <br />&#160;&#160;achievement of a milestone</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_786c6195-76b1-4070-aaf7-1243a51ad6fe" contextRef="C_0e1b6477-b8d1-4ae0-89fa-0e4e1af40ea7" name="vir:StockIssuedDuringPeriodSharesAchievementOfMilestone" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,111,111</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance of common stock in connection with a<br />&#160;&#160;collaboration agreement</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_955878b0-50e1-4441-a638-85d6193d5309" contextRef="C_0e1b6477-b8d1-4ae0-89fa-0e4e1af40ea7" name="vir:StockIssuedDuringPeriodSharesCollaborationAgreement" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,626,027</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8dab024f-8502-42f1-8865-daf195d0ace5" contextRef="C_0e1b6477-b8d1-4ae0-89fa-0e4e1af40ea7" name="vir:StockIssuedDuringPeriodValueCollaborationAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2ed0fcc5-30de-4c40-b9e3-eef6a245281a" contextRef="C_b16f4229-15e5-4b92-a679-7c593814f6cd" name="vir:StockIssuedDuringPeriodValueCollaborationAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">206,698</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9661d157-d84e-4d2c-8879-f4a0b856899e" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="vir:StockIssuedDuringPeriodValueCollaborationAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">206,699</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Issuance of common stock for cashless exercise<br />&#160;&#160;of warrant</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_15f6e701-0b75-4525-ab01-0f1f777058cc" contextRef="C_0e1b6477-b8d1-4ae0-89fa-0e4e1af40ea7" name="vir:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">211,774</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vesting of restricted common stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_47b24196-143c-4aa3-9edb-7f6919cf0b74" contextRef="C_0e1b6477-b8d1-4ae0-89fa-0e4e1af40ea7" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,230,625</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_af06a152-5983-44b0-a380-45e4b7fb61f4" contextRef="C_b16f4229-15e5-4b92-a679-7c593814f6cd" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">889</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69faba5e-98da-4c30-bbda-bc2b71d59964" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">889</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5b3566cf-a246-4f0d-b5b0-c52a8bb2b1d8" contextRef="C_0e1b6477-b8d1-4ae0-89fa-0e4e1af40ea7" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">898,624</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a443e324-ff32-4729-9144-a43d913ac4e8" contextRef="C_b16f4229-15e5-4b92-a679-7c593814f6cd" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,388</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fa0b93d4-d370-4eee-aa5a-aff37f6e1cd5" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,388</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4d083fc4-d2d3-4e70-b888-12d114795c13" contextRef="C_b16f4229-15e5-4b92-a679-7c593814f6cd" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,717</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b53d938-4559-4c3d-9ba0-e19934edf317" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,717</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other comprehensive income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d1c99207-056a-4a5b-a40d-f81ea3c3a6dd" contextRef="C_440aee8c-e7b5-48d3-90f4-51f9d0631f45" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">306</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_31c5d97b-b5c8-41c4-8cf0-8a4802f55f6e" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">306</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd338711-16a4-4b15-86ae-d6936b3cd110" contextRef="C_39a5ff4f-90c0-4385-8a23-486f8b46bf9b" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">108,407</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_72dbfd27-542e-44e3-b0e9-04b662e315d4" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">108,407</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance at June 30, 2020</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a5334d49-576e-461a-a90d-a7f0451ea770" contextRef="C_b6795825-d2b1-4664-92a7-7f4efb4ea7bd" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">117,727,086</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_77dde1d0-0ae4-4f7d-b2db-bee6c943b3c5" contextRef="C_b6795825-d2b1-4664-92a7-7f4efb4ea7bd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7f3727f5-034b-44fe-896d-14d7dccca34c" contextRef="C_0b1f8126-42c0-40fe-81c1-24cbdc0b2ccc" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,040,988</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e208c3da-4659-4e83-ad3a-e62b0bd6a224" contextRef="C_01c272b4-05c2-41fb-90b2-afebf3595d73" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">295</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9b465016-ace1-46f3-bd8a-e40f50cf7e38" contextRef="C_a2db8718-9aa3-44fb-bd21-a5914cb932c2" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">476,926</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_15063881-4972-4489-bada-a958007975ce" contextRef="C_e28f1ecf-80aa-4b09-b8ff-8c09db69a316" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">563,779</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="condensed_consolidated_statements_cash_f"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Condensed Consolidated S</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">tatements of Cash Flows</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(in thousands)</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(unaudited)</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:67.0%;"></td>
    <td style="width:1.62%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.88%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.62%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:12.88%;"></td>
    <td style="width:1.0%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Six Months Ended June&#160;30,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">CASH FLOWS FROM OPERATING ACTIVITIES:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_835ab5db-ba23-4de7-8326-7a1a8ac41714" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">107,098</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2de7b978-7dbb-4005-b369-a34553bde371" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">108,407</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Depreciation and amortization</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9e43e585-242f-4638-8adf-7786606bb51f" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,538</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0b86c4ad-8e96-42eb-99d1-cb40202631e9" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,061</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Amortization of intangible assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bead540e-9574-44cb-8f25-b91b69f7401f" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">266</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec69735e-aa62-429b-acab-43707846651a" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:AmortizationOfIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">612</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Amortization of premiums on investments, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_937a5f46-803b-4bfc-9534-25253b53110b" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">238</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0347c794-e4c5-4f3f-963d-e4a9ec79ab93" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">818</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Noncash lease expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e6370e56-2082-4111-8bc7-56a115069c08" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="vir:NoncashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,973</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a042388f-cdb5-492a-8711-65f66ace2937" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="vir:NoncashLeaseExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,646</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Change in estimated fair value of contingent consideration</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c06f6ae-765b-4096-bdde-e460e58d9df6" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="vir:ChangeInEstimatedFairValueOfContingentConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">42,918</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b25c4b9c-ed7d-467e-acb0-ddd731dc4c3d" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="vir:ChangeInEstimatedFairValueOfContingentConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,790</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Payment of contingent consideration in excess of acquisition date fair value</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8097f809-301a-470c-b4d4-e5af1436a4ba" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9a1c6140-455c-4fcc-8cb8-3ce40f0bb5ee" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">6,453</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Change in estimated fair value of derivative liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d67df2d3-75e0-4a44-bfe8-ba3c198f2306" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7305dd46-356e-4512-bf07-79e74e53e055" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:DerivativeGainLossOnDerivativeNet" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">16,796</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3ceaa6c1-3271-4df3-b499-c17de1751a44" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,469</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5df40c72-9668-4c29-8bc3-7b3b23fedc97" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,717</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_01dc2047-3c78-42b2-907e-f7c7001df48a" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_54b0b8b0-d32d-483f-aab5-80ac45bf9bac" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_12483aac-c12d-469b-92ff-3a7c98339868" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">521</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_010116ac-0f29-476b-9f1e-554767c4bbf4" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,159</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Other assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a069a438-382f-42cc-abc4-7c0599ec1b89" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">857</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_396193a4-e41f-49dd-8099-b202ca7ef112" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">361</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accounts payable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_37c63dd4-31f0-4782-bcc8-987ad508a625" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,933</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5c2ea0a9-7623-490f-8650-a4db122f401d" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,342</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Accrued liabilities and other long-term liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e6163cb0-6ba7-4c81-862a-24f94c15721b" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">22,287</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d1cc8b3-646c-43fc-913d-e04dc5b533f3" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,791</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_586333d7-980b-46bd-89ca-13867610dc7c" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="vir:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">93</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d9bc982f-0989-4ad2-91c5-4a253e742969" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="vir:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,557</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_27f51254-e864-4030-80c0-11b282dd6660" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">90,452</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4b59a80d-a42a-414e-a5c6-0e5b19b73dc0" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:IncreaseDecreaseInDeferredRevenue" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">4,011</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net cash provided by (used in) operating activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_82902b12-f7df-4f75-b357-b48f32c37622" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">50,529</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b409b021-d93a-44a7-b9d9-9c3f267c722c" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">59,048</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">CASH FLOWS FROM INVESTING ACTIVITIES:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Purchases of property and equipment</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_90823156-7d42-4b5d-b358-d31305379f85" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,744</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fb902c09-3c1d-4d6f-bec5-464f8bd6f981" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,645</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Purchases of investments</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8cdfd834-5648-4078-8200-5c498360bcde" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">55,729</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7b33c99c-76dc-4faf-9302-4137d7b3aa86" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:PaymentsToAcquireInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">129,899</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Maturities of investments</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5e8fe093-83a5-4ef9-b7f2-cd9c96ed2e86" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">221,382</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_40431e90-9d8c-4541-82ac-0f58e2b32d2a" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">247,168</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Proceeds from disposal of an asset held for sale</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_53959336-f4ac-4f6c-83ab-c0abf554b669" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:ProceedsFromSaleOfPropertyHeldForSale" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_557ec9e5-8491-43c6-a38a-3979528416c6" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:ProceedsFromSaleOfPropertyHeldForSale" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">180</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net cash provided by investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7f2b7ac5-9c1e-4a86-a949-0b2b14b5e038" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">162,909</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_077bceb9-6012-4e7f-8dbc-80be96612d63" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">114,804</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">CASH FLOWS FROM FINANCING ACTIVITIES:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Proceeds from issuance of common stock in connection with a collaboration agreement</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7dc30800-2134-42c1-a590-5278cba84c83" contextRef="C_7e3f6ce0-b70a-4697-a4fb-c60b7c239059" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">85,213</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cab136fb-deb8-41aa-835d-b4472b2c511a" contextRef="C_f41bf82e-773a-4ae8-995a-1851961c2803" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">206,699</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Payment of contingent consideration</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_23ef4aa7-213d-4ce5-9787-39a2027e2fbb" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="vir:PaymentOfContingentConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c46e961-8b11-4d96-9ebc-41b0e2d54023" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="vir:PaymentOfContingentConsideration" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,547</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Payment of principal on financing lease obligation</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1c879f6c-4b69-4538-8aad-3720df58f753" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">126</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8048b3f3-5c72-40db-a2c4-705d3702039b" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:FinanceLeasePrincipalPayments" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">115</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Proceeds from exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e4a0574d-562b-4b7d-bfe8-0a60973bc27a" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,945</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fdc86b51-bac8-4cb6-b13f-3b2cec2122fb" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,388</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7d8aa132-4555-4d30-8686-16e2258388c9" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">91,032</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bdb8d69d-c483-433a-a739-2fc40414925d" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">205,425</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Net increase in cash, cash equivalents and restricted cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c306199d-4288-47ff-ac23-87b71ccbb6e0" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">304,470</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dc6eada3-7635-4ae9-9e46-65a1c83c6acb" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">261,181</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash and cash equivalents at beginning of period</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f79c9b49-3a86-4ec0-aa99-88fd6f3193ec" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">451,487</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f9903555-270c-464d-8a0e-0b68fd790b7b" contextRef="C_2961edff-bc89-457f-97d0-23460c2e7059" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">122,816</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash and cash equivalents at end of period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b0c2697b-8a73-453b-b935-6a9a01c2c748" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">755,957</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_980e47d6-e5bc-4e9d-85aa-020a073f09bc" contextRef="C_e28f1ecf-80aa-4b09-b8ff-8c09db69a316" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">383,997</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">NONCASH INVESTING AND FINANCING ACTIVITIES:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Property and equipment purchases included in accounts payable and accrued liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d636b02-7616-48b0-b53d-045d637b6431" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,485</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf95428e-c461-447b-a424-ed82236e856c" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">312</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Reclassification of derivative liability to additional paid-in capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_efad1a92-9200-4eda-817d-7991f022af97" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c5cf8396-3c71-4143-b7af-802aef4ad2a8" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29,245</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Deferred offering costs in accounts payable and accrued liabilities</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a90c6357-978d-4190-8e2e-ffd51d0d35f4" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="vir:DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cb92082c-a1e0-4ab7-85af-4ff46a7244a5" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="vir:DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">690</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED<br />&#160;&#160;&#160;CASH TO THE CONDENSED CONSOLIDATED BALANCE SHEETS:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_53d80ac5-266d-482b-8b61-3586167b71e2" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">741,951</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9b9f4978-7977-4ee5-848a-0be0bf2f9b4e" contextRef="C_e28f1ecf-80aa-4b09-b8ff-8c09db69a316" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">371,781</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Restricted cash and cash equivalents, current</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3188da4a-7641-43fd-a8ff-d100fb962882" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,004</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f6a91405-a874-416a-84a5-ce94b096cdcc" contextRef="C_e28f1ecf-80aa-4b09-b8ff-8c09db69a316" name="us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,024</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Restricted cash and cash equivalents, noncurrent</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_432e6902-b44e-437f-a4eb-02925d38e43c" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,002</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_616c82de-2a93-458b-a8fb-f1cea097d46c" contextRef="C_e28f1ecf-80aa-4b09-b8ff-8c09db69a316" name="us-gaap:RestrictedCashAndCashEquivalentsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,192</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:30.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:30.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0f009362-d931-4f4b-a916-d3907e1b523e" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">755,957</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_24f32ea4-19dd-44f0-9fab-96ebc5b9979c" contextRef="C_e28f1ecf-80aa-4b09-b8ff-8c09db69a316" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">383,997</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;font-style:italic;">The accompanying notes are an integral part of these condensed consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_unaudited_condensed_consolidate"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Unaudited Condensed Co</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">nsolidated Financial Statements</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fac0ba40-36cd-4717-983e-b06d6a12effc" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" escape="true" continuedAt="F_fac0ba40-36cd-4717-983e-b06d6a12effc_1"><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Organization</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vir Biotechnology, Inc. (&#x201c;Vir&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Its development pipeline consists of product candidates targeting the current coronavirus disease 2019 (&#x201c;COVID-19&#x201d;), hepatitis B virus (&#x201c;HBV&#x201d;), influenza A virus, and human immunodeficiency virus (&#x201c;HIV&#x201d;). Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. In May 2021, the Company received an Emergency Use Authorization (&#x201c;EUA&#x201d;) from the U.S. Food and Drug Administration for sotrovimab (previously VIR-7831) for the treatment of&#160;mild-to-moderate&#160;COVID-19&#160;in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct&#160;SARS-CoV-2&#160;viral testing, and who are at high risk for progression to severe&#160;COVID-19,&#160;including hospitalization or death.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Follow-On Offering</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 10, 2020, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7aedc160-70b5-45b6-b6ab-907bfcddb45e" contextRef="C_0db18e03-f55e-4678-9eaa-949bdcc27a33" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,214,285</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s common stock pursuant to a registration statement on Form S-1 (File No. 333-239689) and a registration statement on Form S-1 filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;) (File No. 333-239747) (collectively, the &#x201c;Registration Statements&#x201d;). The Registration Statements became effective on July 7, 2020. The price of the shares sold in the follow-on offering was $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_298cc69e-a420-495b-9db8-418036c8015e" contextRef="C_e1c1ce3e-6936-4e79-8e73-e9a37f058e7c" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_USDollarShare" decimals="INF">42.00</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share and the Company received total gross proceeds from the offering of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_354fbbcc-fa76-49fc-9eae-039f63f027a8" contextRef="C_0db18e03-f55e-4678-9eaa-949bdcc27a33" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">345.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. After deducting underwriting discounts and commissions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_09dd6ad9-8243-4d85-8e04-940428f8d8c5" contextRef="C_0db18e03-f55e-4678-9eaa-949bdcc27a33" name="vir:PaymentsOfUnderwritingDiscountsAndCommissions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.7</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and offering expenses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1cb92e87-6cec-4c35-a238-a0254738d4d3" contextRef="C_0db18e03-f55e-4678-9eaa-949bdcc27a33" name="us-gaap:PaymentsOfStockIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, the net proceeds were $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_95cfa9ce-3d1e-498c-b591-e86c9bc206dc" contextRef="C_0db18e03-f55e-4678-9eaa-949bdcc27a33" name="vir:ProceedsFromIssuanceSecondaryPublicOffering" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">323.2</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sales Agreement</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2020, the Company entered into a sales agreement (the &#x201c;Sales Agreement&#x201d;) with Cowen and Company, LLC (&#x201c;Cowen&#x201d;), under which the Company may from time to time offer and sell shares of its common stock, par value $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_adcb031b-cb0a-4fba-8b6a-22b9b253ec61" contextRef="C_02faa5a7-4825-491e-950b-34ee5ddb4d0a" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" decimals="INF">0.0001</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, having an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_55648c16-8c00-40f4-8e9c-360f6cadfba8" contextRef="C_aa261db7-a4b4-4b7f-9010-cd5b869abb50" name="vir:SaleOfStockConsiderationAggregateOfferingPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">300.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, through or to Cowen, acting as sales agent or principal. The shares will be offered and sold under the Company&#x2019;s shelf registration statement on Form S-3 and a related prospectus filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on November 10, 2020. The Company will pay Cowen a commission of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2e44083e-c26e-4219-90cf-6c3c60f36807" contextRef="C_aa261db7-a4b4-4b7f-9010-cd5b869abb50" name="vir:PercentageOfAggregateGrossProceedsFromSaleOfShares" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">3.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. As of June 30, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2a15f836-d015-45ca-8240-8244571228ed" contextRef="C_425979e0-416e-4c32-9ffb-95870c96d614" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares have been issued under the Sales Agreement.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Need for Additional Capital</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_fac0ba40-36cd-4717-983e-b06d6a12effc_1"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has incurred net losses since inception and expects such losses to continue over the next several years. As of June&#160;30, 2021, the Company had an accumulated deficit of </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee82317f-285c-40b8-9dac-b2fae0f7d506" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">774.3</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Management expects to incur additional losses in the future to conduct research and development and recognizes the need to raise additional capital to fully implement its business plan. The Company had, excluding restricted cash, </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_150b4db2-e914-49dd-ad13-96e68f989da0" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:CashCashEquivalentsAndShortTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">876.7</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;of cash, cash equivalents, and investments at June&#160;30, 2021. Based on the Company&#x2019;s business plans, management believes that its cash, cash equivalents, and investments as of June&#160;30, 2021</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> will be sufficient to fund its operations for at least the next 12 months from the issuance date of these condensed consolidated financial statements.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3efc098d-ac30-4bd6-8c34-6746b18e8454" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true"><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Summary of Significant Accounting Policies</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cfe86cd7-b75c-43d4-8cb0-484a59b3f704" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and applicable rules and regulations of the SEC regarding interim financial reporting. The condensed consolidated financial statements include the accounts of Vir and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company&#x2019;s financial information. The condensed consolidated results of operations for the six months ended June&#160;30, 2021 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2021 or for any other future annual or interim period.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Unaudited Condensed Consolidated Financial Statements</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain information and footnote disclosures typically included in the Company&#x2019;s annual consolidated financial statements have been condensed or omitted. As such, these interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and related notes included in the Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on February 25, 2021.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f9ece578-7d78-4b55-9a72-f70c3b96774e" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:UseOfEstimates" escape="true" continuedAt="F_f9ece578-7d78-4b55-9a72-f70c3b96774e_1"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_f9ece578-7d78-4b55-9a72-f70c3b96774e_1"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expense during the reporting periods. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_34616645-87f2-4021-9385-04ff66ce0101" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="vir:ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock" escape="true"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">With the global spread of the ongoing COVID-19 pandemic, the Company has implemented a number of plans and policies designed to address and mitigate the impact of the COVID-19 pandemic on its business. The Company anticipates that the COVID-19 pandemic will continue to have an impact on the clinical development timelines for some of its clinical programs. The extent to which the COVID-19 pandemic impacts the Company&#x2019;s business, clinical development and regulatory efforts, corporate development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States, Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the Company is subject to a number of other challenges and risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#x2019;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#x2019;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investments. Cash and cash equivalents are deposited in checking and sweep accounts at a financial institution. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments, and issuers of the investments to the extent recorded on the condensed consolidated balance sheets. As of June&#160;30, 2021, the Company has no off-balance sheet concentrations of credit risk.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is exposed to credit losses primarily through receivables from customers and collaborators and through its available-for-sale debt securities. The Company&#x2019;s expected loss allowance methodology for the receivables is developed using historical collection experience, current and future economic market conditions, a review of the current aging status and financial condition of the entities. Specific allowance amounts are established to record the appropriate allowance for customers that have a higher probability of default. Balances are written off when determined to be uncollectible. The Company&#x2019;s expected loss allowance methodology for the debt securities is developed by reviewing the extent of the unrealized loss, the size, term, geographical location, and industry of the issuer, the issuers&#x2019; credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers&#x2019; current status and financial condition. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted. During the six months ended June 30, 2021 and 2020, there was </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3edf5a50-befa-400b-817f-82ffe0e965e0" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_8fac4759-5183-4eb4-8adc-b2ae8f616ba1" contextRef="C_e28f1ecf-80aa-4b09-b8ff-8c09db69a316" name="us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> allowance for losses on available-for-sale debt securities attributable to credit risk.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Unaudited Condensed Consolidated Financial Statements</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_74b7fcbd-8a64-4729-8c81-1a7e905eaa67" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:InvestmentPolicyTextBlock" escape="true"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investments</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investments include available-for-sale debt securities and are carried at estimated fair value. The Company&#x2019;s valuations of marketable securities are generally derived from independent pricing services based on quoted prices in active markets for similar securities at period end. Generally, investments with original maturities beyond three months at the date of purchase and which mature at, or less than 12 months from, the condensed consolidated balance sheet date are considered short-term investments, with all others considered to be long-term investments. Unrealized gains and losses deemed temporary in nature are reported as a component of accumulated comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the condensed consolidated statements of operations. The Company&#x2019;s policy is not to measure an allowance for credit losses for interest receivable and to write off any uncollectible interest receivable as a reversal of interest income in the period in which it determines the interest will not be collected.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company, through its investment in Brii Biosciences Limited, holds privately held equity securities in which the Company does not have a controlling interest or significant influence. The Company&#x2019;s investment in Brii Biosciences Limited is recorded at cost and adjusted for impairments and observable price changes with the same or similar security from the same issuer. The valuation of the Company&#x2019;s investment in Brii Biosciences Limited utilizes significant unobservable inputs or data in an inactive market and the valuation requires the Company&#x2019;s judgment due to the absence of market prices and inherent lack of liquidity. Additionally, the determination of whether an orderly transaction is for the same or similar investment requires significant management judgment including the nature of the rights and obligations of its investments, the extent to which differences in those rights and obligations would affect the fair values of those investments, and the impact of any differences based on the stage of operational development of the investee. See Note 6&#x2014;Collaboration and License Agreements for additional information on the Company&#x2019;s investment in Brii Biosciences Limited.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_65b4f3ff-9527-4ed4-ae8c-b0624f621627" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Cash and Cash Equivalents</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash and cash equivalents represent money market funds to secure standby letters of credit and security deposits with financial institutions, both under office and laboratory space lease agreements. Additionally, funds received from certain grants are restricted as to their use and are therefore classified as restricted cash and cash equivalents.</span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bd5985c6-2039-4505-9317-7be8eee6d13b" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaboration, License and Contract Revenue</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;), the Company recognizes revenue when the Company&#x2019;s customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as the Company satisfies a performance obligation.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For collaborative arrangements that fall within the scope of ASC 808, Collaborative Arrangements (&#x201c;ASC 808&#x201d;), the Company first determines which elements of the collaboration are deemed to be a performance obligation with a customer within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808 and are not subject to the guidance in ASC 606, the Company applies the revenue recognition model under ASC 606 or other guidance, as deemed appropriate. The Company has entered into a number of license and collaboration agreements that fall within the scope of ASC 606. The Company evaluates the promised goods or services in these agreements to determine which ones represent distinct performance obligations. These agreements may include the following types of promised goods or services: (i) grants of licenses, (ii) performance of research and development services, and (iii) participation on joint research and/or development committees. They also may include options to obtain licenses to the Company&#x2019;s intellectual property.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period as required. These agreements may include the following types of consideration: non-refundable upfront payments, reimbursement for research services, research, development or regulatory milestone payments, profit-sharing arrangements and royalty and commercial sales milestone payments.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Unaudited Condensed Consolidated Financial Statements</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on their estimated standalone selling prices (&#x201c;SSP&#x201d;). For performance obligations satisfied over time, the Company estimates the efforts needed to complete the performance obligation and recognizes revenue by measuring the progress towards complete satisfaction of the performance obligation using an input measure.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For arrangements that include sales-based royalties, including commercial milestone payments based on pre-specified level of sales, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon performance of the licensee.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Grant Revenue</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grants received, including cost reimbursement agreements, are assessed to determine if the agreement should be accounted for as an exchange transaction or a contribution. An agreement is accounted for as a contribution if the resource provider does not receive commensurate value in return for the assets transferred. Contributions are recognized as grant revenue when all donor-imposed conditions have been met.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cab72e5c-f6fe-4da5-a06b-b98bbb36cd8c" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:BusinessCombinationsPolicy" escape="true"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Acquisitions</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process research and development (&#x201c;IPR&amp;D&#x201d;) projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date. Any excess fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with the business combination are recorded at their fair values on the acquisition date and are remeasured each subsequent reporting period until the related contingencies are resolved and are classified as contingent consideration on the condensed consolidated balance sheets. The changes in fair values of contingent consideration related to the achievement of various development milestones related to product candidates are recorded within research and development expense.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">When the Company determines that entities acquired do not meet the definition of a business, the transaction is accounted for as an acquisition of assets. Therefore, the consideration paid to acquire IPR&amp;D is expensed, and no goodwill is recorded. Any contingent consideration is generally recognized only when it becomes payable or is paid.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0a114bc5-03b8-4723-bc85-c80b134d1857" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:DerivativesEmbeddedDerivatives" escape="true"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Embedded Derivatives</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluates its acquisitions, collaborative arrangements and other business development transactions to determine if embedded components of these contracts meet the definition of a derivative under ASC 815, Derivatives and Hedging. In general, embedded derivatives are required to be bifurcated from the host instrument if (i) the embedded feature is not clearly and closely related to the host contract and (ii) the embedded feature, if considered a freestanding instrument, meets the definition of a derivative. Embedded derivatives are reported on the condensed consolidated balance sheets at their estimated fair values. Contingent consideration related to asset acquisitions that meet the definition of an embedded derivative is classified as contingent consideration on the condensed consolidated balance sheets. Any change in estimated fair values, as determined at each measurement period, are recorded in the condensed consolidated statements of operations based on the nature of the related contingencies.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair values of embedded derivatives related to the achievement of various development milestones for product candidates are recorded within research and development expense. Otherwise, changes in fair values are recorded within other income (expense), net.</span><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div><ix:nonNumeric id="F_490031e3-c37c-4cc6-8f24-52f0bea4cce9" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:8.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:24.5pt;text-indent:-18.0pt;padding-left:18.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;	</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level&#160;1: Inputs which include quoted prices in active markets for identical assets and liabilities.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:24.5pt;text-indent:-18.0pt;padding-left:18.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;	</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level&#160;2: Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:24.5pt;text-indent:-18.0pt;padding-left:18.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#xf0b7;	</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level&#160;3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Unaudited Condensed Consolidated Financial Statements</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The carrying amounts of the Company&#x2019;s financial instruments, including accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c7fb710c-9a15-4753-80ce-33d4761ec5f7" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock" escape="true" continuedAt="F_c7fb710c-9a15-4753-80ce-33d4761ec5f7_1"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables summarize the Company&#x2019;s Level 1 and Level 2 financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.806%;"></td>
        <td style="width:1.083%;"></td>
        <td style="width:9.963%;"></td>
        <td style="width:1.083%;"></td>
        <td style="width:1.037%;"></td>
        <td style="width:7.917%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.083%;"></td>
        <td style="width:1.037%;"></td>
        <td style="width:7.917%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.083%;"></td>
        <td style="width:1.037%;"></td>
        <td style="width:7.917%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.083%;"></td>
        <td style="width:1.037%;"></td>
        <td style="width:7.917%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">June&#160;30, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Valuation<br />Hierarchy</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br />Unrealized<br />Holding<br />Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br />Unrealized<br />Holding<br />Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br />Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span><span style="color:rgba(0,0,0,1);top:-4.6899999999999995pt;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_56109b05-5ebc-4f11-b821-ed99759c2371" contextRef="C_93449051-f049-49fc-bbdb-95aeef0d2e9a" name="vir:FinancialAssetsAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">739,286</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6773aded-723c-495c-83b9-6854a1396b26" contextRef="C_93449051-f049-49fc-bbdb-95aeef0d2e9a" name="vir:FinancialAssetsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">739,286</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Bank time deposits</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d8c1597d-c0ec-49aa-9a3e-f0cb08857084" contextRef="C_0df1d4d3-33f9-423e-ba29-51df45853b5a" name="vir:FinancialAssetsAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_25655252-b2ca-4d40-be97-5ce334ef0fe8" contextRef="C_0df1d4d3-33f9-423e-ba29-51df45853b5a" name="vir:FinancialAssetsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government treasuries</span><span style="color:rgba(0,0,0,1);top:-4.6899999999999995pt;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e1d45d63-d79c-4ab1-8c89-4be796dbbcd7" contextRef="C_c95fa8bf-5f9a-4eec-9c84-72c03b21861f" name="vir:FinancialAssetsAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">129,786</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_27166cde-7091-4715-bef5-9da941265164" contextRef="C_c95fa8bf-5f9a-4eec-9c84-72c03b21861f" name="vir:FinancialAssetsGrossUnrealizedHoldingGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bd6a27fd-8bca-4f9b-b2b4-7aca9663363e" contextRef="C_c95fa8bf-5f9a-4eec-9c84-72c03b21861f" name="vir:FinancialAssetsGrossUnrealizedHoldingLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bbaff870-ba24-4b6f-84f4-7aa037d1f56c" contextRef="C_c95fa8bf-5f9a-4eec-9c84-72c03b21861f" name="vir:FinancialAssetsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">129,787</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total financial assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d0446052-87fe-4303-a2e9-68d6a2824f31" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="vir:FinancialAssetsAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">874,072</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a9376c8b-9928-4b15-a97b-cd1493ac9aee" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="vir:FinancialAssetsGrossUnrealizedHoldingGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d128886a-4482-44ed-814b-caa53d97813e" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="vir:FinancialAssetsGrossUnrealizedHoldingLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d256fab2-b668-4efc-be33-94c364dde756" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="vir:FinancialAssetsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">874,073</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:5.5in;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:-13.5pt;padding-left:13.5pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(1)	</span><ix:footnote id="FNT_d3053df8-07d3-47e7-a42a-fa71bc831f41" xml:lang="en-US"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Includes </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span><span style="font-size:8.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_341fa000-8a0a-45a2-9676-a4a39b5671b1" contextRef="C_93449051-f049-49fc-bbdb-95aeef0d2e9a" name="us-gaap:RestrictedCashEquivalents" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> million</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> of restricted cash equivalents.</span></ix:footnote></p><p style="text-indent:-13.5pt;padding-left:13.5pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(2)	</span><ix:footnote id="FNT_d9b30841-09a6-45ce-abe3-d841782efe16" xml:lang="en-US"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Includes $</span><span style="font-size:8.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d68c8b22-8d0a-4652-8d2f-00783938b0ac" contextRef="C_c95fa8bf-5f9a-4eec-9c84-72c03b21861f" name="us-gaap:LongTermInvestments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.7</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> million classified as long-term investments.</span></ix:footnote></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.769%;"></td>
        <td style="width:1.083%;"></td>
        <td style="width:9.954%;"></td>
        <td style="width:1.083%;"></td>
        <td style="width:1.037%;"></td>
        <td style="width:7.907%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.083%;"></td>
        <td style="width:1.037%;"></td>
        <td style="width:7.907%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.083%;"></td>
        <td style="width:1.037%;"></td>
        <td style="width:7.907%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.083%;"></td>
        <td style="width:1.037%;"></td>
        <td style="width:7.991%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Valuation<br />Hierarchy</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br />Unrealized<br />Holding<br />Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br />Unrealized<br />Holding<br />Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br />Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span><span style="color:rgba(0,0,0,1);top:-4.6899999999999995pt;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Level 1</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5b0ce1b2-dad8-4280-9da4-923155a0d87d" contextRef="C_a5f22e22-a17d-48d9-87ec-0cc77e37762d" name="vir:FinancialAssetsAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">421,835</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a30731d5-b26d-4d84-aaf8-d60f6fae99ba" contextRef="C_a5f22e22-a17d-48d9-87ec-0cc77e37762d" name="vir:FinancialAssetsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">421,835</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government treasuries</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Level 2</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4bdb1be1-61fe-419a-a0fb-9efef2064aa7" contextRef="C_503f5c65-589f-45e0-a4cb-0b480e0d8198" name="vir:FinancialAssetsAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">300,201</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5a5a5a9e-44a9-448f-b474-9427559a097b" contextRef="C_503f5c65-589f-45e0-a4cb-0b480e0d8198" name="vir:FinancialAssetsGrossUnrealizedHoldingGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">91</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e2fcabb4-a74f-44a2-a78e-44981a645e84" contextRef="C_503f5c65-589f-45e0-a4cb-0b480e0d8198" name="vir:FinancialAssetsGrossUnrealizedHoldingLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_62003c5b-98d0-4646-9c2c-37babd12343d" contextRef="C_503f5c65-589f-45e0-a4cb-0b480e0d8198" name="vir:FinancialAssetsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">300,286</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total financial assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_18cdab36-d4e5-43c5-b7db-4b144a08f0ae" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="vir:FinancialAssetsAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">722,036</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c28791e4-69f2-4cbe-ac0c-72839651d1f2" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="vir:FinancialAssetsGrossUnrealizedHoldingGains" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">91</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a952460e-2f80-4a8c-a9a0-922da2613f72" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="vir:FinancialAssetsGrossUnrealizedHoldingLosses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_34bd542a-b913-4dff-a48f-1ec9325a82a1" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="vir:FinancialAssetsFairValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">722,121</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:-13.5pt;padding-left:13.5pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_c7fb710c-9a15-4753-80ce-33d4761ec5f7_1"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(1)	</span><ix:footnote id="FNT_e1cbc8b4-2fd4-49ea-849b-b5db014aa101" xml:lang="en-US"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Includes $</span><span style="font-size:8.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dcd1ca55-e6bd-4725-bf17-df78ae4cae08" contextRef="C_a5f22e22-a17d-48d9-87ec-0cc77e37762d" name="us-gaap:RestrictedCashEquivalents" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.9</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;million of restricted cash equivalents.</span></ix:footnote></ix:continuation></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:-13.5pt;padding-left:13.5pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">	 </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued interest receivable excluded from both the fair value and amortized cost basis of the available-for-sale securities is presented within prepaid expenses and other current assets, and other assets in the condensed consolidated balance sheets, and amounted to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7993b6af-1aa9-4d95-8a20-945d6a216bfe" contextRef="C_5cba9a1a-7684-4b5b-9e26-eb24c2aeb651" name="us-gaap:InterestReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9cd5ecac-21aa-487b-893e-3dc20c4f7c0f" contextRef="C_d42ac1db-ea33-4759-bbf7-4fa64295c694" name="us-gaap:InterestReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June&#160;30, 2021</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and December 31, 2020, respectively. The Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d8dc962a-f70d-4e80-a052-5ba848d2f6ac" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:FinancingReceivableAccruedInterestWriteoff" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen"><ix:nonFraction id="F_c1e03ab9-d79c-4c1e-b165-52c11a44c65d" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:FinancingReceivableAccruedInterestWriteoff" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t write off any accrued interest receivable during the six months ended June 30, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of June&#160;30, 2021, there were no investments that have been in a continuous unrealized loss position for longer than 12 months. Total net unrealized gains recorded in accumulated other comprehensive income (loss) were immaterial at June&#160;30, 2021. All investments with gross unrealized losses as of June 30, 2021 have been in a loss position for less than 12 months and were temporary in nature. The Company currently does not intend, and it is highly unlikely that it will be required to sell these securities before recovery of their amortized cost basis. As of June&#160;30, 2021</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, no securities have contractual maturities of longer than</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad680609-2c31-4ffc-be09-d73962caf992" contextRef="C_7073499b-8aca-4a83-ae2c-8686d7874fe9" name="us-gaap:DebtSecuritiesAvailableForSaleTerm" format="ixt-sec:durwordsen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> two years</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3 liabilities consist of contingent consideration as of June&#160;30, 2021 and December 31, 2020.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingent Consideration</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contingent consideration includes potential milestone payments in connection with the acquisitions of Humabs Biomed SA (&#x201c;Humabs&#x201d;) and TomegaVax, Inc. (&#x201c;TomegaVax&#x201d;). See further discussion in Note 4&#x2014;Acquisitions.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">estimated fair value of the contingent consideration related to the Humabs acquisition was determined by calculating the probability-weighted clinical, regulatory and commercial milestone payments based on the assessment of the likelihood and estimated</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Unaudited Condensed Consolidated Financial Statements</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">timing </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">that certain milestones would be achieved. </span><span><ix:nonNumeric id="F_44606458-4835-4e14-83e1-afd53b9a1399" contextRef="C_2aa1b8d8-ce49-419f-80ad-d249064f51e3" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" escape="true" continuedAt="F_44606458-4835-4e14-83e1-afd53b9a1399_1"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June&#160;30, 2021, the Company calculated the estimated fair value of the clinical and regulatory milestones using the following significant unobservable inputs: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:continuation id="F_44606458-4835-4e14-83e1-afd53b9a1399_1"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.062%;"></td>
        <td style="width:2.562%;"></td>
        <td style="width:32.377%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unobservable input</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Range<br />(Weighted-Average)</span><span style="color:rgba(0,0,0,1);top:-3.752pt;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;">1</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discount rates</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eedf6555-c570-477d-8f16-8cdd93f9b39b" contextRef="C_f7017d66-420f-462d-adcf-f3fb86e73c23" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dfeb5c11-f6ec-465e-a911-219ce65c2da1" contextRef="C_8a64e883-900d-492a-b0a8-528b6645aa64" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">8</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% (</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9c009c67-e6f6-4098-8951-601312e1939e" contextRef="C_d0832ce6-8218-4bd2-a0a0-9ac172d5777a" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Probability of achievement</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a0a30f24-aca0-4941-9090-570e22369935" contextRef="C_943aaa7d-bd8e-4ac3-a401-aaa53e6c2044" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">21</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_00c871dd-ddfa-4fa3-8f32-e1ee2e31543e" contextRef="C_6a378198-8973-420d-8130-5f606a6b57c5" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">76</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% (</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb4b78ac-feb8-4c7b-915d-f82d5be6e70c" contextRef="C_7fcc913c-909b-4375-aabd-561f445a0b0f" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">62</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
       </tr>
      </table><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="margin-left:5.000000000000004E-4in;display:flex;margin-top:0.0pt;line-height:1.2620833333333334;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.1875in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.1875in;">(1)</span><div style="display:inline;"><ix:footnote id="FNT_29cb2c38-3c6e-43b9-9519-fa69c33f0bf5" xml:lang="en-US"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Unobservable inputs were weighted based on the relative fair value of the clinical and regulatory milestone payments.</span></ix:footnote><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></div></div></ix:continuation></div><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the commercial milestones, the Company used a Monte Carlo simulation because of the availability of a discrete revenue forecast and the increased likelihood that the clinical trials would commence. </span><span style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_09359b81-1c1a-4cdd-80fc-b3b1ae55f730" contextRef="C_ea616198-c6e1-442a-bb05-ddf05a1b5bc8" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" escape="true" continuedAt="F_09359b81-1c1a-4cdd-80fc-b3b1ae55f730_1"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June&#160;30, 2021, the Monte Carlo simulation assumed a commercial product launch and associated discrete revenue forecast, as well as the following significant unobservable inputs: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:continuation id="F_09359b81-1c1a-4cdd-80fc-b3b1ae55f730_1" continuedAt="F_09359b81-1c1a-4cdd-80fc-b3b1ae55f730_2"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.062%;"></td>
        <td style="width:2.562%;"></td>
        <td style="width:32.377%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unobservable input</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value or Range<br />(Weighted-Average)</span><span style="color:rgba(0,0,0,1);top:-3.752pt;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;">1</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Volatility</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3fc0effe-077a-457b-be78-cd81563ae0e9" contextRef="C_8482726a-4650-4001-aa57-337a908bb4ee" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">60</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discount rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_daff6193-bbf4-476a-9d8a-157d74ee8503" contextRef="C_ec0ee7d1-1e16-4d9f-82e9-4d32b4f67282" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">11</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Probability of achievement</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_860b67b2-83e8-45e4-a820-8df4f2b81016" contextRef="C_4e1a0849-5b76-49b5-9f9a-4c78c1961b02" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">21</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a9ff057e-0024-4020-9739-bf0e4099abee" contextRef="C_c6864edf-79da-4827-8feb-994154b4369a" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">76</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% (</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3584cc21-6d37-4ef6-87ac-6540b38c433d" contextRef="C_b3b3b775-48e3-4d0e-8077-eeeff976fb8e" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">66</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
       </tr>
      </table><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></ix:continuation></div><div style="margin-left:5.000000000000004E-4in;display:flex;margin-top:0.0pt;line-height:1.2620833333333334;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.1875in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.1875in;">(1)</span><div style="display:inline;"><span><ix:continuation id="F_09359b81-1c1a-4cdd-80fc-b3b1ae55f730_2"><ix:footnote id="FNT_58e4891f-39b5-45d1-8dc4-f916fec2ed20" xml:lang="en-US"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Unobservable inputs were weighted based on the relative fair value of the commercial milestone payments.</span></ix:footnote></ix:continuation></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></div></div><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The discount rate captures the credit risk associated with the payment of the contingent consideration when earned and due. As of June&#160;30, 2021 and December&#160;31, 2020</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the estimated fair value of the contingent consideration related to the Humabs acquisition was $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6486320d-6edc-411e-a7a2-563a87e28f02" contextRef="C_f54bf625-9153-4033-9112-6b27a3bd3803" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">62.5</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7b7437be-3789-4096-b51b-64190a6309fa" contextRef="C_7a088139-2add-4c37-8158-c3dc9538d2fe" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">29.2</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, with changes in the estimated fair value recorded in research and development expense in the condensed consolidated statements of operations.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated fair value of the contingent consideration related to the TomegaVax acquisition was determined by using a Monte Carlo simulation model which included estimates of both the probability and timing to achieve the required per-share price of the Company&#x2019;s common stock, and incorporates assumptions as to expected volatility and discount rate. The discount rate captures the credit risk associated with the payment of the contingent consideration when earned and due. Although the TomegaVax acquisition was accounted for as an asset acquisition, such contingent consideration met the definition of an embedded derivative financial instrument. In February 2021, the Company achieved one of the milestones related to a specified per-share price of its common stock resulting in a $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_869a7a0a-f8c4-4221-b67e-f7b09cd64920" contextRef="C_782d1920-e03d-4185-85d4-a0abdc3fe2bc" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million payable to the former TomegaVax&#x2019;s stockholders which was paid out in July 2021. </span><span style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_215deb6b-ad56-4b6d-834a-89e4dec3baba" contextRef="C_f678eb79-9e2a-44ae-9e54-e1a433974f29" name="us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" escape="true" continuedAt="F_215deb6b-ad56-4b6d-834a-89e4dec3baba_1"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June&#160;30, 2021, the fair value of the remaining contingent consideration was estimated using the following significant unobservable inputs:</span></ix:nonNumeric></span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:continuation id="F_215deb6b-ad56-4b6d-834a-89e4dec3baba_1"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.062%;"></td>
        <td style="width:2.562%;"></td>
        <td style="width:32.377%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unobservable input</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value or Range<br />(Weighted-Average)</span><span style="color:rgba(0,0,0,1);top:-3.752pt;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;">1</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_27fda7ed-591d-4518-af47-9f573ab1e5ce" contextRef="C_f8e1feaf-38cf-4eb8-be71-a6d9ca4cc72d" name="us-gaap:EmbeddedDerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">95</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discount rates</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_18a16493-faf3-428a-b4fb-7c6f1cc4f093" contextRef="C_1f8aa1e7-f35e-48bb-afdc-73dd30c26626" name="us-gaap:EmbeddedDerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e80ccab1-add9-4c97-91bd-79f96dd448ef" contextRef="C_61e10aad-3a2a-4489-b640-a9768ebb4c27" name="us-gaap:EmbeddedDerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% (</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e373577-f4ac-45f8-9fe7-66848eeef012" contextRef="C_20e142d1-b753-47f7-9ab1-dd536e70a74d" name="us-gaap:EmbeddedDerivativeLiabilityMeasurementInput" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
       </tr>
      </table><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="margin-left:5.000000000000004E-4in;display:flex;margin-top:0.0pt;line-height:1.2620833333333334;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.1875in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.1875in;">(1)</span><div style="display:inline;"><ix:footnote id="FNT_975f8be1-254b-40dd-96db-8cb78836fecf" xml:lang="en-US"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Unobservable inputs were weighted based on the relative fair value of the underlying milestones. </span></ix:footnote></div></div></ix:continuation></div><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of June&#160;30, 2021 and December&#160;31, 2020</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the estimated fair value of the contingent consideration related to the TomegaVax acquisition was $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_71c9ff3f-ae7f-4497-8539-7eb4cf98d9b0" contextRef="C_d67bc640-0ce6-494e-ad6f-32b76b35dc04" name="vir:AssetAcquisitionContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.4</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aa13f9bf-0bf3-4c69-bf16-a589d5a8769a" contextRef="C_492c3181-e320-4bbf-9047-04048449d863" name="vir:AssetAcquisitionContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.8</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, with changes in the estimated fair value recorded in other income (expense), net in the condensed consolidated statements of operations.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated fair value of the contingent consideration related to the Humabs and TomegaVax acquisitions involves significant estimates and assumptions which give rise to measurement uncertainty.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Unaudited Condensed Consolidated Financial Statements</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_399c5229-84c2-45c6-8cfd-234d2841c2fc" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" escape="true"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the changes in the estimated fair value of the Company&#x2019;s Level&#160;3 financial liabilities (in thousands):</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.563%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:1.25%;"></td>
        <td style="width:19.942%;"></td>
        <td style="width:0.995%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Contingent<br />Consideration</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0b1d2899-3aab-4bff-bdc6-4447c22c82b4" contextRef="C_8d26edc6-7745-4758-988b-eb4ba800efed" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,974</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair value recognized in research and development expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_94dfd76e-01a4-4902-9a37-7c808931c835" contextRef="C_53ccc202-bb29-4485-bc6c-689015df256e" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">33,300</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair value recognized in other income (expense), net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_175db0b0-ebc8-4a9b-bc68-1ed998518903" contextRef="C_6d69c128-4e88-4988-9333-0cfb938c1233" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,618</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reclassification of contingent consideration to accrued liabilities upon <br />&#160;&#160;achievement of milestone</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5eceb5bd-b911-428d-a9d4-83add358890f" contextRef="C_95a77a5d-c658-44c7-bb81-77f5350143bd" name="vir:FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">10,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at June 30, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9def618c-b995-4e1a-b3a4-a8c3ab02a5f9" contextRef="C_50d30b84-60dd-41c6-9dc3-a2fcb990166c" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68,892</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2535cd7d-9993-4cb7-9c26-2658f3e26700" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:BusinessCombinationDisclosureTextBlock" escape="true" continuedAt="F_2535cd7d-9993-4cb7-9c26-2658f3e26700_1"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Acquisitions</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Acquisition of TomegaVax</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2016, the Company entered into an agreement and plan of merger (&#x201c;TomegaVax Merger Agreement&#x201d;) to acquire all of the equity interests of TomegaVax. The primary asset purchased in the acquisition was an in-process cytomegalovirus vector-based vaccine platform for use in HBV, HIV, and tuberculosis. The acquisition was accounted for as an asset purchase.  &#160;&#160;&#160;&#160;</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the entry into the TomegaVax Merger Agreement, the Company also entered into a letter agreement with TomegaVax (the &#x201c;TomegaVax Letter Agreement&#x201d;), which provides for certain payments to TomegaVax&#x2019;s former stockholders before September 2024, in each case so long as the Company is continuing to pursue the development of the TomegaVax technology. Under the terms of the TomegaVax Letter Agreement, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_18d07983-c2e5-4383-821e-304c16eb2629" contextRef="C_4ba8283a-0045-486b-80d8-2e80d28e4574" name="vir:MilestonePaymentsRelatedTermsDescription"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Company will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_97f10471-4c79-4715-9e00-93ed1d122bb4" contextRef="C_28568052-9082-41a4-83b2-60aaae0ee1be" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million if the per-share price of the Company&#x2019;s publicly traded common stock, or implied price per share of the Company&#x2019;s Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_60ee73e1-9533-4913-aa3a-bbc044ba52bb" contextRef="C_6fc26d34-68e7-4c09-8e67-4e2b004cdc10" name="vir:MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" unitRef="U_USDollarShare" decimals="INF">45</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and/or the stage of the Company&#x2019;s clinical development at the time of the relevant event triggering the payment.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The share price of the Company&#x2019;s publicly traded common stock will be determined using the average of the daily volume-weighted average trading price of the Company&#x2019;s common stock for each trading day during a consecutive 90-day period. The foregoing payments are payable (i) during any date after the completion of an initial public offering by the Company or any successor or affiliate controlling the TomegaVax technology, provided that no payment will be due before the first anniversary of the initial public offering, (ii) upon the sale of all assets related to the TomegaVax technology or (iii) upon a merger or stock sale of the Company or any successor or affiliate controlling the TomegaVax technology, in each case subject to certain conditions with respect to the timing of the payments. The payments under the TomegaVax Letter Agreement can be made in cash or shares of the Company&#x2019;s common stock, at the discretion of the Company&#x2019;s board of directors.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2021, the Company achieved </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bbf42b0c-284c-4d28-96da-0b36982a78c0" contextRef="C_ec6ee7cb-4c4f-4392-b06d-b2cc4c6ba486" name="vir:BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" unitRef="U_Milestone" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the milestones related to the specified per-share price of its common stock, which resulted in a $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_099dbb82-775d-425b-9a71-3a5df69fb6ca" contextRef="C_bc5714bf-f943-475e-bcd8-0aa08e910f85" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million payable to TomegaVax&#x2019;s former stockholders. In July 2021, the Company made the milestone payment to the former TomegaVax stockholders through a combination of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d27e7e9-b2a1-4d1d-96b0-b31ed82c04de" contextRef="C_93f053bf-00d2-4957-b2e8-a0580ba1a1ee" name="vir:PaymentMadeForBusinessCombinationMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.1</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million cash payment and issuance of </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f24f3fc3-474c-4041-9b81-58d522f17a8b" contextRef="C_93f053bf-00d2-4957-b2e8-a0580ba1a1ee" name="vir:CommonStockSharesIssuedForMilestonePaymentShares" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">42,737</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock with a total fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_33839bb7-d9a6-4b38-9c34-57a75e20c4cc" contextRef="C_93f053bf-00d2-4957-b2e8-a0580ba1a1ee" name="vir:ValueOfCommonStockSharesIssuedForMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.9</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The remaining milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_be8c14b3-be88-46b6-b8b4-4f302e478eb1" contextRef="C_4e33744e-999f-4346-9f7e-415731786c7b" name="vir:RemainingPaymentMadeForBusinessCombinationMilestone" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate will be triggered if (i) the per-share price of the Company&#x2019;s publicly traded common stock is at least $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3947ba33-0dd1-465a-932d-66196d87bf88" contextRef="C_59766912-8729-44fa-8223-2711163a2f37" name="vir:MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" unitRef="U_USDollarShare" decimals="INF">45</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (as adjusted in the case of any stock dividend, stock split or other similar recapitalization) and upon the achievement of a certain milestone related to the stage of the Company&#x2019;s clinical development at the time of the relevant event triggering the payment&#160;and/or (ii) the per-share price of the Company&#x2019;s publicly traded common stock is at least $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_74e40ae1-cc0b-4121-98be-0e33c841adba" contextRef="C_31d70583-f863-4f52-9c17-5d19f672cbae" name="vir:MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" unitRef="U_USDollarShare" decimals="INF">90</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (as adjusted in the case of any stock dividend, stock split or other similar recapitalization).&#160;</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determined that the future milestone payments contain net settlement provisions and therefore, they were required to be accounted for as embedded derivatives under the relevant accounting guidance. As of June&#160;30, 2021</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the estimated fair value of the embedded derivative was $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_12c1c551-5b4b-4fc5-8bc4-b0755c70461e" contextRef="C_75ead0cb-5540-4c8d-9421-64e16f11ecda" name="us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">6.4</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Acquisition of Humabs</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2017, the Company acquired all of the outstanding equity of Humabs, a private Swiss company which discovers and develops monoclonal antibodies (&#x201c;mAbs&#x201d;) derived from individuals whose immune systems have successfully responded to major diseases. The Company acquired all of Humabs&#x2019; rights, title and interest in and to substantially all of the assets of Humabs except for rights under certain license agreements with third parties. The Company is obligated to pass-through to the former Humabs shareholders any amounts received by Humabs under such license agreements, net of any program expenses. The transaction was accounted for as an acquisition of a business. In addition to the cash payment and issuance of common stock to the former Humabs shareholders at the acquisition date, the Company also agreed to pay additional amounts in cash upon the achievement of specified milestone events: (i) up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ad07700c-2792-46b2-b91f-ce1ddfa24bf5" contextRef="C_d8c8927a-29a9-44cd-b032-581051ff30bf" name="vir:BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">135.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">upon the achievement of clinical, regulatory and commercial milestones for an HBV</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Unaudited Condensed Consolidated Financial Statements</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product; </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and (ii) up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d7db4be3-4ccf-4355-998e-cc9b6ca07027" contextRef="C_d2c8c218-592c-4345-a42f-8c7f3cefb5aa" name="vir:BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">105.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the achievement of clinical, regulatory and commercial milestones for another product, which the Company elected as a SARS-CoV-2 product.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2020, the Company achieved </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_88845b70-bb12-48a3-ad1a-12f80cfc341b" contextRef="C_ff3535ee-1915-4fab-bcf7-801568ea00ac" name="vir:BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" unitRef="U_Milestone" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_82d27fb1-8aec-4c22-9473-aef36afa7435" contextRef="C_bbedea33-e0d1-40dc-8d3b-acfc0f01d81c" name="vir:BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" unitRef="U_Milestone" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the specified clinical milestones for the HBV product. As such, the Company paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_679867e0-f37b-42ab-8b29-fa63787b94d0" contextRef="C_ff3535ee-1915-4fab-bcf7-801568ea00ac" name="vir:SpecifiedClinicalDevelopmentMilestonesPayment" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to this milestone event in June 2020. In October 2020, the Company achieved another specified clinical milestone for the SARS-CoV-2 product and paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c17fae5f-d3b0-4bd5-9263-7383a90b6711" contextRef="C_bbedea33-e0d1-40dc-8d3b-acfc0f01d81c" name="vir:SpecifiedClinicalDevelopmentMilestonesPayment" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to this milestone event. The estimated fair value of the remaining contingent consideration was $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1b82652-4df9-4395-ae9a-49d6bf1ec792" contextRef="C_1e5484c7-876b-4630-8566-d2b6146b4e47" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">62.5</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June&#160;30, 2021.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Acquisition of Agenovir</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2018, the Company entered into an agreement and plan of merger with Agenovir Corporation (&#x201c;Agenovir&#x201d;), under which the Company purchased all equity interests of Agenovir. The primary assets purchased in the acquisition were in-process research and development programs in human papillomavirus and HBV using CRISPR/Cas9. The acquisition was accounted for as an asset purchase.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the acquisition date, the Company paid cash and issued shares of Series A-2 convertible preferred stock to the former Agenovir stockholders. During a specified period following the closing of the Agenovir acquisition, the Company will be required to pay Agenovir&#x2019;s former stockholders up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8323c232-05cb-43df-9f15-8b943a3df663" contextRef="C_4df49172-31b6-455e-a6d9-ebce7871f7da" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">135.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate for the achievement of specified development, regulatory and commercial milestones for the first HBV product.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_2535cd7d-9993-4cb7-9c26-2658f3e26700_1"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_37be6e1f-c919-4bf3-b891-fbb035643a1c" contextRef="C_a7eab319-293e-4b73-85e4-92da414f023c" name="vir:BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" unitRef="U_Milestone" decimals="INF" format="ixt-sec:numwordsen">None</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the milestones have been achieved as of </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June&#160;30, 2021</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, therefore </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e903d186-e854-4f09-a1a8-a3a27e26fc6c" contextRef="C_20097cda-ecaf-4c10-976d-a846aa4a6d9b" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> amounts were recognized relating to the contingent consideration.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eb3772a6-b070-4eba-8770-b0d4a284dbd9" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="vir:GrantAgreementsDisclosureTextBlock" escape="true" continuedAt="F_eb3772a6-b070-4eba-8770-b0d4a284dbd9_1"><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5.	Grant Agreements</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Bill&#160;&amp; Melinda Gates Foundation Grants</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Human Immunodeficiency Virus (&#x201c;HIV&#x201d;) Grant</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On January&#160;26, 2018, the Company entered into a grant agreement with the Bill&#160;&amp; Melinda Gates Foundation under which it was awarded a grant totaling up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c321077a-0bf1-4daa-a853-d70387396225" contextRef="C_b64fcbdc-5a21-4b8c-8ac7-983b9bfe2eb4" name="vir:GrantAwardedAmountMaximum" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">12.2</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million for its HIV program (the &#x201c;HIV Grant&#x201d;). In February 2020, the parties amended the HIV Grant under which the Company was awarded a supplemental grant of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_794938aa-ad4b-4dea-9406-302e29374f0c" contextRef="C_cd7a1755-2831-46df-a378-33b1c1bbe888" name="vir:GrantAwardedAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">8.6</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. In June 2021, the parties further amended the agreement under which the grant term was extended from December 31, 2021 to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6a95122c-cf5d-4298-a66e-d68e2d2c74d4" contextRef="C_325ad0aa-a95c-4661-a917-fc337e70902e" name="vir:GrantAgreementAmendedExpirationDate" format="ixt:datemonthdayyearen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">October 31, 2022</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, unless earlier terminated by the Bill&#160;&amp; Melinda Gates Foundation for the Company&#x2019;s breach, failure to progress the funded project, in the event of the Company&#x2019;s change of control, change in the Company&#x2019;s tax status, or significant changes in the Company&#x2019;s leadership that the Bill&#160;&amp; Melinda Gates Foundation reasonably believes may threaten the success of the project.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments received in advance that are related to future research activities are deferred and recognized as revenue when the donor-imposed conditions are met, which is as the research and development activities are performed. The Company recognized grant revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a8c729d7-b5a4-495e-a020-a8a4a5eab26a" contextRef="C_a077a0ad-b848-485c-96a1-3489ae549b2f" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fce8a32b-f128-44ea-841c-c0400b0607d0" contextRef="C_cd460f41-06b3-4477-9de5-9e78e41bc13e" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three months ended June&#160;30, 2021 and 2020</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_87c5bdfc-d629-4ef3-8729-4fdd2dbb7b57" contextRef="C_66892b6e-71bf-4e32-a6ae-3770380bc675" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.6</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7e1e6168-bfdd-472b-8a39-94595d833799" contextRef="C_69fd0161-00a7-47b8-8f7e-c649aad213a7" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.4</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">six months ended June&#160;30, 2021 and 2020</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively. As of June 30, 2021 and December 31, 2020, the Company has deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c887b3f5-6009-488e-8280-11a6b78d22e7" contextRef="C_3943c51c-7e55-4e41-b9e4-df3e298c1f39" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.7</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d7a77758-6df0-4b5d-add7-546b46c16ca5" contextRef="C_3b639fc9-2f14-4483-9c0f-de032ca38766" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.8</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, under this grant agreement.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Tuberculosis (&#x201c;TB&#x201d;) Grant</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March&#160;16, 2018, the Company entered into a grant agreement with the Bill&#160;&amp; Melinda Gates Foundation under which it was awarded a grant totaling up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0f0dbfdd-68d8-4fbc-be9c-ff12b467ee04" contextRef="C_6d87011b-3e4c-46db-bad8-0f23e0dcc637" name="vir:GrantAwardedAmountMaximum" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">14.9</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million for its TB program (the &#x201c;TB Grant&#x201d;). The parties amended the agreement in June 2021 under which the grant term was extended from February 28, 2021 to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_27d03d85-2d7b-4da1-884c-c908a06fd897" contextRef="C_c37af972-2bf8-4eff-9bc7-4763e2ab45d0" name="vir:GrantAgreementAmendedExpirationDate" format="ixt:datemonthdayyearen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 31, 2022</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, unless earlier terminated by the Bill&#160;&amp; Melinda Gates Foundation for the Company&#x2019;s breach, failure to progress the funded project, in the event of the Company&#x2019;s change of control, change in the Company&#x2019;s tax status, or significant changes in the Company&#x2019;s leadership that the Bill&#160;&amp; Melinda Gates Foundation reasonably believes may threaten the success of the project. As of June&#160;30, 2021</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_85788bc8-60cc-47c5-bed1-94cff3f7e0d2" contextRef="C_fd53f66c-e257-4732-8340-be571f9ac325" name="vir:UnusedFundsReceivedInAdvance" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of unused funds received in advance and previously recorded as deferred revenue within accrued and other liabilities. </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of June 30, 2021 and December 31, 2020, the Company has deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0a7db4f1-8865-46df-88da-315ca31ed1bb" contextRef="C_26c131f2-0874-4ae2-9e57-8f39b5db6f09" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f5379bb-042c-4983-8a5b-bbefadcdc76a" contextRef="C_eca11749-bb55-4f33-bd21-2d25c913415b" name="us-gaap:ContractWithCustomerLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.6</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, under this grant agreement.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Unaudited Condensed Consolidated Financial Statements</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_eb3772a6-b070-4eba-8770-b0d4a284dbd9_1"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments received in advance that are related to future research activities are deferred and recognized as revenue when the donor-imposed conditions are met, which is as the research and development activities are performed. The Company recognized grant revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3522ec94-8df5-489f-bfc0-5e13c34541b5" contextRef="C_42a0066f-bcc3-4b1a-a379-4a993e12dcb9" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.1</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_20277aea-3c6b-459b-8e35-572945b17e43" contextRef="C_33d141a8-0bd8-4ec8-aaaf-e21290176a35" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">nil</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for the </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three months ended June&#160;30, 2021 and 2020</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f888f8f-fb65-42f7-b5c6-8c6910ddd3f4" contextRef="C_abdc6453-b0c7-4eaa-a85e-f7e083980647" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.8</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cd72c77f-e24b-4429-b267-bcf89d80a948" contextRef="C_237f8a0b-7ccb-4bfe-9900-7d13c307285b" name="us-gaap:RevenueNotFromContractWithCustomer" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">six months ended June&#160;30, 2021 and 2020</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ed42266b-b426-4410-ab53-79bc1cfa6d4d" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6.	Collaboration and License Agreements</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaboration Agreements with GSK</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2020 GSK Collaboration</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On June 9, 2020, the Company, Glaxo Wellcome UK Limited and Beecham S.A. (referred to&#160;</span><span style="color:rgba(35,31,32,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">individually and</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> together, as &#x201c;GSK&#x201d;) entered into a definitive collaboration agreement under the terms set forth in the preliminary collaboration agreement entered into by the Company and certain GSK entities in April 2020 (the &#x201c;2020 Preliminary Agreement&#x201d;) (such definitive collaboration agreement, the &#x201c;2020 GSK Agreement&#x201d;). Concurrently with the execution of the 2020 Preliminary Agreement, the Company entered into a stock purchase agreement (the &#x201c;2020 Stock Purchase Agreement&#x201d;) with Glaxo Group Limited (&#x201c;GGL&#x201d;), an affiliate of GSK, under which GGL purchased </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e9776ca1-436b-42c1-ac54-75771e60539e" contextRef="C_9fb0d2a0-3667-49a0-9e2e-0eb6e51eb0f2" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,626,027</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s common stock on April 29, 2020, at a price per share of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_290671cc-02df-4c49-8f0f-8fb5037cedb0" contextRef="C_99cf4f8f-4dae-413b-b3e0-c9a5646a7659" name="us-gaap:SharePrice" unitRef="U_USDollarShare" decimals="INF">37.73</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, for an aggregate purchase price of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8410b32c-bd05-49f9-951f-c2f9abf3ee90" contextRef="C_9fb0d2a0-3667-49a0-9e2e-0eb6e51eb0f2" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">250.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. After receipt of antitrust clearance on April 22, 2020, the Preliminary Agreement became effective as of April 29, 2020, which was also the closing date for the associated 2020 Stock Purchase Agreement between the parties (&#x201c;Effective Date&#x201d;). Under the terms of the 2020 GSK Agreement, the Company and GSK agreed to collaborate to research, develop and commercialize products for the prevention, treatment and prophylaxis of diseases caused by SARS-CoV-2, the virus that causes COVID-19, and potentially other coronaviruses. The collaboration is focused on the development and commercialization of three types of collaboration products under three programs: (1) antibodies targeting SARS-CoV-2, and potentially other coronaviruses (the &#x201c;Antibody Program&#x201d;); (2) vaccines targeting SARS-CoV-2, and potentially other coronaviruses (the &#x201c;Vaccine Program&#x201d;), and (3) products based on genome-wide CRISPR screening of host targets expressed in connection with exposure to SARS-CoV-2, and potentially other coronaviruses (the &#x201c;Functional Genomics Program&#x201d;).</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9213d111-f718-46ef-90f0-409fca6fb819" contextRef="C_de475ddf-8c37-4d7a-ad85-a7698299ec12" name="vir:NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" format="ixt-sec:durwordsen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four years</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> following the Effective Date, the parties will conduct certain research and development activities under mutually agreed development plans and associated budgets for each of the three programs, and under the oversight of a joint steering committee (&#x201c;JSC&#x201d;). The Company will be primarily responsible for the development and clinical manufacturing activities for the Antibody Program, and for conducting the initial development activities directed to a vaccine in the Vaccine Program. GSK will be primarily responsible for the commercialization activities for the Antibody Program (except in connection with sales of antibody products licensed to WuXi Biologics (Hong Kong) Limited in greater China), the later-stage development, manufacturing and commercialization activities for the Vaccine Program and the development, manufacturing and commercialization activities for the Functional Genomics Program. Subject to an opt-out mechanism, the parties will share all development costs, manufacturing costs and costs and expenses for the commercialization of the collaboration products, with the Company bearing </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d4ab55f0-6335-4118-871f-61b2dea051f6" contextRef="C_3b26811f-118d-4a95-ad64-0f8108301f7e" name="vir:PercentageOfDevelopmentCosts" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">72.5</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of such costs for the antibody products, </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e42d848-ea5f-4e87-8ee9-bc3a15f17919" contextRef="C_f9ac6857-461c-4a04-bd24-2ecc9ae4c36c" name="vir:PercentageOfDevelopmentCosts" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">27.5</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of such costs for the vaccine products, and equal sharing of such costs for the functional genomics products.</span></p><ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Unaudited Condensed Consolidated Financial Statements</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On a collaboration product-by-collaboration product basis, each party will have the one-time right, at specified points in development, to opt-out of its co-funding obligations, and the other party may, at its election, either pursue such program unilaterally, or also cease research and development activities and funding of such collaboration product. If the opt-out provisions are not exercised by either party subject to the terms of the 2020 GSK Agreement, the parties would share all profits and losses arising from any collaboration product in the same ratios in which the parties bore development costs for such collaboration program. For each collaboration product as to which a party exercises its opt-out right, the commercializing party will pay to the opt-out party royalties on net sales of the applicable collaboration product at rates based on factors such as the stage of development of such collaboration product at the time the opt-out party exercises such right, and whether the opt-out party is the lead party, or a portion of the sublicense revenue if the commercializing party chooses to sublicense or otherwise divest rights to such collaboration product. On an antibody product-by-antibody product basis, the Company has a co-promotion right for such antibody product in the United States, under which the Company will have the right to perform up to </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_74eef57c-9d17-44f3-801e-9e2fe39bfe2b" contextRef="C_de475ddf-8c37-4d7a-ad85-a7698299ec12" name="vir:MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">20</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of details in connection with such antibody product.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2020 GSK Agreement will remain in effect with respect to each collaboration program for as long as there is a collaboration product being developed or commercialized by the lead party, or the non-opt-out party, in such program. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7ca59415-87d8-42aa-92f1-fb7194ef45c5" contextRef="C_da489d47-65d8-4ebf-bb93-4ab4e0d479cc" name="vir:CollaborationAgreementTerminationDescription"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Either party has the right to terminate the 2020 GSK Agreement in the case of the insolvency of the other party, an uncured material breach of the other party with respect to a collaboration program or collaboration product, or as mutually agreed by the parties.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The 2020 GSK Agreement superseded and replaced the 2020 Preliminary Agreement between the parties.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considered the ASC 606 criteria for combining contracts and determined that the 2020 GSK Agreement and 2020 Stock Purchase Agreement should be combined into a single contract because they were negotiated and entered into in contemplation of one another. The fair market value of the common stock issued to GGL was $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0a745543-af22-4e11-a2fb-db062e0e8cba" contextRef="C_0e63f2d6-4f5f-4686-b5df-65f256ff2672" name="vir:FairMarketValueOfCommonStockIssued" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">206.7</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, based on the closing stock price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cfbcb13c-ff44-4ad5-b545-ca88246e70f0" contextRef="C_65199b01-efc8-4ecd-92f0-3fdb4dbb14b2" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_USDollarShare" scale="0" decimals="2">36.70</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on the date of execution of the 2020 Preliminary Agreement and 2020 Stock Purchase Agreement and taking into account a discount for the lack of marketability due to the restrictions in place on the underlying shares, resulting in a $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_be655130-e588-4682-b5a2-1e26d72491bc" contextRef="C_0e63f2d6-4f5f-4686-b5df-65f256ff2672" name="vir:PremiumReceivedOnSalePriceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">43.3</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million premium received by the Company.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounted for the common stock issued to GGL based on its fair market value on the transaction date and determined that the premium paid by GSK should be attributed to the transaction price of the 2020 GSK Agreement.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company concluded that the 2020 GSK Agreement contained </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c8160f87-7ae2-454e-8cc7-9fd6c2170257" contextRef="C_8f037847-06a9-43f3-aee1-9f0d4957157f" name="vir:CollaborationAgreementNumberOfUnitsOfAccount" unitRef="U_Unit" decimals="INF" format="ixt-sec:numwordsen">four</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> units of account: (i) the license granted to GSK under the Antibody Program (the &#x201c;Antibody License&#x201d;); (ii) the research and development activities (including clinical manufacturing) under the Antibody Program; (iii) the research and development activities under the Vaccine Program; and (iv) the research and development activities under the Functional Genomics Program. The Company considered the guidance in ASC 606 to determine which of these elements of the 2020 GSK Agreement are performance obligations with a customer. The Company determined that the Antibody License is within the scope of ASC 606 and accordingly, accounted for the Antibody License as a distinct performance obligation under ASC 606. The Antibody License is a functional intellectual property and is distinct from the associated research and development activities to be performed under the program due to its significant standalone functionality. All other elements of the 2020 GSK Agreement including the research and development activities, and participation in the JSC and subcommittees for each collaboration program were not determined to be distinct performance obligations with a customer.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The transaction price for the Antibody License at inception was determined to be $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8ad2b990-e882-4aa3-9eb7-4ce49a7abf20" contextRef="C_3b26811f-118d-4a95-ad64-0f8108301f7e" name="vir:AntibodyLicenseTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">43.3</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, representing the premium on the sale of common stock to GSK. The Company determined that GSK can benefit from the Antibody License at the time of grant and therefore, the related performance obligation is satisfied at a point in time. As such, the Company recognized the $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6abee3a-96d3-44c5-a432-95c92d9d8aa3" contextRef="C_2063058a-a5a7-4574-92c4-5fad668297f8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">43.3</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as contract revenue during the second quarter of 2020. Additionally, the Company is entitled to consideration from GSK related to profit and loss sharing arrangements (including royalties) contingent upon future sales of collaboration products under the Antibody Program.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The remaining units of account of the 2020 GSK Agreement were determined to be within the scope of ASC 808 as the Company and GSK are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on the commercial success of the activities of the arrangement. Furthermore, the Company and GSK participate in the commercial profit and loss sharing arrangement for each program commensurate with each party&#x2019;s cost-sharing responsibilities during research and development. Because ASC 808 does not provide recognition and measurement guidance, the Company determined that the guidance in ASC 730, Research and Development, was appropriate to analogize to, based on the nature of the cost-sharing provisions of the agreement. The Company has concluded that payments to or reimbursements from GSK related to these services will be accounted for as an increase to or reduction of research and development expenses, respectively. The Company also concluded that any payments from GSK related to the profit and loss sharing arrangement (including royalties) contingent upon the commercialization of the products under the Vaccine and Functional Genomics Programs will be analogized to ASC 606 and therefore, will be recognized when the related sales occur.</span></p><ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Unaudited Condensed Consolidated Financial Statements</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2021, the Company and GSK received an EUA for sotrovimab, the first collaboration product under the Antibody Program. As the lead party for all commercialization activities, GSK incurs all of the sales and marketing expenses and is the principal on sales transactions with third parties. As the Company is the agent under the agreement, the Company recognizes its contractual share of the profit sharing amounts or royalties (in case of an opt-out) as revenue, net of any cost of sales and allowable expenses (including distribution, selling and marketing expenses) in the period the sale occurs. During the three months ended June 30, 2021, the Company recorded its share of net profit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_15c94fd0-d358-42a1-bbfd-36b4e7eced9c" contextRef="C_b4f1dc34-56da-4847-88c1-d9bfde49f709" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.3</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as collaboration revenue in the condensed consolidated statement of operations.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs associated with co-development activities performed under the agreement are included in research and development expenses on the condensed consolidated statements of operations, with any reimbursement of costs by GSK reflected as a reduction of such expenses. Under the 2020 GSK Agreement, the Company recognized additional research and development expense of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d8cf98fc-b1e6-4ee4-a647-98f35f7d21ce" contextRef="C_eae8bb82-8872-4a24-ae26-c2e4d2dfb653" name="vir:IncreaseDecreaseInResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.9</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bd08179e-3f90-4f21-841e-b3d52fc33bca" contextRef="C_da489d47-65d8-4ebf-bb93-4ab4e0d479cc" name="vir:IncreaseDecreaseInResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">36.4</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during the </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three and six months ended June&#160;30, 2021</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively. The Company recognized a reduction of research and development expense of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c3cbc28d-00e3-4bca-8797-4217d559e5cb" contextRef="C_0f91c4ca-040c-431f-8606-3532fe5467a6" name="vir:ReductionOfResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_6aebb1f4-b94e-4e54-8769-fb83e738b560" contextRef="C_b649d3cd-def2-4c81-bc48-8799c56de0c7" name="vir:ReductionOfResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.8</ix:nonFraction></ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during the </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three and six months ended June&#160;30, 2020</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company has a payable to GSK of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d29271a7-00de-45ce-abbe-9288020da2e9" contextRef="C_9ae22d18-4ca6-4836-bd15-1b10932c9c7f" name="vir:PayableUnderAgreementCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.7</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8566e0be-5f46-42c3-968e-779e28786155" contextRef="C_89d302b2-5e08-4283-8a49-1c1dc6be912e" name="vir:PayableUnderAgreementCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">28.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million included in accrued and other liabilities as of </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June&#160;30, 2021 and December 31, 2020, respectively.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Expanded GSK Collaboration</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On February&#160;14, 2021, the Company and GSK entered into a binding preliminary collaboration agreement (the &#x201c;2021 Preliminary Agreement&#x201d;), under which the parties agreed to expand the 2020 GSK Agreement to collaborate on </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb626b74-2a01-4a1d-9a42-efb1b9658533" contextRef="C_02f60d12-f390-4dfe-ac4c-a065441e738a" name="vir:CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" unitRef="U_Program" decimals="INF" format="ixt-sec:numwordsen">three</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> separate programs: (1)&#160;a program to research, develop and commercialize mAbs for the prevention, treatment or prophylaxis of the influenza virus (the &#x201c;Influenza Program&#x201d;), excluding VIR-2482 unless GSK exercises its option as described below; (2) an expansion of the parties&#x2019; current Functional Genomics Program to focus on functional genomics screens directed to targets associated with respiratory viruses (the &#x201c;Expanded Functional Genomics Program&#x201d;); and (3)&#160;additional programs to develop neutralizing mAbs directed to up to three&#160;non-influenza&#160;target pathogens selected by GSK (the &#x201c;Selected Pathogens&#x201d; and such programs, the &#x201c;Additional Programs&#x201d;).</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Concurrently with the execution of the 2021 Preliminary Agreement, the Company entered into a stock purchase agreement (the &#x201c;2021 Stock Purchase Agreement&#x201d;) with GGL under which GGL agreed to purchase shares of the Company&#x2019;s common stock for an aggregate purchase price of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_30c224e7-f95e-4d5c-a53b-19b284cfddc2" contextRef="C_502695ad-a686-4d7f-9e55-303eb9e384b6" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">120.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The consummation of the transactions under each of the 2021 Preliminary Agreement and the 2021 Stock Purchase Agreement were subject to the satisfaction of customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, which expiration was effective on March 24, 2021. The 2021 Preliminary Agreement and 2021 Stock Purchase Agreement consummated on March 25, 2021, which the Company used as the measurement date for accounting purposes. On March 31, 2021, the Company closed the sale of </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_415c8348-887d-445a-9be7-5c3e41f89093" contextRef="C_e5e16aa4-a601-484e-b470-db2c156ea530" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,924,927</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock to GGL.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2021 Preliminary Agreement was superseded on May 18, 2021 upon execution of the definitive collaboration agreement (the &#x201c;2021 GSK Agreement&#x201d;, or collectively with the 2021 Preliminary Agreement, the &#x201c;2021 GSK Collaboration&#x201d;). The material terms of the 2021 GSK Agreement, including the promised goods and services, are discussed below and is consistent with those of the 2021 Preliminary Agreement.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the 2021 GSK Collaboration, the parties will conduct certain research and development activities under mutually agreed development plans and associated budgets for the programs within the expanded collaboration for a period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6fe4a76a-adef-4f34-a1f5-5cae2d67e86a" contextRef="C_8078c547-b260-434d-8ab2-1b0f12cd0d5f" name="vir:NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" format="ixt-sec:durwordsen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three years</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> following the effective date. Under the Influenza Program, the parties will collaborate to research, develop and commercialize mAbs for the prevention, treatment or prophylaxis of influenza, including the Company&#x2019;s influenza mAbs (with respect to VIR-2482, only if GSK exercises its option). The Company may conduct the development and clinical manufacturing activities for&#160;VIR-2482&#160;up to completion of a Phase 2 clinical trial. Provided that the Company conducts and completes a Phase 2 clinical trial for VIR-2482, GSK will have the exclusive option to obtain exclusive rights to&#160;co-develop&#160;and commercialize&#160;VIR-2482&#160;under the Influenza Program (the &#x201c;VIR-2482 Option&#x201d;). GSK will be the lead party for development, clinical and commercial manufacturing and commercialization activities for products under the Influenza Program (other than&#160;VIR-2482&#160;unless and until GSK exercises the VIR-2482 Option, if applicable). The parties will mutually agree upon the allocation of responsibility for development of products under the Expanded Functional Genomics Program, and for development and early-stage manufacturing of products under the Additional Programs if and when GSK decides which Selected Pathogens to pursue. GSK will be primarily responsible for commercial manufacturing and commercialization activities for products under the Expanded Functional Genomics Program and Additional Programs, if and when selected by GSK. For each collaboration program, upon execution of the definitive agreement, the Company will grant GSK certain license rights related to the development, manufacturing and commercialization of products arising from the program.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The parties will share </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_90965b46-c62d-43e6-b8e5-3c74eedffc02" contextRef="C_a83f3768-0952-4ecd-91fb-ac4523a646de" name="vir:PercentageOfShareDevelopmentCosts" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of all development costs in accordance with the budget for each of the collaboration programs (other than for&#160;the Selected Pathogens and VIR-2482 unless GSK exercises the VIR-2482 Option), with each party having the right to&#160;opt-out&#160;of its&#160;co-funding&#160;obligations at specified points in development. In such case, the party continuing with the program will pay to</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Unaudited Condensed Consolidated Financial Statements</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the&#160;opt-out&#160;party </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a royalty on net sales of products arising from such program at specified rates based on the stage of development at which the&#160;opt-out&#160;is exercised. Following the exercise of an&#160;opt-out&#160;right by a party, the other party may, at its election, either pursue development and commercialization of such product or program unilaterally, or also cease the conduct and funding of such collaboration product or program. In the absence of any&#160;opt-out,&#160;the parties will also share </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a6a71e06-a562-44c4-ad4b-a08766f069ad" contextRef="C_a83f3768-0952-4ecd-91fb-ac4523a646de" name="vir:ProfitsAndLossesSharingPercentage" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of all profits and losses arising from any collaboration product.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GSK was obligated to make an upfront payment to the Company of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_02aec6ea-265e-4c2d-b25d-2af5ca3d9a90" contextRef="C_cff84f6a-b57e-47a0-a02b-dcac6185a725" name="vir:UpfrontPaymentReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">225.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million, </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5dc4f0ba-e17e-4956-8eaf-ff65bf35f0d5" contextRef="C_cff84f6a-b57e-47a0-a02b-dcac6185a725" name="vir:PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of which became payable at the effective date of the 2021 Preliminary Agreement and </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e3adeeb9-85fe-4431-8d5a-bb8274d56be3" contextRef="C_8f7f9c58-f98b-4a8f-95b9-e5182870c64d" name="vir:PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">50</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of which became payable following execution of the 2021 GSK Agreement. If GSK exercises the VIR-2482 Option, GSK will pay the Company an option exercise fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_29155f18-3655-4243-8693-72e115d36e91" contextRef="C_cff84f6a-b57e-47a0-a02b-dcac6185a725" name="vir:OptionExerciseFeeConsiderationToBeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">300.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million unless certain agreed product criteria for&#160;VIR-2482&#160;are not met, in which case the parties will negotiate an alternative option exercise fee. Upon achievement of a&#160;pre-defined&#160;regulatory milestone for the first product in the Influenza Program, which may be (i) VIR-2482 (if GSK exercised the VIR-2482 Option), (ii) a next-generation mAb, or (iii) any other influenza mAb approved by the JSC to be included in the collaboration, arising from the Influenza Program, GSK will make a milestone payment to the Company of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_17e6aa47-cdd2-4f83-99cf-96c4f24f8b29" contextRef="C_33123595-07a6-4f85-a3a1-bc8546d832b5" name="vir:PreDefinedRegulatoryMilestoneConsiderationReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">200.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company concluded that the 2021 GSK Agreement is a collaboration arrangement as defined in ASC 808, Collaborative Agreements, under which certain elements are required to be accounted for under ASC 606 where the counterparty is a customer for a good or service that is a distinct unit of account. In addition, the 2021 GSK Agreement is considered a contract modification to the 2021 Preliminary Agreement and will be accounted for prospectively, as a termination of the 2021 Preliminary Agreement and commencement of a new contract. There was no impact to the accounting assessment of the original contract as no goods or services had been delivered to GSK, no performance obligations were satisfied, and accordingly,&#160;no contract revenue was recognized under ASC 606 prior to the execution of the 2021 GSK Agreement.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considered the ASC 606 criteria for combining contracts and determined that the 2021 GSK Collaboration and 2021 Stock Purchase Agreement should be combined into a single contract because they were negotiated and entered into in contemplation of one another. The fair market value of the common stock issued to GGL was $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc7e4de1-9d08-442f-8217-4d55f285cad1" contextRef="C_c50def4f-f04d-4b74-a20a-53c116d0b11f" name="vir:FairMarketValueOfCommonStockIssued" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">85.2</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, based on the closing stock price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8bec148c-d86e-4e73-8f7d-e70908c0d868" contextRef="C_52d2443e-0fd8-42f6-9e80-a3310414715c" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_USDollarShare" decimals="INF">52.70</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on March 25, 2021 and taking into account a discount for the lack of marketability due to the restrictions in place on the underlying shares, resulting in a $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5c2a5540-ae32-4f74-b749-e56f607b302f" contextRef="C_c50def4f-f04d-4b74-a20a-53c116d0b11f" name="vir:PremiumReceivedOnSalePriceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">34.8</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million premium received by the Company. The Company accounted for the common stock issued to GGL based on its fair market value on the transaction date and determined that the premium paid by GSK should be attributed to the transaction price of the 2021 GSK Agreement.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company concluded that the 2021 GSK Agreement contained the following units of account: (i) the VIR-2482 Option; (ii) three distinct rights granted to GSK related to the Selected Pathogens (each, a &#x201c;Selected Pathogens Right&#x201d;); (iii) the license and know-how to the next-generation mAbs under the Influenza Program (the &#x201c;Next Gen License&#x201d;); (iv) the research and development activities for next-generation mAbs under the Influenza Program; and (v) the research and development activities, including license rights and know-how, under the Expanded Functional Genomics Program. The Company considered the guidance in ASC 606 to determine which of these elements of the 2021 GSK Agreement are performance obligations with a customer. The Company determined that the distinct performance obligations under ASC 606 consisted of: (i) the Next Gen License and (ii) the three Selected Pathogens Rights, each representing a material right. All other elements of the 2021 GSK Agreement including the VIR-2482 Option, research and development activities, and participation in the JSC and subcommittees for each collaboration program were not determined to be distinct performance obligations with a customer.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The transaction price for the 2021 GSK Agreement included fixed consideration consisting of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e96eae6d-bb0c-4bce-8d93-03e4be96b948" contextRef="C_3b171620-e654-43aa-be16-06e50f0a2698" name="vir:CollaborationAgreementTransactionPriceFixedConsideration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">225.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upfront fee paid by GSK and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_867461b7-6f07-4d68-a7da-02c1a91293d3" contextRef="C_d0b20436-58e4-46d4-92e4-fe201bcf47c2" name="vir:PremiumPaidOnSalePriceOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">34.8</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, representing the premium on the sale of common stock to GSK for a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5270cb65-02e3-46c1-aaa6-8fbba0ed9d7a" contextRef="C_3b171620-e654-43aa-be16-06e50f0a2698" name="vir:CollaborationAgreementTransactionPriceConsideration" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">259.8</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. All potential future milestones and other payments under the 2021 GSK Agreement are constrained since the Company could not conclude it was probable that a significant reversal in the amount recognized would not occur.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The respective estimated SSP for each of the performance obligations was determined to allocate the transaction price. The estimated SSP of each performance obligation was determined considering relevant market conditions, entity-specific factors and information about the customer, while maximizing the use of available observable inputs. For the Next Gen License, the Company determined that GSK can benefit from the license at the time the license is granted and therefore, the related performance obligation is satisfied at a point in time. If any of the Selected Pathogens Rights are exercised, the Company will evaluate the related promises to identify the performance obligations to be transferred and the timing of revenue recognition. If any of the Selected Pathogens Rights expire prior to being exercised, the Company will recognize any deferred revenue allocated to that right as revenue at the time of expiration.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The research and development activities for the next generation mAbs under the Influenza Program and the Expanded Functional Genomics Program were determined to be within the scope of ASC 808 as the Company and GSK are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Unaudited Condensed Consolidated Financial Statements</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the commercial success of the activities of the arrangement. Furthermore, the Company and GSK participate in the commercial profit and loss sharing arrangement for each program commensurate with each party&#x2019;s cost-sharing responsibilities during research and development. Because ASC 808 does not provide recognition and measurement guidance, the Company determined that the guidance in ASC 730, Research and Development, was appropriate to analogize to based on the nature of the cost-sharing provisions of the agreement. The Company has concluded that payments to or reimbursements from GSK related to these services will be accounted for as an increase to or reduction of research and development expenses, respectively. The Company also concluded that any payments from GSK related to the profit and loss sharing arrangement (including royalties) contingent upon the commercialization of the related products will be analogized to ASC 606 and therefore, will be recognized when the related sales occur.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon execution of the 2021 GSK Agreement, the Company granted the Next Gen License to GSK and therefore, recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf0ca705-82ea-43e9-8542-22211ccf8ac0" contextRef="C_9f0a8c2d-23ab-4ba5-9c8d-ca28574c8b2c" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">168.3</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as contract revenue during the three months ended June 30, 2021. As of June 30, 2021, of the total unrecognized transaction price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c861ab76-20e9-4575-840e-893f4f81a979" contextRef="C_51cc81ca-5eda-4a6a-a5dd-56c6a7083323" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">91.5</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_32ea01f2-0938-4709-a590-ecbf4d37621b" contextRef="C_51cc81ca-5eda-4a6a-a5dd-56c6a7083323" name="us-gaap:DeferredRevenueCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">39.8</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_208ae8d8-2f98-419a-9bc1-2a7f3ad3a773" contextRef="C_51cc81ca-5eda-4a6a-a5dd-56c6a7083323" name="us-gaap:DeferredRevenueNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">51.7</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million is classified as current and noncurrent deferred revenue, respectively, on the Company's condensed consolidated balance sheet related to the remaining performance obligations, being the material rights resulting from the Selected Pathogens Rights.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs associated with co-development activities performed under the agreement are included in research and development expenses in the condensed consolidated statements of operations, with any reimbursement of costs by GSK reflected as a reduction of such expenses. During the three and six months ended June 30, 2021, the Company recognized a </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reduction of research and development expense of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1841b788-2750-47bf-8c07-f3c7977058f8" contextRef="C_8d5790db-7c09-460a-9153-c6331074affd" name="vir:ReductionOfResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_6cb891bd-da9f-4969-b64a-d42cc11ed4bb" contextRef="C_cc499f93-896e-4bdf-be24-28ce2921af3f" name="vir:ReductionOfResearchAndDevelopmentExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">under the 2021 GSK Agreement.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Brii Biosciences</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2018, the Company entered into a collaboration, option and license agreement (the &#x201c;Brii Agreement&#x201d;) with Brii Biosciences Limited (previously named BiiG Therapeutics Limited) (&#x201c;Brii Bio Parent&#x201d;) and Brii Biosciences Offshore Limited (&#x201c;Brii Bio&#x201d;), pursuant to which the Company granted to Brii Bio, with respect to up to four of the Company&#x2019;s programs, an exclusive option to obtain exclusive rights to develop and commercialize compounds and products arising from such programs in China, Taiwan, Hong Kong and Macau (collectively, the &#x201c;China Territory&#x201d;) for the treatment, palliation, diagnosis, prevention or cure of acute and chronic diseases of infectious pathogen origin or hosted by pathogen infection (the &#x201c;Field of Use&#x201d;). The Company&#x2019;s HBV siRNA program being developed under the Alnylam Agreement (described below) is included within the Brii Agreement as a program for which Brii Bio may exercise one of its options. In partial consideration for the options granted by the Company to Brii Bio, Brii Bio Parent and Brii Bio granted the Company, with respect to up to four of Brii Bio Parent&#x2019;s or Brii Bio&#x2019;s programs, an exclusive option to be granted exclusive rights to develop and commercialize compounds and products arising from such Brii Bio programs in the United States for the Field of Use. The number of options that the Company may exercise for a Brii Bio program is limited to the corresponding number of options that Brii Bio exercises for a Vir program.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As partial consideration for the Company&#x2019;s entry into the Brii Agreement, upon closing of Brii Bio Parent&#x2019;s Series A preferred stock financing, the Company received ordinary shares equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e240a742-cd59-4d12-8fd3-e02a42cd471a" contextRef="C_c99a0b18-718d-4edc-baf8-ddcb6d2b2cee" name="vir:PercentageOfOrdinaryShareEqualToOutstandingShare" unitRef="U_pure" scale="-2" decimals="INF" format="ixt:numdotdecimal">9.9</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding shares in Brii Bio Parent. As a result of Brii Bio&#x2019;s right to exercise one of its options for the Company&#x2019;s HBV siRNA program, under the terms of the Alnylam Agreement, as amended, the Company transferred to Alnylam a specified percentage of such equity consideration allocable to such program under a share transfer agreement in February 2020.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">With respect to programs for which Brii Bio exercises its options, Brii Bio will be required to pay the Company an option exercise fee for each such Vir program ranging from the mid-single-digit millions up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca4366e3-d51c-48ee-82c4-de012c4e1c1c" contextRef="C_ac8bcb94-38bb-498a-a74f-16bc3f88cf85" name="vir:OptionExerciseFeeConsiderationReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, determined based on the commercial potential of the licensed program. Brii Bio will also be required to pay regulatory milestone payments on a licensed product-by-licensed product basis ranging from the mid-single-digit millions up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6c0607c2-fdd3-4740-8dbf-b00efee7b451" contextRef="C_4b592749-62ec-4fae-9b15-04061affca47" name="vir:RegulatoryMilestoneConsiderationReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, also determined based on the commercial potential of such program. Following commercialization, Brii Bio will be required to make sales milestone payments based on certain specified levels of aggregate annual net sales of products arising from each licensed program in the China Territory, up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_001862ba-9eca-40f8-b87b-6f7cfb530e8b" contextRef="C_ac8bcb94-38bb-498a-a74f-16bc3f88cf85" name="vir:SalesMilestoneConsiderationReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">175.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million per licensed program. Brii Bio also will pay royalties to the Company that range from the mid-teens to the high-twenties, as described below.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon exercise of each option for a Brii Bio program, the Company will be required to pay to Brii Bio an option exercise fee ranging from the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cf886abf-d491-495e-a408-18569468e9fa" contextRef="C_dc5358a1-e8cd-4f63-a453-32242603a269" name="vir:OptionExerciseFeeConsiderationPayableDescription"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">low tens of millions</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fec1634c-b5b3-46fe-9350-ad16a5e20c60" contextRef="C_4830ca2a-0ad5-4a32-b98f-bae2d1970486" name="vir:OptionExerciseFeeConsiderationPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, determined based on the commercial potential of the licensed program. The Company will be required to make regulatory milestone payments to Brii Bio on a licensed product-by-licensed product basis ranging from the low tens of millions up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3aa52cc6-795d-4c38-815d-47c7e27973e1" contextRef="C_8ae3adcd-4938-4c7c-921a-6d25c5205981" name="vir:RegulatoryMilestonePaymentConsiderationPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">100.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, also determined based on the commercial potential of such program. The Company will also be required to make sales milestone payments based on certain specified levels of aggregate annual net sales of products in the United States arising from each licensed program, up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_78a898b8-da9b-400c-8136-584f3474613e" contextRef="C_1f9878a0-4b15-4465-8e06-ac38077a8fcc" name="vir:SalesMilestoneConsiderationPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">175.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million per licensed program.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Unaudited Condensed Consolidated Financial Statements</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the Company is obligated under the Brii Agreement to pay Brii Bio tiered royalties based on net sales of products arising from the licensed programs in the United States, and Brii Bio is obligated to pay the Company tiered royalties based on net sales of products arising from the licensed programs in the China Territory. The rates of royalties payable by the Company to Brii Bio, and by Brii Bio to the Company, on net sales range from mid-teens to high-twenties. Each party&#x2019;s obligations to pay royalties expires, on a product-by-product and territory-by-territory basis, on the latest of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1d9bc0c5-e556-4055-9c53-b2e209c6c30a" contextRef="C_0593f237-da08-4238-8805-6911cc8c2af4" name="vir:RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" format="ixt-sec:duryear"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years after the first commercial sale of such licensed product in the United States or China Territory, as applicable; the expiration or abandonment of licensed patent rights that cover such product in the United States or China Territory, as applicable; and the expiration of regulatory exclusivity in the United States or the China Territory, as applicable. Royalty rates are subject to specified reductions and offsets.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Brii Agreement will remain in force until the expiration of all options or, if any option is exercised, expiration of all royalty payment obligations for all licensed products within such licensed program, unless terminated in its entirety or on a program-by-program basis by either party. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_74b84ad8-2634-4c15-9517-c5985d08032b" contextRef="C_2780ba97-f35b-4286-8d16-f6c692bbc074" name="vir:CollaborationAgreementTerminationDescription"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each party may terminate for convenience all rights and obligations with respect to any program for which it has an option, with </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c5dbc2e5-7397-4daa-b134-a8589ee6e8e3" contextRef="C_69fba054-c419-4e8e-b49f-667d17bf850d" name="vir:WrittenNoticePeriodForLicensedProgramNotExercisedAnOption" format="ixt-sec:durwordsen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30 days</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2019; written notice (if the terminating party has not exercised an option for such program) or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7e0c512f-7a5f-462b-b97d-75c37c2396ba" contextRef="C_69fba054-c419-4e8e-b49f-667d17bf850d" name="vir:WrittenNoticePeriodForLicensedProgramExerciseAnOption" format="ixt-sec:durwordsen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">180 days</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2019; notice (following the exercise of an option for such program). The Brii Agreement may also be terminated by either party for insolvency of the other party, and either party may terminate the Brii Agreement in its entirety or on a program-by-program basis for the other party&#x2019;s uncured material breach on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0cae3f18-2d8f-4025-964c-ee5fb6cf1d7d" contextRef="C_69fba054-c419-4e8e-b49f-667d17bf850d" name="vir:WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" format="ixt-sec:durwordsen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60 days</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2019; written notice (or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1d4f351b-277c-4570-8db6-0ba35073207a" contextRef="C_69fba054-c419-4e8e-b49f-667d17bf850d" name="vir:WrittenNoticePeriodForLicensedProgramFailureToMakePayment" format="ixt-sec:durday"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#x2019; notice following failure to make payment).</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has determined that Brii Bio Parent and its wholly-owned subsidiary Brii Bio are variable interest entities due to their reliance on future financing and having insufficient equity at risk. However, the Company does not have the power to direct activities that most significantly impact the economic success of these entities and is not considered the primary beneficiary of these entities. Therefore, the Company does not consolidate Brii Bio Parent or Brii Bio. The Company also determined that it does not exercise significant influence over Brii Bio Parent or Brii Bio. As of June 30, 2021 and December 31, 2020, the investment in Brii Bio Parent has a carrying value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a697e222-9295-4bbc-96fb-0fe984920474" contextRef="C_f57d1eff-a8c4-4b5c-8802-9f372ef5f371" name="us-gaap:Investments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_7347d1d8-82dd-48a0-8271-dee8457106ee" contextRef="C_66bfb7f9-fc0b-4e62-b6fc-4e629327a410" name="us-gaap:Investments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.7</ix:nonFraction></ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which is included in other assets on the condensed consolidated balance sheets. The Company also has a contract liability of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab17a35f-28bf-4f2a-bfdb-504d2be8f7b0" contextRef="C_8bc5a624-6688-41fd-9d8d-c6c0f2147de0" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.8</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million within deferred revenue which represents deferred consideration for the remaining three options that the Company granted to Brii Bio. The deferred consideration will be recognized when Brii Bio exercises its options or the options expire. The Company accounts for its investment in Brii Bio Parent&#x2019;s ordinary shares at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment in Brii Bio Parent.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s maximum exposure to loss under the Brii Agreement is represented by options to acquire licenses to develop and commercialize potential products and future milestone payments. The ultimate expense that the Company incurs under the Brii Agreement cannot be quantified at this time as the amount will vary based on the timing and outcome of research activities.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Option Exercise by Brii Bio</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2020, Brii Bio exercised its option to obtain exclusive rights to develop and commercialize compounds and products arising from VIR-2218 in the China Territory. In consideration of the Company&#x2019;s grant to Brii Bio of an exclusive license related to VIR-2218 in the China Territory, the Company received a $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_466bc407-020d-47d6-80e7-85c23a54c7c8" contextRef="C_a4c9273d-ad95-4c98-a7c8-805e95b768b3" name="vir:OptionExerciseFeeReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million option exercise fee in connection with the option exercise. Also, the Company is eligible to receive the following payments related to VIR-2218 in the China Territory: a $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_03e8de45-f5be-4bec-893a-5e6bc87db38c" contextRef="C_4b592749-62ec-4fae-9b15-04061affca47" name="vir:RegulatoryMilestoneConsiderationReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million regulatory milestone payment, up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_48845bc4-fc62-42a1-b5c4-ad94d21b57b5" contextRef="C_ac8bcb94-38bb-498a-a74f-16bc3f88cf85" name="vir:SalesMilestoneConsiderationReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">175.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in sales-based milestone payments, and royalties on net sales ranging from high-teens to high-twenties.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluated the transaction under ASC 606 and identified one performance obligation consisting of the license granted to Brii Bio. Under the Brii Agreement, Brii Bio is responsible for performing all research and development activities and the Company does not have any other performance obligations within the context of ASC 606 under the arrangement after the option exercise. The transaction price is determined to be $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0accbfdf-cc8d-4853-a838-63a8f3b5785a" contextRef="C_393392b3-d188-48ce-8ebf-843e5e51a678" name="vir:DeterminedTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">22.7</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million which consists of the $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b72a70c3-208f-4039-b054-8bb36f345573" contextRef="C_ac8bcb94-38bb-498a-a74f-16bc3f88cf85" name="vir:RegulatoryMilestoneConsiderationReceivable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million option exercise fee and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a91cb0c7-0b6e-4dde-a141-a9aa5bb388ef" contextRef="C_ac8bcb94-38bb-498a-a74f-16bc3f88cf85" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.7</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the deferred revenue allocated to the VIR-2218 option at the inception of the Brii Agreement. The Company determined that the license is considered a functional intellectual property that is a distinct performance obligation under ASC 606. Specifically, the Company believes the license is capable of being distinct, as Brii Bio has the capabilities to develop the license either on its own or by contracting other third parties. Brii Bio can benefit from the license at the time of grant and therefore, the related performance obligation is satisfied at a point in time. Additionally, all potential future milestones and other payments are constrained because the Company cannot conclude it is probable that a significant reversal in the amount recognized would not occur. The Company will re-evaluate the transaction price in each reporting period.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Unaudited Condensed Consolidated Financial Statements</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the three and six months ended June 30, 2021, the Company recognized </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0a49f986-3295-4066-82df-b583a608a474" contextRef="C_2aa44c95-3aa8-4eec-9de8-8fa66be5bfc1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-6" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f5ffc929-15af-4dfa-8b61-64847ad5977a" contextRef="C_b213ca27-309b-4229-b799-81e86bb50576" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, as contract revenue from the supply of biological materials to Brii Bio. During the three and six months ended June 30, 2020, the Company recognized the $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e863df7-24f6-4bfb-848a-5e696133e5d4" contextRef="C_10f77595-19f0-40f3-8510-ff21caa1970b" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">22.7</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as license revenue from a related party. The Company separately paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_528026f0-2cca-4646-aece-fd209e33500e" contextRef="C_c3b4e715-3396-4fc0-a8e8-1b7c2ed5260b" name="vir:PaymentToPartnerResultingFromProgramOptionExercise" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, half of the option exercise proceeds, to Alnylam in connection with the Alnylam Agreement that was recognized as research and development expense during the same period.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Alnylam</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">October 2017 Agreement</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2017, the Company entered into the Alnylam Agreement for the development of siRNA products for the treatment of HBV and following the exercise of certain program options, the development and commercialization of siRNA therapeutic products directed to up to four other infectious disease targets selected by the Company. The technology licensed under the Alnylam Agreement forms the basis of the Company&#x2019;s siRNA technology platform.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Alnylam Agreement, the Company obtained a worldwide, exclusive license to develop, manufacture and commercialize the HBV siRNA product candidates, including VIR-2218, for all uses and purposes other than agricultural, horticultural, forestry, aquaculture and other residential applications, such excluded fields, the Excluded Fields. In addition, Alnylam granted the Company an exclusive option, for each of the infectious disease siRNA programs directed to the Company&#x2019;s selected targets, to obtain a worldwide, exclusive license to develop, manufacture and commercialize siRNA products directed to the target of each such program for all uses and purposes other than the Excluded Fields. On a product-by-product basis for each product arising from the HBV and, following the Company&#x2019;s option exercise, the infectious disease programs, Alnylam has an exclusive option, exercisable during a specified period prior to the initiation of a Phase 3 clinical trial for each such product, to negotiate and enter into a profit-sharing agreement for such product.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company and Alnylam are jointly responsible for funding the initial research and development activities for VIR-2218 through the completion of proof of concept trials. Prior to the exercise of the Company&#x2019;s option for each siRNA program directed to one of the Company&#x2019;s selected infectious disease targets, Alnylam is responsible for conducting all development activities, at the Company&#x2019;s expense, in accordance with an agreed upon development plan. Following the Company&#x2019;s exercise of an option for a program and payment of the program option exercise fee and any outstanding program costs due to Alnylam, the Company is solely responsible, at the Company&#x2019;s expense (subject to Alnylam&#x2019;s exercise of a profit-sharing option), for conducting all development, manufacture and commercialization activities for products arising from each such program. If Alnylam exercises a profit-sharing option for a product, the Company will negotiate the terms of such profit-sharing agreement, which will include sharing equally with Alnylam all subsequent costs associated with the development of such product, as well as the profits and losses in connection with such product, subject to reimbursement by Alnylam of a portion of specified development costs in certain circumstances.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Alnylam Agreement, the Company paid Alnylam an upfront fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_59e3318a-6ebf-4c95-b922-ac1469505e56" contextRef="C_b68e43f8-fa5f-4941-a772-ac4ca77f6039" name="vir:UpfrontFeePaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and issued to Alnylam </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6ba58c55-5f53-4fc4-9d72-c1b7265791b5" contextRef="C_b68e43f8-fa5f-4941-a772-ac4ca77f6039" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,111,111</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s common stock. Additionally, the receipt of consideration from Brii Bio as discussed above triggered a requirement under the Alnylam Agreement to transfer a portion of the consideration, consisting of equity in Brii Bio Parent valued at $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69a7284a-7438-40a8-88f6-94927aee376f" contextRef="C_267658dc-f7db-4ab6-94bc-b9662b0d993d" name="vir:SharePayableToCollaborator" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, to Alnylam </span><span style="color:rgba(33,37,41,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon the achievement of a certain development milestone, as further discussed below, the Company was obligated to issue shares of the Company&#x2019;s common stock equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_71b7aae8-ed03-4323-bcd3-acc15d15b44c" contextRef="C_267658dc-f7db-4ab6-94bc-b9662b0d993d" name="vir:MaximumSharesToBeIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,111,111</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares or (ii) a certain number of shares based on the Company&#x2019;s stock price at the time such milestone is achieved (the &#x201c;Milestone Shares&#x201d;). The Company will be required to pay Alnylam up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f3395f2-40ba-43ee-b4f9-5ab82cd256a6" contextRef="C_11d39f80-330e-4128-989f-4084388ad346" name="vir:MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">190.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate for the achievement of specified development and regulatory milestones by the first siRNA product directed to HBV, and up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c1519893-3d0a-4655-9b6d-c3952076da97" contextRef="C_d9b5a18c-ba78-4c5f-bb0f-40e2ed6661d1" name="vir:MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">115.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the achievement of specified development and regulatory milestones by the first product directed to the target of each infectious disease siRNA program for which the Company exercised its option. Following commercialization, the Company will be required to pay to Alnylam up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_888effdc-7b58-4d91-a9d0-3c54ed05a48c" contextRef="C_e2de7da2-b046-4ec0-ad5e-5f3b001ed026" name="vir:MaximumAggregateSalesMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">250.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate for the achievement of specified levels of net sales by siRNA products directed to HBV and up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_82a67608-a379-49a6-8868-d9bc1600c1c2" contextRef="C_e2de7da2-b046-4ec0-ad5e-5f3b001ed026" name="vir:MaximumSalesMilestonePayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">100.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the achievement of specified levels of net sales by products directed to the target of each infectious disease siRNA program for which the Company exercised its option. The Company may also be required to pay Alnylam tiered royalties at percentages ranging from the low double-digits to mid-teens on annual net sales of HBV products, and tiered royalties at percentages ranging from the high single-digits to the sub-teen double-digits on annual net sales of licensed infectious disease products, in each case subject to specified reductions and offsets. The royalties are payable on a product-by-product and country-by-country basis until the later of the expiration of all valid claims of specified patents covering such product in such country and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_379deb3a-5683-44f6-ab21-912f99b01d28" contextRef="C_580342cb-5db5-408f-ae9b-48fd57cdb017" name="vir:RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" format="ixt-sec:durwordsen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10 years</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> after the first commercial sale of such product in such country.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Unaudited Condensed Consolidated Financial Statements</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term of the Alnylam Agreement will continue, on a product-by-product and country-by-country basis, until the expiration of all royalty payment obligations under the Alnylam Agreement. If the Company does not exercise its option for an infectious disease program directed to one of its selected targets, the Alnylam Agreement will expire upon the expiration of the applicable option period with respect to such program. However, if Alnylam exercises its profit-sharing option for any product, the term of the Alnylam Agreement will continue until the expiration of the profit-sharing arrangement for such product. The Company may terminate the Alnylam Agreement on a program-by-program basis or in its entirety for any reason on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d5d1c09-55ee-4d93-bb9d-05599f6be94f" contextRef="C_b68e43f8-fa5f-4941-a772-ac4ca77f6039" name="vir:WrittenNoticePeriodForLicensedProgramExerciseAnOption" format="ixt-sec:durwordsen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90 days</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2019; written notice. Either party may terminate the agreement for cause for the other party&#x2019;s uncured material breach on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6f2bb8a7-25e6-4cc1-b740-86ba0ba8ff3d" contextRef="C_b68e43f8-fa5f-4941-a772-ac4ca77f6039" name="vir:WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" format="ixt-sec:durwordsen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60 days</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2019; written notice (or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fe2c5b9e-49fa-4cda-b4ed-b947d2e2b4ec" contextRef="C_b68e43f8-fa5f-4941-a772-ac4ca77f6039" name="vir:WrittenNoticePeriodForLicensedProgramFailureToMakePayment" format="ixt-sec:durwordsen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30 days</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2019; notice for payment breach), or if the other party challenges the validity or enforceability of any patent licensed to it under the Alnylam Agreement on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ece8a9b7-a4f9-419e-b9c6-454d904cabec" contextRef="C_b68e43f8-fa5f-4941-a772-ac4ca77f6039" name="vir:WrittenNoticePeriodForLicensedProgramOtherPartyChallengesValidityOrEnforceabilityOfPatentLicense" format="ixt-sec:durwordsen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30 days</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2019; notice.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, the Company achieved the specified development milestone relating to the Milestone Shares, which was accounted for as an embedded derivative. Consequently, the Company remeasured and reclassified the derivative liability to additional paid-in capital based on the estimated fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a009c562-0a34-4709-b02e-c87048a20037" contextRef="C_17da886f-2297-41d5-a984-97218fc86f75" name="us-gaap:DerivativeFairValueOfDerivativeLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">29.2</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company issued Alnylam </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_55eeb7ae-0a64-4d34-a208-06a54a9d391f" contextRef="C_cca64f01-43cb-4521-a7c0-b8c072d00e2a" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,111,111</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock and paid Alnylam $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_57e3fcd7-f959-46b0-b022-1d677e33197f" contextRef="C_33c31548-53fa-4da7-9d3c-4b3f3239fd4a" name="vir:ContractualPayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the second quarter of 2020.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Second and Third Amendments</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March and April 2020, the Company and Alnylam entered into the second and third amendments to the Alnylam Agreement (as amended, the &#x201c;Amended Alnylam Agreement&#x201d;) to expand the parties&#x2019; existing collaboration to include the development and commercialization of siRNA products targeting SARS-CoV-2, and potentially other related coronaviruses, and up to three targeting human host factors for SARS-CoV-2 (collectively, the &#x201c;COVID Collaboration Targets&#x201d;).</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company and Alnylam entered into a letter amendment (the &#x201c;Letter Agreement&#x201d;), amending the Amended Alnylam Agreement, to modify certain funding and governance provisions in connection with the siRNA products directed to the COVID Collaboration Targets, including VIR-2703 (the &#x201c;COV Target&#x201d;), and to modify certain rights of each party with respect to products arising from such programs. Pursuant to the Letter Agreement, Alnylam were responsible for conducting pre-clinical research activities set forth in the existing workplan for the COV Target (the &#x201c;COV Workplan&#x201d;) at its discretion and sole expense, and the Company was no longer obligated to reimburse Alnylam for any share of costs incurred by Alnylam in conducting activities under the COV Workplan after July 1, 2020. In July 2021, Alnylam elected to discontinue the development of the COV Target, and all other related research and development activities in accordance with their rights under the Letter Agreement. As a result, the COV Target and related siRNA program is no longer included within the Amended Alnylam Agreement and all rights to the siRNA program directed to the COV Target reverted to Alnylam.&#160;&#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses Recognized for the Period</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company incurred expenses under the Alnylam Agreement of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dcabc38a-e08c-45a9-89f4-7a3cd5ac2040" contextRef="C_97110788-5408-406c-be78-a9a445a7d443" name="vir:CollaborationAgreementRelatedCostsAndExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89c118cd-4ec5-40ed-ba3c-888e59af53d3" contextRef="C_580342cb-5db5-408f-ae9b-48fd57cdb017" name="vir:CollaborationAgreementRelatedCostsAndExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.7</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during the </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three and six months ended June&#160;30, 2021</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively. In addition to the Milestone Shares and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f510a42c-d984-4126-afe1-6bcab5c0bf8b" contextRef="C_b435674c-7a19-45d9-b704-d50d4dea4823" name="vir:MilestonePaymentsPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million milestone payable to Alnylam in the first quarter of 2020, and the $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4b71bf9b-21ae-47c3-b9d9-0083b8f3a5fc" contextRef="C_44f8d63c-2efc-4376-972c-8a2d8299bc16" name="vir:MilestonePaymentsPaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million payment resulting from Brii Bio&#x2019;s option exercise in the second quarter of 2020, the Company incurred expenses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_add6c9f9-c011-41f4-b3b0-ed5f077fee43" contextRef="C_33c31548-53fa-4da7-9d3c-4b3f3239fd4a" name="vir:CollaborationAgreementRelatedCostsAndExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0bada294-e048-4ed0-9099-3c0126c3d256" contextRef="C_f34e6246-fbef-4861-a312-c896b3da8b57" name="vir:CollaborationAgreementRelatedCostsAndExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.8</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million under the Alnylam Agreement during the </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three and six months ended June&#160;30, 2020, respectively.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">WuXi Biologics</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2020, the Company entered into a development and manufacturing collaboration agreement with WuXi Biologics (Hong Kong) Limited (&#x201c;WuXi Biologics&#x201d;) (the &#x201c;WuXi Biologics Collaboration Agreement&#x201d;), for the clinical development, manufacturing, and commercialization of the Company&#x2019;s proprietary antibodies developed for SARS-CoV-2. Under the WuXi Biologics Collaboration Agreement, WuXi Biologics will conduct cell-line development, process and formulation development, and initial manufacturing for clinical development. WuXi Biologics will have the right to commercialize products incorporating such antibodies in greater China under an exclusive license granted for the selected antibodies that have been developed. The Company will have the right to commercialize such products in all other markets worldwide.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">WuXi </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Biologics will perform mutually agreed development and manufacturing activities, under individual statements of work. In addition, the parties agreed that WuXi Biologics will pay the Company tiered royalties at percentages ranging from the high single-digits to mid-teens on annual net sales of all products sold by WuXi Biologics in greater China. The royalties are payable for a specified, standard royalty term. In addition, if WuXi Biologics sublicenses its commercialization rights to a third party, WuXi Biologics will pay the Company a percentage of the sublicense revenue received from such third party. The WuXi Biologics Collaboration Agreement will continue until the expiration of WuXi Biologics&#x2019; payment obligations to the Company, unless</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Unaudited Condensed Consolidated Financial Statements</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">terminated </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">earlier. If terminated earlier, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f633d4c5-f61c-46a9-9400-ed49a37d150e" contextRef="C_416eb633-0ce4-467f-ad2a-37987bfe677b" name="vir:CollaborationAgreementTerminationDescription"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the WuXi Biologics Collaboration Agreement may be terminated by (i) the written agreement of both parties, (ii) WuXi Biologics following the one year anniversary of the WuXi Biologics Collaboration Agreement effective date with respect to the entire agreement or on a product by product basis with 90 days&#x2019; prior written notice or (iii) by either party if the other party materially breaches the WuXi Biologics Collaboration Agreement and fails to cure such breach within sixty days.</span></ix:nonNumeric></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Rockefeller University</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2018, the Company entered into an exclusive license agreement with The Rockefeller University (&#x201c;Rockefeller&#x201d;), which was amended in May 2019, in September 2020, and in March 2021 (the &#x201c;Rockefeller Agreement&#x201d;). Under the Rockefeller Agreement, Rockefeller granted the Company a worldwide exclusive license under certain patent rights, and a worldwide non-exclusive license under certain materials and know-how covering certain antibody variants relating to a specified mutation leading to enhanced antibody function and utility, to develop, manufacture and commercialize infectious disease products covered by the licensed patents, or that involve the use or incorporation of the licensed materials and know-how, in each case for all uses and purposes for infectious diseases. The Company uses technology licensed under the Rockefeller Agreement in the Company&#x2019;s antibody platform and in the Company&#x2019;s product candidates VIR-3434 and VIR-7832.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company paid Rockefeller an upfront fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3131d972-217d-4f92-b462-bd5460898080" contextRef="C_9e18bb3c-4c77-45f7-a376-3d3aa6ea7b8b" name="vir:UpfrontFeePaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million for entry into the Rockefeller Agreement, and is required to pay annual license maintenance fees of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_220a8d1f-2cda-4467-aa61-9ec9d9ebc11d" contextRef="C_cc967922-0ffb-4e42-9643-902ddc2a4a56" name="vir:PaymentOfAnnualLicenseMaintenanceFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million. In addition, for the achievement of specified development, regulatory and commercial success milestone events, the Company will be required to pay up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_658000be-bd4c-4d75-b3b0-d843608661a2" contextRef="C_8e7bbb2c-772e-4f93-ba28-8ef8fd39ba8a" name="vir:MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">80.3</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million, in the aggregate, for up to six infectious disease products. Any follow-on products beyond six products may result in additional milestone event payments. The Company will also be required to pay to Rockefeller a royalty at a low single-digit percentage rate on net sales of licensed products, subject to certain adjustments. The Company&#x2019;s obligation to pay royalties to Rockefeller will terminate, on a product-by-product and jurisdiction-by-jurisdiction basis, upon the latest of the expiration of the last valid claim of a licensed patent in such jurisdiction, the expiration of all regulatory exclusivity in such jurisdiction or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d3951307-0ebb-4c29-9827-100c43529db7" contextRef="C_656e7f8d-dcdb-4596-bc50-c6a3693b2cf4" name="vir:RoyaltyObligationPeriodFromDateOfFirstCommercialSale" format="ixt-sec:durwordsen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12 years</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> following the first commercial sale of the applicable licensed product in such jurisdiction.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Rockefeller Agreement, the Company recognized a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6bff92d-5721-40df-81fc-a0987d715d10" contextRef="C_9e86b99a-0581-4171-849d-e82b23f80034" name="vir:SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees" unitRef="U_USD" scale="3" decimals="-2" format="ixt:numdotdecimal"><ix:nonFraction id="F_618794d9-82f6-44ee-8df7-4e49dc788c93" contextRef="C_8780a7ad-2026-45bc-835f-43e7a4f6e155" name="vir:SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees" unitRef="U_USD" scale="3" decimals="-2" format="ixt:numdotdecimal">4.0</ix:nonFraction></ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_692bb654-0e4e-4ee4-8c7c-e4b7e9362fe6" contextRef="C_30c20ac0-452b-41d8-aabf-b6962ca7e754" name="vir:SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_72c38f0a-3f6e-4333-bdd3-e3bce25983bf" contextRef="C_222e97e5-5f11-45bd-9409-870b0ab08dec" name="vir:SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during the three and six months ended June 30, 2021 and 2020, respectively, as research and development expenses related to certain development milestone payments, annual license maintenance fees, and estimated sublicense fees.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Rockefeller Agreement will remain in force, absent earlier termination, until the expiration of all of the Company&#x2019;s obligations to pay royalties to Rockefeller in all jurisdictions. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6c7d993f-6d91-4b7d-bdec-58fed1927a65" contextRef="C_656e7f8d-dcdb-4596-bc50-c6a3693b2cf4" name="vir:CollaborationAgreementTerminationDescription"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has the right to terminate the Rockefeller Agreement in its entirety, or in part, for any reason on 60 days&#x2019; written notice to Rockefeller. Rockefeller may terminate the Rockefeller Agreement on 90 days&#x2019; written notice for the Company&#x2019;s uncured material breach, or if the Company challenges the validity or enforceability of any of the licensed patents, or immediately in the event of the Company&#x2019;s insolvency. Rockefeller may also terminate the Rockefeller Agreement if the Company ceases to carry on business with respect to the rights granted to the Company under the agreement. </span></ix:nonNumeric></span><span style="font-size:10.0pt;font-family:Times New Roman;"></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">MedImmune</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2018, the Company entered into a license agreement, which was amended in September 2020 (the &#x201c;MedImmune Agreement&#x201d;), with MedImmune, LLC  (&#x201c;MedImmune&#x201d;), under which the Company obtained a worldwide, exclusive license to develop and commercialize half-life extended versions of two specified antibodies under development by MedImmune that target influenza A and influenza B, respectively, for all uses in humans and animals. The Company is developing VIR-2482 using technology licensed under the MedImmune Agreement.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In consideration for the grant of the licenses under the MedImmune Agreement, the Company made an upfront payment to MedImmune of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c95f9d3f-ad04-4dac-881a-8df45095e0cc" contextRef="C_d18e2209-527e-424f-914a-da611d338ba7" name="vir:LicenseAgreementUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company will be obligated to make development, regulatory, and commercial milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2547185c-ee74-4f06-8a03-89fad20a120a" contextRef="C_7ac0807c-bde4-490e-afcd-dd874265ab98" name="vir:DevelopmentRegulatoryAndCommercialMilestonePaymentsMaximumAmount" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">331.5</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million, of which $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4ad5bb28-3e21-4f5c-9f95-06937bb4685c" contextRef="C_7ac0807c-bde4-490e-afcd-dd874265ab98" name="vir:DevelopmentRegulatoryAndCommercialMilestonePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was paid in the third quarter of 2019, in the aggregate relating to influenza A and influenza B products. MedImmune will also be entitled to receive tiered royalties based on net sales of products containing half-life extended versions of antibodies directed to influenza A and/or influenza B at percentages ranging from the mid-single-digits to sub-teen double-digits.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The MedImmune Agreement will remain in force until the expiration on a country-by-country and product-by-product basis of all of the Company&#x2019;s obligations to pay royalties to MedImmune. </span><span style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_68808e86-161f-4c00-af97-3785ef71e150" contextRef="C_17fb449e-4cf8-4a5c-b8a6-4e7113c7b17e" name="vir:CollaborationAgreementTerminationDescription" continuedAt="F_68808e86-161f-4c00-af97-3785ef71e150_1"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company may terminate the MedImmune Agreement in its entirety or on a product-by-product basis, for convenience, upon 120 days&#x2019; notice. Either party may terminate the MedImmune Agreement for cause for the other party&#x2019;s uncured material breach on 60 days&#x2019; notice or immediately in the event of bankruptcy of the other party. </span></ix:nonNumeric></span><span style=""></span></p><ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Unaudited Condensed Consolidated Financial Statements</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_68808e86-161f-4c00-af97-3785ef71e150_1"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">MedImmune may terminate the MedImmune Agreement for cause on 30 days&#x2019; written notice if the Company challenges the validity or enforceability of the patents to which the Company has obtained a license under the MedImmune Agreement.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Xencor</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">August 2019 License Agreement</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2019, the Company entered into a patent license agreement, which was amended in February 2021 (the &#x201c;2019 Xencor Agreement&#x201d;) with Xencor, Inc., (&#x201c;Xencor&#x201d;). Under the 2019 Xencor Agreement, as amended, the Company obtained a non-exclusive, sublicensable (only to its affiliates and subcontractors) license to incorporate Xencor&#x2019;s licensed technologies into, and to evaluate, antibodies that target influenza A and HBV, and a worldwide, non-exclusive, sublicensable license to develop and commercialize products containing such antibodies incorporating such technologies for all uses, including the treatment, palliation, diagnosis and prevention of human or animal diseases, disorders or conditions. The Company is obligated to use commercially reasonable efforts to develop and commercialize an antibody product that incorporates Xencor&#x2019;s licensed technologies, for each of the influenza A and HBV research programs. These technologies are used in the Company&#x2019;s VIR-2482, incorporating Xencor&#x2019;s Xtend technology, and VIR-3434, incorporating Xencor&#x2019;s Xtend and other Fc technologies, product candidates.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In consideration for the grant of the license, the Company paid Xencor an upfront fee. For each of the influenza A and HBV research programs, the Company will be required to pay Xencor development and regulatory milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_876c4b0b-d241-448f-bc6c-38dc41da6822" contextRef="C_6b3098b0-fc6d-48cf-bf55-bfa1dcc811a9" name="vir:MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">17.8</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million in the aggregate, and commercial sales milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9dfcc7eb-a627-435f-a79a-78232527b276" contextRef="C_6b3098b0-fc6d-48cf-bf55-bfa1dcc811a9" name="vir:MaximumAggregateCommercialSalesMilestonePayments" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">60.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million in the aggregate, for a total of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f16fabbf-d370-4ea6-b506-d775a4a14704" contextRef="C_6b3098b0-fc6d-48cf-bf55-bfa1dcc811a9" name="vir:MaximumAggregateMilestonePayments" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal"><ix:nonFraction id="F_51524ee7-c126-4d91-adff-886c09e013b9" contextRef="C_ab45b547-9dd6-4076-8bde-04eaac698732" name="vir:MaximumAggregateMilestonePayments" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">77.8</ix:nonFraction></ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million in aggregate milestones for each program and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5177f989-387d-4964-90b6-9db544fd2fdd" contextRef="C_19b8ac7c-1cc1-4683-98aa-a394a77dd75f" name="vir:MaximumAggregateMilestonePayments" unitRef="U_USD" scale="6" decimals="INF" format="ixt:numdotdecimal">155.5</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million in aggregate milestones for both programs. On a product-by-product basis, the Company will also be obligated to pay tiered royalties based on net sales of licensed products ranging from low- to mid-single-digits. The royalties are payable, on a product-by-product and country-by-country basis, until the expiration of the last to expire valid claim in the licensed patents covering such product in such country.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2019, the Company achieved one of the specified development milestones related to the influenza A program. As such, the Company paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e6b95902-e1a6-44fd-8906-c0c4d436cb06" contextRef="C_eb7ebaf7-00e9-4b11-8346-81d73478b9fa" name="vir:SpecifiedDevelopmentMilestonesPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million related to the upfront fee and this milestone event in September 2019. In May 2020, the Company achieved one of the specified development milestones related to the HBV program. As such, the Company paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4c6ed125-a08d-419f-99c0-04d174318a4b" contextRef="C_be6f5270-fc80-45c9-a95c-b5ef6403279b" name="vir:SpecifiedDevelopmentMilestonesPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to this milestone event in June 2020. The milestone payments are expensed to research and development.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">March 2020 License Agreement</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, the Company entered into a patent license agreement, which was amended in February 2021 (the &#x201c;2020 Xencor Agreement&#x201d;) with Xencor under which the Company obtained a non-exclusive, sublicensable (only to the Company&#x2019;s affiliates and subcontractors) license to incorporate Xencor&#x2019;s licensed technologies into, and to evaluate, antibodies that target any component of a coronavirus, including SARS-CoV-2, SARS-CoV and MERS-CoV, and a worldwide, non-exclusive, sublicensable license to develop and commercialize products containing such antibodies incorporating such technologies for all uses, including the treatment, palliation, diagnosis and prevention of human or animal diseases, disorders or conditions. The Company is obligated to use commercially reasonable efforts to develop and commercialize an antibody product that incorporates Xencor&#x2019;s licensed technologies, for each of the coronavirus research programs. These technologies are used in the Company&#x2019;s sotrovimab, incorporating Xencor&#x2019;s Xtend technology, and VIR-7832, incorporating Xencor&#x2019;s Xtend and other Fc technologies, product candidates.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In consideration for the grant of the license, the Company will be obligated to pay royalties based on net sales of licensed products at the mid-single-digits. The royalties are payable, on a product-by-product and country-by-country basis, until the later of the expiration of the last to expire valid claim in the licensed patents covering such product in such country or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8735c857-c865-4f76-8203-82c26ac64993" contextRef="C_0967f1dd-e649-43d3-b4d5-8e34df7fb432" name="vir:LicensedPatentsExpirationPeriod" format="ixt-sec:durwordsen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12 years</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. During the three months ended June 30, 2021, the Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c2c6b921-fdd8-4e6c-b7ea-5c1ed177e821" contextRef="C_436fb49f-f2d5-49a1-83a3-3a3e54fd290d" name="us-gaap:PaymentsForRoyalties" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.9</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of royalties due to Xencor from the sale of sotrovimab.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The amended 2020 Xencor Agreement and 2019 Xencor Agreement will remain in force, on a product-by-product and country-by-country basis, until the expiration of all royalty payment obligations under each of the respective agreements. The Company may terminate each agreement in its entirety, or on a target-by-target basis, for convenience upon </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f4cda960-abe4-4fa4-b6a4-5e8fdb8e0e73" contextRef="C_c55af785-6145-4ede-ac28-0f3933e1634e" name="vir:WrittenNoticePeriodForTerminationOfLicensedProgram" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_ff525600-173a-482b-9ac3-5890f5f30df0" contextRef="C_0967f1dd-e649-43d3-b4d5-8e34df7fb432" name="vir:WrittenNoticePeriodForTerminationOfLicensedProgram" format="ixt-sec:durwordsen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60 days</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2019; written notice. Either party may terminate each agreement for the other party&#x2019;s uncured material breach upon </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_448fd184-2ea8-4e1a-84a4-b1e9d2c6de5f" contextRef="C_c55af785-6145-4ede-ac28-0f3933e1634e" name="vir:WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_8bbd6c61-681b-426c-80f9-c5fac58bf973" contextRef="C_0967f1dd-e649-43d3-b4d5-8e34df7fb432" name="vir:WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" format="ixt-sec:durwordsen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60 days</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2019; written notice (or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d3efc31-6f53-414c-a8e0-e735df9a7082" contextRef="C_c55af785-6145-4ede-ac28-0f3933e1634e" name="vir:WrittenNoticePeriodForLicensedProgramFailureToMakePayment" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_341b6b60-a8d0-4401-8551-8096a632ca3c" contextRef="C_0967f1dd-e649-43d3-b4d5-8e34df7fb432" name="vir:WrittenNoticePeriodForLicensedProgramFailureToMakePayment" format="ixt-sec:durwordsen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30 days</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in the case of non-payment) or in the event of bankruptcy of the other party immediately upon written notice. Xencor may terminate each agreement immediately upon written notice if the Company challenges, or upon </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0964e134-e494-40fe-b755-1605c816e491" contextRef="C_c55af785-6145-4ede-ac28-0f3933e1634e" name="vir:WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge" format="ixt-sec:durwordsen"><ix:nonNumeric id="F_1e9126fe-0bfe-4c13-b745-62c285c0b1b5" contextRef="C_0967f1dd-e649-43d3-b4d5-8e34df7fb432" name="vir:WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge" format="ixt-sec:durwordsen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30 days</span></ix:nonNumeric></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2019; written notice if any of the Company&#x2019;s sublicensees challenge, the validity or enforceability of any patent licensed to the Company under each respective agreement.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Unaudited Condensed Consolidated Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6ab4f3ed-9a52-4293-8c20-a195c2582789" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:SupplementalBalanceSheetDisclosuresTextBlock" escape="true"><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance Sheet Components</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, net</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_da9fcc2f-d80a-4378-b9b1-558dc7ef0743" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net consists of the following:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:69.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.143%;"></td>
        <td style="width:1.651%;"></td>
        <td style="width:1.449%;"></td>
        <td style="width:11.634%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1.651%;"></td>
        <td style="width:1.449%;"></td>
        <td style="width:11.554%;"></td>
        <td style="width:1.449%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">June&#160;30,<br />2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December&#160;31,<br />2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6b865e9e-41d0-48cf-a302-05c115da3f41" contextRef="C_60e33361-8e0c-4167-99a3-8c9f96e030ef" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">18,168</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_003f2107-1a04-4c5a-8bd3-57f046273054" contextRef="C_a445d18b-0608-4e5b-93b9-215040fa78ac" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,769</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_25f3d4c0-b9a7-4278-9e17-55bb3f206b3b" contextRef="C_669328e0-ec12-4a46-9f8e-7642c8e0853a" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">580</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_55ac52c5-5143-46ed-886c-f8dd8774c7c3" contextRef="C_7d59a58f-5636-44a9-b169-b1a6c7e3176b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">556</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_346aa29a-2231-4f38-b31a-44cb524f1eb6" contextRef="C_a6dafe0c-9e29-491e-9182-9ea032ca7de7" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,444</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_67b0418a-b55f-4811-b126-201361eec166" contextRef="C_b2be4dcd-5221-4917-9b4b-42643238614b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,444</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7f40e704-fafb-4788-b551-fe72116b7358" contextRef="C_8e671199-2ede-4d79-bb43-b621397a4811" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,281</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_33798bf7-34de-4bd0-a184-e1bc044ce446" contextRef="C_565a5874-4857-48d4-82b7-a9f3af6c43c8" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,274</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3bdf7915-fa2e-43cb-bb45-2395e72c2cd6" contextRef="C_78a42173-a11f-4d19-985c-306f3564ed73" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,544</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8049cabe-f931-4a66-8bb4-ea7f43aff81d" contextRef="C_522751c2-1d6d-4f23-b1b2-c7eaa1905197" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,135</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, gross</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7a5344ff-78c3-4951-bae6-211f9df9b852" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">32,017</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0c2c3b71-655d-4652-b4d6-afdc86c53d51" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,178</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_62cd2b04-f65a-4bfd-8c4b-55ee3eda390e" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,766</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a994f32f-d41b-40a8-93a5-1ac7ba712bc2" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,232</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f14afc41-701c-4677-96a7-84f01a8bd84f" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,251</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b545bb1f-1864-46a1-a833-8e223efce5a4" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,946</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization expenses was $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9b6f9e8c-7f3b-4f4a-96b4-29849ff45c3e" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7ee431fd-2ba3-4db3-8544-20c0a492a968" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for the three and six months ended June&#160;30, 2021</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0306dd44-f570-40b0-928a-865d7a572ac8" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f9fce8c-40a6-4bf0-a16e-14485a843b9f" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:DepreciationDepletionAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.1</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for the three and six months ended June&#160;30, 2020, respectively. </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#160;&#160;</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued and Other Liabilities</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4ab2962d-aa5b-483c-b910-671a5c53ea00" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="vir:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" escape="true"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued and other liabilities consist of the following:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:69.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.384%;"></td>
        <td style="width:1.664%;"></td>
        <td style="width:1.463%;"></td>
        <td style="width:11.661%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1.664%;"></td>
        <td style="width:1.463%;"></td>
        <td style="width:11.661%;"></td>
        <td style="width:1.02%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">June&#160;30,<br />2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December&#160;31,<br />2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a9677b4e-48e4-4b6b-8a65-cd61af98cb43" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="vir:ResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30,952</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cc5e6174-3bdc-4fbd-a2cf-5ac7d967d621" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="vir:ResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">49,384</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Milestone payable</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e0ca81d0-41b3-4aa6-a0b6-242f25734f2e" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="vir:MilestonePayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payroll and related expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e525123-f0ca-4ff3-b20c-85f84c0ffc59" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="vir:PayrollAndRelatedExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,353</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_41d1e4a8-7642-4ddf-b7c5-a6581c38044e" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="vir:PayrollAndRelatedExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,060</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Excess funds payable under grant agreements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf2fff1b-875b-4475-9ea0-9eb14b6776b4" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="vir:ExcessFundsPayableUnderGrantAgreementsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,046</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_73f8dbc3-0dd9-4d69-9272-322e466a6d67" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="vir:ExcessFundsPayableUnderGrantAgreementsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,467</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f325ea35-0699-4e1f-93ea-537453528df9" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,522</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f74f8e93-b2f2-4c85-aeea-c01da2121d76" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,625</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other professional and consulting expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e648c8f-3f4e-4eab-b369-f9c53effe429" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,867</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d97a6a8c-4476-43c5-82e0-ac187a9b2b3e" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:AccruedProfessionalFeesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,595</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c321a475-fbb0-4149-a078-e53cbbe6c291" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,334</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0635bfc1-1c44-42a4-8951-61602576eda7" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">805</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total accrued and other liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c534ab75-8672-4396-86e8-4ff4dfeb9db7" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64,074</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9d2dcdd0-0114-4dd2-8f0a-0b4eeb682c48" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">76,936</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_74af05ef-1201-4b82-ace6-938717f02c6b" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true" continuedAt="F_74af05ef-1201-4b82-ace6-938717f02c6b_1"><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Lease Agreements</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has various lease arrangements for office and laboratory spaces located in California, Oregon, Missouri and Switzerland with contractual lease periods expiring between </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6fa7de1f-719c-4e55-b44c-ccaf56f837c2" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="vir:LeaseArrangementContractualExpirationBeginningYear"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_41270209-41e8-46e3-b731-dadbbd7ce211" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="vir:LeaseArrangementContractualExpirationEndingYear"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2033</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_050a889c-0633-4de5-9583-0834e8a7c631" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:LesseeOperatingLeaseOptionToExtend"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain lease agreements also provide the Company with the option to renew for additional periods ranging from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_68e96f79-a508-48f1-bc17-ed7aec35b970;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span></span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_594685a3-15ce-49c2-b342-3b85ce39311e" contextRef="C_7073499b-8aca-4a83-ae2c-8686d7874fe9" name="us-gaap:LesseeOperatingLeaseRenewalTerm" format="ixt-sec:durwordsen"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Most of these renewal options are not considered in the remaining lease term unless it is reasonably certain that the Company will exercise such options. In February 2021, the Company entered into a new lease arrangement for office and laboratory spaces in Oregon. The lease is expected to commence in the fourth quarter of 2021 when the Company obtains access to the leased space. In addition to the operating lease agreements, the Company entered into a sale-leaseback transaction in August 2019.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Throughout the term of the lease agreements, the Company is responsible for paying certain operating costs, in addition to rent, such as common area maintenance, taxes, utilities and insurance. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred. </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#160;&#160;</span></p><ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Unaudited Condensed Consolidated Financial Statements</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9aa2c0d0-7e99-4fe7-82f2-3da31e7ed05c" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The maturity of the Company&#x2019;s operating lease liabilities as of </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June&#160;30, 2021 was as follows (in thousands):</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:59.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:73.525%;"></td>
        <td style="width:1.915%;"></td>
        <td style="width:1.679%;"></td>
        <td style="width:21.861%;"></td>
        <td style="width:1.02%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amounts</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 (excluding the six months ended June 30, 2021)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_58fc6d2c-d8f0-44f5-958b-9b30aefdf98c" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,428</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e65600c-d552-4474-9819-158046df6bd6" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,713</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b83491b9-a066-4490-a01e-9bfb1ffb3e30" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">11,387</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4ae9af29-ad3a-472f-8c65-9f73269792c9" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,564</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f347820-64cd-481d-a6d7-66b4151dbfed" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,042</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e88fc6a7-c7cd-4fc3-8a82-9dc9372228ad" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="vir:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">67,466</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e155b8e4-7d6b-404d-add6-854819d92448" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">110,600</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_63374e32-a37f-4931-ba98-61e3c7674866" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">38,140</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: net tenant improvement allowance yet to be received</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6ea59b13-f866-4100-aa63-3d90fa056f63" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="vir:LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,287</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b994cab5-1477-48d8-8e24-418c0d878583" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="vir:PresentValueOfOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">62,173</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e78239e1-99d0-447c-98d5-2be8124a34e2" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="vir:ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock" escape="true"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following amounts were recorded in the condensed consolidated balance sheets for the periods ended:</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:59.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.954%;"></td>
        <td style="width:1.601%;"></td>
        <td style="width:1.695%;"></td>
        <td style="width:15.207%;"></td>
        <td style="width:1.02%;"></td>
        <td style="width:1.601%;"></td>
        <td style="width:1.695%;"></td>
        <td style="width:15.207%;"></td>
        <td style="width:1.02%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">June&#160;30,<br />2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December&#160;31,<br />2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Operating Leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current operating lease liabilities, net of tenant<br />&#160;&#160;&#160;improvement allowances</span><span style="color:rgba(0,0,0,1);top:-4.6899999999999995pt;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">&#160;(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_621ac5dc-b959-41b4-a949-bfa6ead3db85" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="vir:OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,287</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3d6a3aee-cb76-466b-916d-4d85ca0061f4" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="vir:OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,913</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e73f8073-3d09-4d00-83a7-27c97b615ac9" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">58,972</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f21be78f-3be9-49bd-bcac-2619d2a62130" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,947</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_89b36744-6825-4405-8082-31787f74cb3c;"><span style="-sec-ix-hidden:F_580369ee-3852-4e0f-9dd1-a3ca48903cb6;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued and other liabilities</span></span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a18daa7a-80d9-44ac-b9ac-c00c241e4c63" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,522</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e2414089-5a97-4911-9fbe-6f456942ab5d" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,625</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, noncurrent</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e636a02-a02a-4970-b2bd-eef18f4ca9ed" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">68,938</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b5607c8-878b-441b-b833-9e0587e3bbed" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">66,556</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_74ff2349-4169-4890-a579-9d5233a499cb" contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">72,460</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5b959f8c-2c52-4c59-b46b-52d7746d6573" contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">70,181</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="margin-left:2.777777777777657E-4in;display:flex;margin-top:0.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.19027777777777777in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.19027777777777777in;">(1)</span><div style="display:inline;"><ix:footnote id="FNT_af2a8f75-e140-4119-9483-1f845d2145ab" xml:lang="en-US"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Current portion of lease liabilities recorded in prepaid expenses and other current assets for which the lease incentives to be received exceed the minimum lease payments to be paid over the next twelve months.</span></ix:footnote></div></div></ix:nonNumeric></div><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Manufacturing and Supply Letter Agreements</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2020, the Company and Samsung Biologics Co., Ltd. (&#x201c;Samsung&#x201d;) entered into a binding letter agreement (the &#x201c;Samsung Letter Agreement&#x201d;), pursuant to which Samsung will perform development and manufacturing services for the Company&#x2019;s SARS-CoV-2 antibody program.&#160;In August 2020, the Company, GlaxoSmithKline Trading Services Limited (&#x201c;GSKTSL&#x201d;) and Samsung entered into an Assignment and Novation Agreement effective as of July 31, 2020 pursuant to which the Company assigned and transferred to GSKTSL all of the Company&#x2019;s right, title, and interest in, to and under the Samsung Letter Agreement, and GSKTSL became the Company&#x2019;s successor in interest in and to all of the Company&#x2019;s rights, duties, and obligations in, to and under the Samsung Letter Agreement.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2020, the Company and WuXi Biologics entered into a binding letter of intent (the &#x201c;WuXi Biologics Letter Agreement&#x201d;), pursuant to which WuXi Biologics will perform certain development and manufacturing services for the Company&#x2019;s SARS-CoV-2 antibody program. In August 2020, the Company, GSKTSL and WuXi Biologics entered into an Assignment and Novation Agreement effective as of July 29, 2020 pursuant to which the Company assigned and transferred to GSKTSL all of the Company&#x2019;s right, title, and interest in, to and under the WuXi Biologics Letter Agreement, and GSKTSL became the Company&#x2019;s successor in interest in and to all of the Company&#x2019;s rights, duties, and obligations in, to and under the WuXi Biologics Letter Agreement.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2020, GSKTSL entered into a Master Services Agreement with Samsung (the &#x201c;Samsung MSA&#x201d;) and a non-exclusive Master Services Agreement for Commercial Manufacture of Drug Substance with WuXi Biologics (the &#x201c;WuXi Biologics MSA&#x201d;) in connection with the performance of the obligations of the Company and GSK, pursuant to the 2020 GSK Agreement. In accordance with the terms of the 2020 GSK Agreement, the Company will continue to be responsible for </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6a91cc0c-4236-42f7-8c1f-d2784ba66bde" contextRef="C_2a630976-9689-4329-bdef-af492a67b7b2" name="vir:PercentageOfDevelopmentCosts" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">72.5</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the costs under each of the Samsung MSA and the WuXi Biologics MSA, and GSK will bear </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fdf0a045-e7a0-406c-8074-f747f1e75cd4" contextRef="C_e7b02693-c6da-4de6-a120-f9ea9345d4d8" name="vir:PercentageOfDevelopmentCosts" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">27.5</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of such costs under each of the Samsung MSA and the WuXi Biologics MSA, subject to certain conditions and exceptions.</span></p><ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Unaudited Condensed Consolidated Financial Statements</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Indemnification</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><ix:continuation id="F_74af05ef-1201-4b82-ace6-938717f02c6b_1"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. In some cases, the indemnification obligation will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. In addition, the Company has entered into indemnification agreements with its directors and certain officers that may require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no demands have been made upon the Company to provide indemnification under these agreements, and thus, there are no indemnification claims that the Company is aware of that could have a material effect on the Company&#x2019;s condensed consolidated balance sheets, condensed consolidated statements of operations, or condensed consolidated statements of cash flows.</span></ix:continuation></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> &#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b49c23cc-55fe-4df2-ad9c-c9c6120a86d9" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Related Party Transaction</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a result of the Brii Agreement in May 2018, the Company holds a minority equity interest in Brii Bio through its parent company, Brii Bio Parent. Additionally, a member of the Company&#x2019;s board of directors serves on Brii Bio Parent&#x2019;s board of directors.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective June 22, 2021, the Company's Chief Executive Officer is no longer a member of Brii Bio Parent's board of directors.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:-4.749%;padding-left:4.533%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</span><span><ix:nonNumeric id="F_64c8a998-4341-4896-8c64-4b32d43bc43d" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true" continuedAt="F_64c8a998-4341-4896-8c64-4b32d43bc43d_1"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Stock-Based Awards </span></ix:nonNumeric></span><span style=""></span></p>
  <div><ix:continuation id="F_64c8a998-4341-4896-8c64-4b32d43bc43d_1"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Option Activity</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6439d11b-8e14-4bf3-bed3-dc4e32ee9794" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Activity under the Company&#x2019;s stock option plans is set forth below:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.681%;"></td>
        <td style="width:1.307%;"></td>
        <td style="width:1.008%;"></td>
        <td style="width:12.973%;"></td>
        <td style="width:1.019%;"></td>
        <td style="width:1.317%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:12.942%;"></td>
        <td style="width:1.019%;"></td>
        <td style="width:1.317%;"></td>
        <td style="width:1.019%;"></td>
        <td style="width:12.984%;"></td>
        <td style="width:1.019%;"></td>
        <td style="width:1.317%;"></td>
        <td style="width:1.06%;"></td>
        <td style="width:12.942%;"></td>
        <td style="width:1.019%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br />Options</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br />Average<br />Exercise<br />Price</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br />Average<br />Remaining<br />Contractual<br />Term</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br />Intrinsic<br />Value</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_db244228-85d7-4de7-b453-8cece1e12cf4" contextRef="C_06a67e5e-7cd4-4262-8c8f-9cc28e2a7ddf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,798,282</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a96d2248-c9e5-4630-b0af-279a630beeaf" contextRef="C_06a67e5e-7cd4-4262-8c8f-9cc28e2a7ddf" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">5.25</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d7a853e-d8bb-4790-8b25-49317bf76567" contextRef="C_eda1b75d-a4eb-47cf-a94a-90d8ad6a84c9" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.5</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7b29cdcf-b4be-46ea-a456-e09bad4ac66a" contextRef="C_e877910e-22cc-4649-a193-5d784dba152c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,583,490</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b139d420-52d9-456c-a1fe-08f2868bf2d5" contextRef="C_e877910e-22cc-4649-a193-5d784dba152c" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">61.99</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5b305e1f-bc50-4ac0-8ad4-c490d03ff743" contextRef="C_e877910e-22cc-4649-a193-5d784dba152c" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,050,899</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4732432a-0758-4702-b15c-e7bc69c2f951" contextRef="C_e877910e-22cc-4649-a193-5d784dba152c" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">5.66</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_77f2d7ea-6740-473c-a9c2-d2ac2d8e62ec" contextRef="C_e877910e-22cc-4649-a193-5d784dba152c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">628,801</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4d737a15-8a27-4e8a-911e-6f65602d74f3" contextRef="C_e877910e-22cc-4649-a193-5d784dba152c" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">28.19</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at June 30, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_88e4cd46-60f2-497f-8964-a0ae8ee93506" contextRef="C_7828555d-b746-4f30-8bb5-ef260d0b147b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,702,072</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8297d5b5-b26d-4fe7-b666-e69d1732c496" contextRef="C_7828555d-b746-4f30-8bb5-ef260d0b147b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">30.24</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_05869e98-4af3-44b6-a9ad-d24549c196cd" contextRef="C_e877910e-22cc-4649-a193-5d784dba152c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.5</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c19cfe2f-b80c-4a5e-bac2-491fffa1dea1" contextRef="C_7828555d-b746-4f30-8bb5-ef260d0b147b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">223,581</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested and expected to vest at June 30, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3a5c7edf-02bf-40e3-a82d-11c8fad7feda" contextRef="C_7828555d-b746-4f30-8bb5-ef260d0b147b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,702,072</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dca5a681-ac33-47c9-8f3a-14ae8b15c04c" contextRef="C_7828555d-b746-4f30-8bb5-ef260d0b147b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">30.24</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ad2ab348-d3a3-460a-af8e-13c23d894ac8" contextRef="C_e877910e-22cc-4649-a193-5d784dba152c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.5</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_74c00c0f-15b9-45cb-85df-85c88587f330" contextRef="C_7828555d-b746-4f30-8bb5-ef260d0b147b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">223,581</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested and exercisable at June 30, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_19da3803-acc6-4c96-89b6-e0afa4ad5b1a" contextRef="C_7828555d-b746-4f30-8bb5-ef260d0b147b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,262,612</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f49303b3-1dd8-476d-919c-583d8f2c6819" contextRef="C_7828555d-b746-4f30-8bb5-ef260d0b147b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">13.40</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8447db98-e078-407b-8676-42d82f876a0b" contextRef="C_e877910e-22cc-4649-a193-5d784dba152c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.7</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_28c87811-31c1-45fe-ab32-a47a8ddf643d" contextRef="C_7828555d-b746-4f30-8bb5-ef260d0b147b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">110,878</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of June&#160;30, 2021</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company expects to recognize the remaining unamortized stock-based compensation expense of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_37bee8f9-8033-4ba1-9aef-f41f59b51335" contextRef="C_7828555d-b746-4f30-8bb5-ef260d0b147b" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">203.1</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million related to stock options, over an estimated weighted average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c3dbdc57-86cf-4c51-898b-b91054b6cf01" contextRef="C_e877910e-22cc-4649-a193-5d784dba152c" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.7</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Options Granted to Employees</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">T</span><span style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9139662a-d5ff-4c5c-a2e7-8433ad6eb786" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true" continuedAt="F_9139662a-d5ff-4c5c-a2e7-8433ad6eb786_1"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">he fair value of stock options granted to employees was estimated on the date of grant using the Black-Scholes option-pricing model using the following assumptions: </span></ix:nonNumeric></span><span style=""></span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:continuation id="F_9139662a-d5ff-4c5c-a2e7-8433ad6eb786_1"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:34.787%;"></td>
        <td style="width:1.296%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.0%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.296%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.009%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.296%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.009%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.296%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:13.009%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended June&#160;30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Six Months Ended June&#160;30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term of options (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_484ff5e6-26ad-41b1-8927-e4f7daa90ab6" contextRef="C_33a88677-9ecc-4f3d-aca3-76408bf827c3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f73737db-d0ba-41ff-abb8-c5bebc96ce08" contextRef="C_27542471-f913-4a68-8616-f01ea8e68d78" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d567248c-3805-466e-9371-8c5c162a8762" contextRef="C_e9e35c31-e697-4c7a-a5b4-23131aea2dca" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0976a599-e897-4209-95df-bd255081916d" contextRef="C_24a7634d-6a60-4a00-b501-5473727d2f4a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_272ad4da-33fb-4012-b0c9-1461da708aa6" contextRef="C_3dda4289-3d1f-4bc7-9199-58bb203939aa" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fdc44c48-9bba-4422-99d1-3d413f30f1ce" contextRef="C_a548882f-b462-4623-9763-e036f6ae6cce" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d480baa1-0435-4e9b-883d-924b5da0ee08" contextRef="C_e8581c5a-3e43-44a2-8670-9db42cd8f49a" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9bb3ef06-4a6a-40c5-9d78-87b475f1ef52" contextRef="C_51eb1ee6-e4e4-42a9-b6e3-135a3e77a4ef" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected stock price volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2ac88208-ee24-4219-814c-f0490a91da35" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">106.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bc030479-9c30-4d40-b1c1-88a585291876" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">110.2</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f788772b-79f8-40eb-be0f-599a48dba6bf" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">95.7</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1ac12bb4-3b03-4293-bf04-cf032d84e9ef" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">100.6</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0a8d78d7-0f86-4fbb-98fe-a9daf50f7edd" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">103.1</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fec336b4-af2e-4a7a-8785-1c9993ee66f0" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">110.2</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7ddc94e7-39d9-4ab0-8166-b56bd9d78049" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">88.8</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1ba6d173-a1b6-4dd5-91e8-54bdb3a9c4cb" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">100.6</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f63269e4-0f6b-492f-ae15-d3a3ebb8998d" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.0</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9d6e978d-d864-4e16-8b7c-fb8315c770b5" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.1</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_17a29e5c-cf1b-432c-835c-c8a9a7f48665" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e7b5f795-3413-43e8-940f-e56535e8c591" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5eca9e73-83cd-4051-880a-43f06c8fd90c" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e33d1665-f6ab-44d8-91ab-2a9c0f179637" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5a892188-44f0-4334-9d84-23ce184830ee" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_69f81614-1c2f-4db9-b6dd-0cb56501217e" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0f50243f-9b38-415f-ad73-01f892fb6ea8" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_db7ad2e7-2e41-42fe-b23f-fc3830edcf3a" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a6e51d93-ebf6-4e8d-92a0-da28f34c3cc3" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0661c670-ff67-4ec4-b7b0-c0602ec54b78" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Unaudited Condensed Consolidated Financial Statements</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The valuation assumptions were determined as follows:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:24.45pt;text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Term&#x2014;</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:24.45pt;text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Volatility&#x2014;</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected volatility was determined by examining the historical volatilities for industry peers and using an average of historical volatilities of the Company&#x2019;s industry peers as the Company does not have a sufficient historical trading history for its own stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:24.45pt;text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risk-Free Interest Rate&#x2014;</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:24.45pt;text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Dividend Rate&#x2014;</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its profit interest units in the foreseeable future.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Stock Awards and Restricted Stock Units Activities</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5e64bafd-4422-40c4-b917-3107a57974ad" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" escape="true"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s restricted stock awards (RSAs&#x201d;) and restricted stock units (&#x201c;RSUs&#x201d;) were summarized as follows:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:68.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.746%;"></td>
        <td style="width:1.471%;"></td>
        <td style="width:1.471%;"></td>
        <td style="width:14.597%;"></td>
        <td style="width:1.471%;"></td>
        <td style="width:1.471%;"></td>
        <td style="width:10.226%;"></td>
        <td style="width:1.035%;"></td>
        <td style="width:1.416%;"></td>
        <td style="width:1.471%;"></td>
        <td style="width:7.339%;"></td>
        <td style="width:1.035%;"></td>
        <td style="width:1.471%;"></td>
        <td style="width:7.312%;"></td>
        <td style="width:1.471%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted Average Grant Date Fair Value</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RSU</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RSA</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RSU</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RSA</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5be7b76b-1c3a-48f9-985d-1212f2f1f8ea" contextRef="C_0edc973f-cc4f-4eea-b393-2ad3dc16ecf5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5388b78d-0b04-45d7-8373-1a766c2e94cf" contextRef="C_61924055-2acd-43c4-9155-681af2ed1b88" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">89,261</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_df0d912f-fc6b-4365-adee-d9d839e650cc" contextRef="C_0edc973f-cc4f-4eea-b393-2ad3dc16ecf5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1de30fc9-c0fc-4da0-b9cf-25d264e5f84b" contextRef="C_61924055-2acd-43c4-9155-681af2ed1b88" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2">1.48</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c3612538-146b-424c-8900-08baa6af2bb3" contextRef="C_704b0f66-c02a-4e7b-91c5-906e38831293" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,050,995</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_158a7cd8-3077-4a9a-936c-1f31946dbd1b" contextRef="C_6ed8a63f-0dfd-42e1-84e0-c0de8453fb41" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fcc162a8-9daf-4184-9bb6-66ffb7e16dda" contextRef="C_704b0f66-c02a-4e7b-91c5-906e38831293" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2">64.25</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_41ecb537-f584-47ab-8d5e-799e58fcef1e" contextRef="C_6ed8a63f-0dfd-42e1-84e0-c0de8453fb41" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0a971b8c-0eaa-4f33-a4c4-8186426bda2d" contextRef="C_704b0f66-c02a-4e7b-91c5-906e38831293" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd4f9e24-fb09-4b58-96b7-b965f5321e36" contextRef="C_6ed8a63f-0dfd-42e1-84e0-c0de8453fb41" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">87,409</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5ca9656c-d7ee-4551-9364-8a0bb031fd84" contextRef="C_704b0f66-c02a-4e7b-91c5-906e38831293" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f5041b77-6588-42cf-962e-5e4d8e48736c" contextRef="C_6ed8a63f-0dfd-42e1-84e0-c0de8453fb41" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2">1.48</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a0d9adfd-bef3-4db8-a2f7-b202b5d598ff" contextRef="C_704b0f66-c02a-4e7b-91c5-906e38831293" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">28,550</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca8aee2a-39fe-48a4-8ced-7deb196f7235" contextRef="C_6ed8a63f-0dfd-42e1-84e0-c0de8453fb41" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b8c78a4d-e7c7-43ed-b2bc-ad6ebbe719a5" contextRef="C_704b0f66-c02a-4e7b-91c5-906e38831293" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2">67.38</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e9ea366c-1566-430d-82cb-dcf275f205c5" contextRef="C_6ed8a63f-0dfd-42e1-84e0-c0de8453fb41" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested as of June 30, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_829d11e9-6896-45fa-86dd-18c885027477" contextRef="C_8f01da11-0303-4186-9f77-73befdf1a6bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,022,445</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f5244eb2-15e5-4056-b78e-8eabd71c51b3" contextRef="C_6ef0ac41-102d-42f3-9751-1d32659fb4a7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,852</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_09c751fe-ab57-4a88-ba66-c5f563bc88d9" contextRef="C_8f01da11-0303-4186-9f77-73befdf1a6bc" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2">64.16</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2b4aecda-4740-48d4-96bf-7d77c2ca369b" contextRef="C_6ef0ac41-102d-42f3-9751-1d32659fb4a7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2">1.53</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The unvested shares of RSA and RSU have not been included in the shares issued and outstanding.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of June&#160;30, 2021</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, there was $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_360c4443-36b0-4ca6-90db-27ef029e2575" contextRef="C_8f01da11-0303-4186-9f77-73befdf1a6bc" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">59.7</ix:nonFraction></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million of total unrecognized compensation cost related to unvested RSUs, all of which is expected to be recognized over a remaining weighted-average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bdf46915-8a51-4020-a1d1-eacec344a0c5" contextRef="C_704b0f66-c02a-4e7b-91c5-906e38831293" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.6</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24441ab4-990e-4fbc-a957-be7b24da3b87" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the total stock-based compensation expense for all awards granted to employees and non-employees and the Company's Employee Stock Purchase Plan (&#34;ESPP&#34;) in the condensed consolidated statements of operations:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.195%;"></td>
        <td style="width:1.245%;"></td>
        <td style="width:1.049%;"></td>
        <td style="width:9.146%;"></td>
        <td style="width:1.019%;"></td>
        <td style="width:1.235%;"></td>
        <td style="width:1.049%;"></td>
        <td style="width:9.146%;"></td>
        <td style="width:1.019%;"></td>
        <td style="width:1.235%;"></td>
        <td style="width:1.049%;"></td>
        <td style="width:9.146%;"></td>
        <td style="width:1.019%;"></td>
        <td style="width:1.235%;"></td>
        <td style="width:1.049%;"></td>
        <td style="width:9.146%;"></td>
        <td style="width:1.019%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended June&#160;30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Six Months Ended June&#160;30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_883be59c-f87f-49ea-96d0-6dbf3f8f4f27" contextRef="C_ce595069-e39b-49ee-a1e2-8dcfaf1fc58f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,860</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f0bbef1d-0797-474d-86fa-582bae15fff1" contextRef="C_d09734ea-ce01-4393-81cd-a61fc90f7e98" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,700</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca2624d0-3942-4911-ae60-d79b2698b04f" contextRef="C_e39462a8-8050-424d-a953-9a65943f5705" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,290</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_55cf98df-02b8-44be-9cad-e8ccab174f8f" contextRef="C_3c73e700-bcbb-487f-bdf6-77164c1deeaf" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,188</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Selling, general and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b12c3b79-873d-438b-b1a0-bae7bc594f22" contextRef="C_ad365c4d-bc8d-4cfb-9e07-53dd946f68e3" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,138</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf89bbd0-c5ea-405f-904e-9522fa9f7905" contextRef="C_ee4e07f2-7234-48ee-b89e-21a8a39c2507" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,050</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2048143e-e729-4d23-99ff-11b15c658692" contextRef="C_991c9783-f1f0-4095-b9b0-9d1076bde40f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,179</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e9c60f5-aa97-409d-b47d-28fd083e9c15" contextRef="C_f7225c3a-02c3-4844-a759-8800e4846129" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,529</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_73f1d69d-7cc8-4eb9-8471-31a35baa358e" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,998</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ded514e8-7072-49d3-8632-cbc084c13af5" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,750</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_951bef6d-de73-4b91-b578-71b27dde2194" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">36,469</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ed6b87e8-7d52-46c8-9466-e2a5918cd00a" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8,717</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:continuation></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div><ix:nonNumeric id="F_2aaa8b3c-f3e1-444d-93ec-40d691b4a359" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net Income (Loss) Per Share</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net income (loss) per common share is computed by dividing the net income (loss) by the sum of the weighted average number of common shares outstanding during the period plus any potential dilutive effects of common stock equivalents outstanding during the period calculated in accordance with the treasury stock method. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1edddb2-2637-496c-9b54-5ba32a04d967" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true" continuedAt="F_a1edddb2-2637-496c-9b54-5ba32a04d967_1"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following is a calculation of the basic and diluted net income (loss) per share (in thousands, except share and per share data):</span></ix:nonNumeric></span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:continuation id="F_a1edddb2-2637-496c-9b54-5ba32a04d967_1"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Unaudited Condensed Consolidated Financial Statements</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:43.704%;"></td>
        <td style="width:1.046%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:9.991%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.056%;"></td>
        <td style="width:1.037%;"></td>
        <td style="width:12.361%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.056%;"></td>
        <td style="width:1.037%;"></td>
        <td style="width:10.407%;"></td>
        <td style="width:1.0%;"></td>
        <td style="width:1.056%;"></td>
        <td style="width:1.037%;"></td>
        <td style="width:11.213%;"></td>
        <td style="width:1.0%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended June&#160;30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Six Months Ended June&#160;30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss), basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4f9b8af4-1844-43fa-a5e0-6a429148df79" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">61,813</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4c66319b-f86d-4b9e-8341-91cd90488483" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">31,167</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a6713aea-8871-4dbb-8adc-d06ff3faac87" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">107,098</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab1807b0-9a8e-48fb-8851-247614774a58" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">108,407</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares outstanding, basic</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_03e1fb52-472f-4f05-a11c-901224c6ddd0" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">130,121,943</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6dcafd54-ec67-4aa8-9b75-48eb8250b51e" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">114,980,652</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f24ade01-54f6-492d-8af2-a981551aea87" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">128,938,851</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6c7e1377-f6e7-4c09-a6c6-097c42192523" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">111,684,283</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average effect of dilutive securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_732bf63f-54b3-48d8-b9e1-47feffa47adc" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,635,656</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted shares subject to future vesting</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fc56bd7b-d7bd-4252-b221-6aedcba0ceac" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="vir:IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">19,409</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contingently issuable shares</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_37204caf-d0c5-43b4-bc57-b169730a947c" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">12,969</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares outstanding, diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d5311527-2649-4308-a51e-a44dcc3f867d" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">133,789,977</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9e350c78-e8aa-4324-9cde-93edea97f73a" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">114,980,652</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae1c2028-3239-4677-a09f-822cfcded63f" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">128,938,851</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c5b248f0-c9b0-4db5-bb7f-51ac7762cd96" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">111,684,283</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss) per share, basic</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6fb506e2-2899-4748-918e-858bc7f296fa" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2">0.48</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2ccb2c67-599d-4c77-bb53-245606506213" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-">0.27</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5ce77d44-05b2-4591-a8bd-39bd4dc85dfd" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-">0.83</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_31ee118e-96da-466e-b63e-09c709fe14d3" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:EarningsPerShareBasic" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-">0.97</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss) per share, diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c017e2fd-6790-412a-922a-5b67457c5b2a" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2">0.46</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_44237d65-d3c3-47ba-9c37-83ece647d22a" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-">0.27</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9cd3ef3b-fd37-4c5a-aa4c-5a97aab1ff9a" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-">0.83</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c7d0215-1375-44ec-af99-2d593396ffc3" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:EarningsPerShareDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-">0.97</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></ix:continuation></div><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a7d87c36-b630-453a-bb7a-2e9da6554145" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.909%;"></td>
        <td style="width:1.08%;"></td>
        <td style="width:1.008%;"></td>
        <td style="width:9.887%;"></td>
        <td style="width:1.008%;"></td>
        <td style="width:1.07%;"></td>
        <td style="width:0.998%;"></td>
        <td style="width:12.459%;"></td>
        <td style="width:0.998%;"></td>
        <td style="width:1.07%;"></td>
        <td style="width:1.111%;"></td>
        <td style="width:10.031%;"></td>
        <td style="width:0.998%;"></td>
        <td style="width:1.07%;"></td>
        <td style="width:0.998%;"></td>
        <td style="width:11.307%;"></td>
        <td style="width:0.998%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"><br /></span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended June&#160;30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Six Months Ended June&#160;30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options issued and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_375318a8-08e1-4a1b-b38c-9c1d8cebad74" contextRef="C_23d80066-9c6a-4bf0-aa4b-f95964ef06dc" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,164,036</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7df1b0eb-069c-4c20-ab7f-0061cd7ef166" contextRef="C_bd77d5c8-3f48-412e-8a01-2400a5a99d89" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,932,845</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_caa15d88-2dc2-487c-9c4f-89e7c394c646" contextRef="C_f1864eb6-8023-4cef-ad5b-04b72b08c0df" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,702,072</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7f8e0763-62b1-4e7b-b41e-f4d80a2e77ab" contextRef="C_b863aacc-f9e9-437e-93af-f43803e428c1" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">8,932,845</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Estimated shares issuable under the ESPP</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ef4e0d8f-d89f-4f2a-a7fa-54b645d27b9f" contextRef="C_c85ee215-3e1c-44fb-b984-1097930c5e13" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">71,582</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cdd199cf-8752-4917-ac39-c0fd12e7251a" contextRef="C_63fb600b-266b-4936-b5f6-f0acd37a0f30" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_58bc2415-97d7-4650-befd-f2dfded164e5" contextRef="C_0546abb1-16aa-4fcd-a7d6-0e80f088c135" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">71,582</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f71e725-bbd3-4a4a-90f1-f7f7ea292b7c" contextRef="C_a2ea91d2-7c4a-4260-9f6d-7c6a185c065b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted shares subject to future vesting</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f68449e0-c533-4f29-b969-9c00e9b95cae" contextRef="C_cc9ec168-d4bd-41fa-97ec-80d1e7eac7e4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">933,870</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf7ef683-5bda-4164-8754-07d28bb31767" contextRef="C_7b946c14-81b3-4ee4-9cc6-59aca5e74078" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">844,886</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d1428778-06bf-4df4-a0b6-0d60ee3f83bf" contextRef="C_64416581-7d0b-4707-ab43-2587ae9cbcd4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,024,297</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_498a05c2-09ca-469a-9e7c-c381aed6e78b" contextRef="C_7b508c4b-45d1-41c3-816a-cd29050692e2" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">844,886</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contingently issuable shares</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c90ea2e7-cd85-4492-8284-477b156d3223" contextRef="C_04fdbfd3-0666-4745-bebd-01d2061c67e4" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_af94b75c-aba6-4eef-8a7e-e944dae44b68" contextRef="C_a4e86e58-4404-4536-961e-ac48e8ff6e70" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f441d205-d9e9-4270-9a0b-4759a09a5dbe" contextRef="C_324b7022-f782-4c4b-a128-564a104bd122" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">39,340</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5ba48e56-8305-45dc-a188-94220133d0ba" contextRef="C_eeb1528b-b730-41f5-8477-0b25922ee91b" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_098b0914-4a80-4fe1-8aa8-a61f2ebe6431" contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,169,488</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f0878af0-2e6b-442e-b5ae-4e32930d4dff" contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,777,731</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e81c7dee-c7c4-423d-a5f0-63ef4ce60c69" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">11,837,291</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c9877ba2-4eda-4dda-9da5-9dba69987874" contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">9,777,731</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4728eeb5-1646-49f9-a73d-f37c402c49be" contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12. Subsequent Event</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investment in Brii Bio Parent</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 13, 2021, Brii Bio Parent became a publicly traded company on the Stock Exchange of Hong Kong Limited. As such, the Company's investment in shares of Brii Bio Parent became a marketable equity investment with readily determinable price, which will then be measured at fair value at each reporting period going forward.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="mda"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 2. Management&#x2019;s Discussion and Ana</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">lysis of</span><span id="item_2_managements_discussion_analysis_f"></span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Financial Condition and Results of Operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations in conjunction with our unaudited condensed consolidated financial statements and the related notes and other financial information included elsewhere in this Quarterly Report on Form 10-Q and our audited consolidated financial statements and notes thereto and the related Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations included as part of our Annual Report on Form 10-K for the year ended December 31, 2020. Unless the context requires otherwise, references in this Quarterly Report on Form 10-Q to the &#x201c;Company&#x201d;, &#x201c;Vir,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d; refer to Vir Biotechnology, Inc. and its consolidated subsidiaries.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Infectious diseases are among the leading causes of death worldwide and can cause trillions of dollars of direct and indirect economic burden each year &#x2013; as evidenced by the COVID-19 pandemic. We believe that now is the time to apply the recent and remarkable advances in immunology to combat infectious diseases. Our approach begins with identifying the limitations of the immune system in combating a particular pathogen, the vulnerabilities of that pathogen and the reasons why previous approaches have failed. We then bring to bear powerful technologies that we believe, individually or in combination, will lead to effective therapies.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, or HBV, influenza A virus, and human immunodeficiency virus, or HIV. We have assembled four technology platforms, focused on antibodies, T cells, innate immunity and small interfering ribonucleic acid, or siRNA, through internal development, collaborations and acquisitions. We have built an industry-leading team that has deep experience in immunology, infectious diseases, and product development and commercialization. Given the global impact of infectious diseases, we are committed to developing cost-effective treatments that can be delivered at scale.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">COVID-19</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sotrovimab (previously VIR-7831) is an investigational severe acute respiratory syndrome coronavirus 2, or SARS-CoV-2, neutralizing monoclonal antibody, or mAb, that incorporates Xencor&#x2019;s Xtend&#153; technology.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:7.867%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During and after the quarter, sotrovimab was authorized for emergency use in the U.S., received a positive Committee for Human Medicinal Products, or CHMP, scientific opinion in the European Union, or EU, and was granted interim, emergency or conditional authorization in Bahrain, Canada, Italy, Kuwait, Qatar, Singapore and the United Arab Emirates. </span></div></div>
  <div style="margin-left:7.867%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Together with GlaxoSmithKline plc, or GSK, we have established supply agreements with multiple governments around the world and continue to work actively to make sotrovimab available to patients in need. In July, the companies also signed a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of sotrovimab.&#160;</span></div></div>
  <div style="margin-left:7.867%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Updated in vitro data, published in bioRxiv, demonstrate that sotrovimab retains activity against currently circulating variants of concern and interest of the SARS-CoV-2 virus including Alpha (B.1.1.7), Beta (B.1.351), Delta (B.1.617.2), Delta Plus (AY.1 or AY.2), Epsilon (B.1.427/B.1.429), Eta (B.1.525), Gamma (P.1), Iota (B.1.526), Kappa (B.1.617.1) and Lambda (C.37), as well as new variants from Bristol (B.1.1.7+E484K) and Cameroon (B.1.619), which predominantly includes both N440K and E484K mutations that may lead to reduced activity for other neutralizing mAbs against the SARS-CoV-2 virus. We and GSK are continuing to evaluate the ability of sotrovimab to maintain activity against new and emerging variants through in vitro studies.</span></div></div>
  <div style="margin-left:7.867%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May, the European Medicines Agency&#x2019;s, or EMA, CHMP initiated a rolling review of data on sotrovimab that will continue until enough evidence is available to support a formal marketing authorization application. The rolling review process is expected to be complete in the second half of 2021.</span></div></div>
  <div style="margin-left:7.867%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May, the EMA&#x2019;s CHMP issued a positive scientific opinion on sotrovimab for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19. The CHMP opinion under Article 5(3) can now be considered by the national authorities in EU member states when making evidence-based decisions on the early use of the medicine prior to marketing authorization. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:7.867%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May, the U.S. Food and Drug Administration, or FDA, granted an Emergency Use Authorization, or EUA, to sotrovimab for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. Together with GSK, we plan to submit a Biologics License Application, or BLA, to the FDA in the second half of 2021.</span></div></div>
  <div style="margin-left:7.867%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June, we and GSK announced confirmatory full results for the Phase 3 COMET-ICE (</span><span style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">CO</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VID-19 </span><span style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">M</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">onoclonal antibody </span><span style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">E</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fficacy </span><span style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">T</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">rial - </span><span style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">I</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ntent to </span><span style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">C</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">are </span><span style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">E</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">arly) trial, which resulted in a 79% reduction (adjusted relative risk reduction) (p&lt;0.001) in all-cause hospitalization for more than 24 hours or death due to any cause by Day 29 compared to placebo, meeting the primary endpoint of the trial. </span></div></div>
  <div style="margin-left:7.867%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June, the U.S.&#160;National Institutes of Health, or NIH, updated its COVID-19 treatment guidelines&#160;to recommend sotrovimab for non-hospitalized patients with mild-to-moderate COVID-19 who are at high risk of clinical progression. The NIH guidelines note that sotrovimab appears to retain activity against current variants of concern and interest. The Infectious Disease Society of America also updated its treatment guidelines in June to recommend use of sotrovimab in the same patient population. </span></div></div>
  <div style="margin-left:7.867%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We and GSK are continuing to advance additional trials of sotrovimab:</span></div></div>
  <div style="margin-left:14.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.25in;">o</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Phase 2 COMET-PEAK (</span><span style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">P</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">atient Saf</span><span style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">E</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ty, Toler</span><span style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">A</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">bility, Pharmaco</span><span style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">K</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">inetics) pharmacokinetic trial in outpatients with mild-to-moderate COVID-19 is investigating intramuscular, or IM, administration of sotrovimab (500 mg intravenous, or IV, vs. 500 mg IM and 250 mg IM). Enrollment is complete and initial data are expected in the fall of 2021.</span></div></div>
  <div style="margin-left:14.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.25in;">o</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Phase 3 COMET-TAIL (</span><span style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">T</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reatment of </span><span style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">A</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cute COVID-19 with </span><span style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">I</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ntramuscular monoc</span><span style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">L</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">onal antibody) trial for early treatment of mild-to-moderate COVID-19 in high-risk, non-hospitalized adult and pediatric patients is evaluating the role of IM-administered sotrovimab (500 mg IV vs. 500 mg IM vs 250 mg IM). The trial was initiated in June and data are now expected in the second half of 2021.</span></div></div>
  <div style="margin-left:14.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.25in;">o</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A prophylaxis trial is planned in uninfected immunocompromised adults to determine whether sotrovimab can prevent symptomatic COVID-19 infection.</span></div></div>
  <div style="margin-left:7.867%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We and GSK have established a strategic manufacturing network that will enable the manufacture of approximately two million doses to support emergency supply in the first year following&#160;U.S.&#160;EUA, with approximately 450,000 doses currently on hand.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-7832 is an investigational vaccinal SARS-CoV-2-neutralizing mAb that incorporates Xencor&#x2019;s Xtend and other Fc technologies. In April, the first patient was dosed in the United Kingdom National Health Service-supported AGILE initiative. The trial initiative is the first to evaluate VIR-7832 in a Phase 1b/2a trial of adults with mild-to-moderate COVID-19. VIR-7832 shares the same characteristics as sotrovimab and has been engineered to potentially be a therapeutic T cell vaccine to further help treat and/or prevent COVID-19. Initial safety data are expected in the second half of 2021. Additionally, in July, the FDA cleared our investigational new drug application for VIR-7832.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">HBV</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-2218, an investigational HBV-targeting siRNA, is currently in a Phase 2 trial. We also continued to progress a Phase 2 combination trial of VIR-2218 with pegylated interferon-alpha (PEG-IFN-&#x3b1;) to evaluate the potential for this combination to result in a functional cure for HBV. In June, one year response durability data for VIR-2218 as monotherapy and initial clinical data for the combination of VIR-2218 with PEG-IFN-&#x3b1; were presented at the European Association for the Study of the Liver, or EASL, International Liver Conference 2021. We expect additional data in the second half of 2021.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:7.867%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Data demonstrated a promising safety profile and the potential durable response of VIR-2218 through 48 weeks. </span></div></div>
  <div style="margin-left:7.867%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In a separate analysis evaluating VIR-2218 in combination with PEG-IFN-&#x3b1; for 12 weeks from Day 1, a more rapid and substantial decline in hepatitis B surface antigen, or HBsAg, was observed compared to VIR-2218 alone. The treatment regimen resulted in no new safety signals. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-3434, an investigational HBV-neutralizing mAb that incorporates Xencor&#x2019;s Xtend and other Fc technologies, is currently in a Phase 1 trial.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:7.867%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June, additional safety and efficacy data were presented at the EASL International Liver Conference 2021. Two new analyses from the ongoing Phase 1 trial of VIR-3434 showed no safety signals in healthy volunteers dosed with up to 3,000 mg, and a rapid reduction in HBsAg levels one week after subcutaneous administration of VIR-3434 to virally suppressed patients with chronic HBV infection. We also expect additional data in the second half of 2021. </span></div></div>
  <div style="margin-left:7.867%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July, we initiated a Phase 2 trial to evaluate the combination of VIR-2218 and VIR-3434 as a functional cure regimen for chronic HBV infection. Initial data are expected in the first half of 2022.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Influenza A virus</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-2482, an investigational mAb designed for the prevention of influenza A that incorporates Xencor&#x2019;s Xtend technology, is currently in a Phase 1/2 trial and has been generally well-tolerated. In May 2021, we signed a collaboration agreement, or the 2021 GSK Agreement, with GSK to expand our existing collaboration to include the research and development of new therapies for influenza and other respiratory viruses. The expanded collaboration, which builds on the agreement signed in 2020 to research and develop therapies for coronaviruses, provides GSK exclusive rights to collaborate with us on the development of potential best-in-class mAbs for the prevention or treatment of influenza. As part of the agreement, we and GSK will also engage in two additional research programs: 1) an expansion of the current functional genomics collaboration to include other respiratory virus targets; and 2) the development of up to three neutralizing mAbs identified using our antibody technology platform to target non-influenza pathogens during a three-year research period. Given the relatively low incidence of influenza during the COVID-19 pandemic, and the current rise in COVID-19 cases due to variants, we and GSK are currently evaluating potential timelines for advancing VIR-2482 and other influenza therapies covered under the expanded agreement. Under the terms of the agreement, GSK paid $345.0 million in a combination of an upfront payment and a further equity investment in us. For details regarding this agreement, see Note 6&#x2014;Collaboration and License Agreements to our unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">HIV</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">VIR-1111, an investigational HIV T cell vaccine based on human cytomegalovirus, or HCMV, is currently in a Phase 1 trial. This proof-of concept trial is designed to test the hypothesis that this new approach can elicit potentially protective immune responses that differ from other HIV vaccines. If observed, this T cell vaccine could potentially have utility in additional types of infections and other challenging areas, including cancer.</span><span style="color:rgba(255,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Initial clinical data are expected in the second half of 2021.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We were incorporated in April 2016 and commenced principal operations later that year. To date, we have focused primarily on organizing and staffing our company, business planning, raising capital, identifying, acquiring, developing and in-licensing our technology platforms and product candidates, and conducting preclinical studies and early clinical trials.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have financed our operations primarily through sales of our common stock from our initial public offering and subsequent follow-on offering and convertible preferred securities and payments received under our grant and collaboration agreements. As of June&#160;30, 2021, excluding restricted cash, we had $876.7 million in cash, cash equivalents and investments. Based upon our current operating plan, we believe that our existing cash, cash equivalents and investments as of June&#160;30, 2021 will enable us to fund our operations through at least the next 12 months from the issuance date of the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred significant operating losses since our inception and expect to continue to incur significant operating losses for the foreseeable future. Although we received an EUA for sotrovimab in May 2021, have recently entered into procurement agreements to supply sotrovimab and began recognizing revenue for sotrovimab, the extent of future revenue remains uncertain. We have not obtained regulatory approval for any other product candidates, and we do not expect to generate significant revenue from the sale of our other product candidates until we complete clinical development, submit regulatory filings and receive approvals from the applicable regulatory bodies for such product candidates, if ever. Our net losses were $107.1 million and $108.4 million for the six months ended June&#160;30, 2021 and 2020, respectively. As of June&#160;30, 2021, we had an accumulated deficit of $774.3 million. Our primary use of our capital resources is to fund our operating expenses, which consist primarily of expenditures related to identifying, acquiring, developing, manufacturing and in-licensing our technology platforms and product candidates, and conducting preclinical studies and early clinical trials, and to a lesser extent, general and administrative expenditures. Cash used to fund operating expenses is impacted by the timing of when we pay these expenses, as reflected in the change in our outstanding accounts payable and accrued expenses. Although we recently began recognizing revenue for sotrovimab and have a substantial deferred revenue under our 2021 GSK Agreement, we</span><span style="color:rgba(255,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expect to continue to incur net operating losses for at least the next several years as the extent of future revenue remains uncertain. In particular, we expect our expenses and losses to increase as we continue our research and development efforts,</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">advance our product candidates through preclinical and clinical development, seek regulatory approval, prepare for commercialization, as well as hire additional personnel, protect our intellectual property and incur additional costs associated with being a public company. We also expect to increase the size of our administrative function to support the growth of our business. Our net losses may fluctuate significantly from quarter-to-quarter and year-to-year, depending on the timing of our clinical trials and our expenditures on other research and development activities.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are currently manufacturing product candidates from three of our platforms: antibodies, T cells and siRNAs. We have established our own internal chemistry, manufacturing and control capabilities and are working with contract development and manufacturing organizations, or CDMOs, to supply our early stage product candidates in the near-term. We have completed our internal capacity build in process development, analytical development, quality, manufacturing and supply chain. Specifically, our San Francisco, California and Portland, Oregon facilities include laboratories that support process development, production of HCMV research viral seed stock and selected quality control testing for our product candidates. We have established relationships with multiple CDMOs and have produced material to support preclinical studies and Phase 1 through Phase 3 clinical trials. Material for Phase 3 clinical trials and commercial supply will generally require large-volume, low-cost-of-goods production. For example, for our COVID-19 program, we and our partner GSK have executed manufacturing agreements with large-scale CDMOs to support future scale-up and capacity, particularly for potential commercialization.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">COVID-19 Business Update</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">With the global spread of the current COVID-19 pandemic, we have implemented a number of plans and policies designed to address and mitigate the impact of the COVID-19 pandemic on our employees and our business. We continue to closely monitor the COVID-19 situation and will evolve our plans and policies as needed going forward. As a result of these developments, in March 2020, we implemented work-from-home policies for most of our employees. We have also implemented plans, which continue to evolve based on the current climate and response to the ongoing COVID-19 pandemic, to reopen our offices to allow employees to return when appropriate. Although these plans are based on a phased approach consistent with local government requirements, and focused on employee safety, and contemplate returning to remote work should new restrictions be implemented, there is uncertainty regarding recent phased reopening, which may be rolled back, and restrictions re-implemented. We are also working to provide our employees with the support they need to ensure continuity of business operations. We are working closely with our CDMOs to manage our supply chain activities and mitigate any potential disruptions to our clinical trial supplies as a result of the COVID-19 pandemic. If the COVID-19 pandemic persists for an extended period of time and begins to impact essential distribution systems, we could experience disruptions to our supply chain and operations, and associated delays in the manufacturing of clinical trial supply. For some of our clinical development programs, we are experiencing, and may continue to experience, a disruption or delay in our ability to initiate trial sites and enroll and assess patients. In addition, we rely on contract research organizations or other third parties to assist us with clinical trials, and we cannot guarantee that they will continue to perform their contractual duties in a timely and satisfactory manner as a result of the COVID-19 pandemic.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our License, Collaboration and Grant Agreements</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have entered into grant, license and collaboration arrangements with various third parties. For details regarding these and other agreements, see Note</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5&#x2014;Grant Agreements and Note 6&#x2014;Collaboration and License Agreements to our unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Components of Operating Results</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2021, we received an EUA for sotrovimab in the U.S. and have recently entered into procurement agreements to supply sotrovimab and begun recognizing revenue from our profit share under our 2020 GSK Agreement. However, the extent of future revenue remains uncertain. We have not obtained regulatory approval for any other product candidates, and we do not expect to generate any significant revenue from the sale of our other product candidates until we complete clinical development, submit regulatory filings and receive approvals from the applicable regulatory bodies for such product candidates, if ever.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our revenue consists of the following:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaboration revenue</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> includes recognition of our profit share from the sales of sotrovimab pursuant to the 2020 GSK Agreement. Our contractual share of 72.5% from the sales of sotrovimab is based upon the revenue reported to us by GSK , net of cost of sales and allowable expenses (including distribution, selling and marketing expenses) in the period.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contract revenue</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> includes recognition of the upfront fees from license rights issued to GSK and revenue generated from research and development services.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Grant revenue</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> is comprised of revenue derived from grant agreements with government-sponsored and private organizations.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License revenue from a related party</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> comprised of revenue related to Brii Biosciences Offshore Limited&#x2019;s, or Brii Bio&#x2019;s, exercise of its option to obtain exclusive rights to develop and commercialize compounds arising from VIR-2218 in greater China recognized in prior year.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Expenses</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cost of Revenue</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cost&#160;of&#160;revenue&#160;currently represents payments due to certain of our third-party licensors, who are entitled to future royalties based on net sales of sotrovimab by us or our collaboration partners. We recognize these royalties as cost of revenue when we recognize the corresponding revenue that gives rise to payments due to our licensors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, our research and development expenses have related primarily to discovery efforts and preclinical and clinical development of our product candidates. Research and development expenses are recognized as incurred and payments made prior to the receipt of goods or services to be used in research and development are capitalized until the goods or services are received. We do not track research and development expenses by product candidate.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses consist primarily of costs incurred for our product candidates in development and prior to regulatory approval, which include:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expenses related to license and collaboration agreements, and contingent consideration from business acquisitions; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">personnel-related expenses, including salaries, benefits and stock-based compensation for personnel contributing to research and development activities; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expenses incurred under agreements with third-party contract manufacturing organizations, contract research organizations, and consultants; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical costs, including laboratory supplies and costs related to compliance with regulatory requirements; and </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">other allocated expenses, including expenses for rent and facilities maintenance, and depreciation and amortization. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect our research and development expenses to increase substantially in absolute dollars for the foreseeable future as we advance our product candidates into and through preclinical studies and clinical trials and pursue regulatory approval of our product candidates. The process of conducting the necessary clinical research to obtain regulatory approval is costly and time-consuming. The actual probability of success for our product candidates may be affected by a variety of factors including: the safety and efficacy of our product candidates, early clinical data, investment in our clinical programs, the ability of collaborators to successfully develop our licensed product candidates, competition, manufacturing capability and commercial viability. We have only recently received EUA for sotrovimab and we may never succeed in achieving BLA for sotrovimab or any of our product candidates. As a result of the uncertainties discussed above, we are unable to determine the duration and completion costs of our research and development projects or when and to what extent we will generate significant revenue from the commercialization and sale of sotrovimab or any of our product candidates. Clinical and preclinical development timelines, the probability of success and development costs can differ materially from expectations. We anticipate that we will make determinations as to which product candidates to pursue and how much funding to direct to each product candidate on an ongoing basis in response to the results of ongoing and future preclinical studies and clinical trials, regulatory developments, our ongoing assessments as to each product candidate&#x2019;s commercial potential and the impact of public health epidemics, such as the COVID-19 pandemic. In addition, we cannot forecast which product candidates may be subject to future collaborations, when such arrangements will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our clinical development costs may vary significantly based on factors such as:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether a collaborator is paying for some or all of the costs; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">per patient trial costs; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of trials required for approval; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of sites included in the trials; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the countries in which the trials are conducted; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the length of time required to enroll eligible patients; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of patients that participate in the trials; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number of doses that patients receive; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the drop-out or discontinuation rates of patients; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential additional safety monitoring requested by regulatory agencies; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the duration of patient participation in the trials and follow-up; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost and timing of manufacturing our product candidates; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the phase of development of our product candidates; and </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the efficacy and safety profile of our product candidates. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Selling, General and Administrative</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our selling, general and administrative expenses consist primarily of personnel-related expenses for personnel in executive, finance and other administrative functions, facilities and other allocated expenses, and other expenses for outside professional services, including legal, audit and accounting services, and insurance costs. Personnel-related expenses consist of salaries, benefits and stock-based compensation.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect our selling, general and administrative expenses to increase substantially in absolute dollars for the foreseeable future as we continue to support our continued research and development activities, grow our business and commercialization activities for our EUA product or any of our product candidates, if approved. We also anticipate incurring additional expenses associated with operating as a public company, including increased expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with the rules and regulations of the SEC and standards applicable to companies listed on a national securities exchange, additional insurance expenses, investor relations activities and other administrative and professional services.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Income</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income consists of interest earned on our cash, cash equivalents and investments.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Income (Expense), Net</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income (expense), net consists of gains and losses from foreign currency transactions and the remeasurement of contingent consideration related to our acquisition of TomegaVax, Inc., or TomegaVax.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Provision for Income Taxes</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision for income taxes consisted of international income tax.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Results of Operations</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comparison of the Three and Six Months Ended June 30, 2021 and 2020</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our results of operations for the periods presented:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:27.377%;"></td>
    <td style="width:0.638%;"></td>
    <td style="width:1.049%;"></td>
    <td style="width:9.342%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:0.844%;"></td>
    <td style="width:1.049%;"></td>
    <td style="width:9.146%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:0.844%;"></td>
    <td style="width:1.049%;"></td>
    <td style="width:9.146%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:1.235%;"></td>
    <td style="width:1.049%;"></td>
    <td style="width:9.146%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:0.741%;"></td>
    <td style="width:1.049%;"></td>
    <td style="width:9.146%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:0.844%;"></td>
    <td style="width:1.049%;"></td>
    <td style="width:9.146%;"></td>
    <td style="width:1.019%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended June&#160;30,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Six Months Ended June&#160;30,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="22" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenue:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Collaboration revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,333</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,333</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,333</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,333</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contract revenue</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">168,653</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43,522</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125,131</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">169,266</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44,009</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125,257</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grant revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,082</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">719</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,363</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,453</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,950</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1,497</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">License revenue from a related party</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,747</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(22,747</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,747</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(22,747</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">177,068</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66,988</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110,080</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">179,052</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72,706</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106,346</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cost of revenue</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,144</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,144</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,152</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,152</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86,126</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79,653</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,473</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">220,996</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">144,632</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76,364</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Selling, general and administrative</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,781</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,386</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,395</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54,520</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,035</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25,485</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">116,051</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96,039</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,012</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">276,668</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">173,667</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103,001</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income (loss) from operations</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61,017</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(29,051</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90,068</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(97,616</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(100,961</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,345</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income (expense):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">825</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(728</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">261</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,580</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2,319</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income (expense), net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">752</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2,895</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,647</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(9,494</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(9,964</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">470</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total other income (expense)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">849</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2,070</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,919</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(9,233</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(7,384</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(1,849</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income (loss) before provision for income taxes</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61,866</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(31,121</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92,987</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(106,849</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(108,345</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,496</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision for income taxes</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(53</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(46</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(7</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(249</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(62</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(187</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61,813</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(31,167</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92,980</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(107,098</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(108,407</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,309</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The increase in collaboration revenue for the three and six months ended June 30, 2021 compared to the same periods in 2020 was due to $5.3 million of revenue from our profit-sharing arrangement with GSK for the sale of sotrovimab under our 2020 GSK Agreement, for which there were no comparable revenues recognized in prior year. Our contractual share of 72.5% from the sales of sotrovimab is based upon the revenue reported to us by GSK, net of cost of sales and allowable expenses (including distribution, selling and marketing expenses) in the period.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The increase in contract revenue for the three and six months ended June 30, 2021 compared to the same periods in 2020 was primarily due to $168.3 million from deferred revenue related to the license granted to GSK upon execution of our 2021 GSK Agreement, partially offset by $43.3 million related to the license granted to GSK upon execution of our 2020 GSK Agreement in prior year.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The increase in grant revenue for the three months ended June 30, 2021 compared to the same period in 2020 was primarily due to the timing of research activities under the HIV and TB grants with the Bill &amp; Melinda Gates Foundation. The decrease in grant revenue for the six months ended June 30, 2021 compared to the same period in 2020 was primarily due to a supplemental award received in the first quarter of 2020 under the HIV grant for reimbursement, in part, of prior period costs.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The decrease in license revenue from a related party was due to the $22.7 million of revenue related to Brii Bio&#x2019;s exercise of its option to obtain exclusive rights to develop and commercialize compounds arising from VIR-2218 in greater China recognized in prior year.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cost of Revenue</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The increase in cost of revenue for the three and six months ended June 30, 2021 compared to the same periods in 2020 was due to third-party royalties owed based on the sales of sotrovimab, that received an EUA in May 2021, under our 2020 GSK Agreement.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table shows the primary components of our research and development expenses for the periods presented:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:93.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.099%;"></td>
    <td style="width:1.235%;"></td>
    <td style="width:1.235%;"></td>
    <td style="width:8.642%;"></td>
    <td style="width:1.235%;"></td>
    <td style="width:1.235%;"></td>
    <td style="width:1.235%;"></td>
    <td style="width:7.407%;"></td>
    <td style="width:1.235%;"></td>
    <td style="width:1.085%;"></td>
    <td style="width:1.035%;"></td>
    <td style="width:8.005%;"></td>
    <td style="width:0.986%;"></td>
    <td style="width:1.085%;"></td>
    <td style="width:1.035%;"></td>
    <td style="width:8.005%;"></td>
    <td style="width:0.986%;"></td>
    <td style="width:1.085%;"></td>
    <td style="width:1.035%;"></td>
    <td style="width:8.005%;"></td>
    <td style="width:0.986%;"></td>
    <td style="width:1.085%;"></td>
    <td style="width:1.035%;"></td>
    <td style="width:8.005%;"></td>
    <td style="width:0.986%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended June&#160;30,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Six Months Ended June&#160;30,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="22" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Licenses, collaborations and contingent consideration</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,058</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,563</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(8,505</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71,071</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59,558</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,513</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Personnel</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,025</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,756</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,269</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53,828</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29,165</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24,663</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contract manufacturing</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,322</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,959</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(15,637</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,642</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,644</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(6,002</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,413</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,278</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,135</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46,147</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,499</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38,648</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,308</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,097</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,211</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34,308</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26,766</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,542</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86,126</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79,653</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,473</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">220,996</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">144,632</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76,364</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(33,37,41,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comparison of three months ended June 30, 2021 and 2020</span></p>
  <p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This increase in research and development expenses for the three months ended June 30, 2021 compared to the same period in 2020 was primarily due to the following factors:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.1700000000000002;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">personnel-related expenses increased by $13.3 million, which was primarily attributable to an increase in our headcount;</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.1700000000000002;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical costs increased by $12.1 million, which was primarily attributable to activities related to our sotrovimab and VIR-2218 clinical trials; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.1700000000000002;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">other research and development expenses increased by $5.2 million, which was primarily attributable to increases of $2.7 million in sublicense fees due under a license agreement, and $2.0 million in the allocation of facilities and other costs due to an increase in our headcount and higher lease expense;</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.1700000000000002;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">contract manufacturing expense decreased by $15.6 million, which was primarily related to completion of manufacturing activities for our COVID-19 product candidates in the third quarter of 2020; and</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.1700000000000002;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">licenses, collaborations and contingent consideration expenses decreased by $8.5 million, which was primarily attributable to decreases of $18.8 million related to the change in fair value of the contingent consideration from our acquisition of Humabs Biomed SA, or Humabs, $10.0 million payment to Alnylam Pharmaceuticals, Inc., or Alnylam, resulting from Brii Bio&#x2019;s exercise of its option for VIR-2218 in the second quarter of 2020, and $1.3 million in costs under our collaboration agreement with Alnylam, or Alnylam Agreement, partially offset by an increase of $21.6 million in costs under our collaboration arrangements with GSK.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(33,37,41,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comparison of six months ended June 30, 2021 and 2020</span></p>
  <p style="margin-left:4.133%;text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This increase in research and development expenses for the six months ended June 30, 2021 compared to the same period in 2020 was primarily due to the following factors:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.1700000000000002;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical costs increased by $38.6 million, which was primarily attributable to activities related to our sotrovimab and VIR-2218 clinical trials;</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.1700000000000002;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">personnel-related expenses increased by $24.7 million, which was primarily attributable to an increase in our headcount; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.1700000000000002;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">licenses, collaborations and contingent consideration expenses increased by $11.5 million, which was primarily attributable to increases of $40.1 million in costs under our collaboration arrangements with GSK and $15.0 million related to the change in fair value of the contingent consideration from our acquisition of Humabs, partially offset by decreases of $31.8 million due to achievement of the first development milestone under our Alnylam Agreement in the first quarter of 2020, $10.0 million payment to Alnylam resulting from Brii Bio's exercise of its option for VIR-2218 in the second quarter of 2020, and $1.8 million in collaboration costs under our Alnylam Agreement; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.1700000000000002;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">other research and development expenses increased by $7.5 million, which was primarily attributable to increases of $4.4 million in the allocation of facilities and other costs due to an increase in our headcount and higher lease expense, and $2.7 million in sublicense fees due under a license agreement; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.1700000000000002;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">contract manufacturing expense decreased by $6.0 million, which was primarily related to completion of manufacturing activities for our COVID-19 product candidates in the third quarter of 2020.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Selling, General and Administrative Expenses</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The increase in selling, general and administrative expenses for the three and six months ended June 30, 2021 compared to the same periods in 2020 was primarily due to increases in personnel-related expenses related to additional headcount, external consulting services and recruiting expenses.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Income</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The decrease in interest income was primarily due to lower interest rates and higher amortization of premium on investment balances in the three and six months ended June 30, 2021 compared to the same periods in 2020.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Income (Expense), Net</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The decrease in other expense for the three and six months ended June 30, 2021 compared to the same periods in 2020 was primarily related to the change in fair value of the contingent consideration related to our acquisition of TomegaVax.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liquidity, Capital Resources and Capital Requirements</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sources of Liquidity</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of June&#160;30, 2021, excluding restricted cash, we had $876.7 million in cash, cash equivalents and investments, and an accumulated deficit of $774.3 million. To date, we have financed our operations primarily through sales of our common stock from our initial public offering and follow-on offering; sales of our convertible preferred securities; and payments received under our grant and collaboration agreements.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2020, we entered into a sales agreement, or the Sales Agreement, with Cowen and Company, LLC, or Cowen, pursuant to which we may from time to time offer and sell shares of our common stock for an aggregate offering price of up to $300.0 million, through or to Cowen, acting as sales agent or principal. As of June 30, 2021, no shares have been issued under the Sales Agreement.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2021, in connection with the 2021 Preliminary Agreement with GSK, we issued 1,924,927 shares of our common stock to Glaxo Group Limited (an affiliate of GSK), or GGL, for an aggregate purchase price of approximately $120.0 million. In the second quarter of 2021, we received $225.0 million of upfront fee under the 2021 GSK Agreement.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our primary use of our capital resources is to fund our operating expenses, which consist primarily of expenditures related to identifying, acquiring, developing, manufacturing and in-licensing our technology platforms and product candidates, and conducting preclinical studies and early clinical trials, and to a lesser extent, general and administrative expenditures.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Future Funding Requirements</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based upon our current operating plan, we believe that our existing cash, cash equivalents and investments as of June&#160;30, 2021 will enable us to fund our operations through at least the next 12 months from the issuance date of the condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned. Moreover, it is particularly difficult to estimate with certainty our future expenses given the dynamic and rapidly evolving nature of our business and the COVID-19 pandemic environment generally. We will also need to raise additional capital to complete the development and commercialization of our product candidates and fund certain of our existing manufacturing and other commitments. We anticipate raising additional capital through the sale of our equity securities, incurring debt, entering into collaboration, licensing or similar arrangements with third parties, or receiving research contributions, grants or other sources of financing to fund our operations. To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be or could be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. If we raise funds through collaborations, licenses and other similar arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us and/or may reduce the value of our common stock. There can be no assurance that sufficient</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">funds will be available to us on attractive terms or at all. If we are unable to obtain additional funding from these or other sources, it may be necessary to significantly reduce our rate of spending through reductions in staff and delaying, scaling back, or stopping certain research and development programs. Insufficient liquidity may also require us to relinquish rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. In addition, the COVID-19 pandemic continues to rapidly evolve and has already resulted in a significant disruption of global financial markets. If the disruption persists and deepens, we could experience an inability to access additional capital, which could in the future negatively affect our capacity for certain corporate development transactions or our ability to make other important, opportunistic investments.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have based our projections of operating capital requirements on assumptions that may prove to be incorrect and we may use all of our available capital resources sooner than we expect. Because of the numerous risks and uncertainties associated with research, development and commercialization of biotechnology products, we are unable to estimate the exact amount of our operating capital requirements. Our future funding requirements will depend on many factors, including, but not limited to:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing, progress and results of our ongoing preclinical studies and clinical trials of our product candidates; </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials of other product candidates that we may pursue; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to establish and maintain collaboration, license, grant and other similar arrangements, and the financial terms of any such arrangements, including the timing and amount of any future milestone, royalty or other payments due thereunder; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs, timing and outcome of regulatory review of our product candidates; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs and timing of commercialization activities, including product manufacturing, marketing, sales and distribution, for our EUA product and any of our product candidates for which we receive marketing approval; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the amount of revenue received from commercial sales of our EUA product or any product candidates for which we receive marketing approval; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any expenses needed to attract, hire and retain skilled personnel; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of operating as a public company; and </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent to which we acquire or in-license other companies&#x2019; product candidates and technologies. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Flows</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our cash flows for the periods indicated:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:69.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.667%;"></td>
    <td style="width:1.449%;"></td>
    <td style="width:1.449%;"></td>
    <td style="width:11.594%;"></td>
    <td style="width:1.449%;"></td>
    <td style="width:1.449%;"></td>
    <td style="width:1.449%;"></td>
    <td style="width:13.043%;"></td>
    <td style="width:1.449%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Six Months Ended June&#160;30,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided by (used in):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50,529</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(59,048</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">162,909</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114,804</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91,032</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">205,425</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net increase in cash and cash equivalents and restricted<br />&#160;&#160;&#160;&#160;cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">304,470</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">261,181</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Activities</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the six months ended June&#160;30, 2021, net cash provided by operating activities was $50.5 million. This consisted primarily of a net loss of $107.1 million, offset by a decrease in our net operating assets of $72.7 million and non-cash charges of $85.0 million. The change in our net operating assets of $72.7 million was primarily due to an increase in deferred revenue by $90.5 million driven by the upfront fee received under the 2021 GSK Agreement, and increase in accounts payable by $4.9 million, which was partially offset by decreases in accrued liabilities and other long-term liabilities by $22.3 million due to timing of payments. The non-cash charges of $85.0 million primarily consisted of $42.9 million for revaluation of contingent consideration, $36.5 million for stock-based compensation expense, and $2.5 million for depreciation and amortization.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the six months ended June&#160;30, 2020, net cash used in operating activities was $59.0 million. This consisted primarily of a net loss of $108.4 million, an increase in our net operating assets of $2.6 million, and a payment on contingent consideration of $6.5 million related to a milestone achieved under our Humabs acquisition, partially offset by non-cash charges of $58.5 million. The change in our net operating assets of $2.6 million was primarily due to a decrease in deferred revenue of $4.0 million related to revenue recognized from the Bill &amp; Melinda Gates Foundation grants, an increase of $2.2 million in prepaid expenses and other current assets related to a receivable under our 2020 GSK Agreement, a decrease in operating lease liabilities of $1.6 million due to lease payments, and a decrease in accounts payable of $1.3 million, which was partially offset by an increase in accrued liabilities and other long-term liabilities by $6.8 million due to higher research and development activities. The non-cash charges of $58.5 million primarily consisted of $27.8 million for revaluation of contingent consideration, $16.8 million for the change in fair value of the derivative liability under the Alnylam Agreement, $8.7 million for stock-based compensation expense, and $2.1 million for depreciation and amortization.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investing Activities</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the six months ended June&#160;30, 2021, net cash provided by investing activities was $162.9 million. This consisted primarily of $221.4 million in proceeds received from investments which matured during the period, partially offset by purchases of investments of $55.7 million and property and equipment of $2.7 million.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the six months ended June&#160;30, 2020, net cash provided by investing activities was $114.8 million. This consisted primarily of $247.2 million in proceeds received from investments which matured during the period, partially offset by purchases of investments of $129.9 million and property and equipment of $2.6 million.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:8.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financing Activities</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the six months ended June&#160;30, 2021, net cash provided by financing activities was $91.0 million. This consisted primarily of proceeds received from the issuance of our common stock to GGL of $85.2 million in March 2021 and from exercises of stock options of&#160;$5.9 million.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the six months ended June 30, 2020, net cash provided by financing activities was $205.4 million. This consisted primarily of proceeds received from the issuance of our common stock to GGL of $206.7 million in April 2020 and from exercises of stock options of $2.4 million, partially offset by a payment of contingent consideration related to our Humabs acquisition of $3.5 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Contractual Obligations and Commitments</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There have been no material changes from the contractual obligations previously disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2020.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Off-Balance Sheet Arrangements</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the periods presented we did not have, nor do we currently have, any off-balance sheet arrangements as defined under the rules of the SEC. Brii Biosciences Limited, or Brii Bio Parent, and its wholly owned subsidiary, Brii Bio, are variable interest entities due to their reliance on future financing and insufficient equity at risk. However, we do not have the power to direct activities that most significantly impact the economic success of these entities and are not the primary beneficiary, and therefore we do not consolidate Brii Bio Parent or Brii Bio.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Critical Accounting Policies and Estimates</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States. The preparation of our unaudited condensed consolidated financial statements requires us to make assumptions and estimates about future events and apply judgments that affect the reported amounts of assets, liabilities, revenue and expenses and the related disclosures. We base our estimates on historical experience and other assumptions that we believe to be reasonable under the circumstances. Actual results may differ from these estimates.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There have been no significant changes in our critical accounting policies during the six months ended June&#160;30, 2021, as compared with those previously disclosed in our Annual Report on Form 10-K for the year ended December&#160;31, 2020, filed with the SEC on February 25, 2021.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1429166666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_quantitative_qualitative_disclosu"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 3. Quantitative and Qualitat</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ive Disclosures About Market Risk.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1429166666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are exposed to market risks in the ordinary course of our business. These risks primarily relate to interest rate sensitivities.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1429166666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Rate Risk</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We had cash, cash equivalents and restricted cash and cash equivalents of $756.0 million as of June&#160;30, 2021, which consisted of money market funds and bank time deposits. We also had short- and long-term investments of $134.8 million as of June&#160;30, 2021. The primary objective of our investment activities is to preserve capital to fund our operations. We also seek to maximize income from our investments without assuming significant risk. Because our investments are primarily short-term in duration and our holdings in U.S. government treasury bonds mature prior to our expected need for liquidity, we believe that our exposure to interest rate risk is not significant, and a 1% movement in market interest rates would not have a significant impact on the total value of our portfolio. We had no debt outstanding as of June&#160;30, 2021.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1429166666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Foreign Currency</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The functional currency of our foreign subsidiaries is the U.S. dollar. Monetary assets and liabilities of our foreign subsidiaries are translated into U.S. dollars at period-end exchange rates and non-monetary assets and liabilities are translated to U.S. dollars using historical exchange rates. Revenue and expenses are translated at average rates throughout the respective periods. As of the date of this Quarterly Report on Form 10-Q, we are exposed to foreign currency risk related to the operations of our Swiss and Australian subsidiaries and consequently the Swiss Franc and Australian dollar. Transaction gains and losses are included in other income (expenses), net on the condensed consolidated statements of operations and were not material for the six months ended June&#160;30, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1429166666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Effects of Inflation</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inflation generally affects us by increasing our cost of labor and clinical trial costs. We do not believe that inflation has had a material effect on our results of operations during the periods presented.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.1429166666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_controls_and_procedures"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 4. Controls and Procedures</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1429166666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Evaluation of Disclosure Controls and Procedures</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management, with the participation and supervision of our Chief Executive Officer and our Chief Financial Officer, have evaluated our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Quarterly Report on Form 10-Q. Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer have concluded that, as of the end of the period covered by this Quarterly Report on Form 10-Q, our disclosure controls and procedures were effective to provide reasonable assurance that information we are required to disclose in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that such information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There were no changes in our internal control over financial reporting that occurred during our second fiscal quarter ended June&#160;30, 2021 that materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iior_information"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART II&#x2014;OTHER</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> INFORMATION</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1_legal_proceedings"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1. Legal</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Proceedings.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may become involved in legal proceedings arising in the ordinary course of our business. We are not currently party to any material legal proceedings, and we are not aware of any pending or threatened legal proceeding against us that we believe could have an adverse effect on our business, operating results or financial condition.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_1a_risk_factors"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1A. Ris</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">k Factors.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">An investment in shares of our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as the other information in this Quarterly Report on Form 10-Q, including our unaudited condensed consolidated financial statements and the related notes included elsewhere in this Quarterly Report on Form 10-Q and &#x201c;Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations,&#x201d; before deciding whether to invest in our common stock. The occurrence of any of the events or developments described below could harm our business, financial condition, results of operations and/or prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. In such an event, the market price of our common stock could decline and you may lose all or part of your investment. You should consider all of the risk factors described when evaluating our business.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Financial Position and Capital Needs</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have incurred significant net losses since inception and anticipate that we will continue to incur substantial net losses for the foreseeable future and may never achieve or maintain profitability.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since inception in April 2016, we have incurred significant net losses and have never generated any significant revenue from product sales. Our net loss was $107.1 million and $108.4 million for the six months ended June&#160;30, 2021 and 2020, respectively. As of June&#160;30, 2021, we had an accumulated deficit of $774.3 million. Although we have recently entered into procurement agreements to supply sotrovimab and began to recognize revenue for sotrovimab, the extent of future revenue remains uncertain.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;We expect to continue to incur significant expenses and increasing net losses for the foreseeable future. Since inception, we have devoted substantially all of our efforts to identifying, researching and conducting preclinical and clinical activities of our product candidates, acquiring and developing our technology platforms and product candidates, organizing and staffing our company, business planning, raising capital and establishing our intellectual property portfolio. To date, we have only obtained Emergency Use Authorization, or EUA, for sotrovimab. It could be several years, if ever, before we are able to commercialize any of our other products. The net losses we incur may fluctuate significantly from quarter to quarter and year to year. To become and remain profitable, we must succeed in developing and eventually commercializing products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical studies and clinical trials of our current and future product candidates, obtaining regulatory approval, procuring commercial-scale manufacturing, marketing and selling any products for which we obtain regulatory approval (including through third parties), as well as discovering or acquiring and developing additional product candidates. We are only in the preliminary stages of most of these activities. We may never succeed in these activities and, even if we do, may never generate revenue that is sufficient to offset our expenses and achieve profitability.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of the numerous risks and uncertainties associated with biopharmaceutical product development, we are unable to accurately predict the timing or amount of expenses or when, or if, we will be able to achieve profitability. If we are required by regulatory authorities to perform studies and trials in addition to those currently expected, or if there are any delays in the initiation and completion of our clinical trials or the development of any of our product candidates, our expenses could increase.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our limited operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a clinical-stage company founded in April 2016 and our operations to date have been largely focused on identifying, researching and conducting preclinical and clinical activities of our product candidates, acquiring and developing our technology platforms and product candidates, organizing and staffing our company, business planning, raising capital and establishing our intellectual property portfolio. We have only recently received an EUA</span><span style="color:rgba(255,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">from the U.S. Food and Drug Administration, or the FDA, for sotrovimab and are in the early stages of seeking approval under a BLA and expanding our commercialization capabilities for sotrovimab. As an organization, we have not yet demonstrated an ability to obtain marketing approvals, successfully manufacture a</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">commercial-scale product or conduct sales and marketing activities necessary for successful commercialization or arrange for a third party to conduct these activities on our behalf. Consequently, any predictions about our future success or viability may not be as accurate as they could be if we had a longer operating history.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently have four technology platforms and eight product candidates in our development pipeline. We may encounter unforeseen expenses, difficulties, complications, delays and other known or unknown factors in achieving our business objectives, including with respect to our technology platforms and product candidates.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We will require substantial additional funding to finance our operations. If we are unable to raise capital when needed, we could be forced to delay, reduce or terminate certain of our development programs or other operations.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of June&#160;30, 2021, excluding restricted cash, we had cash, cash equivalents and investments of $876.7 million. Based upon our current operating plan, we believe that our existing cash, cash equivalents and investments as of June&#160;30, 2021 will fund our current operating plans through at least the next 12&#160;months from the issuance date of our consolidated financial statements for the period ended June&#160;30, 2021. However, our operating plan may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned. Moreover, it is particularly difficult to estimate with certainty our future expenses given the dynamic and rapidly evolving nature of our business and the COVID-19 pandemic environment generally. We will also need to raise additional capital to complete the development and commercialization of our EUA product or our product candidates and fund certain of our existing manufacturing and other commitments. We expect to finance our cash needs through public or private equity or debt financings, third-party (including government) funding and marketing and distribution arrangements, as well as other collaborations, strategic alliances and licensing arrangements, or any combination of these approaches. Our future capital requirements will depend on many factors, including:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing, progress and results of our ongoing preclinical studies and clinical trials of our product candidates; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope, progress, results and costs of preclinical development, laboratory testing and clinical trials of other product candidates that we may pursue; </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to establish and maintain collaboration, license, grant and other similar arrangements, and the financial terms of any such arrangements, including timing and amount of any future milestones, royalty or other payments due thereunder; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs, timing and outcome of regulatory review of our product candidates; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs and timing of commercialization activities, including product manufacturing, marketing, sales and distribution, for our EUA product and any of our product candidates for which we receive marketing approval; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the amount of revenue received from commercial sales of our EUA product or any product candidates for which we receive marketing approval; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any expenses needed to attract, hire and retain skilled personnel; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of operating as a public company; and </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.25in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.25in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent to which we acquire or in-license other companies&#x2019; product candidates and technologies. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The COVID-19 pandemic and the evolution of new and existing variants of COVID-19 has resulted in a significant disruption of global financial markets. If the disruption persists and deepens, we could experience an inability to access additional capital, which could in the future negatively affect our capacity for certain corporate development transactions or our ability to make other important, opportunistic investments. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or altogether terminate our research and development programs or commercialization efforts, which may adversely affect our business, financial condition, results of operations and prospects. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our product candidates.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until such time, if ever, as we can generate substantial product revenue, we expect to finance our cash needs through public or private equity or debt financings, third-party (including government) funding and collaborations and strategic alliances, or any combination of these approaches. To the extent that we raise additional capital through the sale of equity or convertible debt securities,</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">your ownership interest in our company may be diluted and the terms of these securities may include liquidation or other preferences that adversely affect your rights as a stockholder. Debt and equity financings, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as redeeming our shares, making investments, incurring additional debt, making capital expenditures, declaring dividends or placing limitations on our ability to acquire, sell or license intellectual property rights.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we raise additional capital through future collaborations or strategic alliances, we may have to relinquish valuable rights to our intellectual property, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. If we are unable to raise additional capital when needed, we may be required to delay, limit, reduce or terminate our product development or commercialization efforts or grant rights to develop and market product candidates that we would otherwise develop and market ourselves.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We received an EUA from the FDA for sotrovimab (previously VIR-7831). If the FDA revokes or terminates our EUA for sotrovimab for the early treatment of COVID-19, such as when the federally-declared COVID-19 public health emergency ends, we will be required to stop commercial distribution of sotrovimab unless we can obtain FDA approval for this product and its currently authorized uses.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sotrovimab is currently made available pursuant to an EUA we received from the FDA on May 26, 2021 for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at risk for progression to severe COVID-19, including hospitalization or death. We cannot predict how long this EUA will remain effective for, and we may not receive advance notice from the FDA regarding revocation of our EUA. If our EUA is terminated or revoked, sotrovimab will no longer be available until and if we have obtained FDA approval of a biologics license application, or BLA. Changing policies and regulatory requirements could limit, delay or prevent further commercialization sotrovimab and could adversely impact our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our near-term success is dependent on the successful roll-out and commercialization of sotrovimab for the early treatment of COVID-19.&#160;If we are unable to successfully roll-out and commercialize sotrovimab, our business, financial condition, results of operations and prospects may be adversely affected.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our near-term success is dependent on the successful roll-out and commercialization of sotrovimab, which is our only currently available product. The commercial success of sotrovimab will depend on a number of factors, some of which are outside of our control, including the following:&#160;</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to comply with all regulatory requirements applicable to our EUA, including applicable FDA marketing, manufacturing and post-market requirements and other requirements of our EUA;</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether we are required by the FDA or other similar regulatory authorities to conduct additional clinical trials or to modify the design of our current trials to support the approval of sotrovimab;</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the receipt of additional marketing authorizations and approvals from the FDA and other similar regulatory authorities;</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to achieve and maintain compliance with all regulatory requirements applicable to sotrovimab;</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">perceptions by the public and members of the medical community, including physicians, as to the safety and efficacy of sotrovimab;</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">demand from the public and members of the medical community for sotrovimab;</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the availability, perceived advantages, relative cost, relative convenience and relative efficacy of sotrovimab compared to other COVID-19 therapies;</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability of sotrovimab to be effective in patients with COVID-19 and its variants;</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">positive or negative media coverage of sotrovimab;</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the effectiveness of our marketing and sales efforts;</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to raise additional capital on acceptable terms, or at all, if needed to support the commercialization of sotrovimab;</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability to enter into additional procurement contracts with government entities or be approved for inclusion in government stockpile programs, and our ability to meet our obligations under such contracts and programs;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our reliance on GSK and other partners for development, commercialization and manufacturing of sotrovimab; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to obtain, maintain and enforce our intellectual property rights;</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to maintain a continued supply of sotrovimab that meets our quality control requirements;</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ability of third-party manufacturing partners to meet demand in a timely manner, in accordance with our specifications, and in compliance with applicable regulatory requirements;</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">limitation on use or warnings required by the FDA; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our current and future arrangements with healthcare providers, physicians and third-party payors; and </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">availability of, or changes in, coverage or reimbursement rates for sotrovimab from government or other commercial or healthcare payors.</span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, COVID-19 treatment standards are susceptible to rapid clinical developments. Sotrovimab may be rendered inferior or obsolete, even if it were to gain widespread market acceptance initially. If we are unable to successfully roll-out and commercialize sotrovimab, our business, financial condition, results of operations and prospects may be adversely affected.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are committing substantial financial resources and personnel and making substantial capital commitments with third parties in furtherance of our pursuit of a potential therapy for&#160;COVID-19,&#160;the disease caused by the virus&#160;SARS-CoV-2,&#160;and we may be unable to secure sufficient capital, market demand or manufacturing capacity to successfully develop and commercialize a therapy that treats the virus in a timely manner, if at all.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In response to the ongoing outbreak of&#160;COVID-19,&#160;the disease caused by the virus&#160;SARS-CoV-2,&#160;we are pursuing various potential therapies to address the disease, including through mAbs using our antibody platform (in collaboration with several partners), such as&#160;sotrovimab&#160;and&#160;VIR-7832.&#160;Although we have received EUA from the FDA for sotrovimab for the early treatment of COVID-19, and positive scientific opinion from the European Medicines Agency, or EMA, related to the use of sotrovimab for the early treatment of COVID-19 and recently entered into procurement agreements to supply sotrovimab, we have not obtained regulatory approval for sotrovimab or any other product candidates, and we may be unable to successfully develop and commercialize a therapy that treats the virus in a timely manner, if at all.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are also committing substantial financial resources, both internally and externally, and personnel to the development of a potential therapy for&#160;COVID-19,&#160;which may cause delays in or otherwise negatively impact our other development programs, despite uncertainties surrounding the market demand and role that antibody therapies will play in the treatment COVID-19. There are no assurances that there will be sufficient market demand for our COVID-19 therapies. Market demand and utilization of our COVID-19 therapies may be adversely impacted by factors such as the&#160;rollout&#160;of vaccines, the emergence of new viral variants, and the current challenges in the delivery and administration of mAbs to patients.&#160;</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to develop a successful therapy will also depend on the success of our manufacturing capabilities, for which we are dependent on third-party manufacturing organizations and which will require significant additional funding. Our current estimated aggregate commitments to GSK under two separate master services agreements with Samsung Biologics Co., Ltd. and WuXi Biologics (Hong Kong) Limited, or WuXi Biologics, for drug substance, drug product and raw material were approximately $365 million as of June 30, 2021, excluding the approximate &#x201c;access fee&#x201d; payable to Biogen, Inc. that is payable only if we use Biogen, Inc.&#x2019;s technology. For additional information regarding our obligations under these agreements, see the section titled &#x201c;Business&#x2014;Our Collaboration, License and Grant Agreements&#x201d; and &#x201c;Business&#x2014;Manufacturing&#x2014;Manufacturing Agreements&#x201d; in our Annual Report on Form 10-K for the year ended December 31, 2020, or 2020 Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While we believe securing such manufacturing capacity and technological expertise is essential to the potential success of our&#160;SARS-CoV-2&#160;antibody development programs, such capital commitments plus any future commitments, in the aggregate, may, in the future, exceed our available cash and cash equivalents and investments.&#160;We may also need to enter into additional manufacturing arrangements in the future in order to create an effective supply chain for sotrovimab and our other COVID-19&#160;product candidates that will adequately support demand. In the event that there is not enough demand for the manufacturing capacity that we have already secured or regulatory approval of our product candidates is delayed or unsuccessful, we may remain obligated to pay for such excess manufacturing capacity, which could adversely affect our business, financial condition, results of operations and prospects. We will need to raise substantial additional capital to fund the development of sotrovimab and our product candidates and meet our capital commitments to our manufacturing partners in connection therewith. There can be no assurance that sufficient funds will be available to us on attractive terms or at all and our ability to obtain additional capital could be adversely affected if there is a significant decline in the&#160;demand&#160;for our products or other significantly unfavorable changes in economic conditions.&#160;If we are unable to obtain additional funding from these or other sources, it may be necessary to significantly reduce our rate of spending through reductions in</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">staff and delaying, scaling back, or stopping certain research and development programs. Insufficient liquidity may also require us to relinquish rights to product candidates at an earlier stage of development or on less favorable terms than we would otherwise choose. Our business could be negatively impacted by our allocation of significant resources to a global health threat that is unpredictable or against which our potential therapies, if developed, may not be partially or fully effective, and may ultimately prove unsuccessful or unprofitable. Furthermore, there are no assurances that we will secure significant supply commitments from governments or that our therapy will be approved for inclusion in government stockpile programs, which may be material to the commercial success of sotrovimab and our product candidates, either in the United States or abroad.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, another party may be successful in producing a more efficacious therapy for&#160;SARS-CoV-2&#160;or in producing a therapy that is easier to deliver and administer to patients in a timelier manner, which may also lead to the diversion of funding away from us and toward other companies or lead to decreased demand for our potential therapies. Numerous large and small pharmaceutical and biotechnology companies are developing COVID-19 therapy programs, including prophylactic vaccines, oral antivirals, immunomodulators, and antibodies some of which are further along in the development process than we are. For example, in November 2020, Regeneron Pharmaceuticals, Inc., or Regeneron, received EUA from the FDA for REGEN-COV (casirivimab with imdevimab), a cocktail of two monoclonal antibodies, which has been shown to reduce hospitalization and death risk by 70% in clinical trials. Other companies like AstraZeneca plc, or AstraZeneca, and Adagio Therapeutics, or Adagio, have been successful in securing government support and funding, respectively, and are in the process of developing antibody treatments that, if successful, could be effective against known viral variants and be administered via intramuscular, or IM, injection. There are also efforts by other companies in developing prophylactic vaccines against COVID-19. For example, in December 2020, Pfizer Inc. and Moderna, Inc. and in February 2021, Janssen Biotech Inc. received EUA from the FDA for their COVID-19 vaccines which have been proven to be 95%, 94% and 85% effective, respectively, in clinical trials. In addition, there are potential small molecule therapies being developed by others such as Merck &amp; Co, Inc. These other entities may be more successful at developing, manufacturing or commercializing a therapy for&#160;COVID-19.&#160;Several of these other organizations are much larger than we are and have access to larger pools of capital, including U.S. government funding, and broader manufacturing infrastructure. There are no assurances that there will be sufficient market demand for our COVID-19 therapies, that we will secure U.S. government funding, that our manufacturing and supply chain infrastructure will remain uninterrupted and reliable, or that the third parties we rely on to manufacture our COVID-19 therapies will be able to satisfy our demand and not have stock-outs due to raw material shortages and/or greater than anticipated demand or quality issues given the operational challenges and raw material shortages that have been experienced during the COVID-19 pandemic, all of which may adversely impact our ability to commercialize a therapy for COVID-19. In addition, several organizations have already secured significant commitments from governments to purchase COVID-19 antibodies and vaccines. The success or failure of other entities, or perceived success or failure, may adversely impact our ability to obtain any future funding for our development and manufacturing efforts or to successfully commercialize a therapy for&#160;COVID-19. Additionally, the availability of superior or competitive therapies, or preventative measures such as vaccines, coupled with the transient nature of pandemics, could negatively impact or eliminate&#160;demand&#160;for our COVID-19 therapies. For additional information regarding our competition see the section below titled &#x201c;&#x2014;Risks Related to the Development and Commercialization &#x2014; We face substantial competition, which may result in others developing or commercializing products before or more successfully than us.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to the Development and Commercialization</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our future success is substantially dependent on the successful clinical development, regulatory approval and commercialization of our EUA product and product candidates in a timely manner. If we are not able to obtain required regulatory approvals, we will not be able to commercialize our product candidates and our ability to generate product revenue will be adversely affected.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have invested a significant portion of our time and financial resources in the development of our product candidates. Our business is dependent on our ability to successfully complete development of, obtain regulatory approval for, and successfully commercialize our EUA product and product candidates, if approved, in a timely manner. We may face unforeseen challenges in our product development strategy, and we can provide no assurances that our product candidates will be successful in clinical trials or will ultimately receive regulatory approval.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We initiated clinical trials for multiple product candidates, have obtained EUA for sotrovimab, but have not obtained BLA approval for any product candidate to date. We operate in a highly regulated field, and it is possible that any product candidate we may seek to develop in the future will not obtain regulatory approval.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to obtaining approval to commercialize any product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or comparable foreign regulatory authorities, that such product candidate is safe and effective for its intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe that the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval for further development, manufacturing or commercialization of our product candidates by the FDA and other regulatory authorities. The FDA may also require us to conduct additional preclinical studies or</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical trials for our product candidates either prior to or post-approval, or it may object to elements of our clinical development program, requiring their alteration.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we eventually complete clinical testing and receive approval of a new drug application, or NDA, BLA, or foreign marketing application for our product candidates, the FDA or the comparable foreign regulatory authorities may grant approval or other marketing authorization contingent on the performance of costly additional clinical trials, including post-market clinical trials. The FDA or the comparable foreign regulatory authorities also may approve or authorize for marketing a product candidate for a more limited indication or patient population than we originally request, and the FDA or comparable foreign regulatory authorities may not approve or authorize the labeling that we believe is necessary or desirable for the successful commercialization of a product candidate. Any delay in obtaining, or inability to obtain, applicable regulatory approval or other marketing authorization would delay or prevent commercialization of that product candidate and would adversely impact our business and prospects.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the FDA or comparable foreign regulatory authorities may change their policies, adopt additional regulations or revise existing regulations or take other actions, which may prevent or delay approval of our future product candidates under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain applicable regulatory approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, even if we obtain regulatory approval for our product candidates, we may still need to develop a commercial organization, establish a commercially viable pricing structure and obtain approval for coverage and adequate reimbursement from third-party and government payors, including government health administration authorities. If we are unable to successfully commercialize our product candidates or if there is an insufficient demand for our product candidates, we may not be able to generate sufficient revenue to continue our business.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The development of additional product candidates is risky and uncertain, and we can provide no assurances that we will be able to replicate our approach for other diseases.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A core element of our business strategy is to expand our product candidate pipeline. Efforts to identify, acquire or in-license, and then develop product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Our efforts may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development, approved products or commercial revenue for many reasons.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have limited financial and management resources and, as a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater market potential. Our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing or other royalty arrangements in circumstances under which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. In addition, we may not be successful in replicating our approach to development for other disease indications. If we are unsuccessful in identifying and developing additional product candidates or are unable to do so, our business may be harmed.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are developing, and in the future may develop, other product candidates in combination with other therapies, which exposes us to additional risks.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are developing VIR-2218 and VIR-3434 for the functional cure of hepatitis B virus, or HBV. Each of these product candidates has the potential to stimulate an effective immune response and also has direct antiviral activity against HBV. We believe that a functional cure for HBV will require an effective immune response, in addition to antiviral activity, based on the observation that severe immunosuppression can reactivate HBV disease. Monotherapy with each of these agents may provide a functional cure in some patients, while combination therapy may be necessary for others. We initiated a Phase 2 clinical trial to combine VIR-2218 with pegylated interferon-alpha and a Phase 2 clinical trial that combine VIR-2218 with VIR-3434. We are also evaluating additional combinations with other immunotherapy agents and direct acting antiviral agents. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the therapy used in combination with our product candidate. There is also a risk that safety, efficacy, manufacturing or supply issues could arise with these other existing therapies. This could result in our own products being removed from the market or being less successful commercially.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also evaluate our future product candidates in combination with one or more other therapies that have not yet been approved for marketing by the FDA or similar regulatory authorities outside of the United States. We will not be able to market any product candidate we develop in combination with any such unapproved therapies that do not ultimately obtain marketing approval.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs or revoke their approval of, or if safety, efficacy, manufacturing or supply issues arise with, the drugs we choose to evaluate in combination with any product candidate we develop, we may be unable to obtain approval.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Success in preclinical studies or earlier clinical trials may not be indicative of results in future clinical trials and we cannot assure you that any ongoing, planned or future clinical trials will lead to results sufficient for the necessary regulatory approvals and market authorizations.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Success in preclinical testing and earlier clinical trials does not ensure that later clinical trials will generate the same results or otherwise provide adequate data to demonstrate the efficacy and safety of a product candidate. Success in preclinical studies and earlier clinical trials does not ensure that later efficacy trials will be successful, nor does it predict final results. Our product candidates may fail to show the desired characteristics in clinical development sufficient to obtain regulatory approval, despite positive results in preclinical studies or having successfully advanced through earlier clinical trials.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A trial design that is considered appropriate for regulatory approval includes a sufficiently large sample size with appropriate statistical power, as well as proper control of bias, to allow a meaningful interpretation of the results. If we do not conduct clinical trials with a large enough patient sample size, we may not achieve statistically significant results or the same level of statistical significance, if any, that would have been possible to achieve in a larger trial.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As an organization, we have limited experience designing clinical trials and may be unable to design and execute a clinical trial to support regulatory approval which could mean we will suffer setbacks. Any such setbacks could negatively impact our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interim, &#x201c;top-line&#x201d; and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may publish interim, &#x201c;top-line&#x201d; or preliminary data from our clinical trials. Interim data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or &#x201c;top-line&#x201d; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data is available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical product development involves a lengthy and expensive process. We may incur additional costs and encounter substantial delays or difficulties in our clinical trials.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not commercialize, market, promote or sell any product candidate without obtaining marketing approval from the FDA or other comparable regulatory authority, and we may never receive such approvals. It is impossible to predict when or if any of our product candidates will prove effective or safe in humans and will receive regulatory approval. Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must complete preclinical development and then conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Clinical testing is expensive, is difficult to design and implement, can take many years to complete and is uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. We may experience numerous unforeseen events prior to, during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue from future product sales or other sources. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional testing to bridge our modified product candidate to earlier versions. Clinical trial delays could also shorten any periods during which we may have the exclusive right to commercialize our product candidates, if approved, or allow our competitors to bring competing products to market before we do, which could impair our ability</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, if the results of our clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates, we may:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be delayed in obtaining marketing approval, or not obtain marketing approval at all; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtain approval for indications or patient populations that are not as broad as intended or desired; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be subject to additional post-marketing testing requirements; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing requirements; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">have regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the form of a risk evaluation and mitigation strategy, or REMS; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be subject to the addition of labeling statements, such as warnings or contraindications; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">be sued; or</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">experience damage to our reputation. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product development costs will also increase if we experience delays in testing or obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, need to be restructured or be completed on schedule, if at all.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, our product candidates are based on certain innovative technology platforms, which makes it even more difficult to predict the time and cost of product candidate development and obtaining necessary regulatory approvals, particularly for our small interfering ribonucleic acid, or siRNA, and cytomegalovirus, or CMV, vector technologies. Relatively few siRNA product candidates have ever been tested in humans and to date very few have received regulatory approval and market authorizations. In addition, the compounds we are developing may not demonstrate in patients the chemical and pharmacological properties ascribed to them in preclinical studies, and they may interact with human biological systems in unforeseen, ineffective or harmful ways.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of our T cell platform, our approach is to use human cytomegalovirus, or HCMV, as a vaccine vector to potentially treat and prevent pathogens refractory to current vaccine technologies because HCMV may induce potent and long-lasting T cell responses to a broader range of epitopes than observed for other viral vaccines. Safety and toxicity trials for this technology have so far only been conducted in animal species, in which HCMV has limited ability to replicate. If our first clinical trial for VIR-1111 causes unexpected side effects that are not tolerable in the treatment of the relevant patient group, the further development of the product candidates and any other potential products based on HCMV-vector technology may be significantly limited or become impossible. Also, because our HCMV-vector technology is novel, regulatory agencies may lack experience with product candidates such as VIR-1111, which may lengthen the regulatory review process, increase our development costs and delay or prevent commercialization of our product candidates. In addition, our HCMV-vector technology utilizes live-attenuated, genetically-modified organisms for which the FDA, the EMA, and other comparable foreign regulatory authorities and other public health authorities, such as the Centers for Disease Control and Prevention and hospitals involved in clinical trials, have established additional safety and contagion rules and procedures, which could establish additional hurdles for the development, manufacture or use of our vectors. These hurdles may lead to delays in the conduct of clinical trials or in obtaining regulatory approvals for further development, manufacturing or commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, we, the FDA, a foreign regulatory authority or an institutional review board may suspend our clinical trials at any time if it appears that we or our collaborators are failing to conduct a trial in accordance with regulatory requirements, including the FDA&#x2019;s current Good Clinical Practice, or GCP, regulations, that we are exposing participants to unacceptable health risks, or if the FDA or foreign regulatory authority finds deficiencies in our INDs, or clinical trial applications, or CTAs, respectively, or the conduct of these trials. Moreover, we may not be able to file INDs to commence additional clinical trials on the timelines we expect because our filing schedule is dependent on further preclinical and manufacturing progress. Therefore, we cannot predict with any certainty the schedule for commencement and completion of future clinical trials. If we experience delays in the commencement or completion of our clinical trials, or if we terminate a clinical trial prior to completion, the commercial prospects of our product candidates could be negatively impacted, and our ability to generate revenue from our product candidates may be delayed.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be delayed, made more difficult or rendered impossible by multiple factors outside our control.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Identifying and qualifying patients to participate in our clinical trials is critical to our success. We are developing sotrovimab and VIR-7832 for the treatment of COVID-19, VIR-2218 and VIR-3434 for the treatment of HBV, VIR-2482 for the prevention of influenza A, and VIR-1111 for the prevention of human immunodeficiency virus, or HIV. In particular, clinical trials for prophylaxis tend to require enrollment of a larger number of subjects than clinical trials for treatments. We may encounter difficulties in enrolling patients in our clinical trials, thereby delaying or preventing development and approval of our product candidates. Even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials. Patient enrollment and retention in clinical trials depends on many factors, including the size of the patient population, the nature of the trial protocol, the existing body of safety and efficacy data, the number and nature of competing treatments and ongoing clinical trials of competing therapies for the same indication, the proximity of patients to clinical sites and the eligibility criteria for the trial. In addition, enrollment and retention of patients in clinical trials could be disrupted by man-made&#160;or natural disasters, or public health pandemics or epidemics or other business interruptions, including, the current COVID-19 pandemic and future outbreaks of the disease.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our efforts to build relationships with patient communities may not succeed, which could result in delays in patient enrollment in our clinical trials. Any negative results we may report in clinical trials of our product candidates may make it difficult or impossible to recruit and retain patients in other clinical trials of that same product candidate. Delays or failures in planned patient enrollment or retention may result in increased costs, program delays or both, which could have a harmful effect on our ability to develop our product candidates or could render further development impossible. In addition, we may rely on CROs and clinical trial sites to ensure proper and timely conduct of our future clinical trials and, while we intend to enter into agreements governing their services, we will be limited in our ability to ensure their actual performance.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The continued spread of&#160;COVID-19&#160;globally, or the evolution of new&#160;variants&#160;of&#160;COVID-19&#160;that are more contagious, have more severe effects or are resistant to treatments or vaccinations, could adversely impact our preclinical or clinical trial operations in the U.S., including our ability to enroll and retain patients as well as CROs and clinical trial site staff who, as healthcare providers, may have heightened exposure to&#160;COVID-19&#160;if an outbreak occurs in their geography.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences following any potential marketing approval.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and discomforts, to their doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions. Regulatory authorities may draw different conclusions and may require us to pause our clinical trials or require additional testing to confirm these determinations, if they occur.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, it is possible that as we test our product candidates in larger, longer and more extensive clinical trials, or as use of these product candidates becomes more widespread if they receive regulatory approval, illnesses, injuries, discomforts and other adverse events that were not observed in earlier trials, as well as conditions that did not occur or went undetected in previous trials, will be reported by subjects or patients. Many times, side effects are only detectable after investigational products are tested in large-scale pivotal trials or, in some cases, after they are made available to patients on a commercial scale after approval. If additional clinical experience indicates that any of our product candidates have side effects or cause serious or life-threatening side effects, the development of the product candidate may fail or be delayed, or, if the product candidate has received regulatory approval, such approval may be revoked, which would harm our business, financial condition, results of operations and prospects. </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are a party to strategic collaboration and license agreements pursuant to which we are obligated to make substantial payments upon achievement of milestone events and, in certain cases, have relinquished important rights over the development and commercialization of certain current and future product candidates. We also intend to explore additional strategic collaborations, which may never materialize or may require that we relinquish rights to and control over the development and commercialization of our product candidates.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a party to various strategic collaboration and license agreements that are important to our business and to our current and future product candidates pursuant to which we license a number of technologies to form our technology platforms. These agreements contain obligations that require us to make substantial payments in the event certain milestone events are achieved. We may in the future be required to make these payments, which could adversely affect our financial condition. In addition, we cannot be certain that we will achieve the results or benefits that justifies entering into these agreements. For additional information regarding these and other collaboration, license and grant agreements, see the section titled &#x201c;Business&#x2014;Our Collaboration, License and Grant Agreements&#x201d; in our 2020 Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A core element of our business strategy also includes continuing to acquire or in-license additional technologies or product candidates for the treatment and prevention of serious infectious diseases. As a result, we intend to periodically explore a variety of possible strategic collaborations or licenses in an effort to gain access to additional product candidates, technologies or resources.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At this time, we cannot predict what form such strategic collaborations or licenses might take in the future. We are likely to face significant competition in seeking appropriate strategic collaborators, and strategic collaborations and licenses can be complicated and time-consuming to negotiate and document. We may not be able to negotiate strategic collaborations on acceptable terms, or at all. We are unable to predict when, if ever, we will enter into any additional strategic collaborations or licenses because of the numerous risks and uncertainties associated with establishing them. Any delays in entering into new strategic collaborations or licenses related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our current and future collaborations and licenses could subject us to a number of risks, including the following:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be required to undertake the expenditure of substantial operational, financial and management resources; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be required to assume substantial actual or contingent liabilities; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may not be able to control the amount and timing of resources that our strategic collaborators devote to the development or commercialization of our product candidates; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">strategic collaborators may select indications or design clinical trials in a way that may be less successful than if we were doing so; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">strategic collaborators may delay clinical trials, provide insufficient funding, terminate a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new version of a product candidate for clinical testing; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">strategic collaborators may not pursue further development and commercialization of products resulting from the strategic collaboration arrangement or may elect to discontinue research and development programs; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disputes may arise between us and our strategic collaborators that result in costly litigation or arbitration that diverts management&#x2019;s attention and consumes resources; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">strategic collaborators may experience financial difficulties; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">strategic collaborators may not properly maintain, enforce or defend our intellectual property rights or may use our proprietary information in a manner that could jeopardize or invalidate our proprietary information or expose us to potential litigation; and</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">strategic collaborators could terminate the arrangement or allow it to expire, which would delay the development and may increase the cost of developing our product candidates. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, license agreements we enter into in the future may not provide exclusive rights to use intellectual property and technology in all relevant fields of use and in all territories in which we may wish to develop or commercialize our technology and products. As a result, we may not be able to prevent competitors from developing and commercializing competitive products in territories included in all of our licenses.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If the market opportunities for our product candidates are smaller than we believe they are or any approval we obtain is based on a narrower definition of the patient population, our business may suffer.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently focus our product development on product candidates for the treatment and prevention of serious infectious diseases. Our eligible patient population, pricing estimates and available coverage and reimbursement may differ significantly from the actual market addressable by our product candidates. Our estimates of the number of people who have these diseases, the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, and the market demand for our product candidates are based on our beliefs and analyses. These estimates have been derived from a variety of sources, including the scientific literature, patient foundations or market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or prevalence of the diseases we are targeting. The number of patients may turn out to be lower than expected. Likewise, the potentially addressable patient population for each of our product candidates may be limited or may not be receptive to treatment with our product candidates, and new patients may become increasingly difficult to identify or access. Additionally, the availability of superior or competitive therapies from our competitors could negatively impact or eliminate&#160;market demand&#160;for our product candidates. If the market opportunities for our product candidates are smaller than we estimate, it could have an adverse effect on our business, financial condition, results of operations and prospects. </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We face substantial competition, which may result in others developing or commercializing products before or more successfully than us.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The biopharmaceutical industry is characterized by rapidly advancing technologies, intense competition and an emphasis on proprietary products. We face potential competition from many different sources, including pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions. The availability of superior or competitive therapies, or preventative measures such as vaccines, coupled with the unpredictable nature of pandemics and the prevalence of new variants of COVID-19, could negatively impact or eliminate&#160;demand&#160;for our COVID-19 therapies. Product candidates that we successfully develop and commercialize may compete with existing therapies, including prophylactic vaccines, competing antibody therapies, small-molecule drugs, oral antivirals, and new therapies that may become available in the future. In addition, one or more of our competitors may be successful in producing a more efficacious therapy for&#160;SARS-CoV-2&#160;and current and future variants or in producing a therapy that is easier to deliver and administer to patients in a timelier manner.&#160;</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercialization potential could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than products that we may develop. The key competitive factors affecting the success of all our programs are likely to be efficacy, safety, convenience and timing. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. For example, there are FDA-approved treatments for COVID-19 including an intravenously administered antiviral, remdesivir, marketed by Gilead Sciences, Inc., which is FDA approved for the treatment of COVID-19 in hospitalized settings, and several treatments and prophylactic vaccines are available under EUA. Currently, the antibody combination of casirivimab and imdevimab by Regeneron are available under EUA, for intravenously administered regimen in the mild-to-moderate setting. Convalescent plasma is also available under EUA. Additionally, COVID-19 vaccines are available in the U.S. under EUA from Janssen Biotech, Inc., Moderna, Inc. and Pfizer Inc. (in partnership with BioNTech SE). Numerous large and small pharmaceutical and biotechnology companies are developing programs with various mechanisms of actions, including prophylactic vaccines, oral antivirals, immunomodulators, and antibodies. Companies with antibodies in clinical development include AbbVie, Inc., Adagio, AstraZeneca, Brii Bio, Celltrion Healthcare Co., Ltd., Eli Lilly and Regeneron. Companies with oral antivirals in clinical development include Merck &amp; Co., Pfizer Inc., and Roche Holding AG,. Companies with prophylactic vaccines in clinical development include AstraZeneca, GSK, Novavax, Inc. and Sanofi S.A.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, regulatory incentives to develop products for treatment of infectious diseases have increased interest and activity in this area and may lead to increased competition for clinical investigators and clinical trial subjects, as well as for future prescriptions, if any of our product candidates are successfully developed and approved.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our competitors may have significantly greater financial resources, established presence in the market, expertise in research and development, manufacturing, preclinical and clinical testing, obtaining regulatory approvals and reimbursement and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific, sales, marketing and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. Additional mergers and acquisitions may result in even more resources being concentrated in our competitors.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a result of these factors, our competitors may achieve patent protection or obtain regulatory approval of their products before we are able to, which may limit our ability to develop or commercialize our product candidates. Our competitors may also develop therapies that are safer, more effective, more widely accepted or less expensive than ours, and may also be more successful than we are in manufacturing and marketing their products. These advantages could render our product candidates obsolete or non-competitive before we can recover the costs of such product candidates&#x2019; development and commercialization. For additional information regarding our competitors, see the section titled &#x201c;Business&#x2014;Competition&#x201d; in our 2020 Form 10-K.&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Even if any product candidates receive marketing approval, they may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if any product candidates receive marketing approval, they may fail to gain market acceptance by physicians, patients, third-party payors and others in the medical community. If such product candidates do not achieve an adequate level of acceptance, we may not generate significant product revenue and may not become profitable. The degree of market acceptance of any product candidate, if approved for commercial sale, will depend on a number of factors, including but not limited to:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the convenience and ease of administration compared to alternative treatments and therapies; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the efficacy and potential advantages compared to alternative treatments and therapies; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the effectiveness of sales and marketing efforts; </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the strength of our relationships with patient communities; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of treatment in relation to alternative treatments and therapies, including any similar generic treatments; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to offer such product for sale at competitive prices; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the strength of marketing and distribution support; </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the availability of third-party coverage and adequate reimbursement, and patients&#x2019; willingness to pay out-of-pocket in the absence of third-party coverage or adequate reimbursement;</span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the prevalence and severity of any side effects; and </span></div></div>
  <div style="margin-left:4.533%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any restrictions on the use of the product together with other medications. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any of our product candidates are approved but fail to achieve market acceptance among physicians, patients, third-party payors and others in the medical community, we will not be able to generate significant revenue, which would compromise our ability to become profitable.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Even if we obtain regulatory approvals for our product candidates, they will remain subject to ongoing regulatory oversight.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we obtain regulatory approval in a jurisdiction, the regulatory authority may still impose significant restrictions on the indicated uses or marketing of our product candidates, or impose ongoing requirements for potentially costly post-approval trials, post-market surveillance or patient or drug restrictions. Additionally, the holder of an approved BLA is required to comply with FDA rules and is subject to FDA review and periodic inspections, in addition to other potentially applicable federal and state laws, to ensure compliance with current good manufacturing practices, or cGMP, and adherence to commitments made in the BLA.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we or a regulatory agency discovers previously unknown problems with a product such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing. Moreover, product labeling, advertising and promotion for any approved product will be subject to regulatory requirements and continuing regulatory review. For example, a company may not promote &#x201c;off-label&#x201d; uses for its drug products. An off-label use is the use of a product for an indication that is not described in the product&#x2019;s FDA-approved label in the U.S. or for uses in other jurisdictions that differ from those approved by the applicable regulatory agencies. Physicians, on the other hand, may prescribe products for off-label uses. Although the FDA and other regulatory agencies do not regulate a physician&#x2019;s choice of drug treatment made in the physician&#x2019;s independent medical judgment, they do restrict promotional communications from companies or their sales force with respect to off-label uses of products for which marketing clearance has not been issued. Failure to comply with such requirements, when and if applicable, could subject us to a number of actions ranging from warning letters to product seizures or significant fines, among other actions. For additional information regarding regulatory approval and ongoing regulatory oversight, see the section titled &#x201c;Business&#x2014;Government Regulation and Product Approval&#x201d; in our 2020 Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any government investigation of alleged violations of laws or regulations could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be successful in commercializing them, if and when they are approved.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To successfully commercialize any product candidate that may result from our development programs, we will need to build out our sales and marketing capabilities, either on our own or with others. The establishment and development of our own commercial team or the establishment of a contract sales force to market any product candidate we may develop will be expensive and time-consuming and could delay any product launch. Moreover, we cannot be certain that we will be able to successfully develop this capability, and have no experience as a company in commercializing products. Establishing sales and marketing capabilities will be particularly important to the commercial success of our product candidates that target diseases with large patient populations throughout the world. We may seek to enter into collaboration agreements with other entities to utilize their established marketing and distribution capabilities, but we may be unable to enter into such agreements on favorable terms, if at all. If any current or future collaborators do not commit sufficient time or resources to commercialize our product candidates, or we are unable to develop the necessary capabilities on our own, we may be unable to generate sufficient revenue to sustain our business. We compete with many</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">companies that currently have extensive, experienced and well-funded marketing and sales operations to recruit, hire, train and retain marketing and sales personnel, and will have to compete with those companies to recruit, hire, train and retain any of our own marketing and sales personnel. We will likely also face competition if we seek third parties to assist us with the sales and marketing efforts of our product candidates. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Even if we obtain and maintain approval for our product candidates from the FDA, we may never obtain approval outside the United States, which would limit our market opportunities.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Approval of a product candidate in the United States by the FDA does not ensure approval of such product candidate by regulatory authorities in other countries or jurisdictions, and approval by one foreign regulatory authority does not ensure approval by regulatory authorities in other foreign countries or by the FDA. Sales of our product candidates outside the United States will be subject to foreign regulatory requirements governing clinical trials and marketing approval. Even if the FDA grants marketing approval for a product candidate, comparable foreign regulatory authorities also must approve the manufacturing and marketing of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and more onerous than, those in the United States, including additional preclinical studies or clinical trials. In many countries outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that country. In some cases, the price that we intend to charge for any product candidates, if approved, is also subject to approval. Obtaining approval for our product candidates in the European Union, or EU, from the European Commission following the opinion of the EMA if we choose to submit a marketing authorization application there, would be a lengthy and expensive process. Even if a product candidate is approved, the EMA may limit the indications for which the product may be marketed, require extensive warnings on the product labeling or require expensive and time-consuming additional clinical trials or reporting as conditions of approval. Approval of certain product candidates outside of the United States, particularly those that target diseases that are more prevalent outside of the United States will be particularly important to the commercial success of such product candidates. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our product candidates in certain countries.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries. Also, regulatory approval for our product candidates may be withdrawn. If we fail to comply with the applicable regulatory requirements, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business, financial condition, results of operations and prospects could be harmed.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we commercialize our product candidates outside the United States, a variety of risks associated with international operations could harm our business.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We intend to seek approval to market our product candidates outside the United States, and may also do so for future product candidates. If we market approved products outside the United States, we expect that we will be subject to additional risks in commercialization.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have no prior experience in these areas. In addition, there are complex regulatory, tax, labor and other legal requirements imposed by many of the individual countries in which we may operate, with which we will need to comply. Many biopharmaceutical companies have found the process of marketing their products in foreign countries to be challenging.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Negative developments and negative public opinion of new technologies on which we rely may damage public perception of our product candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our product candidates.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The clinical and commercial success of our product candidates will depend in part on public acceptance of the use of new technologies for the prevention or treatment of human diseases. For example, we use CMV, a commonly occurring virus in humans, as a vaccine vector to prevent and treat pathogens refractory to current vaccine technologies. We also use CRISPR gene-editing technology as a research tool to systematically identify human genes that control infection.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Public perception may be influenced by claims that CMV technology is unsafe and products incorporating this technology may not gain the acceptance of the public or the medical community, or that CRISPR gene-editing technology is unethical or immoral. Adverse public attitudes may adversely impact our ability to enroll clinical trials. Moreover, our success will depend upon physicians specializing in our targeted diseases prescribing, and their patients being willing to receive, our product candidates as treatments in lieu of, or in addition to, existing, more familiar, treatments for which greater clinical data may be available. Any increase in negative perceptions of the technologies that we rely on may result in fewer physicians prescribing our products or may reduce the willingness of patients to utilize our products or participate in clinical trials for our product candidates.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Increased negative public opinion or more restrictive government regulations in response thereto, would have a negative effect on our business, financial condition, results of operations or prospects and may delay or impair the development and commercialization of our product candidates or demand for such product candidates. Adverse events in our preclinical studies or clinical trials or those of our competitors or of academic researchers utilizing similar technologies, even if not ultimately attributable to product candidates we may discover and develop, and the resulting publicity could result in increased governmental regulation, unfavorable public perception, potential regulatory delays in the testing or approval of potential product candidates we may identify and develop, stricter labeling requirements for those product candidates that are approved, a decrease in demand for any such product candidates and a suspension or withdrawal of approval by regulatory authorities of our product candidates.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidate that we may develop.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We face an inherent risk of product liability exposure related to the testing of our product candidates in clinical trials and may face an even greater risk if we commercialize any product candidate that we may develop. If we cannot successfully defend ourselves against claims that any such product candidates caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">decreased demand for any product candidate that we may develop; </span></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">loss of revenue; </span></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">substantial monetary awards to trial participants or patients; </span></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">significant time and costs to defend the related litigation; </span></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">withdrawal of clinical trial participants; </span></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">increased insurance costs; </span></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the inability to commercialize any product candidate that we may develop; and </span></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injury to our reputation and significant negative media attention. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any such outcomes could negatively impact our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our insurance policies may be inadequate and potentially expose us to unrecoverable risks.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we maintain product liability insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. We anticipate that we will need to increase our insurance coverage each time we commence a clinical trial and if we successfully commercialize any product candidate. Insurance availability, coverage terms and pricing continue to vary with market conditions. We endeavor to obtain appropriate insurance coverage for insurable risks that we identify such as cybersecurity-related issues; however, we may fail to correctly anticipate or quantify insurable risks, we may not be able to obtain appropriate insurance coverage and insurers may not respond as we intend to cover insurable events that may occur. Conditions in the insurance markets relating to nearly all areas of traditional corporate insurance change rapidly and may result in higher premium costs, higher policy deductibles and lower coverage limits. For some risks, we may not have or maintain insurance coverage because of cost or availability.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Regulatory Compliance</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The regulatory pathways for our product candidates targeting&#160;SARS-CoV-2,&#160;the virus that causes&#160;COVID-19,&#160;are continually evolving, and may result in unexpected or unforeseen challenges.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates targeting&#160;SARS-CoV-2,&#160;the virus that causes&#160;COVID-19,&#160;are in various development stages.&#160;We were granted an EUA on May 26, 2021 for sotrovimab for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct SARS-CoV-2 viral testing, and who are at risk for progression to hospitalization or death. Sotrovimab is also currently in a Phase 2 clinical trial evaluating an IM formulation. In the second quarter of 2021, we initiated an additional Phase 3 clinical trial evaluating an IM formulation of sotrovimab and a Phase 1b/2a clinical trial for VIR-7832,&#160;also a&#160;SARS-CoV-2-neutralizing&#160;mAb. The speed at which companies and institutions are acting to create and test many therapeutics and vaccines for&#160;COVID-19&#160;is unusual, and evolving or changing plans or priorities within the FDA, including changes based on new knowledge of COVID-19 and how the disease affects the human body, may significantly affect the regulatory timelines for our COVID-19 product candidates. Results from our continued development and planned clinical trials may raise new questions and require us to redesign proposed clinical trials, including revising proposed endpoints or adding new clinical trial sites or cohorts of subjects. As part of these ongoing discussions, the FDA may require us to conduct additional preclinical studies</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and/or clinical trials than we originally anticipated, which could result in significant delay in our development program for these product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA has the authority to grant an EUA to allow unapproved medical products to be used in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions when, based on the totality of scientific evidence, there is evidence of effectiveness of the medical product, and there are no adequate, approved, and available alternatives. Our EUA for sotrovimab, for example, allows us to commercialize sotrovimab prior to FDA approval. However, the FDA may revoke an EUA where it is determined that the underlying health emergency no longer exists or warrants such authorization, and we cannot predict how long, if ever, an EUA would remain in place. Such revocation could adversely impact our business in a variety of ways, including if one of our COVID-19 product candidates, such as sotrovimab, is not yet approved by the FDA and if we and our commercialization and manufacturing partners have invested in the commercialization and manufacturing of such product candidate under an EUA.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If any of our future small molecule product candidates obtain regulatory approval, additional competitors could enter the market with generic versions of such products, which may result in a material decline in sales of affected products.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, a pharmaceutical manufacturer may file an abbreviated new drug application, or ANDA, seeking approval of a generic version of an approved, small molecule innovator product. Under the Hatch-Waxman Act, a manufacturer may also submit an NDA under section 505(b)(2) of the Federal Food, Drug, and Cosmetic Act that references the FDA&#x2019;s prior approval of the small molecule innovator product. A 505(b)(2) NDA product may be for a new or improved version of the original innovator product. The Hatch-Waxman Act also provides for certain periods of regulatory exclusivity, which preclude FDA approval (or in some circumstances, FDA filing and review) of an ANDA or 505(b)(2) NDA. In addition to the benefits of regulatory exclusivity, an innovator NDA holder may have patents claiming the active ingredient, product formulation or an approved use of the drug, which would be listed with the product in the FDA publication, &#x201c;Approved Drug Products with Therapeutic Equivalence Evaluations,&#x201d; known as the Orange Book, see the section titled &#x201c;&#x2014;Risk Related to Our Intellectual Property&#x2014; Patent terms may be inadequate to protect our competitive position on our product candidates or any products approved in the future for an adequate amount of time and additional competitors could enter the market with generic or biosimilar versions of such products.&#x201d;.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accordingly, if any of our future small molecule product candidates are approved, competitors could file ANDAs for generic versions of these products or 505(b)(2) NDAs that reference our products. If competitors are able to obtain marketing approval for generics referencing our small molecule product candidates, such competitive products may be able to immediately compete with us in each indication for which our product candidates may have received approval. For additional information regarding competition, see the section titled &#x201c;Business&#x2014;Competition&#x201d; in our 2020 Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Any biologic, or large molecule, product candidates for which we intend to seek approval may face competition sooner than anticipated.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are successful in achieving regulatory approval to commercialize any biologic product candidate faster than our competitors, such product candidates may face competition from biosimilar products. In the United States, large molecule product candidates are regulated by the FDA as biologic products subject to approval under the BLA pathway. The Biologics Price Competition and Innovation Act of 2009, or BPCIA, creates an abbreviated pathway for the approval of biosimilar and interchangeable biologic products following the approval of an original BLA. For additional information regarding biosimilars and exclusivity, see the section titled &#x201c;Business&#x2014;Government Regulation and Product Approval&#x2014;Biosimilars and Exclusivity&#x201d; in our 2020 Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If competitors are able to obtain marketing approval for biosimilars referencing our large molecule product candidates, if approved, such products may become subject to competition from such biosimilars, with the attendant competitive pressure and potential adverse consequences. Such competitive products may be able to immediately compete with us in each indication for which our product candidates may have received approval. For additional information regarding competition, see the section titled &#x201c;Business&#x2014;Competition&#x201d; in our 2020 Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our relationships with customers, physicians, and third-party payors are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, and other healthcare laws and regulations. If we are unable to comply, or have not fully complied, with such laws, we could face substantial penalties.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Healthcare providers, physicians and third-party payors in the United States and elsewhere play a primary role in the recommendation and prescription of our EUA product and will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare professionals,</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">principal investigators, consultants, customers and third-party payors subject us to various federal and state fraud and abuse laws and other healthcare laws.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our EUA product and additional product candidates, if approved. For additional information regarding these laws, see the section titled &#x201c;Business&#x2014;Government Regulation and Product Approval&#x201d; in our 2020 Form 10-K. Ensuring that our internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations will likely be costly. It is possible that governmental authorities will conclude that our business practices, including our relationships with physicians and other healthcare providers, some of whom are compensated in the form of stock options for consulting services provided, may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations. </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to significant civil, criminal or administrative sanctions, including exclusions from government-funded healthcare programs. Even if resolved in our favor, litigation or other legal proceedings relating to healthcare laws and regulations may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development, manufacturing, sales, marketing or distribution activities. Uncertainties resulting from the initiation and continuation of litigation or other proceedings relating to applicable healthcare laws and regulations could have an adverse effect on our ability to compete in the marketplace.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Coverage and adequate reimbursement may not be available for our EUA product and any product candidates that we commercialize, if approved, which could make it difficult for us to sell profitably.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Market acceptance and sales of our EUA product and any product candidates that we commercialize, if approved, will depend in part on the extent to which reimbursement for these product and related treatments will be available from third-party payors, including government health administration authorities, managed care organizations and other private health insurers. Third-party payors decide which therapies they will pay for and establish reimbursement levels. While no uniform policy for coverage and reimbursement exists in the United States, third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies. However, decisions regarding the extent of coverage and amount of reimbursement to be provided for our EUA product and any product candidates that we develop will be made on a payor-by-payor basis. Therefore, one payor&#x2019;s determination to provide coverage for a product does not assure that other payors will also provide coverage, and adequate reimbursement, for the product. Additionally, a third-party payor&#x2019;s decision to provide coverage for a therapy does not imply that an adequate reimbursement rate will be approved. Each payor determines whether or not it will provide coverage for a therapy, what amount it will pay the manufacturer for the therapy and on what tier of its formulary it will be placed. The position on a payor&#x2019;s list of covered drugs and biological products, or formulary, generally determines the co-payment that a patient will need to make to obtain the therapy and can strongly influence the adoption of such therapy by patients and physicians. Patients who are prescribed treatments for their conditions and providers prescribing such services generally rely on third-party payors to reimburse all or part of the associated healthcare costs. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of the cost of our products. In addition, because our EUA product and certain of our product candidates are physician-administered, separate reimbursement for the product itself may or may not be available. Instead, the administering physician may only be reimbursed for providing the treatment or procedure in which our product is used.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. We cannot be sure that coverage and reimbursement will be available for our EUA product or any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Inadequate coverage and reimbursement may impact the demand for, or the price of, our EUA product or any product for which we obtain marketing approval. If coverage and adequate reimbursement are not available, or are available only at limited levels, we may not be able to successfully commercialize our EUA product or any product candidates that we develop.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Healthcare legislative reform measures may have a negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States and some foreign jurisdictions, there have been, and we expect there will continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell our EUA product or any product candidates for which we obtain marketing approval. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that additional U.S. federal healthcare reform measures will be adopted in the future, particularly in light of the new Presidential administration, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our current or any future product candidates or additional pricing pressures. It is possible that additional governmental action is taken in response to the COVID-19 pandemic. For example, on June 17, 2021, the U.S. Supreme Court dismissed a challenge on procedural grounds that argued the Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, is unconstitutional in its entirety because the &#x201c;individual mandate&#x201d; was repealed by Congress. Thus, the ACA will remain in effect in its current form. Additionally, In August 2011, the President signed into law the Budget Control Act of 2011, as amended, which, among other things, included aggregate reductions to Medicare payments to providers of 2% per fiscal year, which began in 2013 and, following passage of subsequent legislation, including the Bipartisan Budget Act of 2018, will continue through 2030 unless additional Congressional action is taken. However, COVID-19 relief support legislation suspended the 2% Medicare sequester from May 1, 2020 through December 31, 2021. Further, in February 2021, the FDA issued guidance strongly recommending that individual monoclonal antibody products be developed with the expectation that they will be combined with one or more monoclonal antibody products that bind to different epitopes to minimize the risk of losing activity against emergent variants. This type of government action could have a negative impact on our business, financial condition, results of operations and prospectus. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing or new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our current or any future product candidates we may develop may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability. For additional information regarding other healthcare legislative reform measures, see the section titled &#x201c;Business&#x2014;Government Regulation and Product Approval&#x2014;Healthcare Reform&#x201d; in our 2020 Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that these and other healthcare reform measures that may be adopted in the future may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for our EUA product and any approved product, which could have an adverse effect on demand for our EUA product and product candidates. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability or commercialize our products.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are subject to anti-corruption, anti-bribery, anti-money laundering, and similar laws, and non-compliance with such laws can subject us to criminal and/or civil liability and harm our business.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. &#167; 201, the U.S. Travel Act and other anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption and anti-bribery laws have been enforced aggressively in recent years and are interpreted broadly to generally prohibit companies and their employees and third-party intermediaries from authorizing, offering or providing, directly or indirectly, improper payments or benefits to recipients in the public or private sector. We interact with officials and employees of government agencies and government-affiliated hospitals, universities and other organizations. In addition, we may engage third-party intermediaries to promote our clinical research activities abroad or to obtain necessary permits, licenses and other regulatory approvals. We can be held liable for the corrupt or other illegal activities of these third-party intermediaries, our employees, representatives, contractors, partners and agents, even if we do not explicitly authorize such activities.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">While we have policies and procedures to address compliance with such laws in the United States, we cannot assure you that all of our employees and agents will not take actions in violation of our policies and applicable law, for which we may be ultimately held responsible. Detecting, investigating and resolving actual or alleged violations can require a significant diversion of time, resources and attention from senior management. In addition, noncompliance with anti-corruption, anti-bribery or anti-money laundering laws could subject us to whistleblower complaints, investigations, sanctions, settlements, prosecution, other enforcement actions, disgorgement of profits, significant fines, damages, other civil and criminal penalties or injunctions, suspension and/or debarment from contracting with certain persons, the loss of export privileges, reputational harm, adverse media coverage and other collateral consequences. If any subpoenas or investigations are launched, or governmental or other sanctions are imposed, or if we do not prevail</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in any possible civil or criminal litigation, our business, financial condition, results of operations and prospects could be materially harmed. In addition, responding to any action will likely result in a materially significant diversion of management&#x2019;s attention and resources and significant defense costs and other professional fees. Enforcement actions and sanctions could further harm our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Dependence on Third Parties</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We intend to rely on third parties to produce clinical and commercial supplies of our product candidates.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are currently manufacturing material for product candidates of three different modalities: mAbs, HCMV-based vaccines and siRNAs. Except for limited process development and quality control testing capabilities in certain of our facilities, we do not own or operate facilities for product manufacturing, storage and distribution, or testing. We are dependent on third parties to manufacture the clinical supplies of our current and any future product candidates. We have established relationships with multiple contract development and manufacturing organizations, or CDMOs, that have produced material to support our preclinical, Phase 1, 2, and 3 clinical trials. We have limited experience manufacturing our product candidates on a commercial scale, and we do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing of our future product candidates. Certain of our product candidates may have to compete with existing and future products, such as the annual flu vaccine or any current or future COVID-19 vaccine, that may have a lower price point. The actual cost to manufacture our product candidates could materially and adversely affect the commercial viability of our product candidates.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The facilities used by our contract manufacturers to manufacture our product candidates must be approved by the FDA pursuant to inspections that will be conducted after we submit our NDA or BLA to the FDA. We do not control the manufacturing process of, and are completely dependent on, our contract manufacturing partners for compliance with the cGMP requirements. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or others, we will not be able to secure and/or maintain regulatory approval for our product candidates. In addition, we have no control over the ability of our contract manufacturers to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates, if approved. Any significant delay in the supply of a product candidate, or the raw material components thereof, for an ongoing clinical trial due to the need to replace a third-party manufacturer could considerably delay completion of our clinical trials, product testing and potential regulatory approval of our product candidates.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also intend to rely on third-party manufacturers to supply us with sufficient quantities of our product candidates to be used, if approved, for commercialization. There is, however, no assurance that our third-party manufacturers will meet our working assumptions of manufacturing titer and yield per batch of our product candidates. Any reduction in anticipated manufacturing titer and yield delay may adversely impact our ability to meet market demand for any approved product. Furthermore, if we are not able to produce supply at low enough costs, it would negatively impact our ability to generate revenue, harm our reputation, and could have an adverse effect on our business, financial condition, results of operations and prospects.&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we currently rely on foreign CDMOs, including a CDMO in China which we rely on for the clinical development, manufacturing, and commercialization of our proprietary antibodies developed for SARS-CoV-2, and will likely continue to rely on foreign CDMOs in the future. Foreign CDMOs may be subject to trade restrictions and other foreign regulatory requirements which could increase the cost or reduce the supply of material available to us, delay the procurement of such material or have an adverse effect on our ability to secure significant commitments from governments to purchase our potential therapies.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, the biopharmaceutical industry in particular in China is strictly regulated by the Chinese government. Changes to Chinese regulations or government policies affecting biopharmaceutical companies are unpredictable and may have a material adverse effect on our collaborators in China which could have an adverse effect on our business, financial condition, results of operations and prospects. Evolving changes in China&#x2019;s economic, political, and social conditions and the uncertainty around China&#x2019;s relationship with other governments, such as the United States and the United Kingdom could also negatively impact our ability to manufacture our product candidates for our planned clinical trials or have an adverse effect on our ability to secure government funding , which could adversely affect our financial condition and cause us to delay our clinical development programs.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, our reliance on third-party suppliers and manufacturers entails risks to which we would not be exposed to if we manufactured product candidates ourselves, including:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delay or inability to procure or expand sufficient manufacturing capacity;</span></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in process development; </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">issues related to scale-up of manufacturing; </span></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">excess manufacturing capacity due to insufficient market demand for our product candidates and responsibility for the associated costs;</span></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">costs and validation of new equipment and facilities required for scale-up; </span></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">inability of our third-party manufacturers to execute technology transfers, manufacturing procedures and other logistical support requirements appropriately; </span></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">inability to negotiate manufacturing agreements with third parties under commercially reasonable terms, if at all; </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">breach, termination or nonrenewal of manufacturing agreements with third parties in a manner or at a time that is costly or damaging to us; </span></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reliance on single sources for product components; </span></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">lack of qualified backup suppliers for those components that are currently purchased from a sole or single-source supplier; </span></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">lack of ownership to the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our product candidates; </span></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disruptions to operations of our third-party manufacturers or suppliers by conditions unrelated to our business or operations, including the bankruptcy of the manufacturer or supplier; </span></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disruptions caused by man-made&#160;or natural disasters or public health pandemics or epidemics, including, for example, the ongoing COVID-19 pandemic; and</span></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">carrier disruptions or increased costs that are beyond our control. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot be sure that single source suppliers for our product components will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these components for our intended purpose. In addition, the lead time needed to establish a relationship with a new supplier can be lengthy and we may experience delays in meeting demand in the event we must switch to a new supplier. The time and effort to qualify a new supplier could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, there are a limited number of suppliers and manufacturers that supply synthetic siRNAs. Alnylam is currently supplying clinical material for our VIR-2218 Phase 1/2 clinical trial through its CDMOs. We will assume responsibility for technology transfer and manufacturing ahead of any Phase 3 clinical trials for VIR-2218. Alnylam currently relies on a limited number of CDMOs for our supply of synthetic siRNAs. There are risks inherent in pharmaceutical manufacturing that could affect the ability of Alnylam and Alnylam&#x2019;s CDMOs to meet our delivery time requirements or provide adequate amounts of synthetic siRNAs to meet our needs. Included in these risks are potential synthesis and purification failures and/or contamination during the manufacturing process, as well as other issues with the CDMO&#x2019;s facility and ability to comply with the applicable manufacturing requirements, including use of the proper raw material components, which could result in unusable product. This would cause delays in our manufacturing timelines and ultimately delay our clinical trials and potentially put at risk commercial supply, as well as result in additional expense to us. To fulfill our siRNA requirements, we may need to secure alternative suppliers of synthetic siRNAs and such alternative suppliers are limited and may not be readily available, or we may be unable to enter into agreements with them on reasonable terms and in a timely manner.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, manufacturers may have little or no experience with viral vector products and therefore may require a significant amount of support from us in order to implement and maintain the infrastructure and processes required to manufacture our HCMV vector-based product candidates. The challenges to HCMV-based vaccine manufacturing include the large size of the virus, which precludes terminal sterile filtration, and the attenuation of the engineered human virus, which dramatically reduces high growth yields during manufacturing. To address these challenges, we have made significant internal investments in process development and scale-up, largely funded by grants from the Bill&#160;&amp; Melinda Gates Foundation. We have established a cGMP process in support of Phase 1 and Phase 2 clinical trials that has been successfully transferred and executed at two CDMOs specializing in live vaccine manufacturing (IDT Biologika and Advanced Bioscience Laboratories, Inc.). However, the existing process will require scale-up for later stages of clinical development and commercial supply.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any of these events could lead to clinical trial delays or failure to obtain regulatory approval or impact our ability to successfully commercialize our current or any future product candidates once approved. Some of these events could be the basis for FDA action, including injunction, request for recall, seizure or total or partial suspension of production.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating results.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The U.S. government has made statements and taken actions in recent years that have led to certain changes and may lead to additional changes to U.S. and international trade policies, including imposing several rounds of tariffs affecting certain products manufactured in China. In March 2018, the Trump administration announced the imposition of tariffs on steel and aluminum entering the United States and in June 2018 announced further tariffs targeting goods imported from China. Both China and the United States have each imposed tariffs indicating the potential for further trade barriers. It is unknown whether and to what extent new tariffs (or other new laws or regulations) will be adopted, or the effect that any such actions would have on us or our industry, and it is unclear whether the Biden administration will work to reverse these measures or pursue similar policy initiatives. While we have only recently started commercialization of sotrovimab under EUA, any unfavorable government policies on international trade, such as export controls, capital controls or tariffs, may affect the demand for our drug products, the competitive position of our drug products, and import or export of raw materials used in our drug development, particularly with respect to raw materials that we import from China, including pursuant to our manufacturing arrangements with WuXi Biologics. If any new tariffs, export controls, legislation and/or regulations are implemented, or if existing trade agreements are renegotiated or, in particular, if the U.S. government takes retaliatory trade actions due to the recent U.S.-China trade tension, such changes could have an adverse effect on our business, financial condition and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our business involves the use of hazardous materials and we and our third-party manufacturers and suppliers must comply with environmental, health and safety laws and regulations, which can be expensive and restrict how we do, or interrupt our, business.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our research and development activities and our third-party manufacturers&#x2019; and suppliers&#x2019; activities involve the generation, storage, use and disposal of hazardous materials, including the components of our product candidates and other hazardous compounds and wastes. We and our manufacturers and suppliers are subject to environmental, health and safety laws and regulations governing, among other matters, the use, manufacture, generation, storage, handling, transportation, discharge and disposal of these hazardous materials and wastes and worker health and safety. In some cases, these hazardous materials and various wastes resulting from their use are stored at our and our manufacturers&#x2019; facilities pending their use and disposal. We cannot eliminate the risk of contamination or injury, which could result in an interruption of our commercialization efforts, research and development efforts and business operations, damages and significant cleanup costs and liabilities under applicable environmental, health and safety laws and regulations. We also cannot guarantee that the safety procedures utilized by our third-party manufacturers for handling and disposing of these materials and wastes generally comply with the standards prescribed by these laws and regulations. We may be held liable for any resulting damages costs or liabilities, which could exceed our resources, and state or federal or other applicable authorities may curtail our use of certain materials and/or interrupt our business operations. Furthermore, environmental, health and safety laws and regulations are complex, change frequently and have tended to become more stringent. We cannot predict the impact of such changes and cannot be certain of our future compliance. Failure to comply with these environmental, health and safety laws and regulations may result in substantial fines, penalties or other sanctions. We do not currently carry hazardous waste insurance coverage.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We rely on third parties to conduct, supervise and monitor our preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner, it may harm our business.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not currently have the ability to independently conduct any clinical trials. We intend to rely on CROs and clinical trial sites to ensure the proper and timely conduct of our preclinical studies and clinical trials, and we expect to have limited influence over their actual performance. We rely on CROs to monitor and manage data for our clinical programs, as well as the execution of future preclinical studies. We expect to control only certain aspects of our CROs&#x2019; activities. Nevertheless, we will be responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with the applicable protocol, legal, regulatory and scientific standards, and our reliance on the CROs does not relieve us of our regulatory responsibilities.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We and our CROs are required to comply with the good laboratory practices, or GLPs, and GCPs, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities in the form of International Conference on Harmonization guidelines for any of our product candidates that are in preclinical and clinical development. The regulatory authorities enforce GCPs through periodic inspections of trial sponsors, principal investigators and clinical trial sites. Although we rely on CROs to conduct GCP-compliant clinical trials, we remain responsible for ensuring that each of our GLP preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations. If we or our CROs fail to comply with GCPs, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. Accordingly, if our CROs fail to comply with these regulations or fail to recruit a sufficient number of subjects, we may be required to repeat clinical trials, which would delay the regulatory approval process.&#160;</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our reliance on third parties to conduct clinical trials will result in less direct control over the management of data developed through clinical trials than would be the case if we were relying entirely upon our own staff. Communicating with CROs and other third parties can be challenging, potentially leading to mistakes as well as difficulties in coordinating activities. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines or fail to comply with regulatory requirements, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reasons, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize, any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed. While we will have agreements governing their activities, our CROs will not be our employees and we will not control whether or not they devote sufficient time and resources to our future clinical and preclinical programs. These CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other product development activities which could harm our business. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If our relationship with any of these CROs terminates, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can negatively impact our ability to meet our desired clinical development timelines. While we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have a negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA. The FDA may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the trial. The FDA may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval or rejection of our marketing applications by the FDA and may ultimately lead to the denial of marketing approval of our product candidates.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Intellectual Property</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we breach our license agreements or any of the other agreements under which we acquired, or will acquire, the intellectual property rights to our product candidates, we could lose the ability to continue the development and commercialization of the related product candidates.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We license a number of technologies to form our antibody platform and T cell platform, and the technology we use in our siRNA platform is licensed from Alnylam. We have also developed certain product candidates using intellectual property licensed from third parties. A core element of our business strategy includes continuing to acquire or in-license additional technologies or product candidates for the treatment and prevention of serious infectious diseases.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we fail to meet our obligations under these agreements, our licensors may have the right to terminate our licenses. If any of our license agreements are terminated, and we lose our intellectual property rights under such agreements, this may result in a complete termination of our product development and any commercialization efforts for the product candidates which we are developing under such agreements. While we would expect to exercise all rights and remedies available to us, including seeking to cure any breach by us, and otherwise seek to preserve our rights under such agreements, we may not be able to do so in a timely manner, at an acceptable cost or at all. We may also be subject to risks related to disputes between us and our licensors regarding the intellectual property subject to a license agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to obtain and maintain patent protection for our product candidates and technology, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and commercialize products and technology similar or identical to ours, and our ability to successfully commercialize our product candidates and technology may be adversely affected.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our success depends, in large part, on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates and our technology. We and our licensors have sought, and intend to seek, to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates and our technology that are important to our business.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or product candidates or which effectively prevent others from commercializing competitive technologies and product candidates. Because patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the first to file a patent application relating to any particular aspect of a product candidate. Furthermore, if third parties have filed such patent applications with a priority date before March 16, 2013, an interference proceeding in the United States can be initiated by such third party, or by the U.S. Patent and Trademark Office, or USPTO, itself, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. In addition, changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Similarly, changes in patent law and regulations in other countries or jurisdictions, changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we own or have licensed or that we may obtain in the future.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We or our licensors have not pursued or maintained, and may not pursue or maintain in the future, patent protection for our product candidates in every country or territory in which we may sell our products, if approved. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from infringing our patents in all countries outside the United States, or from selling or importing products that infringe our patents in and into the United States or other jurisdictions.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, the coverage claimed in a patent application can be significantly reduced before the patent is issued and its scope can be reinterpreted after issuance. Even if the patent applications we license or own do issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative products in a non-infringing manner.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and product candidates. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our intellectual property may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. In addition, if the breadth or strength of protection provided by the patents and patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, our owned and in-licensed patents may be subject to a reservation of rights by one or more third parties. For example, the research resulting in certain of our owned and in-licensed patent rights and technology was funded in part by the U.S. government. As a result, the government may have certain rights, or march-in rights, to such patent rights and technology. When new technologies are developed with government funding, the government generally obtains certain rights in any resulting patents, including a nonexclusive license authorizing the government to use the invention for noncommercial purposes. These rights may permit the government to disclose our confidential information to third parties and to exercise march-in rights to use or allow third parties to use our licensed technology. The government can exercise its march-in rights if it determines that action is necessary because we fail to achieve practical application of the government-funded technology, because action is necessary to alleviate health or safety needs, to meet requirements of federal regulations, or to give preference to U.S. industry. In addition, our rights in such inventions may be subject to certain requirements to manufacture products embodying such inventions in the United States. Any exercise by the government of such rights could harm our competitive position, business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Obtaining and maintaining our patent rights depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. In addition, periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents and/or patent applications will have to be paid to the USPTO and various government patent agencies outside the United States over the lifetime of our owned and licensed patents and/or applications and any patent rights we may own or license in the future. We rely on our service providers or our licensors to pay these fees. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and we are also dependent on our licensors to take the necessary action to comply with these requirements with respect to our licensed intellectual property. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, nonpayment of fees and failure to properly legalize and submit formal documents. If we or our licensors fail to maintain the patents and patent applications covering our product candidates or technologies, we may not be able to use such patents and patent applications or stop a competitor from marketing products that are the same as or similar to our product candidates, which would have an adverse effect on our business. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could harm our business.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, if we fail to apply for applicable patent term extensions or adjustments, we will have a more limited time during which we can enforce our granted patent rights. In addition, if we are responsible for patent prosecution and maintenance of patent rights in-licensed to us, any of the foregoing could expose us to liability to the applicable patent owner.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Patent terms may be inadequate to protect our competitive position on our product candidates or any products approved in the future for an adequate amount of time and additional competitors could enter the market with generic or biosimilar versions of such products.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first effective filing date. Although various extensions may be available, the life of a patent and the protection it affords is limited. In addition, although upon issuance in the United States a patent&#x2019;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. If we do not have sufficient patent life to protect our products, our business and results of operations could be adversely affected.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Given the amount of time required for the development, testing and regulatory review of our product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. We expect to seek extensions of patent terms in the United States and, if available, in other countries where we have or will obtain patent rights. In the United States, the Drug Price Competition and Patent Term Restoration Act of 1984, or the Hatch-Waxman Act, permits a patent term extension of up to five years beyond the normal expiration of the patent, provided that the patent is not enforceable for more than 14 years from the date of drug approval, which is limited to the approved indication (or any additional indications approved during the period of extension). Furthermore, only one patent per approved product can be extended and only those claims covering the approved product, a method for using it or a method for manufacturing it may be extended. However, the applicable authorities, including the FDA and the USPTO in the United States, and any equivalent regulatory authority in other countries, may not agree with our assessment of whether such extensions are available, and may refuse to grant extensions to our patents, or may grant more limited extensions than we request. If this occurs, our competitors may be able to take advantage of our investment in development and clinical trials by referencing our clinical and preclinical data and launch their product earlier than might otherwise be the case.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Also, there are detailed rules and requirements regarding the patents that may be submitted to the FDA for listing in the FDA publication, &#x201c;Approved Drug Products with Therapeutic Equivalence Evaluations,&#x201d; known as the Orange Book. We may be unable to obtain patents covering our product candidates that contain one or more claims that satisfy the requirements for listing in the Orange Book. Even if we submit a patent for listing in the Orange Book, the FDA may decline to list the patent, or a manufacturer of generic drugs may challenge the listing. If one of our product candidates is approved and a patent covering that product candidate is not listed in the Orange Book, a manufacturer of generic drugs would not have to provide advance notice to us of any abbreviated new drug application, or ANDA, filed with the FDA to obtain permission to sell a generic version of such product candidate. We cannot predict which, if any, patents in our current portfolio or patents we may obtain in the future will be eligible for listing in the Orange Book, how any generic competitor would address such patents, whether we would sue on any such patents or the outcome of any such suit.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For additional information regarding the Hatch-Waxman Act and exclusivity, see the section titled &#x201c;Business&#x2014;Government Regulation and Product Approval&#x2014;Hatch-Waxman Amendments and Exclusivity&#x201d; in our 2020 Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be successful in securing or maintaining proprietary patent protection for products and technologies we develop or license. Moreover, if any of our owned or in-licensed patents are successfully challenged by litigation, the affected product could immediately face competition and its sales would likely decline rapidly. Any of the foregoing could harm our competitive position, business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Third parties may initiate legal proceedings alleging that we are infringing, misappropriating or otherwise violating their intellectual property rights, the outcome of which would be uncertain and could have a negative impact on the success of our business.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial success depends, in part, upon our ability and the ability of others with whom we may collaborate to develop, manufacture, market and sell our current and any future product candidates and use our proprietary technologies without infringing, misappropriating or otherwise violating the proprietary rights and intellectual property of third parties. The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our current and any future product candidates and technology, including interference proceedings, derivation proceedings, post grant review and inter partes review before the USPTO. If we are found to infringe a third party&#x2019;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our product candidate(s) and technology. Under any such license, we would most likely be required to pay various types of fees, milestones, royalties or other amounts. Moreover, we may not be able to obtain any required license on commercially reasonable terms or at all, and if such an instance arises, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business. Parties making claims against us may also seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The licensing or acquisition of third-party intellectual property rights is a competitive area, and more established companies may also pursue strategies to license or acquire third-party intellectual property rights that we may consider attractive or necessary. These established companies may have a competitive advantage over us due to their size, capital resources and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment or at all. If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of the relevant program or product candidate, which could have an adverse effect on our business, financial condition, results of operations and prospects. Furthermore, even if we were able to obtain a license, it could be nonexclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidate. We may also have to redesign our products, which may not be commercially or technically feasible or require substantial time and expense. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#x2019; fees, if we are found to have willfully infringed a patent or other intellectual property right. We may be required to indemnify collaborators or contractors against such claims. A finding of infringement could prevent us from manufacturing and commercializing our current or any future product candidates or force us to cease some or all of our business operations, which could harm our business. Even if we are successful in defending against such claims, litigation can be expensive and time-consuming and would divert management&#x2019;s attention from our core business. Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common stock.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers or claims asserting ownership of what we regard as our own intellectual property.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#x2019;s current or former employer. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we may in the future be subject to claims by our former employees or consultants asserting an ownership right in our patents or patent applications, as a result of the work they performed on our behalf. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Although it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own, and we cannot be certain that our agreements with such parties will be upheld in the face of a potential challenge or that they will not be breached, for which we may not have an adequate remedy. The assignment of intellectual property rights may not be self-executing or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time-consuming and unsuccessful.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Competitors may infringe, misappropriate or otherwise violate our patents, the patents of our licensors or our other intellectual property rights. To counter infringement or unauthorized use, we may be required to file legal claims, which can be expensive and time-consuming and are likely to divert significant resources from our core business, including distracting our technical and management personnel from their normal responsibilities.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid or is unenforceable, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our owned or licensed patents at risk of being invalidated or interpreted narrowly and could put our owned or licensed patent applications at risk of not issuing. The initiation of a claim against a third party might also cause the third party to bring counterclaims against us, such as claims asserting that our patent rights are invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, non-enablement or lack of statutory subject matter. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant material information from the USPTO, or made a materially misleading statement, during prosecution. Third parties may also raise similar validity claims before the USPTO in post-grant proceedings such as ex parte reexaminations, inter partes review, post-grant review, or oppositions or similar proceedings outside the United States, in parallel with litigation or even outside the context of litigation. Third parties may also challenge inventorship through a derivation proceeding or other litigation proceeding challenging inventorship, which can include claims of misappropriation of intellectual property, filing a patent application without authorization of the true inventor, not listing inventors, or listing non-inventors as inventors. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is or will be no invalidating prior art, of which we and the patent examiner were unaware during prosecution. For the patents and patent applications that we have licensed, we may have limited or no right to participate in the defense of any licensed patents against challenge by a third party. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of any future patent protection on our current or future product candidates. Such a loss of patent protection could harm our business.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States. Our business could be harmed if in litigation the prevailing party does not offer us a license, or if the license offered as a result is not on commercially reasonable terms. Any litigation or other proceedings to enforce our intellectual property rights may fail and, even if successful, may result in substantial costs and distract our management and other employees.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have an adverse effect on the price of our common stock.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Accordingly, despite our efforts, we may not be able to prevent third parties from infringing upon or misappropriating or from successfully challenging our intellectual property rights. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have an adverse effect on our ability to compete in the marketplace.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Filing, prosecuting and defending patents covering our current and any future product candidates and technology platforms in all countries throughout the world would be prohibitively expensive. Competitors may use our technologies in jurisdictions where we or our licensors have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we may obtain patent protection but where patent enforcement is not as strong as that in the United States. These products may compete with our products in jurisdictions where we do not have any issued or licensed patents, and any future patent claims or other intellectual property rights may not be effective or sufficient to prevent them from so competing.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our intellectual property and proprietary rights generally. Proceedings to enforce our intellectual property and proprietary rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly, could put our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property and proprietary rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired, and our business, financial condition, results of operations and prospects may be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If the U.S. government, the World Trade Organization, or WTO, or other governmental body imposes an intellectual property rights waiver, our ability to successfully commercialize our COVID-19 product candidates and protect our related technology could be adversely affected.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The WTO is currently considering a waiver of intellectual property rights for COVID-19 vaccines and the U.S. government recently took a stance in support of the waiver. The current proposal is for a temporary waiver of intellectual property rights that cover COVID-19 vaccines, however, the ultimate timing and scope of the waiver, if approved, is unknown. The scope and timing of such waiver will likely be subject to extensive negotiations given the complexity of the matter, which may result in prolonged uncertainty, which could adversely affect our business. If a waiver is approved and covers COVID-19 treatments or prophylactics, such as sotrovimab and VIR-7832, our ability to successfully commercialize our COVID-19 product candidates and protect our related technology could be adversely affected.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The current waiver proposal is the result of public health concerns from the COVID-19 pandemic and an effort to make vaccines more widely available worldwide. This proposal may also lead to similar waivers of intellectual property rights in the future in connection with other public health pandemics or epidemics or other situations of public health concern. Given that our business is focused on treating and preventing infectious diseases, there is a risk that our business and our ability to protect our technology could be adversely affected in situations beyond COVID-19.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to seeking patent and trademark protection for our product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. Because we rely on third</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">parties to help us discover, develop and manufacture our current and any future product candidates, or if we collaborate with third parties for the development, manufacturing or commercialization of our current or any future product candidates, we must, at times, share trade secrets with them. We may also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We seek to protect our proprietary technology in part by entering into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with our advisors, employees, third-party contractors and consultants prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of these parties to use or disclose our confidential information, including our trade secrets. We also enter into invention or patent assignment agreements with our employees, advisors and consultants. Despite our efforts to protect our trade secrets, the need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others or are disclosed or used in violation of these agreements. Moreover, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our confidential information or proprietary technology and processes. Monitoring unauthorized uses and disclosures is difficult, and we do not know whether the steps we have taken to protect our proprietary technologies will be effective. If any of the collaborators, scientific advisors, employees, contractors and consultants who are parties to these agreements breaches or violates the terms of any of these agreements, we may not have adequate remedies for any such breach or violation, and we could lose our trade secrets as a result. Moreover, if confidential information that is licensed or disclosed to us by our partners, collaborators or others is inadvertently disclosed or subject to a breach or violation, we may be exposed to liability to the owner of that confidential information. Enforcing a claim that a third-party illegally or unlawfully obtained and is using our trade secrets, like patent litigation, is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the United States are sometimes less willing to protect trade secrets.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, our competitors may independently develop knowledge, methods and know-how equivalent to our trade secrets. Competitors could purchase our products and replicate some or all of the competitive advantages we derive from our development efforts for technologies on which we do not have patent protection. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor&#x2019;s discovery of our trade secrets or other unauthorized use or disclosure could have an adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also seek to preserve the integrity and confidentiality of our data and other confidential information by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and detecting the disclosure or misappropriation of confidential information and enforcing a claim that a party illegally disclosed or misappropriated confidential information is difficult, expensive and time-consuming, and the outcome is unpredictable. Further, we may not be able to obtain adequate remedies for any breach. In addition, our confidential information may otherwise become known or be independently discovered by competitors, in which case we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to rely on trademarks as one means to distinguish any of our product candidates that are approved for marketing from the products of our competitors. Additionally, the process of obtaining trademark protection is expensive and time-consuming, and we may not be able to prosecute all necessary or desirable trademark applications at a reasonable cost or in a timely manner or obtain trademark protection in all jurisdictions that we consider to be important to our business. Once we select trademarks and apply to register them, our trademark applications may not be approved. Third parties may oppose our trademark applications or otherwise challenge our use of the trademarks. In the event that our trademarks are successfully challenged, we could be forced to rebrand our products, which could result in loss of brand recognition and could require us to devote resources to advertising and marketing new brands. Our competitors may infringe our trademarks, and we may not have adequate resources to enforce our trademarks.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, any proprietary product name we propose to use with our current or any other product candidate in the United States must be approved by the FDA, regardless of whether we have registered it, or applied to register it, as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of the potential for confusion with other product names. If the FDA objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable proprietary product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The exercise by the Bill&#160;&amp; Melinda Gates Foundation of its licenses to certain of our intellectual property and its development and commercialization of products that we are also developing and commercializing could have an adverse impact on our market position.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We entered into a letter agreement with the Bill&#160;&amp; Melinda Gates Foundation, or the Gates Agreement, in December 2016 in connection with the Bill&#160;&amp; Melinda Gates Foundation&#x2019;s investment in us through the purchase of $20.0&#160;million of shares of our convertible preferred stock. We are obligated to use the proceeds of the Bill&#160;&amp; Melinda Gates Foundation&#x2019;s investment in furtherance of its charitable purposes to perform certain activities set forth in the Gates Agreement. For additional information regarding our obligations under the Gates Agreement, see the section titled &#x201c;Business&#x2014;Our Collaboration, License and Grant Agreements&#x2014;Letter Agreement with the Bill &amp; Melinda Gates Foundation&#x201d; in our 2020 Form 10-K.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we fail to comply with (i)&#160;our obligations to use the proceeds of the Bill&#160;&amp; Melinda Gates Foundation&#x2019;s investment for the purposes described in the paragraph above and to not use such proceeds for specified prohibited uses, (ii)&#160;specified reporting requirements or (iii)&#160;specified applicable laws, or if we materially breach our specified global access commitments (any such failure or material breach, a Specified Default), we will be obligated to redeem or arrange for a third party to purchase all of our stock purchased by the Bill&#160;&amp; Melinda Gates Foundation under the Gates Agreement, at the Bill&#160;&amp; Melinda Gates Foundation&#x2019;s request, at a price equal to the greater of (1)&#160;the original purchase price plus 5% compounding interest or (2)&#160;the fair market value as determined by an independent third-party, which amount may increase in the event of certain underwritten public offerings of our common stock or a sale of our company or all of our material assets relating to the Gates Agreement. Additionally, if a Specified Default occurs or if we are unable or unwilling to continue the HIV program, tuberculosis program or, if applicable, the mutually agreed additional program (except for scientific or technical reasons), or if we institute bankruptcy or insolvency proceedings, then the Bill&#160;&amp; Melinda Gates Foundation will have the right to exercise a non-exclusive, fully-paid license (with the right to sublicense) under our intellectual property to the extent necessary to use, make and sell products arising from such programs, in each case solely to the extent necessary to benefit people in the developing countries in furtherance of the Bill&#160;&amp; Melinda Gates Foundation&#x2019;s charitable purpose.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The exercise by the Bill&#160;&amp; Melinda Gates Foundation of any of its non-exclusive licenses to certain of our intellectual property (or its right to obtain such licenses), and its development and commercialization of product candidates and products that we are also developing and commercializing, could have an adverse impact on our market position.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Business Operations, Employee Matters and Managing Growth</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are highly dependent on our key personnel, and if we are not able to retain these members of our management team or recruit and retain additional management, clinical and scientific personnel, our business will be harmed.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are highly dependent on our management, scientific and medical personnel, including our Chief Executive Officer, Dr.&#160;Scangos. Our key personnel may currently terminate their employment with us at any time. The loss of the services of any of these persons could impede the achievement of our research, development and commercialization objectives. Additionally, we do not currently maintain &#x201c;key person&#x201d; life insurance on the lives of our executives or any of our employees.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Recruiting and retaining other senior executives, qualified scientific and clinical personnel and, if we progress the development of any of our product candidates, commercialization, manufacturing and sales and marketing personnel, will be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize our product candidates. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract and retain high-quality personnel, our ability to pursue our growth strategy will be limited.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future performance will also depend, in part, on our ability to successfully integrate newly hired executive officers into our management team and our ability to develop an effective working relationship among senior management. Our failure to integrate these individuals and create effective working relationships among them and other members of management could result in inefficiencies in the development and commercialization of our product candidates, harming future regulatory approvals, sales of our product candidates and our results of operations.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have in the past and may in the future acquire or invest in other companies or technologies, which could divert our management&#x2019;s attention, result in dilution to our stockholders and otherwise disrupt our operations and adversely affect our operating results.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have in the past and may in the future seek to acquire or invest in additional businesses and/or technologies that we believe complement or expand our product candidates, enhance our technical capabilities or otherwise offer growth opportunities in the United States and internationally. The pursuit of potential acquisitions and investments may divert the attention of management and cause us to incur various expenses in identifying, investigating and pursuing suitable acquisitions, whether or not they are consummated.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For example, we acquired TomegaVax, Inc., or TomegaVax, in September 2016, Humabs BioMed SA, or Humabs, in August 2017, Agenovir Corporation, or Agenovir, in January 2018 and Statera Health, LLC, or Statera, in February 2018. Realizing the benefits of these acquisitions will depend upon the successful integration of the acquired technology into our existing and future product candidates. Furthermore, we may not be able to integrate the acquired personnel, operations and technologies successfully, or effectively manage the combined business following the acquisition. We also may not realize the anticipated benefits from any acquired business. We face many risks in connection with acquisitions and investments, whether or not consummated. A significant portion of the purchase price of companies we acquire may be allocated to acquired goodwill and other intangible assets, which must be assessed for impairment at least annually. If our acquisitions do not yield expected returns, we may in the future be required to take charges to our operating results based on this impairment assessment process, which could adversely affect our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, in connection with our acquisitions of TomegaVax, Humabs and Agenovir, we are required to make future contingent payments upon the achievement of certain milestones. We may in the future be required to make these payments, which could adversely affect our financial condition. For additional information regarding our obligations under these agreements, see the section titled &#x201c;Business&#x2014;Our Acquisition Agreements&#x201d; in our 2020 Form 10-K.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, acquisitions could also result in dilutive issuances of equity securities or the incurrence of debt, which could adversely affect our operating results. In addition, if an acquired business fails to meet our expectations, our business, financial condition, results of operations and prospects may suffer. We cannot assure you that we will be successful in integrating the businesses or technologies we may acquire. The failure to successfully integrate these businesses could have a material adverse effect on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We expect to expand</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">our organization, and we may experience difficulties in managing this growth, which could disrupt our operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of June 30, 2021, we had 367 full-time employees. As the clinical development of our product candidates progresses, we also expect to experience significant growth in the number of our employees and the scope of our operations, particularly in the areas of research, development, regulatory affairs and, if any of our product candidates receives marketing approval, sales, marketing and distribution. In addition, we also expect to hire additional personnel in order to operate as a public company. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities, and continue to recruit and train additional qualified personnel all within the context of the rapidly evolving global pandemic of COVID-19. We continue to closely monitor the COVID-19 situation and will evolve our expansion plans as needed. As a result of the global pandemic, the majority of our workforce has been working from home since March 2020. Despite this, we must continue to effectively integrate, develop and motivate a growing number of new employees, and maintain the beneficial aspects of our corporate culture. We have implemented plans to reopen our offices to allow employees to return when appropriate. Although these plans are consistent with local government requirements, and focused on employee safety, and contemplate returning to remote work should the COVID-19 situation change, there is uncertainty regarding the long-term impact that the COVID-19 pandemic has had on the nature of the office environment and remote working, which could present operational and workplace culture challenges as we seek to expand our organization.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;"> </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expansion of our operations may lead to significant costs and may divert our management and business development resources. We may not be able to effectively manage the expansion of our operations, recruit and train additional qualified personnel, or succeed at effectively integrating employees that have joined during the global pandemic. Any inability to manage growth could delay the execution of our business plans or disrupt our operations. &#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our operations, and those of our CDMOs, CROs and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, public health pandemics or epidemics (including, for example, the ongoing COVID-19 pandemic), and other natural or&#160;man-made&#160;disasters or</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">business interruptions, for which we are predominantly self-insured. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to develop our product candidates could be disrupted if our operations or those of our suppliers are affected by man-made&#160;or natural disasters or other business interruptions. Our corporate headquarters are located in California near major earthquake faults and fire zones. The ultimate impact on us, our significant suppliers and our general infrastructure of being located near major earthquake faults and fire zones and being consolidated in certain geographical areas is unknown, but our operations and financial condition could suffer in the event of a major earthquake, fire or other natural disaster.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our business could be materially adversely affected by the effects of health pandemics or epidemics, including the current outbreak of COVID-19 pandemic and future outbreaks of the disease.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business could be materially adversely affected by the effects of health pandemics or epidemics, including the current COVID-19 pandemic, the multiple SARS-CoV-2 variants that have further complicated the fight to subdue the global pandemic and any future outbreaks of the disease. The COVID-19 pandemic has resulted in travel restrictions, quarantines orders and other restrictions by governments to reduce the spread of the disease. As a result, the majority of our workforce has been working from home since March 2020.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The effects of the restrictions related to the COVID-19 pandemic and our work-from-home policies, including the evolving nature of such policies, may negatively impact productivity, disrupt our business and delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and other limitations on our ability to conduct our business in the ordinary course. In addition, due to the COVID-19 pandemic and our remote workforce, we have experienced an increased risk to our information technology assets and data. We have implemented plans to reopen our offices when appropriate. We may face several challenges or disruptions upon a return back to the workplace, including re-integration challenges by our employees and distractions to management related to such transition.&#160;These and similar, and perhaps more severe, disruptions in our operations could negatively impact our business, operating results and financial condition.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Quarantines, shelter-in-place and similar government orders, or the perception that such orders or other restrictions on the conduct of business operations could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which would disrupt our supply chain. In particular, some of our CDMOs that we use to supply our early-stage product candidates are located in China, where the COVID-19 outbreak was first reported and where there have been government-imposed quarantines. While many of these materials may be obtained by more than one supplier, including suppliers outside of China, port closures and other restrictions resulting from the coronavirus outbreak in the region or other regions may disrupt our supply chain or limit our ability to obtain sufficient materials for our product candidates.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, our clinical trials have been affected by the ongoing COVID-19 pandemic. Site initiation and patient enrollment has been and may be further delayed due to prioritization of hospital resources toward the COVID-19 pandemic, and some patients may not be able or willing to comply with clinical trial protocols if quarantines impede patient movement or interrupt healthcare services. Similarly, our ability to recruit and retain patients and principal investigators and site staff who, as healthcare providers, may have heightened exposure to COVID-19, has been delayed or disrupted, which has adversely impacted our clinical trial operations.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The continued spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, the COVID-19 pandemic, may be difficult to assess or predict, it has already resulted in significant disruption of global financial markets. This disruption, if sustained or recurrent, could make it more difficult for us to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 could materially affect our business and the value of our common stock.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The global pandemic of COVID-19 and the evolution of new and existing variants of COVID-19 that are resistant to existing treatments or vaccinations continue to rapidly evolve. The ultimate impact of the ongoing COVID-19 pandemic or a similar health pandemic or epidemic is highly uncertain and subject to change. We do not yet know the full extent of potential delays or impacts on our business, our clinical trials, healthcare systems or the global economy as a whole. These effects could have a material impact on our operations, and we will continue to monitor the COVID-19 situation closely.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If our information systems, or those maintained on our behalf, fail or suffer security breaches, such events could result in, without limitation, the following: a significant disruption of our product development programs; an inability to operate our business effectively; unauthorized&#160; access to or disclosure of the personal information we process; and other adverse effects on our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our computer and information technology systems, cloud-based computing services and those of our current and any future collaborators, service providers and other parties upon whom we rely are potentially vulnerable to malware, computer viruses, denial-of-service attacks (such as credential stuffing), ransomware attacks, user error or malfeasance, data corruption, cyber-based attacks, natural disasters, public health pandemics or epidemics (including, for example, the ongoing COVID-19 pandemic), terrorism, war and telecommunication and electrical failures that may result in damage to or the interruption or impairment of key business processes, or the loss or corruption of our information, including intellectual property, proprietary business information and personal information collectively, Sensitive Information. We may also experience server malfunction, software or hardware failures, supply-chain cyber-attacks, loss of data or other computer assets and other similar issues. We have recently experienced security breaches of our information technology systems, such as through business email compromises. The techniques used to sabotage or to obtain unauthorized access to information systems, and networks in which cyber threat actors store data or through which they transmit data change frequently and we may be unable to implement adequate preventative measures. Any significant system failure, accident or security breach could have a material adverse effect on our business, financial condition and operations.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may be required to expend significant resources (including financial), fundamentally change our business activities and practices, or modify our operations, including our clinical trial activities, or information technology in an effort to protect against security breaches and to mitigate, detect, and remediate actual and potential vulnerabilities. Relevant laws, regulations, industry standards and contractual obligations, may require us to implement specific security measures or use industry-standard or reasonable measures to protect against security breaches. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, data loss or corruption, delays, cessation of service and other harm to our business and our competitive position. If the information technology systems of our third-party vendors become subject to disruptions or security breaches, we may have insufficient recourse against such third parties and we may have to expend significant resources to mitigate the impact of such an event, and to develop and implement protections to prevent future events of this nature from occurring.&#160;Although we maintain cybersecurity insurance coverage, such insurance may not be adequate to cover all liabilities that we may incur. Furthermore, if a security breach were to occur and cause interruptions in our operations, it could result in a disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For example, we and one of our third-party vendors have experienced social engineering schemes designed to gain access to our systems, including recent business email compromises through phishing attacks, and may be a target of other phishing attacks, social engineering attacks or other cyber-attacks in the future. If a data security breach affects our or third parties&#x2019; systems upon which we rely, corrupts our data or results in the unauthorized disclosure or release of personally identifiable information, our reputation could be materially damaged or our operations, disrupted. In addition, such a breach may require notification to governmental agencies, supervisory bodies, credit reporting agencies, the media, individuals, collaborators or others pursuant to various federal, state and foreign data protection, privacy and security laws, regulations and guidelines, industry standards, our policies and our contracts, if applicable. Such laws may include the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, and the Health Information Technology for Economic and Clinical Health Act, or HITECH. Under these laws specifically, notice of certain security breaches must be made to affected individuals, the Secretary of the Department of Health and Human Services, or the HHS, and for extensive breaches, to the media or state attorneys general. Such a notice could further harm our reputation and our ability to compete. Such disclosures are costly, and the disclosure or the failure to comply with such requirements could lead to a material adverse effect on our reputation, business, or financial condition. Furthermore, a data security breach could result in fines, increased costs or loss of revenue and we could incur liability (such as through regulatory fines and penalties as well as private claims), our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed. Additionally, federal, state and foreign laws and regulations can expose us to enforcement actions and investigations by regulatory authorities, and potentially result in regulatory penalties and significant legal liability, if our information technology security efforts fail.&#160;</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We receive, process, store and use personal information and other data, which subjects us to governmental regulation and other legal obligations, liability and risks related to privacy, security, and data protection, and our actual or perceived failure to comply with such obligations could lead to government enforcement actions (that could include fines and penalties), a disruption of our clinical trials or commercialization of our products, private litigation, harm to our reputation, or other adverse effects on our business or prospects.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We receive, process, store and use personal information and other data about our clinical trial participants, employees, partners and others. We are, or may become, subject to numerous domestic and foreign laws and regulations regarding privacy, data protection, and data security, industry standards, as well as policies, contracts and other obligations that apply to the processing of personal information by us and on our behalf, the scope of which is changing, subject to differing applications and interpretations and may be inconsistent among countries, or conflict with other rules. We strive to comply with all applicable data protection requirements and obligations; however new laws, policies, codes of conduct and legal obligations may arise, continue to evolve, be interpreted and applied in a manner that is inconsistent from one jurisdiction to another and conflict with one another. Any failure or perceived failure by us or third parties working on our behalf to comply with applicable data protection requirements may result in governmental enforcement actions (including fines, penalties, judgments, settlements, additional reporting requirements and/or oversight, temporary or permanent bans on all or some processing of personal information, orders to destroy or not use personal information, imprisonment of company officials and public censure), civil claims, litigation, damage to our reputation and loss of goodwill, any of which could have a material adverse effect on our business, operations and financial performance, interrupt or stop clinical trials, limit our ability to develop or commercialize our products, or require us to revise or restructure our operations. With substantial uncertainty over the interpretation and application of these laws, regulations and other obligations, we may face challenges in addressing their requirements and making necessary changes to our policies and practices, and may incur significant costs and expenses in our efforts to do so. For additional information regarding these laws, see the section titled &#x201c;Business&#x2014;Government Regulation and Product Approval&#x2014;Privacy Laws&#x201d; in our 2020 Form 10-K.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are exposed to the risk of fraud or other misconduct by our employees, principal investigators, consultants and commercial partners. Misconduct by these parties could include intentional failures, reckless and/or negligent conduct or unauthorized activities that violates (i)&#160;the laws and regulations of FDA and other regulatory authorities, including those laws requiring the reporting of true, complete and accurate information to such authorities, (ii)&#160;manufacturing standards, (iii)&#160;federal and state data privacy, security, fraud and abuse and other healthcare laws and regulations in the United States and abroad and (iv)&#160;laws that require the true, complete and accurate reporting of financial information or data. In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Such misconduct also could involve the improper use of individually identifiable information, including, without limitation, information obtained in the course of clinical trials, creating fraudulent data in our preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from government investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could result in significant civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participating in government-funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of noncompliance with these laws, contractual damages, reputational harm and the curtailment or restructuring of our operations, any of which could have a negative impact on our business, financial condition, results of operations and prospects.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our ability to use our</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">net operating losses, or NOLs, to offset future taxable income may be subject to certain limitations.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred substantial losses since inception and have no assurances that we will become profitable in the near future, if ever. As of December&#160;31, 2020, we had net operating loss carryforwards of $483.7&#160;million for federal tax purposes and $216.8&#160;million for state tax purposes. If not utilized, federal carryforwards will begin expiring in 2035 and state carryforwards will begin expiring in 2031. Our ability to use our federal and state net operating losses to offset potential future taxable income is dependent upon our generation of future taxable income before any expiration dates of the net operating losses, and we cannot predict with certainty when, or whether, we will generate sufficient taxable income to use all of our net operating losses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In general, under Sections 382 and 383 of the Code, a corporation that undergoes an &#x201c;ownership change&#x201d; (generally defined as a greater than 50 percentage point change (by value) in its equity ownership by certain stockholders over a rolling three-year period) is subject to limitations on its ability to utilize its pre-change NOLs to offset future taxable income. We may have experienced ownership changes in the past or as a result of the IPO and may experience ownership changes as a result of future offerings and/or subsequent changes in our stock ownership (some of which shifts are outside our control). In addition, Agenovir has experienced at least one ownership change in the past resulting in a limitation under Section&#160;382 of the Code, which has been accounted for in calculating our available NOL carryforwards. As a result, if, and to the extent that we earn net taxable income, our ability to use our pre-change NOLs to offset such taxable income may be subject to limitations.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Tax Act and the Coronavirus Aid, Relief and Economic Security Act include, among other things, changes to U.S. federal tax rates and the rules governing NOL carryforwards. For example, NOLs arising in tax years ending after December&#160;31, 2017 can be carried forward indefinitely, but the deductibility of such federal NOLs may be limited to 80% of current year taxable income for tax years beginning on or after January&#160;1, 2021. Deferred tax assets for NOLs will need to be measured at the applicable tax rate in effect when the NOL is expected to be utilized. The changes in the carryforward periods, as well as the new limitation on use of NOLs may impact our ability to utilize our NOLs to offset taxable income in the future. Because we have been generating taxable losses since inception, we do not expect any changes resulting from the new NOL provision to the current tax benefit and valuation allowance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Ownership of Our Common Stock</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our financial condition and results of operations may fluctuate from quarter to quarter and year to year, which makes them difficult to predict.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect our financial condition and results of operations to fluctuate from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, you should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The market price of our common stock has been, and in the future, may be, volatile and fluctuate substantially, which could result in substantial losses for purchasers of our common stock.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our stock price has been, and in the future, may be, subject to substantial volatility. From October 11, 2019, our first day of trading on The Nasdaq Global Select Market, through July 30, 2021, the closing price of our stock ranged from $11.83 per share to $83.07 per share. As a result of the volatility in our stock price, our stockholders could incur substantial losses.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The stock market in general and the market for biopharmaceutical and pharmaceutical companies in particular, has experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The ongoing COVID-19 pandemic, for example, has negatively affected some sectors of the stock market and investor sentiment and has resulted in significant volatility. As a result of this volatility, you may not be able to sell your common stock at or above the price you paid for your shares. Market and industry factors may cause the market price and demand for our common stock to fluctuate substantially, regardless of our actual operating performance, which may limit or prevent investors from selling their shares at or above the price paid for the shares and may otherwise negatively affect the liquidity of our common stock.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, public statements by us, government agencies, the media or others relating to the ongoing COVID-19 pandemic (including regarding our and others&#x2019; efforts to develop COVID-19 therapies) have in the past resulted, and may in the future result, in significant fluctuations in our stock price. Given the global focus on the COVID-19 pandemic, information in the public arena on this topic, whether or not accurate, has had and will likely continue to have an outsized impact (positive or negative) on our stock price. Information related to our development, manufacturing, regulatory and commercialization efforts with respect to sotrovimab and VIR-7832, or information regarding such efforts by competitors with respect to their potential therapies, may meaningfully impact our stock price.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Some companies that have experienced volatility in the trading price of their shares have been the subject of securities class action litigation. Any lawsuit to which we are a party, with or without merit, may result in an unfavorable judgment. We also may decide to settle lawsuits on unfavorable terms. Any such negative outcome could result in payments of substantial damages or fines, damage to our reputation or adverse changes to our business practices. Defending against litigation is costly and time-consuming, and could divert our management&#x2019;s attention and our resources. Furthermore, during the course of litigation, there could be negative public announcements of the results of hearings, motions or other interim proceedings or developments, which could have a negative effect on the market price of our common stock.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of ownership of our common stock among our existing executive officers, directors and principal stockholders may prevent new investors from influencing significant corporate decisions.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our executive officers, directors and stockholders who own more than 5% of our outstanding common stock beneficially own a significant percentage of our outstanding common stock. If these persons acted together, they may be able to significantly influence all matters requiring stockholder approval, including the election and removal of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. The concentration of voting power and transfer restrictions could delay or prevent an acquisition of our company on terms that other stockholders may desire or result in the management of our company in ways with which other stockholders disagree.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If research analysts do not publish research or reports, or publish unfavorable research or reports, about us, our business or our market, our stock price and trading volume could decline.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The trading market for our common stock will be influenced by the research and reports that industry or financial analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if the clinical trials and operating results fail to meet the expectations of analysts, our stock could decline. If analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Because we do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, will be your sole source of gain.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">You should not rely on an investment in our common stock to provide dividend income. We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. In addition, the terms of any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have incurred and we will continue incur significant increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a public company, we have incurred and we will continue to incur significant legal, accounting, investor relations and other expenses. In addition, the Sarbanes-Oxley Act and rules subsequently implemented by the SEC and Nasdaq have imposed various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Further, in July 2010, the Dodd-Frank Wall Street Reform and Consumer Protection Act was enacted, pursuant to which the SEC adopted rules and regulations related to corporate governance and executive compensation, such as &#x201c;say on pay&#x201d; and proxy access. Emerging growth companies are permitted to implement many of these requirements over time, however, we are no longer an emerging growth company as of December 31, 2020 and expect to incur additional compliance-related expenses as a result.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stockholder activism, the current political environment and the current high level of U.S. government intervention and regulatory reform may also lead to substantial new regulations and disclosure obligations, which may in turn lead to additional compliance costs and impact the manner in which we operate our business in ways we do not currently anticipate. Our management and other personnel will need to devote a substantial amount of time to comply with these requirements. Moreover, these requirements will increase our legal and financial compliance costs and will make some activities more time-consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a public company, we may also be subject to more stringent state law requirements, such as California Senator Bill 826, which generally requires public companies with principal executive offices in California to have a minimum number of females on the company&#x2019;s board of directors, and California Assembly Bill 979, which generally requires public companies with principal executive offices in California to include specified numbers of directors from &#x201c;underrepresented communities.&#x201d; We are currently compliant with the requirements, but there are no assurances that we will be compliant in the future. which generally requires public companies with principal executive offices in California to include specified numbers of directors from &#x201c;underrepresented communities.&#x201d; If we fail to comply with either Senator Bill 826 or Assembly Bill 979, we could be fined by the California Secretary of State, with a $100,000 fine for the first violation and a $300,000 for each subsequent violation, and our reputation may be adversely affected.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, we are required to furnish a report by our management on our internal control over financial reporting, including an attestation report on internal control over financial reporting issued by our independent registered public accounting firm. We were previously not required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting while we were an emerging growth company. However, we are no longer an emerging growth company as of December 31, 2020. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the Sarbanes-Oxley Act, the requirements of being a reporting company under the Exchange Act and any complex accounting rules in the future, we may need to upgrade our information technology systems; implement additional financial and management controls, reporting systems and procedures; and hire additional accounting and finance staff. We are currently in the process of hiring additional accounting and finance staff as we grow our business. If we are unable to hire the additional accounting and finance staff necessary to comply with these requirements, we may need to retain additional outside consultants. If we or, if required, our auditors, are unable to conclude that our internal control over financial reporting is effective, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot assure you that there will not be material weaknesses in our internal control over financial reporting in the future. Our previous acquisitions and strategic transactions and resulting international operations have increased the complexity of our accounting, and additional acquisitions and transactions and further geographic expansion will likely increase this complexity and the related accounting challenges. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines that we have a material weakness in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our reported financial results may be adversely affected by changes in accounting principles generally accepted in the United States.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Generally accepted accounting principles in the United States are subject to interpretation by the Financial Accounting Standards Board, or FASB, or the SEC, and various bodies formed to promulgate and interpret appropriate accounting principles. A change in these principles or interpretations could have a significant effect on our reported financial results, may retroactively affect previously reported results, could cause unexpected financial reporting fluctuations and may require us to make costly changes to our operational processes and accounting systems.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. These provisions also could limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. For a summary of these provisions, see the section titled &#x201c;Anti-Takeover Provisions of Delaware Law and Our Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws&#x2014;Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws&#x201d; in Exhibit 4.3 Description of Capital Stock filed as part of our 2020 Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware (or, if and only if the Court of Chancery of the State of Delaware lacks subject matter jurisdiction, any state court located within the State of</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Delaware or, if and only if all such state courts lack subject matter jurisdiction, the federal district court for the District of Delaware) will be the exclusive forum for the following types of actions or proceedings under Delaware statutory or common law:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any derivative action or proceeding brought on our behalf; </span></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any action or proceeding asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers or other employees to us or our stockholders; </span></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any action or proceeding asserting a claim against us or any of our current or former directors, officers or other employees, arising out of or pursuant to any provision of the DGCL, our certificate of incorporation or our bylaws; </span></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any action or proceeding to interpret, apply, enforce or determine the validity of our certificate of incorporation or our bylaws; and </span></div></div>
  <div style="margin-left:9.067%;display:flex;margin-top:6.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.3402777777777778in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Symbol;justify-content:flex-start;min-width:0.3402777777777778in;">&#xf0b7;</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any action asserting a claim against us or any of our directors, officers or other employees governed by the internal affairs doctrine. </span></div></div>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This provision would not apply to suits brought to enforce a duty or liability created by the Exchange Act or any other claim for which the U.S. federal courts have exclusive jurisdiction. Furthermore, Section 22 of the Securities Act of 1933, as amended, or the Securities Act, creates concurrent jurisdiction for federal and state courts over all such Securities Act actions. Accordingly, both state and federal courts have jurisdiction to entertain such claims. To prevent having to litigate claims in multiple jurisdictions and the threat of inconsistent or contrary rulings by different courts, among other considerations, our amended and restated certificate of incorporation further provides that the federal district courts of the United States will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act of 1933, unless we consent in writing to the selection of an alternative forum. While the Delaware courts have determined that such choice of forum provisions are facially valid, a stockholder may nevertheless seek to bring a claim in a venue other than those designated in the exclusive forum provisions. In such instance, we would expect to vigorously assert the validity and enforceability of the exclusive forum provisions of our amended and restated certificate of incorporation. This may require significant additional costs associated with resolving such action in other jurisdictions and there can be no assurance that the provisions will be enforced by a court in those other jurisdictions.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These exclusive-forum provisions may limit a stockholder&#x2019;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage these types of lawsuits. Furthermore, the enforceability of similar choice of forum provisions in other companies&#x2019; certificates of incorporation has been challenged in legal proceedings, and it is possible that a court could find these types of provisions to be inapplicable or unenforceable. If a court were to find the exclusive-forum provision contained in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur further significant additional costs associated with resolving such action in other jurisdictions, all of which could harm our business.&#160;</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_unregistered_sales_equity_securit"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 2. Unregistered Sales of Equi</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ty Securities and Use of Proceeds.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_defaults_upon_senior_securities"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 3. Defaults Upo</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">n Senior Securities.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 4. Mine Saf</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ety Disclosures.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_5_or_information"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 5. Other </span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Information.</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_6_exhibits"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 6. Exhibits</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(a) Exhibits.</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.17%;"></td>
    <td style="width:2.019%;"></td>
    <td style="width:85.81%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519268465/d820601dex31.htm"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Certificate of Incorporation of the Company (incorporated herein by reference to Exhibit 3.1 to the Company&#x2019;s Current Report on Form 8-K (File No. 001-39083), filed with the SEC on October 16, 2019).</span><span style="color:rgba(5,99,193,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001706431/000119312519268465/d820601dex32.htm"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Bylaws of the Company (incorporated herein by reference to Exhibit 3.2 to the Company&#x2019;s Current Report on Form 8-K (File No. 001-39083), filed with the SEC on October 16, 2019).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1706431/000156459021024948/vir-ex106_307.htm"><span style="color:rgba(0,0,255,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Employment Letter Agreement between the Company and Ann M. Hanly, dated May 4, 2021 (incorporated herein by reference to Exhibit 10.6 to the Company&#x2019;s Quarterly Report on Form 10-Q (File No. 001-39083), filed with the SEC on May 6, 2021).</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.2</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="vir-20210630ex10_2.htm"><span style="color:rgba(0,0,255,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Definitive Collaboration Agreement between the Company, GlaxoSmithKline Intellectual Property Development Limited and GlaxoSmithKline Biologicals SA, dated May 18, 2021</span></a><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.3</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="vir-20210630ex10_3.htm"><span style="color:rgba(0,0,255,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No. 5 to the Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated June 2, 2021.</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.4</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#134;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="vir-20210630ex10_4.htm"><span style="color:rgba(0,0,255,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No. 4 to the Grant Agreement between the Company and the Bill &amp; Melinda Gates Foundation, dated June 16, 2021.</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="vir-20210630ex31_1.htm"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Executive Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="vir-20210630ex31_2.htm"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Financial Officer pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="vir-20210630ex32_1.htm"><span style="color:rgba(5,99,193,1);font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.INS</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Instance Document the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.SCH</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Schema Document.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.CAL</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Calculation Linkbase Document.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.DEF</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Definition Linkbase Document.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.LAB</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Label Linkbase Document.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.PRE</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline XBRL Taxonomy Extension Presentation Linkbase Document.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101).</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:73.333%;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:-2.599%;padding-left:2.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">+	Indicates a management contract or compensatory plan.</span></p>
  <p style="text-indent:-2.557%;padding-left:2.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#134;	</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain portions of this exhibit (indicated by &#x201c;[***]&#x201d;) have been omitted pursuant to confidential treatment.</span></p>
  <p style="text-indent:-2.557%;padding-left:2.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*	The certification attached as Exhibit 32.1 accompanies this Quarterly Report on Form 10-Q pursuant to 18 U.S.C. Section 1350, as  adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#x201c;filed&#x201d; by the Registrant for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SIGNA</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">TURES</span></p>
  <p style="text-indent:4.533%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:54.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:3.0%;"></td>
    <td style="width:42.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">VIR BIOTECHNOLOGY, INC</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: August 5, 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/&#160;</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#160;George Scangos</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">George Scangos, Ph.D.</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">President, Chief Executive Officer and Director</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Executive Officer)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: August 5, 2021</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/&#160;</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Howard Horn</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Howard Horn</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer and Secretary</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Financial and Accounting Officer)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>vir-20210630ex10_2.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html>
 <head>
  <title>EX-10.2</title>
 </head>
 <body>
  <p style="margin-left:86.133%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Exhibit </font><font style="font-variant:small-caps;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">10.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-variant:small-caps;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY [***], HAS BEEN OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:24.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Definitive</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> COLLABORATION AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:24.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">By and Between</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:24.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Glaxo Wellcome UK Limited;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:24.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">And</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:24.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:24.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir Biotechnology, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:1.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.067%;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Table of Contents</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:1.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:1.067%;text-align:center;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:1.067%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:10.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">       Page</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:16.561%;"></td>
    <td style="width:78.945%;"></td>
    <td style="width:4.493%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="text-indent:-81.35pt;padding-left:81.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 1</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">DEFINITIONS</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="text-indent:-81.35pt;padding-left:81.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 2</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">EFFECTIVENESS; OVERVIEW; EXCLUSIVITY</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">26</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2.1</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Effectiveness of the Agreement</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">26</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2.2</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Overview</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">26</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2.3</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Collaboration Program Leads</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">27</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2.4</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exclusivity Obligations</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">27</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2.5</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Compassionate Use Programs.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">30</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2.6</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Parties&#x2019; Assets</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">30</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2.7</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Compliance with Applicable Law</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">31</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="text-indent:-81.35pt;padding-left:81.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 3</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">MANAGEMENT OF THE COLLABORATION</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">31</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3.1</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Joint Steering Committee</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">31</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3.2</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Joint Research and Development Committee</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">32</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3.3</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Joint Commercialization Committee</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">34</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3.4</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Joint Patent Committee</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">35</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3.5</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Joint Manufacturing Committee</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">35</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3.6</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Financial Working Group</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">36</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3.7</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Other Subcommittees</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">37</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3.8</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Membership, Meetings and Meeting Minutes</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">37</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3.9</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Decision-Making</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">38</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3.10</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Alliance Managers</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">40</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3.11</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Most Conservative Approach and Internal Policies</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">41</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="text-indent:-81.35pt;padding-left:81.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 4</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">INFLUENZA PROGRAM</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">41</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4.1</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">General</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">41</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:16.561%;"></td>
    <td style="width:78.945%;"></td>
    <td style="width:4.493%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4.2</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">GSK&#x2019;s Option to VIR-2482</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">41</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4.3</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">VIR-2482XX2 and Other VIR Influenza mAbs</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">42</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="text-indent:-81.35pt;padding-left:81.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 5</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">EXPANDED FUNCTIONAL GENOMICS PROGRAM</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">43</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">5.1</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">General</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">43</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">5.2</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Pre-Expanded Functional Genomics Target Selection</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">43</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">5.3</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Screening Data</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">43</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">5.4</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Selection of Expanded Functional Genomics Targets</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">44</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">5.5</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Independent Programs</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">44</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">5.6</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Rejected Targets</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">44</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">5.7</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Database Technology</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">45</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="text-indent:-81.35pt;padding-left:81.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 6</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ADDITIONAL PATHOGEN PROGRAMS</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">45</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">6.1</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">General</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">45</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">6.2</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Selection of Additional Pathogen</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">45</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">6.3</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Selection of Program mAbs</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">46</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="text-indent:-81.35pt;padding-left:81.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 7</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">DEVELOPMENT ACTIVITIES; OPT-OUT OPTIONS</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">46</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.1</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Development Plans</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">46</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.2</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Development Efforts</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">48</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.3</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Development Records; Exchange of Information</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">48</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.4</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Performance by Affiliates; Subcontracting</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">48</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.5</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Clinical Studies</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">49</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.6</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Rights to Opt-Out</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">50</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="text-indent:-81.35pt;padding-left:81.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 8</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">REGULATORY ACTIVITIES</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">54</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">8.1</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Generally</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">54</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">8.2</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Meetings and Communications</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">54</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">8.3</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Regulatory Submissions</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">54</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:16.561%;"></td>
    <td style="width:78.945%;"></td>
    <td style="width:4.493%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">8.4</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Exchange of Development Data</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">55</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">8.5</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Lead Party Opt-Out</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">55</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="text-indent:-81.35pt;padding-left:81.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 9</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">COMMERCIALIZATION</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">56</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9.1</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">General</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">56</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9.2</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Calibri;">[</font><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">***]</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">56</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9.3</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Commercialization Plan</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">56</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9.4</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Commercialization Efforts</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">57</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9.5</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Right to Subcontract Commercialization Activities; Distribution</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">57</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9.6</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Commercialization Reports</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">57</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9.7</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">GSK Opt-Out</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">57</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="text-indent:-81.35pt;padding-left:81.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 10</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">PHARMACOVIGILANCE AND MEDICAL AFFAIRS</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">57</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">10.1</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Pharmacovigilance Technical Agreement</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">57</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">10.2</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Costs</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">57</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">10.3</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Medical Inquiries</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">58</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="text-indent:-81.35pt;padding-left:81.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 11</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">FINANCIAL PROVISIONS</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">58</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.1</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Upfront Payment</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">58</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.2</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Option Exercise Fee</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">58</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.3</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Milestone Payments</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">58</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.4</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Development Costs</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">59</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.5</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Profit/Loss Sharing</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">59</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.6</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Calibri;">[</font><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">***]</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">59</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.7</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Reconciliation Procedures</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">59</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.8</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Opt-Out Royalties and Payments</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">62</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.9</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Third Party Technologies and [***]</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">62</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.10</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Audits</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">64</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:16.561%;"></td>
    <td style="width:78.945%;"></td>
    <td style="width:4.493%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.11</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Tax Matters</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">64</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.12</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">General Payment Terms</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">66</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.13</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Blocked Payments</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">66</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.14</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Reporting; Financial Records</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">66</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.15</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Calibri;">[</font><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">***]</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">67</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.16</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Resolution of Financial Disputes</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">67</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11.17</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Specific Finance Disputes</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">67</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="text-indent:-81.35pt;padding-left:81.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 12</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">LICENSES</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">67</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12.1</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Collaboration Programs</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">67</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12.2</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Following Opt-Out Option</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">68</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12.3</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Rejected Collaboration Product License</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">69</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12.4</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Sublicenses</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">70</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12.5</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Licensing Program Technology</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">70</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12.6</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">No Implied Licenses</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">70</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12.7</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Retained Rights</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">70</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12.8</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Rights in Bankruptcy</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">70</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12.9</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Existing Third Party Agreements</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">71</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="text-indent:-81.35pt;padding-left:81.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 13</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">MANUFACTURING AND SUPPLY</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">71</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13.1</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">General</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">71</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13.2</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Manufacturing Party</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">71</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13.3</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Collaboration Programs</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">71</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13.4</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Transition of Manufacturing and Supply</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">73</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="text-indent:-81.35pt;padding-left:81.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 14</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">SCIENTIFIC PUBLICATIONS AND PRESENTATIONS</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">73</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14.1</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Research and Pre-Clinical Publications</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">73</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14.2</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Clinical Development Publications</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">73</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:16.561%;"></td>
    <td style="width:78.945%;"></td>
    <td style="width:4.493%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14.3</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Review by the Parties</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">74</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14.4</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Third Parties</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">74</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14.5</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Lead Party Publication</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">74</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14.6</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Publication after Opt-Out</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">75</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="text-indent:-81.35pt;padding-left:81.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 15</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">MATERIALS TRANSFER; INTELLECTUAL PROPERTY; INFORMATION TECHNOLOGY</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">75</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15.1</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Materials Transfer</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">75</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15.2</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Ownership of Intellectual Property</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">77</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15.3</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Prosecution, Maintenance and Defense</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">78</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15.4</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Enforcement Rights</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">80</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15.5</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Joint Patent Committee</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">82</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15.6</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Third Party Technologies</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">82</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15.7</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Infringement Claims by Third Parties</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">82</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15.8</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Product Marks</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">83</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15.9</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Information Technology Requirements</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">84</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="text-indent:-81.35pt;padding-left:81.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 16</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">TERM AND TERMINATION</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">84</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.1</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Term</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">84</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.2</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Mutual Termination</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">85</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.3</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Termination for Cause</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">85</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16.4</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Termination for Insolvency</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">86</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="text-indent:-81.35pt;padding-left:81.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 17</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">EFFECTS OF EXPIRATION OR TERMINATION</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">86</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">17.1</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Accrued Obligations</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">86</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">17.2</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Effects of Termination by Mutual Agreement</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">86</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">17.3</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Effects of Termination for Material Breach or Insolvency</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">86</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">17.4</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Other Termination Consequences</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">87</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">6</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:16.561%;"></td>
    <td style="width:78.945%;"></td>
    <td style="width:4.493%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">17.5</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Survival</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">88</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">17.6</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Termination Not Sole Remedy</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">88</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="text-indent:-81.35pt;padding-left:81.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 18</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">CONFIDENTIALITY</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">88</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">18.1</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Confidentiality</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">88</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">18.2</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Authorized Disclosure</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">89</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">18.3</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Injunctive Relief</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">90</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">18.4</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Return of Confidential Information</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">90</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">18.5</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Press Releases and Other Public Statements</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">90</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="text-indent:-81.35pt;padding-left:81.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 19</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">REPRESENTATIONS AND WARRANTIES AND COVENANTS</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">91</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">19.1</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Mutual Representations and Warranties</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">91</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">19.2</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Representations and Warranties of Vir (Existing Influenza Program mAbs)</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">93</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">19.3</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Calibri;">[</font><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">***] Representations, Warranties and Covenants</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">95</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">19.4</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Post-Closing Covenants</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">95</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">19.5</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Calibri;">[</font><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">***]</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">96</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">19.6</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Disclaimer of Warranty</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">96</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="text-indent:-81.35pt;padding-left:81.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 20</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">INDEMNIFICATION</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">96</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">20.1</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Indemnification</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">96</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">20.2</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Insurance</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">97</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">20.3</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">LIMITATION OF CONSEQUENTIAL DAMAGES</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">98</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="text-indent:-81.35pt;padding-left:81.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 21</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ANTI-BRIBERY AND ANTI-CORRUPTION</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">98</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="text-indent:-81.35pt;padding-left:81.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 22</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="text-transform:uppercase;color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">MISCELLANEOUS</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">98</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22.1</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Dispute Resolution</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">98</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22.2</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Equitable Relief</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">99</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22.3</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Governing Law</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">99</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22.4</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Assignment</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">99</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:16.561%;"></td>
    <td style="width:78.945%;"></td>
    <td style="width:4.493%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22.5</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Change of Control of Vir</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">99</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22.6</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Force Majeure</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">100</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22.7</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Notices</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">100</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22.8</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Export Clause</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">101</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22.9</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Waiver</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">101</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22.10</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Severability.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">101</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22.11</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Entire Agreement; Amendments</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">101</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22.12</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Independent Contractors</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">102</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22.13</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Headings</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">102</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22.14</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Further Actions</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">102</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22.15</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Books and Records</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">102</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22.16</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Construction of Agreement</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">102</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22.17</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Supremacy</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">102</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22.18</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Counterparts</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">103</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(255,255,255,1);text-indent:81.35pt;word-break:break-word;vertical-align:top;"><p style="margin-left:36.0pt;text-indent:-45.35pt;padding-left:45.35pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22.19</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,255,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">No Third Party Beneficiaries</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">103</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:21.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">8</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">SCHEDULES</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Schedule 1.88	Existing Third Party Agreements</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Schedule 1.99	Financial Schedule</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Schedule 1.125	GSK Specified Internal Policies</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Schedule 1.135	Influenza Product Criteria</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Schedule 1.274	Sequences of Vir-2482 and Vir-2482XX2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Schedule 4.1	Vir-2482 &amp; Vir-2482XX2 Clinical Development Plans</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Schedule 4.2.1	Vir-2482 Option Data Package</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Schedule 5.1	Expanded Functional Genomics Program Flow Chart</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Schedule 6.1	[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Schedule 6.2.1	Listed Target Pathogens</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Schedule 7.6.5	Animal Welfare</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Schedule 10.1	Key Terms for Pharmacovigilance Technical Agreement</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Schedule 11.3.2	[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Schedule 11.8.2	Royalties Following Opt-Out</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Schedule 11.8.3	[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Schedule 11.9.1	Existing Third Party Payment Obligations</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Schedule 13.3.2	[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Schedule 15.1.1	Form of Material Transfer Record</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Schedule 22.1	Arbitration</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Definitive</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> COLLABORATION AGREEMENT</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This Definitive Collaboration Agreement (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Agreement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) is made and entered into as of May 18, 2021 (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Execution</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Date</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), by and between Glaxo Wellcome UK Limited, a private company limited by shares organized under the laws of England having an office at 980 Great West Road, Brentford, Middlesex TW8 9GS, England, registered under company number 00480080 (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">GSK</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), and Vir Biotechnology, Inc., a Delaware corporation having an office at 499 Illinois Street, Suite 500, San Francisco, CA 94158 (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  GSK and Vir are sometimes referred to herein, individually, as a &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; and, collectively, as the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Parties</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">BACKGROUND</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">WHEREAS</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, GSK, among other things, conducts programs to discover, develop, manufacture and commercialize innovative pharmaceutical medicines, vaccines and consumer healthcare products;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">WHEREAS</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, Vir, among other things, conducts programs to develop and commercialize therapeutic products for the treatment and prevention of serious infectious diseases;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">WHEREAS</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, GSK, together with an Affiliate, entered into a Definitive Collaboration Agreement with Vir on June 9, 2020, for the development and commercialization of certain products for diseases caused by SARS-COV-2 and other Coronaviruses (as defined below) (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Existing Collaboration Agreement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;);</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">WHEREAS,</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> an Affiliate (as defined below) of GSK and Vir have entered into a new Stock Purchase Agreement, dated February 14, 2021 (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">SPA</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), pursuant to which it has purchased certain additional voting shares of Vir;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">WHEREAS</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, concurrent with the SPA, GSK and Vir entered into a binding Preliminary Collaboration Agreement, dated February 14, 2021 (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">PCA Execution Date</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">,&#x201d;, as amended by the waiver and extension agreement dated as of May 16, 2021, and such agreement, the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Preliminary Collaboration Agreement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), outlining the transactions contemplated therein, which include (a) an antibody program directed towards Influenza Viruses (as defined below), (b) functional genomics approaches to Respiratory Viral Diseases (as defined below), and (c) antibody programs directed towards additional pathogens, each, as further described below;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">WHEREAS</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, as contemplated under the Preliminary Collaboration Agreement, GSK and Vir desire to enter into this Agreement containing a more detailed set of terms governing the collaboration established under the Preliminary Collaboration Agreement, consistent with the terms and conditions set forth therein.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">NOW, THEREFORE</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties agree as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 1<br>Definitionstc &#34;ARTICLE 1	DEFINITIONS&#34;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Capitalized terms used in this Agreement, whether used in the singular or plural, shall have the meanings set forth below, unless otherwise specifically indicated herein.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Accounting Standards</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">means, with respect to GSK, IFRS, and with respect to Vir, GAAP, in each case as consistently applied by the applicable Party and its Affiliates, as the same may be changed from time to time by the Parties; provided that each Party shall promptly notify the other Party in the event that such Party changes its Accounting Standards pursuant to which such Party&#x2019;s records are maintained, and it being understood that each Party may only use internationally recognized accounting principles (e.g., IFRS, GAAP).</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.3	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; means, with respect to [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.4	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Additional Pathogen Product</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.5	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Additional Pathogen Program</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.6	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Additional Products</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.1.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.7	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.8	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Adverse Event</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any untoward medical occurrence in a patient or subject who is administered a product, whether or not considered related to such product, including any undesirable sign (including abnormal laboratory findings of clinical concern), symptom or disease temporally associated with the use of such product.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.9	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Affiliate</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a given Party or Third Party, any corporation, firm, limited liability company, partnership or other entity which directly or indirectly controls, or is controlled by, or is under common control with such Party or such Third Party, respectively.  For the purposes of this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 1.9</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, &#x201c;control&#x201d; means ownership, directly or indirectly through one or more Affiliates, of fifty percent (50%) or more of the shares of stock entitled to vote for the election of directors, in the case of a corporation, or fifty percent (50%) or more of the equity interests in the case of any other type of legal entity, or status as a general partner in the case of any partnership, or any other arrangement whereby a corporation or other entity controls or has the right to control the Board of Directors or equivalent governing body or management of another corporation or other entity.  [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.10	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Agreement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the preamble.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.11	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Alliance Manager</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.12	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Allowable Expenses</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the Financial Schedule.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.13	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.14	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Applicable Internal Policies</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means those Internal Policies of either Party applicable to a Party by virtue of application of </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.11</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.15	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; means [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.16	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Balancing Payment</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;11.7.3(b)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.17	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Biologic</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any composition of matter comprising proteins, nucleic acids, carbohydrates, or any combination of these substances, including antibodies (derivatives or fragments thereof), other binding proteins, peptide molecules, RNA molecules, DNA molecules, viruses, gene therapy vectors, genetically engineered cells, and chemically modified cells.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.18	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Biosimilar</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a Collaboration Product or a Sole Development Product, any product containing a Biologic sold in a country by a Third Party that receives Regulatory Approval (including via Emergency Use Authorization) and is claimed to be biosimilar to, or interchangeable with, such Collaboration Product or Sole Development Product (including a product that is the subject of an application submitted under Section 351(k) of the Public Health Service Act in the United States or under Article 10(4) of Directive 2001/83/EC in the European Union or any member state thereof, in each case citing such Collaboration Product or Sole Development Product as the reference product) or for which the BLA otherwise references or relies on such Collaboration Product or Sole Development Product, including any product containing an active substance with the same core nonproprietary name as the active substance in the Collaboration Product or Sole Development Product.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.19	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">BLA</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a Biologics License Application (as defined in 21 C.F.R. 600 et seq.) or an equivalent application for marketing authorization with respect to a Collaboration Product or Sole Development Product in any jurisdiction in the world.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.20	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Blocking Third Party IP Agreement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.9.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.21	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Blocking Third Party IP Costs</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the Financial Schedule.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.22	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">BPCIA</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.4.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.23	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Business Day</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a day, other than (a) Saturday or Sunday, or any other day on which banking institutions in New York, New York, London, England and Brussels, Belgium are not open for business, (b) [***], or (c) [***], provided that in the case of (b)&#160;and (c), [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.24	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***]</font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.25	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Calendar Quarter</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the respective periods of three (3) consecutive calendar months ending on March 31, June 30, September 30 and December 31.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.26	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Calendar Year</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means each successive period of twelve (12) months commencing on January 1 and ending on December 31.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.27	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Change of Control</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to either Party, an event or transaction or series of events or transactions by which: (a) any Third Party (or group of Third Parties acting in concert) becomes the beneficial owner, directly or indirectly, of more than fifty percent (50%) of the outstanding securities of such Party or the total voting power of such securities normally entitled to vote in elections of directors; (b) (i) such Party reorganizes, consolidates or comes under common control with, or merges into another entity, or (ii) any entity reorganizes, consolidates or comes under common control with, or merges into such Party, in either event of the foregoing ((i) or (ii)) where more than fifty percent (50%) of the total voting power of the securities outstanding of the surviving entity normally entitled to vote in elections of directors is not held by the parties holding at least fifty percent (50%) of the outstanding shares of such Party immediately preceding such consolidation or merger; (c)&#160;such Party conveys, transfers or leases to a Third Party (i) all or substantially all of its assets or the control thereof, or (ii) all or substantially all of its assets or business relating to this Agreement or the control thereof; or (d)&#160;any other arrangement whereby a Third Party (or group of Third Parties acting in concert) obtains control or the right to control the board of directors or equivalent governing body that has the ability to cause the direction of the management, policies or affairs of such Party.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.28	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Change of Control Group</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a Party, the Person, or group of Persons, that is the acquirer of, or successor to, such Party in connection with a Change of Control of such Party, together with all of the Affiliates of such Persons, in each case that are not Affiliates of such Party immediately prior to the closing of such Change of Control of such Party.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.29	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.30	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">China Territory</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means mainland China, Hong Kong, Macau and Taiwan.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.31	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Clinical Development Publication Strategy</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in</font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;"> Section&#160;14.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.32	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Clinical Facility</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a facility for Clinical Manufacture of any Collaboration Product.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.33	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Clinical Manufacture</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means Manufacture for clinical use in Clinical Studies, including (a) reservation of Manufacturing capacity for use in Manufacture for clinical use; (b) selection and use of contract manufacturers; (c) selection of the Clinical Facilities; and (d) subject to the terms of any existing Third Party agreements and as applicable, technology transfer of the then-current Manufacturing process for Collaboration Product to Clinical Facilities.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.34	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Clinical Study</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any human clinical study, including any Phase I Clinical Study, Phase I/IIa Clinical Study, Phase II Clinical Study, Phase II/III Clinical Study, Phase III Clinical Study, Pivotal Clinical Study, or Phase IV Clinical Study.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.35	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">CMO</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 13.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.36	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Co-Chair</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.8.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.37	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Collaboration</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, for each Collaboration Program, (a) any Research activities conducted under the Development Plans, and (b) the Development, Manufacture and Commercialization activities with respect to the Collaboration Products during the Term pursuant to and in accordance with the terms of this Agreement and the Development Plans and Commercialization Plans.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.38	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Collaboration Product</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means (a) an Influenza Product, (b)&#160;an Expanded Functional Genomics Product, or (c) an Additional Pathogen Product, in each case ((a) - (c)), for which a Party has not exercised its Opt-Out Option.  For clarity, (i) [***]; and (ii) a Sole Development Product shall not be a Collaboration Product for purposes of this Agreement.</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.39	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Collaboration Program</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means each of the following programs: (a) the Influenza Program; (b) the Expanded Functional Genomics Program; and (c) the Additional Pathogen Programs.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.40	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Collaboration Screening Data</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 5.3.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.41	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Commercialization</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any and all activities directed to the preparation for sale of (but excluding Development and, other than for purposes of the Manufacturing Plan to be included in the Commercialization Plan and accounted for in the Commercialization Budget, excluding Commercial Manufacture or other Manufacture), offering for sale of, or sale of a Collaboration Product, including activities related to obtaining pricing and reimbursement approvals, as applicable, marketing, promoting, selling, distributing, importing and exporting such Collaboration Product, and interacting with Regulatory Authorities regarding any of the foregoing.  &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Commercialize</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; and &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Commercializing</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall have their correlative meanings.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.42	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Commercialization Budget&#x201d;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> means the annual budget for conducting Commercialization (including the budget for Commercial Manufacture) pursuant to a Collaboration Program for a given Collaboration Product as prepared by GSK as the LCP and reviewed and approved by the JSC, the JCC and the JMC, as applicable, in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and as updated on a Calendar Year basis by the LCP concurrently with the Commercialization Plan in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Sections&#160;3.3.2(a)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">3.1.2(n)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">3.5.2(c)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">9.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Each annual Commercialization Budget shall include (a) a budget, [***], for the estimated FTE Costs and out-of-pocket external costs and expenses expected to be incurred by each Party in the given Calendar Year with respect to such Commercialization Plan, including [***], and (b) a good faith non-binding forecasted budget, [***], for the [***] period following the Calendar Year covered by the budget in (a), of the estimated FTE Costs and out-of-pocket external costs and expenses expected to be incurred by each Party in connection with activities under the applicable Commercialization Plan during such [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.43	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Commercialization Plan</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 9.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.44	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Commercially Reasonable Efforts</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, such efforts that are consistent with the efforts and resources normally used by GSK (in the case of GSK) or a biopharmaceutical company (in the case of Vir) in the exercise of its reasonable business discretion relating to a research program, pharmaceutical product or target owned by it or to which it has exclusive rights, with similar product characteristics, which is of similar market potential at a similar stage in its</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">development or product life as the Collaboration Program, Collaboration Product, Target, or, where applicable, Sole Development Product, taking into account issues of [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.45	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Commercial Facility</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a facility for Commercial Manufacture of any Collaboration Product.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.46	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Commercial Manufacture</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means Manufacture for commercial sale, including (a) reservation of Manufacturing capacity for use in Manufacture for commercial sale; (b) selection and use of contract manufacturers; (c) selection of the Commercial Facilities; (d) subject to the terms of any existing Third Party agreements, technology transfer of the Manufacturing process for Collaboration Product to Commercial Facilities; (e) conduct of process performance qualification batches and other process qualification and validation activities required for Regulatory Approval for Commercial Manufacture of Collaboration Product at the Commercial Facility(ies); and (f) obtaining pre-approval inspection and required licenses and permits for Commercial Facilities.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.47	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.48	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Committee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, individually, the JSC, JRDC, JMC, JCC, JPC, the Financial Working Group and the Program Team or any other Subcommittee established as set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.7</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.49	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Committee Deadlock</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.50	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Companion Diagnostic</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a product designed for use in a diagnostic biomarker assay tailored or optimized for use with a Collaboration Product or a Sole Development Product, for predicting or monitoring the suitability of such Collaboration Product for prophylactic or therapeutic use in human patients or defined subpopulations thereof. A Companion Diagnostic shall be intended for use (a) as a means to select or monitor the patient population for the conduct of Clinical Studies of such Collaboration Product or Sole Development Product, (b) to predict predisposition to treatment in clinical use with such Collaboration Product or Sole Development Product, or (c) to predict or monitor potential safety considerations in clinical use with such Collaboration Product or Sole Development Product.  Use of a Companion Diagnostic to guide use of the Collaboration Product will be contingent on appropriate Regulatory Approvals for such uses as deemed necessary by the FDA or other similar Regulatory Authority with appropriate jurisdiction.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.51	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.52	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; means, [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.53	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Confidential Information</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any technical, business, or other information provided by or on behalf of one Party of any of its Affiliates (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Disclosing Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to the other Party or any of its Affiliates (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Receiving Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) in connection with this Agreement or the Collaboration (including, with respect to the Expanded Functional Genomics Program, information relating to Screening Data and Targets screened under the Existing Collaboration Agreement), whether prior to, on, or after the Effective Date of this Agreement, including information relating to the GSK Licensed Technology, where GSK is the Disclosing</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">15</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Party, and information relating to the Vir Licensed Technology, where Vir is the Disclosing Party, any inventions, Know-How or other information developed in connection with the Collaboration with respect thereto by or on behalf of the Disclosing Party (including GSK Program Technology, where GSK is the Disclosing Party, Vir Program Technology, where Vir is the Disclosing Party, and Joint Program Technology, where both Parties will be deemed to be both Disclosing Party and Receiving Party), or the scientific, regulatory or business affairs or other activities of the Disclosing Party.  For clarity, (i) [***], and (ii) except as otherwise pursuant to subclause (i), Confidential Information [***] related to any Collaboration Product or [***] shall be Confidential Information of both Parties.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.54	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Contribution</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; (including variations such as &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Contribute</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; and the like) has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.6.2.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.55	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Control</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; (including variations such as &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Controlled</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">,&#x201d; &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Controlling</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; and the like) means, with respect to any material, information, or intellectual property, the possession (whether by ownership or license, other than the licenses granted hereunder) of the ability to grant a license or sublicense or other right to exploit, as provided herein, without violating the terms of any agreement or other arrangement with any Third Party, or any applicable Law.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.56	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Controlling Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.4.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.57	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Coronavirus</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any spherical or pleomorphic enveloped virus of the family Coronaviridae containing single-stranded (positive-sense) RNA associated with a nucleoprotein within a capsid comprised of matrix protein, including SARS-COV-2.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.58	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">CRISPR</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the gene editing and engineering technology known as &#x201c;clustered regularly interspaced short palindromic repeats&#x201d;.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.59	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">CRO</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.4.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.60	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Currency Gains and Losses</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the gain or loss resulting from changes in exchange rates between the functional currency and the foreign currency in which the transaction is denominated, to the extent specifically identifiable to a Collaboration Product and shall only include the currency gains and losses realized between the end of a Calendar Quarter and the date of invoice payment for that Calendar Quarter.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.61	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Data</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means preclinical data (including computational validation, genetic data (including genotype, phenotype and genetic sequencing data), in vitro and in vivo data), clinical data (including broad data sets, study and investigator reports, both preliminary and final, statistical analyses, expert opinions and reports, safety and other electronic databases), and regulatory, Manufacturing, marketing, pricing, biological, chemical, pharmacological, toxicological, pharmaceutical, physical, analytical, safety and quality control data, information and documentation, whether in written or electronic form.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.62	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Data Exclusivity</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, on a country-by-country basis, with respect to a product, any exclusive marketing rights or data exclusivity rights conferred by any Regulatory Authority with respect to such product other than a Patent right, including in the European Union, Regulation (EC) No 726/2004 and Directive 2001/83/EC (as amended).</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">16</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.63	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.64	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Defending Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any Party participating in the defense of a Third Party Infringement Claim.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.65	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; means, [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.66	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Development</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any and all Research and development activities conducted to develop or seek, obtain or maintain Regulatory Approvals for the Collaboration Products, which include Non-Clinical GLP Studies, Clinical Studies, quality of life assessments, pharmacoeconomics, Manufacturing process development, Manufacture of Research, non-clinical and clinical supplies, regulatory affairs, and such other activities related to the Collaboration Products as are set forth in the applicable Development Plan approved by the JSC. &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Develop</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; and &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Developing</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall have their correlative meanings. For clarity, Development does not include any of the foregoing activities with respect to Vir-2482 unless GSK exercises the Option, and then only after the Vir-2482 Program Effective Date.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.67	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Development Budget</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means on a Collaboration Program-by-Collaboration Program basis, the budget of Development Costs for conducting activities under such Collaboration Program pursuant to the applicable Development Plan during a given Calendar Year, as prepared by the applicable Lead Party, with input from the other Party with respect to Development Costs to be borne by the other Party, and reviewed by the JRDC in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;3.2.2(c)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and the JMC in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.5.2(c)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and approved by the JSC in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;3.1.2(m)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, which budget shall be updated and amended (if necessary) on a Calendar Year basis concurrently with the Development Plan in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Sections 3.2.2(c)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">3.5.2(c)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">3.1.2(m)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, and at any other time in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.1.3(a)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Each Development Budget shall include (a) a budget, [***] (with the assistance of the JMC with respect to Manufacturing activities), for the estimated Development FTE Costs and out-of-pocket external costs and expenses expected to be incurred by each Party in the given Calendar Year with respect to such Development Plan, and (b) a nonbinding good faith forecasted budget, [***], of the estimated Development Costs to be incurred in connection with activities under the applicable Development Plan, (i) with respect to any [***], for the [***], and (ii) with respect to any [***], for the time period [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.68	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Development Candidate</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to the Influenza Program, the Expanded Functional Genomics Program or the Additional Pathogen Programs, an Influenza Product, an Expanded Functional Genomics Product or an Additional Pathogen Product, respectively, that is selected by the JRDC pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.2.2(d)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> as suitable to progress into further Development, including in Non-Clinical GLP Studies.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.69	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Development Costs</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the Financial Schedule.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.70	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Development FTE Costs</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the Financial Schedule.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.71	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Development FTE Rate</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the Financial Schedule.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">17</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.72	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Development Plan</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a detailed plan and budget mutually agreed to govern the conduct of Development activities for the applicable Collaboration Program.  For clarity, the Parties intend that there will be one Development Plan for all Collaboration Products in a given Collaboration Program, for a total of three Development Plans, but there may be sub-plans for individual Collaboration Products. For clarity, Development Plan does not apply to or govern the conduct of development activities for Vir-2482 unless GSK exercises the Option, and then only after the Vir-2482 Program Effective Date.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.73	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Development Summary</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.74	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Disclosing Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the definition of &#x201c;Confidential Information.&#x201d;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.75	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Discontinued Vir Influenza mAb</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.4.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.76	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Drug Approval Application</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a BLA, NDA or any corresponding application in the applicable country or jurisdiction outside of the United States, including, with respect to the European Union, an application for marketing authorization approval filed with the EMA pursuant to the centralized approval procedure, or with the applicable national Regulatory Authority of a country in the European Union with respect to the mutual recognition procedure, decentralized procedure or any other national approval.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.77	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.78	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Effective Date</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall have the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.79	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">EMA</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the European Medicines Agency, or any successor entity thereto performing similar functions.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.80	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Emergency Use Authorization</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">EUA</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means an emergency use authorization issued by the FDA pursuant to Section 564 of the FDCA.&#160;&#160;The duration of an EUA depends in part on the duration of the declaration of the U.S. Department of Health and Human Services (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">HHS</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) that supports the EUA. The HHS declaration must be current for an EUA to remain in effect. The HHS declaration terminates upon the earlier of (a) HHS determining that the circumstances justifying the EUA&#x2019;s issuance no longer exist or (b) a change in the approval status of the product such that an EUA would no longer be needed. For the purposes of this definition, any references to the FDA, HHS, statutes, or declaration, duration and termination of an EUA, or approval status of a given product, shall, in each case, include any equivalent Regulatory Authority, agency, statute, or declaration, duration and termination of an EUA in any jurisdiction other than the United States.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.81	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Entity</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.11.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.82	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">European Union</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the economic, scientific and political organization of member states in Europe, as it may be constituted from time to time.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.83	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Excess Costs</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.7.2(c)(i)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">18</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.84	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Exclusivity Period</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.4.2(b)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.85	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Execution Date</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the preamble.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.86	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Existing Collaboration Agreement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the preamble.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.87	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Existing Influenza Program mAbs</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means Vir-2482, Vir-2482XX2, [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.88	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Existing Third Party Agreements</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means Vir&#x2019;s existing agreements with Third Parties relating to any Collaboration Program existing as of the PCA Execution Date, as set forth on </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 1.88</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.89	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Existing Third Party IP Agreement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the Financial Schedule.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.90	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Existing</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Third Party Payment Obligations</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.9.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.91	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Expanded Functional Genomics Development Plan</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 5.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.92	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Expanded Functional Genomics</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Independent Program</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a Party and [***] under the Expanded Functional Genomics Program, a program of such Party or its Affiliates outside the Collaboration that is [***], and under which program there are [***], in each case, at the time [***]. For avoidance of doubt, [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.93	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Expanded Functional Genomics Product</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">    </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.94	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Expanded Functional Genomics Program</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.95	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Expanded Functional Genomics Target</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any Target identified to be associated with Respiratory Viral Disease(s) and approved by the JSC for inclusion in the Collaboration for which Expanded Functional Genomics Products will be further Developed.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.96	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">FDA</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the U.S. Food and Drug Administration, or any successor entity thereto performing similar functions.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.97	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Field</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the prevention, treatment and prophylaxis of diseases in humans, including those caused by Influenza Virus, other Respiratory Viruses or Selected Pathogens, or associated with Expanded Functional Genomics Targets, but excluding [***], unless [***], in which case, [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;vertical-align:top;font-size:8.04pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.98	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Financial Report</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;11.7.1(a)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">19</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.99	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Financial Schedule</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the schedule set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 1.99 </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">attached hereto, as the same may be amended from time to time by the written agreement of the Parties.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.100	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Financial Working Group</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;3.6</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.101	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">First Commercial Sale</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a given product in a country, the first commercial sale for use or consumption by the general public in an arms-length transaction of such product by or on behalf of a Party, its Affiliate or its licensee or Sublicensee in such country following receipt of all applicable Regulatory Approvals of such product in such country or, if applicable, following receipt of Emergency Use Authorization for such product; provided that the following shall not constitute a First Commercial Sale: (a) any sale or inter-company transfers to an Affiliate or sublicensee unless the Affiliate or sublicensee is the last entity in the distribution chain of such product, (b) any use of such product in Clinical Studies, preclinical activities or other research or Development activities, or (c) disposal or transfer of such products for a bona fide charitable purpose, compassionate use, so called &#x201c;treatment IND sales&#x201d; and &#x201c;named patient sales&#x201d; or use under the Temporary Authorisation for Use system in France or other equivalent systems, other than under an EUA.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.102	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.103	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Force Majeure</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any event beyond the reasonable control of the affected Party including: embargoes; war or acts of war, including terrorism; insurrections, riots, or civil unrest; strikes, lockouts or other labor disturbances; epidemics (including pandemics), fire, floods, earthquakes or other acts of nature; unavailability of, or impossibility to obtain, materials, components, drug substance, drug product, utilities, equipment, supplies, fuel or other required materials, receipt of warning letters, or loss, infection or failure of cell banks (in each case due to reasons other than the affected Party&#x2019;s negligence or willful misconduct or any other cause within the reasonable control of the affected Party); or acts, omissions or delays in acting by any Governmental Authority (including the refusal of any Regulatory Authority to issue required Regulatory Approvals due to reasons other than the affected Party&#x2019;s negligence or willful misconduct or any other cause within the reasonable control of the affected Party), and failure of plant or machinery (provided that such failure could not have been prevented by the exercise of skill, diligence, and prudence that would be reasonably and ordinarily expected from a skilled and experienced person engaged in the same type of undertaking under the same or similar circumstances).</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.104	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">FTE</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a Person who is an employee or an individual who is an independent contractor of a Party or its Affiliates, the equivalent of the work of one&#160;(1) such Person directly engaged in performing Development, Commercialization or Manufacturing activities under this Agreement full time for one&#160;(1) year (consisting of a total of [***] hours per year, or such other number as may be agreed to by the Parties). [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.105	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">FTE Costs</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the Financial Schedule.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.106	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">GAAP</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means United States generally accepted accounting principles applied on a consistent basis.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">20</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.107	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">GCP</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means all applicable Good Clinical Practice standards for the design, conduct, performance, monitoring, auditing, recording, analyses and reporting of clinical trials, including, as applicable, (a) FDA regulations and guidelines for good clinical practice, as promulgated by the FDA under 21 CFR Parts 50, 54, 56, 312 and 812, (b) as set forth in European Commission Directive 2001/20/EC relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use, and brought into law by European Commission Directive 2005/28/EC laying down the principles and detailed guidelines for good clinical practice for investigational medicinal products, (c) the International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ICH</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) Harmonised Tripartite Guideline for Good Clinical Practice (CPMP/ICH/135/95) and any other guidelines for good clinical practice for trials on medicinal products in the EU, (d) the Declaration of Helsinki (2008), and (e) any further amendments or clarifications with respect to any of the foregoing and any equivalents thereto in the country in which pre-clinical or clinical studies of a product are conducted.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.108	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">General Principles</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the General Principles set forth in Section&#160;1 of the Financial Schedule.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.109	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Generic Entry</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a product in a country in the Territory, such time that, if there are one or more Biosimilars or Generic Products (as applicable) sold in such country, the market penetration of the Biosimilars or Generic Products (as applicable) in such country is equal to or greater than [***], as determined by dividing (a) the aggregate number of units of all Biosimilars or Generic Products (as applicable) sold in such country by (b) the sum of the aggregate number of units of such product and the aggregate number of units of all Biosimilars or Generic Products (as applicable) sold in such country, where unit volume sales will be identified and calculated based on relevant information published by [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.110	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Generic Product</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a Collaboration Product or Sole Development Product in a country in the Territory, any product sold by a Third Party (not licensed, supplied or otherwise authorized by a Party or its Affiliates or Sublicensees) that (a) contains the same active ingredient as such Collaboration Product or Sole Development Product, (b) is sold under a Regulatory Approval that (i) is based upon or relies upon the Regulatory Approval granted to a Party or any of its Affiliates or Sublicensees for such Collaboration Product or Sole Development Product or (ii) is otherwise granted by a Regulatory Authority pursuant to an expedited or abbreviated approval process, and (c) is categorized by the applicable Regulatory Authority in such country to be therapeutically equivalent to, or interchangeable with such Collaboration Product or Sole Development Product.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.111	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; means [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.112	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; means [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.113	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">GLP</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means all applicable Good Laboratory Practice standards, including, as applicable: (a) FDA regulations and guidelines for good laboratory practice, as promulgated by the FDA under 21 CFR Part 58; (b) European Commission Directive 2004/10/EC relating to the application of the principles of good laboratory practices, as may be amended from time to time as well as any Rules Governing Medicinal Products in the European Community Vol.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">21</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">III, ISBN 92.825 9619-2 (ex - OECD principles of GLP); and (c) any further amendments or clarifications with respect to any of the foregoing and any equivalents thereto in the country in which pre-clinical or clinical studies of a product are conducted.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.114	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">GMP</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means all applicable Good Manufacturing Practices, including: (a)&#160;the applicable part of quality assurance to ensure that products are consistently produced and controlled in accordance with the quality standards appropriate for their intended use, as defined in European Commission Directive 2003/94/EC laying down the principals and guidelines of good manufacturing practice; (b) the principles detailed in the U.S. Current Good Manufacturing Practices, 21 C.F.R. Sections 210, 211, 601, 610 and 820; (c) the Rules Governing Medicinal Products in the European Community, Volume IV Good Manufacturing Practice for Medicinal Products; (d) the principles detailed in the ICH Q7A guidelines; and (e) the equivalent Laws in any relevant country, each as may be amended and applicable from time to time.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.115	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Governmental Authority</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any federal, state, provincial, local, municipal, foreign or other governmental or quasi-governmental authority, including any arbitrator and applicable securities exchanges, or any department, minister, agency, commission, commissioner, board, subdivision, bureau, agency, instrumentality, court or other tribunal of any of the foregoing.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.116	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">GSK Asset</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.6.1(b)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.117	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; means any [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.118	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; means [***].</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.119	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.120	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">GSK Indemnitees</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 20.1.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.121	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; means [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.122	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">GSK Licensed Patent</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any Patent included in the GSK Licensed Technology.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.123	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">GSK Licensed Technology</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, (a) in the case of Expanded Functional Genomics Program, [***], and (b) on a Collaboration Program-by-Collaboration Program basis, all Patents and Know-How that are both (i) Controlled by GSK or its Affiliates as of the Effective Date or during the Term, and (ii) [***], provided that GSK Licensed Technology shall not include (A) any GSK Program Technology, or (B) [***].  For clarity, any technology that GSK includes within GSK Licensed Technology for a given Collaboration Program shall not be deemed included in GSK Licensed Technology for any other Collaboration Program, unless GSK expressly agrees to such inclusion in the applicable Development Plan for such other Collaboration Program.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.124	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">GSK Program Technology</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, on a Collaboration Program-by-Collaboration Program basis, GSK&#x2019;s right and interest in any Program Technology generated under such Collaboration Program.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">22</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.125	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">GSK Specified Internal Policies</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the Internal Policies set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 1.125</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> herein, and such other Relevant Internal Policies of GSK as are provided to Vir during the Term.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.126	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Hatch-Waxman Act</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.4.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.127	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">IFRS</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the International Financial Reporting Standards, the set of accounting standards and interpretations and the framework in force on the Effective Date and adopted by the European Union or the United Kingdom, as applicable, as issued by the International Accounting Standards Board (IASB) and the International Financial Reporting Interpretations Committee (IFRS&#160;IC), and as adopted by the European Union or the United Kingdom, as applicable, as such accounting standards may be amended from time to time.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.128	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.129	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Inclusion Notice</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.4.2(b).</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.130	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">IND</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means an Investigational New Drug Application (including any amendments thereto) filed with the FDA pursuant to 21 CFR Part 312 before the Initiation of Clinical Studies of a product, or any equivalent filing with any relevant Regulatory Authority in any jurisdiction.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.131	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Indemnifying Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 20.1.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.132	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Indemnitee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 20.1.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;vertical-align:top;font-size:8.04pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.133	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Influenza Development Plan</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.134	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Influenza Product</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  For clarity, Influenza Product shall not include Vir-2482 unless and until the Vir-2482 Program Effective Date if GSK exercises the Option in accordance with the terms of this Agreement.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.135	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Influenza Product Criteria</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the profile criteria for each Influenza Product, including (a) [***] and (b) [***], in each case, as further described on </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 1.135</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.136	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Influenza Program</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  For clarity, Influenza Program shall not include Vir&#x2019;s activities in connection with Vir-2482 unless and until the Vir-2482 Program Effective Date if GSK exercises the Option in accordance with the terms of this Agreement.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.137	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Influenza Virus</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any influenza virus that belongs to the family orthomyxoviridae, a family of negative strand RNA viruses, including subtypes A, B, C, and D.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.138	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Infringement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.4.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.139	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Infringement Notice</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.4.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">23</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.140	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.141	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Initial Development Term</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the period from the Effective Date through the third (3rd) anniversary thereof, unless otherwise extended by mutual agreement of the Parties.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.142	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Initiation</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a Clinical Study, the first dosing of the first human subject in such Clinical Study. &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Initiating</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the act of Initiating a Clinical Study.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.143	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Institutional Review Board</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means an institutional review board or independent ethics committee that reviews the methods proposed for research and development activities to ensure such methods satisfy ethical requirements.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.144	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Intellectual Property Rights</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means Patents, design rights, copyrights, trademarks, services marks, trade secret rights, or other rights in Know-How, database rights, and all other intellectual property rights or similar proprietary rights of whatever nature, whether registered or not, and including applications to register or rights to apply for registration or renewals or extensions of, and rights to claim priority from, which may now or in the future subsist anywhere in the world.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.145	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Internal Policies</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a Party, such Party&#x2019;s health care compliance, ethical, reputational, anti-bribery and corruption and other policies applicable to such Party&#x2019;s activities under this Agreement, and any standard operating procedures implementing such policies, including the codes of conduct of any self-regulatory body of which that Party is a member. Internal Policies includes the Vir Specified Internal Policies and the GSK Specified Internal Policies.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.146	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; means [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.147	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Joint Commercialization Committee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">JCC</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;3.3.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.148	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Joint Manufacturing Committee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">JMC</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.149	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Joint Patent Committee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">JPC</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;3.4.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.150	</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">&#x201c;Joint Research and Development Committee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; or </font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">&#x201c;JRDC</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.2.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.151	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Joint Steering Committee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">JSC</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;3.1.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.152	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Joint Technology</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any and all Program Technology that is jointly owned by the Parties pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">24</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.153	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Key Product Event</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any event with respect to the Collaboration Program or any Collaboration Product, that: (a) is determined by an independent safety review committee overseeing the safety of the relevant clinical trial to be directly related to the Collaboration Product, and (i) to have resulted in death, (ii)&#160;been life-threatening, (iii) required inpatient hospitalization or a significant prolongation of existing hospitalization, (iv) resulted in persistent or significant disability or incapacity, (v)&#160;resulted in a congenital anomaly or birth defect or (vi) required significant intervention to prevent permanent impairment or damage; and (b)&#160;results in a clinical hold being imposed on such program by the FDA or any comparable state, foreign or other Regulatory Authority to which the Collaboration Program or Collaboration Products are subject.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.154	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Know-How</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means proprietary and confidential trade secrets, models, discoveries, ideas, Data and other types of data, databases, results, assays, instructions, processes, techniques, formulas, algorithms, Materials, inventions, computational models, human-relevant disease models, computer software (including source code), predictive model implementations, data analytic tools, biotechnology hardware and associated algorithms and methodologies, methods of use, expert knowledge and information.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.155	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Knowledge</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a particular fact or matter and a Party, the knowledge [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.156	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Law</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, individually and collectively, any and all laws, ordinances, rules, directives and regulations of any kind whatsoever of any governmental or regulatory authority within the applicable jurisdiction.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.157	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">LCP</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.3.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.158	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Lead Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the Party that is the lead Party and primarily responsible for the Development or Commercialization of a Collaboration Product, as set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.159	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Legal Requirement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 18.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.160	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Licensed Technology</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means (a) GSK Licensed Technology or (b) Vir Licensed Technology, as applicable.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.161	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Listed Target Pathogens</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 6.2.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.162	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Losses</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 20.1.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.163	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">mAb</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any monoclonal antibody that binds to an applicable pathogen and [***].  &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">mAb</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; also includes [***]. For clarity, mAbs shall not include any Vaccine.</font><font style="color:rgba(0,0,0,1);font-weight:normal;vertical-align:top;font-size:8.04pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.164	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Major Market</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 9.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.165	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Malwares</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.9.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">25</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.166	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Manufacturing</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means all activities related to the synthesis, making, production, processing, purifying, formulating, filling, finishing, packaging, labeling, shipping, and holding of any Collaboration Product, or any component or intermediate thereof, and all activities performed in support of the CMC (chemistry, manufacturing and controls, or equivalent) section of an IND, NDA or BLA and other Regulatory Filing, including process and formulation development, process qualification and validation, scale-up, qualification, validation, pre-clinical, clinical and commercial production and analytic development, product characterization, stability testing, quality assurance, and quality control.  &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Manufacture</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall have a correlative meaning. For clarity, Manufacture does not include any of the foregoing activities with respect to Vir-2482 unless GSK exercises the Option, and then only after the Vir-2482 Program Effective Date.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.167	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Manufacturing Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 13.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.168	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Manufacturing Plan</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to Development and Commercialization under the applicable Collaboration Program, a separate plan governing the Manufacturing activities to be included in the Development Plan (with respect to Clinical Manufacturing) and the Commercialization Plan (with respect to Commercial Manufacturing), respectively, including with respect to Manufacturing process, physical product, supply chain for launch and commercial supply and solutions for technical issues.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.169	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Material Receiving Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the Party receiving Materials from the other Party as contemplated in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.170	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Materials</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any chemical or biological substances, including any biological or chemical compounds, drug products, human samples, or other materials, regardless of the route of transfer, which are supplied by a Party or its nominee to the other Party or its nominee for use in the conduct of activities under this Agreement.  Notwithstanding the foregoing, clinical or commercial supplies delivered pursuant to a Supply Agreement and Collaboration Product inventory and other materials (including the Working Cell Bank and Master Cell Bank) transferred pursuant to a Manufacturing technology transfer shall not constitute &#x201c;Materials&#x201d; for purposes of this Agreement.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.171	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Materials Transferring Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;15.1.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.172	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Medical Affairs Activities</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means activities directed to interacting with physicians and other healthcare professionals who utilize or conduct research related to a drug or biological product, including [***]. For the avoidance of doubt, Medical Affairs Activities do not include any activities involving the marketing, promotion or sale of any Collaboration Product.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.173	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Milestone Payment</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.3.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.174	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.175	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Most Conservative Approach</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the approach or position offered by a Party in its Internal Policies, which approach or position, in the aggregate, is [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">26</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.176	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">MTR</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Material Transfer Record</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.177	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">NDA</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a New Drug Application (as more fully defined in 21&#160;C.F.R.&#160;314.5 et seq. or its successor regulation) and all amendments and supplements thereto filed with the FDA.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.178	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Net Sales</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the Financial Schedule.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.179	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Non-Clinical GLP Studies</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means those studies conducted under GLP to produce data intended for inclusion in an IND, including IND-enabling toxicology studies.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.180	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Non-Lead Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a given Collaboration Program, the Party that is not the Lead Party.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.181	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Non Opt-Out Notice</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6.4(a)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.182	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Non Opt-Out Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6.4(a)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.183	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Option</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.184	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Option Exercise Fee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.2.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.185	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Option Exercise Period</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.186	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Opt-Out Effective Date</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6.3(a)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.187	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Opt-Out Notice</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.188	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Opt-Out Option</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.189	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Opt-Out Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.190	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Opt-Out Point</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in</font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;"> Section 7.6.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.191	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Orange Book</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the FDA publication titled &#x201c;Approved Drug Products with Therapeutic Equivalence Evaluations.&#x201d;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.192	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.193	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.194	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.195	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Party Asset</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.6.1(b)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.196	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">27</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.197	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Patents</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means all patents and pending patent applications (including inventor&#x2019;s certificates and utility models) and any patents issuing therefrom, in any country in the Territory, including any and all provisionals, non-provisionals, substitutions, continuations, continuations-in-part, divisional and other continuing applications, supplementary protection certificates, renewals, and any and all reissues, extensions, registrations, reexaminations, extensions, confirmations, registrations and patents of addition on any of the foregoing.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.198	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Payee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.11.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.199	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Payor</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.11.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.200	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">PCA Effective Date</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the date on which the Preliminary Collaboration Agreement became effective, which is March 25, 2021.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.201	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Permitted Overage</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.7.2(b)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.202	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Person</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any natural person, corporation, firm, business trust, joint venture, association, organization, company, partnership or other business entity, or any government, or any agency or political subdivisions thereof.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.203	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Personally Identifiable Information</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">PII</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means information that can be used to distinguish or trace an individual&#x2019;s identity, either alone or when combined with other personal or identifying information that is linked or linkable to a specific individual, including: (a) a first and last name; (b) a home or other physical address, including street name and name of city or town; (c) an email address or other online contact information, such as an instant messaging user identifier or a screen name that reveals an individual&#x2019;s email address; (d) a telephone number; (e) a social security number; (f) a bank, loan, or credit card account number; or (g) a persistent identifier, such as a customer number held in a &#x201c;cookie&#x201d; or processor serial number, that is combined with other available data that identifies an individual consumer.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.204	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Pharmacovigilance Technical Agreement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;10.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.205	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Phase I Clinical Study</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a given product, any clinical study administering such product to humans, whether healthy volunteers or patients, for the first time as a single or repeated dose for a given indication.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.206	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.207	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Phase I/IIa Clinical Study</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a given product, any clinical study of such product, for the purpose of studying pharmacology/pharmacodynamics effects or mechanism of action when administered to humans, whether healthy volunteers or patients, preliminarily determining dose or a range of doses or evaluating preliminary safety and which is not a Phase I Clinical Study.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.208	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Phase II Clinical Study</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a given product, any clinical study of such product, which provides for the trial of such product on a limited number of</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">28</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">patients for the purpose of determining dose or a range of doses and evaluating safety and preliminary efficacy in the proposed therapeutic indication.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.209	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.210	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Phase II/III Clinical Study</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a given product, any clinical study of such product, for the purpose of determining a dose or dose ranges of such product and evaluating safety and effectiveness of dose ranges of such product in patients with the disease or condition being studied for the purposes of filing for Regulatory Approval with the FDA or other applicable Regulatory Authority.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.211	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Phase III Clinical Study</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a given product, any Pivotal Clinical Study of such product for the purpose of establishing to establish safety and efficacy of such product in patients with the disease or condition being studied for purposes of filing for Regulatory Approval with the FDA or other applicable Regulatory Authority, as described under 21 C.F.R. &#167;312.21(c) with respect to the United States, or, with respect to a jurisdiction other than the United States, a similar clinical study.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.212	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Phase IV Clinical Study</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means of such product for the purpose of establishing any clinical study conducted for such product after such product has received Regulatory Approval for marketing in a particular jurisdiction, including trials the principal purpose of which is to (a) continue testing such product to collect information about (i) its safety or efficacy to provide comprehensive data confirming the benefit-risk balance is positive to convert to a standard Regulatory Approval for marketing in broader or various populations, (ii) its long term safety and side effects associated with long term use, or (iii) its use in additional diseases or conditions other than those for which Regulatory Approval was previously granted where the product is likely to be used &#x201c;off label&#x201d; in the disease or condition as a result of a similar mechanism of action, (b)&#160;obtain or widen reimbursement coverage, (c) improve the product&#x2019;s competitive position, or (d)&#160;improve the standard of care. For clarity, Phase IV Clinical Studies do not include investigator-initiated trials.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.213	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Pivotal Clinical Study</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a product, a Clinical Study for the purpose of establishing any randomized, well-controlled, appropriately powered study of product as described in 21 C.F.R. &#167;312.21(c) that is either a Phase II Clinical Study (including any Phase II Clinical Study as described in 21 C.F.R. &#167;312.84(b)), Phase II/III Clinical Study or any Phase III Clinical Study, the results of which, if the pre-defined primary endpoint(s) is met or where the weight of evidence or totality of data provide sufficient data on safety and effectiveness to support a marketing approval (including any conditional approval) of the relevant product in the Territory.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.214	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Plan</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any Development Plan or Commercialization Plan.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.215	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.216	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Pre-Tax Profit or Loss</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the Financial Schedule.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">29</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.217	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Product Mark Controlling Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;15.8.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.218	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Product Mark Non-Controlling Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.8.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.219	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Product Marks</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the trademarks for use in connection with the Commercialization of any Collaboration Product or Sole Development Product, including trademarks, generic names, international nonproprietary names, trade dress, style of packaging and Internet domain names used in connection with the Commercialization of such Collaboration Product or Sole Development Product.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.220	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Program Teams</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.2.2(p)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.221	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Program Technology</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, on a Collaboration Program-by-Collaboration Program basis, all Patents and Know-How generated under such Collaboration Program, including, in the case of Expanded Functional Genomics Program, any Collaboration Screening Data.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.222	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.223	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Public Statement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 18.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.224	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Receiving Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the definition of &#x201c;Confidential Information.&#x201d;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.225	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Regulatory Approval</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a country or jurisdiction in the Territory, all approvals, licenses, registrations or authorizations of any Regulatory Authority (including approvals of Drug Approval Applications), necessary for the Manufacturing, use, storage, import, export, transport, marketing and sale of a product, as applicable, in such country or jurisdiction. For purposes of this Agreement, (a) an Emergency Use Authorization shall not be deemed as a Regulatory Approval, and (b) for clarity, approval of an IND by a Regulatory Authority in any jurisdiction shall not constitute a Regulatory Approval.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.226	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Regulatory Authority</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the FDA, the EMA or any regulatory body with similar regulatory authority in any other jurisdiction anywhere in the world.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.227	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.228	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Regulatory Filing</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any filing or regulatory application or submission related to a product with the FDA or any other Regulatory Authority within or outside the United States, including authorizations, approvals or clearances arising from the foregoing, and all correspondence with a Regulatory Authority, as well as minutes of any material meetings, telephone conferences or discussions with such Regulatory Authority in each case with respect to such product.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.229	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Rejected Target</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to the Expanded Functional Genomics Program, any Target that has been reviewed but not approved by the JRDC for</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">30</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">progression into Target Validation Studies, or reviewed but not selected by the JSC to be an Expanded Functional Genomics Target for inclusion in the applicable Expanded Functional Genomics Development Plan.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.230	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Rejected Target Product</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 5.6.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.231	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Relevant Internal Policies</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.11</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.232	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Research</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means non-clinical and pre-clinical research activities, excluding any Clinical Studies or other clinical Development activities.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.233	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Research and Pre-Clinical Publication Strategy</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;14.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.234	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Respiratory Viral Disease</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any disease in human that is caused by a Respiratory Virus.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.235	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Respiratory Viral Functional Genomic Screens</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any functional genomics screens (including CRISPR screens) using cell lines incorporating or infected with a Respiratory Virus to identify Targets associated with such Respiratory Viruses.  For clarity, Respiratory Viral Functional Genomic Screens [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.236	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Respiratory Virus</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any virus that leads to primary pathology, disease or symptoms in the respiratory system, including Influenza Virus, respiratory syncytial virus (RSV), human rhinovirus, parainfluenza, metapneumovirus (MPV), adenovirus, but excluding Coronavirus.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.237	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.238	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; means [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.239	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Royalty Term</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a product in a country, the period beginning from the First Commercial Sale of such product in such country, and ending on the later of (a) [***] years from the First Commercial Sale of such product in such country and (b) [***] of (i) [***] to such product in such country, and (ii) [***] to such product in such country.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.240	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; means [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.241	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">SARS-COV-2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the severe acute respiratory syndrome Coronavirus 2.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.242	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Screening Data</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means data, know-how and information resulting from Respiratory Viral Functional Genomic Screens, including any analysis thereof.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.243	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Screening Data Analysis</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 5.2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.244	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Selected Pathogen</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 6.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">31</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.245	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Selected Pathogen Development Plan</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 6.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.246	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Senior Managers</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 22.1.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.247	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; means, [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.248	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.249	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.250	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">SPA</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in the preamble.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.251	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Sole Development Product</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means (a) an Influenza Product, (b)&#160;an Additional Pathogen Product, or (c) an Expanded Functional Genomics Product, in each case ((a) - (c)), upon which one Party has exercised its Opt-Out Option and the Non Opt-Out Party has elected to pursue such product unilaterally pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6.4(b)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  In the event GSK has exercised its Opt-Out Option and Vir has elected to pursue such product unilaterally, such product thereafter becomes a &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir Sole Development Product</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; and ceases to be a Collaboration Product.  Similarly, in the event Vir has exercised its Opt-Out Option and GSK has elected to pursue such product unilaterally, such Collaboration Product becomes a &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">GSK Sole Development Product</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; and ceases to be a Collaboration Product.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.252	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Subcommittee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.7</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.253	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Subcommittee Deadlock</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.254	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Sublicensee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any Third Party that is granted a sublicense by a Party under the licenses such Party receives from the other Party pursuant to the terms of this Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.255	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Target</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a biological product of a human host cell, including a protein or gene, having a biological or chemical activity or function that may be modulated by one or more active compounds (including small molecules, monoclonal antibodies, oligonucleotides, gene therapies, or other biomolecules or modalities) or by exposure to pathogens such as viruses.</font><font style="color:rgba(0,0,0,1);font-weight:normal;vertical-align:top;font-size:8.04pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.256	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.257	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.258	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; means [***].  For clarity, [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.259	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Target Validation Studies</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 5.2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.260	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Tax</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Taxes</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any present or future taxes, levies, imposts, duties, charges, assessments or fees of any nature (including interest, penalties and additions thereto), but not including any taxes, levies, imposts, duties, charges, assessments or fees taken into account in the determination of Pre-Tax Profit or Loss pursuant to the Financial Schedule.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">32</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.261	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Term</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 16.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.262	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Terminated Collaboration Product(s)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 17.3.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.263	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Terminated Party&#x201d; </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 17.3.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.264	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Terminating Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 17.3.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.265	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Territory</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means all countries and territories in the world.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.266	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Third Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a person or entity other than (a) Vir and its Affiliates, and (b) GSK and its Affiliates.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.267	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Third Party Infringement Claim</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.7.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.268	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Third Party Patent Rights</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any Patents owned or controlled by a Third Party.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.269	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">United States</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">U.S.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the United States and its territories and possessions.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.270	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">U.S. Bankruptcy Code</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means Title 11 of the United States Code.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.271	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">USD</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;, &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">United States Dollar</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">$</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the official currency of the United States of America.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.272	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vaccine</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any biological product, including nucleic acid(s), protein(s), peptide(s), polysaccharide(s), conjugated polysaccharide(s), live, live-attenuated or inactivated microorganism(s) including replication-competent and replication defective virus(es), bacteriophages(s) and bacteria, in each case comprising or encoding an antigen derived from the pathogen or the disease to be prevented or treated, optionally in combination with one or more biological or non-biological product(s) and that when administered to an subject induces, increases, decreases or qualitatively modifies, an immune response intended to prevent or treat the target disease or condition.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.273	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> &#x201c;[***]&#x201d; means, [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.274	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir-2482</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the Vir Influenza mAb the sequence of which is set forth on </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 1.274</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.275	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir-2482XX2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the Vir Influenza mAb the sequence of which is set forth on </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 1.274</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.276	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir 2482 Licensed Technology</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means all Patents and Know-How that are Controlled by Vir or its Affiliates as of the PCA Execution Date or thereafter at any time up to and including the Execution Date, and with respect to VIR-2482, if GSK exercises the</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">33</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Option, the VIR-2482 Program Effective Date, and that are necessary or reasonably useful for the Development, Manufacture and Commercialization of Vir-2482 or Vir-2482XX2.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.277	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir-2482 Program Effective Date</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.2.3(a)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.278	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir Acquired Asset</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any Vir Asset that is in-licensed or acquired by Vir from a Third Party after the Effective Date.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.279	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.280	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.281	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir Asset</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.6.1(b)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.282	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; means [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.283	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; means [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.284	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir Existing mAb Program</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a Selected Pathogen, any of Vir&#x2019;s neutralizing mAb program directed to such Selected Pathogen existing prior to or as of the date such target pathogen is selected by GSK pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (including such programs directed to the Listed Target Pathogens but excluding, for clarity, any programs that are Vir Acquired Assets or mAbs in such Vir Acquired Assets).</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.285	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; means [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.286	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir Indemnitees</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 20.1.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.287	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.288	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir Influenza mAbs</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means all mAbs for the prevention, treatment, or prophylaxis of diseases caused by Influenza Viruses that are Controlled by Vir or any of its Affiliates as of the Effective Date and during the Term (for clarity, subject to any pre-existing restrictions set forth in the Existing Third Party Agreements), including Vir-2482 and Vir-2482 XX2.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.289	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir License Agreement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any license or other agreement between Vir or any of its Affiliates and a Third Party regarding any Existing Influenza Program mAbs or Vir Licensed Technology, as amended, as of the applicable date.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.290	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir Licensed Technology</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, on a Collaboration Program-by-Collaboration Program basis,</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">(a)	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">in the case of the Influenza Program, all Patents and Know-How that are (i) Controlled by Vir or its Affiliates as of the Effective Date or during the Term, and (ii)&#160;necessary or reasonably useful for the Development, Manufacture and Commercialization of the Influenza Products containing Vir Influenza mAbs ([***]) (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir Influenza IP</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;);</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">34</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">(b)	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">in the case of the Expanded Functional Genomics Program, (i) [***]; and (ii) any Patents Controlled by Vir or its Affiliates and [***] and any Know-How Controlled by Vir or its Affiliates and [***];</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">(c)	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">in the case of [***];</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">provided that in each case ((a) through (c)), Vir Licensed Technology shall not include any Vir Program Technology or, [***]. For clarity, any technology that Vir includes within Vir Licensed Technology for a given Collaboration Program shall not be deemed included in Vir Licensed Technology for any other Collaboration Program, unless Vir expressly agrees to such inclusion in the applicable Development Plan for such other Collaboration Program.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.291	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; has the meaning set forth in [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.292	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[***]&#x201d; means [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">1.293	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir Preexisting Rights</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; has the meaning set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 12.1.1(a)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.294	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir Program Technology</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, on a Collaboration Program-by-Collaboration Program basis, Vir&#x2019;s right and interest in any Patent and Know-How generated under such Collaboration Program.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">1.295	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir Specified Internal Policies</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means Relevant Internal Policies of Vir as are provided by Vir to GSK during the Term.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 2<br>EffectiveNess; Overview; Exclusivitytc &#34;ARTICLE 2	EFFECTIVENESS; OVERVIEW; EXCLUSIVITY&#34;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">2.1	Effectiveness of the Agreement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;2.1	Effectiveness of the Agreement&#34; \f C \l &#34;2&#34; .  This Agreement is effective as of the PCA Effective Date (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Effective Date</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">2.2	Overview</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;2.2	Overview&#34; \f C \l &#34;2&#34; . Generally, the Parties shall, in accordance with the terms of this Agreement, collaborate to Develop pharmaceutical or biological products for the prevention, treatment and prophylaxis of diseases caused by Influenza Virus, other Respiratory Viruses, and Selected Pathogens, each, in accordance with an applicable Development Plan, and collaborate to further Manufacture and Commercialize such products under the terms set forth herein and in accordance with an applicable Development Plan (with respect to Clinical Manufacture and Development) and Commercialization Plan (with respect to Commercial Manufacture and Commercialization).  The Collaboration is comprised of the following three Collaboration Programs for the Development, Manufacture and Commercialization of three types of products: (a) a program for the Development, Manufacture and Commercialization of products containing mAbs targeting Influenza Viruses, including Vir-2482 (if and after the Vir-2482 Program Effective Date if the Option is exercised by GSK in accordance with the terms herein), Vir-2482XX2, and any other Vir Influenza mAb that is approved by the JSC for inclusion in an Influenza Development Plan, excluding, for clarity, any Discontinued Vir Influenza mAb (each, an &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Influenza Product</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;, and such program, an &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Influenza Program</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;); provided that, for clarity,</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">35</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]; (b) additional programs for the Development, Manufacture and Commercialization of products containing any neutralizing mAb that is directed to a Selected Pathogen, for up to three (3) Selected Pathogens (each, an &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Additional Pathogen Product</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; and each such program, an &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Additional Pathogen Program</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;); provided that, for clarity, [***]; and (c) a program for the Development, Manufacture and Commercialization of products in any modality directed to Respiratory Viral Diseases, based on Respiratory Viral Functional Genomic Screens, (each an &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Expanded Functional Genomics Product</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">,&#x201d; and such program, an &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Expanded Functional Genomics Program</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), provided that, (i) if a product containing a mAb arises from the Expanded Functional Genomics Program rather than the Influenza Program or an Additional Pathogen Program, such product shall not be considered an Influenza Product or Additional Pathogen Product, and shall be considered as an Expanded Functional Genomics Product; and (ii)  although the Expanded Functional Genomics Program will be focused on Targets associated with Respiratory Viral Diseases, [***].  During the Initial Development Term, the Parties will collaborate, under mutually agreed Development Plan(s) for each Collaboration Program, to generate and evaluate Development Candidates under such Collaboration Program.  With respect to each Collaboration Product under an applicable Collaboration Program, the Parties will conduct Development, Manufacturing, and regulatory activities in accordance with a Development Plan and Commercialization activities in accordance with a Commercialization Plan.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">2.3	Collaboration Program Leads</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;2.3	Collaboration Program Leads&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Generally, and subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, (a) GSK shall be the Lead Party for the Development of Influenza Products (and, for clarity, with respect to Vir-2482, after the Vir-2482 Program Effective Date, if GSK exercises the Option) under the oversight of the JRDC, the JSC and other applicable Committees in accordance with the terms of this Agreement; (b) with respect to the Expanded Functional Genomics Program and the Additional Pathogen Programs, the Parties, through the JSC, will determine which Party will be the Lead Party for the Development of a Collaboration Product under the oversight of the JRDC, the JSC and other applicable Committees in accordance with the terms of this Agreement, provided that if the Parties cannot agree at the JSC with respect to the determination of the Lead Party, GSK shall have final decision-making authority to determine the Lead Party; and (c) with respect to each Collaboration Program, GSK shall be the Lead Party for Commercialization and Commercial Manufacture activities with respect to each Collaboration Product under such Collaboration Program (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">LCP</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), under the oversight of the JCC, the JSC, the JMC and other applicable Committees in accordance with the terms of this Agreement, and, shall have the final decision-making authority with respect to the Commercialization and Commercial Manufacture under such Collaboration Program.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">2.4	Exclusivity Obligations</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;2.4	Exclusivity Obligations&#34; \f C \l &#34;2&#34; .</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">2.4.1	Influenza Program</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">During the Term, for any Vir Influenza mAb (a) that is not approved by the JSC for inclusion in an Influenza Development Plan, or (b) that has been approved by the JSC for inclusion in an Influenza Development Plan (which, for clarity, includes Vir-2482, if GSK exercises the Option, and Vir-2482XX2), but then the Development under such Influenza Development Plan ceases with respect to such Vir Influenza mAb (each in the case of (a) or (b), a &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Discontinued Vir Influenza mAb</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), the following shall apply:</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	if there is, and for so long as there continues to be, another Vir Influenza mAb being Developed or Commercialized by the Parties or their respective Affiliates as</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">36</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a Collaboration Product, or by either Party or its Affiliate as a Sole Development Product, then Vir shall not, either by itself or via an Affiliate, or by partnering with a Third Party, further Develop or Commercialize such Discontinued Vir Influenza mAb without GSK&#x2019;s consent, and</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii)	if there is no longer any Vir Influenza mAb being Developed or Commercialized by the Parties or their respective Affiliates as a Collaboration Product, or by either Party or its Affiliate as a Sole Development Product, then Vir shall have the right to, either by itself or via an Affiliate, or by partnering with a Third Party, further Develop and Commercialize such Discontinued Vir Influenza mAb without GSK&#x2019;s consent.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">2.4.2	Expanded Functional Genomics Program</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	During the Initial Development Term, neither Party shall, by itself or via an Affiliate, or by partnering with a Third Party, conduct Development activities on any Respiratory Viral Functional Genomic Screens for Targets associated with Respiratory Viruses or Respiratory Viral Diseases outside of the Collaboration without the other Party&#x2019;s prior written consent, provided that, (i) with respect to GSK, the foregoing restrictions shall not apply to [***], and (ii) with respect to Vir, the foregoing restrictions shall not apply to [***].</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	With respect to each Expanded Functional Genomics Target, following the Effective Date, and until the earlier of (x) a Party exercising its Opt-Out Option with respect to such Expanded Functional Genomics Target, or (y) five (5) years following such Target being designated by the JSC as an Expanded Functional Genomics Target (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Exclusivity Period</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), neither Party shall, by itself or via an Affiliate, or by partnering with a Third Party, Develop or Commercialize any compounds or product directed to such Expanded Functional Genomics Target in [***] outside the Expanded Functional Genomics Program, provided that, during the Exclusivity Period, if either Party [***] that is then being progressed within the Expanded Functional Genomics Program, alone or via an Affiliate or partnering with a Third Party, in each case, that would otherwise conflict with the restrictions set forth in this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.4.2(b)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, such Party shall, prior to initiation of such program, first notify the other Party in writing, and offer to include such program in the Collaboration (an &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Inclusion Notice</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), which Inclusion Notice shall, where applicable, include [***] in the Collaboration (&#x201c;[***]&#x201d;).  Such offering Party shall also [***] include the program under the Collaboration.  Upon receipt of an Inclusion Notice from the offering Party, the following shall apply:</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	The other Party shall have [***] from the date on which it receives the Inclusion Notice to determine whether or not it will accept such offer to include such program in the Collaboration and to notify the offering Party of its decision.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii)	If within such [***] period such other Party notifies the offering Party in writing that such other Party accepts such offer to include such program in the Collaboration, then such program shall be included in the Collaboration, the scope of which will be included in the applicable Development Plan, and shall constitute part of the Expanded Functional Genomics Program, and the terms and conditions of this Agreement shall apply, subject to any additional terms and conditions as may be agreed by the Parties.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">   </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">37</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iii)	If such other Party declines, or fails to notify the offering Party in writing within such [***] period that it wishes to include such program in the Collaboration, then the offering Party or its Affiliates shall have the right to exploit such program outside of the Collaboration solely to the extent [***], and such exploitation shall not constitute a breach of this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.4.2(b)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> by such offering Party, provided that (A) such offering Party shall have no right to Develop or Commercialize any compound or product within such program that is directed to [***] associated with such Expanded Functional Genomics Target [***] for which an Expanded Functional Genomics Product directed to such Expanded Functional Genomics Target is being progressed at the time the Inclusion Notice was provided, and (B) the offering Party shall ensure that no Confidential Information of the other Party (including Confidential Information that is the Confidential Information of both Parties, but for clarity excluding any Confidential Information that is the Confidential Information of only the offering Party) generated from the Collaboration with respect to such Expanded Functional Genomics Target (including the Collaboration Screening Data with respect to such Expanded Functional Genomics Target) is used for such program, compound or product outside the Collaboration.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	During the Initial Development Term, except as provided in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 5.6</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> with respect to Rejected Targets, [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	Notwithstanding </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.4.2(b)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.4.2(c)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, with respect to an Expanded Functional Genomics Independent Program of a Party directed to a Target that exists as of the date the Screening Data Analysis for such Target is provided to the JRDC, such Party may, in its discretion: (i) continue with such Expanded Functional Genomics Independent Program, subject to the limitations set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 5.5.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> with respect to the use of the Collaboration Screening Data, provided that such Party shall not, [***]; or (ii)&#160;subject to any pre-existing obligation to a Third Party and agreement of such Party, offer to include such Expanded Functional Genomics Independent Program in the Collaboration, at which time the Parties will negotiate in good faith the terms upon which such Expanded Functional Genomics Independent Program will be included in the Collaboration.  [***].</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">2.4.3	Additional Pathogen Programs</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">During the Initial Development Term, with respect to the Selected Pathogen under each Additional Pathogen Program, prior to the applicable Party exercising its Opt-Out Option for an Additional Pathogen Product directed at such Selected Pathogen, the following shall apply with respect to all Additional Pathogen Products directed to such Selected Pathogen, (a) Vir shall not, alone or via an Affiliate or partnering with a Third Party, Develop or Commercialize any compound or product (whether or not such compound or product is an antibody) directed to such Selected Pathogen, and (b) GSK shall not, alone or via an Affiliate or partnering with a Third Party, Develop or Commercialize any neutralizing mAb therapeutic product directed to such Selected Pathogen, in each case ((a) and (b)), outside the Collaboration.  Notwithstanding the foregoing, if at the time a Selected Pathogen is selected pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, a Party has, either alone or via an Affiliate or partnering with a Third Party, a program directed to such Selected Pathogen, then such Party may, in its discretion: (i) continue with such program, provided that such Party shall not, [***]; or (ii) subject to any pre-existing obligation to a Third Party and agreement of such Party, offer to include such program in the Collaboration, at which time the Parties will negotiate in good faith the terms upon which such program would be included in the Collaboration.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">38</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">2.4.4	No Other Exclusivity Obligations</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Other than the exclusivity restrictions set forth in this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.6.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 6.2.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, there will be no exclusivity provisions applicable to either Party for the Influenza Program, the Expanded Functional Genomics Program, or the Additional Pathogen Programs.  In addition, none of the exclusivity restrictions set forth in those Sections specified above in this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.4.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall apply to (a) [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">2.5	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]. TC &#34;2.5	Compassionate Use Programs.&#34; \f C \l &#34;2&#34; </font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> With respect to each Collaboration Product, the Parties shall, through the JMC, the JRDC and the JSC, discuss and agree on [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">2.6	Parties&#x2019; Assets</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;2.6	Parties&#x2019; Assets&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">2.6.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">For each Collaboration Program,</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	GSK is not required to include any antibodies, compounds or products, including platform technologies (collectively, &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Assets</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), Controlled by GSK or its Affiliates (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">GSK Assets</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) in the Collaboration for use in any such Collaboration Program, [***];</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	Vir is not required to include any Assets Controlled by Vir or its Affiliates (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir Assets</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) in the Collaboration for use in any such Collaboration Program, except for (i) Vir Influenza mAbs which, (A) with respect to Vir-2482XX2, shall be included in the Influenza Program as of the Effective Date, (B) with respect to Vir-2482, shall be included in the Influenza Program as of the Vir-2482 Program Effective Date if GSK exercises the Option, and (C) with respect to each other Vir Influenza mAb that becomes an Influenza Product, shall be included in the Influenza Program as of the date such Vir Influenza mAb is approved by the JSC for inclusion in an Influenza Development Plan, (ii) [***], and (iii) Vir Existing mAb Programs directed to a Selected Pathogen, which shall be included in the applicable Additional Pathogen Program following the selection of such Selected Pathogen in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Vir Assets and GSK Assets, with respect to Vir and GSK, respectively, are referred to as &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Party Assets</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.&#x201d;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">2.6.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except for the Party Assets that are required to be included in the applicable Collaboration Program pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.6.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, if the Parties agree to include any Party Asset in the Collaboration, then the Parties shall mutually agree on the relevant terms, including relevant intellectual property terms and financial terms (which, for clarity, shall govern the financial terms for the Collaboration Products Developed from such Party Asset under the applicable Collaboration Program) with respect to such Party Asset, before such Party Asset can be included in the Collaboration (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Contribution</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), and the scope of such Party Asset Contributed by such Party (including any applicable intellectual property terms and financial terms) shall be further set forth in the applicable Development Plan pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> or an amendment to this Agreement pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 22.11</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, provided that, for the Expanded Functional Genomics Program, with respect to any Party Asset provided by a Party to the other Party pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.1.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, as described in the applicable MTR, for purposes of conducting Screening Data Analysis and Target Validation Studies, the Materials Transferring Party with respect to such Party Asset shall grant and hereby grants to the Materials Receiving Party a limited, non-exclusive, non-sublicenseable, and non-transferrable license under any Patents and Know-How Controlled by the</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">39</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Materials Transferring Party with respect to such Party Asset, solely to the extent necessary for, and for the purposes of, allowing the Materials Receiving Party to conduct Screening Data Analysis and Target Validation Studies using such Party Asset, which license will terminate upon completion of the relevant Screening Data Analysis and Target Validation Studies. For clarity, (a)&#160;the foregoing provisions in this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall not apply to [***], and (b) if GSK Contributes [***], GSK shall, [***].  Notwithstanding the foregoing, and subject to [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">2.6.3	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Vir further agrees that following the Effective Date, and until the date on which GSK [***], Vir [***]. For clarity, without limiting Vir&#x2019;s exclusivity obligations hereunder, the foregoing sentence is not intended to restrict Vir from [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">2.7	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Compliance with Applicable Law</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;2.7	Compliance with Applicable Law&#34; \f C \l &#34;2&#34; .  Each Party shall, and shall cause their Affiliates, Sublicensees, permitted subcontractors and distributors to conduct its or their activities under this Agreement in compliance with applicable Law.  Without limiting the foregoing, any information exchanged between the Parties under this Agreement shall be subject to, and limited to the extent permitted by any applicable Law, including any applicable competition Law.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 3<br>Management of the Collaborationtc &#34;ARTICLE 3	MANAGEMENT OF THE COLLABORATION&#34;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.1	Joint Steering Committee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;3.1	Joint Steering Committee&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.1.1	Establishment of JSC</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Prior to the Execution Date, the Parties established a Joint Steering Committee (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Joint Steering Committee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">JSC</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), which is constituted in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;3.8</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. The JSC shall operate in accordance with the provisions of </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;3.8</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;3.9</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. At its meetings, the JSC shall discuss the matters described below and such other matters as are reasonably requested by either Party&#x2019;s Alliance Managers.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.1.2	Responsibilities of the JSC</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The JSC shall perform the following functions:</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	oversee, guide and approve the overall strategic direction of the Collaboration (but without modifying or limiting the rights or obligations of either Party as otherwise set forth herein);</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	discuss and determine which Party will be the Lead Party for the Development of a Collaboration Product under the Expanded Functional Genomics Program and the Additional Pathogen Programs;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	facilitate communications between the Parties regarding the identification and evaluation of Collaboration Products;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">40</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	with respect to Vir Influenza mAbs other than Vir-2482 and Vir 2482XX2, approve each such other Vir Influenza mAb for inclusion in an Influenza Development Plan based on agreed candidate criteria;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)	with respect to the Expanded Functional Genomics Program, approve selection of Expanded Functional Genomics Targets (including in connection with reconsideration of a Rejected Target resubmitted by a Party);</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(f)	with respect to the Additional Pathogen Programs, facilitate the discussion with respect to the selection of each Selected Pathogen and approve such selection;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(g)	establish, as appropriate, additional sub-committees or working groups responsible for managing specific aspects of the Collaboration as contemplated herein;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(h)	delegate decision-making authority with respect to specified issues to the applicable subcommittees, provided that any such delegated decision-making shall remain subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	oversee and supervise the subcommittees and resolve issues or Dispute elevated to it by any subcommittee, Program Team or working group the JSC may establish;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(j)	serve as a forum for each Party to communicate regarding each Party&#x2019;s interest in participation in further Development of each Collaboration Product, including approval of proposals from the JRDC for the inclusion of, and terms for, Third Party assets or Intellectual Property Rights within a given Collaboration Program;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(k)	serve as a forum for the Parties to discuss any proposal from either Party for inclusion of programs in the Collaboration in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.4.2(b), Section 2.4.2(d)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> or </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.4.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, as applicable;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(l)	[***];</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(m)	for each Collaboration Product, review and approve the initial Development Plan (and the Development Budget therein) in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.1.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and any material updates or amendments thereto in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.1.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(n)	for each Collaboration Product, review and approve the initial Commercialization Plan (including the associated Commercialization Budget) and proposed material updates and amendments thereto [***];</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(o)	[***];</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(p)	with respect to any Additional Pathogen Program, determine which Party shall have Manufacturing responsibility for supply of the applicable Additional Pathogen Product for preclinical studies, Phase I Clinical Studies and Phase II Clinical Studies of such Additional Pathogen Product;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">41</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(q)	review to determine whether any additional Internal Policy of a Party shall be included as a Relevant Internal Policy; and</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(r)	perform such other functions as are assigned to the JSC in this Agreement, or otherwise agreed by the Parties in writing.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.2	Joint Research and Development Committee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;3.2	Joint Research and Development Committee&#34; \f C \l &#34;2&#34; .</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.2.1	Establishment of JRDC</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Parties shall, [***], establish a joint research and development committee (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Joint Research and Development Committee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">JRDC</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to oversee Development of Collaboration Products and to coordinate Development activities of both Parties with respect to such Collaboration Products.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.2.2	Responsibilities of the JRDC</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The JRDC shall perform the following functions:</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	oversee, review and coordinate the conduct, implementation and progress of the Development (including any Research) activities of each Collaboration Product with respect thereto under this Agreement, as described in the applicable Development Plan;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	discuss and develop the Development (including Research) strategy for the Collaboration, including any next-generation Collaboration Products;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	review and approve the applicable initial Development Plan and proposed updates and amendments thereto, in each case, as prepared by the Lead Party in conjunction with the Program Teams with respect to clinical Development of any Collaboration Product, including the applicable Development Budget and the allocation of responsibilities between the Parties, from time to time, and submit such Development Plan, updates, and other amendments to the JSC for review and approval in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.1.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> or </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;7.1.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, as applicable;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	review and evaluate any results or reports delivered to the JRDC with respect to the Research activities, including validation and designation of each Development Candidate;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)	with respect to the Expanded Functional Genomics Program, determine to progress a Target to Target Validation Studies, and submit Targets to the JSC for the designation of Expanded Functional Genomics Targets;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(f)	review and evaluate any results or reports delivered to the JRDC with respect to further Development activities in addition to Research activities under the Development Plans, including the protocol concepts for Clinical Studies of the Collaboration Products and any revision of such protocols with respect to issues that are referred to the JRDC, in each case pursuant and subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.5.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(g)	address issues escalated from Program Teams, [***], and oversee risk mitigation plans proposed by Program Teams;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">42</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(h)	[***];</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	approve CROs and other subcontractors in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.4.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, excluding manufacturing subcontractors, which shall be approved by the JMC;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">   </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(j)	[***] under applicable Collaboration Programs;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(k)	[***];</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(l)	for each Collaboration Program, discuss each Party&#x2019;s interest in participation in further Development activities in connection with the applicable Opt-Out Points;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(m)	review and approve any Research and Pre-Clinical Publication Strategy or Clinical Development Publication Strategy proposed by the Lead Party of a Collaboration Program, pursuant to</font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;"> Section&#160;14.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> or </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;14.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(n)	[***]</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">(o)	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">provide periodic updates to the JSC and otherwise supporting the JSC&#x2019;s decision-making;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">(p)	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">establish a working functional teams for each Collaboration Program (each, a &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Program Team</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to oversee the Development activities under each Collaboration Program, and delegate one or more of its functions under this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> to such Program Team, with the supervision of the JRDC; and</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">(q)	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">perform such other functions as are specifically designated to the JRDC in this Agreement, or as the Parties otherwise agree in writing are appropriate to further the purposes of this Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.3	Joint Commercialization Committee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;3.3	Joint Commercialization Committee&#34; \f C \l &#34;2&#34; .</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.3.1	Establishment of JCC</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Parties shall establish a joint commercialization committee (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Joint Commercialization Committee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">JCC</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), by [***], to oversee and review progress of Commercialization activities with respect to such Collaboration Products.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.3.2	Responsibilities of the JCC</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The JCC shall perform the following functions:</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	review and approve the initial Commercialization Plan, including the associated Commercialization Budget, and proposed material updates thereto proposed by either Party (including any updates to the Commercialization Budget), in each case, as prepared by the LCP, with respect to Commercialization of each Collaboration Product, and submit the initial Commercialization Plan (including the associated Commercialization Budget) for each Collaboration Product to the JSC for review and approval and submit proposed material updates thereto [***] to the JSC for review and approval in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;9.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">43</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	provide a forum for discussing the need for significant updates to Commercialization Plan and [***], as applicable;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	review and discuss the [***] forecast for the Commercialization Budget, in conjunction with the Financial Working Group;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	review reports delivered to the JCC with respect to material Commercialization activities conducted by GSK and, [***];</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)	to the extent not addressed by a Program Team, [***]; and</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">(f)	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> perform such other functions as are specifically designated to the JCC in this Agreement, as applicable, or as the Parties otherwise agree in writing are appropriate to further the purposes of this Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.4	Joint Patent Committee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;3.4	Joint Patent Committee&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.4.1	Establishment of JPC</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***], the Parties shall establish a joint patent committee (&#x201c;J</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">oint Patent Committee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">JPC</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to oversee patent matters relating to the Collaboration, as more specifically described below.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.4.2	Responsibilities of the JPC</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The JPC shall perform the following functions.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	serve as a forum for the discussion of the overall intellectual property strategies for the Collaboration, including the prosecution, maintenance, defense and enforcement of Program Patents, GSK Licensed Patents and Vir Licensed Patents, and submission of patent information to the FDA for listing in the Orange Book, &#x201c;Purple Book&#x201d; (or Orange Book-equivalent framework document for Biologics) or any foreign equivalents thereof;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	[***];</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	[***];</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	review proposed publication by the Parties for any Patent-related issues;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)	[***]; and</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(f)	perform such other functions regarding Patents included in the Program Patents, GSK Licensed Patents and Vir Licensed Patents that are specifically designated to the JPC in this Agreement, or as the Parties otherwise agree in writing are appropriate to further the purposes of this Agreement.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.4.3	Decision-Making of the JPC</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> For matters relating to prosecution, maintenance or defense of a Patent, the Party [***].  For matters relating to submission of patent information for listing in the Orange Book or any foreign equivalents thereof, the LCP shall have the final decision-making authority pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 8.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  For matters relating to whether to</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">44</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">enter into a Blocking Third Party IP Agreement (and the agreement on the material terms thereof), any dispute shall be resolved in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.9.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  For matters relating to whether to include any Third Party Intellectual Property Rights under a Third Party IP Agreement, any dispute shall be resolved in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 12.9</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  [***].  For all other matters under the JPC authority, if the JPC cannot resolve a dispute with respect to such matter, the JPC shall be submitted such dispute to the JSC for resolution in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.5	Joint Manufacturing Committee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;3.5	Joint Manufacturing Committee&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.5.1	Establishment of the JMC</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***] the Parties shall establish a joint Manufacturing committee (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Joint Manufacturing Committee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; or &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">JMC</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to oversee matters relating to Manufacturing (including Clinical Manufacturing and Commercial Manufacturing and technology transfer) of any Collaboration Product under the Collaboration. The JMC shall be chaired by [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.5.2	Responsibilities of the JMC</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The JMC shall perform the following functions:</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	serve as a forum for the discussion of the overall Manufacturing strategies and plans for the Collaboration, including [***];</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	review and approve each Manufacturing Plan included in a Development Plan and Commercialization Plan and proposed updates and amendments thereto;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	assist the JRDC, the JCC and the JSC in review and approval of the Development Budget and Commercialization Budget and proposed updates and amendments thereto to the extent relating to Manufacturing activities;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	provide recommendations to JSC for the selection of CMOs for Clinical Manufacturing and Commercial Manufacturing and the terms and conditions of the proposed CMO agreement; and</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)	perform such other functions as are specifically designated to the JMC in this Agreement, or as the Parties otherwise agree in writing are appropriate to further the purposes of this Agreement.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">3.5.3	</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Decision-Making of the JMC</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The JMC shall operate in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.8</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, and the JMC shall make decisions generally in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. If the JMC is unable, despite the good faith efforts of all members, to resolve any dispute relating to matters within the JMC&#x2019;s authority within [***] after a disputed issue has been referred to the JMC by either Party, the disputed issue shall be referred to the JRDC, and shall be resolved in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.6	Financial Working Group</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;3.6	Financial Working Group&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Within thirty (30) days following the Effective Date, the JSC will establish a financial working group subcommittee (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Financial Working Group</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) that will be responsible for initially reviewing all budgets included as part of the Development Plans and Commercialization Plans,</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">45</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">and for overseeing the operational aspects of all co-funding and payment activities under this Agreement.  The JSC shall determine the appropriate number of representatives of each Party that will constitute the Financial Working Group.  Promptly following the Effective Date, each Party shall designate their respective initial representatives to the Financial Working Group to allow such Financial Working Group to begin organizing information for the initial meetings of each of the JRDC and JSC.  Unless otherwise specified by the JSC, the Financial Working Group shall operate generally in accordance with the provisions of </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.8</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, and shall have no authority to alter or amend the terms and conditions of this Agreement.  Both Parties&#x2019; representatives on the Financial Working Group shall make decisions and act in accordance with the General Principles.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.7	Other Subcommittees</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;3.7	Other Subcommittees&#34; \f C \l &#34;2&#34; . From time to time, the JSC and the JRDC may establish other subcommittees to oversee particular projects or activities under this Agreement, and such subcommittees shall be constituted and have such responsibility as the JSC or JRDC approves (such subcommittees, along with the other subcommittees established hereunder, each referred to herein as a &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Subcommittee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;). The Subcommittees shall operate in accordance with the provisions of </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.8</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, and shall have no authority to alter or amend the terms and conditions of this Agreement.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.8	Membership, Meetings and Meeting Minutes</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;3.8	Membership, Meetings and Meeting Minutes&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.8.1	Membership</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Except as otherwise stated herein, each Committee shall be composed of [***] in each case from each of Vir and GSK, or such other equal number of representatives as the Parties may agree.  As of the Effective Date, the Parties anticipate that the JSC will be composed of [***] representatives of each Party, and the JRDC will be composed of [***] representatives of each Party.  Either Party may replace its respective Committee representatives at any time with prior written notice to the other Party, provided that such replacement is of comparable authority and scope of functional responsibility within that Party&#x2019;s organization as the person he or she is replacing. Each Party&#x2019;s representatives to each Committee shall be individuals suitable in seniority and experience and amongst such representatives shall be [***] from each Party with relevant decision-making authority to make decisions within the scope of the applicable Committee&#x2019;s responsibilities, provided that it is understood that [***].  For each Committee, or where applicable, Subcommittees, each Party shall designate one of its representatives on such Committee to co-chair the meetings for such Committee (each, a &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Co-Chair</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;). The Co-Chairs shall, with and through the assistance of the Alliance Managers, coordinate and prepare the agenda for, and ensure the orderly conduct of, the meetings of such Committee. The Co-Chairs shall, with and through the assistance of the Alliance Managers, solicit agenda items from Committee members and provide an agenda, along with appropriate information for such agenda, reasonably in advance of any meeting, including [***]. Such agenda shall include all items requested by either Co-Chair for inclusion therein. In the event the Co-Chairs or another Committee member from either Party is unable to attend or participate in a meeting of such Committee, the Party whose Co-Chair or member is unable to attend may designate a substitute co-chair or other representative for the meeting.  For clarity, while the Alliance Managers may attend meetings of all Committees, the Alliance Managers shall not: (a)&#160;serve as a voting member of any such Committee; nor (b) be counted towards either Party&#x2019;s representation on any such Committee.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">46</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.8.2	Meetings</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. The JSC shall meet at least [***] per year, or at a frequency determined by the JSC, for so long as the Parties are engaging in Development activities as part of the Collaboration or a Collaboration Product is in Development or being Commercialized, in each case, for clarity, not as a Sole Development Product, and JSC meetings can be called at other times to resolve Committee Deadlocks in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  [***] will be in-person, unless the JSC members agree to meet by an alternative mechanism (e.g., telephone or videoconference).  The JRDC and the JCC, once formed, shall meet [***], or in each case at a frequency determined by the JRDC or JCC, as applicable.  The Financial Working Group, Program Teams and other Subcommittees, if any, shall each meet at least quarterly after the Subcommittee is formed, or as more or less often as otherwise agreed by the applicable Subcommittee; provided that the Financial Working Group will meet </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">as and when necessary</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> to carry out its responsibilities set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;11.6</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  During the [***].  Committee meetings may be conducted by telephone, videoconference or in person.  Any in-person Committee meetings shall be held on an alternating basis between Vir&#x2019;s and GSK&#x2019;s facilities, unless otherwise agreed by the Parties.  Each Party shall be responsible for its own expenses in attending such meetings.  As appropriate, the Committee may [***].  Each Party may also call for special meetings of a Committee to discuss particular matters requested by such Party. The Alliance Managers shall provide the members of each Committee with no less than [***] notice of each regularly scheduled meeting and, to the extent reasonably practicable under the circumstances, no less than [***] notice of any special meetings called by either Party.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.8.3	Meeting Minutes.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Minutes will be kept of all Committee meetings by one of the Alliance Managers (or his or her designees), or by one of the Co-Chairs (if an Alliance Manager is not present) on a rotating basis (commencing with GSK&#x2019;s representative) and sent to all members of the Committee by facsimile or e-mail for review and approval within [***] after each meeting.  The Parties may agree at the JSC on the format of the meeting minutes for the JSC and each other Committee.  If a Party&#x2019;s Alliance Manager (or his or her designee) is not present at a Committee meeting and that Party is responsible for keeping minutes, such Party shall designate one of its Committee members to keep minutes.  Minutes shall record all action items and decisions of the applicable Committee.  The Committee shall formally accept the minutes of the previous Committee meeting [***]. Minutes will be deemed approved unless any member of the Committee objects to the accuracy of such minutes by [***].  Minutes shall list action items and shall designate any issues that need to be resolved by the JSC or applicable dispute resolution process.  In the event of any such objection to the minutes that is not resolved by mutual agreement of the Parties, such minutes will be amended to reflect such unresolved dispute.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.9	Decision-Making</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;3.9	Decision-Making&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.9.1	Committee Decision Making</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Decisions of each Committee shall be made by unanimous vote, with each Party having one vote. To the extent a Party has voted in favor of a particular action, after commencement of the implementation of such action it shall not be permitted to reverse such vote absent changed facts and circumstances that were not present at the time of the initial vote.  In order to make any decision, any Committee must have present (in person or via telephone or videoconference) and voting at least one representative of each Party.  Representatives of each Party under each Committee shall use reasonable efforts to resolve any dispute within the authority of such Committee in good faith.  If (a) the JRDC, the JCC, the Financial Working Group, or the JPC (subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;3.4.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) cannot or does not reach consensus</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">47</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">with respect to a bona fide dispute within the authority of such Subcommittee (a &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Subcommittee Deadlock</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) after endeavoring for [***] to do so, such matter shall be referred to the JSC for discussion and attempted resolution, and (b) any Program Team or other Subcommittee cannot or does not reach consensus with respect to Subcommittee Deadlock after endeavoring for [***] to do so, then such Subcommittee Deadlock shall be first referred to the JRDC (in case of Program Teams and the JMC) or the applicable establishing Committee for resolution before they are submitted to the JSC pursuant to subsection (a).  In the event that the JSC does not reach a decision with respect to a Subcommittee Deadlock, or if the JSC cannot or does not reach consensus with respect to any other matter within its authority, in each case, after endeavoring for [***] to do so, then such matter (a &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Committee Deadlock</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) shall be decided by the Parties in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> below.  For clarity, all commitments and other matters decided by the JSC or any other Committee between the Effective Date and the Execution Date (inclusive), to the extent that such commitments and other matters are actually approved and documented in the JSC meeting minutes, shall be deemed to be approved by and mutually agreed through the JSC and such other Committee, respectively, for purposes of this Agreement.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.9.2	Decision Making Authority</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Committee Deadlock shall be submitted by either Party to the Senior Managers of both Parties.  The Senior Managers of each Party, or their respective designees, shall attempt to resolve such Committee Deadlock within [***] after submission.  If the Senior Managers (or their respective designees) cannot resolve the Committee Deadlock, then GSK, as the Lead Party and the LCP for the applicable Collaboration Product, shall have the final decision-making authority, except that:</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	if the JSC determines (with GSK having the final decision-making authority) that Vir shall be the Lead Party for the Development of a Collaboration Product under the Expanded Functional Genomics Program or any Additional Pathogen Program, then, prior to the first filing for Drug Approval Application of such Collaboration Product, if a Committee Deadlock is with respect to Development and regulatory matters regarding such Collaboration Product, including clinical Manufacturing and supply of clinical trial material for Clinical Studies, then Vir, as the Lead Party for such Collaboration Product, shall have the final decision making authority [***];</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	 [***];</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	with respect to the Expanded Functional Genomics Program,</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:30.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	if at the time a Target is submitted by the JRDC to the JSC for approval as an Expanded Functional Genomics Target, [***];</font></p>
  <p style="text-indent:30.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii)	if [***];</font></p>
  <p style="text-indent:30.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iii)	if the Parties [***].</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	with respect to the Additional Pathogens Program,</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:30.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	except with respect to the [***] designated by GSK from the Listed Target Pathogens and any Program mAbs directed to such Selected Pathogen (for which, for clarity, GSK shall have the final decision-making authority), [***] (A) [***], or (B) [***], and,</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">48</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">in each case ((A) or (B)), such decision shall [***]; provided that, the foregoing [***] (x) [***], or (y) [***];</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:30.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii)	GSK shall not have the right [***];</font></p>
  <p style="text-indent:30.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iii)	GSK shall not have the right [***];</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)	with respect to inclusion of any additional Internal Policy of a Party as a Relevant Internal Policy, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.11</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall apply;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(f)	with respect to the [***] for each Collaboration Product, if the Committee Deadlock is with respect to (i) [***], or (ii) [***] (A) [***]; and (B) [***], in each case ((A) and (B)) to the extent that [***], in each case ((x) or (y)), [***], then GSK shall have the final decision-making authority, but [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.9.3	Limits on Decision-Making Authority</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Notwithstanding </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.4.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, (a) neither Party may exercise its final decision-making authority to (i) impose additional obligations upon the other Party not otherwise provided in this Agreement without such Party&#x2019;s consent, (ii) cause the other Party to violate any applicable Law, or the terms of any agreement it may have with any Third Party entered into prior to the Execution Date, or (iii) modify, violate, breach or waive compliance with this Agreement, or cause the other Party to do so, (b) a Party may only exercise its final decision-making authority with respect to a matter after giving good faith consideration to the other Party&#x2019;s comments (through its JSC members or its Senior Manager, as applicable) on such matter, and (c) if a Party elects its Opt-Out Option at any time with respect to a Collaboration Product, then thereafter, to the extent such</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Opt-Out Party</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">would have the final decision-making authority pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, then, such Opt-Out Party shall no longer have such final decision-making authority with respect to such Collaboration Product and, without limiting the preceding clauses (a) and (b), any dispute that would be subject to such Opt-Out Party&#x2019;s final decision-making authority shall then be subject to the Non Opt-Out Party&#x2019;s final decision-making authority.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.9.4	Day-to-Day Decision-Making Authority</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Each Party shall have decision-making authority with respect to the day-to-day activities of such Party (and such Party&#x2019;s employees, agents and subcontractors) under this Agreement in accordance with this Agreement, including applicable Development Plan or Commercialization Plan, provided that such decisions are not inconsistent with the terms and conditions of this Agreement (including any applicable Plan) or the decisions and actions of the JSC, the JRDC, the JCC, the JMC, the Financial Working Group or any other Subcommittee, as applicable.  Subject to the foregoing, each Party shall keep the relevant Committees reasonably informed of material developments regarding the Collaboration Products.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.9.5	Limitation of Powers</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Each Committee will have only the powers as are specifically delegated to it under this Agreement. The JSC is not a substitute for the rights of the Parties under this Agreement and is intended to coordinate and facilitate the activities of the Parties during the Term.  The JSC will not be involved with the day-to-day management of activities to be performed by a Party under this Agreement. Matters explicitly reserved to the consent, approval or other decision-making authority of one or both Parties, as expressly provided</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">49</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">in this Agreement, are outside the jurisdiction and authority of the JSC, including amendment, modification or waiver of compliance with the Agreement, which shall be made by the Parties in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 22.11</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.10	Alliance Managers</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;3.10	Alliance Managers&#34; \f C \l &#34;2&#34; . [***], each Party shall designate an individual to serve as the main point of contact for each Party [***] to exchange information, facilitate communication and coordinate the Parties&#x2019; activities hereunder (each, an &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Alliance Manager</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  [***]. The applicable Alliance Managers shall attend the JSC meetings (or designate an appropriate representative to attend JSC meetings on the Alliance Manager&#x2019;s behalf).  For all other Committees, the Alliance Managers may participate in meetings but are not required to participate.  The Alliance Managers shall not be counted as members of any Committee (and shall not vote on matters discussed at any Committee meeting).  Each Party may change its designated Alliance Manager from time to time upon written notice to the other Party.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">3.11	Most Conservative Approach and Internal Policies</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;3.11	Most Conservative Approach and Internal Policies&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">For all activities with respect to Collaboration Products, each Party will provide the other with copies of Internal Policies that are relevant and material to the activities being conducted by the Parties hereunder (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Relevant Internal Policies</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) [***], and will provide updates of such Relevant Internal Policies as appropriate.  [***].  If there is a conflict between the Relevant Internal Policies with respect to a particular issue, the Parties shall [***], and, except as otherwise set forth in an applicable Development Plan, each Party shall [***] with respect to Development, Manufacturing and Commercialization activities hereunder.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 4<br>Influenza Program TC &#34;ARTICLE 4	INFLUENZA PROGRAM&#34; \f C \l &#34;1&#34;</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">4.1	General</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;4.1	General&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Influenza Program shall include Vir-2482XX2 and, subject to any restrictions set forth in the Existing Third Party Agreements, shall include all other Vir Influenza mAbs that are approved by the JSC for inclusion in Influenza Development Plan(s), except for Vir-2482, which shall not be part of the Influenza Program unless and until GSK exercises the Option pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  During the Term, the Parties shall discuss and agree, through the JRDC and the JSC, on Development Plans for Influenza Products under the Influenza Program in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (each, an &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Influenza Development Plan</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;). Without limiting the foregoing, the Influenza Development Plan will set forth (a) [***]; (b) [***]; (c) [***]; and (d) [***]. An initial Development Plan for Vir-2482XX2 as of the Effective Date is set forth on </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule&#160;4.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. As the Lead Party, GSK shall be primarily responsible for the Development, Clinical Manufacturing and Commercialization of the Influenza Products (for clarity, not including Vir-2482 unless GSK exercises the Option, and then only after the Vir-2482 Program Effective Date), under the oversight of the JRDC, JMC, JCC and the JSC.</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">4.2	GSK&#x2019;s Option to Vir-2482</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;4.2	GSK&#x2019;s Option to VIR-2482&#34; \f C \l &#34;2&#34; .</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">4.2.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Vir may conduct development activities with respect to Vir-2482 up to completion of Phase II Clinical Studies of Vir-2482, without support of GSK. For clarity, Vir is not obligated to conduct, and may in its discretion elect not to proceed with, development</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">50</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">of Vir-2482 through completion of Phase II Clinical Studies.  If Vir elects to conduct such development, Vir will be responsible for the development activities set forth on </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule&#160;4.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> through completion of Phase II Clinical Studies at its own cost and expense, and [***], Vir shall provide to GSK a package of data and results for such Phase II Clinical Studies completed by Vir in accordance with the development plan for Vir-2482 (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Option Data Package</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  The Option Data Package shall include the data and information [***].</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">4.2.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">GSK shall have, and Vir hereby grants to GSK, an exclusive option (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Option</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to exclusively collaborate with Vir on the Development, Manufacture and Commercialization of Vir-2482, provided it is understood that such Option shall only be exercisable provided that Vir completes Phase II Clinical Studies for Vir-2482.  The Option is exercisable in GSK&#x2019;s sole discretion during the period between the date on which GSK receives the Option Data Package and [***] thereafter (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Option Exercise Period</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;). If, upon receipt of the Option Data Package, GSK [***], provided that neither Party shall be required to conduct further development activities to support any inquiry about any data or results included in such Option Data Package, and to the extent [***], the Option Exercise Period shall be [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">4.2.3	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If the Option is exercised by GSK in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, then:</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, on the date on which GSK gives written notice of exercise of the Option or, if any antitrust approvals in connection with exercise of such Option are required, on the date on which all such approvals have been obtained (such date, the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir-2482 Program Effective Date</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), the licenses granted by Vir to GSK under </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 12.1.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> will be deemed to have been automatically expanded to include the right to Develop, Manufacture, and Commercialize Vir-2482 in the Field in the Territory; and</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	following the Vir-2482 Program Effective Date, (i) GSK will pay, as applicable, the Option Exercise Fee to Vir in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">; (ii) the Influenza Program shall be automatically expanded to include Vir-2482; (iii) Vir and GSK will collaborate on the Phase III trials of Vir-2482 and for any future Development, Manufacturing and Commercialization of Vir-2482, with GSK being the Lead Party; and (iv) each Party will share fifty percent (50%) of the Development Costs and Pre-Tax Profits or Losses for Vir-2482 incurred following the Vir-2482 Program Effective Date in accordance with applicable Influenza Development Plan and Commercialization Plan, subject to each Party&#x2019;s applicable Opt-Out Option set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">4.2.4	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If GSK elects not to exercise the Option with respect to Vir-2482 or fails to exercise the Option during the Option Exercise Period (subject to any extension, where applicable), then Vir shall have the right to further Develop and Commercialize Vir-2482 independently, alone or via an Affiliate or with a Third Party, provided that in such case,</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	[***], and, without limiting the foregoing, [***], and</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	[***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">51</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">4.3	Vir-2482XX2 and Other Vir Influenza mAbs</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;4.3	VIR-2482XX2 and Other VIR Influenza mAbs&#34; \f C \l &#34;2&#34; .</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">4.3.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">GSK shall have, and Vir hereby grants to GSK, effective as of the Effective Date, the exclusive right to collaborate with Vir on the Development, Manufacture and Commercialization of Vir-2482XX2 and other Influenza Products on and after the Effective Date.  Without limiting the foregoing, the JSC may agree to pursue another Vir Influenza mAb (other than Vir-2482 or Vir-2482XX2) [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">4.3.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Either Party may identify a Vir Influenza mAb, which, if approved by the JSC for inclusion in an Influenza Development Plan, shall be an Influenza Product included in the Influenza Program, subject to any restrictions set forth in the Existing Third Party Agreements, and thereafter, the Parties will further Develop such Influenza Product in accordance with the applicable Influenza Development Plan (including an associated Development Budget) consistent with the diligence obligations of each Party as set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 5<br>Expanded functional genomics Program TC &#34;ARTICLE 5	EXPANDED FUNCTIONAL GENOMICS PROGRAM&#34; \f C \l &#34;1&#34;</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">5.1	General</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;5.1	General&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Promptly following the Screening Data Analysis, the Parties will, through the JRDC, discuss and mutually agree on the Development Plan for the Expanded Functional Genomics Program in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Expanded Functional Genomics Development Plan</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;). Without limiting the foregoing, the Expanded Functional Genomics Development Plan will include (a) [***], (b) [***]; (c) [***], and (d) [***].  A flowchart of the work stream for the Expanded Functional Genomics Program is set forth on </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 5.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> attached hereto.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">5.2	 Pre-Expanded Functional Genomics Target Selection</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;5.2	Pre-Expanded Functional Genomics Target Selection&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">5.2.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Following the Effective Date, the Parties will, under the oversight of the JRDC, collaborate on identifying Targets of interest associated with a Respiratory Viral Disease [***] (such process, the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Screening Data Analysis</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;). [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">5.2.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Following the Screening Data Analysis, if the JRDC agrees to progress such Target and to further conduct target validation activities, the Parties will agree on an the Expanded Functional Genomics Development Plan to include applicable target validation activities for such Target (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Target Validation Studies</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  Any Target evaluated by the JRDC on the basis of the Screening Data Analysis that the Parties do not elect to progress into Target Validation Studies shall become a Rejected Target.  For clarity, Target Validation Studies may also include additional Respiratory Viral Functional Genomic Screens with respect to such Target,</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">52</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">which will be agreed by the Parties and provided in the applicable Expanded Functional Genomics Development Plan.  [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">5.3	Screening Data</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;5.3	Screening Data&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">5.3.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">With respect to each Target or the associated Respiratory Viral Disease that becomes the subject of Screening Data Analysis, each Party will contribute, at its discretion [***], data, information and Know-How Controlled by such Party and relevant to the Respiratory Viral Disease associated with such Target, to be used in the Screening Data Analysis and, if the JRDC decides to progress such Target to the Target Validation Studies, in addition to data, information and Know-How, each Party may, subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.6.2,</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> contribute, at its discretion, compounds or products to be used in Target Validation Studies for the screening, selection, and validation of such Target.  For clarity, Vir shall Contribute to the Expanded Functional Genomics Program [***] and, [***], GSK shall Contribute to the Expanded Functional Genomics Program [***].  The Parties may, upon approval by the JRDC, (i) [***], or (ii) [***].  For clarity, neither Party shall, nor shall either Party be required to, contribute to the Expanded Functional Genomics Program any Screening Data not related to Respiratory Viral Diseases.  Each Party shall [***].  For clarity, as between the Parties, [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">5.3.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">All Screening Data arising from activities conducted within the Expanded Functional Genomics Program, including such Screening Data [***] (such Screening Data, &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Collaboration Screening Data</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;). The Parties shall coordinate, through the Joint Patent Committee, with respect to the filing of any patent applications disclosing or claiming the Collaboration Screening Data.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">5.4	Selection of Expanded Functional Genomics Targets</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;5.4	Selection of Expanded Functional Genomics Targets&#34; \f C \l &#34;2&#34; .</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">5.4.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Following the Target Validation Studies with respect to a Target, the JRDC will deliver the results and data from the Screening Data Analysis and Target Validation Studies for such Target to the JSC for further evaluation.  The JSC will select Expanded Functional Genomics Targets based on [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">5.4.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Following the selection of an Expanded Functional Genomics Target by the JSC, the Parties will, through the JSC and in accordance with an Expanded Functional Genomics Development Plan (including associated budget), further Develop and Commercialize Expanded Functional Genomics Product directed to such Expanded Functional Genomics Target, with the primary focus on Respiratory Viral Diseases.  If the Parties identify other diseases associated with an Expanded Functional Genomics Target, then, [***].</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">5.4.3	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Following the selection of an Expanded Functional Genomics Target by the JSC (as may be further determined pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">), neither Party shall [***] outside the Expanded Functional Genomics Program, until [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">5.5	Independent Programs</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;5.5	Independent Programs&#34; \f C \l &#34;2&#34; .</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">5.5.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If, at the time a Target becomes an Expanded Functional Genomics Target, such Target is the subject of an Expanded Functional Genomics Independent Program of</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">53</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">a Party (either by itself, through an Affiliate or with a Third Party) outside the Expanded Functional Genomics Program, then, such Party shall have the right to continue with such Expanded Functional Genomics Independent Program, provided such Party and its Affiliates, Third Party licensees and Sublicensees shall not have the right to [***] of the other Party in connection with such Expanded Functional Genomics Independent Program.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">5.5.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If, at the time a Target becomes an Expanded Functional Genomics Target, either Party has [***].  For clarity, neither Party has an obligation to Contribute to the Expanded Functional Genomics Program [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">   </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">5.6	Rejected Targets</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;5.6	Rejected Targets&#34; \f C \l &#34;2&#34; .</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">5.6.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 5.6.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, either Party may progress a Rejected Target independently, either alone or via an Affiliate or partnering with a Third Party (each, a &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Rejected Target Program</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), and [***], provided that except as set forth in</font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;"> Section 5.6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, neither Party shall [***] until [***]. For clarity, except for [***], either Party shall have the right to [***] (except as set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 5.6.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">), in any Rejected Target Program.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">5.6.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Notwithstanding </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 5.6.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, during [***], subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 5.6.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, if a Party wishes to pursue further development activities [***] with respect to a Rejected Target [***] then such Party shall be permitted to do so; provided that (a) if a Party Develops [***], and wishes to continue further Development, or (b) if such Party wishes to [***] in connection with a [***]; then in each case ((a) or (b)) such Party shall be [***] as an Expanded Functional Genomics Target, including [***], then the offering Party shall have the right to progress a Rejected Target Program with respect to such Rejected Target [***], itself or with any Affiliate or Third Party.  For clarity, either Party shall have the right to [***].</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">5.6.3	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If a Target [***] within the Expanded Functional Genomics Program, and at such time, such Target is the subject of an Expanded Functional Genomics Independent Program of GSK (and not of Vir), then (a) GSK shall have the right to continue with such Expanded Functional Genomics Independent Program, provided GSK shall not have the right to [***], and (b) Vir may progress a Rejected Target Program, [***], including in relation to [***], subject to the payment of royalties to GSK on Net Sales of the Rejected Target Product(s) arising from such Rejected Target Program pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 5.6.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">5.6.4	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If a Party elects to progress a Rejected Target in accordance with the terms of this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 5.6</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> with respect to any Respiratory Viral Disease, and (a) [***], and (b) [***] for a product directed to such Rejected Target [***] (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Rejected Target Product</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), then following such Regulatory Approval, such Party shall pay to the other Party a royalty of [***] on Net Sales of such Rejected Target Product starting from the First Commercial Sale of such Rejected Target Product [***], for so long as such Rejected Target Product is [***].  In addition, on a Rejected Target Product-by-Rejected Target Product basis, the royalty reductions set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.8.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.9.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall apply, </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">mutatis mutandis</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, with respect to royalties due on Net Sales of each applicable Rejected Target Product in each Calendar Quarter, provided that such</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">54</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">deductions, in the aggregate, shall not reduce the royalties payable in each applicable Calendar Quarter for such applicable Rejected Target Product [***] on such Net Sales.  [***].</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">5.7	Database Technology</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;5.7	Database Technology&#34; \f C \l &#34;2&#34; . Any databases and data mining technologies [***] shall only be included in the Expanded Functional Genomics Program to the extent agreed by the applicable Party in its sole discretion and [***], and in each case shall be subject to any applicable Third Party agreements, including, [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 6<br>Additional Pathogen Programs TC &#34;ARTICLE 6	ADDITIONAL PATHOGEN PROGRAMS&#34; \f C \l &#34;1&#34;</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">6.1	General</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;6.1	General&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Three (3) target pathogens (other than Influenza Viruses) will be selected in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (each a &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Selected Pathogen</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to be included in the Collaboration as Additional Pathogen Programs. Notwithstanding the foregoing, the Parties agree that [***] set forth on </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 6.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> attached hereto [***]</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">. </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> Promptly following the selection of a Selected Pathogen and, where applicable, the associated Program mAbs, the Parties will, through the JRDC, discuss and mutually agree on the Development Plan for each Selected Pathogen under the Additional Pathogen Program in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Selected Pathogen Development Plan</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;). Without limiting the foregoing, the Selected Pathogen Development Plan for each Selected Pathogen will set forth (a) [***]; (b) [***]; (c) [***]; (d) [***]; and (e) [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">6.2	Selection of Additional Pathogen</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;6.2	Selection of Additional Pathogen&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">6.2.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">During the period of [***], GSK shall have the right, but not the obligation, to select [***] from the list of target pathogens set forth on </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 6.2.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Listed Target Pathogens</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), and during such [***].  For clarity, if GSK does not select [***] from the Listed Target Pathogens within such [***], it shall still have the right to select up to three (3) target pathogens pursuant to the remainder of this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">6.2.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">GSK shall have the right to select [***] at any time between the Effective Date and [***] from any target pathogen [***], subject in each case to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9.2(d)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">6.2.3	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except as otherwise provided pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9.2(d)(i)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> or </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9.2(d)(ii)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, GSK shall have final decision-making authority with respect to the selection of the Selected Pathogens.  For clarity, subject to Vir&#x2019;s exclusivity obligations under </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.4.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 6.2.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, Vir shall not be restricted with respect to the conduct of its internal antibody programs (or from acquiring or in-licensing any antibody program from a Third Party) prior to GSK selecting the Selected Pathogens, provided that [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">6.3	Selection of Program mAbs</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;6.3	Selection of Program mAbs&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">For each Selected Pathogen, the Parties will agree via the JSC, to select neutralizing mAbs directed to such Selected Pathogen (such mAbs selected by the JSC, &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Program mAbs</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  The JSC may select Program mAbs from a Vir Existing mAb Program or from a Vir Acquired Asset, subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9.2(d)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  In addition, Vir and GSK will collaborate to identify novel neutralizing mAbs outside of Vir Existing mAb Programs and Vir Acquired Assets that broadly neutralize strains of</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">55</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">the Selected Pathogen (including mAbs disclosed in the literature or brought in by a Party from outside the Collaboration in its sole discretion, subject to any obligations to a Third Party), and the Parties will collaborate to test and validate activity of such neutralizing mAbs in accordance with a Selected Pathogen Development Plan, upon which time [***] to include such mAbs in the applicable Additional Pathogen Program as Program mAbs.  If the JSC cannot agree on the selection of a Program mAb, then, [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 7<br>Development Activities; OPT-Out Options TC &#34;ARTICLE 7	DEVELOPMENT ACTIVITIES; OPT-OUT OPTIONS&#34; \f C \l &#34;1&#34;</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.1	Development Plans</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;7.1	Development Plans&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.1.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Parties shall conduct Development activities under each Collaboration Program in accordance with applicable Development Plans.  Each Development Plan shall (a) [***], and (b) set forth (i)&#160;[***], (ii) [***], (iii) [***], (iv) [***], (v) [***].  For clarity, the Development Plan will [***].</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.1.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The JRDC, [***], shall review and approve each initial Development Plan (to the extent not approved prior to the Execution Date) within [***], and shall submit such Development Plan to the JSC for the JSC to review and approve, except that the JMC shall review and approve the Manufacturing Plan (and associated Manufacturing budget) included in the Development Plan [***].  If the JRDC or the JMC, as applicable, cannot agree on the Development Plan within such [***], then such dispute shall also be submitted to the JSC.  If the JSC cannot agree on such proposed Development Plan within [***], then such dispute shall be resolved in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. The proposed Development Plan (including the initial Development Budget that is part of the Development Plan) will go into effect once approved by the JSC in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Once approved by the JSC, the Parties shall conduct Development activities under the Development Plan in accordance with this Agreement.  All such Development activities shall be conducted under the supervision of the JRDC, as applicable and in accordance with the approved Development Plan.  Activities of a Party&#x2019;s Affiliates, licensees or Sublicensees shall be considered activities of such Party for purposes of this Agreement.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.1.3	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Following approval by the JSC of the initial Development Plan (including the associated Development Budget) for a Collaboration Program in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.1.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, such Development Plan shall be updated or amended as follows:</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	the JRDC [***] and the JMC (with respect to the Manufacturing Plan included in the Development Plan) shall review each Development Plan not less frequently than [***] and the Lead Party shall prepare [***] Development Plan updates, which shall include, as applicable, updates to the existing Development Budget, including to provide for the Development Budget for the [***] for the particular Collaboration Program.  The Lead Party shall submit all such updates to the JRDC [***] and to the JMC (with respect to the Manufacturing Plan included in the Development Plan) for review and approval no later than [***] and the JRDC and the JMC shall submit such updated Development Plan to the JSC for review and approval.  If the JSC cannot agree on such proposed updated Development Plan within [***], then such dispute</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">56</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">shall be resolved in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Upon the JSC&#x2019;s preliminary approval, such updates shall be submitted to each Party for its internal budgeting process with a target for final approval no later than [***], at which time any such approved updates shall be appended to the Development Plan, provided that, [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	The Lead Party may also develop and submit to the JRDC [***] and JMC (if applicable) from time to time other proposed amendments to the Development Plan, which the JRDC [***] and/or the JMC (as applicable) will review and approve. The JRDC or the JMC (with respect to the Manufacturing Plan included in the Development Plan) shall submit all [***] amendments to the Development Plan [***] to the JSC for review and approval and, if the JRDC or JMC, as applicable, cannot agree with respect to any matter in any other proposed amendments to the Development Plan within [***], the JRDC or JMC shall submit such amendments to the JSC for review and approval. If the JSC cannot agree on such proposed amendments to the Development Plan within [***], then such dispute shall be resolved in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Proposed amendments to the Development Plan shall not go into effect until approved by the JRDC or the JMC (with respect to the Manufacturing Plan included in the Development Plan) or, if applicable, the JSC, at which time such approved amendments shall be appended to the Development Plan.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	For clarity, when providing the JRDC with information regarding the projected Development Budget anticipated to be expended under a particular Collaboration Program, the Lead Party shall provide to the JRDC the level and quality of information that the Parties have agreed through the Financial Working Group, which level and quality of information shall be agreed to by the Financial Working Group within [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.1.4	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Development Plan may include [***], in each case, solely if the Parties mutually agree to include such product in the applicable Development Plan or an amendment to such Development Plan (each agreed product, an &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Additional Products</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  For clarity, with respect to any portion of an Additional Product that is [***] the Development Plan for such Additional Product.  [***].  The Development Plan may also include [***] the Development and Commercialization of Collaboration Products, for which the Parties will mutually agree on any Development activities associated therewith.  For clarity, unless otherwise agreed by the Parties, the sharing of Development Costs applicable to [***] such Development Plan.  If the Parties agree to include in the Collaboration</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">an Additional Product that is [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.2	Development Efforts</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;7.2	Development Efforts&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Each Party shall use its Commercially Reasonable Efforts to (a) perform the obligations assigned to it under each Development Plan, and (b) enable GSK to seek and obtain Regulatory Approval for any Collaboration Product progressed thereunder in the United States, the European Union, and the United Kingdom.  Each Party shall conduct its Development activities in good scientific manner and in compliance with all applicable Law, including Laws regarding the environment, safety and industrial hygiene, and GMP, GLP, GCP, informed consent and Institutional Review Board regulations, current standards for pharmacovigilance practice, and all applicable requirements relating to the protection of human subjects.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.3	Development Records; Exchange of Information</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;7.3	Development Records; Exchange of Information&#34; \f C \l &#34;2&#34; </font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">57</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.3.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Each Party shall maintain, in good scientific manner, complete and accurate books and records pertaining to its activities under each Development Plan, in sufficient detail to verify compliance with its obligations under this Agreement and which books and records shall (a) be appropriate for Patent and regulatory purposes, (b) be kept and maintained in compliance with applicable Law, (c) properly reflect all work done and results achieved in the performance of its activities hereunder and (d) record only such activities and not include or be commingled with records of activities outside the scope of this Agreement (such books and records, &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Program Records</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  As part of keeping the Program Records, each Party shall maintain records in sufficient detail as will properly reflect all work done, in the performance of activities arising out of, in conducting, or otherwise in connection with the Development Plan. Program Records specifically related to a Collaboration Product shall be retained by the applicable Party for at least [***] after the expiration or termination of the applicable Collaboration Program with respect to such Collaboration Product, or for such longer period as may be required by applicable Law. The JRDC shall have the right, during normal business hours and upon reasonable notice, to inspect and copy all Program Records kept by a Party, which inspection will not be more than once per Calendar Year, unless for quality or safety issues.  Each Party shall provide the JRDC with detailed reports relating to its activities under each Collaboration Program each Calendar Quarter for the applicable Collaboration Program.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.3.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">With respect to any Collaboration Program, within [***] of each year, each Party shall prepare and provide to the other Party a written report that summarizes the Development activities (including Manufacturing-related development activities) performed and the status of activities and progress with respect to the information included the Development Plan, [***].  The Parties may agree that minutes or presentations from Committee meetings may be used to satisfy this reporting requirement.  Each Party shall have the right to review all reports related to any Clinical Studies for a Collaboration Product, whether such reports are generated by or on behalf of GSK, Vir or a CRO or subcontractor, provided that such Party has not exercised its Opt-Out Option.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.4	Performance by Affiliates; Subcontracting</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;7.4	Performance by Affiliates; Subcontracting&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.4.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Each Party conducting any Development activities under each Development Plan shall have the right to subcontract any of the activities assigned to it under any Development Plan to any of its Affiliates without further approval of the JRDC or the other Party; provided that no such permitted subcontracting shall relieve the subcontracting Party of any obligation hereunder and the subcontracting Party shall cause its permitted subcontractors to comply with its applicable obligations under this Agreement.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.4.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.4.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, each Party conducting any Development activities under each Development Plan may subcontract any of the activities assigned to it under any Development Plan to a Third Party subcontractor, including clinical research organizations (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">CROs</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), contract manufacturing organizations, subject to the following terms and conditions: (a) any such subcontracting to a Third Party shall be approved by the JRDC; (b)&#160;none of the rights of the other Party hereunder are diminished or otherwise adversely affected as a result of such subcontract; (c) such Third Party subcontractor shall be bound by a written agreement that is consistent with terms and conditions of this Agreement, including applicable confidentiality,</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">58</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">publication and intellectual property ownership and assignment provisions; and (d) such Party shall remain responsible under this Agreement for ensuring, and shall be liable to the other Party for, the compliance of such Third Party subcontractor with this Agreement. Notwithstanding the foregoing, at the time of preparation of the Development Plan for a given Collaboration Product, where reasonably practicable, the Parties will discuss through the JRDC and agree upon any Third Party subcontractors that the Non-Lead Party anticipates it may wish to use to perform activities for or on behalf of such Non-Lead Party.  Such pre-approved Third Party subcontractors will be listed in the Development Plan, and, no separate approval by the JRDC shall be required for the Non-Lead Party to use such Third Parties to perform activities with respect to any Collaboration Product under the same Collaboration Program. [***].</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.4.3	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Notwithstanding </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.4.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.4.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, the Parties agree that [***], provided that for clarity, (a) [***], and (b) [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.5	Clinical Studies</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;7.5	Clinical Studies&#34; \f C \l &#34;2&#34; .</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.5.1	Generally</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. All Clinical Studies of the Collaboration Products conducted by the applicable Party shall be conducted only pursuant to this Agreement and the applicable Development Plan.  Any Clinical Studies of the Collaboration Product will be conducted in accordance with the Applicable Internal Policies and GCP standards and involve investigators of recognized competence.  If agreed to by the Parties in writing or approved by the JRDC, or if a Party has a reasonable basis to believe a violation of applicable Law has occurred with respect to a given Clinical Study, each Party shall have the right, at its own expense and subject to the terms and conditions of any applicable agreements, to audit all Clinical Study sites used by the other Party, and have all other audit rights to ensure that any necessary compliance standards are upheld.  Such audit shall be made at reasonable times during regular business hours and upon [***] prior notice to such other Party and the Clinical Study site.  Summaries of results of all Clinical Studies conducted by either Party with respect to any Collaboration Product shall be published on GSK&#x2019;s clinical trial register, unless GSK has exercised its Opt-Out Option and is not conducting or funding any activity with regard to the applicable Collaboration Program.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.5.2	Investigator-Initiated Studies</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. The Lead Party shall determine, and the Development Plan shall set forth any sponsorship of investigator-initiated studies of the Collaboration Products.  All sponsorship of such investigator-initiated studies shall be subject to approval by the JRDC or, where applicable, the JSC.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.5.3	Clinical Study Protocol</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. All Clinical Studies conducted under a Development Plan will first be approved in concept by the JRDC.  For any Clinical Studies that are to be conducted solely by a Party (including through an affiliated entity or a subsidiary) or its contractors, the protocol and related investigator&#x2019;s brochures shall be designed by such Party in accordance with the approved Development Plan with review and input from the other Party within [***] after submission to the JRDC of the draft protocol; provided, that if the other Party identifies a material issue in the protocol, it may refer the issue to the JRDC for revision.  Except as otherwise specified in the applicable Development Plan, the Lead Party will secure any required approvals from any Institutional Review Boards, safety boards or the like.  Notwithstanding the foregoing, the Party conducting the Clinical Study may make modifications to the protocol on an emergency</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">59</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">basis for patient safety reasons and in such case, shall notify the JRDC and the other Party as promptly as practical.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.6	Rights to Opt-Out</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;7.6	Rights to Opt-Out&#34; \f C \l &#34;2&#34; .</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.6.1	Opt-Out Points</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  On a Collaboration Product-by-Collaboration Product basis with respect to the Influenza Program and each Additional Pathogen Program, and on an Expanded Functional Genomics Target-by-Expanded Functional Genomics Target basis with respect to the Expanded Functional Genomics Program, each Party (whether the Lead Party or the Non-Lead Party, such Party, an &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Opt-Out Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) will have the one-time right to elect, pursuant to the procedures set forth in this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> to cease funding its share of the Development Costs for a Collaboration Product (in the case of the Influenza Program and Additional Pathogen Programs), or all Collaboration Products directed to an Expanded Functional Genomics Target (in the case of Expanded Functional Genomics Program) in all indications (unless the Parties mutually agree otherwise) (each, an &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Opt-Out Option</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), as further provided in this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	With respect to each Collaboration Product in the Influenza Program or an Additional Pathogen Program, either Party may exercise its Opt-Out Option by providing the required written notice (an &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Opt-Out Notice</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to the other Party on or prior to each of the following milestone events (collectively, the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Opt-Out Points</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;):</font></p>
  <p style="margin-left:26.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">For clarity, with respect to the Influenza Product containing Vir-2482, if GSK exercises the Option pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	With respect to each Expanded Functional Genomics Target in the Expanded Functional Genomics Program,</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	if, [***], then, without limiting [***], Vir shall [***] with respect to [***]; and</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii)	either Party may exercise its Opt-Out Option with respect to an Expanded Functional Genomics Target by providing the Opt-Out Notice to the other Party on or prior to each of the following Opt-Out Points: [***].</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.6.2	Share of Data and Materials</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Within [***] for a Collaboration Product, the Lead Party (and the Non-Lead Party if applicable) conducting Development activities with respect to such Collaboration Product shall submit to the JRDC a summary of the [***] derived from the Development activities conducted by such Party for such Collaboration Product from last Opt-Out Point (if any) to such Opt-Out Point (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Development Summary</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;). The Development Summary shall include, where applicable, [***].  Following presentation and discussion between the Parties, and within [***] after submission of the Development Summary to the JRDC, [***] shall be provided by the Party conducting the Development activities upon reasonable request by the other Party, provided that [***].  For clarity, this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall apply with respect to [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">60</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.6.3	Exercise of Opt-Out Option</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	Except with respect to the Target-Selection Opt-Out Option, either Party may exercise an Opt-Out Option by delivering an Opt-Out Notice at any time prior to, and no later than [***] following the receipt of the Development Summary by the JRDC with respect to the applicable Collaboration Product [***].  Except with respect to the Target-Selection Opt-Out Option, the Opt-Out Option shall be deemed to be exercised upon (i) [***], or (ii) [***] (such date in (i)&#160;or (ii), the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Opt-Out Effective Date</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	[***] may exercise the [***] by providing the Opt-Out Notice within [***] following the applicable [***], and the date of delivery of such Opt-Out Notice shall be deemed as the Opt-Out Effective Date with respect to such [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	If a Party exercises an Opt-Out Option with respect to a Collaboration Product (in the case of the Influenza Program or the Additional Pathogen Programs) or all Collaboration Products directed to an Expanded Functional Genomics Target (in the case of the Expanded Functional Genomics Program), in each case, in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6.3(a)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, or, where applicable, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6.3(b),</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> then:</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:32.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	The Opt-Out Party shall be responsible for [***], in each case, [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:32.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii)	Notwithstanding the foregoing, an Opt-Out Party delivering [***] shall not be liable for any [***].  For clarity, [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:32.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iii)	The Opt-Out Party shall also be responsible for [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:32.507%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iv)	if such exercised Opt-Out Option is with respect to an Expanded Functional Genomics Target (including, with respect to Vir, the Target-Selection Opt-Out Option) under the Expanded Functional Genomics Program, and at the time such Party opts out, [***], then unless the Parties mutually agree otherwise, exercise of such Opt-Out Option shall apply to [***]. Subject to the foregoing, after a Party exercises the Opt-Out Option with respect to an Expanded Functional Genomics Target, such Opt-Out Party shall have the right, either alone or via an Affiliate or partnering with a Third Party, to develop programs and exploit products and compounds directed to such Target outside the Collaboration provided that (A) such Party shall not use the Collaboration Screening Data to initiate or conduct such programs, and (B) [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	If a Party does not elect to exercise its Opt-Out Option at one of the above Opt-Out Points within the specified time periods in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6.3(a), </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">or, where applicable, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6.3(b)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, it will be obligated to continue to fund all Development Costs for such Collaboration Product(s) in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, until such time as the next Opt-Out Point becomes available, if any; [***] existing at the time the Opt-Out Notice or Early Opt-Out Notice is delivered.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.6.4	Parties&#x2019; Rights after Opt-Out</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	Upon receipt of any Opt-Out Notice timely delivered by the Opt-Out Party in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> with respect to a Collaboration Product (in the</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">61</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">case of the Influenza Program or the Additional Pathogen Programs) or all Collaboration Products directed to an Expanded Functional Genomics Target (in the case of the Expanded Functional Genomics Program), the other Party (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Non Opt-Out Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) shall have the right, at any time after the Opt-Out Effective Date with respect to such Collaboration Product(s), as applicable, to elect either to (i) continue with the Development and Commercialization of such Collaboration Product(s), at its own cost; or (ii) subject to the remainder of this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, cease bearing Development Costs for future Development activities with respect to such Collaboration Product(s), in which case the Non Opt-Out Party may wind down the Development activities with respect to such Collaboration Product(s), or (iii) subject to the Opt-Out Party&#x2019;s agreement, propose to out-license or otherwise divest such Collaboration Product(s).  After the Opt-Out Party exercises its Opt-Out Option with respect to any Collaboration Product(s), the Non Opt-Out Party shall notify the Opt-Out Party of its decision to elect subsection (i), (ii) or (iii) in the foregoing within [***] following the Opt-Out Effective Date for such Collaboration Product(s) (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Non Opt-Out Notice</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), provided that, [***], the election by the Non Opt-Out Party of subsections (i), (ii) or (iii) in the Non Opt-Out Notice shall not [***].  The Opt-Out Party shall, upon reasonable request by the Non Opt-Out Party, discuss with the Non Opt-Out Party in good faith, and cooperate to facilitate its decision-making, including by [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	If, after the Opt-Out Party exercises its Opt-Out Option with respect to a Collaboration Product (in the case of the Influenza Program or the Additional Pathogen Programs) or all Collaboration Products directed to an Expanded Functional Genomics Target (in the case of the Expanded Functional Genomics Program), the Non Opt-Out Party elects to continue with the Development and Commercialization of such Collaboration Product(s) (which shall thereafter become Sole Development Product(s) and cease being Collaboration Product(s)), then:</font></p>
  <p style="margin-left:46.667%;text-indent:64.075%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	the Opt-Out Party&#x2019;s rights to share any Pre-Tax Profit or Loss in such Collaboration Product(s) pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall cease upon receipt of the Non Opt-Out Notice and the Opt-Out Party shall be entitled to receive royalties from the Non Opt-Out Party on Net Sales of such Sole Development Product(s) in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.8</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, as applicable;</font></p>
  <p style="margin-left:46.667%;text-indent:64.075%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii)	the Non Opt-Out Party shall continue to [***] to perform such activities with respect to such Sole Development Product(s), similar to the Commercially Reasonable Efforts used with respect to the corresponding Collaboration Product prior the Opt-Out Party opting out and taking into the account the fact that the Non Opt-Out Party will be solely funding the Development,</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">62</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:46.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Manufacture and Commercialization of such Sole Development Product;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:46.667%;text-indent:64.075%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iii)	the Opt-Out Party shall, subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 12.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, provide reasonable assistance requested by the Non Opt-Out Party to (A) transfer or transition to the Non Opt-Out Party (or wind down, if applicable) all activities for which such Opt-Out Party was responsible prior to the exercise of the Opt-Out Option, including [***]; (B) transfer to the Non Opt-Out Party relevant Data, information and materials [***], in each case ((A) or (B)), to the extent necessary for the Non Opt-Out Party&#x2019;s continued conduct of Development, Manufacturing and Commercialization of such Sole Development Product(s), [***];</font></p>
  <p style="margin-left:46.667%;text-indent:64.075%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iv)	with respect to [***], the Opt-Out Party shall, at the Non Opt-Out Party&#x2019;s request and [***], if the Opt-Out Party is required to [***] with respect to the Development, Manufacture and Commercialization of any Sole Development Product(s), then [***]; and</font></p>
  <p style="margin-left:46.667%;text-indent:64.075%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">(v)	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">the JRDC, the JSC or other Committees shall no longer have authority over such Sole Development Product(s), and the applicable Development Plan and Development Budget will be of no further effect with respect to such Sole Development Product other than with respect to costs incurred prior to the Opt-Out Effective Date.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	If, after the Opt-Out Party exercises its Opt-Out Option with respect to a Collaboration Product (in the case of the Influenza Program or the Additional Pathogen Programs) or all Collaboration Products directed to an Expanded Functional Genomics Target (in the case of the Expanded Functional Genomics Program), the Non Opt-Out Party elects, [***], to cease and wind down the Development activities with respect to such Collaboration Product(s), the Non Opt-Out Party shall conduct winding down activities in accordance with all applicable Law, and the Opt-Out Party shall, upon Non Opt-Out Party&#x2019;s reasonable request, provide reasonable assistance with such winding down activities.  [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">63</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	If, after the Opt-Out Party exercises its Opt-Out Option with respect to a Collaboration Product (in the case of the Influenza Program or the Additional Pathogen Programs) or all Collaboration Products directed to an Expanded Functional Genomics Target (in the case of the Expanded Functional Genomics Program), (i) the Non Opt-Out Party elects to, [***], or (ii) [***], and the Non Opt-Out Party elects to, [***], in either case ((i) or (ii)), cease any further funding of, or Development or Commercialization activities with respect to such Collaboration Product(s), and out-license or otherwise divest such Collaboration Product(s), then (A) [***], (B) [***], and (C) [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)	If, after the Opt-Out Party exercises its Opt-Out Option with respect to a Collaboration Product (in the case of the Influenza Program or the Additional Pathogen Programs) or all Collaboration Products directed to an Expanded Functional Genomics Target (in the case of the Expanded Functional Genomics Program), (i) the Non Opt-Out Party elects to, at any time [***], cease any further funding of, or Development or Commercialization activities with respect to such Sole Development Product(s), and out-license or otherwise divest such Sole Development Product(s), and (ii) [***], then (A) [***], (B) [***], and (C) [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">     </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">7.6.5	Animal Welfare</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  With respect to any Development activities conducted by either Party under this Agreement that involve the use of animals, including any animal studies, such Party agrees to comply with the terms of </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 7.6.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  For the avoidance of doubt, during the Term, [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 8<br>Regulatory Activities TC &#34;ARTICLE 8	REGULATORY ACTIVITIES&#34; \f C \l &#34;1&#34;</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">8.1	Generally</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;8.1	Generally&#34; \f C \l &#34;2&#34; .  Generally, the Parties will discuss and seek to agree upon the appropriate regulatory strategy for each Collaboration Product.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">8.2	Meetings and Communications</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;8.2	Meetings and Communications&#34; \f C \l &#34;2&#34; .  During the Term, each Party shall keep the other Party reasonably informed of any material communications from, or meetings with, any Regulatory Authority pertaining to such Party&#x2019;s Development activities performed under this Agreement.  To the extent relating to a Collaboration Product, the Party that is the regulatory sponsor or, following the release of headline data of the relevant Clinical Study, the applicant for the Drug Approval Application with respect to such Collaboration Product, shall provide the other Party with: (a) to the extent allowable by applicable Laws and the relevant Regulatory Authority and to the extent practicable, an opportunity to have one or more of its representatives attend and observe [***] in substantive discussions and meetings with the FDA or any other Regulatory Authority with respect to any Clinical Studies or other matters (e.g., CMC or non-clinical issues); (b) a copy of any material documents, reports or correspondence submitted to the FDA or any other Regulatory Authority; and (c) reasonable advanced notice (to the extent practicable) of substantive meetings, scheduled or unscheduled, with the FDA or any other Regulatory Authority.  All such documents or reports described in subclause (b) above shall be provided to the JRDC at least [***] prior to their submission to the applicable Regulatory Authority (or such later date as the Parties may reasonably agree).  To the extent a Party receives material written or oral communications from the FDA or any other Regulatory Authority relating to a Collaboration Product or activities under this</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">64</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Agreement with respect to a Collaboration Product, such Party shall notify the other Party and provide a copy of any such written communications to the other Party [***]. In addition, upon a reasonable request from the other Party, each Party shall provide copies of other documents, reports or communications from or to Regulatory Authorities relating to Collaboration Products.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">8.3	Regulatory Submissions</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;8.3	Regulatory Submissions&#34; \f C \l &#34;2&#34; .</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">8.3.1	Regulatory Filings</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. For each Collaboration Product, the Lead Party (and the LCP) for such Collaboration Product shall, in its own name, obtain and maintain all Regulatory Filings and Regulatory Approvals for Development, Manufacture and Commercialization of such Collaboration Products, including INDs, NDAs, BLAs, Regulatory Approvals for product labeling or promotional materials and other items filed with the FDA or other Regulatory Authorities with respect to any Collaboration Product under such Collaboration Program, provided that, with respect to Vir-2482, if GSK exercises the Option pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, then, within [***], Vir shall assign to GSK, with no additional costs, all Regulatory Filings relating to Vir-2482 Controlled by Vir as of the Vir-2482 Program Effective Date, including the IND, and thereafter, GSK, as the Lead Party, shall be responsible for obtaining and maintaining all Regulatory Filings and Regulatory Approvals for Vir-2482.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">8.3.2	Other Filings</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Parties may discuss, through the JPC, regarding submission of patent information to the FDA as required for listing in the Orange Book (as required by 21 C.F.R. &#167;214.53 (d)(2) and 35 U.S.C. &#167;156 (Hatch-Waxman Act)), the &#x201c;Purple Book&#x201d; (or other Orange Book-equivalent database or listing for Biologics), or any foreign equivalents thereof, provided that the LCP shall have the decision-making authority and shall be responsible for such submission.  Additionally, the LCP shall be responsible for all acts required of the reference product sponsor under the US Biologicals Price Competition and Innovation Act of 2009 (42 U.S.C. &#167; 262) (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Biologics Act</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), or any foreign equivalents thereof.  The Lead Party for each Collaboration Product will control all of the actions, filings, and communications with any follow-on biologic applicant under the Biologics Act with respect to such Collaboration Product, including generating the following documents: [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">8.4	Exchange of Development Data</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;8.4	Exchange of Development Data&#34; \f C \l &#34;2&#34; . Without limiting the other provisions of this Agreement, at the request of the Lead Party, or upon direction by the JSC or JRDC, the Non-Lead Party shall provide to the Lead Party [***] pertinent Data developed by or on behalf of the Non-Lead Party, as applicable, in connection with the Development of a Collaboration Product this Agreement or the performance of other activities under the applicable Development Plans [***] for the Lead Party to satisfy Regulatory Approval requirements for application or maintenance of Regulatory Approvals of such Collaboration Product. The format of, and media for exchanging, such Data shall be decided by the JRDC.  Each Party shall have the right, without obtaining the approval of the other Party and without additional payment to such other Party (other than payments expressly provided in this Agreement), to reference, access and use such Data, and all reports, documents and other information developed by any Party that is derived from such Data, (a) for purposes of preparing and submitting INDs, NDAs, BLAs and other Regulatory Filings for the Collaboration Products in the applicable Collaboration Program,</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">and (b) preparing and filing patent applications, in each case ((a) and (b)) in accordance with this Agreement, and, with respect to such Data, reports,</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">65</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">documents and other information developed by the other Party, solely to the extent permitted under this Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">8.5	Lead Party Opt-Out</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;8.5	Lead Party Opt-Out&#34; \f C \l &#34;2&#34; .  If the Lead Party exercises its Opt-Out Option with respect to any Collaboration Product(s) pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, and the Non-Lead Party elects to continue with the Development and Commercialization of such Collaboration Product(s) as Sole Development Product(s), then the Non-Lead Party shall notify the Lead Party in writing of such election, and thereafter shall be solely responsible for any Regulatory Filing or other regulatory activities with respect to such product.  The Lead Party shall, upon reasonable request of the Non-Lead Party and to the extent permissible under applicable Law, transfer all regulatory documentation, including any Regulatory Filing or Regulatory Approval for such product Controlled by such Lead Party to the Non-Lead Party, and the Parties shall share the cost of such regulatory transfer in accordance with the profit-share percentages set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, as applicable.  To the extent that such regulatory transfer is not permissible under applicable Law, the Parties shall discuss in good faith, and agree on a regulatory strategy to maintain such regulatory documentation for such Collaboration Product.</font><font style="color:rgba(0,0,0,1);font-weight:normal;vertical-align:top;font-size:8.04pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 9<br>Commercialization TC &#34;ARTICLE 9	COMMERCIALIZATION&#34; \f C \l &#34;1&#34;</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">9.1	General</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;9.1	General&#34; \f C \l &#34;2&#34; .  Subject to the remainder of this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 9</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, GSK shall be the LCP for each Collaboration Product, and GSK or its Affiliates shall have the sole right and responsibility for (a) Commercializing all Collaboration Products in the Territory, including [***]; and (b) all decisions for all Commercialization activities relating to each Collaboration Product, including [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">9.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***] TC &#34;9.2	Commercialization Budget Caps&#34; \f C \l &#34;2&#34; .  With respect to each Collaboration Product, [***], GSK will propose to Vir a good faith estimate of the [***].  If Vir [***] considers, [***], that [***], and the Parties are unable to agree on the [***], then Vir shall [***].  At the time GSK provides the initial Commercialization Plan (and Commercialization Budget) for such Collaboration Product to the JCC pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 9.3.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, the Parties shall [***], which shall be equal to [***].  The remainder of [***] associated with activities under the applicable Commercialization Plan (and in connection with any subsequent amended Commercialization Plan and Commercialization Budget) that [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">9.3	Commercialization Plan</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;9.3	Commercialization Plan&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">9.3.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">With respect to each Collaboration Product, in connection with the determination to file the first Drug Approval Application for such Collaboration Product, GSK shall prepare and provide to the JCC a commercialization plan (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Commercialization Plan</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) for such Collaboration Product. GSK shall provide the initial Commercialization Plan for each Collaboration Product to the JCC [***].  Each such initial Commercialization Plan shall include, (a) [***]; (b) [***]; (c) [***]; (d) [***]; and (e) [***].  With respect to the initial Commercialization Plan (including the associated Commercialization Budget) for each Collaboration Product, the JCC shall review and approve such Commercialization Plan and shall submit such Commercialization Plan to the JSC for the JSC to review and approve, except that the JMC shall review and approve the Manufacturing Plan (and associated budget) included in the</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">66</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">initial Commercialization Plan prior to submission to the JSC for review and approval.  If the JSC cannot agree on the Commercialization Plan submitted by the JCC or the JMC [***], then such dispute shall be resolved in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">9.3.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">GSK shall prepare and submit to the JCC for review and approval, on an annual basis, any material changes to each Commercialization Plan, including any updates to the Commercialization Budget for each Collaboration Product, no later than [***] of each Calendar Year.  With respect to the Commercialization Plan (including the associated Commercialization Budget) for each Collaboration Product, the JCC and the JMC (with respect to the Manufacturing Plan included in the Development Plan) shall review and approve such annual updates and shall submit such updates to the JSC for review and approval.  If the JSC cannot agree on such updates submitted by the JCC or the JMC [***], then such dispute shall be resolved in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Upon the JSC&#x2019;s preliminary approval, such updates shall be submitted to each Party for its internal budgeting process with a target for final approval no later than [***], at which time any such approved update shall be appended to the Commercialization Plan for the applicable Collaboration Product, provided that, [***].  Any material updates to the Commercialization Plans, including any updates to the associated Commercialization Budgets, for each Collaboration Product shall not be effective without the approval of the JSC, subject to the terms and conditions of </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;3.9</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">9.4	Commercialization Efforts</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;9.4	Commercialization Efforts&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The LCP, by itself or through its Affiliates or Sublicensees, shall, following the receipt of Regulatory Approval for each Collaboration Product by the applicable Regulatory Authority in the applicable jurisdiction, use Commercially Reasonable Efforts to seek pricing and reimbursement approvals for and Commercialize such Collaboration Product in accordance with the Commercialization Plan in the United States, [***] and the United Kingdom (each, a &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Major Market</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  With respect to any Collaboration Product, the LCP shall be responsible for and have the exclusive right to seek and attempt to obtain pricing and reimbursement approvals for each Collaboration Product.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">9.5	Right to Subcontract Commercialization Activities; Distribution</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;9.5	Right to Subcontract Commercialization Activities; Distribution&#34; \f C \l &#34;2&#34; .  GSK shall have the right to (sub) contract, license or sublicense to its Affiliates or Third Parties with respect to the performance of any or all of its Commercialization activities.  GSK and its Affiliates shall book all sales of Collaboration Products and [***]. Vir and its Affiliates shall not accept orders for any Collaboration Products or sell any Collaboration Products for its or their own account or for GSK&#x2019;s or its Affiliate&#x2019;s account, and if Vir or its Affiliates receive any order for Collaboration Products in the Territory, they shall refer such orders to GSK or its designated Affiliate(s) for acceptance or rejection.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">9.6	Commercialization Reports</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;9.6	Commercialization Reports&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> GSK shall provide a written report to the JCC describing material Commercialization activities with respect to all Collaboration Products Commercialized by GSK or any of its Affiliates, Sublicensees or distributors [***]. Such reports shall include [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">9.7	GSK Opt-Out</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;9.7	GSK Opt-Out&#34; \f C \l &#34;2&#34; .  If GSK exercises its Opt-Out Option with respect to a Collaboration Product pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, and if Vir, as the</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">67</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Non Opt-Out Party, elects to continue with Commercialization of such Collaboration Product, then, notwithstanding anything to the contrary in this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 9</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, Vir shall be the LCP for the Sole Development Product(s) corresponding to such Collaboration Product(s), and the rights and obligations of GSK set forth in this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 9</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, shall apply to Vir </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">mutatis mutandis</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 10<br>Pharmacovigilance and Medical Affairs TC &#34;ARTICLE 10	PHARMACOVIGILANCE AND MEDICAL AFFAIRS&#34; \f C \l &#34;1&#34;</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">10.1	Pharmacovigilance Technical Agreement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;10.1	Pharmacovigilance Technical Agreement&#34; \f C \l &#34;2&#34; .  For each Collaboration Product the Parties shall enter into, no later than such date as required to comply with applicable Law, an appropriate agreement setting forth the processes and procedures for the collection, management, assessment and reporting of Adverse Event with respect to such Collaboration Product and [***] (each, a &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Pharmacovigilance Technical Agreement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), which shall include the terms set forth on </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 10.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  For clarity, this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 10.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall not apply with respect to Vir-2482 unless and until GSK exercises the Option pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">10.2	Costs</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;10.2	Costs&#34; \f C \l &#34;2&#34; .  The incremental portion of the Parties&#x2019; costs and expenses incurred in maintaining the databases described in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 10.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> attributable to the Collaboration Product and the Parties&#x2019; costs and expenses incurred in conducting audits pursuant to a Pharmacovigilance Technical Agreement shall [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">10.3	Medical Inquiries</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;10.3	Medical Inquiries&#34; \f C \l &#34;2&#34; .  The Lead Party for a Collaboration Product shall handle all medical questions or inquiries from members of the medical profession for such Collaboration Product.  In the event a Non-Lead Party receives any medical questions or inquiries, the Non-Lead Party shall refer the question or inquiry to the Lead Party within [***] of receipt (or such other timeframe as the Parties may agree in writing) in accordance with the relevant policies of the Lead Party as provided to the Non-Lead Party from time to time.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 11<br>Financial Provisions TC &#34;ARTICLE 11	FINANCIAL PROVISIONS&#34; \f C \l &#34;1&#34;</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.1	Upfront Payment</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;11.1	Upfront Payment&#34; \f C \l &#34;2&#34; .  In partial consideration of the rights granted by Vir to GSK hereunder, and subject to the terms and conditions of this Agreement, GSK shall pay Vir a one-time upfront payment of $225 Million USD ($225,000,000) as follows: (a) if not already paid by GSK, $112.5 Million USD ($112,500,000) shall be payable within [***]; and (b) $112.5 Million USD ($112,500,000) shall be payable within [***]e; provided that, in each case ((a) and (b)), [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.2	Option Exercise Fee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;11.2	Option Exercise Fee&#34; \f C \l &#34;2&#34; .  Subject to the terms and conditions of this Agreement, if GSK elects to exercise the Option, then following the Vir-2482 Program Effective Date, GSK shall pay Vir a one-time option exercise fee (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Option Exercise Fee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">68</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.2.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If, at the time GSK exercises the Option in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, Vir-2482 has satisfied the Influenza Product Criteria, the Option Exercise Fee shall be $300 Million USD ($300,000,000);</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.2.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If, at the time GSK exercises the Option in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, Vir-2482 has not satisfied the Influenza Product Criteria, then the Parties will negotiate in good faith for a period of [***] to agree upon the applicable Option Exercise Fee.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	If the Parties agree the Option Exercise Fee within such [***] period, then the Vir-2482 Program Effective Date shall be the date on which such agreement is made, or, if any antitrust approvals in connection with exercise of such Option are required, on the date on which all such approvals have been obtained.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	If the Parties are unable to agree within such [***] period, then it will be deemed that GSK has withdrawn its Option exercise, and there shall be no Option Exercise Fee payable by GSK, in which case, Vir may continue the Development and Commercialization of Vir-2482, alone, via an Affiliate or in partnership with a Third Party, without further obligation to GSK, provided that if, [***], Vir [***].  If GSK [***], then [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.2.3	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.3	Milestone Payments</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;11.3	Milestone Payments&#34; \f C \l &#34;2&#34; .</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.3.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.3.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, GSK will pay Vir a one-time milestone payment of $200 Million USD ($200,000,000) upon [***] (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Milestone Payment</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;). GSK shall make the Milestone Payment (or where applicable pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.3.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, each applicable milestone payment) in accordance with [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.3.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If [***], then instead of the Milestone Payment, GSK will pay to Vir a milestone payment determined as follows, but in no event shall such payment exceed $200 Million USD:</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	The Parties shall negotiate in good faith at the time of [***], the amount of the applicable milestone to be paid for such Influenza Product under this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.3.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  If the Parties cannot agree on the amount of such milestone payment within [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	If GSK [***], and subsequently, another Vir Influenza mAb [***], then GSK shall [***] $200 Million USD.</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">    </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.3.3	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If [***], then, [***] GSK will [***].</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.3.4	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The maximum aggregate amount payable by GSK under </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.3.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.3.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.3.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall not exceed $200 Million.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.4	Development Costs</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;11.4	Development Costs&#34; \f C \l &#34;2&#34; .  Unless otherwise agreed by the Parties in writing with respect to a Party Asset contributed by a Party at its sole discretion in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, prior to a Party exercising its Opt-Out Option with respect to a Collaboration Product or Expanded Functional Genomics Target under a</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">69</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Collaboration Program, or thereafter as required by </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, as applicable, the Parties will share equally (50%/50%) all Development Costs associated with activities under the applicable Development Plan for such Collaboration Program, in accordance with the existing Development Budget therefor. The calculation of the Development Costs shall be in accordance with the provisions set out in the Financial Schedule attached hereto.  Any Development Costs incurred in excess of the agreed upon Development Budget (including any Permitted Overage and Excess Costs) in a Collaboration Program will be subject to the terms set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.7</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.5	Profit/Loss Sharing</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;11.5	Profit/Loss Sharing&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Unless otherwise agreed by the Parties in writing with respect to a Party Asset contributed by a Party at its sole discretion in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, and subject to either Party becoming an Opt-Out Party pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> in respect of a particular Collaboration Product or Expanded Functional Genomics Target, as applicable, [***], share equally (50%/50%) all Pre-Tax Profit or Loss for each Collaboration Product in a particular Collaboration Program in the Territory. The calculation of the Pre-Tax Profit or Loss shall be in accordance with the provisions set out in the Financial Schedule.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.6	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***] TC &#34;11.6	Adjustment of Actual Profits &#34; \f C \l &#34;2&#34; . If, with respect to any Collaboration Product, the JSC cannot agree [***], then the following shall apply [***]:</font></p>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.7	Reconciliation Procedures</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;11.7	Reconciliation Procedures&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.7.1	Reporting</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Reporting Generally</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. On a Collaboration Product-by-Collaboration Product basis, within [***], each Party shall provide to the Financial Working Group a report of its actual Development Costs incurred with respect to such Collaboration Product for such [***] and, beginning with the first [***] in which the First Commercial Sale of such Collaboration Product occurs, a report of its calculation of actual Pre-Tax Profit or Loss with respect to such Collaboration Product for such [***] (each, a &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Financial Report</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), [***] in accordance with its Accounting Standards; </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">provided</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that the Financial Report of a Party&#x2019;s calculation of Pre-Tax Profit or Loss for the [***] in which the First Commercial Sale of a Collaboration Product occurs will include any Allowable Expenses incurred by such Party with respect to such Collaboration Product prior to such [***]. Each Financial Report shall specify in reasonable detail, as applicable, [***] for such Collaboration Product in the corresponding [***] received and incurred by the reporting Party or any of its Affiliates or (sub)licensees in accordance with this Agreement in such [***].  [***].</font></p>
  <p style="text-indent:28.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Net Sales Reporting</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Without limiting the generality of </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.7.1(a)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, within [***] after the end of each [***], beginning with the first Calendar Quarter in which the First Commercial Sale of such Collaboration Product occurs, GSK shall provide the Financial Working Group with a report of the Net Sales for the preceding [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:28.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	[***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">70</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:28.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	[***].</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)	</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir Reporting</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. In the event that GSK exercises its Opt-Out Option with respect to a Collaboration Product pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, the reporting obligations that GSK is subject to as set out in this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.7.1(a)-(d)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall apply to Vir </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">mutatis mutandis</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> in respect of the Vir Sole Development Product that corresponds to such Collaboration Product for which Vir undertakes Commercialization as a Vir Sole Development Product.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.7.2	Overruns</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">.</font></p>
  <p style="text-indent:28.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	Each Party shall notify the other Party [***] that the anticipated Development Costs or Allowable Expenses to be incurred by such Party for a Collaboration Product for a given Calendar Year shall be in excess of the applicable approved Development Budget or Commercialization Budget, respectively, for such Collaboration Product for such Calendar Year.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	Following such notification, the Financial Working Group shall discuss the causes of any such increase and evaluate potential mitigation measures to prevent a further increase of Development Costs or Allowable Expenses, as applicable. To the extent, based on this discussion, the Financial Working Group concludes that the anticipated amount of the concerned category of Development Costs or Allowable Expenses is likely not to exceed [***] of the aggregate annual amounts budgeted (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Permitted Overage</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to be incurred by or on behalf of the concerned Party for its activities for the Collaboration Product in such Calendar Year as set forth in the then-current applicable Development Budget or Commercialization Budget, respectively, such anticipated costs or expenses shall be included in the calculation of the applicable Development Costs or applicable Allowable Expenses for the purposes of calculating the Development Cost sharing pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> or calculating the profit or loss sharing pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, provided that:</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:30.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	[***]; and</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:30.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii)	 [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:28.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	If the Financial Working Group concludes that:</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:30.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)	the anticipated amount of the applicable Development Costs or Allowable Expenses is likely to exceed&#160;the Permitted Overage (such amount the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Excess Costs</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;); and</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:30.84%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii)	there are no mitigation measures to prevent such Excess Costs, the JSC shall discuss in good faith a corresponding amendment of the concerned Development Budget or Commercialization Budget, as applicable, to reflect the anticipated Excess Costs. [***].</font></p>
  <p style="text-indent:28.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	[***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:28.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)	[***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">71</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:28.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(f)	[***].</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.7.3	Reconciliation and Payment</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Reconciliation Discussion</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">In the event that either Party has any questions or concerns regarding the Development Costs or calculation of Pre-Tax Profit or Loss reported by the other Party in a Financial Report pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.7.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, the Financial Working Group shall endeavor to resolve such questions and concerns of either Party [***]. Additionally, the Financial Working Group may by mutual agreement adjust the timing for notification or payment of any reconciliation payments hereunder.</font></p>
  <p style="text-indent:28.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	[***]. Unless such timing is otherwise modified by the Financial Working Group, within [***] after receipt of each Party&#x2019;s Financial Report provided pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.7.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, the Financial Working Group shall confer and agree in writing on a reconciliation report setting out the calculation of any payment to be paid by Vir to GSK or by GSK to Vir, as the case may be, (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Balancing Payment</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) in order to effect the sharing of Development Costs in accordance</font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;"> Section 11.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and the sharing of Pre-Tax Profit or Loss in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, [***].  In the event of any dispute regarding any Balancing Payment due, the Parties shall use good faith efforts to resolve the dispute provided that, if not so resolved within [***], such dispute shall be resolved pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.16</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Each Party that is owed a Balancing Payment shall invoice the other Party for the amount of the Balancing Payment due and the other Party shall pay such invoiced amount within [***] after delivery of such invoice; provided that, in the event of any dispute regarding the Balancing Payment due, the undisputed portion of such Balancing Payment shall be paid in accordance with the foregoing timetable by the applicable Party, and the remaining, disputed portion shall be paid in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.16</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.8	Opt-Out Royalties and Payments</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;11.8	Opt-Out Royalties and Payments&#34; \f C \l &#34;2&#34; .</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.8.1	General</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  In the event that a Party exercises its Opt-Out Option in respect of a Collaboration Product pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, from the Opt-Out Effective Date with respect to such Collaboration Product, the Opt-Out Party&#x2019;s rights to share in future Pre-Tax Profit or Loss in respect of such Collaboration Product shall cease, and the Opt-Out Party shall be entitled to royalties and payments pursuant to this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.8</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.8.2	Net Sales Royalties</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. With respect to any Sole Development Product, on a country-by-country basis, commencing on the First Commercial Sale of the applicable Sole Development Product in the Territory, during the applicable Royalty Term, the Non Opt-Out Party shall pay to the Opt-Out Party royalties (determined by the timing of the exercise of the Opt-Out Option) on Net Sales of such Sole Development Product in the Territory during each Calendar Year at the rates set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 11.8.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  In addition, [***], if GSK [***], then, [***].</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.8.3	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***].</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***], the Parties will discuss, [***], an equitable reduction to the royalties payable to the Opt-Out Party pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;11.8.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">72</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.8.4	Royalty Payment and Reporting</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The paying Party shall, within [***], pay to the receiving Party the royalties due for such [***]. At the same time as such payment, the paying Party shall furnish to the receiving Party a written report showing on a Sole Development Product-by-Sole Development Product and country-by-country basis the total Net Sales of a Sole Development Product in a country in the Territory for that [***] stated in U.S. Dollars and the royalties due thereon.  The paying Party will keep complete and accurate records in sufficient detail to enable the royalties payable to be determined and the information provided to be verified.  With respect to Net Sales of Sole Development Products invoiced in a currency other than U.S. Dollars, such amounts and the royalty amounts payable under this Agreement shall be expressed in U.S. Dollar equivalent calculated using [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.9	Third Party Technologies and </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***] TC &#34;11.9	Third Party Technologies and Government Funding&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.9.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Vir has disclosed to GSK and the Parties have agreed on all payments payable to Third Parties under Existing Third Party IP Agreements in connection with the Existing Influenza Program mAbs existing as of the Execution Date, as set forth on </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 11.9.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Existing</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Third Party Payment Obligations</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  Vir shall disclose to GSK [***] with respect to [***].  All Existing Third Party Payment Obligations incurred after the Effective Date with respect to Vir-2482XX2, (and, with respect to Vir-2482, after the Vir-2482 Program Effective Date if the Option is exercised by GSK) to the extent relating to Influenza Products containing Vir-2482XX2 (or Vir-2482, if the Option is exercised by GSK) Developed, Manufactured or Commercialized under the Influenza Program will be included as Development Costs and/or Pre-Tax Profits or Losses and shared by the Parties in accordance with the terms of this Agreement, in each case, subject to any applicable opt-out mechanics set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. In addition, any royalties and other payments payable to Third Parties in connection with rights or licenses to Intellectual Property Rights with respect to any [***] that are disclosed by Vir and that are agreed to be included by the Parties pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.9.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> or </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 12.9</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (or, if the Parties cannot agree, determined to be [***] pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.9.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> or </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 12.9</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, as applicable) [***] shall be Third Party IP Payments to the extent relating to Collaboration Products Developed, Manufactured or Commercialized under such Collaboration Program and will be included as Development Costs and/or Pre-Tax Profits or Losses and shared by the Parties in accordance with the terms of this Agreement, in each case, subject to any applicable opt-out mechanics set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  For clarity, Vir shall [***].  Notwithstanding the foregoing, Vir shall [***].</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.9.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If, during the Term, in connection with a Collaboration Program, either Party determines, [***], that it is [***] to (a) obtain rights under any Third Party Intellectual Property Rights, or (b) [***], in order to Develop, Manufacture or Commercialize any Collaboration Products pursuant to this Agreement, then it shall notify the JPC of such Third Party Intellectual Property Rights, along with (where reasonably practical) a proposal of the terms upon which such Third Party Intellectual Property Rights are available to license or acquire for use in connection with the applicable Collaboration Products [***].  The JPC, and if the JPC cannot agree, then upon escalation, the JSC, shall determine whether or not to seek a license under or to acquire or [***] (as applicable) such Third Party Intellectual Property Rights for purposes of Developing, Manufacturing or Commercializing such Collaboration Products.  If the JPC or the JSC, as applicable, determines to seek such a license or acquisition, then, the Lead Party shall take the lead in negotiating the agreement pursuant to which a license under or acquisition of such Third</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">73</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Party Intellectual Property Rights would be obtained (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Blocking Third Party IP Agreement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), provided that [***].  If the Parties cannot agree through the JPC or the JSC on whether to enter into a Blocking Third Party IP Agreement, [***] or upon the terms of such Blocking Third Party IP Agreement, then, (a) with respect to any Third Party Intellectual Property Rights that [***], and (b) with respect to any Third Party Intellectual Property Rights that [***].</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.9.3	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If a Blocking Third Party IP Agreement is entered into in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.9.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> with respect to a Collaboration Product, any amounts paid by the Lead Party to any Third Party under such Blocking Third Party IP Agreement that are attributable or allocable to such Collaboration Product shall be deemed Blocking Third Party IP Costs and included within Development Costs (to the extent applicable to Development or Manufacturing for Development) for purposes of Development Cost sharing or included within Allowable Expenses (to the extent applicable to Commercialization and Commercial Manufacture) for calculating Pre-Tax Profits or Loss pursuant to the Financial Schedule.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.9.4	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If, following the Opt-Out Effective Date for a Collaboration Product, the Non Opt-Out Party has elected to continue with the Development and Commercialization of such Collaboration Product in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6.4(a)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, then:</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	If, with respect to a Sole Development Product, the Non Opt-Out Party determines, [***], that it is [***] to obtain rights under any Third Party Intellectual Property Rights in order to Develop, Manufacture or Commercialize such Sole Development Product, the Non Opt-Out Party shall have right, but not the obligation, to take the lead in negotiating the agreement pursuant to which a license under such Third Party Intellectual Property Rights would be obtained.  If the Non Opt-Out Party (i) obtains a license to or acquires any such Third Party Intellectual Property Rights that are [***] for the Development, Manufacture or Commercialization of a Sole Development Product (i.e. where the Opt-Out Party is receiving only royalties in the Territory and not a share of Pre-Tax Profits or Loss) or (ii) is required to make payments under (A) any Existing Third Party IP Agreement, or (B) any Blocking Third Party IP Agreement existing as of the effective date of the applicable Opt-Out Option, in each case ((A) and (B)) with respect to a Sole Development Product, then the Non Opt-Out Party shall be permitted to offset [***] paid to the applicable Third Party in consideration for the grant of such a license (in the case of subclause (i)), and under such Existing Third Party IP Agreement or Blocking Third Party IP Agreement [***], against the royalties payable to the Opt-Out Party in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.8</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, provided that, in each case ((i) or (ii)), [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	If the Opt-Out Party is required to make payments under any Existing Third Party IP Agreement or any Blocking Third Party IP Agreement entered into by the Opt-Out Party prior the effective date of the applicable Opt-Out Option with respect to the Development, Manufacture or Commercialization of the Non Opt-Out Party&#x2019;s Sole Development Product, then the Non Opt-Out Party shall reimburse the Opt-Out Party for all such payments and the Non Opt-Out Party shall be permitted to offset [***] reimbursed to the Opt-Out Party [***] against the royalties payable to the Opt-Out Party in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.8</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> with respect to such Sole Development Product, provided that, [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">74</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.9.5	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If, during the Term on a Collaboration Program-by-Collaboration Program basis, either Party wishes to [***], unless such Party exercises its Opt-Out Options with respect to a Collaboration Program, it shall [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.10	Audits</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;11.10	Audits&#34; \f C \l &#34;2&#34; .  Each Party shall, and shall ensure that its Affiliates and licensees and Sublicensees, keep complete and accurate records of [***]. Each Party will have the right, at its own expense and [***], to have an independent, certified public accountant, selected by such Party [***], review any such records of the other Party in the location(s) where such records are maintained by the other Party upon [***] prior written notice and during regular business hours and under obligations of confidentiality, for the sole purpose of verifying the basis and accuracy of payments made under this Agreement, with respect to any Calendar Year ending not more than [***] prior to the request of the auditing Party. If the review of such records reveals that the other Party has failed to accurately report financial information required to be reported hereunder, or to make any payment (or portion thereof) required under this Agreement, then the other Party shall pay, within [***], to the auditing Party any underpaid amounts due hereunder, together with interest calculated in the manner provided in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;11.12</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. If any such discrepancies are greater than [***] of the amounts actually due for the audited period, the other Party shall pay all reasonable costs incurred in conducting such review. Once a Party has conducted a review and audit of the other Party pursuant to this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> in respect of any given period, it may not subsequently re-inspect the other Party&#x2019;s records in respect of such period, unless [***]. For clarity, however, if a discrepancy is identified by the accountant during the course of an audit and the Parties do not agree upon a resolution of such discrepancy, then the auditing Party&#x2019;s accountant may re-inspect the books and records to the extent reasonably relevant to resolving such discrepancy.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.11	Tax Matters</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;11.11	Tax Matters&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Each Party will make all payments to each other under this Agreement without deduction or withholding for Taxes (as that term is defined below) except to the extent that any such deduction or withholding is required by applicable Law in effect at the time of payment. The Parties shall [***] cooperate with one another to reduce or minimize any such deduction or withholding required by applicable Law, including by providing reasonable advance notice of such deduction or withholding by providing any forms or other certifications necessary to reduce the amount of such withholding. Each Party (including successors and assignees) shall, [***], provide the other Parties [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.11.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Any amount payable by one Party to the other under this Agreement is deemed to be exclusive of any amount in respect of any VAT chargeable on the supply for which that sum is the consideration (in whole or in part) for VAT purposes. If anything done by one Party under this Agreement constitutes, for VAT purposes, the making of a supply to the other Party and VAT is or becomes chargeable on that supply, the Party receiving the supply shall pay the other Party, in addition to any amount otherwise payable under this Agreement by the Party receiving the supply, a sum equal to the amount of the VAT chargeable on that supply against delivery of a valid VAT invoice to the Party receiving the supply.  &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">VAT</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any value added, goods and services, sales, use, purchase, turnover or consumption tax as may be applicable in any relevant jurisdiction, including but not limited to value added tax chargeable under legislation implementing EU Council Directive 2006/112/EC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">75</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.11.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Any Tax required to be withheld on amounts payable under this Agreement will be [***] paid by the Party making the payment (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Payor</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) on behalf of the Party receiving the payment (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Payee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to the appropriate Governmental Authority, and Payor will furnish Payee with proof of payment of such Tax. Any such Tax required to be withheld will be an expense of and borne by Payee and any amounts withheld and paid to the applicable Tax authority shall be treated as paid to the applicable Party for purposes of this Agreement. Notwithstanding anything to the contrary in this Agreement, if a Payor redomiciles, assigns, transfers, sublicenses or otherwise disposes of some or all of its rights and obligations to any Person (without the prior written consent of the Payee) (including an assignment of this Agreement as permitted under </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;22.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> of this Agreement) and if, as a result of such action, the withholding or deduction of tax required by applicable Law with respect to payments under this Agreement is increased (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Increased Withholding Taxes</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), then any amount payable to the Payee under this Agreement shall be increased to take into account such Increased Withholding Taxes as may be necessary so that, after making all required withholdings (including withholdings on the withheld amounts), the Payee receives an amount equal to the sum it would have received had no such action occurred. For the avoidance of doubt, [***].</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.11.3	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Parties will reasonably cooperate with respect to all documentation required by any taxing authority or reasonably requested by either Party to secure a reduction in the rate of applicable withholding Taxes or an exemption from withholding Taxes. Notwithstanding the foregoing, if a Party is entitled under any applicable tax treaty to a reduction of rate of, or the elimination of, or recovery of, applicable withholding tax, then it may deliver to the other Party or the appropriate Governmental Authority the prescribed forms necessary to reduce the applicable rate of withholding or to relieve the payor of its obligation to withhold tax. If a Payee [***] delivers to the Payor a validly executed form establishing a reduced rate or exemption from withholding, the Payor shall apply the reduced rate of withholding, or not withhold, as the case may be, provided that the Payor is in receipt of evidence, in a form reasonably satisfactory to the Payor. If, in accordance with the foregoing, the Payor withholds any amount, then it will pay to the Payee the balance when due, [***] remit to the proper taxing authority of the withheld amount, and send the Payee proof of such remittance within [***] following the Payee&#x2019;s request for such proof of remittance.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.11.4	No Partnership</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Nothing contained in this Agreement shall be deemed or construed by the Parties, any of their Affiliates, a Third Party, or any third person to treat the relationship between the Parties contemplated by this Agreement as a partnership, joint venture or other business entity under Treasury Regulations Section&#160;301.7701-1(a)(2) (or any corresponding provision under state, local or non-U.S. tax Law) (an &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Entity</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;). Without the prior written consent of the Parties (such consent not to be unreasonably withheld, delayed or conditioned), no Party (or successor or assignee) shall, for Tax purposes, report the relationships established by this Agreement as an Entity, including either (a)&#160;making any disclosure that the relationships established by this Agreement may give rise to an Entity (whether on a U.S. Internal Revenue Service Form 8275 or otherwise) or (b)&#160;withholding any amounts from payments made to the other Party pursuant to Section&#160;1446 of the Code (or any corresponding provision under state, local or non-U.S. tax law), unless required by a tax authority on audit or other examination.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.11.5	Independent Parties</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. The Parties agree and acknowledge that they are acting for their own account and do not intend this Agreement to result in an Entity. Each Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">76</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">is acting on its own behalf and has obtained its own legal, tax, and investment advice regarding the execution of this Agreement and the rights and obligations arising herein.  The Parties shall not maintain joint bank accounts and shall not commingle funds. No Party shall hold itself out as being an agent of any other Party or as having the legal right to bind or act on behalf of any other Party.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.12	General Payment Terms</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;11.12	General Payment Terms&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Unless otherwise expressly set forth herein, including in respect of the payment of Balancing Payments (which shall be paid in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.7.3(b)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) and in respect of the payment of royalties (which shall be paid in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.8</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">), [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.12.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Without limiting either Party&#x2019;s remedies under this Agreement, if a Party fails to pay any amount due under this Agreement by the relevant payment date when such amounts are due, the other Party may, [***].</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.12.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except as otherwise agreed by the Parties, all payments to be made by either Party to the other Party under this Agreement shall be made by such Party or its Affiliate in U.S. Dollars to the account designated by the Party to which the relevant payment is due.  In the case of any amounts designated in another currency, then each Party shall convert such foreign currency into U.S. Dollars [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.13	Blocked Payments</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;11.13	Blocked Payments&#34; \f C \l &#34;2&#34; .  In the event that, by reason of applicable Laws in any country, it becomes impossible or illegal for a Party or its Affiliate, licensee or Sublicensee to transfer, or have transferred on its behalf, payments to the other Party, such Party shall [***] notify the other Party of the conditions preventing such transfer and such payments shall [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.14	Reporting; Financial Records</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;11.14	Reporting; Financial Records&#34; \f C \l &#34;2&#34; .  Unless otherwise defined or stated, financial terms shall be calculated by the accrual method under the applicable Party&#x2019;s Accounting Standards.  Financial records shall be maintained (in such form as may be available) for a period of no less than [***] following the end of the period to which they pertain.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.15	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***] TC &#34;11.15	Cooperation on Inter-Party Structure&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Parties will [***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.16	Resolution of Financial Disputes</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;11.16	Resolution of Financial Disputes&#34; \f C \l &#34;2&#34; .  In the event there is a dispute, claim or controversy relating to any financial obligation by one Party to the other Party pursuant to this Agreement, such Party shall provide such other Party with a written notice setting forth in reasonable detail the nature and factual basis for such good-faith dispute and, unless the Financial Working Group has already attempted to resolve the dispute, each Party agrees that it shall seek to resolve such dispute within [***] within the Financial Working Group after the date such written notice is received.  If no resolution is reached by the Financial Working Group, the dispute shall be referred to the JSC for resolution, and if the JSC is unable to reach resolution within [***], then (a) if such dispute relates to[***], and (b) if such dispute relates to [***], then such dispute shall be subject to the dispute resolution process set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.17</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Notwithstanding any other provision of this Agreement to the</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">77</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">contrary, the obligation to pay any reasonably disputed amount shall not be deemed to have been triggered until such dispute is resolved hereunder, provided that any undisputed portion of such payment shall be paid by the paying Party in accordance with the payment terms set forth in this Agreement including as set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.12</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (General Payment Terms).  Any disputed portion of any payment shall be paid by the responsible Party within [***] after the date on which the Parties, using good faith efforts, or the JSC (as applicable) resolve the dispute or, if not so resolved within [***], within [***] after such dispute is resolved pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 22.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">11.17	Specific Finance Disputes</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;11.17	Specific Finance Disputes&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If the Parties are unable to reach a mutually acceptable resolution of any dispute falling within </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.16(b)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> within [***], the dispute shall be submitted for resolution to [***].  Any amounts owed by one Party to the other Party as a result of such resolution shall be paid or reimbursed by the owing Party within [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 12<br>Licenses TC &#34;ARTICLE 12	LICENSES&#34; \f C \l &#34;1&#34;</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">12.1	Collaboration Programs</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;12.1	Collaboration Programs&#34; \f C \l &#34;2&#34; .</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">12.1.1	License Grant to GSK</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  On a Collaboration Program-by-Collaboration Program basis, Vir hereby grants to GSK as of the Effective Date the following:</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	a co-exclusive (with Vir), worldwide, sublicensable (subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 12.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) license under the Vir Licensed Technology and Vir Program Technology to Develop and Manufacture Collaboration Products arising from such Collaboration Program in the Field in the Territory (which license shall remain in effect for any Collaboration Product that becomes a Sole Development Product of GSK but shall become [***] with respect to such product, as further modified by </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 12.2.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">), subject in each case (including where modified by </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 12.2.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) to (i) (A) in the case of the Existing Influenza mAbs, [***], and (B) in the case of any other Vir Influenza mAbs, the Expanded Functional Genomics Program and each Additional Pathogen Program, any rights granted by Vir to Third Parties [***] under agreements with respect to the applicable Vir Licensed Technology that are in existence as of [***] for such Collaboration Program; and (ii) any modified or additional IP terms with respect to applicable Vir Assets pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (collectively, (i) and (ii), the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir Preexisting Rights</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;);</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	an exclusive, worldwide, sublicensable (subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 12.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) license under the Vir Licensed Technology and Vir Program Technology to Commercialize Collaboration Products arising from such Collaboration Program in the Field in the Territory (which license shall remain in effect for any Collaboration Product that becomes a Sole Development Product of GSK, as further modified by </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 12.2.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">), subject in each case (including where modified by </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 12.2.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) to the Vir Preexisting Rights; and</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	a non-exclusive, worldwide, royalty-free, perpetual license under the Vir Program Technology for GSK&#x2019;s Research purposes only, subject to any modified or additional IP terms with respect to applicable Vir Asset pursuant to</font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;"> Section 2.6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">78</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">12.1.2	License Grant to Vir</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  On a Collaboration Program-by-Collaboration Program basis, GSK hereby grants to Vir as of the Effective Date the following:</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	a non-exclusive, worldwide, sublicensable (subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 12.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) license under the GSK Licensed Technology to Develop and Manufacture Collaboration Products arising from such Collaboration Program in the Field in the Territory (which license shall remain in effect for each Collaboration Product that becomes a Sole Development Product of Vir, as further modified by </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 12.2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">), subject in each case (including where modified by </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 12.2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) to, for each Collaboration Program, (i) any rights granted by GSK to Third Parties [***] under agreements with respect to the applicable GSK Licensed Technology that are in existence as of [***] for such Collaboration Program and (ii) any modified or additional IP terms with respect to applicable GSK Asset pursuant to</font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;"> Section 2.6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	a co-exclusive (with GSK), worldwide, sublicensable (subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Sections 7.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 12.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) license under GSK Program Technology to Develop and Manufacture Collaboration Products arising from such Collaboration Program in the Field in the Territory (which license shall remain in effect for any Collaboration Product that becomes a Sole Development Product of Vir and shall become [***] with respect to such product, as further modified by </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 12.2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">), subject in each case (including where modified by </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 12.2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) to any modified or additional IP terms with respect to applicable GSK Asset pursuant to</font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;"> Section 2.6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">; and</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	a non-exclusive, worldwide, royalty-free, perpetual license under the GSK Program Technology for Vir&#x2019;s Research purposes only, subject to any modified or additional IP terms with respect to any applicable GSK Asset pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> [***].</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">12.1.3	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The licenses set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Sections 12.1.1(a)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">(b)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Sections 12.1.2(a)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">(b)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall remain in effect for each Collaboration Program until termination of this Agreement with respect to such Collaboration Program (but shall be adjusted as specified above and in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 12.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">).</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">12.2	Following Opt-Out Option</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;12.2	Following Opt-Out Option&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">12.2.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">GSK Sole Development Product</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> The licenses granted to GSK pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Sections 12.1.1(a)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">(b)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> with respect to any GSK Sole Development Product shall be automatically adjusted to include only any Vir Licensed Technology or Vir Program Technology that (a) was used to conduct Development, Manufacturing or Commercialization activities in connection with such GSK Sole Development Product prior to Vir exercising its Opt-Out Option for such Collaboration Product and such Collaboration Product being designated as a GSK Sole Development Product, and (b) is necessary for continued Development, Manufacturing or Commercialization of such GSK Sole Development Product, [***].</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">12.2.2	Vir Sole Development Product</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The licenses granted to Vir pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Sections 12.1.2(a)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">(b)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> with respect to any Vir Sole Development Product shall be automatically adjusted to include only any GSK Licensed Technology or GSK Program Technology that (a) was used to conduct Development, Manufacture or Commercialization</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">79</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">activities in connection with such Vir Sole Development Product prior to GSK exercising its Opt-Out Option for such Collaboration Product and such Collaboration Product being designated as a Vir Sole Development Product, and (b) is necessary for continued Development, Manufacture or Commercialization of such Vir Sole Development Product, but [***]. In addition, the licenses granted to Vir pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Sections 12.1.2(a)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">(b)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> with respect to any Vir Sole Development Product shall be modified to include the right to Commercialize such Vir Sole Development Product.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">12.3	Rejected Collaboration Product License</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;12.3	Rejected Collaboration Product License&#34; \f C \l &#34;2&#34; .  In the event that, following the exercise of the Opt-Out Option by one Party for a Collaboration Product, the other Party does not wish to continue the further Development, Manufacturing or Commercialization of the applicable Collaboration Product (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Rejected Collaboration Product</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), then,</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">12.3.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">if the Non Opt-Out Party has elected to wind down Development activities and has the right to take the lead on winding down Development activities with respect to such Rejected Collaboration Product in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6.4(c)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, then, except to the extent necessary for the purposes of winding down all Development activities with respect to such Collaboration Product, neither Party or its Affiliates shall have the right to use, infringe or otherwise exploit the Program Technology, GSK Licensed Technology and Vir Licensed Technology, in each case, with respect to the Rejected Collaboration Product, and neither such Party or its Affiliates shall grant the right to any Third Party to engage in any activities with respect to such Rejected Collaboration Product.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">12.3.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">if the Non Opt-Out Party has proposed to out-license or otherwise divest such rejected Collaboration Product and has the right to take the lead on (sub)licensing or otherwise divesting rights to such Rejected Collaboration Product pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6.4(d)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, then neither Party or its Affiliates shall have the right to use or otherwise exploit the Program Technology, GSK Licensed Technology and Vir Licensed Technology, in each case, with respect to the Rejected Collaboration Product, and, except for purposes of such (sub)licensing or divestiture, neither such Party or its Affiliates shall grant the right to any Third Party to engage in any activities with respect to such Rejected Collaboration Product, in each case without the consent of the other Party.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">12.4	Sublicenses</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;12.4	Sublicenses&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Sections 7.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">9.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">12.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, each Party shall have the right to grant sublicenses to its Affiliates or a Third Party, provided that, [***].  Any and all sublicenses granted by either Party to its Affiliates or Sublicensees shall be in writing and shall be subject to, and consistent with, the terms and conditions of this Agreement (including the Development Plan) applicable to such Affiliates or Sublicensees. The Party granting the sublicense shall be responsible for ensuring the compliance of its applicable Affiliates and Sublicensees with all obligations owed to the other Party under this Agreement.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">12.5	Licensing Program Technology</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;12.5	Licensing Program Technology&#34; \f C \l &#34;2&#34; . For purposes of the licenses granted to Program Technology hereunder, unless otherwise agreed by the Parties in writing, such licenses are not intended to include any Program Technology arising from the other Party&#x2019;s activities with respect to any Sole</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">80</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Development Product after the date on which the Opt-Out Option is exercised.  For clarity, with respect to a Collaboration Program, solely to the extent agreed by the JPC and the JRDC, the licenses granted to Program Technology shall include Program Technology arising from any other Collaboration Program.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">12.6	No Implied Licenses</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;12.6	No Implied Licenses&#34; \f C \l &#34;2&#34; .  Each Party acknowledges that the licenses granted under this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 12</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> are limited to the scope expressly granted, and all other rights to Patents and Know-How licensed hereunder are expressly reserved to the Party granting the license to such Patents or Know-How. Without limiting the foregoing, it is understood that where an exclusive license under Patents or Know-How is granted to a Party under this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 12</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> for a particular purpose, the Party granting such license retains all of its rights to such Patents or Know-How for all other purposes not expressly stated herein.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">12.7	Retained Rights</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;12.7	Retained Rights&#34; \f C \l &#34;2&#34; .  Any rights of a Party not expressly granted to the other Party under the provisions of this Agreement will be retained by such first Party.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">12.8	Rights in Bankruptcy</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;12.8	Rights in Bankruptcy&#34; \f C \l &#34;2&#34; .  The Parties intend to take advantage of the protections of Section 365(n) (or any successor provision) of the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction to the maximum extent permitted by law.  All rights and licenses granted under or pursuant to this Agreement, but only to the extent they constitute licenses of a right to &#x201c;intellectual property&#x201d; as defined in Section 101 of the U.S. Bankruptcy Code, shall be deemed to be &#x201c;intellectual property&#x201d; for the purposes of Section 365(n) or any analogous provisions in any other country or jurisdiction.  The Parties shall retain and may fully exercise all of their rights and elections under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, including the right to obtain the intellectual property from another entity.  In the event of the commencement of a bankruptcy proceeding by or against either Party under the U.S. Bankruptcy Code or any analogous provisions in any other country or jurisdiction, the Party that is not subject to such proceeding shall be entitled to [***] all such intellectual property [***], which, if not already in the non-subject Party&#x2019;s possession, shall be [***] delivered to it [***].  [***]. In the case of an insolvency that is governed by non-U.S. bankruptcy law, the Parties agree that, to the extent not prohibited by the applicable insolvency law, the non-subject Party will be entitled to at least the same rights and protections afforded by the U.S. Bankruptcy Code, including survival of the licenses granted hereunder even if the subject Party revokes or terminates this Agreement and a copy of the embodiments of such intellectual property, without conditions other than any legally required payment of royalties.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">12.9	Existing Third Party Agreements</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;12.9	Existing Third Party Agreements&#34; \f C \l &#34;2&#34; .  Each Party shall have the right to [***] in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (as further described in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 5.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, or </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 6.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, as applicable), and such [***].  If the Parties cannot agree [***], then, (a) with respect to any such Third Party Intellectual Property Rights that are [***] to Develop, Manufacture or Commercialize any Collaboration Product pursuant to this Agreement, [***], and (b) with respect to any such Third Party Intellectual Property Rights that are [***] to Develop, Manufacture or Commercialize any Collaboration Product pursuant to this Agreement, [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">81</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 13  <br>Manufacturing and Supply TC &#34;ARTICLE 13	MANUFACTURING AND SUPPLY&#34; \f C \l &#34;1&#34;</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">13.1	General</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;13.1	General&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">For each Collaboration Program, the Parties will jointly through the JMC (and subject to GSK&#x2019;s applicable final decision-making authority) determine a Manufacturing strategy with respect to the Manufacture and supply of any Collaboration Product, which may as appropriate include Clinical Manufacturing capabilities of both Parties or contract manufacturers.  Following commencement of each Collaboration Program, if agreed by the JMC with respect to Clinical Manufacture, and if agreed by the JMC with respect to Commercial Manufacture, no later than [***], the Parties shall negotiate in good faith and execute any supply agreements between GSK and Vir required for the supply from GSK to Vir, or vice versa (each, a &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Supply Agreement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) for the applicable Collaboration Products under applicable Collaboration Program(s), each, in accordance with the terms set forth herein, [***].  The Parties will, in connection with each such Supply Agreement, either (a) enter into a new quality agreement (each, a &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Quality Agreement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) that governs the quality of the applicable Collaboration Products supplied by one Party to the other Party thereunder or (b) amend the existing Quality Agreement entered into by the Parties under the Existing Collaboration Agreement to include the Collaboration Products supplied by one Party to the other Party under this Agreement.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">13.2	Manufacturing Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;13.2	Manufacturing Party&#34; \f C \l &#34;2&#34; .  The Party that has the right to conduct Manufacturing and supply for a particular Collaboration Product hereunder shall be referred to as the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Manufacturing Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; with respect to such Collaboration Program.  Except as may be otherwise specified in a Supply Agreement or in this Agreement, the Manufacturing Party may Manufacture and supply the applicable Collaboration Product by itself and through Affiliates or through one or more contract manufacturers (each, a &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">CMO</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) provided that any such subcontracting to a CMO shall be approved by the JMC.  The Manufacturing Party for a Collaboration Product shall keep the JMC apprised regarding any material developments relating to the Manufacture and supply of such Collaboration Product. For clarity, Vir-2482 is not a Collaboration Product unless and until the Vir-2482 Program Effective Date, if GSK exercises the Option in accordance with the terms of this Agreement, and the terms of </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 13.3.1(a)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> govern the Manufacture of Vir-2482 prior to the Vir-2482 Program Effective Date.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">13.3	Collaboration Programs</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;13.3	Collaboration Programs&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">13.3.1	Parties&#x2019; Roles</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  GSK shall be the Manufacturing Party for all Manufacturing activities (including Clinical Manufacture and Commercial Manufacture) for the Influenza Program, Expanded Functional Genomics Program and the Additional Pathogen Programs, except as follows:</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	With respect to Vir-2482, Vir shall be responsible, and shall have final decision-making authority, for all Manufacturing activities for any Clinical Studies for Vir-2482 prior to the Option exercise and, if such Option is exercised by GSK, until the Vir-2482 Program Effective Date [***]; provided that, (i) [***]; and (ii) if GSK exercises the Option, then, prior to the Vir-2482 Program Effective Date, [***].  Without limiting the foregoing, prior to the</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">82</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Option exercise and, if such Option is exercised by GSK, until the Vir-2482 Program Effective Date: (A) [***], Vir shall [***]; and (B) GSK shall, [***]; provided, in each case, ((A) and (B)), GSK shall [***].  For clarity, if GSK exercises the Option pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 4.2.2,</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> GSK shall be the Manufacturing Party for Vir-2482 after the Vir-2482 Program Effective Date and shall have the final decision-making authority on the Manufacturing process for Vir-2482 thereafter. If GSK elects not to or fails to exercise the Option (subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.2.2(b)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">), then Vir shall have the sole right with respect to and the sole responsibility for Manufacturing of Vir-2482 and thereafter the terms of this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 13.3.1(a)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall not apply.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	With respect to a Collaboration Product that is an Additional Pathogen Product, the JSC shall determine the Manufacturing Party for preclinical, Phase I Clinical Studies and Phase II Clinical Studies for such Collaboration Product, provided that, if the JSC cannot agree, then GSK shall have the final decision-making authority. With respect to each such Collaboration Product for preclinical, Phase I Clinical Studies and Phase II Clinical Studies, the Party that is responsible for Manufacturing shall [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">13.3.2	Manufacturing Technology Transfer</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  With respect to Vir-2482, if GSK exercises the Option, and with respect to any applicable Additional Pathogen Product that is a Program mAb Controlled by Vir and for which the JSC determines that GSK will be responsible for Clinical Manufacture for the pre-clinical studies, Phase I Clinical Studies and Phase II Clinical Studies, [***], in each case, as applicable, Vir shall, upon GSK&#x2019;s request, use reasonable efforts to facilitate a Manufacturing technology transfer to GSK or its designee to enable GSK to conduct its Clinical Manufacture activities with respect to Vir-2482 or such Additional Pathogen Product, including, [***].  Without limiting the foregoing, with respect to (a) Vir-2482, following GSK&#x2019;s exercise of the Option, and (b) any Additional Pathogen Product that is a Program mAb Controlled by Vir and for which the JSC determines that GSK will be responsible for Clinical Manufacture for the pre-clinical studies, Phase I Clinical Studies and Phase II Clinical Studies, [***], in each case ((a) and (b)), [***], Vir shall [***]. All costs incurred by Vir (x) with respect to Vir-2482, if GSK exercises the Option, after the VIR-2482 Program Effective Date or (y) with respect to any applicable Additional Pathogen Product, [***]. Without limiting the foregoing, GSK shall have the right [***].  In addition, if GSK exercises the Option, the Parties shall, upon GSK&#x2019;s request, discuss and agree on a plan to transfer any inventory of Vir-2482 to GSK, [***].  Further, as and when agreed by the Parties and set forth in a Manufacturing Plan or other written document, Vir will [***].</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">13.3.3	Reservation of Manufacturing Capacity</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Unless agreed by the Parties through the JMC and where applicable, the JSC, and except in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 13.3.1(a)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> with respect to Vir-2482, [***], Vir shall [***].  If the JSC, prior to Vir entering into any agreement to acquire Manufacturing capacity, approves Vir&#x2019;s request to contract for Manufacturing capacity with a specific CMO, the costs for acquiring such Manufacturing capacity will be shared as Development Costs or Allowable Expenses, as applicable, [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">13.4	Transition of Manufacturing and Supply</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;13.4	Transition of Manufacturing and Supply&#34; \f C \l &#34;2&#34; .  If the Manufacturing Party for a Collaboration Product elects to exercise its Opt-Out Option pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.6.4(b)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, then promptly following the exercise of such Opt-Out Option by the Manufacturing Party, the Parties shall discuss through the JMC and agree upon a Manufacturing technology transfer plan, including a reasonable allocation</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">83</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">of costs, for (a) the transfer to the new Manufacturing Party of responsibility for Manufacture of the applicable Collaboration Product for Development and Commercialization, including (i) the transfer of the required Manufacturing process, (ii) transfer of physical possession of the applicable Master Cell Bank and Working Cell Bank (including transfer of title and risk of loss), and (iii) transfer and assignment to the new Manufacturing Party of any existing agreement (or portion thereof) relating to the Manufacturing and supply of the Collaboration Products, and the terms of </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;13.3.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall apply </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">mutatis mutandis</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, (b)&#160;any technical assistance agreed in such Manufacturing technology transfer plan and assumption of Manufacturing by the new Manufacturing Party or its designee, and (c) any licenses required to be granted to the new Manufacturing Party in connection with such Manufacturing.  During the period following the exercise of the applicable Opt-Out Option by the Manufacturing Party, and until Manufacturing for the applicable Collaboration Product is transferred in accordance with the foregoing subclauses (a) through (c), but in no event for longer than a period of [***], the previous Manufacturing Party shall continue to Manufacture and supply (itself or through an Affiliate or Third Party) the applicable Collaboration Product to the new Manufacturing Party, [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 14<br>Scientific Publications and Presentations TC &#34;ARTICLE 14	SCIENTIFIC PUBLICATIONS AND PRESENTATIONS&#34; \f C \l &#34;1&#34;</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">14.1	Research and Pre-Clinical Publications</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;14.1	Research and Pre-Clinical Publications&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">For each Collaboration Program, within 120 days after JSC approval of the applicable Development Plan, the Lead Party shall propose to the JRDC a global publication strategy for the Research and pre-clinical Development activities conducted with respect to such Collaboration Program (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Research and Pre-Clinical Publication Strategy</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) that is consistent with the applicable Development Plan.  The JRDC (with consultation from the JPC, where applicable) shall review and approve such Research and Pre-Clinical Publication Strategy for each Collaboration Program, and may amend it from time to time. The Parties shall have no right to publish in relation to any Research or pre-clinical Development activities conducted hereunder other than as specified in the Research and Pre-Clinical Publication Strategy; provided that either Party shall have the right to re-publish or reference any publication (or information therein) previously published in accordance with the Research and Pre-Clinical Publication Strategy and any publication (or information therein) published prior to the Execution Date.  If a Party desires to make a publication relating to activities being conducted under the applicable Development Plan, then it shall make such request to the other Party through the JRDC, and such publication shall be subject to review under </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;14.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and the consent of such other Party, which shall not be unreasonably withheld.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">14.2	Clinical Development Publications</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;14.2	Clinical Development Publications&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">For each Collaboration Program, the Lead Party shall propose to the JRDC a global publication strategy for the clinical Development activities related to the Collaboration Product(s) Developed under such Collaboration Program (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Clinical Development Publication Strategy</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) that is consistent with the Development Plan.  The JRDC (with consultation from the JPC, where applicable) shall review and approve such Clinical Development Publication Strategy, and may amend it from time to time upon mutual agreement of the Parties.  The Parties shall have no right to publish in relation to any clinical Development activities other than as specified in the Clinical Development Publication Strategy; provided that</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">84</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">either Party shall have the right to re-publish or reference any publication (or information therein) previously published in accordance with the Clinical Development Publication Strategy and any publication (or information therein) published prior to the Execution Date.  If a Party desires to make a publication relating to a Clinical Study that is being conducted under the Development Plan, then it shall make such request to the other Party through the JRDC, and such publication shall be subject to review under </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;14.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, and the consent of such other Party, which shall not be unreasonably withheld.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">14.3	Review by the Parties</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;14.3	Review by the Parties&#34; \f C \l &#34;2&#34; .  Except as required by applicable Law or court order, any proposed scientific or medical publications or public scientific or medical presentations covered by </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;14.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> or </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;14.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall be subject to the provisions of this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;14.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  For any such publication or presentation, the publishing Party shall submit a copy of the proposed publication or presentation (including manuscripts, abstracts, posters, slides, scheduled interviews or the like) to the representative of the other Party designated to receive such proposed publications [***] prior to any submission or disclosure to any Third Party to allow the other Party to review such proposed publication or presentation.  The reviewing Party shall provide the publishing Party with its comments, if any, in writing within [***] after receipt of such proposed publication.  The publishing Party shall consider [***] any comments thereto provided by the reviewing Party and shall comply with the reviewing Party&#x2019;s request to remove any and all of the reviewing Party&#x2019;s Confidential Information from the proposed publication.  In addition, upon the reviewing Party&#x2019;s reasonable request, the publishing Party shall delay the submission for a period up to forty [***] to permit the preparation and filing of a patent application.  If the reviewing Party fails to provide its comments to the publishing Party within such [***], the reviewing Party shall be deemed to not have any comments.  Each Party shall not, and shall cause each of its Affiliates and its and their Sublicensees not to, from and after the Execution Date, make any publications or public disclosures regarding any Collaboration Product, Development Candidate or Target under the Collaboration Programs in accordance with this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;14.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">14.4	Third Parties</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;14.4	Third Parties&#34; \f C \l &#34;2&#34; .  With respect to any agreements between a Party and Third Parties (including clinical investigators) that a Party enters into after the Effective Date relating to the Development of any Collaboration Product or otherwise relating to Development activities under this Agreement, such Party shall use reasonable efforts to include publication provisions regarding results of preclinical studies or Clinical Studies for such Collaboration Products that allow such Party to receive and provide a copy of any proposed publications or public presentations to the other Party, which such Party shall submit to the other Party with a reasonable amount of time for review as described in this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 14</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">14.5	Lead Party Publication</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;14.5	Lead Party Publication&#34; \f C \l &#34;2&#34; .  Notwithstanding the provisions of </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 18</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Sections 14.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">14.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, subject to the review process and each Party&#x2019;s obligations set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;14.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, the Lead Party for a given Collaboration Program (such Party, as applicable, the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Lead Publication Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) or its Affiliates shall have the right as required by applicable Law or the Lead Publication Party&#x2019;s or its Affiliates&#x2019; policies and standard operating procedures to (a)&#160;publish protocol summaries, results summaries, protocols, clinical study reports, plain language summaries and other study documents of all Clinical Studies conducted by or on behalf of such Lead Publication Party with respect to any Collaboration Product during the Term of this Agreement in any clinical trial register; (b) publish</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">85</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">the results at scientific congresses and in peer-reviewed journals; (c) publicly disclose results from other Clinical Studies where the Lead Party determines that the results are scientifically important or relevant for patient care; and (d) make any other public disclosures of clinical Data that become required of the Lead Publication Party due to its internal policies and procedures or applicable Laws. Any publication or disclosure made by either Party pursuant to this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;14.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall contain appropriate acknowledgements of the contribution of the other Party or Third Party to the Research or Development activities that are the subject of such publication, in accordance with generally accepted academic practice.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">14.6	Publication after Opt-Out</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;14.6	Publication after Opt-Out&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">With respect to a Sole Development Product, the Opt-Out Party shall not have the right to make any publication following its delivery of an Opt-Out Notice with respect to such Sole Development Product without the Non Opt-Out Party&#x2019;s prior written consent; provided that the Opt-Out Party shall have the right, without the Non Opt-Out Party&#x2019;s prior written consent, to re-publish or reference any publication (or information therein) previously published in accordance with this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 14</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and any publication (or information therein) published prior to the Execution Date.  The Non Opt-Out Party shall have the right to make any publication relating to the pre-clinical or clinical Development activities with respect to such Sole Development Product, subject to review in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;14.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 15<br>Materials Transfer; Intellectual Property; Information Technology TC &#34;ARTICLE 15	MATERIALS TRANSFER; INTELLECTUAL PROPERTY; INFORMATION TECHNOLOGY&#34; \f C \l &#34;1&#34;</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.1	Materials Transfer</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;15.1	Materials Transfer&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.1.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">During the course of a Collaboration Program, either Party (or such Party&#x2019;s designee) (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Materials Transferring Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) may transfer to the other Party or its designee (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Materials Receiving Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) certain Materials for use in connection with activities contemplated under this Agreement.  Such Materials will be provided under the terms and conditions of this Agreement and in such amount as described in the material transfer record for the particular transfer (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">MTR</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), in the form attached hereto as </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 15.1.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, which MTR shall set forth the type and name of the Materials transferred, the amount of the Materials transferred, the date of the transfer of such Materials and the proposed use of such Materials by the Material Receiving Party.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.1.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">MATERIALS SUPPLIED BY THE MATERIALS TRANSFERRING PARTY HEREUNDER ARE SUPPLIED IN &#x201c;AS IS&#x201d; CONDITION WITH NO WARRANTY, EXPRESS, IMPLIED OR STATUTORY, INCLUDING WARRANTIES OF MERCHANTABILITY, TITLE, NON-INFRINGEMENT, EXCLUSIVITY, OR FITNESS FOR A PARTICULAR PURPOSE.  ANY MATERIAL DELIVERED PURSUANT TO THIS AGREEMENT IS UNDERSTOOD TO BE EXPERIMENTAL IN NATURE AND MAY HAVE HAZARDOUS PROPERTIES.  THE MATERIALS RECEIVING PARTY WILL HANDLE THE MATERIAL ACCORDINGLY AND WILL INFORM THE MATERIALS TRANSFERRING PARTY IN WRITING OF ANY ADVERSE EFFECTS EXPERIENCED BY PERSONS HANDLING THE MATERIAL.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">86</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.1.3	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Materials Receiving Party acknowledges that, except for the licenses and other express rights granted herein, it does not have any claim to the Materials supplied by the Materials Transferring Party, or any license or rights to any proprietary information or intellectual property rights in or to the Materials.  For clarity, the Materials (and any Intellectual Property Rights, including Patents, relating thereto) shall remain the sole and exclusive property of the Materials Transferring Party and shall be returned or destroyed at the request of the Materials Transferring Party.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.1.4	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Materials Receiving Party agrees that the Material(s):</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	will be used solely for, and in compliance with, the applicable Development Plan or in the MTR, and to conduct analyses to confirm identity and purity as may be reasonable required for the purposes of the applicable Collaboration Program;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	will be used in compliance with all applicable Laws;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	will not be used in human subjects, in Clinical Studies, or for diagnostic purposes involving human subjects;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	will not be used in animals intended to be kept as domestic pets;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)	will be used only by the Materials Receiving Party and only in the Materials Receiving Party&#x2019;s laboratory, except with the prior written consent of the Materials Transferring Party; and</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(f)	will not be transferred to a Third Party without the prior written consent of the Materials Transferring Party.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Materials Receiving Party shall not reverse engineer or attempt to determine the chemical structure, make-up or sequence of, or determine the chemical or biological properties of, or make or attempt to make any analogues, progeny or derivatives of, or modifications to, such Materials except as may be necessary to carry-out such Party&#x2019;s obligations hereunder, including its activities pursuant to any Development Plan.  In the event that the Materials Receiving Party identifies or reasonably believes that there are any safety concerns related to the Material provided by the Materials Transferring Party, the Materials Receiving Party shall promptly notify the Materials Transferring Party in writing of such concerns and upon receiving such notification, the Materials Receiving Party shall promptly conduct investigations to address such concerns and shall keep the Materials Receiving Party reasonably informed of such investigation.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.1.5	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Materials Receiving Party assumes all liability for damages which may arise from its use, storage or disposal of the Materials.  The Materials Transferring Party shall not be liable to the Materials Receiving Party for any loss, claim or demand made by the Materials Receiving Party, or made against the Materials Receiving Party by any Third Party, due to or arising from the use of the Materials, except to the extent permitted by applicable Law when caused by the gross negligence or willful misconduct of the Materials Transferring Party.  Upon the expiration or the earlier termination of a Collaboration Program, as applicable, except for any continuing rights as set forth in this Agreement, the Materials Receiving Party shall</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">87</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">discontinue its use of any Materials and shall, upon direction of the Materials Transferring Party, return or destroy (and certify destruction of) any remaining Material.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.2	Ownership of Intellectual Property</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;15.2	Ownership of Intellectual Property&#34; \f C \l &#34;2&#34; .</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.2.1	Ownership of Intellectual Property</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	Each Party shall retain all right, title and interest to its respective Licensed Technology and, except as expressly set forth in this Agreement, no right or license to such Patents or, Know-How included in such Licensed Technology is granted by either Party to the other Party.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	Except as otherwise agreed by the Parties with respect to Intellectual Property Rights related to applicable Party Assets contributed by such Party pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, and subject to [***], (i) all patentable inventions within the Program Technology, and all Patents claiming such inventions, and (ii) all other Know-How and other Intellectual Property Rights in such Program Technology, in each case ((i) and (ii)) discovered, created or developed solely by a Party&#x2019;s employees, Affiliates, agents or independent contractors in connection with their activities under a Collaboration Program shall be owned solely by the inventing, discovering, creating or developing Party, and if discovered, created or developed jointly by both Party&#x2019;s employees, Affiliates, agents or independent contractors shall be owned jointly and deemed Joint Technology.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	With respect to the Expanded Functional Genomics Program, subject to [***], each Party shall be the exclusive owner of the Compound Specific Program Technology related to the Party Asset Contributed by such Party to the Collaboration, and the Parties shall jointly own the Target Specific Program Technology, provided that, [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	For purposes of this Agreement, the determination of inventorship of any Know-How, whether or not patentable, first invented, discovered, created or developed in the course of performing activities under the Collaboration pursuant to this Agreement, and whether solely or jointly by or on behalf of a Party, including by its employees, Affiliates, agents or independent contractors, shall be made in accordance with United States patent Law without regard to conflict of law, irrespective of where or when such invention, discovery, creation or development occurs.  Each Party shall, and does hereby, assign and shall cause its Affiliates and its and their subcontractors and Sublicensees, where applicable, to assign, to the other Party without additional compensation of the other Party, such right, title and interest in and to any Patents and Know-How, as well as any other Intellectual Property Rights with respect thereto, as is necessary to fully effect, the ownership of applicable Intellectual Property Rights provided in this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.2.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.2.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;vertical-align:top;font-size:8.04pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.2.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***].  Except (i) as otherwise agreed by the Parties with respect to Intellectual Property Rights related to applicable Party Assets contributed by such Party pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, and (ii) with respect to the ownership of Compound Specific Program Technology and Target Specific Program Technology arising from the Expanded Functional Genomics</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">88</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Program, which is provided pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.2.1(c)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, [***], then the following provisions shall apply.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	[***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	[***].</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	[***];</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	[***]; and</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.2.3	Party Technology</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Notwithstanding [***]</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	[***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	[***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.2.4	Joint Technology</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:bold;vertical-align:top;font-size:8.04pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except as otherwise agreed by the Parties with respect to Intellectual Property Rights related to applicable Party Assets contributed by such Party pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, and subject to the licenses granted under this Agreement, exclusivity obligations set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and any other express restrictions set forth in this Agreement, each Party (or its Affiliates):</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	may assign and transfer its interest in the Joint Technology in connection with a divestiture of the applicable Collaboration Program to a Third Party or in the case of a permitted assignment of this Agreement with respect to the applicable Collaboration Program, but may not otherwise assign or transfer its interest in the Joint Technology, whether within or outside the Collaboration, without the prior written consent of the other Party;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	may license its interest in the Joint Technology to (i) a permitted Sublicensee pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 12.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, (ii) a Third Party in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 12.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> with respect to a Rejected Collaboration Product, (iii) a Third Party as otherwise permitted under this Agreement (</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">e.g.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 9.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">), or (iv) with respect to Collaboration Screening Data, to an Affiliate or a Third Party pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 5.6</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> in connection with further Development or Commercialization of a Rejected Target; but may not otherwise license or transfer its interest in the Joint Technology to a Third Party, whether within or outside the Collaboration, without the other Party&#x2019;s prior written consent.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.3	Prosecution, Maintenance and Defense</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;15.3	Prosecution, Maintenance and Defense&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except as otherwise agreed by the Parties with respect to Intellectual Property Rights related to applicable Party Assets contributed by such Party pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, the following provisions shall apply with respect to the prosecution, maintenance and defense of any Patent included in Licensed Technology or Program Technology.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.3.1	Program Patents</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  As between the Parties, the Lead Party in respect of each Collaboration Program shall be entitled to direct the prosecution, maintenance and defense (including patent term extensions and supplementary protection certificates) of all Patents within the Program Technology (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Program Patents</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) for the relevant Collaboration Program</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">89</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">worldwide using mutually acceptable outside counsel appointed by the Parties.  The Parties shall [***], through the JPC, to ensure that the Party not entitled to direct the prosecution, maintenance and defense of a particular Program Patent is kept reasonably informed on a regular basis regarding, and provided with reasonable opportunity to comment and consult on, all such activities in respect of such Program Patent.  The costs associated with prosecution, maintenance and defense of Program Patents, including the fees of jointly-appointed outside counsel, shall be allocated between the Parties as set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> or </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.5, </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">irrespective of which Party incurs such costs.  The Party with the right to direct the prosecution, maintenance and defense of a particular Program Patent will give reasonable notice to the other Party before determining to abandon the prosecution, maintenance or defense of such Program Patent, and the other Party would, upon receipt of such notice or the first Party&#x2019;s otherwise abandoning the prosecution, maintenance or defense of the Program Patent, be entitled to assume and thereafter direct such prosecution, maintenance or defense activities, at its own cost and expense.  In such circumstances, the Party relinquishing direction of the prosecution, maintenance or defense activities will still be kept reasonably informed on a regular basis regarding, and provided with reasonable opportunity to comment and consult on, all such activities.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.3.2	Other Patents</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	Vir shall have the right to pursue and direct the prosecution, maintenance and defense of Patents within the Vir Licensed Technology (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir Licensed Patents</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) (including patent term extensions and supplementary protection certificates), provided that Vir will keep GSK reasonably informed through the JPC on a regular basis regarding, and provided with reasonable opportunity to comment and consult on, all such activities.  The costs associated with such activities will be allocated between the Parties as set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> or </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	GSK shall have the right to pursue and direct, at its own cost, the prosecution, maintenance and defense of GSK Licensed Patents (including patent term extensions and supplementary protection certificates), provided that GSK will keep Vir reasonably informed through the JPC on a regular basis regarding, and provided with reasonable opportunity to comment and consult on, all such activities.  The costs associated with such activities will be allocated between the Parties as set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;11.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> or </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.3.3	Cooperation</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Party not directing the prosecution, maintenance or defense of a particular Patent as set forth in this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> will cooperate with the other Party, including furnishing a power of attorney, inventor declaration or assignment documentation, to allow such prosecution, maintenance or defense activities to be carried out effectively and expeditiously.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.3.4	Patent Prosecution after Opt-Out</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. If a Party exercises its Opt-Out Option with respect to a Collaboration Product, and the Non Opt-Out Party elects to continue to Develop, Manufacture and Commercialize the corresponding Sole Development Product in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;7.6.4(a)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, then with respect to any Program Patent Controlled by the Opt-Out Party that is solely related to such Sole Development Product, the Non Opt-Out Party shall have the right, but not the obligation to be responsible for the prosecution, maintenance and defense of such Program Patent, at its own cost and expense, in its sole discretion. The Non</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">90</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Opt-Out Party shall keep the Opt-Out Party [***] informed of any [***] development and communications with applicable intellectual property offices with respect to any such Program Patent solely or jointly owned by the Opt-Out Party, and in the event the Non Opt-Out Party determines to abandon the prosecution, maintenance or defense of any such Program Patent, the Non Opt-Out Party will give reasonable notice to the Opt-Out Party and Opt-Out Party would, upon receipt of such notice or the Non Opt-Out Party&#x2019;s otherwise abandoning the prosecution, maintenance or defense of such Program Patent, be entitled to assume and thereafter direct such prosecution, maintenance or defense activities with respect to such Program Patents. For clarity, the Non Opt-Out Party shall have the sole right, but not the obligation, to be responsible for the prosecution, maintenance and defense of Program Patents that are solely owned by the Non Opt-Out Party, at its own cost and expense, in its sole discretion.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.4	Enforcement Rights</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;15.4	Enforcement Rights&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except as otherwise agreed by the Parties with respect to Intellectual Property Rights related to applicable Party Assets contributed by such Party pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, the following provisions shall apply with respect to the enforcement of any Patent included in Licensed Technology or Program Technology.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.4.1	Notification of Infringement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. If either Party learns of any infringement or threatened or suspected infringement, or misappropriation or threatened or suspected misappropriation, of any (i) Program Technology, Vir Licensed Technology, or GSK Licensed Technology, by the manufacture, use, development or commercialization by a Third Party of a product that competes with a Collaboration Product (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Competing Product</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) or (ii) any Joint Technology, whether or not relating to a Competing Product (each of (i) and (ii), an &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Infringement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), such Party shall promptly provide notice to the JPC describing such Infringement (each, an &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Infringement Notice</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) and, in the case of any certification filed under the &#x201c;U.S. Drug Price Competition and Patent Term Restoration Act of 1984&#x201d; (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Hatch-Waxman</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Act</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) or notification of the submission of an Abbreviated Biologics License Application wherein a Collaboration Product is the &#x201c;Reference Product&#x201d; under the Biologics Price Competition and Innovation Act of 2009 (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">BPCIA</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) or receipt of manufacturing process from a subsection (k) applicant or other similar procedure where a response is required under applicable Law (in order to avoid waiving rights), such Party shall provide notice as quickly as possible and in no event later than thirty (30) days prior to the applicable deadline for filing a response.  For clarity, any certification filed under the Hatch-Waxman Act or notification or submission under the BPCIA shall constitute an Infringement for the purposes of this Agreement.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.4.2	Enforcement and Recoveries</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	The Party having the right to direct the prosecution, maintenance and defense of Program Patents as set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.3.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Program Patent Controlling Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) shall have the right, at its cost and expense, to pursue and direct enforcement of such Program Patents with respect to any Infringement, provided that such Program Patent Controlling Party would provide written notice to the other Party and consult with the other Party, in advance of commencing any enforcement activities in respect of a Program Patent with respect to the Collaboration, subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Program Patent Controlling Party would keep the other Party reasonably informed on a regular basis regarding, and provide such other Party with reasonable opportunity to consult and comment on, all enforcement activities in respect of</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">91</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">the Program Patents.  The other Party shall have the right, to the extent permitted by applicable Laws and procedural rules to join, at its own cost and using its own counsel, as a party to the enforcement actions included in such enforcement activities.  Any damages or other monetary awards recovered from the settlement of or judgment from such enforcement actions shall be allocated first to reimburse the Parties for the costs and expenses incurred by it in connection with such enforcement actions (excluding any cost of separate counsel engaged by the other Party pursuant to the preceding sentence).  Any amounts remaining will be allocated between the Parties in a manner consistent with the applicable split of Pre-Tax Profit or Loss percentages as set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	Vir shall have the right to pursue and direct, at its own cost, enforcement of Vir Licensed Patents with respect to any Infringement, provided that Vir would provide written notice to GSK and consult with GSK, in advance of commencing any such enforcement activities with respect to the Collaboration, subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Vir shall keep GSK reasonably informed on a regular basis regarding, and provide GSK with reasonable opportunity to consult and comment on, all enforcement activities in respect of each Vir Licensed Patent with respect to the Collaboration.  Any damages or other monetary awards recovered from the settlement of or judgment from such enforcement actions shall be allocated first to reimburse Vir for the costs and expenses incurred by it in connection with such enforcement actions.  Any amounts remaining will be allocated between the Parties in a manner consistent with the applicable split of Pre-Tax Profit or Loss percentages as set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	GSK shall have the right to pursue and direct, at its own cost, enforcement of GSK Licensed Patents with respect to any Infringement, provided that GSK would provide written notice to Vir and consult with Vir, in advance of commencing any such enforcement activities with respect to the Collaboration, subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  GSK shall keep Vir reasonably informed on a regular basis regarding, and provide Vir with reasonable opportunity to consult and comment on, all enforcement activities in respect of each GSK Licensed Patent with respect to the Collaboration.  Any damages or other monetary awards recovered from the settlement of or judgment from such enforcement actions shall be allocated first to reimburse GSK for the costs and expenses incurred by it in connection with such enforcement actions.  Any amounts remaining will be allocated between the Parties in a manner consistent with the applicable split of Pre-Tax Profit or Loss percentages.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.4.3	Cooperation</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If the Party having the right to pursue and direct the enforcement as set forth in each of subclauses (a), (b) and (c) in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.4.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (collectively, the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Controlling Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) brings an enforcement action or proceeding with respect to any Infringement in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.4.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, then the other Party shall cooperate as reasonably requested, at such Controlling Party&#x2019;s reasonable expense, in the pursuit of such enforcement action, including if necessary by joining as a party to any such enforcement action for which it is a necessary or indispensable party or taking such other actions as are necessary for standing, furnishing a power of attorney, or for the Controlling Party to otherwise maintain or pursue such enforcement action effectively and expeditiously.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.4.4	Settlement with a Third Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. The Controlling Party for an enforcement action with respect to any Infringement shall also have the right to control the settlement of such enforcement action; provided that the Controlling Party shall not admit the</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">92</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">unenforceability or invalidity of Patents Controlled by the other Party, or of Patents within the Joint Technology without such other Party&#x2019;s prior written consent.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.4.5	Invalidity and Unenforceability</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  For any invalidity and unenforceability claims arising in such enforcement action, the Controlling Party for the enforcement action shall control the response thereto (but may not admit invalidity or unenforceability of any Patent owned by the other Party).  Any other proceeding involving an invalidity or unenforceability challenge, including inter partes review, post-grant review, and any other post-grant proceedings for any issued Patent within the Program Patents, Vir Licensed Patents or GSK Licensed Patents, including reexamination, reissue, opposition, revocation and other similar proceedings, shall be controlled by the Controlling Party that would have the right under this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> if it were to have arisen in an enforcement action.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.4.6	Other Enforcement Activities</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Non Opt-Out Party pursuing any Sole Development Product assumes responsibility for enforcement against any infringement of Program Patents to the extent it relates to such Sole Development Product at its own costs and expense, in its sole discretion.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.5	Joint Patent Committee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;15.5	Joint Patent Committee&#34; \f C \l &#34;2&#34; .  GSK and Vir shall, in advance of taking any actions to enforce Program Patents, GSK Licensed Patents or Vir Licensed Patents with respect to a Competing Product, present the proposed enforcement to the JPC for discussion and reasonably consider comments from members of the JPC representing the other Party.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.6	Third Party Technologies</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;15.6	Third Party Technologies&#34; \f C \l &#34;2&#34; .  For any in-licensed technologies of either Party, the foregoing provisions of this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 15</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall be subject to and limited by the terms and conditions of the applicable existing agreements and any agreement entered into after the Effective Date pursuant to which the in-licensing Party has acquired rights to the applicable Patent</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  Each Party agrees with respect to such agreements as to which it is a party to take such actions and exercise such rights under any such agreements as reasonably necessary to give effect to the foregoing provisions of </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and, where such agreements are inconsistent with any term of this Agreement, such Party shall notify the other Party in writing, including a description of the difference.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.7	Infringement Claims by Third Parties</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;15.7	Infringement Claims by Third Parties&#34; \f C \l &#34;2&#34; .</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.7.1	Notice; Control</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Each Party shall promptly notify the other Party in writing of (a) any allegation by a Third Party that any Development, Manufacture or Commercialization or other activities with respect to any Collaboration Product pursuant to this Agreement infringes or misappropriates or may infringe or misappropriate the Intellectual Property Rights of such Third Party (a &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Product Third Party Infringement Claim</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), or (b) any allegation by a Third Party of infringement or misappropriation of its Intellectual Property Rights with respect to the activities hereunder that is not covered by subclause (a) of this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.7.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (a &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Non-Product Third Party Infringement Claim</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;, and collectively with any Product Third Party Infringement Claim, &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Third Party Infringement Claim</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  For any Product Third Party Infringement Claim, [***] shall be the &#x201c;Defending Party&#x201d; and shall have the right to control the</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">93</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">defense of the Third Party Infringement Claim, but the other Party shall have the right to control its own defense of any such Third Party Infringement Claim brought against it, by counsel of its own choice. In such case, the Parties shall coordinate in good faith. For any Non-Product Third Party Infringement Claim, each Party that is a defendant in such claim shall be the &#x201c;Defending Party&#x201d; and shall have the right to defend itself against such claim.  For clarity, the Non Opt-Out Party shall have the right to control the defense of any Product Third Party Infringement Claim alleged against a Sole Development Product.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.7.2	Cooperation; Settlement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Except with respect to a Sole Development Product, each Defending Party shall keep the other Party reasonably informed of all material developments in connection with any Third Party Infringement Claim.  Each Defending Party agrees to provide the other Party with copies of all pleadings filed in any suit or proceeding relating to such Third Party Infringement Claim.  The Defending Party may enter into a settlement or compromise of any Third Party Infringement Claim, provided, that if such settlement or compromise would admit liability on the part of the non-Defending Party or any of its Affiliates or would otherwise have a material adverse effect on the rights or interests of the non-Defending Party or its Affiliates, the Defending Party shall not enter into such settlement or compromise without the prior written consent of the non-Defending Party.  In the event a proposed settlement involves obtaining a license under Third Party Patent Rights, the applicable provisions of </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 12</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall apply.  Any counterclaims of Infringement shall be handled as set forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.7.3	Costs; Recoveries</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  All out-of-pocket expenses incurred by a Defending Party in defending a Third Party Infringement Claim (including outside counsel fees), and all amounts payable by either Party as a judgment based on a Third Party Infringement Claim or in settlement of such Third Party Infringement Claim, shall be included in the Pre-Tax Profit or Loss calculation.  For clarity, the terms of this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.7.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall not apply to a Third Party Infringement Claim</font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">alleged against a Sole Development Product.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.8	Product Marks</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;15.8	Product Marks&#34; \f C \l &#34;2&#34; .</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.8.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">GSK shall have the sole right to select, obtain and maintain any Product Marks for Collaboration Products and GSK Sole Development Products.  (b) Vir shall have the sole right to select, obtain and maintain any Product Marks for Vir Sole Development Products.  In the case of (a) and (b), respectively, GSK and Vir are each referred to as the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Product Mark Controlling Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;, while the other Party is referred to as the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Product Mark Non-Controlling Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.&#x201d;  The costs associated with such activities for the Collaboration Products shall be included in the Development Costs and Pre-Tax Profit or Loss calculations for the applicable Collaboration Product (excluding Sole Development Products).  Upon reasonable request of the Product Mark Controlling Party, the Product Mark Non-Controlling Party shall provide reasonable assistance in the selection of Product Marks for a Collaboration Product.  As between the Parties, GSK shall be the owner of the Product Marks for any Collaboration Product.  In the case in which a Collaboration Product becomes a Vir Sole Development Product, then Vir may continue to use Product Marks selected by GSK and approved by the FDA or other applicable Regulatory Authority, provided that Vir shall not have the right to use any trademarks owned or controlled by GSK (other than the Product Marks), or that are confusingly similar to such trademarks owned or controlled by GSK.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">94</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.8.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If the Product Mark Non-Controlling Party has a reasonable basis to believe that a Third Party is engaging in infringement of a Product Mark, such Party shall promptly notify the Product Mark Controlling Party in writing and provide it with any evidence of such infringement that is reasonably available.  As between the Parties, the Party owning the infringed Product Mark, or its designee, shall have the sole right and option, at its sole expense, to respond to any infringement or potential infringement with respect to such Product Mark by appropriate steps, including filing an infringement suit or taking other similar action. The non-owning Party shall provide reasonable assistance to the other Party, or the other Party&#x2019;s designee, at such other (owning) Party&#x2019;s expense, with respect to any enforcement activities with respect to such Product Mark, including providing access to relevant documents and other evidence, making its employees reasonably available during business hours, and joining the action to the extent necessary to maintain the action.  Any amounts recovered pursuant to this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 15.8</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> whether by settlement or judgment, shall first be used to reimburse the applicable Party(ies) for their costs and expenses in making such recovery, and any remaining recovery shall be retained by the Product Mark Controlling Party except to the extent included in the Pre-Tax Profit or Loss calculation.</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Product Mark Controlling shall solely control any infringement claim brought by any Third Party with regard to the Product Marks and the costs thereof shall be included in the Pre-Tax Profit or Loss calculated.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.9	Information Technology Requirements</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;15.9	Information Technology Requirements&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Each Party shall use all reasonable efforts, including operating commercially available anti-virus applications (and maintaining up to date virus definitions for such applications), to ensure that no portion of the activities conducted under this Agreement comprising software will contain any unauthorized code, or virus, Trojan horse, worm, or any other software routine or hardware component designed to permit, either automatically or through externally applied controls, unauthorized access or use to disable, erase, or otherwise harm software, hardware, or data (collectively &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Malwares</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  To the extent that any Party, in conducting activities under this Agreement, uses any system or software belonging to the other Party, such Party shall use its best efforts to avoid the introduction of any Malwares into such systems or software.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.9.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">To the extent that any Malwares are discovered in any deliverables provided under this Agreement or is introduced to a Party&#x2019;s systems or software by the other Party (or is reasonably likely to have been so introduced), such other Party shall use all reasonable efforts to assist the Party to which the Malware was delivered in removing such Malware from the software in question and shall be responsible for the costs of such removal.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.9.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Each Party shall ensure that it has up to date information on all personnel who have access to the other Party&#x2019;s IT systems and agrees to provide periodic updates on the names of such personnel.  Each Party shall, no more than [***] after any change in such information or any new information, notify the other Party promptly of any individual IT user access change.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">15.9.3	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Both Parties agree to maintain reasonable security measures, in line with industry best practices for systems storing, accessing, or otherwise processing any Data. The Parties agree to coordinate in good faith regarding any requested updates or modifications to the security practices of the other Party as applicable to the Collaboration.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">95</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 16<br>Term and Termination TC &#34;ARTICLE 16	TERM AND TERMINATION&#34; \f C \l &#34;1&#34;</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">16.1	Term</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;16.1	Term&#34; \f C \l &#34;2&#34; .  This Agreement shall be effective as of the Effective Date and, unless terminated under this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 16</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (in its entirety, on a Collaboration Program basis or a Collaboration Product basis, as the case may be),</font><font style="color:rgba(43,87,154,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">shall remain in effect (a) with respect to the Influenza Program, unless and until such time as there is no Influenza Product being Developed or Commercialized by the Lead Party or the LCP, or in the case of a corresponding Sole Development Product, by the Non Opt-Out Party, (b) with respect to each Additional Pathogen Program, unless and until such time as there is no Additional Pathogen Product with respect to such Additional Pathogen Program being Developed or Commercialized by the Lead Party or the LCP, or in the case of a corresponding Sole Development Product, by the Non Opt-Out Party, and (c) with respect to the Expanded Functional Genomics Program, unless and until (i) the end of the Initial Development Term if no Expanded Functional Genomics Targets are selected by the JSC during the Initial Development Term or (ii) if there is at least one Expanded Functional Genomics Target selected by the JSC during the Initial Development Term, then until such time as there is no Expanded Functional Genomics Product being Developed or Commercialized by the Lead Party or the LCP, or in the case of a corresponding Sole Development Product, by the Non Opt-Out Party (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Term</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">   </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">16.2	Mutual Termination</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;16.2	Mutual Termination&#34; \f C \l &#34;2&#34; .  The Parties may terminate this Agreement in its entirety or with respect to a particular Collaboration Program or Collaboration Product at any time by mutual written agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">16.3	Termination for Cause</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;16.3	Termination for Cause&#34; \f C \l &#34;2&#34; .  In addition to any other remedies conferred by this Agreement or by applicable Law or in equity, either Party (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Non-Breaching Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) may terminate this Agreement with respect to a particular Collaboration Program or a particular Collaboration Product upon written notice to the other Party (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Breaching Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) if there is an uncured material breach by the Breaching Party that impacts such Collaboration Program or such Collaboration Product.  To exercise its termination rights under this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 16.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, the Non-Breaching Party shall provide the Breaching Party with written notice identifying the material breach [***] and indicating whether the Non-Breaching Party is intending to terminate this Agreement with respect to the applicable Collaboration Program or Collaboration Product.  If the Breaching Party, upon receiving such written notice identifying such material breach in reasonable detail, fails to cure such material breach within [***] after the date of such notice of breach is received, then this Agreement with respect to such particular Collaboration Program or Collaboration Product shall terminate.  Notwithstanding the foregoing, if such breach is curable but cannot reasonably be cured within such [***], such cure period shall be extended if the Breaching Party provides the Non-Breaching Party with a written plan for curing such breach and uses Commercially Reasonable Efforts to cure such breach in accordance with such written plan; provided that no such extension shall exceed [***] without the consent of the Non-Breaching Party.  If the existence or materiality of such alleged breach or if the failure to cure is contested in good faith by the alleged Breaching Party in writing within [***] after the delivery of the breach notice, then the dispute resolution procedure pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 22.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> may be initiated by either Party to determine whether a material breach or a failure to cure has actually occurred.  If either Party so initiates the dispute resolution</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">96</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">procedure, then the Non-Breaching Party shall not have the right to terminate this Agreement under this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;16.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> until such time as (a) the dispute is resolved pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 22.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> with a determination that the Breaching Party has materially breached this Agreement or has failed to cure such breach, and (b) the Breaching Party has failed to cure such material breach within [***] thereafter (or within such other cure period prescribed by the arbitrators).  It is understood and agreed that, during the pendency of such dispute, all of the terms and conditions of this Agreement shall remain in effect and the Parties shall continue to perform all of their respective obligations hereunder.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">16.4	Termination for Insolvency</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;16.4	Termination for Insolvency&#34; \f C \l &#34;2&#34; .  Either Party may terminate this Agreement in its entirety or with respect to a Collaboration Program or Collaboration Product, effective immediately upon written notice to the other Party if, at any time such other Party (or any Affiliate that controls such Party) (a) files in any court or agency pursuant to any statute or regulation of any state or country a petition in bankruptcy or insolvency or for reorganization (except for solvent reorganization or solvent reconstruction) or for an arrangement or for the appointment of a receiver or trustee of the Party or of substantially all of its assets, (b)&#160;proposes a written agreement of composition or extension of substantially all of its debts, (c)&#160;is served with an involuntary petition against it, filed in any insolvency proceeding, and such petition is not be dismissed within [***] after the filing thereof, (d) proposes to be a party to any dissolution or liquidation, (e)&#160;admits in writing its inability generally to meet its obligations as they fall due in the general course or (f) makes an assignment of substantially all of its assets for the benefit of creditors.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 17<br>Effects of Expiration or Termination TC &#34;ARTICLE 17	EFFECTS OF EXPIRATION OR TERMINATION&#34; \f C \l &#34;1&#34;</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">17.1	Accrued Obligations</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;17.1	Accrued Obligations&#34; \f C \l &#34;2&#34; .  The expiration or termination of this Agreement (in whole or in part) for any reason shall not release either Party from any liability that, at the time of such expiration or termination, has already accrued to the other Party or that is attributable to a period prior to such expiration or termination, nor will any early termination of this Agreement preclude either Party from pursuing any and all rights and remedies it may have under this Agreement, or at law or in equity, with respect to breach of this Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">17.2	Effects of Termination by Mutual Agreement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;17.2	Effects of Termination by Mutual Agreement&#34; \f C \l &#34;2&#34; .  In the case of a termination under </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 16.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> of this Agreement with respect to a particular Collaboration Program or Collaboration Product by mutual written agreement, the Parties shall also agree on the consequences of such a termination, including winding down of any Development activities with respect to any Collaboration Products.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">17.3	Effects of Termination for Material Breach or Insolvency</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;17.3	Effects of Termination for Material Breach or Insolvency&#34; \f C \l &#34;2&#34; .  If this Agreement is terminated, in whole or in part pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 16.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> or </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 16.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, then:</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">17.3.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Regardless whether the Party that is subject to such termination (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Terminated Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) is a Lead Party at the time of such termination, (a) except to the extent set</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">97</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">forth in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 17.3.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> below with respect to payments owed to the Terminated Party following such termination, such termination shall be treated as though the Terminated Party had exercised an Opt-Out Option with respect to the Collaboration Product(s) subject to such termination (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Terminated Collaboration Product(s)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) on the effective date of such termination; (b) the licenses granted to the Party terminating this Agreement (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Terminating Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) under </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 12.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall remain in effect only to the extent actually used for or incorporated in such terminated Collaboration Product(s) on or prior to the effective date of such termination, and subject to the terms and conditions (including any financial terms for such licenses) and any rights granted to a Third Party in a Third Party agreement with respect to such Terminated Collaboration Product existing prior to the effective date of such termination; (c) the Terminating Party may continue with the Development and Commercialization of such Terminated Collaboration Product(s) at its discretion, and shall retain the sole right to out-license or otherwise divest the Terminated Collaboration Product(s) at its discretion in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;7.6.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, including by sublicensing to Third Parties, subject to any applicable terms in the license granted with respect to such Terminated Collaboration Product; (d) following the effective date of such termination, the Terminating Party shall [***]; and (e) the Terminated Party shall [***].</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">17.3.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If the Terminating Party elects to continue with the Development and Commercialization of the Terminated Collaboration Product(s), [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">17.3.3	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Without limiting </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 17.3.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, if the Party that is subject to the termination is the Lead Party, the Terminating Party shall have the right to assume the role of the Lead Party in the manner otherwise set forth in this Agreement with respect to any Terminated Collaboration Product(s).  Subject to the proviso in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;17.3.1(c)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, the terminated Party shall, in accordance with the terms of this Agreement, effect transfer of relevant regulatory documentation and Manufacturing solely with respect to the Terminated Collaboration Product(s) to the Terminating Party in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 8.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> or </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 13.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, as applicable.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">17.4	Other Termination Consequences</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;17.4	Other Termination Consequences&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If this Agreement is terminated for any reason pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Sections 16.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> through </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">16.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, then the following provisions shall apply:</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">17.4.1	Development Costs and Pre-Tax Profit or Loss</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">There shall be a final accounting for any Development Costs and Pre-Tax Profits or Losses that are required to be shared by the Parties hereunder for the Collaboration Program or Collaboration Product that is terminated, which shall include any such Development Costs and Pre-Tax Profits or Losses that are incurred (a) prior to the effective date of such termination of this Agreement, in whole or in part, (b) after the effective date of termination of this Agreement, in whole or in part, but relating to activities conducted during the Term (including any non-cancellable commitments incurred pursuant to the terminated Collaboration Program(s) in accordance with this Agreement), and (c) after the effective date of termination of this Agreement, in whole or in part, and required to be conducted in order to wind-down activities under the terminated Collaboration Program(s) in a manner compliant with applicable Law.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">17.4.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">98</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	If, upon (i) [***], (ii) [***], or (iii) [***], in each case ((i)-(iii)), with respect to a Collaboration Product, there are [***] (&#x201c;[***]&#x201d;), then such [***], and such [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	In the case of [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	In the case of [***] for (i) [***] or (ii) [***], in each case ((i) or (ii)), [***], provided that, in the case of </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 17.4.2(c)(i)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, if [***], then [***].</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">17.4.3	Unaffected Programs or Products</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If this Agreement is terminated only with respect to a particular Collaboration Program or Collaboration Product, then all unaffected Collaboration Programs and Collaboration Products shall remain in effect in accordance with and subject to the terms and conditions of this Agreement.  Without limiting the foregoing, the rights granted by each Party to the other Party with respect to such Collaboration Programs and Collaboration Product that are not subject to the termination shall remain in effect in accordance with and subject to terms and conditions of this Agreement.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">17.5	Survival</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;17.5	Survival&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The following provisions shall survive expiration or termination of this Agreement in</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">its entirety, or with respect to a particular Collaboration Program or Collaboration Product: </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Sections 5.6</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (excluding </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">5.6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, except that the first sentence of </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">5.6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> before the proviso (but none of the remainder of </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">5.6.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> including the proviso) shall survive, if the Agreement is terminated during the Restricted Data Period), </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">7.3.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (for the applicable time period set forth therein), </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">11.7.1 </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(for payment obligations accruing during the Term and for costs required to be shared hereunder following expiration or termination), </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">11.7.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (only with respect to payment obligations accruing during the Term and for amounts accruing after expiration or termination that are required to be shared hereunder), </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">11.8</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (as applied in connection with any final accounting, and with respect to payment obligations accruing during the Term and after termination in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 17.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">), </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">11.9.4</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (as applied in connection with any final accounting, and with respect to payment obligations accruing during the Term and after termination in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 17.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">), </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">11.10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (for the applicable time period set forth therein), </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">11.11</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">11.12</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (only with respect to payment obligations accruing during the Term and for costs required to be shared hereunder following expiration or termination), </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">11.13</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (solely with respect to payments owed as of the effective date of termination), </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">11.14,</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">11.16(b)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">11.17</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">12.1.1(c)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">12.1.2(c)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">12.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">12.4,</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">12.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">12.8</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (each, as relating to any surviving licenses hereunder), </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">12.6</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">12.7</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">14.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (solely with respect to the obligation to remove the other Party&#x2019;s Confidential Information) </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">14.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (last sentence), </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">15.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (excluding </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">15.1.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">), </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">15.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">20.1,</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">20.2 </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(as required to stand-by any post-termination liabilities), </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">20.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.6</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (solely with respect to the performance by a Party of its obligations under this Agreement that survive expiration or termination) </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.7</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.9</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.11</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.12</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.13</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (to the extent applicable to other surviving provisions), </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 17</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 18</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 19</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (solely with respect to claims for breaches occurring prior to the end of the Term), </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 1.99</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (with respect to any post-termination calculations), and any applicable definitions of any capitalized terms.  In the event of expiration or termination, each Party shall remain obligated to share in any costs as to which it is committed as of the date of expiration or termination and where applicable, </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 13.3.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall apply with respect to both Parties.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">99</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">17.6	Termination Not Sole Remedy</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;17.6	Termination Not Sole Remedy&#34; \f C \l &#34;2&#34; .  Termination is not the sole remedy under this Agreement and, whether or not termination is effected, all other remedies at equity or law shall remain available to the Parties except as agreed to otherwise herein.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 18<br>Confidentiality  TC &#34;ARTICLE 18	CONFIDENTIALITY &#34; \f C \l &#34;1&#34;</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">18.1	Confidentiality</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;18.1	Confidentiality&#34; \f C \l &#34;2&#34; .  Except to the extent expressly authorized by this Agreement or otherwise agreed by the Parties in writing, during the Term and for a period of [***] following termination or expiration thereof, each Party will be obligated to keep confidential and not publish or otherwise disclose to a Third Party, and not to use, directly or indirectly, for any purpose other than the Collaboration, any Confidential Information furnished or otherwise made known to it, directly or indirectly, by the other Party, except to the extent such disclosure or use is expressly permitted by the terms of this Agreement, or is reasonably necessary or useful for the performance of, or the exercise of such Party&#x2019;s rights under, this Agreement. The confidentiality and non-use obligations with respect to a Party&#x2019;s Confidential Information in this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 18.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> will not include any information that:</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	Is or becomes part of the public domain through no wrongful act, fault or negligence on the part of the Receiving Party;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	can be demonstrated by competent proof to have been in the Receiving Party&#x2019;s possession prior to disclosure by the Disclosing Party without any obligation of confidentiality with respect to such information;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	is subsequently received by the Receiving Party from a Third Party who is not bound by any obligation of confidentiality with respect to such information;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	has been published by a Third Party or otherwise enters the public domain through no fault of the Receiving Party in breach of its contractual obligations to the Disclosing Party; or</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)	can be demonstrated by competent proof to have been independently developed (outside the scope of the Collaboration) by or for the Receiving Party without reference to the Disclosing Party&#x2019;s Confidential Information.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">18.2	Authorized Disclosure</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;18.2	Authorized Disclosure&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Receiving Party may disclose Confidential Information of the Disclosing Party to the extent that such disclosure is:</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	made in response to a valid order of a court or other Governmental Authority or, if in the reasonable opinion of the Receiving Party, such disclosure is otherwise required by Law, including by reason of filing with securities regulators; provided</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">that the Receiving Party shall, to the extent permitted by Law, first have given notice to the Disclosing Party and given the Disclosing Party a reasonable opportunity, at the Disclosing Party&#x2019;s expense, to quash such order or to obtain a protective order or confidential treatment; and provided further that the Confidential Information disclosed in response to such court or governmental order shall</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">100</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">be limited to that information which is legally required to be disclosed in response to such court or governmental order;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	made by or on behalf of the Receiving Party to Regulatory Authorities as required in connection with any filing, application or request for marketing or other Regulatory Approval; provided that reasonable measures shall be taken to assure confidential treatment of such information to the extent practicable and consistent with applicable Law;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	made by or on behalf of the Receiving Party to a patent authority as may be reasonably necessary or useful for purposes of obtaining or enforcing a Patent; provided that reasonable measures shall be taken to assure confidential treatment of such information, to the extent such protection is available; or</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	made by the Receiving Party to its attorneys, auditors, advisors, consultants, contractors, existing or prospective collaboration partners, licensees, sublicensees, existing or prospective investors, prospective acquirers, or other Third Parties as may be necessary or useful in connection with exploitation of Collaboration Products as contemplated by the Collaboration or otherwise in connection with the performance of its obligations or exercise of its rights as contemplated by this Agreement; provided that such Persons shall be subject to obligations of confidentiality and non-use with respect to such Confidential Information substantially similar to the obligations of confidentiality and non-use of the Receiving Party set forth herein.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">18.3	</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Injunctive Relief</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;18.3	Injunctive Relief&#34; \f C \l &#34;2&#34; .  Each Party, as a Receiving Party, acknowledges and agrees that due to the unique nature of a Disclosing Party&#x2019;s Confidential Information, there may be no adequate remedy at law for any breach of its obligations hereunder and that any such breach may allow a Receiving Party or Third Parties unfairly to compete with the Disclosing Party, resulting in irreparable harm to the Disclosing Party. Therefore, notwithstanding the provisions of </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 22.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, the Parties agree that upon any such breach or any threat thereof, the Disclosing Party shall be entitled to seek appropriate equitable relief at the Disclosing Party&#x2019;s option in either (a) a court of competent jurisdiction where such Disclosing Party resides, or (b) as provided in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;22.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, as applicable, in addition to whatever remedies it might have at law in connection with any breach or enforcement of a Receiving Party&#x2019;s obligations hereunder for the unauthorized use or release of any such Confidential Information.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">18.4	</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Return of Confidential Information</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;18.4	Return of Confidential Information&#34; \f C \l &#34;2&#34; .  At the written request of the Disclosing Party promptly following the termination of this Agreement, the Receiving Party shall (and shall cause its Affiliates and their respective representatives to) return to the Disclosing Party or destroy all originals of documents (in paper or electronic form) and physical materials then in its possession, and copies thereof, containing Confidential Information received from the Disclosing Party and constituting its exclusive Confidential Information, and destroy all documents and other materials that it created including any such Confidential Information; provided that the Receiving Party may retain in confidence (a) one (1) archival copy of the Confidential Information in its legal files solely to permit the Receiving Party to determine compliance with its obligations hereunder; (b)&#160;any portion of the Confidential Information of the other Party which is contained in the Receiving Party&#x2019;s laboratory notebooks; (c) any portion of the Confidential Information of the other Party which a</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">101</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Receiving Party is required by applicable Law to retain; and (d) any Confidential Information that the Receiving Party has the right to continue to use after the date of the Disclosing Party&#x2019;s request after termination or expiration of this Agreement, as applicable. Notwithstanding the return or destruction of the documents and tangible items described above, the Parties will continue to be bound by their obligations under this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 18</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">18.5	</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Press Releases and Other Public Statements</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;18.5	Press Releases and Other Public Statements&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">  </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Except for any publications or presentations that are made consistent with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 14</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> and those certain press releases made in connection with the execution of the SPA and the Preliminary Collaboration Agreement, neither Party nor its Affiliates will make any public announcements, press releases, regulatory filing or other public disclosures, written or oral, whether to the public, the press, stockholders or otherwise, concerning this Agreement or the terms and conditions or the subject matter hereof, the performance hereof or the Parties&#x2019; activities hereunder, or any results or data arising hereunder (a &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Public Statement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), except: (a) with the prior written consent of the other Party (which may be conditional upon certain restrictions as to the content or distribution of such Public Statement); or (b) for such Public Statements, as in the opinion of the Party intending to make such Public Statement, are required to comply with applicable Law, regulation, rule or legal process (including the regulations of any stock exchange) (a &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Legal Requirement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) and which in any event contain only the minimum disclosure necessary to comply with the relevant Legal Requirement.  Each Party agrees, to the extent permitted by Legal Requirements, in any event to provide the other Party with a copy of any proposed Public Statement as soon as reasonably practicable under the circumstances prior to its scheduled release.  Except under extraordinary circumstances, when the following notice may not be possible but in which event the proposed Public Statement will still be provided to the other Party for comment before release (which the releasing Party shall use reasonable efforts to provide at least forty-eight (48) hours prior to the intended time of publication), and to the extent permitted by Legal Requirements, each Party shall provide the other Party with an advance copy of any such Public Statement at least seven (7) days prior to its scheduled release.  Each Party furthermore shall have the right to review and recommend changes to any such announcement and, except as otherwise required by Legal Requirement, the Party whose announcement has been reviewed shall remove any Confidential Information of the reviewing Party that the reviewing Party reasonably deems to be inappropriate for disclosure, subject to the exceptions in </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;18.2(a)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Each Party agrees in any event to give the other Party a reasonable opportunity (to the extent consistent with Legal Requirements) to review all [***] Public Statements required by Legal Requirements to be filed with the Securities and Exchange Commission or similar body prior to submission of such filings, and will give due consideration to any reasonable comments by the non-filing Party relating to such filing, including the provisions of this Agreement for which confidential treatment should be sought.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 19<br>Representations and Warranties AND COVENANTS TC &#34;ARTICLE 19	REPRESENTATIONS AND WARRANTIES AND COVENANTS&#34; \f C \l &#34;1&#34;</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.1	Mutual Representations and Warranties</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;19.1	Mutual Representations and Warranties&#34; \f C \l &#34;2&#34; .  Each Party represents and warrants to the other Party as of the Execution Date and the Effective Date, that:</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">102</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.1.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">such Party is duly organized, validly existing and in good standing under the Laws of the jurisdiction of its incorporation and has full corporate power and authority and legal right to enter into this Agreement and to carry out the provisions hereof;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.1.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">such Party has the right to grant the licenses to the other Party purported to be granted pursuant to this Agreement;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.1.3	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">such Party has taken all necessary action on its part required to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.1.4	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">such Party has received all necessary laboratory licenses and certificates with respect to facilities within such Party&#x2019;s ownership or control sufficient to allow such Party to conduct the activities assigned to such Party under this Agreement, and such Party is in compliance with the requirements of such licenses and certificates;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.1.5	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">this Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid and binding obligation of such Party that is enforceable against it in accordance with the terms and conditions hereof, subject to the effects of bankruptcy, insolvency or other laws of general application affecting the enforcement of creditor rights, judicial principles affecting the availability of specific performance and general principles of equity (whether enforceability is considered a proceeding at law or equity);</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.1.6	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">the execution, delivery and performance of this Agreement by such Party (i) will not constitute a default under, or conflict with, any agreement, instrument or understanding, oral or written, to which it is a party or by which it is bound, (ii) violate any Law or regulation of any court, governmental body or administrative or other agency having jurisdiction over such Party; and (iii) is not prohibited or limited by, and shall not result in the breach of or a default under, any provision of the certificate or articles of incorporation or bylaws of such Party;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.1.7	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">except for any filings that may be required to comply with the HSR Act or any other applicable antitrust law, no government authorization, consent, approval, license, exemption of or filing or registration with any court or governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign, under any applicable Laws, rules or regulations currently in effect, is or will be necessary for, or in connection with, the transaction contemplated by this Agreement or any other agreement or instrument executed in connection herewith, or for the performance by it of its obligations under this Agreement and such other agreements;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.1.8	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">such Party and its Affiliates have not employed (and, to its knowledge, has not used a (sub)contractor or consultant that has employed) and, during the Term, will not knowingly employ (or, to its knowledge, use any (sub)contractor or consultant that employs, provided that such Party may reasonably rely on a representation made by such (sub)contractor or consultant) any Person debarred by the FDA (or subject to a similar sanction of EMA or foreign equivalent), or any Person which is the subject of an FDA debarment investigation or proceeding (or similar proceeding of EMA or foreign equivalent);</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">103</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.1.9	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">such Party and its Affiliates performing activities under the Collaboration has in place or will have in place prior to its conduct of its activities under the Collaboration a written agreement with its employees and other personnel it appoints to perform such activities hereunder sufficient to ensure that such Party has sufficient ownership or license rights to any Program Technology developed or created by such Party to grant the rights to the other Party as required to be granted under this Agreement;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.1.10	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">with respect to any Research and Development activities conducted by such Party or its Affiliates under this Agreement that involve the use of animals, including any animal studies, such Party and its Affiliates agree to comply with the terms of </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 7.6.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.1.11	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">to the knowledge of such Party, as it is relevant to this Agreement:</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	such Party respects the human rights of its staff and does not employ child labor, forced labor, unsafe working conditions, or cruel or abusive disciplinary practices in the workplace;</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	such Party does not discriminate against any workers on any ground (including race, religion, disability, gender, sexual orientation or gender identity);</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	such Party pays each employee at least the minimum wage, provides each employee with all legally mandated benefits, and complies with the laws on working hours and employment rights in the countries in which it operates; and</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	such Party is respectful of its employees right to freedom of association; and</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.1.12	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">such Party is in material compliance with (a) all applicable Laws relating to data privacy and data security, including with respect to the collection, use, storage, sharing, transfer, disposition, protection and processing of PII; (b) all privacy policies and other related policies, programs and other notices of such Party relating to the privacy, protection and security of PII; and (c) all contractual and other legal requirements to which such Party is subject with respect to the privacy, protection, and security of PII; and has in place reasonable safeguards to protect the confidentiality and security of PII, including from unauthorized access or misuse, based on applicable Law.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.2	Representations and Warranties of Vir (Existing Influenza Program mAbs)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;19.2	Representations and Warranties of Vir (Existing Influenza Program mAbs)&#34; \f C \l &#34;2&#34; .  Vir represents and warrants to GSK, as of the Execution Date and the Effective Date, and, with respect to Vir-2482, if GSK exercises the Option, the Vir-2482 Program Effective Date, each as follows:</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.2.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***];</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.2.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">except as reasonably disclosed by Vir [***], Vir or one of its Affiliates solely owns or exclusively licenses and Controls the Existing Influenza Program mAbs and Vir 2482 Licensed Technology;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">104</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.2.3	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">except as reasonably disclosed by Vir [***], neither Vir nor any of its Affiliates has entered into any agreement (other than agreements with subcontractors) granting any right, interest or claim in or to, any Existing Influenza Program mAbs or Vir 2482 Licensed Technology that would conflict with the rights and licenses to GSK granted or required to be granted in this Agreement;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.2.4	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">except as reasonably disclosed by Vir [***], neither Vir nor any of its Affiliates has previously entered into any agreement, whether written or oral, to assign, transfer, license, convey or otherwise encumber its right, title or interest in or to any Patent or other Know-How that is necessary for the Development, Manufacture, or Commercialization of any Existing Influenza Program mAbs, in each case, where such Patent or other Know-How would be Vir 2482 Licensed Technology but for such assignment, transfer, license, conveyance or encumbrance;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.2.5	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">except as reasonably disclosed by Vir [***];</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.2.6	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">except as reasonably disclosed by Vir [***], Vir has not granted any right to any Third Party that would conflict with the rights granted to GSK hereunder with respect to the Existing Influenza Program mAbs and Vir 2482 Licensed Technology;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.2.7	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">each Person who has or has had any rights in or to any Vir 2482 Licensed Technology owned by Vir and that is [***] has assigned and has executed an agreement assigning its entire right, title and interest in and to such Vir 2482 Licensed Technology to Vir or one of its Affiliates;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.2.8	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">all Vir Licensed Patents are subsisting and all Vir Licensed Patents for which Vir controls prosecution and maintenance activities are being diligently prosecuted in the patent offices in accordance with applicable Law and, to Vir&#x2019;s Knowledge, are not invalid or unenforceable in whole or in part;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.2.9	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">to Vir&#x2019;s Knowledge, no Person is infringing or threatening to infringe or misappropriating or threatening to misappropriate any Vir 2482 Licensed Technology and there are no activities by Third Parties that would constitute infringement or misappropriation of the Vir 2482 Licensed Technology;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.2.10	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">except as reasonably disclosed by Vir [***], no claim or litigation has been brought or threatened in writing by any Person against Vir or any of its Affiliates alleging, and Vir has no Knowledge of any reasonable basis for any such claim or allegation, whether or not asserted, that (a) any Vir Licensed Patents are invalid or unenforceable, or (b) the use or practice of any Vir 2482 Licensed Technology, or the disclosing, copying, making, assigning or licensing of any Vir 2482 Licensed Technology, or the exploitation of the Existing Influenza Program mAbs, does or will violate, infringe, misappropriate or otherwise conflict or interfere with, any Patent or other intellectual property or proprietary right of any Third Party;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.2.11	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***];</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.2.12	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Vir has provided or made available to GSK all material adverse information with respect to the safety and efficacy of the Existing Influenza Program mAbs of</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">105</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">which Vir is aware and </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">to Vir&#x2019;s Knowledge</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> is or could be reportable to the applicable Regulatory Authorities;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.2.13	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***];</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.2.14	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***];</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.2.15	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">except as reasonably disclosed by Vir [***];</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.2.16	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">except as reasonably disclosed by Vir [***], Vir or one of its Affiliates has obtained the right (including under any Patents and other intellectual property rights) to use all information and all other materials (including any formulations and manufacturing processes and procedures) developed or delivered by any Third Party under any agreements between Vir or one of its Affiliates and any such Third Party with respect to any Existing Influenza Program mAbs to the extent necessary to provide GSK with the rights granted to it hereunder, and Vir or one of its Affiliates has the rights to grant GSK the right to use such information or other materials in the Development or Commercialization of the Program mAbs as contemplated in this Agreement;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.2.17	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***];</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.2.18	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Vir is in material compliance with (i) all applicable laws relating to data privacy and data security, including with respect to the collection, use, storage, sharing, transfer, disposition, protection and processing of personally identifiable information (PII); (ii) all privacy policies and other related policies, programs and other notices of Vir relating to the privacy, protection and security of PII; and (iii) all contractual and other legal requirements to which Vir is subject with respect to the privacy, protection, and security of PII; and has in place reasonable safeguards to protect the confidentiality and security of PII, including from unauthorized access or misuse, based on applicable law;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.2.19	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***];</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.2.20	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]; and</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.2.21	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***].</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.3	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> Representations, Warranties and Covenants</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;19.3	China Territory Representations, Warranties and Covenants&#34; \f C \l &#34;2&#34; .</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.3.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Vir hereby represents and warrants that, as of the Execution Date and the Effective Date, with respect to [***] that are subject to this Agreement [***], other than [***], Vir has not [***]; and</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.3.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Following the Execution Date, Vir covenants that it will not [***]. Vir acknowledges and agrees that, [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.4	Post-Closing Covenants</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;19.4	Post-Closing Covenants&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">106</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.4.1	Negative Covenants</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. After the Effective Date and during the Term, neither Party shall, and shall cause its Affiliates not to, without the prior written consent of the other Party (such consent not to be unreasonably withheld, conditioned or delayed):</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	enter into any agreement with any Third Party, whether written or oral, with respect to, or otherwise assign, transfer, license or convey its right, title or interest in or to, (i) the Vir Licensed Technology or GSK Licensed Technology, as applicable, relating to any Collaboration Program or Collaboration Product, (ii) [***] or (iii) [***], in each case, in a manner that creates a material conflict with the rights granted or purported to be granted by such Party to the other Party under this Agreement;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	(i) sell, out-license or otherwise dispose of any assets or rights relating to (1) any Collaboration Program or Collaboration Product, (2) [***] or (3) [***], in each case, in a manner that creates a material conflict with the rights granted or purported to be granted by such Party to the other Party under this Agreement, (ii) amend any agreements, licenses or other rights of such Party or any of its Affiliates, including, for clarity, any Existing Third Party Agreements, relating to (1) any Collaboration Program or Collaboration Product, (2) [***] or (3) [***], in each case, in a manner that creates a material conflict with the rights granted or purported to be granted by such Party to the other Party under this Agreement, or (iii) grant any security interest or otherwise encumber material assets and properties (including Vir Licensed Technology or GSK Licensed Technology, as applicable), relating to (1) any Collaboration Program or Collaboration Product, (2) [***] or (3) [***];</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	 [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.4.2	Affirmative Covenants</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  After the Effective Date and during the Term, each Party covenants that:</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)	it shall, and shall cause its Affiliates and its and their respective contractors, licensees and consultants to, conduct the Collaboration Programs and all other activities undertaken pursuant to this Agreement in accordance with applicable Law;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)	with respect to all intellectual property that it purports to license to the other Party under this Agreement that is, may be or becomes subject to the Bayh-Dole Act, it shall, and shall cause its Affiliates and the relevant research partners to, continue to comply with the applicable provisions of the Bayh-Dole Act, in a manner that protects and preserves such Party&#x2019;s right, title and interest in the subject intellectual property to the maximum extent permitted by applicable Law;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)	it shall promptly notify the other Party of the occurrence of a Key Product Event, and in no event more than [***] after such occurrence; and</font></p>
  <p style="text-indent:26.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)	[***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.5	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***] TC &#34;19.5	Disclosure&#34; \f C \l &#34;2&#34; . If Vir [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">19.6	Disclaimer of Warranty</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;19.6	Disclaimer of Warranty&#34; \f C \l &#34;2&#34; .  EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, EACH PARTY</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">107</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">SPECIFICALLY DISCLAIMS ANY GUARANTEE THAT ANY PLAN WILL BE SUCCESSFUL, IN WHOLE OR IN PART.  EXCEPT AS OTHERWISE EXPRESSLY STATED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATION OR WARRANTY OF ANY KIND, AND BOTH PARTIES EXPRESSLY DISCLAIM ALL WARRANTIES, EXPRESS OR IMPLIED, INCLUDING WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE AND NONINFRINGEMENT.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 20<br>Indemnification TC &#34;ARTICLE 20	INDEMNIFICATION&#34; \f C \l &#34;1&#34;</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">20.1	Indemnification</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;20.1	Indemnification&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:normal;vertical-align:top;font-size:8.04pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">20.1.1	Indemnification by Vir</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Vir hereby agrees to indemnify, defend and hold harmless GSK and its Affiliates and their respective directors, officers, employees and agents, and the respective successors and assigns any of the foregoing (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">GSK Indemnitees</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), from and against any and all suits, claims, actions, demands, losses, damages, liabilities, settlements, penalties, fines, costs and expenses (including reasonable attorneys&#x2019; fees and other expenses of litigation) (collectively, &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Losses</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) asserted by a Third Party to the extent arising from [***], except in each case ((i) to (iv)), to the extent such Losses are indemnifiable by GSK under </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;20.1.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">20.1.2	Indemnification by GSK</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. GSK hereby agrees to indemnify, defend and hold harmless Vir and its Affiliates and their respective directors, officers, employees and agents, and the respective successors and assigns of any of the foregoing (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir Indemnitees</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), from and against any and all Losses asserted by a Third Party to the extent arising from [***]; except in each case ((i) to (v)), to the extent such Losses are indemnifiable by Vir under </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;20.1.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">20.1.3	Indemnification Procedures</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Upon becoming aware or receipt of notice of any Third Party claim that may be subject to indemnification by the other Party (the &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Indemnifying Party</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) under this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;20.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, any GSK Indemnitee or any Vir Indemnitee (each, an &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Indemnitee</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), as the case may be, shall [***] notify the Indemnifying Party in writing (it being understood and agreed, however, that the failure by an Indemnitee to timely give such notice shall not relieve the Indemnifying Party of its indemnification obligation under this Agreement except and only to the extent that the Indemnifying Party is actually prejudiced as a result of such failure to give timely notice).  The Indemnifying Party shall have the right, but not the obligation, to conduct and control, through counsel of its choosing, any action for which indemnification is sought, and if the Indemnifying Party elects to assume the defense thereof, the Indemnifying Party shall not be liable to the Indemnitee for any legal expenses of other legal counsel or any other expenses subsequently incurred by such Indemnitee in connection with the defense thereof.  The Indemnifying Party may not settle any action, claim or suit for which the Indemnitee is seeking indemnification without such Indemnitee&#x2019;s prior written approval, such approval not to be unreasonably withheld, conditioned or delayed. The Parties and their employees shall cooperate fully with each other and their legal representatives in the investigation, defense, prosecution, negotiation, or settlement of any such claim or suit.  The Indemnitee shall not settle or compromise any action, claim or suit for which the Indemnitee is seeking indemnification</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">108</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">without the prior written consent of the Indemnifying Party.  In no event shall the Indemnifying Party settle or abate any Third Party claim in a manner that would diminish the rights or interests of the Indemnitee or obligate the Indemnitee to make any payment, take any action, or refrain from taking any action, without the prior written approval of the Indemnitee. Notwithstanding the foregoing, no party shall settle any action, claim, or suit with respect to Taxes that are indemnified pursuant to this Agreement without the prior written approval of the other Party, such approval not to be unreasonably withheld, conditioned or delayed.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">20.2	Insurance</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;20.2	Insurance&#34; \f C \l &#34;2&#34; </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">20.2.1	Vir&#x2019;s Insurance Obligations</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Vir shall maintain, at its cost, reasonable insurance against liability and other risks associated with its activities contemplated by this Agreement, including its indemnification obligations herein, in such amounts and on such terms as are determined to be advisable by Vir, based on advice from insurance professionals, for companies of similar size and with similar resources for the activities to be conducted by Vir under this Agreement taking into account the scope of the activities for which Vir is responsible hereunder.  [***].  Vir shall furnish to GSK evidence of such insurance, upon reasonable request.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">20.2.2	GSK&#x2019;s Insurance Obligations</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  GSK shall maintain, at its cost, insurance or self-insurance with respect to liabilities and other risks associated with its activities and obligations under this Agreement, including its indemnification obligations herein, in such amounts and on such terms as are customary for prudent practices for large companies in the pharmaceutical industry for the activities to be conducted by GSK under this Agreement.  GSK shall furnish to Vir evidence of such insurance or self-insurance, upon reasonable request.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">20.3	LIMITATION OF CONSEQUENTIAL DAMAGES</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;20.3	LIMITATION OF CONSEQUENTIAL DAMAGES&#34; \f C \l &#34;2&#34; .  EXCEPT FOR A PARTY&#x2019;S INDEMNIFICATION OBLIGATIONS UNDER </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">SECTION&#160;20.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, [***], OR A BREACH OF A PARTY&#x2019;S CONFIDENTIALITY OBLIGATIONS IN </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 18</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, NEITHER VIR NOR GSK, NOR ANY OF THEIR AFFILIATES OR SUBLICENSEES WILL BE LIABLE TO THE OTHER PARTY TO THIS AGREEMENT, ITS AFFILIATES OR ANY OF THEIR SUBLICENSEES, FOR ANY INCIDENTAL, CONSEQUENTIAL, SPECIAL, PUNITIVE OR OTHER INDIRECT DAMAGES, LOST PROFITS, OR LOST DATA WHETHER LIABILITY IS ASSERTED IN CONTRACT, TORT (INCLUDING NEGLIGENCE AND STRICT PRODUCT LIABILITY) OR CONTRIBUTION, AND IRRESPECTIVE OF WHETHER THAT PARTY OR ANY REPRESENTATIVE OF THAT PARTY HAS BEEN ADVISED OF, OR OTHERWISE MIGHT HAVE ANTICIPATED THE POSSIBILITY OF, ANY SUCH LOSS OR DAMAGE</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 21<br>Anti-Bribery and Anti-Corruption TC &#34;ARTICLE 21	ANTI-BRIBERY AND ANTI-CORRUPTION&#34; \f C \l &#34;1&#34;</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">21.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Each Party shall comply fully at all times with all applicable Laws and regulations, including anti-corruption Laws.  Neither Party has, and covenants that it will not, in connection with the performance of this Agreement, directly or indirectly, make, promise, authorize, ratify, offer to make, or take any act in furtherance of any payment or transfer of</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">109</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">anything of value for the purpose of influencing, inducing or rewarding any act, omission or decision to secure an improper advantage, or improperly assisting it or the other Party in obtaining or retaining business, or in any way with the purpose or effect of public or commercial bribery, and each Party warrants that it has taken reasonable measures to prevent subcontractors, agents or any other Third Parties subject to its control or determining influence from doing so.  For the avoidance of doubt, the foregoing includes facilitating payments which are unofficial, improper small payments or gifts offered or made to government officials to secure or expedite a routine or necessary action to which other Party is legally entitled.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 22<br>Miscellaneous TC &#34;ARTICLE 22	MISCELLANEOUS&#34; \f C \l &#34;1&#34;</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">22.1	Dispute Resolution</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;22.1	Dispute Resolution&#34; \f C \l &#34;2&#34; .  Except as otherwise pursuant to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 3.9</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> or with respect to any matter for which a Party has a final-decision making authority as expressly provided herein, any dispute arising out of or relating to the Agreement, or the breach, termination or validity thereof (a &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Dispute</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), shall be finally resolved pursuant to the following provision:</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">22.1.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">In the event a Dispute arises, the parties agree that they shall attempt in good faith to resolve the Dispute by negotiation between [***] (or their respective designee with power and authority to resolve such dispute) (each, a &#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Senior Manager</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  Either Party may refer a Dispute to the applicable Senior Manager of the other Party by serving notice that Dispute has arisen and demand that negotiations commence.  If the Senior Managers of both Parties are unable for any reason to resolve a Dispute within [***] after service of the notice, either party shall [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">22.1.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Parties agree that they shall try in good faith to resolve the Dispute by [***] shall be finally resolved by arbitration in accordance with the procedures set forth on </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 22.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">22.2	Equitable Relief</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;22.2	Equitable Relief&#34; \f C \l &#34;2&#34; .  Notwithstanding anything in this Agreement to the contrary, each Party has the right to pursue provisional equitable relief from any court to avoid irreparable harm, maintain the status quo, or preserve the subject matter of any Dispute, prior to the commencement of, or while the Parties are engaged in, the escalation process or dispute resolution process set forth above.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">22.3	Governing Law</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;22.3	Governing Law&#34; \f C \l &#34;2&#34; .  This Agreement and any dispute arising from the performance or breach hereof shall be governed by and construed in accordance with the laws of the State of Delaware, without reference to conflicts of laws principles.  The Parties acknowledge that this Agreement evidences a transaction involving interstate commerce and a foreign (non-U.S.) Party.  Notwithstanding the provision in the preceding sentence with respect to the applicable substantive law, any arbitration, decision, or award rendered hereunder and the validity, effect, and interpretation of the arbitration provision shall be governed by the Federal Arbitration Act.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">22.4	Assignment</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;22.4	Assignment&#34; \f C \l &#34;2&#34; .  Subject to any restrictions in the case of subcontracting set forth herein, this Agreement shall not be assignable by either Party in whole or in part without the prior written consent of the other Party(ies) hereto. Notwithstanding</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">110</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">the foregoing, and subject (in the case of Vir) to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 22.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, (a) GSK may assign its rights and delegate its obligations under this Agreement, in whole or in part, without consent of Vir, to an Affiliate of GSK, or a Third Party that acquires all or substantially all of the business or assets of GSK to which the subject matter of this Agreement pertains (whether by merger, reorganization, acquisition, sale of assets or otherwise); (b) Vir may assign this Agreement, without consent of GSK, but with written notice to GSK, to an Affiliate of Vir, or a Third Party that acquires all or substantially all of the business or assets of Vir (whether by merger, reorganization, acquisition, sale of assets or otherwise).  All validly assigned rights of a Party shall inure to the benefit of and be enforceable by, and all validly delegated obligations of such Party shall be binding on and be enforceable against, the permitted successors and assigns of such Party.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">22.5	Change of Control of Vir</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;22.5	Change of Control of Vir&#34; \f C \l &#34;2&#34; .  If there is a Change of Control of Vir in which Vir is acquired by an acquirer, then Vir shall [***] notify GSK in writing of such Change of Control within [***] following the consummation of such Change of Control, and upon consummation of such Change of Control of Vir, the following provisions shall apply:</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">22.5.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">All Vir Licensed Technology and Vir Program Technology Controlled by Vir or any of its Affiliates immediately before such Change of Control shall continue to be Vir Licensed Technology and Vir Program Technology, as applicable, for purposes of this Agreement.  The Intellectual Property Rights of such acquirer and its Affiliates that existed prior to the Change of Control transaction shall not be included within the Vir Licensed Technology or Vir Program Technology licensed to GSK hereunder and shall not otherwise become subject to this Agreement, except to the extent such Intellectual Property Rights were so included in or subject to this Agreement prior to the consummation of such Change of Control or are used by such acquirer after the consummation of such Change of Control in the Development, Manufacture or Commercialization of Collaboration Products pursuant to this Agreement.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.5.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Each of the Committees, subcommittees and working groups shall be disbanded, and </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> (except for </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;3.11</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">) shall terminate and be of no further force and effect.  Any matters within the authority of a Committee, subcommittee or working group shall be determined, approved or resolved solely by the Lead Party for the applicable Collaboration Program. [***].  Any functions assigned to the Committees, subcommittees or working groups under this Agreement shall be performed solely by the Lead Party.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.5.3	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***].</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.5.4	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Any reports or information that one Party is obligated to provide to a Committee in connection with the Development and Commercialization of any Collaboration Product shall be provided instead to the other Party, provided that (a) [***], and (b) [***].</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">22.5.5	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.5.6	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Vir may retain its existing rights to any Vir Sole Development Product following a Change of Control.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">22.6	Force Majeure</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;22.6	Force Majeure&#34; \f C \l &#34;2&#34; .  Both Parties shall be excused from the performance of their obligations, and have no liability under this Agreement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">111</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">for failure or delay in performance of their obligations, to the extent such performance is hindered, delayed or prevented by a Force Majeure and the nonperforming Party promptly provides notice to the other Party.  Such excuse shall be continued so long as the condition constituting Force Majeure continues and the non-performing Party takes reasonable efforts to remove the condition, for up to a maximum of [***], after which time the Parties will negotiate in good faith any modifications of the terms and conditions of this Agreement, to the extent possible, that may be necessary to arrive at an equitable solution.  To the extent possible, each Party shall use reasonable efforts to minimize the duration of any Force Majeure.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">22.7	Notices</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;22.7	Notices&#34; \f C \l &#34;2&#34; .  Any notice required or permitted to be given by either Party under this Agreement shall be in writing and shall be personally delivered or sent by a nationally recognized private express courier, or by first class mail (registered or certified), or by facsimile confirmed by first class mail (registered or certified), to the respective Parties as set forth below. Notices will be deemed effective (a) [***]; (b) [***]. Either Party may change its address for purposes hereof by written notice to the other in accordance with the provisions of this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 22.7</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If to GSK:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Attn: [***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Each, with a copy (which shall not constitute notice) to:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Attn: [***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">If to Vir:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Vir Biotechnology, Inc.<br>499 Illinois Street, Suite 500<br>San Francisco, CA 94158<br>Attention: [***]<br>E-mail: [***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Vir Biotechnology, Inc.<br>499 Illinois Street, Suite 500<br>San Francisco, CA 94158<br>Attention: [***]<br>E-mail: [***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">With a copy (which shall not constitute notice) to:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">112</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Cooley LLP<br>3175 Hanover Street<br>Palo Alto, CA 94304-1130<br>Attention: [***]<br>E-mail: [</font><font><font style="font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">***</font></font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">]</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.8	</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Export Clause</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;22.8	Export Clause&#34; \f C \l &#34;2&#34; .  Each Party acknowledges that the Laws and regulations of the United States and other applicable Laws restrict the export and re-export of certain commodities and technical data.  Each Party agrees that it will not export or re-export restricted commodities or technical data of the other Party in any form without the appropriate United States or foreign government licenses.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.9	</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Waiver</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;22.9	Waiver&#34; \f C \l &#34;2&#34; .  The terms and conditions of this Agreement may be waived or released only by a written instrument executed by the Party or Parties waiving or releasing compliance.  The failure of either Party to assert a right hereunder or to insist upon compliance with any term or condition of this Agreement shall not constitute a waiver of that right or excuse a similar subsequent failure to perform any such term or condition.  No waiver by either Party of any condition or term in any one or more instances shall be construed as a continuing waiver or subsequent waiver of such condition or term or of another condition or term.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.10	</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Severability</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. TC &#34;22.10	Severability.&#34; \f C \l &#34;2&#34; </font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> If any provision hereof should be held invalid, illegal or unenforceable in any jurisdiction, the Parties shall negotiate in good faith a valid, legal and enforceable substitute provision that most nearly reflects the original intent of the Parties and all other provisions hereof shall remain in full force and effect in such jurisdiction and shall be liberally construed in order to carry out the intentions of the Parties hereto as nearly as may be possible.  Such invalidity, illegality or unenforceability shall not affect the validity, legality or enforceability of such provision in any other jurisdiction.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.11	</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Entire Agreement; Amendments</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;22.11	Entire Agreement; Amendments&#34; \f C \l &#34;2&#34; .  Subject to </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 2.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, this Agreement, together with the Schedules attached hereto, the Supply Agreements, Quality Agreements, and the SPA constitute the entire agreement between the Parties with respect to the subject matter hereof and thereof.  Except for the SPA, this Agreement supersedes all prior agreements and understandings between the Parties with respect to the subject matter hereof, including the Preliminary Collaboration Agreement; provided that the following provisions in the Preliminary Collaboration Agreement shall be incorporated by reference in this Agreement and shall only apply with respect to any acts, omissions or events occurring between the PCA Execution Date and the Effective Date: Sections 1-3, and 18-24 of the Preliminary Collaboration Agreement (together with the appendices referenced in such sections), provided further that </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">ARTICLE 20</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall apply with respect to any indemnification claim a Party may have against the other Party with respect to any acts, omissions or events occurring between the PCA Execution Date and the Effective Date relating to the Preliminary Collaboration Agreement. There are no restrictions, promises, warranties or undertakings, other than those set forth or referred to herein or therein.  No subsequent alteration, amendment, change or addition to this Agreement shall be binding upon the Parties hereto unless reduced to writing and signed by the respective authorized officers of both Parties.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">113</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.12	</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Independent Contractors</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;22.12	Independent Contractors&#34; \f C \l &#34;2&#34; .  Nothing herein shall be construed to create a partnership, or any relationship of employer and employee, agent and principal, or joint venture between the Parties.  Each Party is an independent contractor.  Neither Party shall assume, either directly or indirectly, any liability of or for the other Party.  Neither Party shall have the authority to bind or obligate the other Party, and neither Party shall represent that it has such authority.</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.13	</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Headings</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;22.13	Headings&#34; \f C \l &#34;2&#34; .  Headings used herein are for convenience only and shall not in any way affect the construction of or be taken into consideration in interpreting this Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.14	</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Further Actions</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;22.14	Further Actions&#34; \f C \l &#34;2&#34; .  Each Party shall execute, acknowledge and deliver such further instruments, and do all such other acts, as may be reasonably necessary or appropriate in order to carry out the expressly stated purposes and the clear intent of this Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.15	</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Books and Records</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;22.15	Books and Records&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.15.1	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Any books and records to be maintained under this Agreement by a Party or its Affiliates or Sublicensees shall be maintained in accordance with the Accounting Standards applicable to such Party or its Affiliates in the jurisdiction in which it operates and need not be audited.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.15.2	</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">In the event a legal matter arises requiring preservation of certain records, each Party will suspend the destruction of such records as requested by the other Party or as requested by any governmental body.  During the Term and thereafter, in accordance with any such applicable records retention notice period(s), in the event that a Party has reasonable cause to conduct an audit of the other Party, such Party requesting the audit shall have the right upon reasonable notice (which shall be not less than [***] prior written notice) and during normal working hours to inspect, copy and audit such records.  Each Party shall cooperate in any such inspection or audit of its records.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.16	</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Construction of Agreement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;22.16	Construction of Agreement&#34; \f C \l &#34;2&#34; .</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> Section 11.5 of the SPA is hereby incorporated herein, </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">mutatis mutandis</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.17	</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Supremacy</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;22.17	Supremacy&#34; \f C \l &#34;2&#34; .  In the event of any express conflict or inconsistency between this Agreement and any Schedule hereto, the terms and conditions of this Agreement shall control. The Parties understand and agree that the Schedules hereto are not intended to be the final and complete embodiment of any terms or conditions of this Agreement, and are to be updated from time to time during the Term, as appropriate and in accordance with the provisions of this Agreement.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.18	</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Counterparts</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;22.18	Counterparts&#34; \f C \l &#34;2&#34; .  This Agreement may be executed and delivered (including by facsimile transmission or PDF or any other electronically transmitted signatures) in counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">114</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">22.19	</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">No Third Party Beneficiaries</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> TC &#34;22.19	No Third Party Beneficiaries&#34; \f C \l &#34;2&#34; .  This Agreement is intended for the benefit of the Parties, their respective permitted successors and assigns, and is not for the benefit of, nor many any provision hereof be enforced by, any other Person.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">[Signature page follows]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">115</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">IN WITNESS WHEREOF, the Parties have caused this Agreement to be executed as of the Execution Date by their respective duly authorized representatives as set forth below.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:2.992361111111111in;border-spacing:0;table-layout:fixed;width:54.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="font-variant:small-caps;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Glaxo Wellcome UK Limited</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By:</font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">&#160;&#160;/s/ John Sadler</font></p><p style="margin-left:21.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:0.75in;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.75in;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Its: 	Authorized Signatory</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.75in;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">For and on behalf of Edinburgh</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:0.75in;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Pharmaceutical Industries Limited</font></p><p style="margin-left:21.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:0.75in;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="font-variant:small-caps;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Vir Biotechnology, Inc.</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By:</font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">&#160;&#160;/s/ George Scangos</font></p><p style="margin-left:21.6pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:0.75in;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;margin-right:0.5520833333333334in;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Its: 	President and Chief Executive Officer</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">116</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">SCHEDULE 1.88</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Existing Third Party Agreements</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">117</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">SCHEDULE 1.99</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">FINANCIAL SCHEDULE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">General Principles</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Pre-tax profit or loss for the Territory (&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Pre-Tax Profit or Loss</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) and Development Costs shall be calculated in accordance with this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 1.99</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Unless otherwise agreed by the Financial Working Group, Pre-Tax Profit or Loss shall [***], and any other cost not specifically included in Allowable Expenses and Development Costs shall exclude any cost not specifically included in the definition of &#x201c;Development Costs&#x201d;, including, [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Principles for Calculation of Development Costs, Pre-Tax Profit or Loss</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;"> </font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1.	Pre-Tax Profit or Loss shall be calculated for each [***] by determining [***] incurred during such [***]. Notwithstanding the foregoing, on a [***] basis, the terms of </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.7.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> shall apply.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2.	No cost item shall be allocated to more than one cost category, i.e., [***], [***].</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3.	Costs incurred by a Party in connection with Commercialization or Commercial Manufacture shall be allocated to the appropriate category of Allowable Expenses in accordance with [***].</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4.	Where a Party incurs costs under this Agreement that apply to (a) more than one Collaboration Product, (b) more than one Collaboration Program, or (c) one or more Collaboration Programs as well as products or programs that are not included under this Agreement then such Party shall [***].</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">5.	All undefined terms shall be construed in accordance with such Accounting Standards, but only to the extent consistent with their usage and the other definitions in this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 1.99</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#160;and the Agreement.  To the extent [***] requested by the Non-Lead Party, the Lead Party shall provide the Non-Lead Party the appropriate back-up detail for Development Costs and Pre-Tax Profit or Loss to enable the Non-Lead Party to state its share of such Development Costs and Pre-Tax Profit or Loss in its applicable Accounting Standard. In addition, following the Effective Date, each Party shall consider in good faith reasonable procedures proposed by the other Party for sharing financial information in order to permit each Party to close its books periodically in a timely manner.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">6.	The Parties shall comply with any reporting requirements under securities law. For the avoidance of doubt, income and withholding Taxes imposed on either of the Parties shall not be included in the calculation of Pre-Tax Profit or Loss.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">118</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Financial Definitions</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The following definitions shall apply for the purposes of calculating Pre-Tax Profit or Loss, and other financial terms in the Agreement, including Development Cost sharing.  If a financial term is not defined in this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule&#160;1.99</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, then such term shall, on a Collaboration Product-by-Collaboration Product basis, be defined by the Financial Working Group.  For purposes for the following definitions, the terms &#x201c;costs&#x201d; and &#x201c;expenses&#x201d; shall mean all direct Third Party invoiced costs and FTE Costs, unless otherwise expressly provided herein.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Allowable Expenses</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the sum of the following costs and expenses incurred during the Term by the Parties or their Affiliates, in the conduct of Commercial Manufacture and Commercialization of the Collaboration Products in the Territory, in accordance with this Agreement during the applicable [***]:</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Allowable Expenses shall, subject the annual Commercialization Budget and the terms of </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section&#160;11.7.2</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, include all Third Party invoiced expenses as well as FTE Costs reasonably necessary and identifiable to the Collaboration Products, either direct expenses or expenses that shall be allocated based on [***]. Upon request by either Party, the Financial Working Group shall review the methodology used to allocate expenses in connection with the calculation of Allowable Expenses. If the Financial Working Group does not approve such methodology, the Financial Working Group shall agree upon a revised methodology. Notwithstanding any other clauses in this </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 1.99</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">***</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">]&#x201d; means [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Blocking Third Party IP Costs</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means [***] attributable or allocable to, Development, Manufacture, and Commercialization of the applicable Collaboration Product and paid to a Third Party to license or acquire Intellectual Property Rights for the Development, Manufacture or Commercialization of the applicable Collaboration Product in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 11.9</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> or as otherwise set forth in this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Development Costs</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the following costs incurred by the Parties following the Effective Date in conducting Development under the applicable Collaboration Programs, in each case to the extent incurred in accordance with this Agreement and the applicable Development Plan and Development Budget (as may be amended and approved by the JSC in accordance with </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Section 7.1.3</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:11.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">and [***]:</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">***</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">]&#x201d; means [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">***</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">]&#x201d; means [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Existing Third Party IP Agreement</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means any license, acquisition or other agreement pursuant to which a Party has obtained any Intellectual Property Rights included within Licensed</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">119</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Technology, which agreement is existing, as applicable, (a) as of the Effective Date, including the agreements listed on </font><font style="color:rgba(0,0,0,1);font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule&#160;11.9.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, (b) [***], or (c) [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">FTE Costs</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, as applicable with respect to any period, [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">***</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">]&#x201d; means, [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">***</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">]&#x201d; means [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Manufacturing Cost</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means, with respect to a Collaboration Product, a Party&#x2019;s reasonable and necessary FTE Costs and Third Party invoiced cost, determined in accordance with GAAP for Vir and IFRS for GSK, as applicable and consistently applied, and the terms and conditions of this Agreement (including approval by the JSC), incurred in Manufacturing or acquisition or securing Manufacturing capacity for such Collaboration Product. Manufacturing Costs are comprised of [***]:</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Manufacturing Cost shall [***].  For clarity, Blocking Third Party IP Costs shall not be included in Manufacturing Cost. Notwithstanding the foregoing or anything to the contrary herein, [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">***</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">]&#x201d; means [***]:</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">***</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">]&#x201d; means [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Net Sales</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means the actual gross amount invoiced by the LCP or the Non Opt-Out Party (with respect to a Sole Development Product), or the selling Party (with respect to a Rejected Target Product</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">)</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, or its respective Affiliates, licensee or permitted Sublicensee, for sales or other commercial disposition of a Collaboration Product, Sole Development Product, or Rejected Target Product, as the case may be, [***] to a Third Party purchaser, excluding sales between or among the LCP, Non Opt-Out Party or the selling Party and its respective Affiliates, or its licensees or Sublicensees, less the following deductions (if not already deducted from the amount invoiced), in each case to the extent [***]</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">***</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">]&#x201d; means [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">***</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">]&#x201d; means [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;vertical-align:top;font-size:8.04pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">***</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">]&#x201d; means [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">***</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">]&#x201d; means [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">***</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">]&#x201d; means [***].</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">***</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">]&#x201d;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">means:</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">120</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">***</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">]&#x201d; means [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">***</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">]&#x201d; means [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201c;[</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">***</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">]&#x201d; means [***].</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">121</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">SCHEDULE 1.125</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">GSK SPECIFIED INTERNAL POLICIES</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(See Attached)</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">122</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">SCHEDULE 1.135</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Influenza Product Criteria</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">123</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 1.274</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Sequences of Vir-2482 and Vir-2482XX2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">124</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule&#160;4.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Vir-2482 &amp; Vir-2482XX2 Clinical Development Plans</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">125</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 4.2.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">Vir-2482 Option Data Package</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">126</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 5.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Expanded Functional Genomics Program Flow Chart</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="font-size:11.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">127</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 6.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">128</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 6.2.1</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Listed Target Pathogens</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">129</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">SCHEDULE 7.6.5</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"><br><br></font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ANIMAL WELFARE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">130</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">SCHEDULE 10.1</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"><br><br></font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">KEY TERMS FOR PHARMACOVIGILANCE TECHNICAL AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">131</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule</font><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;"> 11.3.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">132</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">SCHEDULE 11.8.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ROYALTIES FOLLOWING OPT-OUT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">133</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">SCHEDULE 11.8.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">134</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">SCHEDULE 11.9.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">EXISTING THIRD PARTY PAYMENT OBLIGATIONS</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">135</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">SCHEDULE 13.3.2</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">[***]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">136</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">SCHEDULE 15.1.1</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">FORM OF MATERIAL TRANSFER RECORD</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Material Transfer Record</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">137</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="margin-left:90.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Schedule 22.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Arbitration</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[***]</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">- </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">138</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> -</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">224298306 v10</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.3
<SEQUENCE>3
<FILENAME>vir-20210630ex10_3.htm
<DESCRIPTION>EX-10.3
<TEXT>
<html>
 <head>
  <title>EX-10.3</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">Exhibit 10.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">CERTAIN&#160;CONFIDENTIAL&#160;INFORMATION&#160;CONTAINED&#160;IN&#160;THIS&#160;DOCUMENT,&#160;MARKED&#160;BY&#160;[***],&#160;HAS&#160;BEEN&#160;OMITTED&#160;BECAUSE&#160;IT&#160;IS&#160;BOTH&#160;(I)&#160;NOT&#160;MATERIAL&#160;AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20.803%;"></td>
    <td style="width:79.197%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="border-top:1.000pt solid rgba(0,0,0,1);background-color:rgba(192,192,192,1);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">AMENDMENT INFORMATION</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Agreement to be Amended:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Grant agreement between the Bill &amp; Melinda Gates Foundation and Vir Biotechnology, Inc. effective January 26, 2018, as amended, and bearing Investment ID INV-010344 (formerly OPP1187970)</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Amendment Purpose:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">No Cost Extension and Reporting &amp; Payment Schedule Change</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid;word-break:break-word;border-left:1.000pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Amendment Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Date of this email&#160;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid;word-break:break-word;border-left:1.000pt solid;padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Amended &#x201c;End Date&#x201d;:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid;word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">The term of the Agreement is extended by changing the End Date to October 31, 2022</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">THIS AMENDMENT</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;amends, and is made part of, the above-referenced Agreement and is effective as of the date of this email. Capitalized terms not defined in this Amendment will have the meaning provided in the Agreement. Except as modified by this Amendment, all other terms and conditions of the Agreement remain in full force and effect. In the event of a conflict between the Agreement and this Amendment, the terms of this Amendment will prevail.</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:11.0pt;font-family:Calibri;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">UPDATED REPORTING &amp; PAYMENT SCHEDULE</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">This Amendment notifies You that the reporting and/or payment schedule for Your grant has changed. Your updated Reporting &amp; Payment Schedule is deleted and replaced with the following:</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:19.004%;"></td>
    <td style="width:23.715%;"></td>
    <td style="width:19.422%;"></td>
    <td style="width:18.919%;"></td>
    <td style="width:18.94%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="5" style="border-top:1.000pt solid rgba(0,0,0,1);background-color:rgba(192,192,192,1);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">REPORTING &amp; PAYMENT SCHEDULE</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:11.0pt;font-family:Calibri;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:11.0pt;font-family:Calibri;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td rowspan="2" style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:11.0pt;font-family:Calibri;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:11.0pt;font-family:Calibri;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(255,255,255,1);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05277777777777778in;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
   <tr style="height:14.4pt;">
    <td style="background-color:rgba(217,217,217,1);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:11.0pt;font-family:Calibri;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;margin-right:0.05277777777777778in;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:11.0pt;font-family:Calibri;">&#160;</font></p></td>
    <td style="background-color:rgba(217,217,217,1);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="4" style="background-color:rgba(192,192,192,1);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Amended Total Grant Amount</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3650000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Up to $20,776,349.00</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.4
<SEQUENCE>4
<FILENAME>vir-20210630ex10_4.htm
<DESCRIPTION>EX-10.4
<TEXT>
<html>
 <head>
  <title>EX-10.4</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">Exhibit 10.4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">CERTAIN&#160;CONFIDENTIAL&#160;INFORMATION&#160;CONTAINED&#160;IN&#160;THIS&#160;DOCUMENT,&#160;MARKED&#160;BY&#160;[***],&#160;HAS&#160;BEEN&#160;OMITTED&#160;BECAUSE&#160;IT&#160;IS&#160;BOTH&#160;(I)&#160;NOT&#160;MATERIAL&#160;AND (II) IS THE TYPE THAT VIR BIOTECHNOLOGY, INC. TREATS AS PRIVATE OR CONFIDENTIAL.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:16.403%;"></td>
    <td style="width:83.597%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="border-top:1.000pt solid rgba(0,0,0,1);background-color:rgba(192,192,192,1);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">AMENDMENT INFORMATION</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Agreement to be Amended:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Grant agreement between the Bill &amp; Melinda Gates Foundation and Vir Biotechnology Inc effective March 16, 2018, as amended, and bearing Investment ID INV-009475/OPP1182112</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Amendment Purpose:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">No Cost Extension</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Amendment Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Date of this email&#160;</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Amended &#x201c;End Date&#x201d;:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.075in;vertical-align:middle;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">The term of the Agreement is extended by changing the End Date to January 31, 2022</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:19.765%;"></td>
    <td style="width:0.214%;"></td>
    <td style="width:19.744%;"></td>
    <td style="width:19.776%;"></td>
    <td style="width:19.797%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:0.705%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="7" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">THIS AMENDMENT</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;amends, and is made part of, the above-referenced Agreement and is effective as of the date of this email. Capitalized terms not defined in this Amendment will have the meaning provided in the Agreement. Except as modified by this Amendment, all other terms and conditions of the Agreement remain in full force and effect. In the event of a conflict between the Agreement and this Amendment, the terms of this Amendment will prevail.</font></p></td>
   </tr>
   <tr>
    <td colspan="7" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="7" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">UPDATED REPORTING &amp; PAYMENT SCHEDULE</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="7" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">This Amendment notifies You that the reporting and/or payment schedule for Your grant has changed. Your updated Reporting &amp; Payment Schedule is deleted and replaced with the following:</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;"> </font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="7" style="background-color:rgba(0,0,0,0);word-break:break-word;padding-left:0.075in;vertical-align:top;padding-right:0.075in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="6" style="background-color:rgba(192,192,192,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.010in;vertical-align:top;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">REPORTING &amp; PAYMENT SCHEDULE</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.010in;vertical-align:top;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(217,217,217,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);text-indent:18.0pt;word-break:break-word;padding-left:0.010in;vertical-align:top;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:-18.0pt;padding-left:18.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Times New Roman;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(217,217,217,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(217,217,217,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(217,217,217,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(217,217,217,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:11.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:top;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:11.0pt;font-family:Calibri;">[***]</font></p></td>
    <td style="background-color:rgba(217,217,217,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(217,217,217,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="5" style="background-color:rgba(192,192,192,1);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Arial;">Total Grant Amount</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;padding-left:0.010in;vertical-align:middle;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">Up to $14,882,418.08&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>5
<FILENAME>vir-20210630ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 31.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I, George Scangos, Ph.D., certify that:</font></p>
  <div style="display:flex;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">1.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I have reviewed this quarterly report on Form 10-Q of Vir Biotechnology, Inc;</font></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">2.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">3.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">4.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">(a)</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">(b)</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">(c)</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">(d)</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">5.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">(a)</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">(b)</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:54.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:3.0%;"></td>
    <td style="width:42.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: August 5, 2021</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/&#160;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#160;George Scangos</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">George Scangos, Ph.D.</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">President, Chief Executive Officer and Director</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>6
<FILENAME>vir-20210630ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 31.2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I, Howard Horn, certify that:</font></p>
  <div style="display:flex;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">1.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">I have reviewed this quarterly report on Form 10-Q of Vir Biotechnology, Inc;</font></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">2.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </font></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">3.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </font></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">4.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant&#x2019;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">(a)</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">(b)</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">(c)</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">(d)</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">5.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The registrant&#x2019;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">(a)</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and </font></div></div>
  <div style="margin-left:6.667%;display:flex;margin-top:12.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">(b)</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:54.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:3.0%;"></td>
    <td style="width:42.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td colspan="2" style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: August 5, 2021</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;border-bottom:0.250pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/&#160;</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Howard Horn</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:middle;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Howard Horn</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.010in;word-break:break-word;vertical-align:bottom;padding-right:0.010in;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer and Secretary</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>7
<FILENAME>vir-20210630ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATION PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended, (the &#x201c;Exchange Act&#x201d;) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. &#167;1350),</font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">George Scangos, Ph.D., President, Chief Executive Officer and Director of Vir Biotechnology, Inc. (the &#x201c;Company&#x201d;), and Howard Horn, Chief Financial Officer and Secretary of the Company, each hereby certifies that, to the best of his knowledge:</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:12.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">1.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s Quarterly Report on Form 10-Q for the period ended June 30, 2021, to which this Certification is attached as Exhibit 32.1 (the &#x201c;Periodic Report&#x201d;), fully complies with the requirements of Section 13(a) or Section 15(d) of the Exchange Act; and</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:12.0pt;min-width:0.5in;"><font style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.5in;">2.</font><div style="display:inline;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information contained in the Periodic Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-variant:small-caps;color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">In Witness Whereof</font><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the undersigned have set their hands hereto as of the 5th day of August 2021.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.0%;"></td>
    <td style="width:2.0%;"></td>
    <td style="width:49.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ </font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">George Scangos</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:11.0pt;font-family:Calibri;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ </font><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Howard Horn</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">George Scangos, Ph.D.</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:11.0pt;font-family:Calibri;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Howard Horn</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">President, Chief Executive Officer and Director</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:11.0pt;font-family:Calibri;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer and Secretary</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Executive Officer)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:11.0pt;font-family:Calibri;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.4029166666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201c;This certification accompanies the Form 10-Q to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Vir Biotechnology, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Form 10-Q), irrespective of any general incorporation language contained in such filing.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="font-size:11.0pt;font-family:Calibri;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>vir-20210630_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-08-05T15:34:55.8692+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="vir-20210630.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:href="vir-20210630.xsd#Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:href="vir-20210630.xsd#Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="vir-20210630.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" xlink:href="vir-20210630.xsd#StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:href="vir-20210630.xsd#Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="vir-20210630.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganization" xlink:href="vir-20210630.xsd#Role_DisclosureOrganization" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="vir-20210630.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="vir-20210630.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitions" xlink:href="vir-20210630.xsd#Role_DisclosureAcquisitions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreements" xlink:href="vir-20210630.xsd#Role_DisclosureGrantAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" xlink:href="vir-20210630.xsd#Role_DisclosureCollaborationAndLicenseAgreements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponents" xlink:href="vir-20210630.xsd#Role_DisclosureBalanceSheetComponents" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:href="vir-20210630.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureRelatedPartyTransaction" xlink:href="vir-20210630.xsd#Role_DisclosureRelatedPartyTransaction" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwards" xlink:href="vir-20210630.xsd#Role_DisclosureStockBasedAwards" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShare1" xlink:href="vir-20210630.xsd#DisclosureNetIncomeLossPerShare1" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/DisclosureSubsequentEvents" xlink:href="vir-20210630.xsd#DisclosureSubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="vir-20210630.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="vir-20210630.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" xlink:href="vir-20210630.xsd#Role_DisclosureBalanceSheetComponentsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:href="vir-20210630.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsTables" xlink:href="vir-20210630.xsd#Role_DisclosureStockBasedAwardsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareTables" xlink:href="vir-20210630.xsd#DisclosureNetIncomeLossPerShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" xlink:href="vir-20210630.xsd#Role_DisclosureOrganizationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="vir-20210630.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" xlink:href="vir-20210630.xsd#Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" xlink:href="vir-20210630.xsd#Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="vir-20210630.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" xlink:href="vir-20210630.xsd#Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" xlink:href="vir-20210630.xsd#Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" xlink:href="vir-20210630.xsd#Role_DisclosureAcquisitionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" xlink:href="vir-20210630.xsd#Role_DisclosureGrantAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="vir-20210630.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="vir-20210630.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:href="vir-20210630.xsd#Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" xlink:href="vir-20210630.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="vir-20210630.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="vir-20210630.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetsDetails" xlink:href="vir-20210630.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" xlink:href="vir-20210630.xsd#Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" xlink:href="vir-20210630.xsd#Role_DisclosureStockBasedAwardsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" xlink:href="vir-20210630.xsd#Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityAndRestrictedStockUnitsDetails" xlink:href="vir-20210630.xsd#Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityAndRestrictedStockUnitsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails" xlink:href="vir-20210630.xsd#Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:href="vir-20210630.xsd#DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:href="vir-20210630.xsd#DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentQuarterlyReport" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_PreferredStockValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_LongTermInvestments" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssets" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationRevenueMember" xlink:label="vir_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ContractRevenueMember" xlink:label="vir_ContractRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueNotFromContractWithCustomer" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfRevenue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_CollaborationRevenueMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_ContractRevenueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_StockIssuedDuringPeriodSharesAchievementOfMilestone" xlink:label="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_StockIssuedDuringPeriodValueCollaborationAgreement" xlink:label="vir_StockIssuedDuringPeriodValueCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_StockIssuedDuringPeriodSharesCollaborationAgreement" xlink:label="vir_StockIssuedDuringPeriodSharesCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" xlink:label="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_StockIssuedDuringPeriodValueLicenseAgreement" xlink:label="vir_StockIssuedDuringPeriodValueLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_StockIssuedDuringPeriodSharesLicenseAgreement" xlink:label="vir_StockIssuedDuringPeriodSharesLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue" xlink:label="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares" xlink:label="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_18"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_19"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodValueCollaborationAgreement" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesCollaborationAgreement" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodValueLicenseAgreement" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesLicenseAgreement" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_18" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding_19" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementMember" xlink:label="vir_CollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PaymentOfContingentConsideration" xlink:label="vir_PaymentOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities" xlink:label="vir_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_NoncashLeaseExpense" xlink:label="vir_NoncashLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:label="us-gaap_ProceedsFromSaleOfPropertyHeldForSale"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="vir_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ChangeInEstimatedFairValueOfContingentConsideration" xlink:label="vir_ChangeInEstimatedFairValueOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" xlink:label="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_CollaborationAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="vir_PaymentOfContingentConsideration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="vir_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="vir_NoncashLeaseExpense" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyHeldForSale" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="vir_IncreaseDecreaseInOperatingLeaseLiabilities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="vir_ChangeInEstimatedFairValueOfContingentConsideration" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganization" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_GrantAgreementsDisclosureTextBlock" xlink:label="vir_GrantAgreementsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="vir_GrantAgreementsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureRelatedPartyTransaction" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwards" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShare1" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:label="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesEmbeddedDerivatives" xlink:label="us-gaap_DerivativesEmbeddedDerivatives"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InvestmentPolicyTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DerivativesEmbeddedDerivatives" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ClinicalAndRegulatoryMilestonesMember" xlink:label="vir_ClinicalAndRegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CommercialMilestonesMember" xlink:label="vir_CommercialMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="vir_ClinicalAndRegulatoryMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_TomegaVaxIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="vir_CommercialMilestonesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" xlink:label="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock" xlink:label="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FollowOnOfferingMember" xlink:label="vir_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SalesAgreementMember" xlink:label="vir_SalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="vir_PaymentsOfUnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ProceedsFromIssuanceSecondaryPublicOffering" xlink:label="vir_ProceedsFromIssuanceSecondaryPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PercentageOfAggregateGrossProceedsFromSaleOfShares" xlink:label="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SaleOfStockConsiderationAggregateOfferingPrice" xlink:label="vir_SaleOfStockConsiderationAggregateOfferingPrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vir_FollowOnOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:to="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:to="vir_SalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_PaymentsOfUnderwritingDiscountsAndCommissions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_ProceedsFromIssuanceSecondaryPublicOffering" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_SaleOfStockConsiderationAggregateOfferingPrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FinancialAssetsAmortizedCostBasis" xlink:label="vir_FinancialAssetsAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FinancialAssetsGrossUnrealizedHoldingGains" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingGains"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BankTimeDepositsMember" xlink:label="us-gaap_BankTimeDepositsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FinancialAssetsGrossUnrealizedHoldingLosses" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingLosses"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FinancialAssetsFairValue" xlink:label="vir_FinancialAssetsFairValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FinancialAssetsAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FinancialAssetsGrossUnrealizedHoldingGains" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_BankTimeDepositsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FinancialAssetsGrossUnrealizedHoldingLosses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FinancialAssetsFairValue" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalents" xlink:label="us-gaap_RestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_RestrictedCashEquivalents" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LongTermInvestments" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LetterAgreementMember" xlink:label="vir_LetterAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancingReceivableAccruedInterestWriteoff" xlink:label="us-gaap_FinancingReceivableAccruedInterestWriteoff"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ContingentConsiderationLiabilityMember" xlink:label="vir_ContingentConsiderationLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AssetAcquisitionContingentConsiderationLiability" xlink:label="vir_AssetAcquisitionContingentConsiderationLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InterestReceivable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_LetterAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancingReceivableAccruedInterestWriteoff" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_TomegaVaxIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="vir_ContingentConsiderationLiabilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTerm" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_AssetAcquisitionContingentConsiderationLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ClinicalAndRegulatoryMilestonesMember" xlink:label="vir_ClinicalAndRegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CommercialMilestonesMember" xlink:label="vir_CommercialMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeLiabilityMeasurementInput" xlink:label="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MeasurementInputProbabilityRateMember" xlink:label="vir_MeasurementInputProbabilityRateMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MeasurementInputExpectedRevenueVolatilityMember" xlink:label="vir_MeasurementInputExpectedRevenueVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="vir_ClinicalAndRegulatoryMilestonesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_TomegaVaxIncMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="vir_CommercialMilestonesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="vir_MeasurementInputProbabilityRateMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="vir_MeasurementInputExpectedRevenueVolatilityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ContingentConsiderationLiabilityMember" xlink:label="vir_ContingentConsiderationLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" xlink:label="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="vir_ContingentConsiderationLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_HepatitisBVirusProductMember" xlink:label="vir_HepatitisBVirusProductMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ClinicalDevelopmentMember" xlink:label="vir_ClinicalDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LetterAgreementMember" xlink:label="vir_LetterAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AnotherProductMember" xlink:label="vir_AnotherProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" xlink:label="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AgenovirCorporationMember" xlink:label="vir_AgenovirCorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MilestonePaymentsRelatedTermsDescription" xlink:label="vir_MilestonePaymentsRelatedTermsDescription"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SARSCoV2ProductMember" xlink:label="vir_SARSCoV2ProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" xlink:label="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PaymentMadeForBusinessCombinationMilestone" xlink:label="vir_PaymentMadeForBusinessCombinationMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RemainingPaymentMadeForBusinessCombinationMilestone" xlink:label="vir_RemainingPaymentMadeForBusinessCombinationMilestone"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CommonStockSharesIssuedForMilestonePaymentShares" xlink:label="vir_CommonStockSharesIssuedForMilestonePaymentShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ValueOfCommonStockSharesIssuedForMilestonePayment" xlink:label="vir_ValueOfCommonStockSharesIssuedForMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" xlink:label="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" xlink:label="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SpecifiedClinicalDevelopmentMilestonesPayment" xlink:label="vir_SpecifiedClinicalDevelopmentMilestonesPayment"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_HepatitisBVirusProductMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="vir_ClinicalDevelopmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_LetterAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_TomegaVaxIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_AnotherProductMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_AgenovirCorporationMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_MilestonePaymentsRelatedTermsDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_SARSCoV2ProductMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ProductOrServiceAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_PaymentMadeForBusinessCombinationMilestone" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_RemainingPaymentMadeForBusinessCombinationMilestone" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_CommonStockSharesIssuedForMilestonePaymentShares" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_ValueOfCommonStockSharesIssuedForMilestonePayment" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_SpecifiedClinicalDevelopmentMilestonesPayment" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_GrantAwardedAmountMaximum" xlink:label="vir_GrantAwardedAmountMaximum"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_HumanImmunodeficiencyVirusGrantMember" xlink:label="vir_HumanImmunodeficiencyVirusGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_BillAndMelindaGatesFoundationMember" xlink:label="vir_BillAndMelindaGatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TuberculosisTBGrantMember" xlink:label="vir_TuberculosisTBGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_GrantAwardedAmount" xlink:label="vir_GrantAwardedAmount"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_UnusedFundsReceivedInAdvance" xlink:label="vir_UnusedFundsReceivedInAdvance"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_GrantAgreementAmendedExpirationDate" xlink:label="vir_GrantAgreementAmendedExpirationDate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAwardedAmountMaximum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_HumanImmunodeficiencyVirusGrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_BillAndMelindaGatesFoundationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TuberculosisTBGrantMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAwardedAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueNotFromContractWithCustomer" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_UnusedFundsReceivedInAdvance" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAgreementAmendedExpirationDate" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandTwentyStockPurchaseAgreementMember" xlink:label="vir_TwoThousandTwentyStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AntibodyProgramMember" xlink:label="vir_AntibodyProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AccruedLiabilitiesAndOtherLiabilitiesMember" xlink:label="vir_AccruedLiabilitiesAndOtherLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_GlaxoGroupLimitedMember" xlink:label="vir_GlaxoGroupLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:label="country_CN"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="country_US"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PreliminaryCollaborationAgreementMember" xlink:label="vir_PreliminaryCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ContractRevenueMember" xlink:label="vir_ContractRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_GlaxoGroupLimitedMember" xlink:label="vir_GlaxoGroupLimitedMember_2"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationRevenueMember" xlink:label="vir_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_DefinitiveCollaborationAgreementMember" xlink:label="vir_DefinitiveCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ProfitShareRevenueMember" xlink:label="vir_ProfitShareRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_BriiBioParentMember" xlink:label="vir_BriiBioParentMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" xlink:label="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PercentageOfDevelopmentCosts" xlink:label="vir_PercentageOfDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_BriiBiosciencesOffshoreLimitedMember" xlink:label="vir_BriiBiosciencesOffshoreLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandTwentyOneStockPurchaseAgreementMember" xlink:label="vir_TwoThousandTwentyOneStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_VaccineProgramMember" xlink:label="vir_VaccineProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" xlink:label="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AlnylamPharmaceuticalsIncMember" xlink:label="vir_AlnylamPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LicensedProductByLicensedProductMember" xlink:label="vir_LicensedProductByLicensedProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_BiologicalMaterialsMember" xlink:label="vir_BiologicalMaterialsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandAndTwentyOneGSKCollaborationMember" xlink:label="vir_TwoThousandAndTwentyOneGSKCollaborationMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementTerminationDescription" xlink:label="vir_CollaborationAgreementTerminationDescription"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WuXiBiologicsLimitedMember" xlink:label="vir_WuXiBiologicsLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RockefellerUniversityMember" xlink:label="vir_RockefellerUniversityMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FairMarketValueOfCommonStockIssued" xlink:label="vir_FairMarketValueOfCommonStockIssued"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandAndTwentyOneGSKAgreementMember" xlink:label="vir_TwoThousandAndTwentyOneGSKAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FirstSiRNAProductMember" xlink:label="vir_FirstSiRNAProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MedImmuneLimitedLiabilityCompanyMember" xlink:label="vir_MedImmuneLimitedLiabilityCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_BriiAgreementMember" xlink:label="vir_BriiAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AlnylamAgreementMember" xlink:label="vir_AlnylamAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_XencorIncorporationMember" xlink:label="vir_XencorIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PremiumReceivedOnSalePriceOfCommonStock" xlink:label="vir_PremiumReceivedOnSalePriceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_EachInfectiousDiseaseSiRNAMember" xlink:label="vir_EachInfectiousDiseaseSiRNAMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CommercializationMember" xlink:label="vir_CommercializationMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_DevelopmentAndManufacturingCollaborationAgreementMember" xlink:label="vir_DevelopmentAndManufacturingCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementNumberOfUnitsOfAccount" xlink:label="vir_CollaborationAgreementNumberOfUnitsOfAccount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FirstInfectiousDiseaseProductMember" xlink:label="vir_FirstInfectiousDiseaseProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RockefellerAgreementMember" xlink:label="vir_RockefellerAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AntibodyLicenseTransactionPrice" xlink:label="vir_AntibodyLicenseTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_HBVProgramMember" xlink:label="vir_HBVProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MedImmuneAgreementMember" xlink:label="vir_MedImmuneAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:label="vir_IncreaseDecreaseInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandNineteenXencorAgreementMember" xlink:label="vir_TwoThousandNineteenXencorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_InfluenzaAAndInfluenzaBMember" xlink:label="vir_InfluenzaAAndInfluenzaBMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_InfluenzaAResearchProgramsMember" xlink:label="vir_InfluenzaAResearchProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ReductionOfResearchAndDevelopmentExpense" xlink:label="vir_ReductionOfResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandTwentyXencorAgreementMember" xlink:label="vir_TwoThousandTwentyXencorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_HBVResearchProgramsMember" xlink:label="vir_HBVResearchProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PayableUnderAgreementCurrent" xlink:label="vir_PayableUnderAgreementCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_InfluenzaAAndHBVResearchProgramsMember" xlink:label="vir_InfluenzaAAndHBVResearchProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" xlink:label="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PercentageOfShareDevelopmentCosts" xlink:label="vir_PercentageOfShareDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ProfitsAndLossesSharingPercentage" xlink:label="vir_ProfitsAndLossesSharingPercentage"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_UpfrontPaymentReceivable" xlink:label="vir_UpfrontPaymentReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_OptionExerciseFeeConsiderationToBeReceived" xlink:label="vir_OptionExerciseFeeConsiderationToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PreDefinedRegulatoryMilestoneConsiderationReceivable" xlink:label="vir_PreDefinedRegulatoryMilestoneConsiderationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AggregateValueOfCommonStockToBeIssued" xlink:label="vir_AggregateValueOfCommonStockToBeIssued"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementTransactionPriceFixedConsideration" xlink:label="vir_CollaborationAgreementTransactionPriceFixedConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementPercentageOfUpfrontFee" xlink:label="vir_CollaborationAgreementPercentageOfUpfrontFee"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PremiumPaidOnSalePriceOfCommonStock" xlink:label="vir_PremiumPaidOnSalePriceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementRemainingUpfrontFee" xlink:label="vir_CollaborationAgreementRemainingUpfrontFee"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ReceivableFromCollaboration" xlink:label="vir_ReceivableFromCollaboration"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PercentageOfOrdinaryShareEqualToOutstandingShare" xlink:label="vir_PercentageOfOrdinaryShareEqualToOutstandingShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_OptionExerciseFeeConsiderationReceivable" xlink:label="vir_OptionExerciseFeeConsiderationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RegulatoryMilestoneConsiderationReceivable" xlink:label="vir_RegulatoryMilestoneConsiderationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SalesMilestoneConsiderationReceivable" xlink:label="vir_SalesMilestoneConsiderationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_OptionExerciseFeeConsiderationPayable" xlink:label="vir_OptionExerciseFeeConsiderationPayable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_OptionExerciseFeeConsiderationPayableDescription" xlink:label="vir_OptionExerciseFeeConsiderationPayableDescription"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RegulatoryMilestonePaymentConsiderationPayable" xlink:label="vir_RegulatoryMilestonePaymentConsiderationPayable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SalesMilestoneConsiderationPayable" xlink:label="vir_SalesMilestoneConsiderationPayable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" xlink:label="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WrittenNoticePeriodForLicensedProgramNotExercisedAnOption" xlink:label="vir_WrittenNoticePeriodForLicensedProgramNotExercisedAnOption"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WrittenNoticePeriodForLicensedProgramExerciseAnOption" xlink:label="vir_WrittenNoticePeriodForLicensedProgramExerciseAnOption"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" xlink:label="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WrittenNoticePeriodForLicensedProgramFailureToMakePayment" xlink:label="vir_WrittenNoticePeriodForLicensedProgramFailureToMakePayment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_OptionExerciseFeeReceived" xlink:label="vir_OptionExerciseFeeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_DeterminedTransactionPrice" xlink:label="vir_DeterminedTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PaymentToPartnerResultingFromProgramOptionExercise" xlink:label="vir_PaymentToPartnerResultingFromProgramOptionExercise"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_UpfrontFeePaid" xlink:label="vir_UpfrontFeePaid"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SharePayableToCollaborator" xlink:label="vir_SharePayableToCollaborator"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MaximumSharesToBeIssued" xlink:label="vir_MaximumSharesToBeIssued"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" xlink:label="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MaximumSalesMilestonePayment" xlink:label="vir_MaximumSalesMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MaximumAggregateSalesMilestonePayment" xlink:label="vir_MaximumAggregateSalesMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WrittenNoticePeriodForLicensedProgramOtherPartyChallengesValidityOrEnforceabilityOfPatentLicense" xlink:label="vir_WrittenNoticePeriodForLicensedProgramOtherPartyChallengesValidityOrEnforceabilityOfPatentLicense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ContractualPayments" xlink:label="vir_ContractualPayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MilestonePaymentsPaid" xlink:label="vir_MilestonePaymentsPaid"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ChangeInFairValueOfMilestoneShares" xlink:label="vir_ChangeInFairValueOfMilestoneShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementRelatedCostsAndExpenses" xlink:label="vir_CollaborationAgreementRelatedCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PaymentOfAnnualLicenseMaintenanceFees" xlink:label="vir_PaymentOfAnnualLicenseMaintenanceFees"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale" xlink:label="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees" xlink:label="vir_SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LicenseMaintenanceFees" xlink:label="vir_LicenseMaintenanceFees"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LicenseAgreementUpfrontPayment" xlink:label="vir_LicenseAgreementUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_DevelopmentRegulatoryAndCommercialMilestonePaymentsMaximumAmount" xlink:label="vir_DevelopmentRegulatoryAndCommercialMilestonePaymentsMaximumAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_DevelopmentRegulatoryAndCommercialMilestonePayments" xlink:label="vir_DevelopmentRegulatoryAndCommercialMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" xlink:label="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MaximumAggregateCommercialSalesMilestonePayments" xlink:label="vir_MaximumAggregateCommercialSalesMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MaximumAggregateMilestonePayments" xlink:label="vir_MaximumAggregateMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SpecifiedDevelopmentMilestonesPayment" xlink:label="vir_SpecifiedDevelopmentMilestonesPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LicensedPatentsExpirationPeriod" xlink:label="vir_LicensedPatentsExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WrittenNoticePeriodForTerminationOfLicensedProgram" xlink:label="vir_WrittenNoticePeriodForTerminationOfLicensedProgram"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge" xlink:label="vir_WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementTransactionPriceConsideration" xlink:label="vir_CollaborationAgreementTransactionPriceConsideration"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandTwentyStockPurchaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_AntibodyProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="vir_AccruedLiabilitiesAndOtherLiabilitiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_GlaxoGroupLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_PreliminaryCollaborationAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherAssetsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_ContractRevenueMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_GlaxoGroupLimitedMember_2" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_CollaborationRevenueMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_DefinitiveCollaborationAgreementMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_ProfitShareRevenueMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_BriiBioParentMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfDevelopmentCosts" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_BriiBiosciencesOffshoreLimitedMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandTwentyOneStockPurchaseAgreementMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_VaccineProgramMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_AlnylamPharmaceuticalsIncMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_LicensedProductByLicensedProductMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_BiologicalMaterialsMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyOneGSKCollaborationMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementTerminationDescription" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_WuXiBiologicsLimitedMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_RockefellerUniversityMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_FairMarketValueOfCommonStockIssued" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyOneGSKAgreementMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_FirstSiRNAProductMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_MedImmuneLimitedLiabilityCompanyMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_BriiAgreementMember" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_AlnylamAgreementMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_XencorIncorporationMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PremiumReceivedOnSalePriceOfCommonStock" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_EachInfectiousDiseaseSiRNAMember" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_CommercializationMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_DevelopmentAndManufacturingCollaborationAgreementMember" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementNumberOfUnitsOfAccount" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_FirstInfectiousDiseaseProductMember" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_RockefellerAgreementMember" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_AntibodyLicenseTransactionPrice" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_HBVProgramMember" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_MedImmuneAgreementMember" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_IncreaseDecreaseInResearchAndDevelopmentExpense" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandNineteenXencorAgreementMember" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_InfluenzaAAndInfluenzaBMember" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_InfluenzaAResearchProgramsMember" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ReductionOfResearchAndDevelopmentExpense" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandTwentyXencorAgreementMember" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_HBVResearchProgramsMember" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PayableUnderAgreementCurrent" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_InfluenzaAAndHBVResearchProgramsMember" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfShareDevelopmentCosts" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ProfitsAndLossesSharingPercentage" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_UpfrontPaymentReceivable" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeConsiderationToBeReceived" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PreDefinedRegulatoryMilestoneConsiderationReceivable" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_AggregateValueOfCommonStockToBeIssued" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementTransactionPriceFixedConsideration" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementPercentageOfUpfrontFee" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PremiumPaidOnSalePriceOfCommonStock" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementRemainingUpfrontFee" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ReceivableFromCollaboration" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfOrdinaryShareEqualToOutstandingShare" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeConsiderationReceivable" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RegulatoryMilestoneConsiderationReceivable" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_SalesMilestoneConsiderationReceivable" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeConsiderationPayable" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeConsiderationPayableDescription" order="39" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RegulatoryMilestonePaymentConsiderationPayable" order="40" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_SalesMilestoneConsiderationPayable" order="41" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" order="42" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodForLicensedProgramNotExercisedAnOption" order="43" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodForLicensedProgramExerciseAnOption" order="44" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" order="45" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodForLicensedProgramFailureToMakePayment" order="46" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="47" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Investments" order="48" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeReceived" order="49" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_DeterminedTransactionPrice" order="50" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PaymentToPartnerResultingFromProgramOptionExercise" order="51" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_UpfrontFeePaid" order="52" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_SharePayableToCollaborator" order="53" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumSharesToBeIssued" order="54" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" order="55" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumSalesMilestonePayment" order="56" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateSalesMilestonePayment" order="57" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodForLicensedProgramOtherPartyChallengesValidityOrEnforceabilityOfPatentLicense" order="58" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" order="59" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ContractualPayments" order="60" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MilestonePaymentsPaid" order="61" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ChangeInFairValueOfMilestoneShares" order="62" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementRelatedCostsAndExpenses" order="63" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PaymentOfAnnualLicenseMaintenanceFees" order="64" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale" order="65" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees" order="66" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_LicenseMaintenanceFees" order="67" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_LicenseAgreementUpfrontPayment" order="68" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_DevelopmentRegulatoryAndCommercialMilestonePaymentsMaximumAmount" order="69" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_DevelopmentRegulatoryAndCommercialMilestonePayments" order="70" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" order="71" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateCommercialSalesMilestonePayments" order="72" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateMilestonePayments" order="73" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_SpecifiedDevelopmentMilestonesPayment" order="74" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_LicensedPatentsExpirationPeriod" order="75" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodForTerminationOfLicensedProgram" order="76" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge" order="77" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsForRoyalties" order="78" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementTransactionPriceConsideration" order="79" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LaboratoryEquipmentMember" xlink:label="vir_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="vir_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ResearchAndDevelopmentExpensesCurrent" xlink:label="vir_ResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MilestonePayable" xlink:label="vir_MilestonePayable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PayrollAndRelatedExpensesCurrent" xlink:label="vir_PayrollAndRelatedExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ExcessFundsPayableUnderGrantAgreementsCurrent" xlink:label="vir_ExcessFundsPayableUnderGrantAgreementsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="vir_ResearchAndDevelopmentExpensesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="vir_MilestonePayable" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="vir_PayrollAndRelatedExpensesCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="vir_ExcessFundsPayableUnderGrantAgreementsCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CommitmentsAndContingenciesLineItems" xlink:label="vir_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LeaseArrangementContractualExpirationBeginningYear" xlink:label="vir_LeaseArrangementContractualExpirationBeginningYear"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember" xlink:label="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CommitmentsAndContingenciesTable" xlink:label="vir_CommitmentsAndContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AntibodyProgramMember" xlink:label="vir_AntibodyProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_GlaxoSmithKlineTradingServiceLimitedMember" xlink:label="vir_GlaxoSmithKlineTradingServiceLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" xlink:label="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LeaseArrangementContractualExpirationEndingYear" xlink:label="vir_LeaseArrangementContractualExpirationEndingYear"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PercentageOfDevelopmentCosts" xlink:label="vir_PercentageOfDevelopmentCosts"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_CommitmentsAndContingenciesLineItems" xlink:to="vir_LeaseArrangementContractualExpirationBeginningYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_CommitmentsAndContingenciesTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_AntibodyProgramMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_GlaxoSmithKlineTradingServiceLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="vir_CommitmentsAndContingenciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_CommitmentsAndContingenciesLineItems" xlink:to="vir_LeaseArrangementContractualExpirationEndingYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_CommitmentsAndContingenciesTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_CommitmentsAndContingenciesTable" xlink:to="srt_ProductOrServiceAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_CommitmentsAndContingenciesTable" xlink:to="vir_CommitmentsAndContingenciesLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="vir_CommitmentsAndContingenciesLineItems" xlink:to="vir_PercentageOfDevelopmentCosts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="vir_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" xlink:label="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PresentValueOfOperatingLeaseLiabilities" xlink:label="vir_PresentValueOfOperatingLeaseLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="vir_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="vir_PresentValueOfOperatingLeaseLiabilities" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid" xlink:label="vir_OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="vir_OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeasesOperatingAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_11" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityAndRestrictedStockUnitsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RestrictedStockAwardsRSAMember" xlink:label="vir_RestrictedStockAwardsRSAMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="vir_RestrictedStockAwardsRSAMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensationAbstract" xlink:label="us-gaap_SalariesWagesAndOfficersCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SalariesWagesAndOfficersCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" xlink:label="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RestrictedSharesSubjectToFutureVesting" xlink:label="vir_RestrictedSharesSubjectToFutureVesting"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="vir_RestrictedSharesSubjectToFutureVesting" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_EarningsPerShareBasic" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_EstimatedSharesIssuableUnderTheESPPMember" xlink:label="vir_EstimatedSharesIssuableUnderTheESPPMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ContingentlyIssuableSharesMember" xlink:label="vir_ContingentlyIssuableSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WarrantsToPurchaseCommonStockMember" xlink:label="vir_WarrantsToPurchaseCommonStockMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="vir_EstimatedSharesIssuableUnderTheESPPMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="vir_ContingentlyIssuableSharesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="vir_WarrantsToPurchaseCommonStockMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>vir-20210630.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-08-05T15:34:55.5483+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.vir.bio/20210630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:country="http://xbrl.sec.gov/country/2020-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2020-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31" xmlns:srt-types="http://fasb.org/srt-types/2020-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:vir="http://www.vir.bio/20210630" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd" namespace="http://fasb.org/us-gaap/2020-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2020-01-31"/>
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd" namespace="http://fasb.org/srt/2020-01-31"/>
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd" namespace="http://xbrl.sec.gov/country/2020-01-31"/>
  <xsd:import schemaLocation="http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd" namespace="http://fasb.org/srt-types/2020-01-31"/>
  <xsd:import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vir-20210630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vir-20210630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vir-20210630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="vir-20210630_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" id="Role_StatementCondensedConsolidatedBalanceSheetsUnaudited">
        <link:definition>100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical" id="Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical">
        <link:definition>100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited">
        <link:definition>100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" id="StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited">
        <link:definition>100040 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss )(Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited">
        <link:definition>100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" id="Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
        <link:definition>100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganization" id="Role_DisclosureOrganization">
        <link:definition>100070 - Disclosure - Organization</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100090 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitions" id="Role_DisclosureAcquisitions">
        <link:definition>100100 - Disclosure - Acquisitions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreements" id="Role_DisclosureGrantAgreements">
        <link:definition>100110 - Disclosure - Grant Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements" id="Role_DisclosureCollaborationAndLicenseAgreements">
        <link:definition>100120 - Disclosure - Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponents" id="Role_DisclosureBalanceSheetComponents">
        <link:definition>100130 - Disclosure - Balance Sheet Components</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100140 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureRelatedPartyTransaction" id="Role_DisclosureRelatedPartyTransaction">
        <link:definition>100150 - Disclosure - Related Party Transaction</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwards" id="Role_DisclosureStockBasedAwards">
        <link:definition>100160 - Disclosure - Stock-Based Awards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShare1" id="DisclosureNetIncomeLossPerShare1">
        <link:definition>100170 - Disclosure - Net Income (Loss) Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/DisclosureSubsequentEvents" id="DisclosureSubsequentEvents">
        <link:definition>100180 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100190 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100200 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables" id="Role_DisclosureBalanceSheetComponentsTables">
        <link:definition>100210 - Disclosure - Balance Sheet Components (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100220 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsTables" id="Role_DisclosureStockBasedAwardsTables">
        <link:definition>100230 - Disclosure - Stock-Based Awards (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareTables" id="DisclosureNetIncomeLossPerShareTables">
        <link:definition>100240 - Disclosure - Net Income (Loss) Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" id="Role_DisclosureOrganizationAdditionalInformationDetails">
        <link:definition>100250 - Disclosure - Organization - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100260 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" id="Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails">
        <link:definition>100270 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" id="Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails">
        <link:definition>100280 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100290 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" id="Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails">
        <link:definition>100300 - Disclosure - Fair Value Measurements - Estimated Fair Value of Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" id="Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails">
        <link:definition>100310 - Disclosure - Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" id="Role_DisclosureAcquisitionsAdditionalInformationDetails">
        <link:definition>100320 - Disclosure - Acquisitions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" id="Role_DisclosureGrantAgreementsAdditionalInformationDetails">
        <link:definition>100330 - Disclosure - Grant Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" id="Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails">
        <link:definition>100340 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" id="Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails">
        <link:definition>100350 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails" id="Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails">
        <link:definition>100360 - Disclosure - Balance Sheet Components - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" id="Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails">
        <link:definition>100370 - Disclosure - Balance Sheet Components - Schedule of Accrued and Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
        <link:definition>100380 - Disclosure - Commitments and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails">
        <link:definition>100390 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetsDetails" id="Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetsDetails">
        <link:definition>100400 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" id="Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails">
        <link:definition>100410 - Disclosure - Stock-Based Awards - Summary of Stock Option Plans Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" id="Role_DisclosureStockBasedAwardsAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Stock-Based Awards - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" id="Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails">
        <link:definition>100430 - Disclosure - Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityAndRestrictedStockUnitsDetails" id="Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityAndRestrictedStockUnitsDetails">
        <link:definition>100440 - Disclosure - Stock-Based Awards - Summary of Restricted Stock Activity and Restricted Stock Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>100450 - Disclosure - Stock-Based Awards - Summary of Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails" id="DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails">
        <link:definition>100460 - Disclosure - Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (loss) Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" id="DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails">
        <link:definition>100470 - Disclosure - Net Income (Loss) Per Share - Schedule of Potentially Dilutive Securities Not Included in Diluted Per Share Calculations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="vir_AggregateValueOfCommonStockToBeIssued" name="AggregateValueOfCommonStockToBeIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_AntibodyLicenseTransactionPrice" name="AntibodyLicenseTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_AssetAcquisitionContingentConsiderationLiability" name="AssetAcquisitionContingentConsiderationLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" name="BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" name="BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" name="BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ChangeInEstimatedFairValueOfContingentConsideration" name="ChangeInEstimatedFairValueOfContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_ChangeInFairValueOfMilestoneShares" name="ChangeInFairValueOfMilestoneShares" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" name="CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_CollaborationAgreementNumberOfUnitsOfAccount" name="CollaborationAgreementNumberOfUnitsOfAccount" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_CollaborationAgreementPercentageOfUpfrontFee" name="CollaborationAgreementPercentageOfUpfrontFee" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_CollaborationAgreementRelatedCostsAndExpenses" name="CollaborationAgreementRelatedCostsAndExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_CollaborationAgreementRemainingUpfrontFee" name="CollaborationAgreementRemainingUpfrontFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_CollaborationAgreementTerminationDescription" name="CollaborationAgreementTerminationDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_CollaborationAgreementTransactionPriceConsideration" name="CollaborationAgreementTransactionPriceConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_CollaborationAgreementTransactionPriceFixedConsideration" name="CollaborationAgreementTransactionPriceFixedConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_CommonStockSharesIssuedForMilestonePaymentShares" name="CommonStockSharesIssuedForMilestonePaymentShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vir_ContractualPayments" name="ContractualPayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities" name="DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_DeterminedTransactionPrice" name="DeterminedTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_DevelopmentRegulatoryAndCommercialMilestonePayments" name="DevelopmentRegulatoryAndCommercialMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_DevelopmentRegulatoryAndCommercialMilestonePaymentsMaximumAmount" name="DevelopmentRegulatoryAndCommercialMilestonePaymentsMaximumAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ExcessFundsPayableUnderGrantAgreementsCurrent" name="ExcessFundsPayableUnderGrantAgreementsCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_FairMarketValueOfCommonStockIssued" name="FairMarketValueOfCommonStockIssued" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" name="FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_FinancialAssetsAmortizedCostBasis" name="FinancialAssetsAmortizedCostBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_FinancialAssetsFairValue" name="FinancialAssetsFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_FinancialAssetsGrossUnrealizedHoldingGains" name="FinancialAssetsGrossUnrealizedHoldingGains" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_FinancialAssetsGrossUnrealizedHoldingLosses" name="FinancialAssetsGrossUnrealizedHoldingLosses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_GrantAgreementAmendedExpirationDate" name="GrantAgreementAmendedExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_GrantAwardedAmount" name="GrantAwardedAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_GrantAwardedAmountMaximum" name="GrantAwardedAmountMaximum" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" name="IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_IncreaseDecreaseInResearchAndDevelopmentExpense" name="IncreaseDecreaseInResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" name="IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_LeaseArrangementContractualExpirationBeginningYear" name="LeaseArrangementContractualExpirationBeginningYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_LeaseArrangementContractualExpirationEndingYear" name="LeaseArrangementContractualExpirationEndingYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" name="LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" name="LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_LicenseAgreementUpfrontPayment" name="LicenseAgreementUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_LicensedPatentsExpirationPeriod" name="LicensedPatentsExpirationPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_LicenseMaintenanceFees" name="LicenseMaintenanceFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_MaximumAggregateCommercialSalesMilestonePayments" name="MaximumAggregateCommercialSalesMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" name="MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumAggregateMilestonePayments" name="MaximumAggregateMilestonePayments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumAggregateSalesMilestonePayment" name="MaximumAggregateSalesMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" name="MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" name="MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_MaximumSalesMilestonePayment" name="MaximumSalesMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MaximumSharesToBeIssued" name="MaximumSharesToBeIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vir_MilestonePayable" name="MilestonePayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_MilestonePaymentsPaid" name="MilestonePaymentsPaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_MilestonePaymentsRelatedTermsDescription" name="MilestonePaymentsRelatedTermsDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" name="MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_NoncashLeaseExpense" name="NoncashLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" name="NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid" name="OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_OptionExerciseFeeConsiderationPayable" name="OptionExerciseFeeConsiderationPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_OptionExerciseFeeConsiderationPayableDescription" name="OptionExerciseFeeConsiderationPayableDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_OptionExerciseFeeConsiderationReceivable" name="OptionExerciseFeeConsiderationReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_OptionExerciseFeeConsiderationToBeReceived" name="OptionExerciseFeeConsiderationToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_OptionExerciseFeeReceived" name="OptionExerciseFeeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_PayableUnderAgreementCurrent" name="PayableUnderAgreementCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_PaymentMadeForBusinessCombinationMilestone" name="PaymentMadeForBusinessCombinationMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_PaymentOfAnnualLicenseMaintenanceFees" name="PaymentOfAnnualLicenseMaintenanceFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_PaymentOfContingentConsideration" name="PaymentOfContingentConsideration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_PaymentsOfUnderwritingDiscountsAndCommissions" name="PaymentsOfUnderwritingDiscountsAndCommissions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_PaymentToPartnerResultingFromProgramOptionExercise" name="PaymentToPartnerResultingFromProgramOptionExercise" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_PayrollAndRelatedExpensesCurrent" name="PayrollAndRelatedExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares" name="PercentageOfAggregateGrossProceedsFromSaleOfShares" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_PercentageOfDevelopmentCosts" name="PercentageOfDevelopmentCosts" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_PercentageOfOrdinaryShareEqualToOutstandingShare" name="PercentageOfOrdinaryShareEqualToOutstandingShare" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_PercentageOfShareDevelopmentCosts" name="PercentageOfShareDevelopmentCosts" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" name="PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="vir_PreDefinedRegulatoryMilestoneConsiderationReceivable" name="PreDefinedRegulatoryMilestoneConsiderationReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_PremiumPaidOnSalePriceOfCommonStock" name="PremiumPaidOnSalePriceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_PremiumReceivedOnSalePriceOfCommonStock" name="PremiumReceivedOnSalePriceOfCommonStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_PresentValueOfOperatingLeaseLiabilities" name="PresentValueOfOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ProceedsFromIssuanceSecondaryPublicOffering" name="ProceedsFromIssuanceSecondaryPublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_ProfitsAndLossesSharingPercentage" name="ProfitsAndLossesSharingPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_ReceivableFromCollaboration" name="ReceivableFromCollaboration" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" name="ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" name="ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ReductionOfResearchAndDevelopmentExpense" name="ReductionOfResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_RegulatoryMilestoneConsiderationReceivable" name="RegulatoryMilestoneConsiderationReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_RegulatoryMilestonePaymentConsiderationPayable" name="RegulatoryMilestonePaymentConsiderationPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_RemainingPaymentMadeForBusinessCombinationMilestone" name="RemainingPaymentMadeForBusinessCombinationMilestone" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_ResearchAndDevelopmentExpensesCurrent" name="ResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_RestrictedSharesSubjectToFutureVesting" name="RestrictedSharesSubjectToFutureVesting" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale" name="RoyaltyObligationPeriodFromDateOfFirstCommercialSale" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" name="RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_SaleOfStockConsiderationAggregateOfferingPrice" name="SaleOfStockConsiderationAggregateOfferingPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_SalesMilestoneConsiderationPayable" name="SalesMilestoneConsiderationPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_SalesMilestoneConsiderationReceivable" name="SalesMilestoneConsiderationReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_SharePayableToCollaborator" name="SharePayableToCollaborator" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_SpecifiedClinicalDevelopmentMilestonesPayment" name="SpecifiedClinicalDevelopmentMilestonesPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees" name="SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_SpecifiedDevelopmentMilestonesPayment" name="SpecifiedDevelopmentMilestonesPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares" name="StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue" name="StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone" name="StockIssuedDuringPeriodSharesAchievementOfMilestone" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" name="StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_StockIssuedDuringPeriodSharesCollaborationAgreement" name="StockIssuedDuringPeriodSharesCollaborationAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_StockIssuedDuringPeriodSharesLicenseAgreement" name="StockIssuedDuringPeriodSharesLicenseAgreement" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_StockIssuedDuringPeriodValueCollaborationAgreement" name="StockIssuedDuringPeriodValueCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_StockIssuedDuringPeriodValueLicenseAgreement" name="StockIssuedDuringPeriodValueLicenseAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_UnusedFundsReceivedInAdvance" name="UnusedFundsReceivedInAdvance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_UpfrontFeePaid" name="UpfrontFeePaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_UpfrontPaymentReceivable" name="UpfrontPaymentReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="vir_ValueOfCommonStockSharesIssuedForMilestonePayment" name="ValueOfCommonStockSharesIssuedForMilestonePayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="vir_WrittenNoticePeriodForLicensedProgramExerciseAnOption" name="WrittenNoticePeriodForLicensedProgramExerciseAnOption" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticePeriodForLicensedProgramFailureToMakePayment" name="WrittenNoticePeriodForLicensedProgramFailureToMakePayment" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticePeriodForLicensedProgramNotExercisedAnOption" name="WrittenNoticePeriodForLicensedProgramNotExercisedAnOption" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticePeriodForLicensedProgramOtherPartyChallengesValidityOrEnforceabilityOfPatentLicense" name="WrittenNoticePeriodForLicensedProgramOtherPartyChallengesValidityOrEnforceabilityOfPatentLicense" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" name="WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticePeriodForTerminationOfLicensedProgram" name="WrittenNoticePeriodForTerminationOfLicensedProgram" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge" name="WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" name="OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_AccruedLiabilitiesAndOtherLiabilitiesMember" name="AccruedLiabilitiesAndOtherLiabilitiesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_AgenovirCorporationMember" name="AgenovirCorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_AlnylamAgreementMember" name="AlnylamAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_AlnylamPharmaceuticalsIncMember" name="AlnylamPharmaceuticalsIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_AnotherProductMember" name="AnotherProductMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_AntibodyProgramMember" name="AntibodyProgramMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_BillAndMelindaGatesFoundationMember" name="BillAndMelindaGatesFoundationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_BiologicalMaterialsMember" name="BiologicalMaterialsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_BriiAgreementMember" name="BriiAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_BriiBioParentMember" name="BriiBioParentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_BriiBiosciencesOffshoreLimitedMember" name="BriiBiosciencesOffshoreLimitedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ClinicalAndRegulatoryMilestonesMember" name="ClinicalAndRegulatoryMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ClinicalDevelopmentMember" name="ClinicalDevelopmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_CollaborationAgreementMember" name="CollaborationAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_CollaborationRevenueMember" name="CollaborationRevenueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_CommercializationMember" name="CommercializationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_CommercialMilestonesMember" name="CommercialMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ContingentConsiderationLiabilityMember" name="ContingentConsiderationLiabilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ContingentlyIssuableSharesMember" name="ContingentlyIssuableSharesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ContractRevenueMember" name="ContractRevenueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_DefinitiveCollaborationAgreementMember" name="DefinitiveCollaborationAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_DevelopmentAndManufacturingCollaborationAgreementMember" name="DevelopmentAndManufacturingCollaborationAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_EachInfectiousDiseaseSiRNAMember" name="EachInfectiousDiseaseSiRNAMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_EstimatedSharesIssuableUnderTheESPPMember" name="EstimatedSharesIssuableUnderTheESPPMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_FirstInfectiousDiseaseProductMember" name="FirstInfectiousDiseaseProductMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_FirstSiRNAProductMember" name="FirstSiRNAProductMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_FollowOnOfferingMember" name="FollowOnOfferingMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_GlaxoGroupLimitedMember" name="GlaxoGroupLimitedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" name="GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_GlaxoSmithKlineTradingServiceLimitedMember" name="GlaxoSmithKlineTradingServiceLimitedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_HBVProgramMember" name="HBVProgramMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_HBVResearchProgramsMember" name="HBVResearchProgramsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_HepatitisBVirusProductMember" name="HepatitisBVirusProductMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_HumabsBiomedSAMember" name="HumabsBiomedSAMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_HumanImmunodeficiencyVirusGrantMember" name="HumanImmunodeficiencyVirusGrantMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_InfluenzaAAndHBVResearchProgramsMember" name="InfluenzaAAndHBVResearchProgramsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_InfluenzaAAndInfluenzaBMember" name="InfluenzaAAndInfluenzaBMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_InfluenzaAResearchProgramsMember" name="InfluenzaAResearchProgramsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_LetterAgreementMember" name="LetterAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_LicensedProductByLicensedProductMember" name="LicensedProductByLicensedProductMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_MeasurementInputExpectedRevenueVolatilityMember" name="MeasurementInputExpectedRevenueVolatilityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_MeasurementInputProbabilityRateMember" name="MeasurementInputProbabilityRateMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_MedImmuneAgreementMember" name="MedImmuneAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_MedImmuneLimitedLiabilityCompanyMember" name="MedImmuneLimitedLiabilityCompanyMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_PreliminaryCollaborationAgreementMember" name="PreliminaryCollaborationAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ProfitShareRevenueMember" name="ProfitShareRevenueMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_RestrictedStockAwardsRSAMember" name="RestrictedStockAwardsRSAMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_RockefellerAgreementMember" name="RockefellerAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_RockefellerUniversityMember" name="RockefellerUniversityMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_SalesAgreementMember" name="SalesAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_SARSCoV2ProductMember" name="SARSCoV2ProductMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TomegaVaxIncMember" name="TomegaVaxIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TuberculosisTBGrantMember" name="TuberculosisTBGrantMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandAndTwentyOneGSKAgreementMember" name="TwoThousandAndTwentyOneGSKAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandAndTwentyOneGSKCollaborationMember" name="TwoThousandAndTwentyOneGSKCollaborationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" name="TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" name="TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandNineteenXencorAgreementMember" name="TwoThousandNineteenXencorAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" name="TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember" name="TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandTwentyOneStockPurchaseAgreementMember" name="TwoThousandTwentyOneStockPurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandTwentyStockPurchaseAgreementMember" name="TwoThousandTwentyStockPurchaseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_TwoThousandTwentyXencorAgreementMember" name="TwoThousandTwentyXencorAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_VaccineProgramMember" name="VaccineProgramMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_WarrantsToPurchaseCommonStockMember" name="WarrantsToPurchaseCommonStockMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember" name="WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_WuXiBiologicsLimitedMember" name="WuXiBiologicsLimitedMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_XencorIncorporationMember" name="XencorIncorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock" name="ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" name="OrganizationConsolidationAndPresentationOfFinancialStatementsTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" name="ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock" name="ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="vir_GrantAgreementsDisclosureTextBlock" name="GrantAgreementsDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>10
<FILENAME>vir-20210630_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-08-05T15:34:57.5409+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ClinicalDevelopmentMember" xlink:label="vir_ClinicalDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RemainingPaymentMadeForBusinessCombinationMilestone" xlink:label="vir_RemainingPaymentMadeForBusinessCombinationMilestone"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_OptionExerciseFeeConsiderationPayableDescription" xlink:label="vir_OptionExerciseFeeConsiderationPayableDescription"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_GrantAgreementAmendedExpirationDate" xlink:label="vir_GrantAgreementAmendedExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" xlink:label="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_OptionExerciseFeeConsiderationPayable" xlink:label="vir_OptionExerciseFeeConsiderationPayable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PaymentMadeForBusinessCombinationMilestone" xlink:label="vir_PaymentMadeForBusinessCombinationMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ValueOfCommonStockSharesIssuedForMilestonePayment" xlink:label="vir_ValueOfCommonStockSharesIssuedForMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CommonStockSharesIssuedForMilestonePaymentShares" xlink:label="vir_CommonStockSharesIssuedForMilestonePaymentShares"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationRevenueMember" xlink:label="vir_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RestrictedSharesSubjectToFutureVesting" xlink:label="vir_RestrictedSharesSubjectToFutureVesting"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ProfitShareRevenueMember" xlink:label="vir_ProfitShareRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ContractRevenueMember" xlink:label="vir_ContractRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementMember" xlink:label="vir_CollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementTransactionPriceConsideration" xlink:label="vir_CollaborationAgreementTransactionPriceConsideration"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandAndTwentyOneGSKAgreementMember" xlink:label="vir_TwoThousandAndTwentyOneGSKAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandAndTwentyOneGSKCollaborationMember" xlink:label="vir_TwoThousandAndTwentyOneGSKCollaborationMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_EstimatedSharesIssuableUnderTheESPPMember" xlink:label="vir_EstimatedSharesIssuableUnderTheESPPMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ContingentlyIssuableSharesMember" xlink:label="vir_ContingentlyIssuableSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FinancialAssetsAmortizedCostBasis" xlink:label="vir_FinancialAssetsAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TuberculosisTBGrantMember" xlink:label="vir_TuberculosisTBGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_HumanImmunodeficiencyVirusGrantMember" xlink:label="vir_HumanImmunodeficiencyVirusGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ReductionOfResearchAndDevelopmentExpense" xlink:label="vir_ReductionOfResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities" xlink:label="vir_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PaymentOfContingentConsideration" xlink:label="vir_PaymentOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" xlink:label="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SaleOfStockConsiderationAggregateOfferingPrice" xlink:label="vir_SaleOfStockConsiderationAggregateOfferingPrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" xlink:label="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_StockIssuedDuringPeriodSharesAchievementOfMilestone" xlink:label="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementTransactionPriceFixedConsideration" xlink:label="vir_CollaborationAgreementTransactionPriceFixedConsideration"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RestrictedStockAwardsRSAMember" xlink:label="vir_RestrictedStockAwardsRSAMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_InfluenzaAResearchProgramsMember" xlink:label="vir_InfluenzaAResearchProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MaximumSharesToBeIssued" xlink:label="vir_MaximumSharesToBeIssued"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees" xlink:label="vir_SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SalariesWagesAndOfficersCompensationAbstract" xlink:label="us-gaap_SalariesWagesAndOfficersCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalents" xlink:label="us-gaap_RestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FollowOnOfferingMember" xlink:label="vir_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SalesAgreementMember" xlink:label="vir_SalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FinancialAssetsGrossUnrealizedHoldingGains" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingGains"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FinancialAssetsGrossUnrealizedHoldingLosses" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingLosses"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FinancialAssetsFairValue" xlink:label="vir_FinancialAssetsFairValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="vir_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" xlink:label="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PresentValueOfOperatingLeaseLiabilities" xlink:label="vir_PresentValueOfOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_StockIssuedDuringPeriodSharesCollaborationAgreement" xlink:label="vir_StockIssuedDuringPeriodSharesCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_StockIssuedDuringPeriodValueCollaborationAgreement" xlink:label="vir_StockIssuedDuringPeriodValueCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_StockIssuedDuringPeriodValueLicenseAgreement" xlink:label="vir_StockIssuedDuringPeriodValueLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue" xlink:label="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_StockIssuedDuringPeriodSharesLicenseAgreement" xlink:label="vir_StockIssuedDuringPeriodSharesLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares" xlink:label="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_NoncashLeaseExpense" xlink:label="vir_NoncashLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ChangeInEstimatedFairValueOfContingentConsideration" xlink:label="vir_ChangeInEstimatedFairValueOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="vir_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:label="us-gaap_ProceedsFromSaleOfPropertyHeldForSale"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BankTimeDepositsMember" xlink:label="us-gaap_BankTimeDepositsMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AggregateValueOfCommonStockToBeIssued" xlink:label="vir_AggregateValueOfCommonStockToBeIssued"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementPercentageOfUpfrontFee" xlink:label="vir_CollaborationAgreementPercentageOfUpfrontFee"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PremiumPaidOnSalePriceOfCommonStock" xlink:label="vir_PremiumPaidOnSalePriceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementRemainingUpfrontFee" xlink:label="vir_CollaborationAgreementRemainingUpfrontFee"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ReceivableFromCollaboration" xlink:label="vir_ReceivableFromCollaboration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PercentageOfOrdinaryShareEqualToOutstandingShare" xlink:label="vir_PercentageOfOrdinaryShareEqualToOutstandingShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_OptionExerciseFeeConsiderationReceivable" xlink:label="vir_OptionExerciseFeeConsiderationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RegulatoryMilestoneConsiderationReceivable" xlink:label="vir_RegulatoryMilestoneConsiderationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SalesMilestoneConsiderationReceivable" xlink:label="vir_SalesMilestoneConsiderationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RegulatoryMilestonePaymentConsiderationPayable" xlink:label="vir_RegulatoryMilestonePaymentConsiderationPayable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SalesMilestoneConsiderationPayable" xlink:label="vir_SalesMilestoneConsiderationPayable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" xlink:label="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WrittenNoticePeriodForLicensedProgramNotExercisedAnOption" xlink:label="vir_WrittenNoticePeriodForLicensedProgramNotExercisedAnOption"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WrittenNoticePeriodForLicensedProgramExerciseAnOption" xlink:label="vir_WrittenNoticePeriodForLicensedProgramExerciseAnOption"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" xlink:label="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WrittenNoticePeriodForLicensedProgramFailureToMakePayment" xlink:label="vir_WrittenNoticePeriodForLicensedProgramFailureToMakePayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_OptionExerciseFeeReceived" xlink:label="vir_OptionExerciseFeeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_DeterminedTransactionPrice" xlink:label="vir_DeterminedTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LetterAgreementMember" xlink:label="vir_LetterAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ContingentConsiderationLiabilityMember" xlink:label="vir_ContingentConsiderationLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancingReceivableAccruedInterestWriteoff" xlink:label="us-gaap_FinancingReceivableAccruedInterestWriteoff"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MeasurementInputProbabilityRateMember" xlink:label="vir_MeasurementInputProbabilityRateMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MeasurementInputExpectedRevenueVolatilityMember" xlink:label="vir_MeasurementInputExpectedRevenueVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeLiabilityMeasurementInput" xlink:label="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AssetAcquisitionContingentConsiderationLiability" xlink:label="vir_AssetAcquisitionContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" xlink:label="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MilestonePaymentsRelatedTermsDescription" xlink:label="vir_MilestonePaymentsRelatedTermsDescription"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" xlink:label="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" xlink:label="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_HepatitisBVirusProductMember" xlink:label="vir_HepatitisBVirusProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AnotherProductMember" xlink:label="vir_AnotherProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SARSCoV2ProductMember" xlink:label="vir_SARSCoV2ProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AgenovirCorporationMember" xlink:label="vir_AgenovirCorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" xlink:label="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" xlink:label="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SpecifiedClinicalDevelopmentMilestonesPayment" xlink:label="vir_SpecifiedClinicalDevelopmentMilestonesPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_GrantAwardedAmountMaximum" xlink:label="vir_GrantAwardedAmountMaximum"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_GrantAwardedAmount" xlink:label="vir_GrantAwardedAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_DefinitiveCollaborationAgreementMember" xlink:label="vir_DefinitiveCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandTwentyOneStockPurchaseAgreementMember" xlink:label="vir_TwoThousandTwentyOneStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_BillAndMelindaGatesFoundationMember" xlink:label="vir_BillAndMelindaGatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_UnusedFundsReceivedInAdvance" xlink:label="vir_UnusedFundsReceivedInAdvance"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandTwentyStockPurchaseAgreementMember" xlink:label="vir_TwoThousandTwentyStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_GlaxoGroupLimitedMember" xlink:label="vir_GlaxoGroupLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PreliminaryCollaborationAgreementMember" xlink:label="vir_PreliminaryCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AntibodyProgramMember" xlink:label="vir_AntibodyProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AccruedLiabilitiesAndOtherLiabilitiesMember" xlink:label="vir_AccruedLiabilitiesAndOtherLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_GrantAgreementsDisclosureTextBlock" xlink:label="vir_GrantAgreementsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:label="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="us-gaap_InvestmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativesEmbeddedDerivatives" xlink:label="us-gaap_DerivativesEmbeddedDerivatives"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ClinicalAndRegulatoryMilestonesMember" xlink:label="vir_ClinicalAndRegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CommercialMilestonesMember" xlink:label="vir_CommercialMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" xlink:label="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock" xlink:label="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="vir_PaymentsOfUnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ProceedsFromIssuanceSecondaryPublicOffering" xlink:label="vir_ProceedsFromIssuanceSecondaryPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PercentageOfAggregateGrossProceedsFromSaleOfShares" xlink:label="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_BriiAgreementMember" xlink:label="vir_BriiAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_BriiBioParentMember" xlink:label="vir_BriiBioParentMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_BriiBiosciencesOffshoreLimitedMember" xlink:label="vir_BriiBiosciencesOffshoreLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LicensedProductByLicensedProductMember" xlink:label="vir_LicensedProductByLicensedProductMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:label="country_CN"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="country_US"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AlnylamPharmaceuticalsIncMember" xlink:label="vir_AlnylamPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid" xlink:label="vir_OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:label="us-gaap_LeasesOperatingAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_BiologicalMaterialsMember" xlink:label="vir_BiologicalMaterialsMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AlnylamAgreementMember" xlink:label="vir_AlnylamAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FirstSiRNAProductMember" xlink:label="vir_FirstSiRNAProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_EachInfectiousDiseaseSiRNAMember" xlink:label="vir_EachInfectiousDiseaseSiRNAMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PreDefinedRegulatoryMilestoneConsiderationReceivable" xlink:label="vir_PreDefinedRegulatoryMilestoneConsiderationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PaymentToPartnerResultingFromProgramOptionExercise" xlink:label="vir_PaymentToPartnerResultingFromProgramOptionExercise"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_UpfrontFeePaid" xlink:label="vir_UpfrontFeePaid"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SharePayableToCollaborator" xlink:label="vir_SharePayableToCollaborator"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" xlink:label="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MaximumSalesMilestonePayment" xlink:label="vir_MaximumSalesMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MaximumAggregateSalesMilestonePayment" xlink:label="vir_MaximumAggregateSalesMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WrittenNoticePeriodForLicensedProgramOtherPartyChallengesValidityOrEnforceabilityOfPatentLicense" xlink:label="vir_WrittenNoticePeriodForLicensedProgramOtherPartyChallengesValidityOrEnforceabilityOfPatentLicense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ContractualPayments" xlink:label="vir_ContractualPayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_VaccineProgramMember" xlink:label="vir_VaccineProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ChangeInFairValueOfMilestoneShares" xlink:label="vir_ChangeInFairValueOfMilestoneShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementRelatedCostsAndExpenses" xlink:label="vir_CollaborationAgreementRelatedCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MilestonePaymentsPaid" xlink:label="vir_MilestonePaymentsPaid"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PaymentOfAnnualLicenseMaintenanceFees" xlink:label="vir_PaymentOfAnnualLicenseMaintenanceFees"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale" xlink:label="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LicenseMaintenanceFees" xlink:label="vir_LicenseMaintenanceFees"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LicenseAgreementUpfrontPayment" xlink:label="vir_LicenseAgreementUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_DevelopmentRegulatoryAndCommercialMilestonePaymentsMaximumAmount" xlink:label="vir_DevelopmentRegulatoryAndCommercialMilestonePaymentsMaximumAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_DevelopmentRegulatoryAndCommercialMilestonePayments" xlink:label="vir_DevelopmentRegulatoryAndCommercialMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" xlink:label="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MaximumAggregateCommercialSalesMilestonePayments" xlink:label="vir_MaximumAggregateCommercialSalesMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MaximumAggregateMilestonePayments" xlink:label="vir_MaximumAggregateMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SpecifiedDevelopmentMilestonesPayment" xlink:label="vir_SpecifiedDevelopmentMilestonesPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LicensedPatentsExpirationPeriod" xlink:label="vir_LicensedPatentsExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WrittenNoticePeriodForTerminationOfLicensedProgram" xlink:label="vir_WrittenNoticePeriodForTerminationOfLicensedProgram"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge" xlink:label="vir_WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LaboratoryEquipmentMember" xlink:label="vir_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ResearchAndDevelopmentExpensesCurrent" xlink:label="vir_ResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MilestonePayable" xlink:label="vir_MilestonePayable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PayrollAndRelatedExpensesCurrent" xlink:label="vir_PayrollAndRelatedExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ExcessFundsPayableUnderGrantAgreementsCurrent" xlink:label="vir_ExcessFundsPayableUnderGrantAgreementsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LeaseArrangementContractualExpirationBeginningYear" xlink:label="vir_LeaseArrangementContractualExpirationBeginningYear"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LeaseArrangementContractualExpirationEndingYear" xlink:label="vir_LeaseArrangementContractualExpirationEndingYear"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CommitmentsAndContingenciesLineItems" xlink:label="vir_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CommitmentsAndContingenciesTable" xlink:label="vir_CommitmentsAndContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_GlaxoSmithKlineTradingServiceLimitedMember" xlink:label="vir_GlaxoSmithKlineTradingServiceLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" xlink:label="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember" xlink:label="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WarrantsToPurchaseCommonStockMember" xlink:label="vir_WarrantsToPurchaseCommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CommercializationMember" xlink:label="vir_CommercializationMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_DevelopmentAndManufacturingCollaborationAgreementMember" xlink:label="vir_DevelopmentAndManufacturingCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WuXiBiologicsLimitedMember" xlink:label="vir_WuXiBiologicsLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RockefellerAgreementMember" xlink:label="vir_RockefellerAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RockefellerUniversityMember" xlink:label="vir_RockefellerUniversityMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FirstInfectiousDiseaseProductMember" xlink:label="vir_FirstInfectiousDiseaseProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_HBVProgramMember" xlink:label="vir_HBVProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MedImmuneAgreementMember" xlink:label="vir_MedImmuneAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MedImmuneLimitedLiabilityCompanyMember" xlink:label="vir_MedImmuneLimitedLiabilityCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_InfluenzaAAndInfluenzaBMember" xlink:label="vir_InfluenzaAAndInfluenzaBMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandNineteenXencorAgreementMember" xlink:label="vir_TwoThousandNineteenXencorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_XencorIncorporationMember" xlink:label="vir_XencorIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_HBVResearchProgramsMember" xlink:label="vir_HBVResearchProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_InfluenzaAAndHBVResearchProgramsMember" xlink:label="vir_InfluenzaAAndHBVResearchProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandTwentyXencorAgreementMember" xlink:label="vir_TwoThousandTwentyXencorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PercentageOfDevelopmentCosts" xlink:label="vir_PercentageOfDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" xlink:label="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" xlink:label="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementTerminationDescription" xlink:label="vir_CollaborationAgreementTerminationDescription"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FairMarketValueOfCommonStockIssued" xlink:label="vir_FairMarketValueOfCommonStockIssued"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PremiumReceivedOnSalePriceOfCommonStock" xlink:label="vir_PremiumReceivedOnSalePriceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementNumberOfUnitsOfAccount" xlink:label="vir_CollaborationAgreementNumberOfUnitsOfAccount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AntibodyLicenseTransactionPrice" xlink:label="vir_AntibodyLicenseTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PayableUnderAgreementCurrent" xlink:label="vir_PayableUnderAgreementCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:label="vir_IncreaseDecreaseInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" xlink:label="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PercentageOfShareDevelopmentCosts" xlink:label="vir_PercentageOfShareDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ProfitsAndLossesSharingPercentage" xlink:label="vir_ProfitsAndLossesSharingPercentage"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_UpfrontPaymentReceivable" xlink:label="vir_UpfrontPaymentReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_OptionExerciseFeeConsiderationToBeReceived" xlink:label="vir_OptionExerciseFeeConsiderationToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ClinicalDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RemainingPaymentMadeForBusinessCombinationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Remaining payment made for business combination milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RemainingPaymentMadeForBusinessCombinationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Remaining Payment Made For Business Combination Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ClinicalDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeConsiderationPayableDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option exercise fee of ranging from low tens description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeConsiderationPayableDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Exercise Fee Consideration Payable Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeConsiderationPayableDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option Exercise Fee Consideration Payable Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementAmendedExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant agreement amended expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementAmendedExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant agreement amended expiration date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of restricted shares subject to future vesting using the treasury stock method.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted shares subject to future vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable To Dilutive Effect Of Restricted Share Subject To Future Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options to purchase common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Incremental Common Shares Attributable to Share-based Payment Arrangements, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Income (Loss) Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeConsiderationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option exercise fee of ranging from low tens</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (loss) before provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income (loss) from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cost of revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted-average shares outstanding, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average share outstanding, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentMadeForBusinessCombinationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment made for business combination milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentMadeForBusinessCombinationMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment made for business combination milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ValueOfCommonStockSharesIssuedForMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Value of common stock shares Issued for milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ValueOfCommonStockSharesIssuedForMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of common shares issued for milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockSharesIssuedForMilestonePaymentShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common stock shares Issued for milestone payment| shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommonStockSharesIssuedForMilestonePaymentShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Total number of common shares issued for milestone payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CostOfRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cost of Revenue, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive income ( loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss) per share, diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net income (loss) per share, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingently issuable shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RestrictedSharesSubjectToFutureVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted shares subject to future vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options to purchase common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RestrictedSharesSubjectToFutureVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Shares Subject To Future Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RestrictedSharesSubjectToFutureVesting_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted shares subject to future vesting.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted Average Number of Shares Outstanding, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Basic and Diluted Net Income (loss) Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProfitShareRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Profit Share Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProfitShareRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit Share Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProfitShareRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Profit Share Revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContractRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Contract Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected stock price volatility, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected stock price volatility, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTransactionPriceConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTransactionPriceConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Transaction Price Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTransactionPriceConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement transaction price consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value; 300,000,000 shares authorized as of June 30, 2021 and December 31, 2020; 130,479,975 and 127,416,740 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOneGSKAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 GSK Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOneGSKAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One G S K Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOneGSKAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2021 GSK Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOneGSKCollaborationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 GSK Collaboration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOneGSKCollaborationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One G S K Collaboration [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOneGSKCollaborationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">2021 GSK Collaboration [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRoyalties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Royalties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Selling, general and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Selling, General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Selling, General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EstimatedSharesIssuableUnderTheESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated shares issuable under the ESPP</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EstimatedSharesIssuableUnderTheESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Shares Issuable Under the E S P P [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EstimatedSharesIssuableUnderTheESPPMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated Shares Issuable Under the E S P P [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContingentlyIssuableSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingently issuable shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross proceeds from the offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Contingent Consideration, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash and Cash Equivalents, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investment Income, Net, Amortization of Discount and Premium, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Additional Paid in Capital, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Intangible Assets, Net (Excluding Goodwill), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and Cash Equivalents, at Carrying Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash and Cash Equivalents, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Allowance for Credit Loss, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale, Maturity and Collection of Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Liabilities, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Investments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortization of Intangible Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Contract with Customer, Asset, after Allowance for Credit Loss, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContingentlyIssuableSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingently Issuable Shares [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContingentlyIssuableSharesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingently issuable shares member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Long-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Assets, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TuberculosisTBGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tuberculosis ('TB') Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HumanImmunodeficiencyVirusGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Human Immunodeficiency Virus ('HIV') Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReductionOfResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduction of research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReductionOfResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reduction of Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReductionOfResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reduction of research and development expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred offering costs in accounts payable and accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Offering Costs In Accounts Payable And Accrued Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred offering costs in accounts payable and accrued liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of contingent consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of contingent consideration in excess of acquisition date fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Payment Of Contingent Consideration In Excess Of Acquisition Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in payment of contingent consideration in excess of acquisition date fair value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SaleOfStockConsiderationAggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate offering price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liabilities, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for cashless exercise of warrant (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Cashless Exercise Of Warrant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares cashless exercise of warrant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with the achievement of a milestone (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Achievement Of Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares achievement of milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 (excluding the six months ended June 30, 2021)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of June 30, 2021 and December 31, 2020; no shares issued and outstanding as of June 30, 2021 and December 31, 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContractRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContractRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContractRevenueMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Revenue [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Balance Sheet Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HumabsBiomedSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Humabs Biomed SA.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HumabsBiomedSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Humabs Biomed S A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HumabsBiomedSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Humabs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">U S Treasury Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USTreasurySecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. Government Treasuries</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTransactionPriceFixedConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement, transaction price fixed consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTransactionPriceFixedConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Transaction Price Fixed Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTransactionPriceFixedConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Liability Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term,Vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RestrictedStockAwardsRSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Restricted stock awards (RSA).</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RestrictedStockAwardsRSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Awards R S A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAResearchProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Influenza A research programs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAResearchProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Influenza A Research Programs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAResearchProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Influenza A Research Programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSharesToBeIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum shares to be issued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSharesToBeIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Shares To Be Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSharesToBeIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum shares to be issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Specified development milestones and annual license maintenance fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Specified Development Milestones And Annual License Maintenance Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Specified development milestones and annual license maintenance fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RestrictedStockAwardsRSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Awards (RSAs)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SalariesWagesAndOfficersCompensationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Salaries Wages And Officers Compensation [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Other Operating Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Restricted Cash Equivalents, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative Liability, Fair Value, Gross Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable Securities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic and Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Derivative, Gain (Loss) on Derivative, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Quarterly Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentQuarterlyReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Quarterly Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation State Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Address Line1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address City Or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address State Or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Revenue from Contract with Customer, Excluding Assessed Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CURRENT ASSETS:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents At Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash and cash equivalents, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract With Customer Asset Net Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intangible Assets Net Excluding Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Right Of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating right-of-use assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash And Cash Equivalents Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash and cash equivalents, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL ASSETS</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CURRENT LIABILITIES:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities And Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accrued and other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Current deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration, current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Liability Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration, noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL LIABILITIES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 8)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">STOCKHOLDERS&#8217; EQUITY:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductOrServiceAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ProductsAndServicesDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Product and Service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Follow On Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Follow-on Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Support To Nonconsolidated Legal Entity [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Support to Nonconsolidated Legal Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Support To Nonconsolidated Legal Entity [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Support to Nonconsolidated Legal Entity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Not From Contract With Customer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueNotFromContractWithCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue from grants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Contract With Customer Excluding Assessed Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Revenues_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Income Net Amortization Of Discount And Premium</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingGains_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial assets gross unrealized holding gains.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingGains_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Assets Gross Unrealized Holding Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingGains_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Assets, Gross Unrealized Holding Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial assets gross unrealized holding losses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingLosses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Assets Gross Unrealized Holding Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingLosses_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Financial Assets, Gross Unrealized Holding Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial assets fair value.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Assets Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Assets, Aggregate Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability payments due after year four.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due After Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lessee operating lease liability net tenant improvement allowance yet to be received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Net Tenant Improvement Allowance Yet To Be Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: net tenant improvement allowance yet to be received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PresentValueOfOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Present value of lessee's discounted obligation for lease payments from operating lease, net of tenant improvement allowance yet to be received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PresentValueOfOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Present Value Of Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security12b Title</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Depreciation and amortization expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AmortizationOfIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Amortization Of Discounts And Premiums Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of premiums on investments, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Gain Loss On Derivative Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Change in estimated fair value of derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Operating Activities Cash Flow Statement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Other Operating Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Liabilities And Other Operating Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued liabilities and other long-term liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM INVESTING ACTIVITIES:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonoperating Income Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other income (expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares outstanding, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Reclassification Adjustment From A O C I Pension And Other Postretirement Benefit Plans For Net Gain Loss Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of actuarial loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other comprehensive income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with a collaboration agreement (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueCollaborationAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with a collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification of derivative liability to additional paid In capital.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Derivative Liability To Additional Paid In Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of derivative liability to additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of common stock issued in connection with a license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodValueLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with a license agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Value of promissory notes related to vested shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Repayment Of Promissory Notes Net Of Unvested Common Stock Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment of promissory notes, net of unvested shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of common stock issued in connection with a license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodSharesLicenseAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock in connection with a license agreement (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vested shares related to repayment of promissory notes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Repayment Of Promissory Notes Net Of Unvested Common Stock Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Repayment of promissory notes, net of unvested shares (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Restricted Stock Award Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of restricted common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Restricted Stock Award Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Vesting of restricted common stock (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of stock option (in shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options,Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Noncash lease expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Lease Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NoncashLeaseExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ChangeInEstimatedFairValueOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in estimated fair value of contingent consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ChangeInEstimatedFairValueOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Estimated Fair Value Of Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ChangeInEstimatedFairValueOfContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in estimated fair value of contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Reclassification&#8203; of derivative liability&#8203; to additional paid-&#8203;in capital upon achievement of development milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Reclassification Of Derivative Liability To Additional Paid In Capital Upon Achievement Of Development Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of derivative liability to additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Arrangement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Arrangements And Nonarrangement Transactions [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM OPERATING ACTIVITIES:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Maturity And Collections Of Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyHeldForSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale Of Property Held For Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleOfPropertyHeldForSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from disposal of an asset held for sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">CASH FLOWS FROM FINANCING ACTIVITIES:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease Principal Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeasePrincipalPayments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Payment of principal on financing lease obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase in cash, cash equivalents and restricted cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash and cash equivalents at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash and cash equivalents at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">NONCASH INVESTING AND FINANCING ACTIVITIES:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment purchases included in accounts payable and accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH TO THE CONDENSED CONSOLIDATED BALANCE SHEETS:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BankTimeDepositsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bank Time Deposits [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BankTimeDepositsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bank Time Deposits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AggregateValueOfCommonStockToBeIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock to be issued, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementPercentageOfUpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement, percentage of upfront fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementPercentageOfUpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Percentage Of Upfront Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementPercentageOfUpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of upfront fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PremiumPaidOnSalePriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Premium paid on sale price of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PremiumPaidOnSalePriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Premium Paid On Sale Price Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PremiumPaidOnSalePriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Premium paid on sale price of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementRemainingUpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement, remaining upfront fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementRemainingUpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Remaining Upfront Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementRemainingUpfrontFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining upfront fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReceivableFromCollaboration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount due from collaboration partner under the collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReceivableFromCollaboration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Receivable From Collaboration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ReceivableFromCollaboration_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Receivable from collaboration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfOrdinaryShareEqualToOutstandingShare_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of ordinary share equal to outstanding share.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfOrdinaryShareEqualToOutstandingShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Ordinary Share Equal To Outstanding Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfOrdinaryShareEqualToOutstandingShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of ordinary share equal to outstanding share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeConsiderationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option exercise fee consideration receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeConsiderationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Exercise Fee Consideration Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeConsiderationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option exercise fee ranging from mid-single-digit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestoneConsiderationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestone consideration receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestoneConsiderationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestone Consideration Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestoneConsiderationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment on basis ranging from mid-single-digit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SalesMilestoneConsiderationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale milestone consideration receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SalesMilestoneConsiderationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestone Consideration Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SalesMilestoneConsiderationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales milestone receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeConsiderationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option exercise fee consideration payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeConsiderationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Exercise Fee Consideration Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonePaymentConsiderationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regulatory milestone payment consideration payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonePaymentConsiderationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regulatory Milestone Payment Consideration Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RegulatoryMilestonePaymentConsiderationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payment on basis of ranging from low tens</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SalesMilestoneConsiderationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales milestone consideration payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SalesMilestoneConsiderationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Milestone Consideration Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SalesMilestoneConsiderationPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty payment obligation expiration period after first commercial sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Payment Obligation Expiration Period After First Commercial Sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty payment obligation expiration period after first commercial sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForLicensedProgramNotExercisedAnOption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice for period for licensed program not exercised an option.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForLicensedProgramNotExercisedAnOption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Notice Period For Licensed Program Not Exercised An Option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForLicensedProgramNotExercisedAnOption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice period for not exercising an option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForLicensedProgramExerciseAnOption_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice period for licensed program, exercise an option.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForLicensedProgramExerciseAnOption_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Notice Period For Licensed Program Exercise An Option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForLicensedProgramExerciseAnOption_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice period for exercise an option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice period for licensed program, uncured material breach.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Notice Period For Licensed Program Uncured Material Breach</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice period for uncured material breach</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForLicensedProgramFailureToMakePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice period for licensed program, failure to make payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForLicensedProgramFailureToMakePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Notice Period For Licensed Program Failure To Make Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForLicensedProgramFailureToMakePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice period for failure to make payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Investments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Investments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying value of investment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option exercise fee received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Exercise Fee Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option exercise fee received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeterminedTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Determined transaction price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LetterAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Letter agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LetterAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letter Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LetterAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TomegaVax Letter Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContingentConsiderationLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContingentConsiderationLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Liability [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContingentConsiderationLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest receivable excluded from fair value and amortized cost basis of available for sale securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableAccruedInterestWriteoff_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Receivable Accrued Interest Writeoff</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancingReceivableAccruedInterestWriteoff_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Write off of accrued interest receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Securities contractual term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Discount Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputDiscountRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Discount Rates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MeasurementInputProbabilityRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Measurement input, probability rate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MeasurementInputProbabilityRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Probability Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MeasurementInputProbabilityRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Probability of Achievement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_WeightedAverageMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_WeightedAverageMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MeasurementInputExpectedRevenueVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Measurement input expected revenue volatility.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MeasurementInputExpectedRevenueVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Expected Revenue Volatility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MeasurementInputExpectedRevenueVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Input Price Volatility [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Input, Price Volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Liability Measurement Input</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value contingent consideration measurement input</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated fair value of contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Embedded Derivative Liability Measurement Input</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value contingent consideration measurement input</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AssetAcquisitionContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of liability recognized arising from contingent consideration in an asset acquisition.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AssetAcquisitionContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Acquisition Contingent Consideration Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AssetAcquisitionContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value of contingent consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value, reclassification of contingent consideration to accrued liabilities upon achievement of milestone.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Reclassification Of Contingent Consideration To Accrued Liabilities Upon Achievement Of Milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reclassification of contingent consideration to accrued liabilities upon achievement of milestone</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Liability Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByLiabilityClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Derivative Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value by Liability Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at March 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at December 31, 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in fair value recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentsRelatedTermsDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments related terms description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentsRelatedTermsDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Related Terms Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentsRelatedTermsDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments related terms</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business acquisition number of milestones achieved related to contingent consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Number Of Milestones Achieved Related To Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of milestones achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum common stock conversion price for milestone payments consideration.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Common Stock Conversion Price For Milestone Payments Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum common stock conversion price for milestone payments consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Business Acquisitions By Acquisition [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Business Acquisitions By Acquisition [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HepatitisBVirusProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Hepatitis B Virus Product Member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HepatitisBVirusProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Hepatitis B Virus Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HepatitisBVirusProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">HBV Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AnotherProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Another product.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AnotherProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Another Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AnotherProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Another Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SARSCoV2ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">SARS-CoV-2 product.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SARSCoV2ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">S A R S Co V2 Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SARSCoV2ProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SARS-CoV-2 Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AgenovirCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agenovir Corporation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AgenovirCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agenovir Corporation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AgenovirCorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agenovir</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments aggregate amount payable, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Embedded Derivative Fair Value Of Embedded Derivative Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Estimated fair value of embedded derivative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combinations additional consideration payable upon achievement of specified events.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations Additional Consideration Payable Upon Achievement Of Specified Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional consideration payable upon achievement of specified milestone events, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business acquisition number of specified clinical milestones achieved.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Number Of Specified Clinical Milestones Achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of specified clinical milestones achieved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedClinicalDevelopmentMilestonesPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Specified clinical development milestones payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedClinicalDevelopmentMilestonesPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Specified Clinical Development Milestones Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedClinicalDevelopmentMilestonesPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Specified clinical development milestones payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAwardedAmountMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum grant awarded amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAwardedAmountMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Awarded Amount Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAwardedAmountMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant awarded amount. maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAwardedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant awarded amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one Glaxo Wellcome UK Limited and Beecham S.A.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Glaxo Wellcome U K Limited And Beecham S A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 GSK</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DefinitiveCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Definitive collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DefinitiveCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Definitive Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DefinitiveCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Definitive Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyOneStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty one stock purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAwardedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Awarded Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAwardedAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant awarded amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HumanImmunodeficiencyVirusGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Human immunodeficiency virus grant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HumanImmunodeficiencyVirusGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Human Immunodeficiency Virus Grant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BillAndMelindaGatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Bill &amp; Melinda Gates Foundation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BillAndMelindaGatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Bill And Melinda Gates Foundation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BillAndMelindaGatesFoundationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bill And Melinda Gates Foundation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TuberculosisTBGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tuberculosis (&#8220;TB&#8221;) grant.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TuberculosisTBGrantMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tuberculosis T B Grant [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UnusedFundsReceivedInAdvance_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unused funds received in advance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UnusedFundsReceivedInAdvance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unused Funds Received In Advance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UnusedFundsReceivedInAdvance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unused funds received in advance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementAmendedExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Agreement Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty stock purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Stock Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Glaxo Group Limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Glaxo Group Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoGroupLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GGL</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PreliminaryCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Preliminary Collaboration Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PreliminaryCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preliminary Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PreliminaryCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preliminary Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AntibodyProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Antibody Program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AccruedLiabilitiesAndOtherLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities And Other Liabilities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AccruedLiabilitiesAndOtherLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisitions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant agreements disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Agreements Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GrantAgreementsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Related Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Concentration of credit risk credit loss and other risks and uncertainties.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Of Credit Risk Credit Loss And Other Risks And Uncertainties Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investment Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations Policy</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisitions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesEmbeddedDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivatives Embedded Derivatives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativesEmbeddedDerivatives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Embedded Derivatives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Acquiree [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration By Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration by Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContingentConsiderationTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ClinicalAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Clinical and regulatory milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ClinicalAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Clinical And Regulatory Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ClinicalAndRegulatoryMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Clinical and Regulatory Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercial milestones.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Milestones [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommercialMilestonesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TomegaVaxIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">TomegaVax, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TomegaVaxIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tomega Vax Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TomegaVaxIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TomegaVax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets Measured On Recurring Basis [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Financial Assets Measured at Fair Value on a Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value of Significant Unobservable Inputs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Changes in Estimated Fair Value of Financial Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Property and Equipment Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of accrued liabilities and other liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accrued Liabilities And Other Liabilities Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Accrued and Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Maturity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of operating lease amounts recorded in condensed consolidated balance sheet.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Operating Lease Amounts Recorded In Condensed Consolidated Balance Sheet Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options Issued and Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Plans Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Nonvested Restricted Stock Units Activity Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Activity and Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Potentially Dilutive Securities Not Included in the Diluted Per Share Calculations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentsOfUnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payments of underwriting discounts and commissions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentsOfUnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Underwriting Discounts And Commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentsOfUnderwritingDiscountsAndCommissions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments of underwriting discounts and commissions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromIssuanceSecondaryPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The cash inflow associated with the amount received from entity's follow on offering of stock to the public.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromIssuanceSecondaryPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Secondary Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProceedsFromIssuanceSecondaryPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds after deducting underwriting discounts, commissions and offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization consolidation and presentation of financial statements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization Consolidation And Presentation Of Financial Statements [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FollowOnOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Follow-on offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments Of Stock Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of aggregate gross proceeds from sale of shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Aggregate Gross Proceeds From Sale Of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of aggregate gross proceeds from sale of shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SaleOfStockConsiderationAggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sale of stock consideration aggregate offering price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SaleOfStockConsiderationAggregateOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Consideration Aggregate Offering Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Cash Equivalents And Short Term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities Available For Sale Allowance For Credit Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Allowance for losses on available-for-sale debt securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Financial assets amortized cost basis.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Assets Amortized Cost Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FinancialAssetsAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial Assets, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByAssetClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Asset Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyOneStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty One Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyOneStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Stock Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty one preliminary collaboration agreement and stock purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty One Preliminary Collaboration Agreement And Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021 Preliminary Collaboration Agreement and Stock Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Brii Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Brii Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Brii Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiBioParentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Brii Bio Parent.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiBioParentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Brii Bio Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiBioParentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Brii Bio Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiBiosciencesOffshoreLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Brii Biosciences Offshore Limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiBiosciencesOffshoreLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Brii Biosciences Offshore Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BriiBiosciencesOffshoreLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Brii Bio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LicensedProductByLicensedProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Licensed product-by-licensed product.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LicensedProductByLicensedProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licensed Product By Licensed Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LicensedProductByLicensedProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licensed Product-By-Licensed Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement Geographical [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementGeographicalAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Geographical [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_SegmentGeographicalDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Geographical</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CN_lbl" xlink:role="http://www.xbrl.org/2003/role/label">CHINA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_CN_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">China Territory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/label">UNITED STATES</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="country_US_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">United States</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AlnylamPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Alnylam Pharmaceuticals, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AlnylamPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alnylam Pharmaceuticals Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AlnylamPharmaceuticalsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alnylam Pharmaceuticals Inc</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Current portion of lease liabilities recorded in prepaid expenses and other current assets for which the lease incentives to be received exceed the minimum lease payments to be paid over the next twelve months.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current Net Of Tenant Improvement Allowances Included In Prepaid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current operating lease liabilities, net of tenant improvement allowances</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leases Operating [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current Statement Of Financial Position Extensible List</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Options,Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Options,Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options,Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Options,Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options,Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Options,Vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Exercise Price, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Exercise Price, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price, Forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price,Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Exercise Price,Vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Remaining Contractual Term,Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">RSUs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unamortized stock-based compensation expense related to stock option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated weighted average period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected term of options (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected stock price volatility</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BiologicalMaterialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Biological materials.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BiologicalMaterialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Biological Materials [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_BiologicalMaterialsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biological Materials</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LicenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AlnylamAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Alnylam agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AlnylamAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Alnylam Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AlnylamAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Alnylam Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstSiRNAProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First siRNA product member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstSiRNAProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Si R N A Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstSiRNAProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First siRNA product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EachInfectiousDiseaseSiRNAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Each infectious disease siRNA.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EachInfectiousDiseaseSiRNAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Each Infectious Disease Si R N A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_EachInfectiousDiseaseSiRNAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Each Infectious Disease siRNA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PreDefinedRegulatoryMilestoneConsiderationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pre Defined Regulatory Milestone Consideration Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PreDefinedRegulatoryMilestoneConsiderationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pre-defined regulatory milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AggregateValueOfCommonStockToBeIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate value of common stock to be issued under the Stock Purchase Agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AggregateValueOfCommonStockToBeIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Value Of Common Stock To Be Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeterminedTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Determined Transaction Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DeterminedTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Determined transaction price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentToPartnerResultingFromProgramOptionExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount of payment to a collaborator due to a program option exercise under a separate agreement .</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentToPartnerResultingFromProgramOptionExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment To Partner Resulting From Program Option Exercise</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentToPartnerResultingFromProgramOptionExercise_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UpfrontFeePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront fee paid.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UpfrontFeePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Fee Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UpfrontFeePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront fee paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SharePayableToCollaborator_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Portion of the carrying value of the equity investment due to a third party that is payable within one year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SharePayableToCollaborator_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Payable To Collaborator</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SharePayableToCollaborator_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognized liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum milestone payment for achievement of specified development and regulatory.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Milestone Payment For Achievement Of Specified Development And Regulatory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum milestone payment for achievement of specified development and regulatory</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSalesMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum milestone payment for achievement of specified annual net sales.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSalesMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Sales Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumSalesMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum sales milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateSalesMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate milestone payment for achievement of specified annual net sales</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateSalesMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Sales Milestone Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateSalesMilestonePayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate sales milestone payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForLicensedProgramOtherPartyChallengesValidityOrEnforceabilityOfPatentLicense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice period for licensed program other party challenges validity or enforceability of patent license.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForLicensedProgramOtherPartyChallengesValidityOrEnforceabilityOfPatentLicense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Notice Period For Licensed Program Other Party Challenges Validity Or Enforceability Of Patent License</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForLicensedProgramOtherPartyChallengesValidityOrEnforceabilityOfPatentLicense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice period for licensed program other party challenges validity or enforceability of patent license.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContractualPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContractualPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ContractualPayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Fair Value Of Derivative Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value of the derivative liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AntibodyProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antibody Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AntibodyProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antibody Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_VaccineProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vaccine Program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_VaccineProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vaccine Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_VaccineProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vaccine Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand wenty Glaxo Wellcome UK Limited and Beecham S.A.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Glaxo Wellcome U K Limited And Beecham S A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 GSK</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201409 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASC 606</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand and twenty preliminary collaboration agreement and stock purchase agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand And Twenty Preliminary Collaboration Agreement And Stock Purchase Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Preliminary Collaboration Agreement and Stock Purchase Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AccruedLiabilitiesAndOtherLiabilitiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued Liabilities And Other Liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ChangeInFairValueOfMilestoneShares_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value of milestone shares.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ChangeInFairValueOfMilestoneShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Of Milestone Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ChangeInFairValueOfMilestoneShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of Milestone Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementRelatedCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Costs and expenses for the period incurred under the collaboration agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementRelatedCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Related Costs And Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementRelatedCostsAndExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses incurred under agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments paid.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePaymentsPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments paid.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentOfAnnualLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payment of annual license maintenance fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentOfAnnualLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payment Of Annual License Maintenance Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PaymentOfAnnualLicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payment of annual license maintenance fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Royalty obligation period from date of first commercial sale.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Obligation Period From Date Of First Commercial Sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty obligation period from date of first commercial sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License maintenance fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Maintenance Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LicenseMaintenanceFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License maintenance fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LicenseAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement upfront payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LicenseAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LicenseAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentRegulatoryAndCommercialMilestonePaymentsMaximumAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development, regulatory, and commercial milestone payments maximum amount.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentRegulatoryAndCommercialMilestonePaymentsMaximumAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Regulatory And Commercial Milestone Payments Maximum Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentRegulatoryAndCommercialMilestonePaymentsMaximumAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development, regulatory, and commercial milestone payments maximum amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentRegulatoryAndCommercialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development regulatory and commercial milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentRegulatoryAndCommercialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development Regulatory And Commercial Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentRegulatoryAndCommercialMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development, regulatory, and commercial milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate development and regulatory milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Development And Regulatory Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate development and regulatory milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateCommercialSalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate commercial sales milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateCommercialSalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Commercial Sales Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateCommercialSalesMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate commercial sales milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate milestone payments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Milestone Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumAggregateMilestonePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate milestone payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedDevelopmentMilestonesPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Specified development milestones payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedDevelopmentMilestonesPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Specified Development Milestones Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_SpecifiedDevelopmentMilestonesPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Specified development milestones payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LicensedPatentsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Licensed patents expiration period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LicensedPatentsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licensed Patents Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LicensedPatentsExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licensed patents expiration period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForTerminationOfLicensedProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice period for termination of licensed program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForTerminationOfLicensedProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Notice Period For Termination Of Licensed Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForTerminationOfLicensedProgram_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice period for termination of licensed program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Written notice period for termination of licensed program based on challenge.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Written Notice Period For Termination Of Licensed Program Based On Challenge</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Written notice period for termination of licensed program based on challenge</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory equipment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Carrying value as of the balance sheet date of current obligations incurred and payable to vendors for goods and services attributable to the entity's research and development activities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MilestonePayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PayrollAndRelatedExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payroll and related expenses current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PayrollAndRelatedExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payroll And Related Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PayrollAndRelatedExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payroll and related expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ExcessFundsPayableUnderGrantAgreementsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Excess funds payable under grant agreements current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ExcessFundsPayableUnderGrantAgreementsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Excess Funds Payable Under Grant Agreements Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ExcessFundsPayableUnderGrantAgreementsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Excess funds payable under grant agreements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease Liability Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other professional and consulting expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LeaseArrangementContractualExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease arrangement, contractual expiration beginning year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LeaseArrangementContractualExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Arrangement Contractual Expiration Beginning Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LeaseArrangementContractualExpirationBeginningYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease arrangement, contractual expiration period, beginning year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LeaseArrangementContractualExpirationEndingYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease arrangement, contractual expiration ending year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LeaseArrangementContractualExpirationEndingYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Arrangement Contractual Expiration Ending Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_LeaseArrangementContractualExpirationEndingYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease arrangement, contractual expiration period, ending year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommitmentsAndContingenciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommitmentsAndContingenciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoSmithKlineTradingServiceLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Glaxo SmithKline Trading Service Limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoSmithKlineTradingServiceLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Glaxo Smith Kline Trading Service Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoSmithKlineTradingServiceLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GSKTSL</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">GlaxoSmithKline Intellectual Property Development Limited and GlaxoSmithKline Biologicals SA.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Glaxo Smith Kline Intellectual Property Development Limited And Glaxo Smith Kline Biologicals S A [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">GSK</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">WuXi biologics and Samsung letter agreement assignments and master services agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Wuxi Biologics And Samsung Letter Agreement Assignments And Master Services Agreements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WuXi Biologics MSA and Samsung MSA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Existence Of Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, existence of option to extend [true false]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Option To Extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, option to extend</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lessee, operating lease, renewal term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Remainder Of Fiscal Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Operating Lease Liability Payments Due Next Twelve Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares, Unvested, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares, Unvested, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares, Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted Average Grant Date Fair Value, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted Average Grant Date Fair Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation cost related to unvested restricted stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Shares Subject to Future Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WarrantsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Warrants to purchase common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WarrantsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants To Purchase Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommercializationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Commercialization.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommercializationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercialization [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CommercializationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercialization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentAndManufacturingCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Development and manufacturing collaboration agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentAndManufacturingCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development And Manufacturing Collaboration Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_DevelopmentAndManufacturingCollaborationAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Development and Manufacturing Collaboration Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WuXiBiologicsLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">WuXi Biologics Limited.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WuXiBiologicsLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Wu Xi Biologics Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WuXiBiologicsLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">WuXi Biologics</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RockefellerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rockefeller agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RockefellerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rockefeller Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RockefellerAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rockefeller Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RockefellerUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Rockefeller University.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RockefellerUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Rockefeller University [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_RockefellerUniversityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rockefeller</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstInfectiousDiseaseProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">First infectious disease product.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstInfectiousDiseaseProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">First Infectious Disease Product [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FirstInfectiousDiseaseProductMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">First Infectious Disease Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HBVProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">HBV program.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HBVProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">H B V Program [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HBVProgramMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">HBV Program</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MedImmuneAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MedImmune agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MedImmuneAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Med Immune Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MedImmuneAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MedImmune Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MedImmuneLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">MedImmune, limited liability company.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MedImmuneLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Med Immune Limited Liability Company [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MedImmuneLimitedLiabilityCompanyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">MedImmune</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAAndInfluenzaBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Influenza A and Influenza B member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAAndInfluenzaBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Influenza A And Influenza B [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAAndInfluenzaBMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Influenza A and Influenza B</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenXencorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand nineteen xencor agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenXencorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Nineteen Xencor Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandNineteenXencorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019 Xencor Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_XencorIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Xencor, incorporation member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_XencorIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Xencor Incorporation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_XencorIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Xencor</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HBVResearchProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">HBV research programs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HBVResearchProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">H B V Research Programs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_HBVResearchProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">HBV Research Programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAAndHBVResearchProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Influenza A and HBV research programs member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAAndHBVResearchProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Influenza A And H B V Research Programs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_InfluenzaAAndHBVResearchProgramsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Influenza A and HBV Research Programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyXencorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand twenty xencor agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyXencorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Twenty Xencor Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_TwoThousandTwentyXencorAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020 Xencor Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share purchase price per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of development costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of years conduct certain research and development activities under mutually agreed development plans.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Years Conduct Certain Research And Development Activities Under Mutually Agreed Development Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of years conduct certain research and development activities under mutually agreed development plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum percentage of right to perform details in connection with antibody product.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Percentage Of Right To Perform Details In Connection With Antibody Product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage of right to perform details in connection with antibody product</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement termination description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Termination Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FairMarketValueOfCommonStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair market value of common stock issued.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FairMarketValueOfCommonStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Market Value Of Common Stock Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_FairMarketValueOfCommonStockIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair market value of the common stock issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PremiumReceivedOnSalePriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Premium received on sale price of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PremiumReceivedOnSalePriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Premium Received On Sale Price Of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PremiumReceivedOnSalePriceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Premium received on sale price of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementNumberOfUnitsOfAccount_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement, number of units of account.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementNumberOfUnitsOfAccount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Number Of Units Of Account</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementNumberOfUnitsOfAccount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of units of account</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AntibodyLicenseTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transaction price for the Antibody License under the collaboration agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AntibodyLicenseTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antibody License Transaction Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_AntibodyLicenseTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antibody license transaction price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PayableUnderAgreementCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Payable under agreement, current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PayableUnderAgreementCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payable Under Agreement Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PayableUnderAgreementCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase (decrease) in research And development expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration agreement, number of separate programs agreed to collaborate.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreement Number Of Separate Programs Agreed To Collaborate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of separate programs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfShareDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of share development costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfShareDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Share Development Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfShareDevelopmentCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of share development costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProfitsAndLossesSharingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Profits and losses sharing percentage.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProfitsAndLossesSharingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Profits And Losses Sharing Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_ProfitsAndLossesSharingPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of share Profit and loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UpfrontPaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UpfrontPaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Upfront Payment Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_UpfrontPaymentReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of upfront payment receivable at effective date of agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Upfront Payment Receivable At Effective Date Of Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of upfront payment receivable at effective date of agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeConsiderationToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option exercise fee consideration to be received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeConsiderationToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option Exercise Fee Consideration To Be Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_OptionExerciseFeeConsiderationToBeReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option exercise fee to be received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_PreDefinedRegulatoryMilestoneConsiderationReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pre-defined regulatory milestone consideration receivable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="vir_WarrantsToPurchaseCommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants to Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantMember" xlink:to="us-gaap_GrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiability" xlink:to="us-gaap_ContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ClinicalDevelopmentMember" xlink:to="vir_ClinicalDevelopmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RemainingPaymentMadeForBusinessCombinationMilestone" xlink:to="vir_RemainingPaymentMadeForBusinessCombinationMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OptionExerciseFeeConsiderationPayableDescription" xlink:to="vir_OptionExerciseFeeConsiderationPayableDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GrantAgreementAmendedExpirationDate" xlink:to="vir_GrantAgreementAmendedExpirationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting" xlink:to="vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements" xlink:to="us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OptionExerciseFeeConsiderationPayable" xlink:to="vir_OptionExerciseFeeConsiderationPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CostOfRevenue" xlink:to="us-gaap_CostOfRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PaymentMadeForBusinessCombinationMilestone" xlink:to="vir_PaymentMadeForBusinessCombinationMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ValueOfCommonStockSharesIssuedForMilestonePayment" xlink:to="vir_ValueOfCommonStockSharesIssuedForMilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CommonStockSharesIssuedForMilestonePaymentShares" xlink:to="vir_CommonStockSharesIssuedForMilestonePaymentShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationRevenueMember" xlink:to="vir_CollaborationRevenueMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:to="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RestrictedSharesSubjectToFutureVesting" xlink:to="vir_RestrictedSharesSubjectToFutureVesting_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract" xlink:to="us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ProfitShareRevenueMember" xlink:to="vir_ProfitShareRevenueMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ContractRevenueMember" xlink:to="vir_ContractRevenueMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationAgreementMember" xlink:to="vir_CollaborationAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationAgreementTransactionPriceConsideration" xlink:to="vir_CollaborationAgreementTransactionPriceConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandAndTwentyOneGSKAgreementMember" xlink:to="vir_TwoThousandAndTwentyOneGSKAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandAndTwentyOneGSKCollaborationMember" xlink:to="vir_TwoThousandAndTwentyOneGSKCollaborationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRoyalties" xlink:to="us-gaap_PaymentsForRoyalties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_EstimatedSharesIssuableUnderTheESPPMember" xlink:to="vir_EstimatedSharesIssuableUnderTheESPPMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ContingentlyIssuableSharesMember" xlink:to="vir_ContingentlyIssuableSharesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Investments" xlink:to="us-gaap_Investments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AmortizationOfIntangibleAssets" xlink:to="us-gaap_AmortizationOfIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetNetCurrent" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermInvestments" xlink:to="us-gaap_LongTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FinancialAssetsAmortizedCostBasis" xlink:to="vir_FinancialAssetsAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TuberculosisTBGrantMember" xlink:to="vir_TuberculosisTBGrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_HumanImmunodeficiencyVirusGrantMember" xlink:to="vir_HumanImmunodeficiencyVirusGrantMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ReductionOfResearchAndDevelopmentExpense" xlink:to="vir_ReductionOfResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities" xlink:to="vir_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PaymentOfContingentConsideration" xlink:to="vir_PaymentOfContingentConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" xlink:to="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SaleOfStockConsiderationAggregateOfferingPrice" xlink:to="vir_SaleOfStockConsiderationAggregateOfferingPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" xlink:to="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone" xlink:to="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock" xlink:to="us-gaap_SupplementalBalanceSheetDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_HumabsBiomedSAMember" xlink:to="vir_HumabsBiomedSAMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USTreasurySecuritiesMember" xlink:to="us-gaap_USTreasurySecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationAgreementTransactionPriceFixedConsideration" xlink:to="vir_CollaborationAgreementTransactionPriceFixedConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RestrictedStockAwardsRSAMember" xlink:to="vir_RestrictedStockAwardsRSAMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_InfluenzaAResearchProgramsMember" xlink:to="vir_InfluenzaAResearchProgramsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumSharesToBeIssued" xlink:to="vir_MaximumSharesToBeIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees" xlink:to="vir_SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalariesWagesAndOfficersCompensationAbstract" xlink:to="us-gaap_SalariesWagesAndOfficersCompensationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashEquivalents" xlink:to="us-gaap_RestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireInvestments" xlink:to="us-gaap_PaymentsToAcquireInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeGainLossOnDerivativeNet" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductsAndServicesDomain" xlink:to="srt_ProductsAndServicesDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FollowOnOfferingMember" xlink:to="vir_FollowOnOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:to="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:to="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SalesAgreementMember" xlink:to="vir_SalesAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueNotFromContractWithCustomer" xlink:to="us-gaap_RevenueNotFromContractWithCustomer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FinancialAssetsGrossUnrealizedHoldingGains" xlink:to="vir_FinancialAssetsGrossUnrealizedHoldingGains_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FinancialAssetsGrossUnrealizedHoldingLosses" xlink:to="vir_FinancialAssetsGrossUnrealizedHoldingLosses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FinancialAssetsFairValue" xlink:to="vir_FinancialAssetsFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:to="vir_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" xlink:to="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PresentValueOfOperatingLeaseLiabilities" xlink:to="vir_PresentValueOfOperatingLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodSharesCollaborationAgreement" xlink:to="vir_StockIssuedDuringPeriodSharesCollaborationAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodValueCollaborationAgreement" xlink:to="vir_StockIssuedDuringPeriodValueCollaborationAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:to="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodValueLicenseAgreement" xlink:to="vir_StockIssuedDuringPeriodValueLicenseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue" xlink:to="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodSharesLicenseAgreement" xlink:to="vir_StockIssuedDuringPeriodSharesLicenseAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares" xlink:to="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_NoncashLeaseExpense" xlink:to="vir_NoncashLeaseExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ChangeInEstimatedFairValueOfContingentConsideration" xlink:to="vir_ChangeInEstimatedFairValueOfContingentConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="vir_IncreaseDecreaseInOperatingLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" xlink:to="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:to="us-gaap_ProceedsFromSaleOfPropertyHeldForSale_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeasePrincipalPayments" xlink:to="us-gaap_FinanceLeasePrincipalPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueByAssetClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BankTimeDepositsMember" xlink:to="us-gaap_BankTimeDepositsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AggregateValueOfCommonStockToBeIssued" xlink:to="vir_AggregateValueOfCommonStockToBeIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationAgreementPercentageOfUpfrontFee" xlink:to="vir_CollaborationAgreementPercentageOfUpfrontFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PremiumPaidOnSalePriceOfCommonStock" xlink:to="vir_PremiumPaidOnSalePriceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationAgreementRemainingUpfrontFee" xlink:to="vir_CollaborationAgreementRemainingUpfrontFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ReceivableFromCollaboration" xlink:to="vir_ReceivableFromCollaboration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PercentageOfOrdinaryShareEqualToOutstandingShare" xlink:to="vir_PercentageOfOrdinaryShareEqualToOutstandingShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OptionExerciseFeeConsiderationReceivable" xlink:to="vir_OptionExerciseFeeConsiderationReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RegulatoryMilestoneConsiderationReceivable" xlink:to="vir_RegulatoryMilestoneConsiderationReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SalesMilestoneConsiderationReceivable" xlink:to="vir_SalesMilestoneConsiderationReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RegulatoryMilestonePaymentConsiderationPayable" xlink:to="vir_RegulatoryMilestonePaymentConsiderationPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SalesMilestoneConsiderationPayable" xlink:to="vir_SalesMilestoneConsiderationPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" xlink:to="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticePeriodForLicensedProgramNotExercisedAnOption" xlink:to="vir_WrittenNoticePeriodForLicensedProgramNotExercisedAnOption_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticePeriodForLicensedProgramExerciseAnOption" xlink:to="vir_WrittenNoticePeriodForLicensedProgramExerciseAnOption_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" xlink:to="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticePeriodForLicensedProgramFailureToMakePayment" xlink:to="vir_WrittenNoticePeriodForLicensedProgramFailureToMakePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OptionExerciseFeeReceived" xlink:to="vir_OptionExerciseFeeReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_DeterminedTransactionPrice" xlink:to="vir_DeterminedTransactionPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_LetterAgreementMember" xlink:to="vir_LetterAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ContingentConsiderationLiabilityMember" xlink:to="vir_ContingentConsiderationLiabilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivable" xlink:to="us-gaap_InterestReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancingReceivableAccruedInterestWriteoff" xlink:to="us-gaap_FinancingReceivableAccruedInterestWriteoff_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputDiscountRateMember" xlink:to="us-gaap_MeasurementInputDiscountRateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MeasurementInputProbabilityRateMember" xlink:to="vir_MeasurementInputProbabilityRateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_WeightedAverageMember" xlink:to="srt_WeightedAverageMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MeasurementInputExpectedRevenueVolatilityMember" xlink:to="vir_MeasurementInputExpectedRevenueVolatilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MeasurementInputPriceVolatilityMember" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput" xlink:to="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AssetAcquisitionContingentConsiderationLiability" xlink:to="vir_AssetAcquisitionContingentConsiderationLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" xlink:to="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueByLiabilityClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherExpenseMember" xlink:to="us-gaap_OtherExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MilestonePaymentsRelatedTermsDescription" xlink:to="vir_MilestonePaymentsRelatedTermsDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" xlink:to="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" xlink:to="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_HepatitisBVirusProductMember" xlink:to="vir_HepatitisBVirusProductMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AnotherProductMember" xlink:to="vir_AnotherProductMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SARSCoV2ProductMember" xlink:to="vir_SARSCoV2ProductMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AgenovirCorporationMember" xlink:to="vir_AgenovirCorporationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" xlink:to="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" xlink:to="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SpecifiedClinicalDevelopmentMilestonesPayment" xlink:to="vir_SpecifiedClinicalDevelopmentMilestonesPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GrantAwardedAmountMaximum" xlink:to="vir_GrantAwardedAmountMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GrantAwardedAmount" xlink:to="vir_GrantAwardedAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:to="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_DefinitiveCollaborationAgreementMember" xlink:to="vir_DefinitiveCollaborationAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandTwentyOneStockPurchaseAgreementMember" xlink:to="vir_TwoThousandTwentyOneStockPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BillAndMelindaGatesFoundationMember" xlink:to="vir_BillAndMelindaGatesFoundationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_UnusedFundsReceivedInAdvance" xlink:to="vir_UnusedFundsReceivedInAdvance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandTwentyStockPurchaseAgreementMember" xlink:to="vir_TwoThousandTwentyStockPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GlaxoGroupLimitedMember" xlink:to="vir_GlaxoGroupLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PreliminaryCollaborationAgreementMember" xlink:to="vir_PreliminaryCollaborationAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AntibodyProgramMember" xlink:to="vir_AntibodyProgramMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AccruedLiabilitiesAndOtherLiabilitiesMember" xlink:to="vir_AccruedLiabilitiesAndOtherLiabilitiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GrantAgreementsDisclosureTextBlock" xlink:to="vir_GrantAgreementsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetRelatedDisclosuresAbstract" xlink:to="us-gaap_BalanceSheetRelatedDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock" xlink:to="vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentPolicyTextBlock" xlink:to="us-gaap_InvestmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativesEmbeddedDerivatives" xlink:to="us-gaap_DerivativesEmbeddedDerivatives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="us-gaap_ContingentConsiderationTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ClinicalAndRegulatoryMilestonesMember" xlink:to="vir_ClinicalAndRegulatoryMilestonesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CommercialMilestonesMember" xlink:to="vir_CommercialMilestonesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TomegaVaxIncMember" xlink:to="vir_TomegaVaxIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock" xlink:to="vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock" xlink:to="vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:to="vir_PaymentsOfUnderwritingDiscountsAndCommissions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ProceedsFromIssuanceSecondaryPublicOffering" xlink:to="vir_ProceedsFromIssuanceSecondaryPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares" xlink:to="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" xlink:to="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BriiAgreementMember" xlink:to="vir_BriiAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BriiBioParentMember" xlink:to="vir_BriiBioParentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BriiBiosciencesOffshoreLimitedMember" xlink:to="vir_BriiBiosciencesOffshoreLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_LicensedProductByLicensedProductMember" xlink:to="vir_LicensedProductByLicensedProductMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_SegmentGeographicalDomain" xlink:to="srt_SegmentGeographicalDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_CN" xlink:to="country_CN_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_US" xlink:to="country_US_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsMember" xlink:to="us-gaap_OtherAssetsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AlnylamPharmaceuticalsIncMember" xlink:to="vir_AlnylamPharmaceuticalsIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid" xlink:to="vir_OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_BiologicalMaterialsMember" xlink:to="vir_BiologicalMaterialsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseMember" xlink:to="us-gaap_LicenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AlnylamAgreementMember" xlink:to="vir_AlnylamAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FirstSiRNAProductMember" xlink:to="vir_FirstSiRNAProductMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_EachInfectiousDiseaseSiRNAMember" xlink:to="vir_EachInfectiousDiseaseSiRNAMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PreDefinedRegulatoryMilestoneConsiderationReceivable" xlink:to="vir_PreDefinedRegulatoryMilestoneConsiderationReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PaymentToPartnerResultingFromProgramOptionExercise" xlink:to="vir_PaymentToPartnerResultingFromProgramOptionExercise_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_UpfrontFeePaid" xlink:to="vir_UpfrontFeePaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SharePayableToCollaborator" xlink:to="vir_SharePayableToCollaborator_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" xlink:to="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumSalesMilestonePayment" xlink:to="vir_MaximumSalesMilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumAggregateSalesMilestonePayment" xlink:to="vir_MaximumAggregateSalesMilestonePayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticePeriodForLicensedProgramOtherPartyChallengesValidityOrEnforceabilityOfPatentLicense" xlink:to="vir_WrittenNoticePeriodForLicensedProgramOtherPartyChallengesValidityOrEnforceabilityOfPatentLicense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ContractualPayments" xlink:to="vir_ContractualPayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_VaccineProgramMember" xlink:to="vir_VaccineProgramMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:to="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201409Member" xlink:to="us-gaap_AccountingStandardsUpdate201409Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" xlink:to="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ChangeInFairValueOfMilestoneShares" xlink:to="vir_ChangeInFairValueOfMilestoneShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationAgreementRelatedCostsAndExpenses" xlink:to="vir_CollaborationAgreementRelatedCostsAndExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MilestonePaymentsPaid" xlink:to="vir_MilestonePaymentsPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PaymentOfAnnualLicenseMaintenanceFees" xlink:to="vir_PaymentOfAnnualLicenseMaintenanceFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale" xlink:to="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_LicenseMaintenanceFees" xlink:to="vir_LicenseMaintenanceFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_LicenseAgreementUpfrontPayment" xlink:to="vir_LicenseAgreementUpfrontPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_DevelopmentRegulatoryAndCommercialMilestonePaymentsMaximumAmount" xlink:to="vir_DevelopmentRegulatoryAndCommercialMilestonePaymentsMaximumAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_DevelopmentRegulatoryAndCommercialMilestonePayments" xlink:to="vir_DevelopmentRegulatoryAndCommercialMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" xlink:to="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumAggregateCommercialSalesMilestonePayments" xlink:to="vir_MaximumAggregateCommercialSalesMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumAggregateMilestonePayments" xlink:to="vir_MaximumAggregateMilestonePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_SpecifiedDevelopmentMilestonesPayment" xlink:to="vir_SpecifiedDevelopmentMilestonesPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_LicensedPatentsExpirationPeriod" xlink:to="vir_LicensedPatentsExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticePeriodForTerminationOfLicensedProgram" xlink:to="vir_WrittenNoticePeriodForTerminationOfLicensedProgram_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge" xlink:to="vir_WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_LaboratoryEquipmentMember" xlink:to="vir_LaboratoryEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ResearchAndDevelopmentExpensesCurrent" xlink:to="vir_ResearchAndDevelopmentExpensesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MilestonePayable" xlink:to="vir_MilestonePayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PayrollAndRelatedExpensesCurrent" xlink:to="vir_PayrollAndRelatedExpensesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ExcessFundsPayableUnderGrantAgreementsCurrent" xlink:to="vir_ExcessFundsPayableUnderGrantAgreementsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_LeaseArrangementContractualExpirationBeginningYear" xlink:to="vir_LeaseArrangementContractualExpirationBeginningYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_LeaseArrangementContractualExpirationEndingYear" xlink:to="vir_LeaseArrangementContractualExpirationEndingYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CommitmentsAndContingenciesLineItems" xlink:to="vir_CommitmentsAndContingenciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CommitmentsAndContingenciesTable" xlink:to="vir_CommitmentsAndContingenciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GlaxoSmithKlineTradingServiceLimitedMember" xlink:to="vir_GlaxoSmithKlineTradingServiceLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" xlink:to="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember" xlink:to="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WarrantsToPurchaseCommonStockMember" xlink:to="vir_WarrantsToPurchaseCommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CommercializationMember" xlink:to="vir_CommercializationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_DevelopmentAndManufacturingCollaborationAgreementMember" xlink:to="vir_DevelopmentAndManufacturingCollaborationAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_WuXiBiologicsLimitedMember" xlink:to="vir_WuXiBiologicsLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RockefellerAgreementMember" xlink:to="vir_RockefellerAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_RockefellerUniversityMember" xlink:to="vir_RockefellerUniversityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FirstInfectiousDiseaseProductMember" xlink:to="vir_FirstInfectiousDiseaseProductMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_HBVProgramMember" xlink:to="vir_HBVProgramMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MedImmuneAgreementMember" xlink:to="vir_MedImmuneAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MedImmuneLimitedLiabilityCompanyMember" xlink:to="vir_MedImmuneLimitedLiabilityCompanyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_InfluenzaAAndInfluenzaBMember" xlink:to="vir_InfluenzaAAndInfluenzaBMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandNineteenXencorAgreementMember" xlink:to="vir_TwoThousandNineteenXencorAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_XencorIncorporationMember" xlink:to="vir_XencorIncorporationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_HBVResearchProgramsMember" xlink:to="vir_HBVResearchProgramsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_InfluenzaAAndHBVResearchProgramsMember" xlink:to="vir_InfluenzaAAndHBVResearchProgramsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_TwoThousandTwentyXencorAgreementMember" xlink:to="vir_TwoThousandTwentyXencorAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PercentageOfDevelopmentCosts" xlink:to="vir_PercentageOfDevelopmentCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" xlink:to="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" xlink:to="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationAgreementTerminationDescription" xlink:to="vir_CollaborationAgreementTerminationDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_FairMarketValueOfCommonStockIssued" xlink:to="vir_FairMarketValueOfCommonStockIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PremiumReceivedOnSalePriceOfCommonStock" xlink:to="vir_PremiumReceivedOnSalePriceOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationAgreementNumberOfUnitsOfAccount" xlink:to="vir_CollaborationAgreementNumberOfUnitsOfAccount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_AntibodyLicenseTransactionPrice" xlink:to="vir_AntibodyLicenseTransactionPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PayableUnderAgreementCurrent" xlink:to="vir_PayableUnderAgreementCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:to="vir_IncreaseDecreaseInResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" xlink:to="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PercentageOfShareDevelopmentCosts" xlink:to="vir_PercentageOfShareDevelopmentCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_ProfitsAndLossesSharingPercentage" xlink:to="vir_ProfitsAndLossesSharingPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_UpfrontPaymentReceivable" xlink:to="vir_UpfrontPaymentReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" xlink:to="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="vir_OptionExerciseFeeConsiderationToBeReceived" xlink:to="vir_OptionExerciseFeeConsiderationToBeReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>vir-20210630_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-08-05T15:34:56.5289+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="vir-20210630.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:href="vir-20210630.xsd#Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="vir-20210630.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="vir-20210630.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsTables" xlink:href="vir-20210630.xsd#Role_DisclosureStockBasedAwardsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails" xlink:href="vir-20210630.xsd#Role_DisclosureOrganizationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" xlink:href="vir-20210630.xsd#Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" xlink:href="vir-20210630.xsd#Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="vir-20210630.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" xlink:href="vir-20210630.xsd#Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" xlink:href="vir-20210630.xsd#Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails" xlink:href="vir-20210630.xsd#Role_DisclosureAcquisitionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails" xlink:href="vir-20210630.xsd#Role_DisclosureGrantAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:href="vir-20210630.xsd#Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="vir-20210630.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:href="vir-20210630.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" xlink:href="vir-20210630.xsd#Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails" xlink:href="vir-20210630.xsd#Role_DisclosureStockBasedAwardsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" xlink:href="vir-20210630.xsd#Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityAndRestrictedStockUnitsDetails" xlink:href="vir-20210630.xsd#Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityAndRestrictedStockUnitsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails" xlink:href="vir-20210630.xsd#Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:href="vir-20210630.xsd#DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenuesAbstract" xlink:label="us-gaap_RevenuesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationRevenueMember" xlink:label="vir_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ContractRevenueMember" xlink:label="vir_ContractRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueNotFromContractWithCustomer" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_CollaborationRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RevenuesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_CostOfRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_ContractRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareDiluted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_StockIssuedDuringPeriodSharesAchievementOfMilestone" xlink:label="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_StockIssuedDuringPeriodValueCollaborationAgreement" xlink:label="vir_StockIssuedDuringPeriodValueCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_StockIssuedDuringPeriodSharesCollaborationAgreement" xlink:label="vir_StockIssuedDuringPeriodSharesCollaborationAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" xlink:label="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_StockIssuedDuringPeriodValueLicenseAgreement" xlink:label="vir_StockIssuedDuringPeriodValueLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_StockIssuedDuringPeriodSharesLicenseAgreement" xlink:label="vir_StockIssuedDuringPeriodSharesLicenseAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue" xlink:label="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares" xlink:label="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesAchievementOfMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodValueCollaborationAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesCollaborationAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodValueLicenseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodSharesLicenseAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementMember" xlink:label="vir_CollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" xlink:label="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PaymentOfContingentConsideration" xlink:label="vir_PaymentOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities" xlink:label="vir_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_NoncashLeaseExpense" xlink:label="vir_NoncashLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:label="us-gaap_ProceedsFromSaleOfPropertyHeldForSale"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ChangeInEstimatedFairValueOfContingentConsideration" xlink:label="vir_ChangeInEstimatedFairValueOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="vir_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" xlink:label="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_CollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="vir_PaymentOfContingentConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AmortizationOfIntangibleAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_FinanceLeasePrincipalPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="vir_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="vir_NoncashLeaseExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyHeldForSale" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="vir_ChangeInEstimatedFairValueOfContingentConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="vir_IncreaseDecreaseInOperatingLeaseLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ClinicalAndRegulatoryMilestonesMember" xlink:label="vir_ClinicalAndRegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CommercialMilestonesMember" xlink:label="vir_CommercialMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="vir_ClinicalAndRegulatoryMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="vir_CommercialMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_TomegaVaxIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsTables">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:label="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FollowOnOfferingMember" xlink:label="vir_FollowOnOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:label="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SalesAgreementMember" xlink:label="vir_SalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="vir_PaymentsOfUnderwritingDiscountsAndCommissions"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ProceedsFromIssuanceSecondaryPublicOffering" xlink:label="vir_ProceedsFromIssuanceSecondaryPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PercentageOfAggregateGrossProceedsFromSaleOfShares" xlink:label="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SaleOfStockConsiderationAggregateOfferingPrice" xlink:label="vir_SaleOfStockConsiderationAggregateOfferingPrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="vir_FollowOnOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:to="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" xlink:to="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain" xlink:to="vir_SalesAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_PaymentsOfUnderwritingDiscountsAndCommissions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_ProceedsFromIssuanceSecondaryPublicOffering" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_PercentageOfAggregateGrossProceedsFromSaleOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="vir_SaleOfStockConsiderationAggregateOfferingPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FinancialAssetsAmortizedCostBasis" xlink:label="vir_FinancialAssetsAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BankTimeDepositsMember" xlink:label="us-gaap_BankTimeDepositsMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FinancialAssetsGrossUnrealizedHoldingGains" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingGains"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FinancialAssetsGrossUnrealizedHoldingLosses" xlink:label="vir_FinancialAssetsGrossUnrealizedHoldingLosses"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FinancialAssetsFairValue" xlink:label="vir_FinancialAssetsFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FinancialAssetsAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_BankTimeDepositsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FinancialAssetsGrossUnrealizedHoldingGains" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FinancialAssetsGrossUnrealizedHoldingLosses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_FinancialAssetsFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashEquivalents" xlink:label="us-gaap_RestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:label="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByAssetClassAxis" xlink:label="us-gaap_FairValueByAssetClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="us-gaap_USTreasurySecuritiesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_RestrictedCashEquivalents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByAssetClassAxis" xlink:to="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LongTermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain" xlink:to="us-gaap_USTreasurySecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByAssetClassAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InterestReceivable" xlink:label="us-gaap_InterestReceivable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LetterAgreementMember" xlink:label="vir_LetterAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinancingReceivableAccruedInterestWriteoff" xlink:label="us-gaap_FinancingReceivableAccruedInterestWriteoff"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ContingentConsiderationLiabilityMember" xlink:label="vir_ContingentConsiderationLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleTerm" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTerm"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AssetAcquisitionContingentConsiderationLiability" xlink:label="vir_AssetAcquisitionContingentConsiderationLiability"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_InterestReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_LetterAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancingReceivableAccruedInterestWriteoff" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_TomegaVaxIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="vir_ContingentConsiderationLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="vir_AssetAcquisitionContingentConsiderationLiability" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationByTypeAxis" xlink:label="us-gaap_ContingentConsiderationByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContingentConsiderationTypeDomain" xlink:label="us-gaap_ContingentConsiderationTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputDiscountRateMember" xlink:label="us-gaap_MeasurementInputDiscountRateMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ClinicalAndRegulatoryMilestonesMember" xlink:label="vir_ClinicalAndRegulatoryMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeAxis" xlink:label="us-gaap_MeasurementInputTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputTypeDomain" xlink:label="us-gaap_MeasurementInputTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MeasurementInputProbabilityRateMember" xlink:label="vir_MeasurementInputProbabilityRateMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeLiabilityMeasurementInput" xlink:label="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CommercialMilestonesMember" xlink:label="vir_CommercialMilestonesMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_WeightedAverageMember" xlink:label="srt_WeightedAverageMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MeasurementInputExpectedRevenueVolatilityMember" xlink:label="vir_MeasurementInputExpectedRevenueVolatilityMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MeasurementInputPriceVolatilityMember" xlink:label="us-gaap_MeasurementInputPriceVolatilityMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ContingentConsiderationByTypeAxis" xlink:to="us-gaap_ContingentConsiderationTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputDiscountRateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="vir_ClinicalAndRegulatoryMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MeasurementInputTypeAxis" xlink:to="us-gaap_MeasurementInputTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="vir_MeasurementInputProbabilityRateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_ContingentConsiderationByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_EmbeddedDerivativeLiabilityMeasurementInput" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ContingentConsiderationTypeDomain" xlink:to="vir_CommercialMilestonesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_TomegaVaxIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="us-gaap_MeasurementInputTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_WeightedAverageMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="vir_MeasurementInputExpectedRevenueVolatilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MeasurementInputTypeDomain" xlink:to="us-gaap_MeasurementInputPriceVolatilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueByLiabilityClassAxis" xlink:label="us-gaap_FairValueByLiabilityClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:label="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ContingentConsiderationLiabilityMember" xlink:label="vir_ContingentConsiderationLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherExpenseMember" xlink:label="us-gaap_OtherExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" xlink:label="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByLiabilityClassAxis" xlink:to="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain" xlink:to="vir_ContingentConsiderationLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_FairValueByLiabilityClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems" xlink:to="vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_HepatitisBVirusProductMember" xlink:label="vir_HepatitisBVirusProductMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ClinicalDevelopmentMember" xlink:label="vir_ClinicalDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LetterAgreementMember" xlink:label="vir_LetterAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TomegaVaxIncMember" xlink:label="vir_TomegaVaxIncMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" xlink:label="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AnotherProductMember" xlink:label="vir_AnotherProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_HumabsBiomedSAMember" xlink:label="vir_HumabsBiomedSAMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MilestonePaymentsRelatedTermsDescription" xlink:label="vir_MilestonePaymentsRelatedTermsDescription"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SARSCoV2ProductMember" xlink:label="vir_SARSCoV2ProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AgenovirCorporationMember" xlink:label="vir_AgenovirCorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" xlink:label="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PaymentMadeForBusinessCombinationMilestone" xlink:label="vir_PaymentMadeForBusinessCombinationMilestone"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RemainingPaymentMadeForBusinessCombinationMilestone" xlink:label="vir_RemainingPaymentMadeForBusinessCombinationMilestone"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CommonStockSharesIssuedForMilestonePaymentShares" xlink:label="vir_CommonStockSharesIssuedForMilestonePaymentShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ValueOfCommonStockSharesIssuedForMilestonePayment" xlink:label="vir_ValueOfCommonStockSharesIssuedForMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" xlink:label="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" xlink:label="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" xlink:label="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SpecifiedClinicalDevelopmentMilestonesPayment" xlink:label="vir_SpecifiedClinicalDevelopmentMilestonesPayment"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_HepatitisBVirusProductMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="vir_ClinicalDevelopmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_LetterAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_TomegaVaxIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_AnotherProductMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_HumabsBiomedSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_MilestonePaymentsRelatedTermsDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_SARSCoV2ProductMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_AgenovirCorporationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_PaymentMadeForBusinessCombinationMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_RemainingPaymentMadeForBusinessCombinationMilestone" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_CommonStockSharesIssuedForMilestonePaymentShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_ValueOfCommonStockSharesIssuedForMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="vir_SpecifiedClinicalDevelopmentMilestonesPayment" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_GrantAwardedAmountMaximum" xlink:label="vir_GrantAwardedAmountMaximum"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_HumanImmunodeficiencyVirusGrantMember" xlink:label="vir_HumanImmunodeficiencyVirusGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GrantMember" xlink:label="us-gaap_GrantMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_BillAndMelindaGatesFoundationMember" xlink:label="vir_BillAndMelindaGatesFoundationMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_GrantAwardedAmount" xlink:label="vir_GrantAwardedAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TuberculosisTBGrantMember" xlink:label="vir_TuberculosisTBGrantMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiability" xlink:label="us-gaap_ContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_UnusedFundsReceivedInAdvance" xlink:label="vir_UnusedFundsReceivedInAdvance"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_GrantAgreementAmendedExpirationDate" xlink:label="vir_GrantAgreementAmendedExpirationDate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAwardedAmountMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_HumanImmunodeficiencyVirusGrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_GrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_BillAndMelindaGatesFoundationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAwardedAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TuberculosisTBGrantMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueNotFromContractWithCustomer" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_UnusedFundsReceivedInAdvance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_GrantAgreementAmendedExpirationDate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="srt_SegmentGeographicalDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandTwentyStockPurchaseAgreementMember" xlink:label="vir_TwoThousandTwentyStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AccruedLiabilitiesAndOtherLiabilitiesMember" xlink:label="vir_AccruedLiabilitiesAndOtherLiabilitiesMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AntibodyProgramMember" xlink:label="vir_AntibodyProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_GlaxoGroupLimitedMember" xlink:label="vir_GlaxoGroupLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_CN" xlink:label="country_CN"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="us-gaap_AccountingStandardsUpdate201409Member"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssetsMember" xlink:label="us-gaap_OtherAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember" xlink:label="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ContractRevenueMember" xlink:label="vir_ContractRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PreliminaryCollaborationAgreementMember" xlink:label="vir_PreliminaryCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd#country_US" xlink:label="country_US"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationRevenueMember" xlink:label="vir_CollaborationRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" xlink:label="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ProfitShareRevenueMember" xlink:label="vir_ProfitShareRevenueMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" xlink:label="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_BriiBioParentMember" xlink:label="vir_BriiBioParentMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_DefinitiveCollaborationAgreementMember" xlink:label="vir_DefinitiveCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandTwentyOneStockPurchaseAgreementMember" xlink:label="vir_TwoThousandTwentyOneStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PercentageOfDevelopmentCosts" xlink:label="vir_PercentageOfDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_VaccineProgramMember" xlink:label="vir_VaccineProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_BriiBiosciencesOffshoreLimitedMember" xlink:label="vir_BriiBiosciencesOffshoreLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AlnylamPharmaceuticalsIncMember" xlink:label="vir_AlnylamPharmaceuticalsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" xlink:label="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LicensedProductByLicensedProductMember" xlink:label="vir_LicensedProductByLicensedProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" xlink:label="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_BiologicalMaterialsMember" xlink:label="vir_BiologicalMaterialsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandAndTwentyOneGSKCollaborationMember" xlink:label="vir_TwoThousandAndTwentyOneGSKCollaborationMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementTerminationDescription" xlink:label="vir_CollaborationAgreementTerminationDescription"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WuXiBiologicsLimitedMember" xlink:label="vir_WuXiBiologicsLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RockefellerUniversityMember" xlink:label="vir_RockefellerUniversityMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LicenseMember" xlink:label="us-gaap_LicenseMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FairMarketValueOfCommonStockIssued" xlink:label="vir_FairMarketValueOfCommonStockIssued"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandAndTwentyOneGSKAgreementMember" xlink:label="vir_TwoThousandAndTwentyOneGSKAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FirstSiRNAProductMember" xlink:label="vir_FirstSiRNAProductMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MedImmuneLimitedLiabilityCompanyMember" xlink:label="vir_MedImmuneLimitedLiabilityCompanyMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_BriiAgreementMember" xlink:label="vir_BriiAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_EachInfectiousDiseaseSiRNAMember" xlink:label="vir_EachInfectiousDiseaseSiRNAMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AlnylamAgreementMember" xlink:label="vir_AlnylamAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PremiumReceivedOnSalePriceOfCommonStock" xlink:label="vir_PremiumReceivedOnSalePriceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_XencorIncorporationMember" xlink:label="vir_XencorIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementNumberOfUnitsOfAccount" xlink:label="vir_CollaborationAgreementNumberOfUnitsOfAccount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_DevelopmentAndManufacturingCollaborationAgreementMember" xlink:label="vir_DevelopmentAndManufacturingCollaborationAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CommercializationMember" xlink:label="vir_CommercializationMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AntibodyLicenseTransactionPrice" xlink:label="vir_AntibodyLicenseTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RockefellerAgreementMember" xlink:label="vir_RockefellerAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_FirstInfectiousDiseaseProductMember" xlink:label="vir_FirstInfectiousDiseaseProductMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MedImmuneAgreementMember" xlink:label="vir_MedImmuneAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_HBVProgramMember" xlink:label="vir_HBVProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_IncreaseDecreaseInResearchAndDevelopmentExpense" xlink:label="vir_IncreaseDecreaseInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_InfluenzaAAndInfluenzaBMember" xlink:label="vir_InfluenzaAAndInfluenzaBMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandNineteenXencorAgreementMember" xlink:label="vir_TwoThousandNineteenXencorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_TwoThousandTwentyXencorAgreementMember" xlink:label="vir_TwoThousandTwentyXencorAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_InfluenzaAResearchProgramsMember" xlink:label="vir_InfluenzaAResearchProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ReductionOfResearchAndDevelopmentExpense" xlink:label="vir_ReductionOfResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_HBVResearchProgramsMember" xlink:label="vir_HBVResearchProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PayableUnderAgreementCurrent" xlink:label="vir_PayableUnderAgreementCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_InfluenzaAAndHBVResearchProgramsMember" xlink:label="vir_InfluenzaAAndHBVResearchProgramsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" xlink:label="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PercentageOfShareDevelopmentCosts" xlink:label="vir_PercentageOfShareDevelopmentCosts"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ProfitsAndLossesSharingPercentage" xlink:label="vir_ProfitsAndLossesSharingPercentage"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_UpfrontPaymentReceivable" xlink:label="vir_UpfrontPaymentReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" xlink:label="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_OptionExerciseFeeConsiderationToBeReceived" xlink:label="vir_OptionExerciseFeeConsiderationToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PreDefinedRegulatoryMilestoneConsiderationReceivable" xlink:label="vir_PreDefinedRegulatoryMilestoneConsiderationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AggregateValueOfCommonStockToBeIssued" xlink:label="vir_AggregateValueOfCommonStockToBeIssued"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementTransactionPriceFixedConsideration" xlink:label="vir_CollaborationAgreementTransactionPriceFixedConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementPercentageOfUpfrontFee" xlink:label="vir_CollaborationAgreementPercentageOfUpfrontFee"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PremiumPaidOnSalePriceOfCommonStock" xlink:label="vir_PremiumPaidOnSalePriceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementRemainingUpfrontFee" xlink:label="vir_CollaborationAgreementRemainingUpfrontFee"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ReceivableFromCollaboration" xlink:label="vir_ReceivableFromCollaboration"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerAssetNetCurrent" xlink:label="us-gaap_ContractWithCustomerAssetNetCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PercentageOfOrdinaryShareEqualToOutstandingShare" xlink:label="vir_PercentageOfOrdinaryShareEqualToOutstandingShare"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_OptionExerciseFeeConsiderationReceivable" xlink:label="vir_OptionExerciseFeeConsiderationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RegulatoryMilestoneConsiderationReceivable" xlink:label="vir_RegulatoryMilestoneConsiderationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SalesMilestoneConsiderationReceivable" xlink:label="vir_SalesMilestoneConsiderationReceivable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_OptionExerciseFeeConsiderationPayable" xlink:label="vir_OptionExerciseFeeConsiderationPayable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_OptionExerciseFeeConsiderationPayableDescription" xlink:label="vir_OptionExerciseFeeConsiderationPayableDescription"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RegulatoryMilestonePaymentConsiderationPayable" xlink:label="vir_RegulatoryMilestonePaymentConsiderationPayable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SalesMilestoneConsiderationPayable" xlink:label="vir_SalesMilestoneConsiderationPayable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" xlink:label="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WrittenNoticePeriodForLicensedProgramNotExercisedAnOption" xlink:label="vir_WrittenNoticePeriodForLicensedProgramNotExercisedAnOption"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WrittenNoticePeriodForLicensedProgramExerciseAnOption" xlink:label="vir_WrittenNoticePeriodForLicensedProgramExerciseAnOption"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" xlink:label="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WrittenNoticePeriodForLicensedProgramFailureToMakePayment" xlink:label="vir_WrittenNoticePeriodForLicensedProgramFailureToMakePayment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Investments" xlink:label="us-gaap_Investments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_OptionExerciseFeeReceived" xlink:label="vir_OptionExerciseFeeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_DeterminedTransactionPrice" xlink:label="vir_DeterminedTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PaymentToPartnerResultingFromProgramOptionExercise" xlink:label="vir_PaymentToPartnerResultingFromProgramOptionExercise"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_UpfrontFeePaid" xlink:label="vir_UpfrontFeePaid"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SharePayableToCollaborator" xlink:label="vir_SharePayableToCollaborator"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MaximumSharesToBeIssued" xlink:label="vir_MaximumSharesToBeIssued"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" xlink:label="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MaximumSalesMilestonePayment" xlink:label="vir_MaximumSalesMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MaximumAggregateSalesMilestonePayment" xlink:label="vir_MaximumAggregateSalesMilestonePayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WrittenNoticePeriodForLicensedProgramOtherPartyChallengesValidityOrEnforceabilityOfPatentLicense" xlink:label="vir_WrittenNoticePeriodForLicensedProgramOtherPartyChallengesValidityOrEnforceabilityOfPatentLicense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeFairValueOfDerivativeLiability" xlink:label="us-gaap_DerivativeFairValueOfDerivativeLiability"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ContractualPayments" xlink:label="vir_ContractualPayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MilestonePaymentsPaid" xlink:label="vir_MilestonePaymentsPaid"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ChangeInFairValueOfMilestoneShares" xlink:label="vir_ChangeInFairValueOfMilestoneShares"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementRelatedCostsAndExpenses" xlink:label="vir_CollaborationAgreementRelatedCostsAndExpenses"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PaymentOfAnnualLicenseMaintenanceFees" xlink:label="vir_PaymentOfAnnualLicenseMaintenanceFees"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale" xlink:label="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees" xlink:label="vir_SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LicenseMaintenanceFees" xlink:label="vir_LicenseMaintenanceFees"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LicenseAgreementUpfrontPayment" xlink:label="vir_LicenseAgreementUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_DevelopmentRegulatoryAndCommercialMilestonePaymentsMaximumAmount" xlink:label="vir_DevelopmentRegulatoryAndCommercialMilestonePaymentsMaximumAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_DevelopmentRegulatoryAndCommercialMilestonePayments" xlink:label="vir_DevelopmentRegulatoryAndCommercialMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" xlink:label="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MaximumAggregateCommercialSalesMilestonePayments" xlink:label="vir_MaximumAggregateCommercialSalesMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MaximumAggregateMilestonePayments" xlink:label="vir_MaximumAggregateMilestonePayments"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_SpecifiedDevelopmentMilestonesPayment" xlink:label="vir_SpecifiedDevelopmentMilestonesPayment"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LicensedPatentsExpirationPeriod" xlink:label="vir_LicensedPatentsExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WrittenNoticePeriodForTerminationOfLicensedProgram" xlink:label="vir_WrittenNoticePeriodForTerminationOfLicensedProgram"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge" xlink:label="vir_WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsForRoyalties" xlink:label="us-gaap_PaymentsForRoyalties"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CollaborationAgreementTransactionPriceConsideration" xlink:label="vir_CollaborationAgreementTransactionPriceConsideration"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_SegmentGeographicalDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandTwentyStockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="vir_AccruedLiabilitiesAndOtherLiabilitiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_AntibodyProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="vir_GlaxoGroupLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_CN" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_OtherAssetsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SharePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_ContractRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_PreliminaryCollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_SegmentGeographicalDomain" xlink:to="country_US" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_CollaborationRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_GlaxoGroupLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_ProfitShareRevenueMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_BriiBioParentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_DefinitiveCollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandTwentyOneStockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfDevelopmentCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_VaccineProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_BriiBiosciencesOffshoreLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_AlnylamPharmaceuticalsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_LicensedProductByLicensedProductMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_StatementGeographicalAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_BiologicalMaterialsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyOneGSKCollaborationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementTerminationDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_WuXiBiologicsLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_RockefellerUniversityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="us-gaap_LicenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_FairMarketValueOfCommonStockIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandAndTwentyOneGSKAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_SaleOfStockPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_FirstSiRNAProductMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_MedImmuneLimitedLiabilityCompanyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_BriiAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_EachInfectiousDiseaseSiRNAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_AlnylamAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PremiumReceivedOnSalePriceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_XencorIncorporationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementNumberOfUnitsOfAccount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_DevelopmentAndManufacturingCollaborationAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_CommercializationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_AntibodyLicenseTransactionPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_RockefellerAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_FirstInfectiousDiseaseProductMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_MedImmuneAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_HBVProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_IncreaseDecreaseInResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_InfluenzaAAndInfluenzaBMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandNineteenXencorAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_TwoThousandTwentyXencorAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_InfluenzaAResearchProgramsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ReductionOfResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_HBVResearchProgramsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PayableUnderAgreementCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_InfluenzaAAndHBVResearchProgramsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfShareDevelopmentCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ProfitsAndLossesSharingPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_UpfrontPaymentReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeConsiderationToBeReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PreDefinedRegulatoryMilestoneConsiderationReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_AggregateValueOfCommonStockToBeIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementTransactionPriceFixedConsideration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementPercentageOfUpfrontFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PremiumPaidOnSalePriceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementRemainingUpfrontFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DeferredRevenueNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ReceivableFromCollaboration" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerAssetNetCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PercentageOfOrdinaryShareEqualToOutstandingShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeConsiderationReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RegulatoryMilestoneConsiderationReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_SalesMilestoneConsiderationReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeConsiderationPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="39" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeConsiderationPayableDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="40" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RegulatoryMilestonePaymentConsiderationPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="41" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_SalesMilestoneConsiderationPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="42" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="43" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodForLicensedProgramNotExercisedAnOption" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="44" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodForLicensedProgramExerciseAnOption" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="45" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="46" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodForLicensedProgramFailureToMakePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="47" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="48" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_Investments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="49" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_OptionExerciseFeeReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="50" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_DeterminedTransactionPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="51" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PaymentToPartnerResultingFromProgramOptionExercise" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="52" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_UpfrontFeePaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="53" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_SharePayableToCollaborator" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="54" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumSharesToBeIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="55" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="56" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumSalesMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="57" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateSalesMilestonePayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="58" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodForLicensedProgramOtherPartyChallengesValidityOrEnforceabilityOfPatentLicense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="59" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_DerivativeFairValueOfDerivativeLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="60" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ContractualPayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="61" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MilestonePaymentsPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="62" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_ChangeInFairValueOfMilestoneShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="63" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementRelatedCostsAndExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="64" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_PaymentOfAnnualLicenseMaintenanceFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="65" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="66" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="67" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_LicenseMaintenanceFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="68" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_LicenseAgreementUpfrontPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="69" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_DevelopmentRegulatoryAndCommercialMilestonePaymentsMaximumAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="70" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_DevelopmentRegulatoryAndCommercialMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="71" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="72" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateCommercialSalesMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="73" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_MaximumAggregateMilestonePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="74" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_SpecifiedDevelopmentMilestonesPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="75" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_LicensedPatentsExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="76" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodForTerminationOfLicensedProgram" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="77" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="78" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_PaymentsForRoyalties" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="79" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="vir_CollaborationAgreementTransactionPriceConsideration" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LaboratoryEquipmentMember" xlink:label="vir_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="vir_LaboratoryEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CommitmentsAndContingenciesLineItems" xlink:label="vir_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_CommitmentsAndContingenciesTable" xlink:label="vir_CommitmentsAndContingenciesTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LeaseArrangementContractualExpirationBeginningYear" xlink:label="vir_LeaseArrangementContractualExpirationBeginningYear"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember" xlink:label="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="srt_ProductsAndServicesDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_AntibodyProgramMember" xlink:label="vir_AntibodyProgramMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_GlaxoSmithKlineTradingServiceLimitedMember" xlink:label="vir_GlaxoSmithKlineTradingServiceLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" xlink:label="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LeaseArrangementContractualExpirationEndingYear" xlink:label="vir_LeaseArrangementContractualExpirationEndingYear"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseOptionToExtend"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PercentageOfDevelopmentCosts" xlink:label="vir_PercentageOfDevelopmentCosts"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="vir_CommitmentsAndContingenciesLineItems" xlink:to="vir_CommitmentsAndContingenciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_CommitmentsAndContingenciesLineItems" xlink:to="vir_LeaseArrangementContractualExpirationBeginningYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductsAndServicesDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_CommitmentsAndContingenciesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ProductsAndServicesDomain" xlink:to="vir_AntibodyProgramMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_GlaxoSmithKlineTradingServiceLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_CommitmentsAndContingenciesLineItems" xlink:to="vir_LeaseArrangementContractualExpirationEndingYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_CommitmentsAndContingenciesTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_CommitmentsAndContingenciesTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="vir_CommitmentsAndContingenciesTable" xlink:to="srt_ProductOrServiceAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseOptionToExtend" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="vir_CommitmentsAndContingenciesLineItems" xlink:to="vir_PercentageOfDevelopmentCosts" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityAndRestrictedStockUnitsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RestrictedStockAwardsRSAMember" xlink:label="vir_RestrictedStockAwardsRSAMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="vir_RestrictedStockAwardsRSAMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails">
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_EstimatedSharesIssuableUnderTheESPPMember" xlink:label="vir_EstimatedSharesIssuableUnderTheESPPMember"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ContingentlyIssuableSharesMember" xlink:label="vir_ContingentlyIssuableSharesMember"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_WarrantsToPurchaseCommonStockMember" xlink:label="vir_WarrantsToPurchaseCommonStockMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="vir_EstimatedSharesIssuableUnderTheESPPMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="vir_ContingentlyIssuableSharesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="vir_WarrantsToPurchaseCommonStockMember" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>vir-20210630_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2021-08-05T15:34:56.6911+00:00 -->
<!-- Copyright (c) 2021 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:href="vir-20210630.xsd#Role_StatementCondensedConsolidatedBalanceSheetsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xlink:href="vir-20210630.xsd#Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" xlink:href="vir-20210630.xsd#StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:href="vir-20210630.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:href="vir-20210630.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" xlink:href="vir-20210630.xsd#Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="vir-20210630.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetsDetails" xlink:href="vir-20210630.xsd#Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:href="vir-20210630.xsd#DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IntangibleAssetsNetExcludingGoodwill" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_MarketableSecuritiesCurrent" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapital" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_LongTermInvestments" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssets" order="7" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="us-gaap_IntangibleAssetsNetExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_MarketableSecuritiesCurrent" xlink:label="us-gaap_MarketableSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="us-gaap_LongTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsNoncurrent" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RevenueNotFromContractWithCustomer" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_NonoperatingIncomeExpense" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_SellingGeneralAndAdministrativeExpense" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_CostOfRevenue" order="2" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueNotFromContractWithCustomer" xlink:label="us-gaap_RevenueNotFromContractWithCustomer"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium" xlink:label="us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CostOfRevenue" xlink:label="us-gaap_CostOfRevenue"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="0" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="vir_PaymentOfContingentConsideration" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireInvestments" order="1" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AmortizationOfIntangibleAssets" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_FinanceLeasePrincipalPayments" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyHeldForSale" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="vir_NoncashLeaseExpense" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="vir_ChangeInEstimatedFairValueOfContingentConsideration" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DerivativeGainLossOnDerivativeNet" order="7" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherOperatingActivitiesCashFlowStatement" order="9" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherOperatingAssets" order="11" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="12" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="13" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="vir_IncreaseDecreaseInOperatingLeaseLiabilities" order="14" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="15" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PaymentOfContingentConsideration" xlink:label="vir_PaymentOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PaymentsToAcquireInvestments" xlink:label="us-gaap_PaymentsToAcquireInvestments"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments" xlink:label="us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="us-gaap_AmortizationOfIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_FinanceLeasePrincipalPayments" xlink:label="us-gaap_FinanceLeasePrincipalPayments"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyHeldForSale" xlink:label="us-gaap_ProceedsFromSaleOfPropertyHeldForSale"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_NoncashLeaseExpense" xlink:label="vir_NoncashLeaseExpense"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ChangeInEstimatedFairValueOfContingentConsideration" xlink:label="vir_ChangeInEstimatedFairValueOfContingentConsideration"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue" xlink:label="vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="us-gaap_DerivativeGainLossOnDerivativeNet"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:label="us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherOperatingAssets"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="vir_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="vir_ResearchAndDevelopmentExpensesCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="vir_MilestonePayable" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="vir_PayrollAndRelatedExpensesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="vir_ExcessFundsPayableUnderGrantAgreementsCurrent" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="6" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ResearchAndDevelopmentExpensesCurrent" xlink:label="vir_ResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_MilestonePayable" xlink:label="vir_MilestonePayable"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PayrollAndRelatedExpensesCurrent" xlink:label="vir_PayrollAndRelatedExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_ExcessFundsPayableUnderGrantAgreementsCurrent" xlink:label="vir_ExcessFundsPayableUnderGrantAgreementsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" order="4" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="vir_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="vir_PresentValueOfOperatingLeaseLiabilities" order="8" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour" xlink:label="vir_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived" xlink:label="vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_PresentValueOfOperatingLeaseLiabilities" xlink:label="vir_PresentValueOfOperatingLeaseLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="vir_RestrictedSharesSubjectToFutureVesting" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" order="3" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:loc xlink:type="locator" xlink:href="vir-20210630.xsd#vir_RestrictedSharesSubjectToFutureVesting" xlink:label="vir_RestrictedSharesSubjectToFutureVesting"/>
    <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd#us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares" xlink:label="us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>vir-20210630_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2020-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2020-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2020-01-31"
  xmlns:vir="http://www.vir.bio/20210630"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="vir-20210630.xsd" xlink:type="simple"/>
    <context id="C_eb4adf6c-364c-4b79-92fd-28aa9a50e441">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_fd53f66c-e257-4732-8340-be571f9ac325">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_cc499f93-896e-4bdf-be24-28ce2921af3f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_97dded0d-16f2-4d7e-ae2b-6fc06ecdfde2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <instant>2021-08-02</instant>
        </period>
    </context>
    <context id="C_1ef15310-89d7-4a2b-81fa-497de643a6d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_3b171620-e654-43aa-be16-06e50f0a2698">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-14</startDate>
            <endDate>2021-02-14</endDate>
        </period>
    </context>
    <context id="C_393392b3-d188-48ce-8ebf-843e5e51a678">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_d18e2209-527e-424f-914a-da611d338ba7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:MedImmuneLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:MedImmuneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_8780a7ad-2026-45bc-835f-43e7a4f6e155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HBVProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_09789d61-addd-4c37-ab93-6605597b8a60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_f1864eb6-8023-4cef-ad5b-04b72b08c0df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_33c31548-53fa-4da7-9d3c-4b3f3239fd4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_502695ad-a686-4d7f-9e55-303eb9e384b6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyOneStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-14</startDate>
            <endDate>2021-02-14</endDate>
        </period>
    </context>
    <context id="C_8f01da11-0303-4186-9f77-73befdf1a6bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_2ff7bfd4-ce79-493b-87b6-550ee9f49df4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_de475ddf-8c37-4d7a-ad85-a7698299ec12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-29</startDate>
            <endDate>2020-04-29</endDate>
        </period>
    </context>
    <context id="C_a4e86e58-4404-4536-961e-ac48e8ff6e70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vir:ContingentlyIssuableSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_c50def4f-f04d-4b74-a20a-53c116d0b11f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-23</startDate>
            <endDate>2021-03-25</endDate>
        </period>
    </context>
    <context id="C_20e142d1-b753-47f7-9ab1-dd536e70a74d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_9d811492-0ef4-42f2-b9e1-20840319d292">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_503f5c65-589f-45e0-a4cb-0b480e0d8198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_037841ec-b5b1-4809-aef7-1a37b14ddff9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_492c3181-e320-4bbf-9047-04048449d863">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_943aaa7d-bd8e-4ac3-a401-aaa53e6c2044">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_7ac0807c-bde4-490e-afcd-dd874265ab98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:MedImmuneLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfluenzaAAndInfluenzaBMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:MedImmuneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="C_02f60d12-f390-4dfe-ac4c-a065441e738a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-14</endDate>
        </period>
    </context>
    <context id="C_d0832ce6-8218-4bd2-a0a0-9ac172d5777a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_ff3535ee-1915-4fab-bcf7-801568ea00ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HepatitisBVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="C_914881ac-2ab5-47f4-8eed-c4210e53dc3a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_a2dda4ba-cdd3-4a25-95df-9f71c39ebfdf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_cd460f41-06b3-4477-9de5-9e78e41bc13e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_8e7bbb2c-772e-4f93-ba28-8ef8fd39ba8a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:FirstInfectiousDiseaseProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="C_329ccbc8-94c6-4565-9ecf-7b34632b826e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_ac8bcb94-38bb-498a-a74f-16bc3f88cf85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_ea616198-c6e1-442a-bb05-ddf05a1b5bc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_9b52dd29-86c0-42a1-9b29-10e07e25991f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_86f05426-07f5-4481-b708-0d76a9b442e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0f91c4ca-040c-431f-8606-3532fe5467a6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_e28f1ecf-80aa-4b09-b8ff-8c09db69a316">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_e2de7da2-b046-4ec0-ad5e-5f3b001ed026">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_11d39f80-330e-4128-989f-4084388ad346">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:FirstSiRNAProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_f41bf82e-773a-4ae8-995a-1851961c2803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_28568052-9082-41a4-83b2-60aaae0ee1be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-30</instant>
        </period>
    </context>
    <context id="C_a6dafe0c-9e29-491e-9182-9ea032ca7de7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_b6d51956-3a22-4bd6-95a5-dad4c1d17f90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_45bc5026-51b3-4f16-b7d4-61e29f251c4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_aa261db7-a4b4-4b7f-9010-cd5b869abb50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">vir:SalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_78a42173-a11f-4d19-985c-306f3564ed73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_f678eb79-9e2a-44ae-9e54-e1a433974f29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_2aa1b8d8-ce49-419f-80ad-d249064f51e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_f7225c3a-02c3-4844-a759-8800e4846129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_6f7a01e9-125b-4678-81a3-a6efb1b4d77e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0b1f8126-42c0-40fe-81c1-24cbdc0b2ccc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_522751c2-1d6d-4f23-b1b2-c7eaa1905197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_bc5714bf-f943-475e-bcd8-0aa08e910f85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="C_1f9878a0-4b15-4465-8e06-ac38077a8fcc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="C_b6795825-d2b1-4664-92a7-7f4efb4ea7bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_3c73e700-bcbb-487f-bdf6-77164c1deeaf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_cc9ec168-d4bd-41fa-97ec-80d1e7eac7e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_d67bc640-0ce6-494e-ad6f-32b76b35dc04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_17fb449e-4cf8-4a5c-b8a6-4e7113c7b17e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:MedImmuneLimitedLiabilityCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:MedImmuneAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_cce66117-e613-4efa-aee1-873b41ff2cc8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_656e7f8d-dcdb-4596-bc50-c6a3693b2cf4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_61924055-2acd-43c4-9155-681af2ed1b88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vir:RestrictedStockAwardsRSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_7fcc913c-909b-4375-aabd-561f445a0b0f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_d8c8927a-29a9-44cd-b032-581051ff30bf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HepatitisBVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="C_7b946c14-81b3-4ee4-9cc6-59aca5e74078">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_eae8bb82-8872-4a24-ae26-c2e4d2dfb653">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_8d5790db-7c09-460a-9153-c6331074affd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_355e350c-6186-4712-9d71-af22d0b9a120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_b863aacc-f9e9-437e-93af-f43803e428c1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_4df49172-31b6-455e-a6d9-ebce7871f7da">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HepatitisBVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:AgenovirCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-31</instant>
        </period>
    </context>
    <context id="C_be538fc0-b3da-4933-b596-db6f96112f97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_b9591672-a7df-4119-8763-beff32620126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_06a67e5e-7cd4-4262-8c8f-9cc28e2a7ddf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_416eb633-0ce4-467f-ad2a-37987bfe677b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:WuXiBiologicsLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:DevelopmentAndManufacturingCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_42a0066f-bcc3-4b1a-a379-4a993e12dcb9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_782d1920-e03d-4185-85d4-a0abdc3fe2bc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="C_ab45b547-9dd6-4076-8bde-04eaac698732">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HBVResearchProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="C_39a5ff4f-90c0-4385-8a23-486f8b46bf9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_ec6ee7cb-4c4f-4392-b06d-b2cc4c6ba486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="C_a7eab319-293e-4b73-85e4-92da414f023c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:AgenovirCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_ec0ee7d1-1e16-4d9f-82e9-4d32b4f67282">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_a2ea91d2-7c4a-4260-9f6d-7c6a185c065b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vir:EstimatedSharesIssuableUnderTheESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_f8e1feaf-38cf-4eb8-be71-a6d9ca4cc72d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputExpectedRevenueVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_66bfb7f9-fc0b-4e62-b6fc-4e629327a410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_b4f1dc34-56da-4847-88c1-d9bfde49f709">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_60e33361-8e0c-4167-99a3-8c9f96e030ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vir:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_61ac6d35-003c-4932-8b7f-75b0994fe73e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_ad365c4d-bc8d-4cfb-9e07-53dd946f68e3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_6b3098b0-fc6d-48cf-bf55-bfa1dcc811a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfluenzaAResearchProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="C_440aee8c-e7b5-48d3-90f4-51f9d0631f45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_69fba054-c419-4e8e-b49f-667d17bf850d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="C_7d59a58f-5636-44a9-b169-b1a6c7e3176b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_23d80066-9c6a-4bf0-aa4b-f95964ef06dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_8078c547-b260-434d-8ab2-1b0f12cd0d5f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-14</startDate>
            <endDate>2021-02-14</endDate>
        </period>
    </context>
    <context id="C_cca64f01-43cb-4521-a7c0-b8c072d00e2a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_33d141a8-0bd8-4ec8-aaaf-e21290176a35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_c6864edf-79da-4827-8feb-994154b4369a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_64416581-7d0b-4707-ab43-2587ae9cbcd4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_24a7634d-6a60-4a00-b501-5473727d2f4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_da489d47-65d8-4ebf-bb93-4ab4e0d479cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_8482726a-4650-4001-aa57-337a908bb4ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputExpectedRevenueVolatilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_17da886f-2297-41d5-a984-97218fc86f75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_d42ac1db-ea33-4759-bbf7-4fa64295c694">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_c3b4e715-3396-4fc0-a8e8-1b7c2ed5260b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_d0b20436-58e4-46d4-92e4-fe201bcf47c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-14</endDate>
        </period>
    </context>
    <context id="C_918fa4e1-d7cd-4bf6-82cc-f13652a23ef9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_4e33744e-999f-4346-9f7e-415731786c7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="C_31d70583-f863-4f52-9c17-5d19f672cbae">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="C_61e10aad-3a2a-4489-b640-a9768ebb4c27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_324b7022-f782-4c4b-a128-564a104bd122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vir:ContingentlyIssuableSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_be6f5270-fc80-45c9-a95c-b5ef6403279b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HBVResearchProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_7c63340d-0674-48e2-b11f-13fdad617a64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_eca11749-bb55-4f33-bd21-2d25c913415b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_01c272b4-05c2-41fb-90b2-afebf3595d73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_0db18e03-f55e-4678-9eaa-949bdcc27a33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vir:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-07-10</startDate>
            <endDate>2020-07-10</endDate>
        </period>
    </context>
    <context id="C_b435674c-7a19-45d9-b704-d50d4dea4823">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="C_7b508c4b-45d1-41c3-816a-cd29050692e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_59766912-8729-44fa-8223-2711163a2f37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">vir:ClinicalDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="C_7e3f6ce0-b70a-4697-a4fb-c60b7c239059">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_4830ca2a-0ad5-4a32-b98f-bae2d1970486">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="C_d8427988-1d9b-42d6-a158-ce5e24c17b41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_c99a0b18-718d-4edc-baf8-ddcb6d2b2cee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-01</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="C_befad2fc-309f-4f88-99dc-baaef6380944">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_7828555d-b746-4f30-8bb5-ef260d0b147b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_9f0a8c2d-23ab-4ba5-9c8d-ca28574c8b2c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_a2db8718-9aa3-44fb-bd21-a5914cb932c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_1e5484c7-876b-4630-8566-d2b6146b4e47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HepatitisBVirusProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_3edca66f-50fb-4438-8b85-01c89b9c1b0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="C_93449051-f049-49fc-bbdb-95aeef0d2e9a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_d2c8c218-592c-4345-a42f-8c7f3cefb5aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AnotherProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="C_2aa44c95-3aa8-4eec-9de8-8fa66be5bfc1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:BiologicalMaterialsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_b64fcbdc-5a21-4b8c-8ac7-983b9bfe2eb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-26</instant>
        </period>
    </context>
    <context id="C_0e1b6477-b8d1-4ae0-89fa-0e4e1af40ea7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_8162e8b4-3609-4bdc-ba16-5e1d76bb3c6b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_d82c1375-fe52-423c-8c26-277c32efef51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_3dda4289-3d1f-4bc7-9199-58bb203939aa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_1ff555c9-cb2a-45df-8631-74d23812f12b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_6d87011b-3e4c-46db-bad8-0f23e0dcc637">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-16</instant>
        </period>
    </context>
    <context id="C_e39462a8-8050-424d-a953-9a65943f5705">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_e7b02693-c6da-4de6-a120-f9ea9345d4d8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AntibodyProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="C_02faa5a7-4825-491e-950b-34ee5ddb4d0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">vir:SalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="C_66892b6e-71bf-4e32-a6ae-3770380bc675">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_3e223018-5e3f-452c-824b-e2e4d71405b7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_78af002d-b722-4eae-8f4a-2d0c76fa8ae0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_1e87793a-cf2d-4040-b332-0a1245e6d6f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_44f8d63c-2efc-4376-972c-8a2d8299bc16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_1f9d182b-02f1-4140-983b-012691d8ce35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_7a088139-2add-4c37-8158-c3dc9538d2fe">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_bbedea33-e0d1-40dc-8d3b-acfc0f01d81c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:SARSCoV2ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_19b8ac7c-1cc1-4683-98aa-a394a77dd75f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfluenzaAAndHBVResearchProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-08-31</endDate>
        </period>
    </context>
    <context id="C_27542471-f913-4a68-8616-f01ea8e68d78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_3b26811f-118d-4a95-ad64-0f8108301f7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AntibodyProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-29</startDate>
            <endDate>2020-04-29</endDate>
        </period>
    </context>
    <context id="C_4ba8283a-0045-486b-80d8-2e80d28e4574">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_b213ca27-309b-4229-b799-81e86bb50576">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:BiologicalMaterialsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_b68e43f8-fa5f-4941-a772-ac4ca77f6039">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_b16f4229-15e5-4b92-a679-7c593814f6cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_53ccc202-bb29-4485-bc6c-689015df256e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_a548882f-b462-4623-9763-e036f6ae6cce">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_dc5358a1-e8cd-4f63-a453-32242603a269">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-05-31</startDate>
            <endDate>2018-05-31</endDate>
        </period>
    </context>
    <context id="C_580342cb-5db5-408f-ae9b-48fd57cdb017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_237f8a0b-7ccb-4bfe-9900-7d13c307285b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_fa28c391-ecec-4c12-bcfb-f369058e9862">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_e5e16aa4-a601-484e-b470-db2c156ea530">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyOneStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_e403ff64-40f3-494a-998d-769d7e8bb228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_52d977a7-74c8-43be-9bfc-01aba0a3d398">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_6a378198-8973-420d-8130-5f606a6b57c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_2a63cca2-9347-45c4-8512-1e97604d2422">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f34e6246-fbef-4861-a312-c896b3da8b57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_e9e35c31-e697-4c7a-a5b4-23131aea2dca">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_ce595069-e39b-49ee-a1e2-8dcfaf1fc58f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_f54bf625-9153-4033-9112-6b27a3bd3803">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_b3b3b775-48e3-4d0e-8077-eeeff976fb8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_436fb49f-f2d5-49a1-83a3-3a3e54fd290d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyXencorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_a8995a77-2e40-4bdd-a7bd-5c2389acc76c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_704b0f66-c02a-4e7b-91c5-906e38831293">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_bd77d5c8-3f48-412e-8a01-2400a5a99d89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_222e97e5-5f11-45bd-9409-870b0ab08dec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HBVProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_33123595-07a6-4f85-a3a1-bc8546d832b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-14</instant>
        </period>
    </context>
    <context id="C_e1c1ce3e-6936-4e79-8e73-e9a37f058e7c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">vir:FollowOnOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-07-10</instant>
        </period>
    </context>
    <context id="C_26c131f2-0874-4ae2-9e57-8f39b5db6f09">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_3943c51c-7e55-4e41-b9e4-df3e298c1f39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_8f7f9c58-f98b-4a8f-95b9-e5182870c64d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:DefinitiveCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-14</instant>
        </period>
    </context>
    <context id="C_6ed8a63f-0dfd-42e1-84e0-c0de8453fb41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vir:RestrictedStockAwardsRSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_63fb600b-266b-4936-b5f6-f0acd37a0f30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vir:EstimatedSharesIssuableUnderTheESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_e1137d24-689b-45da-9ecd-65f97451d124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_8e671199-2ede-4d79-bb43-b621397a4811">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_2a630976-9689-4329-bdef-af492a67b7b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:GlaxoSmithKlineTradingServiceLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AntibodyProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-08-01</startDate>
            <endDate>2020-08-31</endDate>
        </period>
    </context>
    <context id="C_d09734ea-ce01-4393-81cd-a61fc90f7e98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_4e1a0849-5b76-49b5-9f9a-4c78c1961b02">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:CommercialMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">vir:MeasurementInputProbabilityRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_51cc81ca-5eda-4a6a-a5dd-56c6a7083323">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_d9b5a18c-ba78-4c5f-bb0f-40e2ed6661d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:EachInfectiousDiseaseSiRNAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="C_9e18bb3c-4c77-45f7-a376-3d3aa6ea7b8b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="C_0edc973f-cc4f-4eea-b393-2ad3dc16ecf5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_a23df604-43e8-477f-95be-d67c4d36ef27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_7073499b-8aca-4a83-ae2c-8686d7874fe9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_cd7a1755-2831-46df-a378-33b1c1bbe888">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-02-29</instant>
        </period>
    </context>
    <context id="C_95a77a5d-c658-44c7-bb81-77f5350143bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_a5f22e22-a17d-48d9-87ec-0cc77e37762d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_cc967922-0ffb-4e42-9643-902ddc2a4a56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CommercializationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-01</startDate>
            <endDate>2018-07-31</endDate>
        </period>
    </context>
    <context id="C_08207110-60df-4348-8106-e824e9e44ab8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_89d302b2-5e08-4283-8a49-1c1dc6be912e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vir:AccruedLiabilitiesAndOtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_8bc5a624-6688-41fd-9d8d-c6c0f2147de0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="C_669328e0-ec12-4a46-9f8e-7642c8e0853a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_65199b01-efc8-4ecd-92f0-3fdb4dbb14b2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-29</instant>
        </period>
    </context>
    <context id="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_c37af972-2bf8-4eff-9bc7-4763e2ab45d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_2063058a-a5a7-4574-92c4-5fad668297f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:AntibodyProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_5cba9a1a-7684-4b5b-9e26-eb24c2aeb651">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:PrepaidExpensesAndOtherCurrentAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_4b592749-62ec-4fae-9b15-04061affca47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:LicensedProductByLicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-30</instant>
        </period>
    </context>
    <context id="C_d438ee24-58b2-47f8-b7c8-f3890a19f797">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_96589541-95bc-4aef-a913-79c4b0b517f0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_c4e13756-0547-45df-9116-975dfa1cdf28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <instant>2020-03-31</instant>
        </period>
    </context>
    <context id="C_6fc26d34-68e7-4c09-8e67-4e2b004cdc10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-01</startDate>
            <endDate>2016-09-30</endDate>
        </period>
    </context>
    <context id="C_425979e0-416e-4c32-9ffb-95870c96d614">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialSupportToNonconsolidatedLegalEntityAxis">vir:SalesAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_75ead0cb-5540-4c8d-9421-64e16f11ecda">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:LetterAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_a077a0ad-b848-485c-96a1-3489ae549b2f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_f9ac6857-461c-4a04-bd24-2ecc9ae4c36c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:VaccineProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-29</startDate>
            <endDate>2020-04-29</endDate>
        </period>
    </context>
    <context id="C_04fdbfd3-0666-4745-bebd-01d2061c67e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vir:ContingentlyIssuableSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_9fb0d2a0-3667-49a0-9e2e-0eb6e51eb0f2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-29</startDate>
            <endDate>2020-04-29</endDate>
        </period>
    </context>
    <context id="C_8d26edc6-7745-4758-988b-eb4ba800efed">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_6d69c128-4e88-4988-9333-0cfb938c1233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0967f1dd-e649-43d3-b4d5-8e34df7fb432">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyXencorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_99cf4f8f-4dae-413b-b3e0-c9a5646a7659">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandTwentyStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-29</instant>
        </period>
    </context>
    <context id="C_a445d18b-0608-4e5b-93b9-215040fa78ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">vir:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_cff84f6a-b57e-47a0-a02b-dcac6185a725">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-14</instant>
        </period>
    </context>
    <context id="C_9ae22d18-4ca6-4836-bd15-1b10932c9c7f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">vir:AccruedLiabilitiesAndOtherLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_f57d1eff-a8c4-4b5c-8802-9f372ef5f371">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_10f77595-19f0-40f3-8510-ff21caa1970b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_33a88677-9ecc-4f3d-aca3-76408bf827c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_0e63f2d6-4f5f-4686-b5df-65f256ff2672">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-29</startDate>
            <endDate>2020-04-29</endDate>
        </period>
    </context>
    <context id="C_1f8aa1e7-f35e-48bb-afdc-73dd30c26626">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_a83f3768-0952-4ecd-91fb-ac4523a646de">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOneGSKCollaborationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-12</startDate>
            <endDate>2021-02-14</endDate>
        </period>
    </context>
    <context id="C_2780ba97-f35b-4286-8d16-f6c692bbc074">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_991c9783-f1f0-4095-b9b0-9d1076bde40f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_a4c9273d-ad95-4c98-a7c8-805e95b768b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBioParentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-30</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_9e86b99a-0581-4171-849d-e82b23f80034">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HBVProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_24d34ab3-57a3-4b9e-8de9-5279d44dd035">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_267658dc-f7db-4ab6-94bc-b9662b0d993d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-10-31</instant>
        </period>
    </context>
    <context id="C_0593f237-da08-4238-8805-6911cc8c2af4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BriiBiosciencesOffshoreLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_4504c120-b2bc-4009-8fb3-837091fb0248">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_97110788-5408-406c-be78-a9a445a7d443">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:AlnylamPharmaceuticalsIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:AlnylamAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_eb7ebaf7-00e9-4b11-8346-81d73478b9fa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:InfluenzaAResearchProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-01</startDate>
            <endDate>2019-09-30</endDate>
        </period>
    </context>
    <context id="C_b649d3cd-def2-4c81-bc48-8799c56de0c7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_766775c9-df87-46ac-a6ca-0995a7c65d87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:CollaborationRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_8f037847-06a9-43f3-aee1-9f0d4957157f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:PreliminaryCollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-27</startDate>
            <endDate>2020-04-29</endDate>
        </period>
    </context>
    <context id="C_b570c7a7-2e4b-4988-8066-7fc9aded3533">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_eda1b75d-a4eb-47cf-a94a-90d8ad6a84c9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_eeb1528b-b730-41f5-8477-0b25922ee91b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vir:ContingentlyIssuableSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_69fd0161-00a7-47b8-8f7e-c649aad213a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_2961edff-bc89-457f-97d0-23460c2e7059">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_52d2443e-0fd8-42f6-9e80-a3310414715c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:GlaxoGroupLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-25</instant>
        </period>
    </context>
    <context id="C_e8581c5a-3e43-44a2-8670-9db42cd8f49a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_f7017d66-420f-462d-adcf-f3fb86e73c23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_3c3d0c98-1fee-4858-be8f-d493a8a73e1e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f55782eb-212f-4f4e-9bf4-65f42e20a89a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_30c20ac0-452b-41d8-aabf-b6962ca7e754">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:RockefellerUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:HBVProgramMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:RockefellerAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_0df1d4d3-33f9-423e-ba29-51df45853b5a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_8ae3adcd-4938-4c7c-921a-6d25c5205981">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:LicensedProductByLicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:BriiAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-05-31</instant>
        </period>
    </context>
    <context id="C_0546abb1-16aa-4fcd-a7d6-0e80f088c135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vir:EstimatedSharesIssuableUnderTheESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_de3d836a-48cf-4d4f-8714-440719392b2e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_c85ee215-3e1c-44fb-b984-1097930c5e13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">vir:EstimatedSharesIssuableUnderTheESPPMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_69917036-35e4-4dc8-8976-064800b680f9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_5ef16289-589c-49ff-b97d-b1ade8c4d8c4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">vir:ContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_50d30b84-60dd-41c6-9dc3-a2fcb990166c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByLiabilityClassAxis">vir:ContingentConsiderationLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_6ef0ac41-102d-42f3-9751-1d32659fb4a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">vir:RestrictedStockAwardsRSAMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_325ad0aa-a95c-4661-a917-fc337e70902e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_ee4e07f2-7234-48ee-b89e-21a8a39c2507">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_c95fa8bf-5f9a-4eec-9c84-72c03b21861f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByAssetClassAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_1978c92a-9f5f-463a-83b8-88d2ffb3548f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_20097cda-ecaf-4c10-976d-a846aa4a6d9b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:AgenovirCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_8a64e883-900d-492a-b0a8-528b6645aa64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:HumabsBiomedSAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ContingentConsiderationByTypeAxis">vir:ClinicalAndRegulatoryMilestonesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:MeasurementInputTypeAxis">us-gaap:MeasurementInputDiscountRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_565a5874-4857-48d4-82b7-a9f3af6c43c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_abdc6453-b0c7-4eaa-a85e-f7e083980647">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TuberculosisTBGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_93f053bf-00d2-4957-b2e8-a0580ba1a1ee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">vir:TomegaVaxIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-01</instant>
        </period>
    </context>
    <context id="C_9b221d24-b45a-4cc0-b6cb-8320c56dc6fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:GrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_3b639fc9-2f14-4483-9c0f-de032ca38766">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:BillAndMelindaGatesFoundationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:HumanImmunodeficiencyVirusGrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_c55af785-6145-4ede-ac28-0f3933e1634e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">vir:XencorIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">vir:TwoThousandNineteenXencorAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_b2be4dcd-5221-4917-9b4b-42643238614b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_51eb1ee6-e4e4-42a9-b6e3-135a3e77a4ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_e877910e-22cc-4649-a193-5d784dba152c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001706431</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_Unit">
        <measure>vir:Unit</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Milestone">
        <measure>vir:Milestone</measure>
    </unit>
    <unit id="U_Program">
        <measure>vir:Program</measure>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="U_USDollarShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:AmendmentFlag
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_1b048b11-a161-4358-a429-9cf7cce4559b">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_aef41f24-e203-4eae-9d46-eb6b4157b2f3">0001706431</dei:EntityCentralIndexKey>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      id="F_89b36744-6825-4405-8082-31787f74cb3c">us-gaap:AccruedLiabilitiesAndOtherLiabilities</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      id="F_580369ee-3852-4e0f-9dd1-a3ca48903cb6">us-gaap:AccruedLiabilitiesAndOtherLiabilities</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:LongTermInvestments
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      id="F_6e3929ca-6385-4783-8f59-917256874890"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_1e87793a-cf2d-4040-b332-0a1245e6d6f5"
      id="F_68e96f79-a508-48f1-bc17-ed7aec35b970">P1Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_d37f8ac9-179a-4133-8028-433301ccfa33">Q2</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PreferredStockValue
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      id="F_1c9962ee-a190-465d-aa07-6d3629acaf80"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      id="F_cca64ea2-fd50-4e06-8f49-480df4e815bb"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      id="F_97d90c09-330b-4395-957c-d835eae45d99"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_c18ffe7d-7fee-436a-8b7b-480a5133bb74">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_bb06e195-126d-4785-a160-62ee3e70bc39">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      id="F_4f731a02-7364-48b7-9bec-4e3793c9b91b"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_c17d272b-0384-4c5b-aa45-b3a63197fa45">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_e52c80d7-6d31-47cd-b3a8-b5263ef32111">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_0d9d628d-bb84-4ef0-b69d-f11491446c1d">2021-06-30</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_8587c59c-e8fc-4544-b6e5-3c58030c0430">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_23ad3275-a838-476a-aeed-156778510dba">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_67d2b434-8991-4bc1-ab36-85defd45e5c5">001-39083</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_a8dd6d3d-bdd9-4292-a1be-bafac289c717">Vir Biotechnology, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_59e17f76-f5d0-4bda-a452-f74067014a69">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_73ea5cbd-a651-48ef-8528-4717eabe3d7c">81-2730369</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_88f958ce-3eab-4489-83ca-b527f6c66543">499 Illinois Street, Suite 500</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_c42f376a-49ce-4e6d-9cf6-01ce3b8108dc">San Francisco</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_01ae5a1f-8d07-447a-a5be-2a8003ef9811">CA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_4c222883-a93a-481a-89ee-d8f8e46c066a">94158</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_b0a84a5f-3219-4d65-9386-e3c021e8b583">415</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_af233e57-f938-4c4b-8df2-3ad47f07ef67">906-4324</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_1fc6f078-8b14-486c-a775-490aecd6ebb2">Common stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_e1c3a8d4-76e5-4a85-8ed8-ad16128d0625">VIR</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_fa7ee57a-51c2-40e5-9874-7acdc084cccc">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityCurrentReportingStatus
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_d6ab0cfc-def3-4c32-a1fb-e8a3f4df2d4f">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_4983a0ac-f54c-47e7-aaa7-8f15b3685ee9">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_46c608ae-2a9f-4178-a704-b47a942a1650">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_819aee21-d7fe-4535-9e4e-8c8305df6ca1">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_aaa5b50f-2fa0-49eb-91b4-331816674020">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_0b544c9a-09e4-4480-896c-889905137da8">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_97dded0d-16f2-4d7e-ae2b-6fc06ecdfde2"
      decimals="INF"
      id="F_b5f1c57e-f242-4f84-9391-38b69ec4991a"
      unitRef="U_shares">130611795</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_6988bbe6-9b5a-425b-9e22-8909027e2a1a"
      unitRef="U_USD">741951000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_f5298bb7-9ad1-49eb-9f72-1eb2fd92ac21"
      unitRef="U_USD">436575000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_07a8b252-7113-4f4f-afb2-c8a6768a0ccf"
      unitRef="U_USD">84107000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_5711558c-de9e-4753-a400-0db149dc4e5d"
      unitRef="U_USD">300286000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_80b85232-2a97-42d5-b5b4-b21e088a1475"
      unitRef="U_USD">7004000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_cce3f174-0368-4431-a1cd-d121da844f25"
      unitRef="U_USD">7993000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_4fa0ee7c-3cc3-4cde-9030-54e4eea02f22"
      unitRef="U_USD">29233000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_1c21f11d-f955-4d4f-89a7-0ebfad41a7f2"
      unitRef="U_USD">27511000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_057f86b5-436a-4350-ad84-3aaacedbf02b"
      unitRef="U_USD">862295000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_bf381f47-3200-45da-a2ef-cec9d4a34dea"
      unitRef="U_USD">772365000</us-gaap:AssetsCurrent>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_bedc34ef-8037-45a1-a27d-0a314bee56e1"
      unitRef="U_USD">33554000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_27766c45-a4a3-4b21-8460-73d3d5eaaad0"
      unitRef="U_USD">33820000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_d76ea190-8005-4e52-a812-5f03ecb5d0ff"
      unitRef="U_USD">16937000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_8968be21-57be-49f2-adfb-793e6748fa46"
      unitRef="U_USD">16937000</us-gaap:Goodwill>
    <us-gaap:LongTermInvestments
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_d50e7cca-7858-4cfc-8681-cd772c3c17c9"
      unitRef="U_USD">50680000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_a11d501a-4c85-4da7-9395-028f72a08af4"
      unitRef="U_USD">20251000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_2dda9dc6-16e6-4844-9e22-3c08210f5541"
      unitRef="U_USD">17946000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_99366022-3310-4a99-bede-4dc9c86a6353"
      unitRef="U_USD">58972000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_549406fb-634c-461b-8b5d-09c642dc916b"
      unitRef="U_USD">61947000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_522b8900-e2fe-4e0e-ba10-3afe8325888f"
      unitRef="U_USD">7002000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_0b0e61f4-444f-40b2-9de4-c56e43ff3cc6"
      unitRef="U_USD">6919000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:OtherAssets
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_59bd3b10-5a27-40e3-acde-732567558119"
      unitRef="U_USD">7890000</us-gaap:OtherAssets>
    <us-gaap:OtherAssets
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_77c9935a-d72b-4726-919c-ac37af3fd1b5"
      unitRef="U_USD">8827000</us-gaap:OtherAssets>
    <us-gaap:Assets
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_4272b3f3-5c1d-40a8-8475-eeb119575c59"
      unitRef="U_USD">1057581000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_80769845-5e61-48fa-9839-12aae4c97d8d"
      unitRef="U_USD">918761000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_5125c50f-4ecf-4e8f-a079-abd5018b68dc"
      unitRef="U_USD">11032000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_49b036ba-0d3b-4d58-865c-8b321ff60f05"
      unitRef="U_USD">5077000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_cd0484e2-cc8b-41d5-a208-f3f406157a0d"
      unitRef="U_USD">64074000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_90e07ee8-fb02-448e-b185-fd073b2b1ab6"
      unitRef="U_USD">76936000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_65beeb24-ac07-415c-b94e-8720349608cc"
      unitRef="U_USD">44718000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_c3caf2a8-1cc7-4d51-80d2-c9c0d4760529"
      unitRef="U_USD">6451000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_70007cf2-23bc-4580-8d00-d0117d05c5f6"
      unitRef="U_USD">26200000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_60897f55-2f98-4e61-aab6-3a73c9031ea8"
      unitRef="U_USD">10600000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_b25b1135-b856-4a6f-a0ef-51bcfd1162e2"
      unitRef="U_USD">146024000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_07d436da-54b5-4bb0-99c0-41e407ec194d"
      unitRef="U_USD">99064000</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_b6e58135-38c1-4ab3-abd5-2b580ad7955b"
      unitRef="U_USD">55496000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_e60392d8-24df-41ec-b55b-d7e3d6ceb784"
      unitRef="U_USD">3815000</us-gaap:DeferredRevenueNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_5091f7c7-d718-4b6a-80b4-dc9e8bed2a08"
      unitRef="U_USD">68938000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_9ff4b0d7-70f2-49ac-bd62-30ec612fc3fa"
      unitRef="U_USD">66556000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_fa3dbf68-686d-4476-bbed-c0c6e436c079"
      unitRef="U_USD">42692000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_00493518-86b6-4564-8605-531f2b6c1555"
      unitRef="U_USD">25374000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_eafc95a4-7851-4d2f-8216-cf1f81fb6ddf"
      unitRef="U_USD">3253000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_a2edb736-d180-4ec6-a872-45c787b8c281"
      unitRef="U_USD">3253000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_c95aa721-164d-4e28-9428-18348589cce5"
      unitRef="U_USD">3853000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_e2caebd4-cfe8-4d11-bcef-bccd7d8b5df4"
      unitRef="U_USD">3847000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_6a59100c-604d-45c6-8b55-d9021ecbe716"
      unitRef="U_USD">320256000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_22fa36fc-9d8c-48d5-a5f6-2a4d0447ea32"
      unitRef="U_USD">201909000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="INF"
      id="F_8f1209ce-0356-4ae4-add2-055b0f4c79e4"
      unitRef="U_USDollarShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="INF"
      id="F_cc021883-70c1-4d12-a2a5-3c891a7b5e83"
      unitRef="U_USDollarShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="INF"
      id="F_2b96796c-6cab-4a62-8b65-1ee887635f26"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="INF"
      id="F_a109a352-b0b5-498c-a550-445605bca080"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="INF"
      id="F_28ea79b7-9574-4569-ad84-cbf6bd5319b3"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="INF"
      id="F_0ffd6645-a43d-4337-9295-2aa8682d71f2"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="INF"
      id="F_9d596b1e-16df-4b35-9148-063d2e7187b0"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="INF"
      id="F_ed79dc29-48a3-445c-8722-3da45bd431d3"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="INF"
      id="F_5f5625f1-04b1-43bb-9b3d-46656f75cd96"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="INF"
      id="F_846000c0-9054-4f81-ac82-9e648d344522"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="INF"
      id="F_34dbfb57-0273-4612-a2dd-aa62296087fd"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="INF"
      id="F_8ac8dfbe-f497-4559-921f-b27c71e1ce44"
      unitRef="U_shares">300000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="INF"
      id="F_1060a573-ee40-40ec-8b0a-9a750c15bb82"
      unitRef="U_shares">130479975</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="INF"
      id="F_3cb62ffc-480a-4918-a794-cd80786f1156"
      unitRef="U_shares">130479975</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="INF"
      id="F_1b7245e2-c2af-4679-ab0d-52e1deaf7901"
      unitRef="U_shares">127416740</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="INF"
      id="F_277bb349-54c1-40f8-b879-20c5d4c67bfd"
      unitRef="U_shares">127416740</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_11b189fc-23ea-4552-b374-1981fbd82297"
      unitRef="U_USD">13000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_f4bbf45f-6c07-4a87-a54b-e8a2bac0b16b"
      unitRef="U_USD">13000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_16021e03-1412-4e61-97ca-698c0ae12d02"
      unitRef="U_USD">1512928000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_f6a80554-8bff-44a6-b806-bb2fc3e491cf"
      unitRef="U_USD">1385301000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_0ed0f8f7-243c-4924-a430-6cde58bf8d40"
      unitRef="U_USD">-1334000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_6fd0ef94-3335-4f95-bd4b-d115936951f8"
      unitRef="U_USD">-1278000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_5c0a38d1-359e-4915-8f9e-18897ccd7826"
      unitRef="U_USD">774282000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_a029a6bb-22fa-41b3-a655-1429dd579668"
      unitRef="U_USD">667184000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_10db0ad5-d12c-4ced-b8a6-fad7714a4306"
      unitRef="U_USD">737325000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_4bec80df-9a35-4406-bdbf-982b61e02ea4"
      unitRef="U_USD">716852000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_68a4b240-6234-48ef-ab5b-e0dc976ecd2c"
      unitRef="U_USD">1057581000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_dc383a89-a5bf-43bd-a527-8892485876c4"
      unitRef="U_USD">918761000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_8162e8b4-3609-4bdc-ba16-5e1d76bb3c6b"
      decimals="-3"
      id="F_59d64f78-8c37-4dc5-aa82-0fe2604dacde"
      unitRef="U_USD">5333000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_09789d61-addd-4c37-ab93-6605597b8a60"
      decimals="-3"
      id="F_ebc51404-5879-4538-8bbe-dc0720ec3b99"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_766775c9-df87-46ac-a6ca-0995a7c65d87"
      decimals="-3"
      id="F_5d6b5343-c3f6-415e-bb01-0ae5210236be"
      unitRef="U_USD">5333000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_86f05426-07f5-4481-b708-0d76a9b442e3"
      decimals="-3"
      id="F_b4570d29-2dcb-4681-990a-da468d7e0d12"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_037841ec-b5b1-4809-aef7-1a37b14ddff9"
      decimals="-3"
      id="F_027914bb-549d-4da1-8ac8-4c1553b069dc"
      unitRef="U_USD">168653000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_d438ee24-58b2-47f8-b7c8-f3890a19f797"
      decimals="-3"
      id="F_5bb46ba9-22b9-470a-8a7e-68b0bbcab172"
      unitRef="U_USD">43522000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_5ef16289-589c-49ff-b97d-b1ade8c4d8c4"
      decimals="-3"
      id="F_a216013e-b53e-4586-93b6-fcb25dee7020"
      unitRef="U_USD">169266000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_4504c120-b2bc-4009-8fb3-837091fb0248"
      decimals="-3"
      id="F_8e88873b-f35c-451f-afd6-c279bd42fd56"
      unitRef="U_USD">44009000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_9b221d24-b45a-4cc0-b6cb-8320c56dc6fc"
      decimals="-3"
      id="F_7b77b554-1849-489a-809b-04dc89d75104"
      unitRef="U_USD">3082000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_08207110-60df-4348-8106-e824e9e44ab8"
      decimals="-3"
      id="F_cf2f5b1b-1f0b-4e95-abda-2526101cc3a2"
      unitRef="U_USD">719000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_eb4adf6c-364c-4b79-92fd-28aa9a50e441"
      decimals="-3"
      id="F_1441bc52-0a84-451d-bf7c-57692002a221"
      unitRef="U_USD">4453000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_1f9d182b-02f1-4140-983b-012691d8ce35"
      decimals="-3"
      id="F_a5e13a12-d76c-4132-bfc7-d50cf0a0f918"
      unitRef="U_USD">5950000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_de3d836a-48cf-4d4f-8714-440719392b2e"
      decimals="-3"
      id="F_5f9ddcbc-5fc6-4a78-8b3f-5e40efe9a23a"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_69917036-35e4-4dc8-8976-064800b680f9"
      decimals="-3"
      id="F_b37c0904-8585-4aa0-888e-c5e39c003079"
      unitRef="U_USD">22747000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_de3d836a-48cf-4d4f-8714-440719392b2e"
      decimals="-3"
      id="F_d2e3e3c8-58ef-4d32-a44b-e9f9cf5e233e"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_1ff555c9-cb2a-45df-8631-74d23812f12b"
      decimals="-3"
      id="F_4e70905f-6d51-4dde-9093-0330384d7fbd"
      unitRef="U_USD">22747000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:Revenues
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="-3"
      id="F_b1006b24-6abc-4859-b21c-0b42c2acce17"
      unitRef="U_USD">177068000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_dcd8d349-919d-43c6-ba4d-af599b1222ea"
      unitRef="U_USD">66988000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_b09de97d-1c44-44ec-813c-c7e5c5809aa8"
      unitRef="U_USD">179052000</us-gaap:Revenues>
    <us-gaap:Revenues
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_17dd57b8-331a-4dec-8057-5beef9b44831"
      unitRef="U_USD">72706000</us-gaap:Revenues>
    <us-gaap:CostOfRevenue
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="-3"
      id="F_7f38ff6e-9f50-402a-9ba1-7ef362739c93"
      unitRef="U_USD">1144000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_e30badf5-1e39-4e28-b6ff-811ea469d568"
      unitRef="U_USD">0</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_ab7d6943-876e-48f3-84e1-f47d8cfd6b4d"
      unitRef="U_USD">1152000</us-gaap:CostOfRevenue>
    <us-gaap:CostOfRevenue
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_88262048-d8c6-4fc8-81d6-bd921a95ed0d"
      unitRef="U_USD">0</us-gaap:CostOfRevenue>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="-3"
      id="F_8d49289c-f248-4dd7-8b88-10da9f6bb76e"
      unitRef="U_USD">86126000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_1fff5c7c-a5b5-4602-bcf2-909c78f07c12"
      unitRef="U_USD">79653000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_4976527f-d869-43de-bdf1-b2c8d01007ee"
      unitRef="U_USD">220996000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_9e74061f-ee0a-4859-b307-3808e7f6dd7c"
      unitRef="U_USD">144632000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="-3"
      id="F_7e31dccb-a7c0-4c20-8141-064dbc8e7126"
      unitRef="U_USD">28781000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_cdd5e4ff-b4f6-42ae-a20e-3fd7e03ad76e"
      unitRef="U_USD">16386000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_a4d378b4-b72b-4da5-bbaa-0cef3e581a49"
      unitRef="U_USD">54520000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_83970c4d-393f-4cb9-97d0-e8bf463dcb3f"
      unitRef="U_USD">29035000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="-3"
      id="F_69938ab2-e08d-4db6-ad01-f19d4790cb78"
      unitRef="U_USD">116051000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_e96f63e2-b2d1-463a-b555-e3c8df3d32ff"
      unitRef="U_USD">96039000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_cd7bdb4b-db31-4e37-abf0-e34f9ceeabe3"
      unitRef="U_USD">276668000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_6cde6a54-6405-41ae-8068-348c57f67518"
      unitRef="U_USD">173667000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="-3"
      id="F_c1ee6600-5853-4b35-8f14-c5f66a72e334"
      unitRef="U_USD">61017000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_eb49efde-4a09-437b-9c94-1700c3f0d04c"
      unitRef="U_USD">-29051000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_360aad54-d59c-46ba-afbd-0cb3495c54a1"
      unitRef="U_USD">-97616000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_06dcc6d4-8b51-453e-ad41-bd3abf99775f"
      unitRef="U_USD">-100961000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="-3"
      id="F_84b34ca1-65f7-4a1d-898c-fc164674169b"
      unitRef="U_USD">97000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_29e19332-12c3-4011-9243-9342a37b5521"
      unitRef="U_USD">825000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_b3af91af-5238-475a-bce3-96065a497401"
      unitRef="U_USD">261000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_9b94e75e-868e-4c27-95ca-31fe6ec89597"
      unitRef="U_USD">2580000</us-gaap:InvestmentIncomeNetAmortizationOfDiscountAndPremium>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="-3"
      id="F_5d2f3d70-35d7-425c-b749-7c8a106b0975"
      unitRef="U_USD">752000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_837f9a4a-b9e4-4460-8a39-a2c004d8fa82"
      unitRef="U_USD">-2895000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_0df41ec4-fc64-42f0-9d0f-dd7f9a10d306"
      unitRef="U_USD">-9494000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_8b797c3a-1649-4f55-829d-38051f2ed0f9"
      unitRef="U_USD">-9964000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="-3"
      id="F_ec6e4828-74b2-414f-bcf4-a976b1bdee31"
      unitRef="U_USD">849000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_70e40a95-3a56-41ed-841d-195a1d1add21"
      unitRef="U_USD">-2070000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_b27690a3-76be-4854-bcd0-3ee238d82d70"
      unitRef="U_USD">-9233000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_7c4258e3-97d2-4f07-82e0-8bccf3e053f7"
      unitRef="U_USD">-7384000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="-3"
      id="F_56ff4683-d328-4dc7-bb4f-a06b57cf7b3a"
      unitRef="U_USD">61866000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_48dd4009-1e24-45e9-a607-48a620b475e4"
      unitRef="U_USD">-31121000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_56a17daa-158a-4b20-a5d0-72e168f888c3"
      unitRef="U_USD">-106849000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_5648483d-01cb-44dd-beb4-235e2c51ccda"
      unitRef="U_USD">-108345000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="-3"
      id="F_ef3d854f-7899-421c-8257-3abcf00a7433"
      unitRef="U_USD">53000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_93e39219-9cd8-45a0-adca-7d8fc77c7968"
      unitRef="U_USD">46000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_b017fa04-cdb3-4a8c-9ab1-5cc87518f5a2"
      unitRef="U_USD">249000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_3802c99d-921c-48cc-be9b-b9353f374f35"
      unitRef="U_USD">62000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="-3"
      id="F_65725035-4a19-478b-9296-c556ff67797e"
      unitRef="U_USD">61813000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_73c4ba26-2695-45ba-8368-9f592be03031"
      unitRef="U_USD">-31167000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_dc2caf53-a2a0-4267-bdb4-279fb7619d5d"
      unitRef="U_USD">-107098000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_660bada9-1c80-4367-869c-b0d02aaa37e4"
      unitRef="U_USD">-108407000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="2"
      id="F_f060d18c-5f42-42c6-a19f-1e5c6b7f9b87"
      unitRef="U_USDollarShare">0.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="2"
      id="F_919de847-dcc6-4b4f-a1d3-1e6802b40470"
      unitRef="U_USDollarShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="2"
      id="F_8a9b7f1d-1ce3-41fa-9b51-53beb48a56a2"
      unitRef="U_USDollarShare">-0.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="2"
      id="F_d9dad893-fe35-4f58-976d-d15289ec9e2f"
      unitRef="U_USDollarShare">-0.97</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="2"
      id="F_0f7c6813-19e5-4024-a28a-4291876670d7"
      unitRef="U_USDollarShare">0.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="2"
      id="F_bda12359-b715-4fd8-b72c-30c60aa1f364"
      unitRef="U_USDollarShare">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="2"
      id="F_9257cc0d-7844-416f-87f7-4e0a32666fcb"
      unitRef="U_USDollarShare">-0.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="2"
      id="F_f0f890fd-5ffa-4a0b-aad4-28496db6eb7a"
      unitRef="U_USDollarShare">-0.97</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="0"
      id="F_c8349f07-42f6-46ea-8f77-ae9f6e42a59a"
      unitRef="U_shares">130121943</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="0"
      id="F_0a180304-c711-4a7c-ac1f-a8d179379af2"
      unitRef="U_shares">114980652</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="0"
      id="F_2b9d7829-6762-4465-b0e0-25922ea23d22"
      unitRef="U_shares">128938851</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="0"
      id="F_071cd25e-f97a-4f34-bdc0-2ce5c9e1085d"
      unitRef="U_shares">111684283</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="0"
      id="F_df8fbf92-4f42-402d-b8cb-90589a49eee0"
      unitRef="U_shares">133789977</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="0"
      id="F_2bf7bb9b-4728-48b8-ab3d-86c7767bf861"
      unitRef="U_shares">114980652</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="0"
      id="F_400842ff-9c75-4461-8e05-2711a7066486"
      unitRef="U_shares">128938851</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="0"
      id="F_6c34880e-df2e-4cca-96eb-553c5cce0237"
      unitRef="U_shares">111684283</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="-3"
      id="F_ab579a8e-48e7-4206-8f14-644e06cb0f3a"
      unitRef="U_USD">61813000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_7c682319-507f-43c5-8d59-3b20492bacbb"
      unitRef="U_USD">-31167000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_163378d5-3189-424c-9e63-522e13c44e6e"
      unitRef="U_USD">-107098000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_303eb488-ddf2-49bf-9f0e-273b86a287b9"
      unitRef="U_USD">-108407000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="-3"
      id="F_143c1028-9e9f-412b-8703-f146ddedbf6f"
      unitRef="U_USD">-44000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_ab0ed29f-c176-4ac4-9c07-7fee5d481a69"
      unitRef="U_USD">-549000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_eab350e8-338f-44ad-a195-7e51b94eaad6"
      unitRef="U_USD">-84000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_e0de3e8a-1429-4f4e-be6f-7f86e4b5b808"
      unitRef="U_USD">295000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="-3"
      id="F_3f8beb47-1553-4b27-9ac2-0df0b42daaa6"
      unitRef="U_USD">-14000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_0ad625dc-3130-4c8a-999f-c5ad567740f3"
      unitRef="U_USD">-6000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_1ff04aaf-ebf3-49cc-bbc2-ae1543251399"
      unitRef="U_USD">-28000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_caf5eb1e-1adf-4e4e-8381-566cf279fa37"
      unitRef="U_USD">-11000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="-3"
      id="F_8bdf9e30-6286-4ef7-8ee5-66ddccd20d38"
      unitRef="U_USD">-30000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_dbc9c5e4-7771-49e4-bb5a-3337d142faae"
      unitRef="U_USD">-543000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_133bedce-911d-4e4b-b6ff-00c7949737a9"
      unitRef="U_USD">-56000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_52a36831-a045-41fb-80ad-e66078386842"
      unitRef="U_USD">306000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="-3"
      id="F_f6a0782b-18a2-483b-8e6a-b260f0e66d97"
      unitRef="U_USD">61783000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_20cea3ba-faa7-4db6-ba88-eb887e916aed"
      unitRef="U_USD">-31710000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_9aa12b1a-2080-4448-8138-5510ef6a2f07"
      unitRef="U_USD">-107154000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_f9b25390-5ee9-4fb2-83a3-c5c3ae6d98db"
      unitRef="U_USD">-108101000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_61ac6d35-003c-4932-8b7f-75b0994fe73e"
      decimals="INF"
      id="F_8e73838e-3ac6-419c-806a-437122e47861"
      unitRef="U_shares">129891856</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_61ac6d35-003c-4932-8b7f-75b0994fe73e"
      decimals="-3"
      id="F_9c369f08-bf64-4474-9418-5047e040036c"
      unitRef="U_USD">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_914881ac-2ab5-47f4-8eed-c4210e53dc3a"
      decimals="-3"
      id="F_a4aa7b30-7e1b-4a4d-a2b8-5bf820b9db4b"
      unitRef="U_USD">1488337000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_7c63340d-0674-48e2-b11f-13fdad617a64"
      decimals="-3"
      id="F_b6ecd0b9-c99e-406d-8061-ae515e8907ed"
      unitRef="U_USD">-1304000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_d8427988-1d9b-42d6-a158-ce5e24c17b41"
      decimals="-3"
      id="F_c3edfd1d-e217-47ea-95a8-6a004051e6a5"
      unitRef="U_USD">-836095000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_3edca66f-50fb-4438-8b85-01c89b9c1b0a"
      decimals="-3"
      id="F_45413892-4842-4a3c-a25b-2d8f6d541cba"
      unitRef="U_USD">650951000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_a2dda4ba-cdd3-4a25-95df-9f71c39ebfdf"
      decimals="INF"
      id="F_6de5df55-ba05-4a13-8846-6615d67fd7a6"
      unitRef="U_shares">34446</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_a2dda4ba-cdd3-4a25-95df-9f71c39ebfdf"
      decimals="INF"
      id="F_05a6fe23-ec2c-4234-a15a-302ffc8aae68"
      unitRef="U_shares">553673</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_6f7a01e9-125b-4678-81a3-a6efb1b4d77e"
      decimals="-3"
      id="F_ba46021a-151d-465b-b775-f06d4508b679"
      unitRef="U_USD">3593000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="-3"
      id="F_9f6962bf-9fe2-479b-a58a-fe25e564fb38"
      unitRef="U_USD">3593000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_6f7a01e9-125b-4678-81a3-a6efb1b4d77e"
      decimals="-3"
      id="F_5f6e3177-2ef1-4bc5-9b16-5c0dd89dc899"
      unitRef="U_USD">20998000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="-3"
      id="F_65708f24-03a1-4762-bb9e-f385b959c114"
      unitRef="U_USD">20998000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_be538fc0-b3da-4933-b596-db6f96112f97"
      decimals="-3"
      id="F_e39fd306-c286-4d51-803f-7efc8465f974"
      unitRef="U_USD">-30000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="-3"
      id="F_85347c94-96bb-4704-ae9e-93ea2ebddef1"
      unitRef="U_USD">-30000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_2ff7bfd4-ce79-493b-87b6-550ee9f49df4"
      decimals="-3"
      id="F_3041fc68-b40d-411f-9f5d-add5664401d7"
      unitRef="U_USD">61813000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="-3"
      id="F_9529635b-3877-466f-995e-5540768d929c"
      unitRef="U_USD">61813000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_45bc5026-51b3-4f16-b7d4-61e29f251c4a"
      decimals="INF"
      id="F_e2e69a9e-5f8a-49bb-8115-08d55b8b2420"
      unitRef="U_shares">130479975</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_45bc5026-51b3-4f16-b7d4-61e29f251c4a"
      decimals="-3"
      id="F_ab6ce2d3-bc1a-4886-a110-9e37f06473de"
      unitRef="U_USD">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_befad2fc-309f-4f88-99dc-baaef6380944"
      decimals="-3"
      id="F_7fa5d680-d1a0-431e-947f-04498daf5361"
      unitRef="U_USD">1512928000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_918fa4e1-d7cd-4bf6-82cc-f13652a23ef9"
      decimals="-3"
      id="F_e630a151-4f12-422f-b096-4ac2228dff14"
      unitRef="U_USD">-1334000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1978c92a-9f5f-463a-83b8-88d2ffb3548f"
      decimals="-3"
      id="F_2f26ccd4-e978-4ed9-a32f-9681c54afc93"
      unitRef="U_USD">-774282000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_1b9c0bca-4a6a-4632-a601-0a4ffebdf8f2"
      unitRef="U_USD">737325000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_355e350c-6186-4712-9d71-af22d0b9a120"
      decimals="INF"
      id="F_95fd3208-34f9-4b4e-905c-1842ea30cd9c"
      unitRef="U_shares">108350368</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_355e350c-6186-4712-9d71-af22d0b9a120"
      decimals="-3"
      id="F_06a86a79-5fb1-4b9b-a80e-93a99c56a452"
      unitRef="U_USD">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b6d51956-3a22-4bd6-95a5-dad4c1d17f90"
      decimals="-3"
      id="F_436bbf04-6eb8-4199-92ca-b2911b0b9773"
      unitRef="U_USD">825833000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a8995a77-2e40-4bdd-a7bd-5c2389acc76c"
      decimals="-3"
      id="F_ebc03b3f-5247-4475-a4a4-0faedc1b40ce"
      unitRef="U_USD">248000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1ef15310-89d7-4a2b-81fa-497de643a6d3"
      decimals="-3"
      id="F_2eeb7791-7141-4b63-9407-6657f7d2a925"
      unitRef="U_USD">-445759000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_c4e13756-0547-45df-9116-975dfa1cdf28"
      decimals="-3"
      id="F_e17369f3-a5d9-4422-a40b-8a8172e465b2"
      unitRef="U_USD">380333000</us-gaap:StockholdersEquity>
    <vir:StockIssuedDuringPeriodSharesAchievementOfMilestone
      contextRef="C_fa28c391-ecec-4c12-bcfb-f369058e9862"
      decimals="INF"
      id="F_f91af005-a652-4587-aa67-46c2b19a5402"
      unitRef="U_shares">1111111</vir:StockIssuedDuringPeriodSharesAchievementOfMilestone>
    <vir:StockIssuedDuringPeriodSharesCollaborationAgreement
      contextRef="C_fa28c391-ecec-4c12-bcfb-f369058e9862"
      decimals="INF"
      id="F_6f8ec0eb-f47b-4f6c-88c2-463badc63a7e"
      unitRef="U_shares">6626027</vir:StockIssuedDuringPeriodSharesCollaborationAgreement>
    <vir:StockIssuedDuringPeriodValueCollaborationAgreement
      contextRef="C_fa28c391-ecec-4c12-bcfb-f369058e9862"
      decimals="-3"
      id="F_53104dd9-3156-4c72-828a-7078f9729266"
      unitRef="U_USD">1000</vir:StockIssuedDuringPeriodValueCollaborationAgreement>
    <vir:StockIssuedDuringPeriodValueCollaborationAgreement
      contextRef="C_cce66117-e613-4efa-aee1-873b41ff2cc8"
      decimals="-3"
      id="F_bdde06db-57b6-4119-8415-ab9f8709266a"
      unitRef="U_USD">206698000</vir:StockIssuedDuringPeriodValueCollaborationAgreement>
    <vir:StockIssuedDuringPeriodValueCollaborationAgreement
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_854184ae-7b8a-4080-9e8d-ca9176bbfae9"
      unitRef="U_USD">206699000</vir:StockIssuedDuringPeriodValueCollaborationAgreement>
    <vir:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant
      contextRef="C_fa28c391-ecec-4c12-bcfb-f369058e9862"
      decimals="INF"
      id="F_fbcf8621-b968-48f4-8de3-b774d4e1264d"
      unitRef="U_shares">211774</vir:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_fa28c391-ecec-4c12-bcfb-f369058e9862"
      decimals="INF"
      id="F_4dd7d7b2-7d7a-4075-89bc-7e4c07358cc4"
      unitRef="U_shares">612546</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_cce66117-e613-4efa-aee1-873b41ff2cc8"
      decimals="-3"
      id="F_cb3c8ba8-543e-4085-980c-06c4e4c5284c"
      unitRef="U_USD">462000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_4c4e4667-2eab-4b21-b7cb-f9c8411ea658"
      unitRef="U_USD">462000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_fa28c391-ecec-4c12-bcfb-f369058e9862"
      decimals="INF"
      id="F_24cf6a24-3582-4500-9bf1-0e00ea160e36"
      unitRef="U_shares">815260</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_cce66117-e613-4efa-aee1-873b41ff2cc8"
      decimals="-3"
      id="F_2679d91c-5c20-48a5-a6bb-814c05a71294"
      unitRef="U_USD">2245000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_bfa84db9-5378-4175-bc27-1657a46564bb"
      unitRef="U_USD">2245000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_cce66117-e613-4efa-aee1-873b41ff2cc8"
      decimals="-3"
      id="F_89945d7f-dae1-4ddd-9555-2c7e22bcfe03"
      unitRef="U_USD">5750000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_646a663c-4b19-4488-8156-e63bc668e61f"
      unitRef="U_USD">5750000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_a23df604-43e8-477f-95be-d67c4d36ef27"
      decimals="-3"
      id="F_020c8337-8f93-4475-b45b-c909ce21a4a3"
      unitRef="U_USD">-543000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_034a748a-1da6-4d39-b597-7921a475e44d"
      unitRef="U_USD">-543000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_329ccbc8-94c6-4565-9ecf-7b34632b826e"
      decimals="-3"
      id="F_1e7d7b44-6d09-44b4-9065-9fa50eff3634"
      unitRef="U_USD">-31167000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_4f6f1871-fc3d-4951-ae98-52b5a8fef0f1"
      unitRef="U_USD">-31167000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_b6795825-d2b1-4664-92a7-7f4efb4ea7bd"
      decimals="INF"
      id="F_629c7fab-f72b-48b4-8697-4d2ce50b8f1d"
      unitRef="U_shares">117727086</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_b6795825-d2b1-4664-92a7-7f4efb4ea7bd"
      decimals="-3"
      id="F_e261d2be-3037-425f-965a-08a59cdb92f9"
      unitRef="U_USD">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0b1f8126-42c0-40fe-81c1-24cbdc0b2ccc"
      decimals="-3"
      id="F_ab1d401c-b548-4b95-b4af-dcc81b71e2fe"
      unitRef="U_USD">1040988000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_01c272b4-05c2-41fb-90b2-afebf3595d73"
      decimals="-3"
      id="F_556ce8c6-3046-4bd0-9b35-486b1a6bf283"
      unitRef="U_USD">-295000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a2db8718-9aa3-44fb-bd21-a5914cb932c2"
      decimals="-3"
      id="F_b052b4c1-deee-44a7-9b9e-84dcd80105c7"
      unitRef="U_USD">-476926000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e28f1ecf-80aa-4b09-b8ff-8c09db69a316"
      decimals="-3"
      id="F_14bb7acc-0679-413d-89f1-0c26dfd7a682"
      unitRef="U_USD">563779000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_3c3d0c98-1fee-4858-be8f-d493a8a73e1e"
      decimals="INF"
      id="F_74e511ac-6592-487d-8613-9217d99a37ef"
      unitRef="U_shares">127416740</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_3c3d0c98-1fee-4858-be8f-d493a8a73e1e"
      decimals="-3"
      id="F_9c6bd07d-185f-4762-acf4-b54b7638452a"
      unitRef="U_USD">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_9b52dd29-86c0-42a1-9b29-10e07e25991f"
      decimals="-3"
      id="F_4aac2db0-97a3-485c-a150-a894391723e3"
      unitRef="U_USD">1385301000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2a63cca2-9347-45c4-8512-1e97604d2422"
      decimals="-3"
      id="F_294319b5-8f10-44ec-824e-ed9f6fb4d598"
      unitRef="U_USD">-1278000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f55782eb-212f-4f4e-9bf4-65f42e20a89a"
      decimals="-3"
      id="F_7fcd96d6-a3dd-4838-9b34-7fb5ffde4d37"
      unitRef="U_USD">-667184000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_808e4739-eb12-4955-9f33-c7877cdf766a"
      unitRef="U_USD">716852000</us-gaap:StockholdersEquity>
    <vir:StockIssuedDuringPeriodSharesCollaborationAgreement
      contextRef="C_78af002d-b722-4eae-8f4a-2d0c76fa8ae0"
      decimals="INF"
      id="F_acb1c808-9b2f-4812-9b73-12b4150c44f9"
      unitRef="U_shares">1924927</vir:StockIssuedDuringPeriodSharesCollaborationAgreement>
    <vir:StockIssuedDuringPeriodValueCollaborationAgreement
      contextRef="C_96589541-95bc-4aef-a913-79c4b0b517f0"
      decimals="-3"
      id="F_72f69b12-ceb7-43a9-8b44-4de9285dab8f"
      unitRef="U_USD">85213000</vir:StockIssuedDuringPeriodValueCollaborationAgreement>
    <vir:StockIssuedDuringPeriodValueCollaborationAgreement
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_72326b77-0629-4488-801f-433c93c09436"
      unitRef="U_USD">85213000</vir:StockIssuedDuringPeriodValueCollaborationAgreement>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_78af002d-b722-4eae-8f4a-2d0c76fa8ae0"
      decimals="INF"
      id="F_6bce667a-8b27-42e4-b2ae-e8f421f3399d"
      unitRef="U_shares">87409</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_78af002d-b722-4eae-8f4a-2d0c76fa8ae0"
      decimals="INF"
      id="F_7cba796e-6f31-49ad-9150-d2bacd9f869b"
      unitRef="U_shares">1050899</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_96589541-95bc-4aef-a913-79c4b0b517f0"
      decimals="-3"
      id="F_e2515e63-01ab-445f-8b52-e5005494917f"
      unitRef="U_USD">5945000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_55191f36-e3f6-4932-925d-8595e8e0a7c5"
      unitRef="U_USD">5945000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_96589541-95bc-4aef-a913-79c4b0b517f0"
      decimals="-3"
      id="F_c1c6d423-b69e-4a48-aded-c08d2ff72990"
      unitRef="U_USD">36469000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_7c4645d0-e8d7-4e7f-839b-d09eaee92ffb"
      unitRef="U_USD">36469000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_3e223018-5e3f-452c-824b-e2e4d71405b7"
      decimals="-3"
      id="F_61d31b80-6900-44cd-9bed-ce4a9725efff"
      unitRef="U_USD">-56000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_c9b17ed9-9239-4ba1-9cb4-3474475bf7d9"
      unitRef="U_USD">-56000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_24d34ab3-57a3-4b9e-8de9-5279d44dd035"
      decimals="-3"
      id="F_a1821dbb-aeb3-410b-98e2-805338304d84"
      unitRef="U_USD">-107098000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_6976c72e-3cc3-4beb-bfae-dd007fa23c1b"
      unitRef="U_USD">-107098000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_45bc5026-51b3-4f16-b7d4-61e29f251c4a"
      decimals="INF"
      id="F_2077898e-be83-4f10-9459-8b99e2a8864f"
      unitRef="U_shares">130479975</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_45bc5026-51b3-4f16-b7d4-61e29f251c4a"
      decimals="-3"
      id="F_89c1acbb-25bc-4b50-9bc7-2c86919edaf4"
      unitRef="U_USD">13000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_befad2fc-309f-4f88-99dc-baaef6380944"
      decimals="-3"
      id="F_4adee54c-732c-4456-bb7b-8b41def63eec"
      unitRef="U_USD">1512928000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_918fa4e1-d7cd-4bf6-82cc-f13652a23ef9"
      decimals="-3"
      id="F_db4e5228-275e-4802-9621-e31ee0255789"
      unitRef="U_USD">-1334000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_1978c92a-9f5f-463a-83b8-88d2ffb3548f"
      decimals="-3"
      id="F_de432f40-0e21-4a04-a292-cc4212fc4e42"
      unitRef="U_USD">-774282000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_4ea03af9-725e-4b2d-b387-42a6353de101"
      unitRef="U_USD">737325000</us-gaap:StockholdersEquity>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_9d811492-0ef4-42f2-b9e1-20840319d292"
      decimals="INF"
      id="F_532bc040-e9c2-4f7c-91b5-358f3fbe823a"
      unitRef="U_shares">107648925</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_9d811492-0ef4-42f2-b9e1-20840319d292"
      decimals="-3"
      id="F_a4c9b880-9419-4163-9ee5-bc52afac12f3"
      unitRef="U_USD">11000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b9591672-a7df-4119-8763-beff32620126"
      decimals="-3"
      id="F_e23dcde1-fb60-4cf7-bf70-26470a18cb10"
      unitRef="U_USD">793051000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e1137d24-689b-45da-9ecd-65f97451d124"
      decimals="-3"
      id="F_2d94f5a4-385f-4edd-a4c3-dc66462301d2"
      unitRef="U_USD">-601000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_b570c7a7-2e4b-4988-8066-7fc9aded3533"
      decimals="-3"
      id="F_94c210c5-f768-417e-bab1-f4128b372cb3"
      unitRef="U_USD">-368519000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_2961edff-bc89-457f-97d0-23460c2e7059"
      decimals="-3"
      id="F_e2181808-c371-4d3b-b6cf-7c543288d716"
      unitRef="U_USD">423942000</us-gaap:StockholdersEquity>
    <vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital
      contextRef="C_b16f4229-15e5-4b92-a679-7c593814f6cd"
      decimals="-3"
      id="F_4b2f1989-6784-4b4f-864d-021e72737f27"
      unitRef="U_USD">29245000</vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital>
    <vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_180136c5-718f-40f6-ad31-db53c37431fa"
      unitRef="U_USD">29245000</vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital>
    <vir:StockIssuedDuringPeriodSharesAchievementOfMilestone
      contextRef="C_0e1b6477-b8d1-4ae0-89fa-0e4e1af40ea7"
      decimals="INF"
      id="F_786c6195-76b1-4070-aaf7-1243a51ad6fe"
      unitRef="U_shares">1111111</vir:StockIssuedDuringPeriodSharesAchievementOfMilestone>
    <vir:StockIssuedDuringPeriodSharesCollaborationAgreement
      contextRef="C_0e1b6477-b8d1-4ae0-89fa-0e4e1af40ea7"
      decimals="INF"
      id="F_955878b0-50e1-4441-a638-85d6193d5309"
      unitRef="U_shares">6626027</vir:StockIssuedDuringPeriodSharesCollaborationAgreement>
    <vir:StockIssuedDuringPeriodValueCollaborationAgreement
      contextRef="C_0e1b6477-b8d1-4ae0-89fa-0e4e1af40ea7"
      decimals="-3"
      id="F_8dab024f-8502-42f1-8865-daf195d0ace5"
      unitRef="U_USD">1000</vir:StockIssuedDuringPeriodValueCollaborationAgreement>
    <vir:StockIssuedDuringPeriodValueCollaborationAgreement
      contextRef="C_b16f4229-15e5-4b92-a679-7c593814f6cd"
      decimals="-3"
      id="F_2ed0fcc5-30de-4c40-b9e3-eef6a245281a"
      unitRef="U_USD">206698000</vir:StockIssuedDuringPeriodValueCollaborationAgreement>
    <vir:StockIssuedDuringPeriodValueCollaborationAgreement
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_9661d157-d84e-4d2c-8879-f4a0b856899e"
      unitRef="U_USD">206699000</vir:StockIssuedDuringPeriodValueCollaborationAgreement>
    <vir:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant
      contextRef="C_0e1b6477-b8d1-4ae0-89fa-0e4e1af40ea7"
      decimals="INF"
      id="F_15f6e701-0b75-4525-ab01-0f1f777058cc"
      unitRef="U_shares">211774</vir:StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="C_0e1b6477-b8d1-4ae0-89fa-0e4e1af40ea7"
      decimals="INF"
      id="F_47b24196-143c-4aa3-9edb-7f6919cf0b74"
      unitRef="U_shares">1230625</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_b16f4229-15e5-4b92-a679-7c593814f6cd"
      decimals="-3"
      id="F_af06a152-5983-44b0-a380-45e4b7fb61f4"
      unitRef="U_USD">889000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_69faba5e-98da-4c30-bbda-bc2b71d59964"
      unitRef="U_USD">889000</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_0e1b6477-b8d1-4ae0-89fa-0e4e1af40ea7"
      decimals="INF"
      id="F_5b3566cf-a246-4f0d-b5b0-c52a8bb2b1d8"
      unitRef="U_shares">898624</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_b16f4229-15e5-4b92-a679-7c593814f6cd"
      decimals="-3"
      id="F_a443e324-ff32-4729-9144-a43d913ac4e8"
      unitRef="U_USD">2388000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_fa0b93d4-d370-4eee-aa5a-aff37f6e1cd5"
      unitRef="U_USD">2388000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_b16f4229-15e5-4b92-a679-7c593814f6cd"
      decimals="-3"
      id="F_4d083fc4-d2d3-4e70-b888-12d114795c13"
      unitRef="U_USD">8717000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_1b53d938-4559-4c3d-9ba0-e19934edf317"
      unitRef="U_USD">8717000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_440aee8c-e7b5-48d3-90f4-51f9d0631f45"
      decimals="-3"
      id="F_d1c99207-056a-4a5b-a40d-f81ea3c3a6dd"
      unitRef="U_USD">306000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_31c5d97b-b5c8-41c4-8cf0-8a4802f55f6e"
      unitRef="U_USD">306000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:NetIncomeLoss
      contextRef="C_39a5ff4f-90c0-4385-8a23-486f8b46bf9b"
      decimals="-3"
      id="F_fd338711-16a4-4b15-86ae-d6936b3cd110"
      unitRef="U_USD">-108407000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_72dbfd27-542e-44e3-b0e9-04b662e315d4"
      unitRef="U_USD">-108407000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_b6795825-d2b1-4664-92a7-7f4efb4ea7bd"
      decimals="INF"
      id="F_a5334d49-576e-461a-a90d-a7f0451ea770"
      unitRef="U_shares">117727086</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_b6795825-d2b1-4664-92a7-7f4efb4ea7bd"
      decimals="-3"
      id="F_77dde1d0-0ae4-4f7d-b2db-bee6c943b3c5"
      unitRef="U_USD">12000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_0b1f8126-42c0-40fe-81c1-24cbdc0b2ccc"
      decimals="-3"
      id="F_7f3727f5-034b-44fe-896d-14d7dccca34c"
      unitRef="U_USD">1040988000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_01c272b4-05c2-41fb-90b2-afebf3595d73"
      decimals="-3"
      id="F_e208c3da-4659-4e83-ad3a-e62b0bd6a224"
      unitRef="U_USD">-295000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_a2db8718-9aa3-44fb-bd21-a5914cb932c2"
      decimals="-3"
      id="F_9b465016-ace1-46f3-bd8a-e40f50cf7e38"
      unitRef="U_USD">-476926000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_e28f1ecf-80aa-4b09-b8ff-8c09db69a316"
      decimals="-3"
      id="F_15063881-4972-4489-bada-a958007975ce"
      unitRef="U_USD">563779000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_835ab5db-ba23-4de7-8326-7a1a8ac41714"
      unitRef="U_USD">-107098000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_2de7b978-7dbb-4005-b369-a34553bde371"
      unitRef="U_USD">-108407000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_9e43e585-242f-4638-8adf-7786606bb51f"
      unitRef="U_USD">2538000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_0b86c4ad-8e96-42eb-99d1-cb40202631e9"
      unitRef="U_USD">2061000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_bead540e-9574-44cb-8f25-b91b69f7401f"
      unitRef="U_USD">266000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_ec69735e-aa62-429b-acab-43707846651a"
      unitRef="U_USD">612000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_937a5f46-803b-4bfc-9534-25253b53110b"
      unitRef="U_USD">238000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_0347c794-e4c5-4f3f-963d-e4a9ec79ab93"
      unitRef="U_USD">-818000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <vir:NoncashLeaseExpense
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_e6370e56-2082-4111-8bc7-56a115069c08"
      unitRef="U_USD">2973000</vir:NoncashLeaseExpense>
    <vir:NoncashLeaseExpense
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_a042388f-cdb5-492a-8711-65f66ace2937"
      unitRef="U_USD">1646000</vir:NoncashLeaseExpense>
    <vir:ChangeInEstimatedFairValueOfContingentConsideration
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_8c06f6ae-765b-4096-bdde-e460e58d9df6"
      unitRef="U_USD">42918000</vir:ChangeInEstimatedFairValueOfContingentConsideration>
    <vir:ChangeInEstimatedFairValueOfContingentConsideration
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_b25c4b9c-ed7d-467e-acb0-ddd731dc4c3d"
      unitRef="U_USD">27790000</vir:ChangeInEstimatedFairValueOfContingentConsideration>
    <vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_8097f809-301a-470c-b4d4-e5af1436a4ba"
      unitRef="U_USD">0</vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue>
    <vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_9a1c6140-455c-4fcc-8cb8-3ce40f0bb5ee"
      unitRef="U_USD">-6453000</vir:IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_d67df2d3-75e0-4a44-bfe8-ba3c198f2306"
      unitRef="U_USD">0</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_7305dd46-356e-4512-bf07-79e74e53e055"
      unitRef="U_USD">-16796000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:ShareBasedCompensation
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_3ceaa6c1-3271-4df3-b499-c17de1751a44"
      unitRef="U_USD">36469000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_5df40c72-9668-4c29-8bc3-7b3b23fedc97"
      unitRef="U_USD">8717000</us-gaap:ShareBasedCompensation>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_01dc2047-3c78-42b2-907e-f7c7001df48a"
      unitRef="U_USD">32000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_54b0b8b0-d32d-483f-aab5-80ac45bf9bac"
      unitRef="U_USD">11000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_12483aac-c12d-469b-92ff-3a7c98339868"
      unitRef="U_USD">-521000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_010116ac-0f29-476b-9f1e-554767c4bbf4"
      unitRef="U_USD">2159000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_a069a438-382f-42cc-abc4-7c0599ec1b89"
      unitRef="U_USD">857000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_396193a4-e41f-49dd-8099-b202ca7ef112"
      unitRef="U_USD">361000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_37c63dd4-31f0-4782-bcc8-987ad508a625"
      unitRef="U_USD">4933000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_5c2ea0a9-7623-490f-8650-a4db122f401d"
      unitRef="U_USD">-1342000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_e6163cb0-6ba7-4c81-862a-24f94c15721b"
      unitRef="U_USD">-22287000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_6d1cc8b3-646c-43fc-913d-e04dc5b533f3"
      unitRef="U_USD">6791000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <vir:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_586333d7-980b-46bd-89ca-13867610dc7c"
      unitRef="U_USD">-93000</vir:IncreaseDecreaseInOperatingLeaseLiabilities>
    <vir:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_d9bc982f-0989-4ad2-91c5-4a253e742969"
      unitRef="U_USD">-1557000</vir:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_27f51254-e864-4030-80c0-11b282dd6660"
      unitRef="U_USD">90452000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:IncreaseDecreaseInDeferredRevenue
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_4b59a80d-a42a-414e-a5c6-0e5b19b73dc0"
      unitRef="U_USD">-4011000</us-gaap:IncreaseDecreaseInDeferredRevenue>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_82902b12-f7df-4f75-b357-b48f32c37622"
      unitRef="U_USD">50529000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_b409b021-d93a-44a7-b9d9-9c3f267c722c"
      unitRef="U_USD">-59048000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_90823156-7d42-4b5d-b358-d31305379f85"
      unitRef="U_USD">2744000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_fb902c09-3c1d-4d6f-bec5-464f8bd6f981"
      unitRef="U_USD">2645000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_8cdfd834-5648-4078-8200-5c498360bcde"
      unitRef="U_USD">55729000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:PaymentsToAcquireInvestments
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_7b33c99c-76dc-4faf-9302-4137d7b3aa86"
      unitRef="U_USD">129899000</us-gaap:PaymentsToAcquireInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_5e8fe093-83a5-4ef9-b7f2-cd9c96ed2e86"
      unitRef="U_USD">221382000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_40431e90-9d8c-4541-82ac-0f58e2b32d2a"
      unitRef="U_USD">247168000</us-gaap:ProceedsFromSaleMaturityAndCollectionsOfInvestments>
    <us-gaap:ProceedsFromSaleOfPropertyHeldForSale
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_53959336-f4ac-4f6c-83ab-c0abf554b669"
      unitRef="U_USD">0</us-gaap:ProceedsFromSaleOfPropertyHeldForSale>
    <us-gaap:ProceedsFromSaleOfPropertyHeldForSale
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_557ec9e5-8491-43c6-a38a-3979528416c6"
      unitRef="U_USD">180000</us-gaap:ProceedsFromSaleOfPropertyHeldForSale>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_7f2b7ac5-9c1e-4a86-a949-0b2b14b5e038"
      unitRef="U_USD">162909000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_077bceb9-6012-4e7f-8dbc-80be96612d63"
      unitRef="U_USD">114804000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_7e3f6ce0-b70a-4697-a4fb-c60b7c239059"
      decimals="-3"
      id="F_7dc30800-2134-42c1-a590-5278cba84c83"
      unitRef="U_USD">85213000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_f41bf82e-773a-4ae8-995a-1851961c2803"
      decimals="-3"
      id="F_cab136fb-deb8-41aa-835d-b4472b2c511a"
      unitRef="U_USD">206699000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <vir:PaymentOfContingentConsideration
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_23ef4aa7-213d-4ce5-9787-39a2027e2fbb"
      unitRef="U_USD">0</vir:PaymentOfContingentConsideration>
    <vir:PaymentOfContingentConsideration
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_7c46e961-8b11-4d96-9ebc-41b0e2d54023"
      unitRef="U_USD">3547000</vir:PaymentOfContingentConsideration>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_1c879f6c-4b69-4538-8aad-3720df58f753"
      unitRef="U_USD">126000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:FinanceLeasePrincipalPayments
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_8048b3f3-5c72-40db-a2c4-705d3702039b"
      unitRef="U_USD">115000</us-gaap:FinanceLeasePrincipalPayments>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_e4a0574d-562b-4b7d-bfe8-0a60973bc27a"
      unitRef="U_USD">5945000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_fdc86b51-bac8-4cb6-b13f-3b2cec2122fb"
      unitRef="U_USD">2388000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_7d8aa132-4555-4d30-8686-16e2258388c9"
      unitRef="U_USD">91032000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_bdb8d69d-c483-433a-a739-2fc40414925d"
      unitRef="U_USD">205425000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_c306199d-4288-47ff-ac23-87b71ccbb6e0"
      unitRef="U_USD">304470000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_dc6eada3-7635-4ae9-9e46-65a1c83c6acb"
      unitRef="U_USD">261181000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_f79c9b49-3a86-4ec0-aa99-88fd6f3193ec"
      unitRef="U_USD">451487000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_2961edff-bc89-457f-97d0-23460c2e7059"
      decimals="-3"
      id="F_f9903555-270c-464d-8a0e-0b68fd790b7b"
      unitRef="U_USD">122816000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_b0c2697b-8a73-453b-b935-6a9a01c2c748"
      unitRef="U_USD">755957000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_e28f1ecf-80aa-4b09-b8ff-8c09db69a316"
      decimals="-3"
      id="F_980e47d6-e5bc-4e9d-85aa-020a073f09bc"
      unitRef="U_USD">383997000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_2d636b02-7616-48b0-b53d-045d637b6431"
      unitRef="U_USD">2485000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_bf95428e-c461-447b-a424-ed82236e856c"
      unitRef="U_USD">312000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_efad1a92-9200-4eda-817d-7991f022af97"
      unitRef="U_USD">0</vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone>
    <vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_c5cf8396-3c71-4143-b7af-802aef4ad2a8"
      unitRef="U_USD">29245000</vir:ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone>
    <vir:DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_a90c6357-978d-4190-8e2e-ffd51d0d35f4"
      unitRef="U_USD">0</vir:DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities>
    <vir:DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_cb92082c-a1e0-4ab7-85af-4ff46a7244a5"
      unitRef="U_USD">690000</vir:DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_53d80ac5-266d-482b-8b61-3586167b71e2"
      unitRef="U_USD">741951000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_e28f1ecf-80aa-4b09-b8ff-8c09db69a316"
      decimals="-3"
      id="F_9b9f4978-7977-4ee5-848a-0be0bf2f9b4e"
      unitRef="U_USD">371781000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_3188da4a-7641-43fd-a8ff-d100fb962882"
      unitRef="U_USD">7004000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue
      contextRef="C_e28f1ecf-80aa-4b09-b8ff-8c09db69a316"
      decimals="-3"
      id="F_f6a91405-a874-416a-84a5-ce94b096cdcc"
      unitRef="U_USD">11024000</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_432e6902-b44e-437f-a4eb-02925d38e43c"
      unitRef="U_USD">7002000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsNoncurrent
      contextRef="C_e28f1ecf-80aa-4b09-b8ff-8c09db69a316"
      decimals="-3"
      id="F_616c82de-2a93-458b-a8fb-f1cea097d46c"
      unitRef="U_USD">1192000</us-gaap:RestrictedCashAndCashEquivalentsNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_0f009362-d931-4f4b-a916-d3907e1b523e"
      unitRef="U_USD">755957000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_e28f1ecf-80aa-4b09-b8ff-8c09db69a316"
      decimals="-3"
      id="F_24f32ea4-19dd-44f0-9fab-96ebc5b9979c"
      unitRef="U_USD">383997000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_fac0ba40-36cd-4717-983e-b06d6a12effc">&lt;p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;1.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;	&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Organization&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vir Biotechnology, Inc. (&#x201c;Vir&#x201d; or the &#x201c;Company&#x201d;) is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Its development pipeline consists of product candidates targeting the current coronavirus disease 2019 (&#x201c;COVID-19&#x201d;), hepatitis B virus (&#x201c;HBV&#x201d;), influenza A virus, and human immunodeficiency virus (&#x201c;HIV&#x201d;). Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. In May 2021, the Company received an Emergency Use Authorization (&#x201c;EUA&#x201d;) from the U.S. Food and Drug Administration for sotrovimab (previously VIR-7831) for the treatment of&#160;mild-to-moderate&#160;COVID-19&#160;in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct&#160;SARS-CoV-2&#160;viral testing, and who are at high risk for progression to severe&#160;COVID-19,&#160;including hospitalization or death.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Follow-On Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On July 10, 2020, the Company issued and sold &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,214,285&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s common stock pursuant to a registration statement on Form S-1 (File No. 333-239689) and a registration statement on Form S-1 filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the &#x201c;Securities Act&#x201d;) (File No. 333-239747) (collectively, the &#x201c;Registration Statements&#x201d;). The Registration Statements became effective on July 7, 2020. The price of the shares sold in the follow-on offering was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;42.00&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share and the Company received total gross proceeds from the offering of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;345.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. After deducting underwriting discounts and commissions of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.7&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and offering expenses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.1&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, the net proceeds were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;323.2&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Sales Agreement&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In November 2020, the Company entered into a sales agreement (the &#x201c;Sales Agreement&#x201d;) with Cowen and Company, LLC (&#x201c;Cowen&#x201d;), under which the Company may from time to time offer and sell shares of its common stock, par value $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0001&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, having an aggregate offering price of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;300.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, through or to Cowen, acting as sales agent or principal. The shares will be offered and sold under the Company&#x2019;s shelf registration statement on Form S-3 and a related prospectus filed with the Securities and Exchange Commission (the &#x201c;SEC&#x201d;) on November 10, 2020. The Company will pay Cowen a commission of up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. As of June 30, 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares have been issued under the Sales Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Need for Additional Capital&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has incurred net losses since inception and expects such losses to continue over the next several years. As of June&#160;30, 2021, the Company had an accumulated deficit of &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;774.3&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Management expects to incur additional losses in the future to conduct research and development and recognizes the need to raise additional capital to fully implement its business plan. The Company had, excluding restricted cash, &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;876.7&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;of cash, cash equivalents, and investments at June&#160;30, 2021. Based on the Company&#x2019;s business plans, management believes that its cash, cash equivalents, and investments as of June&#160;30, 2021&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; will be sufficient to fund its operations for at least the next 12 months from the issuance date of these condensed consolidated financial statements.&lt;/span&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0db18e03-f55e-4678-9eaa-949bdcc27a33"
      decimals="INF"
      id="F_7aedc160-70b5-45b6-b6ab-907bfcddb45e"
      unitRef="U_shares">8214285</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_e1c1ce3e-6936-4e79-8e73-e9a37f058e7c"
      decimals="INF"
      id="F_298cc69e-a420-495b-9db8-418036c8015e"
      unitRef="U_USDollarShare">42.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_0db18e03-f55e-4678-9eaa-949bdcc27a33"
      decimals="-5"
      id="F_354fbbcc-fa76-49fc-9eae-039f63f027a8"
      unitRef="U_USD">345000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <vir:PaymentsOfUnderwritingDiscountsAndCommissions
      contextRef="C_0db18e03-f55e-4678-9eaa-949bdcc27a33"
      decimals="-5"
      id="F_09dd6ad9-8243-4d85-8e04-940428f8d8c5"
      unitRef="U_USD">20700000</vir:PaymentsOfUnderwritingDiscountsAndCommissions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="C_0db18e03-f55e-4678-9eaa-949bdcc27a33"
      decimals="-5"
      id="F_1cb92e87-6cec-4c35-a238-a0254738d4d3"
      unitRef="U_USD">1100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <vir:ProceedsFromIssuanceSecondaryPublicOffering
      contextRef="C_0db18e03-f55e-4678-9eaa-949bdcc27a33"
      decimals="-5"
      id="F_95cfa9ce-3d1e-498c-b591-e86c9bc206dc"
      unitRef="U_USD">323200000</vir:ProceedsFromIssuanceSecondaryPublicOffering>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_02faa5a7-4825-491e-950b-34ee5ddb4d0a"
      decimals="INF"
      id="F_adcb031b-cb0a-4fba-8b6a-22b9b253ec61"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <vir:SaleOfStockConsiderationAggregateOfferingPrice
      contextRef="C_aa261db7-a4b4-4b7f-9010-cd5b869abb50"
      decimals="-5"
      id="F_55648c16-8c00-40f4-8e9c-360f6cadfba8"
      unitRef="U_USD">300000000.0</vir:SaleOfStockConsiderationAggregateOfferingPrice>
    <vir:PercentageOfAggregateGrossProceedsFromSaleOfShares
      contextRef="C_aa261db7-a4b4-4b7f-9010-cd5b869abb50"
      decimals="3"
      id="F_2e44083e-c26e-4219-90cf-6c3c60f36807"
      unitRef="U_pure">0.030</vir:PercentageOfAggregateGrossProceedsFromSaleOfShares>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_425979e0-416e-4c32-9ffb-95870c96d614"
      decimals="INF"
      id="F_2a15f836-d015-45ca-8240-8244571228ed"
      unitRef="U_shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-5"
      id="F_ee82317f-285c-40b8-9dac-b2fae0f7d506"
      unitRef="U_USD">774300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:CashCashEquivalentsAndShortTermInvestments
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-5"
      id="F_150b4db2-e914-49dd-ad13-96e68f989da0"
      unitRef="U_USD">876700000</us-gaap:CashCashEquivalentsAndShortTermInvestments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_3efc098d-ac30-4bd6-8c34-6746b18e8454">&lt;p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;	&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and applicable rules and regulations of the SEC regarding interim financial reporting. The condensed consolidated financial statements include the accounts of Vir and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company&#x2019;s financial information. The condensed consolidated results of operations for the six months ended June&#160;30, 2021 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2021 or for any other future annual or interim period.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Certain information and footnote disclosures typically included in the Company&#x2019;s annual consolidated financial statements have been condensed or omitted. As such, these interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and related notes included in the Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on February 25, 2021.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expense during the reporting periods. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;With the global spread of the ongoing COVID-19 pandemic, the Company has implemented a number of plans and policies designed to address and mitigate the impact of the COVID-19 pandemic on its business. The Company anticipates that the COVID-19 pandemic will continue to have an impact on the clinical development timelines for some of its clinical programs. The extent to which the COVID-19 pandemic impacts the Company&#x2019;s business, clinical development and regulatory efforts, corporate development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States, Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In addition, the Company is subject to a number of other challenges and risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#x2019;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#x2019;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investments. Cash and cash equivalents are deposited in checking and sweep accounts at a financial institution. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments, and issuers of the investments to the extent recorded on the condensed consolidated balance sheets. As of June&#160;30, 2021, the Company has no off-balance sheet concentrations of credit risk.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is exposed to credit losses primarily through receivables from customers and collaborators and through its available-for-sale debt securities. The Company&#x2019;s expected loss allowance methodology for the receivables is developed using historical collection experience, current and future economic market conditions, a review of the current aging status and financial condition of the entities. Specific allowance amounts are established to record the appropriate allowance for customers that have a higher probability of default. Balances are written off when determined to be uncollectible. The Company&#x2019;s expected loss allowance methodology for the debt securities is developed by reviewing the extent of the unrealized loss, the size, term, geographical location, and industry of the issuer, the issuers&#x2019; credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers&#x2019; current status and financial condition. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted. During the six months ended June 30, 2021 and 2020, there was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; allowance for losses on available-for-sale debt securities attributable to credit risk.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Investments include available-for-sale debt securities and are carried at estimated fair value. The Company&#x2019;s valuations of marketable securities are generally derived from independent pricing services based on quoted prices in active markets for similar securities at period end. Generally, investments with original maturities beyond three months at the date of purchase and which mature at, or less than 12 months from, the condensed consolidated balance sheet date are considered short-term investments, with all others considered to be long-term investments. Unrealized gains and losses deemed temporary in nature are reported as a component of accumulated comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the condensed consolidated statements of operations. The Company&#x2019;s policy is not to measure an allowance for credit losses for interest receivable and to write off any uncollectible interest receivable as a reversal of interest income in the period in which it determines the interest will not be collected.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company, through its investment in Brii Biosciences Limited, holds privately held equity securities in which the Company does not have a controlling interest or significant influence. The Company&#x2019;s investment in Brii Biosciences Limited is recorded at cost and adjusted for impairments and observable price changes with the same or similar security from the same issuer. The valuation of the Company&#x2019;s investment in Brii Biosciences Limited utilizes significant unobservable inputs or data in an inactive market and the valuation requires the Company&#x2019;s judgment due to the absence of market prices and inherent lack of liquidity. Additionally, the determination of whether an orderly transaction is for the same or similar investment requires significant management judgment including the nature of the rights and obligations of its investments, the extent to which differences in those rights and obligations would affect the fair values of those investments, and the impact of any differences based on the stage of operational development of the investee. See Note 6&#x2014;Collaboration and License Agreements for additional information on the Company&#x2019;s investment in Brii Biosciences Limited.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Restricted Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash and cash equivalents represent money market funds to secure standby letters of credit and security deposits with financial institutions, both under office and laboratory space lease agreements. Additionally, funds received from certain grants are restricted as to their use and are therefore classified as restricted cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Collaboration, License and Contract Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;), the Company recognizes revenue when the Company&#x2019;s customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as the Company satisfies a performance obligation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For collaborative arrangements that fall within the scope of ASC 808, Collaborative Arrangements (&#x201c;ASC 808&#x201d;), the Company first determines which elements of the collaboration are deemed to be a performance obligation with a customer within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808 and are not subject to the guidance in ASC 606, the Company applies the revenue recognition model under ASC 606 or other guidance, as deemed appropriate. The Company has entered into a number of license and collaboration agreements that fall within the scope of ASC 606. The Company evaluates the promised goods or services in these agreements to determine which ones represent distinct performance obligations. These agreements may include the following types of promised goods or services: (i) grants of licenses, (ii) performance of research and development services, and (iii) participation on joint research and/or development committees. They also may include options to obtain licenses to the Company&#x2019;s intellectual property.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period as required. These agreements may include the following types of consideration: non-refundable upfront payments, reimbursement for research services, research, development or regulatory milestone payments, profit-sharing arrangements and royalty and commercial sales milestone payments.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on their estimated standalone selling prices (&#x201c;SSP&#x201d;). For performance obligations satisfied over time, the Company estimates the efforts needed to complete the performance obligation and recognizes revenue by measuring the progress towards complete satisfaction of the performance obligation using an input measure.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For arrangements that include sales-based royalties, including commercial milestone payments based on pre-specified level of sales, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon performance of the licensee.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Grant Revenue&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Grants received, including cost reimbursement agreements, are assessed to determine if the agreement should be accounted for as an exchange transaction or a contribution. An agreement is accounted for as a contribution if the resource provider does not receive commensurate value in return for the assets transferred. Contributions are recognized as grant revenue when all donor-imposed conditions have been met.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Acquisitions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date. Any excess fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with the business combination are recorded at their fair values on the acquisition date and are remeasured each subsequent reporting period until the related contingencies are resolved and are classified as contingent consideration on the condensed consolidated balance sheets. The changes in fair values of contingent consideration related to the achievement of various development milestones related to product candidates are recorded within research and development expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;When the Company determines that entities acquired do not meet the definition of a business, the transaction is accounted for as an acquisition of assets. Therefore, the consideration paid to acquire IPR&amp;amp;D is expensed, and no goodwill is recorded. Any contingent consideration is generally recognized only when it becomes payable or is paid.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Embedded Derivatives&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company evaluates its acquisitions, collaborative arrangements and other business development transactions to determine if embedded components of these contracts meet the definition of a derivative under ASC 815, Derivatives and Hedging. In general, embedded derivatives are required to be bifurcated from the host instrument if (i) the embedded feature is not clearly and closely related to the host contract and (ii) the embedded feature, if considered a freestanding instrument, meets the definition of a derivative. Embedded derivatives are reported on the condensed consolidated balance sheets at their estimated fair values. Contingent consideration related to asset acquisitions that meet the definition of an embedded derivative is classified as contingent consideration on the condensed consolidated balance sheets. Any change in estimated fair values, as determined at each measurement period, are recorded in the condensed consolidated statements of operations based on the nature of the related contingencies.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Changes in fair values of embedded derivatives related to the achievement of various development milestones for product candidates are recorded within research and development expense. Otherwise, changes in fair values are recorded within other income (expense), net.&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_cfe86cd7-b75c-43d4-8cb0-484a59b3f704">&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Basis of Presentation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#x201c;GAAP&#x201d;) and applicable rules and regulations of the SEC regarding interim financial reporting. The condensed consolidated financial statements include the accounts of Vir and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company&#x2019;s financial information. The condensed consolidated results of operations for the six months ended June&#160;30, 2021 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2021 or for any other future annual or interim period.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Certain information and footnote disclosures typically included in the Company&#x2019;s annual consolidated financial statements have been condensed or omitted. As such, these interim condensed consolidated financial statements should be read in conjunction with the Company&#x2019;s audited consolidated financial statements and related notes included in the Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on February 25, 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_f9ece578-7d78-4b55-9a72-f70c3b96774e">&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expense during the reporting periods. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.&lt;/span&gt;</us-gaap:UseOfEstimates>
    <vir:ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_34616645-87f2-4021-9385-04ff66ce0101">&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;With the global spread of the ongoing COVID-19 pandemic, the Company has implemented a number of plans and policies designed to address and mitigate the impact of the COVID-19 pandemic on its business. The Company anticipates that the COVID-19 pandemic will continue to have an impact on the clinical development timelines for some of its clinical programs. The extent to which the COVID-19 pandemic impacts the Company&#x2019;s business, clinical development and regulatory efforts, corporate development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States, Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In addition, the Company is subject to a number of other challenges and risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#x2019;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#x2019;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investments. Cash and cash equivalents are deposited in checking and sweep accounts at a financial institution. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments, and issuers of the investments to the extent recorded on the condensed consolidated balance sheets. As of June&#160;30, 2021, the Company has no off-balance sheet concentrations of credit risk.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is exposed to credit losses primarily through receivables from customers and collaborators and through its available-for-sale debt securities. The Company&#x2019;s expected loss allowance methodology for the receivables is developed using historical collection experience, current and future economic market conditions, a review of the current aging status and financial condition of the entities. Specific allowance amounts are established to record the appropriate allowance for customers that have a higher probability of default. Balances are written off when determined to be uncollectible. The Company&#x2019;s expected loss allowance methodology for the debt securities is developed by reviewing the extent of the unrealized loss, the size, term, geographical location, and industry of the issuer, the issuers&#x2019; credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers&#x2019; current status and financial condition. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted. During the six months ended June 30, 2021 and 2020, there was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; allowance for losses on available-for-sale debt securities attributable to credit risk.&lt;/span&gt;&lt;/p&gt;</vir:ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="INF"
      id="F_3edf5a50-befa-400b-817f-82ffe0e965e0"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss
      contextRef="C_e28f1ecf-80aa-4b09-b8ff-8c09db69a316"
      decimals="INF"
      id="F_8fac4759-5183-4eb4-8adc-b2ae8f616ba1"
      unitRef="U_USD">0</us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_74b7fcbd-8a64-4729-8c81-1a7e905eaa67">&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Investments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Investments include available-for-sale debt securities and are carried at estimated fair value. The Company&#x2019;s valuations of marketable securities are generally derived from independent pricing services based on quoted prices in active markets for similar securities at period end. Generally, investments with original maturities beyond three months at the date of purchase and which mature at, or less than 12 months from, the condensed consolidated balance sheet date are considered short-term investments, with all others considered to be long-term investments. Unrealized gains and losses deemed temporary in nature are reported as a component of accumulated comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the condensed consolidated statements of operations. The Company&#x2019;s policy is not to measure an allowance for credit losses for interest receivable and to write off any uncollectible interest receivable as a reversal of interest income in the period in which it determines the interest will not be collected.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company, through its investment in Brii Biosciences Limited, holds privately held equity securities in which the Company does not have a controlling interest or significant influence. The Company&#x2019;s investment in Brii Biosciences Limited is recorded at cost and adjusted for impairments and observable price changes with the same or similar security from the same issuer. The valuation of the Company&#x2019;s investment in Brii Biosciences Limited utilizes significant unobservable inputs or data in an inactive market and the valuation requires the Company&#x2019;s judgment due to the absence of market prices and inherent lack of liquidity. Additionally, the determination of whether an orderly transaction is for the same or similar investment requires significant management judgment including the nature of the rights and obligations of its investments, the extent to which differences in those rights and obligations would affect the fair values of those investments, and the impact of any differences based on the stage of operational development of the investee. See Note 6&#x2014;Collaboration and License Agreements for additional information on the Company&#x2019;s investment in Brii Biosciences Limited.&lt;/span&gt;&lt;/p&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_65b4f3ff-9527-4ed4-ae8c-b0624f621627">&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Restricted Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash and cash equivalents represent money market funds to secure standby letters of credit and security deposits with financial institutions, both under office and laboratory space lease agreements. Additionally, funds received from certain grants are restricted as to their use and are therefore classified as restricted cash and cash equivalents.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_bd5985c6-2039-4505-9317-7be8eee6d13b">&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Collaboration, License and Contract Revenue&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) Topic 606, Revenue from Contracts with Customers (&#x201c;ASC 606&#x201d;), the Company recognizes revenue when the Company&#x2019;s customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as the Company satisfies a performance obligation.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For collaborative arrangements that fall within the scope of ASC 808, Collaborative Arrangements (&#x201c;ASC 808&#x201d;), the Company first determines which elements of the collaboration are deemed to be a performance obligation with a customer within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808 and are not subject to the guidance in ASC 606, the Company applies the revenue recognition model under ASC 606 or other guidance, as deemed appropriate. The Company has entered into a number of license and collaboration agreements that fall within the scope of ASC 606. The Company evaluates the promised goods or services in these agreements to determine which ones represent distinct performance obligations. These agreements may include the following types of promised goods or services: (i) grants of licenses, (ii) performance of research and development services, and (iii) participation on joint research and/or development committees. They also may include options to obtain licenses to the Company&#x2019;s intellectual property.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period as required. These agreements may include the following types of consideration: non-refundable upfront payments, reimbursement for research services, research, development or regulatory milestone payments, profit-sharing arrangements and royalty and commercial sales milestone payments.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on their estimated standalone selling prices (&#x201c;SSP&#x201d;). For performance obligations satisfied over time, the Company estimates the efforts needed to complete the performance obligation and recognizes revenue by measuring the progress towards complete satisfaction of the performance obligation using an input measure.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For arrangements that include sales-based royalties, including commercial milestone payments based on pre-specified level of sales, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon performance of the licensee.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Grant Revenue&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Grants received, including cost reimbursement agreements, are assessed to determine if the agreement should be accounted for as an exchange transaction or a contribution. An agreement is accounted for as a contribution if the resource provider does not receive commensurate value in return for the assets transferred. Contributions are recognized as grant revenue when all donor-imposed conditions have been met.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_cab72e5c-f6fe-4da5-a06b-b98bbb36cd8c">&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Acquisitions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process research and development (&#x201c;IPR&amp;amp;D&#x201d;) projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date. Any excess fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with the business combination are recorded at their fair values on the acquisition date and are remeasured each subsequent reporting period until the related contingencies are resolved and are classified as contingent consideration on the condensed consolidated balance sheets. The changes in fair values of contingent consideration related to the achievement of various development milestones related to product candidates are recorded within research and development expense.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;When the Company determines that entities acquired do not meet the definition of a business, the transaction is accounted for as an acquisition of assets. Therefore, the consideration paid to acquire IPR&amp;amp;D is expensed, and no goodwill is recorded. Any contingent consideration is generally recognized only when it becomes payable or is paid.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:DerivativesEmbeddedDerivatives
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_0a114bc5-03b8-4723-bc85-c80b134d1857">&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Embedded Derivatives&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company evaluates its acquisitions, collaborative arrangements and other business development transactions to determine if embedded components of these contracts meet the definition of a derivative under ASC 815, Derivatives and Hedging. In general, embedded derivatives are required to be bifurcated from the host instrument if (i) the embedded feature is not clearly and closely related to the host contract and (ii) the embedded feature, if considered a freestanding instrument, meets the definition of a derivative. Embedded derivatives are reported on the condensed consolidated balance sheets at their estimated fair values. Contingent consideration related to asset acquisitions that meet the definition of an embedded derivative is classified as contingent consideration on the condensed consolidated balance sheets. Any change in estimated fair values, as determined at each measurement period, are recorded in the condensed consolidated statements of operations based on the nature of the related contingencies.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Changes in fair values of embedded derivatives related to the achievement of various development milestones for product candidates are recorded within research and development expense. Otherwise, changes in fair values are recorded within other income (expense), net.&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:DerivativesEmbeddedDerivatives>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_490031e3-c37c-4cc6-8f24-52f0bea4cce9">&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:8.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;3.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;	&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair Value Measurements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;text-indent:-18.0pt;padding-left:18.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Symbol;"&gt;&#xf0b7;	&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level&#160;1: Inputs which include quoted prices in active markets for identical assets and liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;text-indent:-18.0pt;padding-left:18.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Symbol;"&gt;&#xf0b7;	&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level&#160;2: Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.5pt;text-indent:-18.0pt;padding-left:18.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Symbol;"&gt;&#xf0b7;	&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level&#160;3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The carrying amounts of the Company&#x2019;s financial instruments, including accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following tables summarize the Company&#x2019;s Level 1 and Level 2 financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.806%;"/&gt;
        &lt;td style="width:1.083%;"/&gt;
        &lt;td style="width:9.963%;"/&gt;
        &lt;td style="width:1.083%;"/&gt;
        &lt;td style="width:1.037%;"/&gt;
        &lt;td style="width:7.917%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.083%;"/&gt;
        &lt;td style="width:1.037%;"/&gt;
        &lt;td style="width:7.917%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.083%;"/&gt;
        &lt;td style="width:1.037%;"/&gt;
        &lt;td style="width:7.917%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.083%;"/&gt;
        &lt;td style="width:1.037%;"/&gt;
        &lt;td style="width:7.917%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;June&#160;30, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Valuation&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);top:-4.6899999999999995pt;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;739,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;739,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Bank time deposits&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. government treasuries&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);top:-4.6899999999999995pt;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;129,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;129,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;874,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;874,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:5.5in;text-align:left;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-13.5pt;padding-left:13.5pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;(1)	&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;Includes &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;14.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; of restricted cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-13.5pt;padding-left:13.5pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;(2)	&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;Includes $&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;50.7&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; million classified as long-term investments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.769%;"/&gt;
        &lt;td style="width:1.083%;"/&gt;
        &lt;td style="width:9.954%;"/&gt;
        &lt;td style="width:1.083%;"/&gt;
        &lt;td style="width:1.037%;"/&gt;
        &lt;td style="width:7.907%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.083%;"/&gt;
        &lt;td style="width:1.037%;"/&gt;
        &lt;td style="width:7.907%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.083%;"/&gt;
        &lt;td style="width:1.037%;"/&gt;
        &lt;td style="width:7.907%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.083%;"/&gt;
        &lt;td style="width:1.037%;"/&gt;
        &lt;td style="width:7.991%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Valuation&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);top:-4.6899999999999995pt;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;Level 1&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;421,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;421,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. government treasuries&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;Level 2&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;300,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;300,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;722,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;722,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:-13.5pt;padding-left:13.5pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;(1)	&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;Includes $&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;14.9&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;million of restricted cash equivalents.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-13.5pt;padding-left:13.5pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;	 &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued interest receivable excluded from both the fair value and amortized cost basis of the available-for-sale securities is presented within prepaid expenses and other current assets, and other assets in the condensed consolidated balance sheets, and amounted to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;June&#160;30, 2021&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and December 31, 2020, respectively. The Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t write off any accrued interest receivable during the six months ended June 30, 2021 and 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of June&#160;30, 2021, there were no investments that have been in a continuous unrealized loss position for longer than 12 months. Total net unrealized gains recorded in accumulated other comprehensive income (loss) were immaterial at June&#160;30, 2021. All investments with gross unrealized losses as of June 30, 2021 have been in a loss position for less than 12 months and were temporary in nature. The Company currently does not intend, and it is highly unlikely that it will be required to sell these securities before recovery of their amortized cost basis. As of June&#160;30, 2021&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, no securities have contractual maturities of longer than&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; two years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 3 liabilities consist of contingent consideration as of June&#160;30, 2021 and December 31, 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Contingent Consideration&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Contingent consideration includes potential milestone payments in connection with the acquisitions of Humabs Biomed SA (&#x201c;Humabs&#x201d;) and TomegaVax, Inc. (&#x201c;TomegaVax&#x201d;). See further discussion in Note 4&#x2014;Acquisitions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;estimated fair value of the contingent consideration related to the Humabs acquisition was determined by calculating the probability-weighted clinical, regulatory and commercial milestone payments based on the assessment of the likelihood and estimated&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;timing &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;that certain milestones would be achieved. &lt;/span&gt;&lt;span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;June&#160;30, 2021, the Company calculated the estimated fair value of the clinical and regulatory milestones using the following significant unobservable inputs: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.062%;"/&gt;
        &lt;td style="width:2.562%;"/&gt;
        &lt;td style="width:32.377%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unobservable input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Range&lt;br/&gt;(Weighted-Average)&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);top:-3.752pt;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Discount rates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% (&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%)&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Probability of achievement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% (&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;62&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%)&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:5.000000000000004E-4in;display:flex;margin-top:0.0pt;line-height:1.2620833333333334;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.1875in;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.1875in;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;Unobservable inputs were weighted based on the relative fair value of the clinical and regulatory milestone payments.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For the commercial milestones, the Company used a Monte Carlo simulation because of the availability of a discrete revenue forecast and the increased likelihood that the clinical trials would commence. &lt;/span&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;June&#160;30, 2021, the Monte Carlo simulation assumed a commercial product launch and associated discrete revenue forecast, as well as the following significant unobservable inputs: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.062%;"/&gt;
        &lt;td style="width:2.562%;"/&gt;
        &lt;td style="width:32.377%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unobservable input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Value or Range&lt;br/&gt;(Weighted-Average)&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);top:-3.752pt;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Volatility&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Probability of achievement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% (&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;66&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%)&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="margin-left:5.000000000000004E-4in;display:flex;margin-top:0.0pt;line-height:1.2620833333333334;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.1875in;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.1875in;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;Unobservable inputs were weighted based on the relative fair value of the commercial milestone payments.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The discount rate captures the credit risk associated with the payment of the contingent consideration when earned and due. As of June&#160;30, 2021 and December&#160;31, 2020&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the estimated fair value of the contingent consideration related to the Humabs acquisition was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;62.5&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29.2&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, with changes in the estimated fair value recorded in research and development expense in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The estimated fair value of the contingent consideration related to the TomegaVax acquisition was determined by using a Monte Carlo simulation model which included estimates of both the probability and timing to achieve the required per-share price of the Company&#x2019;s common stock, and incorporates assumptions as to expected volatility and discount rate. The discount rate captures the credit risk associated with the payment of the contingent consideration when earned and due. Although the TomegaVax acquisition was accounted for as an asset acquisition, such contingent consideration met the definition of an embedded derivative financial instrument. In February 2021, the Company achieved one of the milestones related to a specified per-share price of its common stock resulting in a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million payable to the former TomegaVax&#x2019;s stockholders which was paid out in July 2021. &lt;/span&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;June&#160;30, 2021, the fair value of the remaining contingent consideration was estimated using the following significant unobservable inputs:&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.062%;"/&gt;
        &lt;td style="width:2.562%;"/&gt;
        &lt;td style="width:32.377%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unobservable input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Value or Range&lt;br/&gt;(Weighted-Average)&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);top:-3.752pt;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;95&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Discount rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% (&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%)&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:5.000000000000004E-4in;display:flex;margin-top:0.0pt;line-height:1.2620833333333334;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.1875in;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.1875in;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;Unobservable inputs were weighted based on the relative fair value of the underlying milestones. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of June&#160;30, 2021 and December&#160;31, 2020&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the estimated fair value of the contingent consideration related to the TomegaVax acquisition was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.4&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.8&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, with changes in the estimated fair value recorded in other income (expense), net in the condensed consolidated statements of operations.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The estimated fair value of the contingent consideration related to the Humabs and TomegaVax acquisitions involves significant estimates and assumptions which give rise to measurement uncertainty.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table sets forth the changes in the estimated fair value of the Company&#x2019;s Level&#160;3 financial liabilities (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:76.563%;"/&gt;
        &lt;td style="width:1.25%;"/&gt;
        &lt;td style="width:1.25%;"/&gt;
        &lt;td style="width:19.942%;"/&gt;
        &lt;td style="width:0.995%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Contingent&lt;br/&gt;Consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Changes in fair value recognized in research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Changes in fair value recognized in other income (expense), net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Reclassification of contingent consideration to accrued liabilities upon &lt;br/&gt;&#160;&#160;achievement of milestone&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;68,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_c7fb710c-9a15-4753-80ce-33d4761ec5f7">&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following tables summarize the Company&#x2019;s Level 1 and Level 2 financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.806%;"/&gt;
        &lt;td style="width:1.083%;"/&gt;
        &lt;td style="width:9.963%;"/&gt;
        &lt;td style="width:1.083%;"/&gt;
        &lt;td style="width:1.037%;"/&gt;
        &lt;td style="width:7.917%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.083%;"/&gt;
        &lt;td style="width:1.037%;"/&gt;
        &lt;td style="width:7.917%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.083%;"/&gt;
        &lt;td style="width:1.037%;"/&gt;
        &lt;td style="width:7.917%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.083%;"/&gt;
        &lt;td style="width:1.037%;"/&gt;
        &lt;td style="width:7.917%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;June&#160;30, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Valuation&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);top:-4.6899999999999995pt;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;739,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;739,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Bank time deposits&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. government treasuries&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);top:-4.6899999999999995pt;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;(2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;129,786&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;129,787&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;874,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;874,073&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:5.5in;text-align:left;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-13.5pt;padding-left:13.5pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;(1)	&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;Includes &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;14.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; of restricted cash equivalents.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-13.5pt;padding-left:13.5pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;(2)	&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;Includes $&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;50.7&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; million classified as long-term investments.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:44.769%;"/&gt;
        &lt;td style="width:1.083%;"/&gt;
        &lt;td style="width:9.954%;"/&gt;
        &lt;td style="width:1.083%;"/&gt;
        &lt;td style="width:1.037%;"/&gt;
        &lt;td style="width:7.907%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.083%;"/&gt;
        &lt;td style="width:1.037%;"/&gt;
        &lt;td style="width:7.907%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.083%;"/&gt;
        &lt;td style="width:1.037%;"/&gt;
        &lt;td style="width:7.907%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.083%;"/&gt;
        &lt;td style="width:1.037%;"/&gt;
        &lt;td style="width:7.991%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Valuation&lt;br/&gt;Hierarchy&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Gross&lt;br/&gt;Unrealized&lt;br/&gt;Holding&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);top:-4.6899999999999995pt;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;Level 1&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;421,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;421,835&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;U.S. government treasuries&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;Level 2&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;300,201&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;300,286&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total financial assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;722,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;91&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;722,121&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;(1)	&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;Includes $&lt;/span&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;14.9&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;million of restricted cash equivalents.&lt;/span&gt;</us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock>
    <vir:FinancialAssetsAmortizedCostBasis
      contextRef="C_93449051-f049-49fc-bbdb-95aeef0d2e9a"
      decimals="-3"
      id="F_56109b05-5ebc-4f11-b821-ed99759c2371"
      unitRef="U_USD">739286000</vir:FinancialAssetsAmortizedCostBasis>
    <vir:FinancialAssetsFairValue
      contextRef="C_93449051-f049-49fc-bbdb-95aeef0d2e9a"
      decimals="-3"
      id="F_6773aded-723c-495c-83b9-6854a1396b26"
      unitRef="U_USD">739286000</vir:FinancialAssetsFairValue>
    <vir:FinancialAssetsAmortizedCostBasis
      contextRef="C_0df1d4d3-33f9-423e-ba29-51df45853b5a"
      decimals="-3"
      id="F_d8c1597d-c0ec-49aa-9a3e-f0cb08857084"
      unitRef="U_USD">5000000</vir:FinancialAssetsAmortizedCostBasis>
    <vir:FinancialAssetsFairValue
      contextRef="C_0df1d4d3-33f9-423e-ba29-51df45853b5a"
      decimals="-3"
      id="F_25655252-b2ca-4d40-be97-5ce334ef0fe8"
      unitRef="U_USD">5000000</vir:FinancialAssetsFairValue>
    <vir:FinancialAssetsAmortizedCostBasis
      contextRef="C_c95fa8bf-5f9a-4eec-9c84-72c03b21861f"
      decimals="-3"
      id="F_e1d45d63-d79c-4ab1-8c89-4be796dbbcd7"
      unitRef="U_USD">129786000</vir:FinancialAssetsAmortizedCostBasis>
    <vir:FinancialAssetsGrossUnrealizedHoldingGains
      contextRef="C_c95fa8bf-5f9a-4eec-9c84-72c03b21861f"
      decimals="-3"
      id="F_27166cde-7091-4715-bef5-9da941265164"
      unitRef="U_USD">8000</vir:FinancialAssetsGrossUnrealizedHoldingGains>
    <vir:FinancialAssetsGrossUnrealizedHoldingLosses
      contextRef="C_c95fa8bf-5f9a-4eec-9c84-72c03b21861f"
      decimals="-3"
      id="F_bd6a27fd-8bca-4f9b-b2b4-7aca9663363e"
      unitRef="U_USD">7000</vir:FinancialAssetsGrossUnrealizedHoldingLosses>
    <vir:FinancialAssetsFairValue
      contextRef="C_c95fa8bf-5f9a-4eec-9c84-72c03b21861f"
      decimals="-3"
      id="F_bbaff870-ba24-4b6f-84f4-7aa037d1f56c"
      unitRef="U_USD">129787000</vir:FinancialAssetsFairValue>
    <vir:FinancialAssetsAmortizedCostBasis
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_d0446052-87fe-4303-a2e9-68d6a2824f31"
      unitRef="U_USD">874072000</vir:FinancialAssetsAmortizedCostBasis>
    <vir:FinancialAssetsGrossUnrealizedHoldingGains
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_a9376c8b-9928-4b15-a97b-cd1493ac9aee"
      unitRef="U_USD">8000</vir:FinancialAssetsGrossUnrealizedHoldingGains>
    <vir:FinancialAssetsGrossUnrealizedHoldingLosses
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_d128886a-4482-44ed-814b-caa53d97813e"
      unitRef="U_USD">7000</vir:FinancialAssetsGrossUnrealizedHoldingLosses>
    <vir:FinancialAssetsFairValue
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_d256fab2-b668-4efc-be33-94c364dde756"
      unitRef="U_USD">874073000</vir:FinancialAssetsFairValue>
    <us-gaap:RestrictedCashEquivalents
      contextRef="C_93449051-f049-49fc-bbdb-95aeef0d2e9a"
      decimals="-5"
      id="F_341fa000-8a0a-45a2-9676-a4a39b5671b1"
      unitRef="U_USD">14000000.0</us-gaap:RestrictedCashEquivalents>
    <us-gaap:LongTermInvestments
      contextRef="C_c95fa8bf-5f9a-4eec-9c84-72c03b21861f"
      decimals="-5"
      id="F_d68c8b22-8d0a-4652-8d2f-00783938b0ac"
      unitRef="U_USD">50700000</us-gaap:LongTermInvestments>
    <vir:FinancialAssetsAmortizedCostBasis
      contextRef="C_a5f22e22-a17d-48d9-87ec-0cc77e37762d"
      decimals="-3"
      id="F_5b0ce1b2-dad8-4280-9da4-923155a0d87d"
      unitRef="U_USD">421835000</vir:FinancialAssetsAmortizedCostBasis>
    <vir:FinancialAssetsFairValue
      contextRef="C_a5f22e22-a17d-48d9-87ec-0cc77e37762d"
      decimals="-3"
      id="F_a30731d5-b26d-4d84-aaf8-d60f6fae99ba"
      unitRef="U_USD">421835000</vir:FinancialAssetsFairValue>
    <vir:FinancialAssetsAmortizedCostBasis
      contextRef="C_503f5c65-589f-45e0-a4cb-0b480e0d8198"
      decimals="-3"
      id="F_4bdb1be1-61fe-419a-a0fb-9efef2064aa7"
      unitRef="U_USD">300201000</vir:FinancialAssetsAmortizedCostBasis>
    <vir:FinancialAssetsGrossUnrealizedHoldingGains
      contextRef="C_503f5c65-589f-45e0-a4cb-0b480e0d8198"
      decimals="-3"
      id="F_5a5a5a9e-44a9-448f-b474-9427559a097b"
      unitRef="U_USD">91000</vir:FinancialAssetsGrossUnrealizedHoldingGains>
    <vir:FinancialAssetsGrossUnrealizedHoldingLosses
      contextRef="C_503f5c65-589f-45e0-a4cb-0b480e0d8198"
      decimals="-3"
      id="F_e2fcabb4-a74f-44a2-a78e-44981a645e84"
      unitRef="U_USD">6000</vir:FinancialAssetsGrossUnrealizedHoldingLosses>
    <vir:FinancialAssetsFairValue
      contextRef="C_503f5c65-589f-45e0-a4cb-0b480e0d8198"
      decimals="-3"
      id="F_62003c5b-98d0-4646-9c2c-37babd12343d"
      unitRef="U_USD">300286000</vir:FinancialAssetsFairValue>
    <vir:FinancialAssetsAmortizedCostBasis
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_18cdab36-d4e5-43c5-b7db-4b144a08f0ae"
      unitRef="U_USD">722036000</vir:FinancialAssetsAmortizedCostBasis>
    <vir:FinancialAssetsGrossUnrealizedHoldingGains
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_c28791e4-69f2-4cbe-ac0c-72839651d1f2"
      unitRef="U_USD">91000</vir:FinancialAssetsGrossUnrealizedHoldingGains>
    <vir:FinancialAssetsGrossUnrealizedHoldingLosses
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_a952460e-2f80-4a8c-a9a0-922da2613f72"
      unitRef="U_USD">6000</vir:FinancialAssetsGrossUnrealizedHoldingLosses>
    <vir:FinancialAssetsFairValue
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_34bd542a-b913-4dff-a48f-1ec9325a82a1"
      unitRef="U_USD">722121000</vir:FinancialAssetsFairValue>
    <us-gaap:RestrictedCashEquivalents
      contextRef="C_a5f22e22-a17d-48d9-87ec-0cc77e37762d"
      decimals="-5"
      id="F_dcd1ca55-e6bd-4725-bf17-df78ae4cae08"
      unitRef="U_USD">14900000</us-gaap:RestrictedCashEquivalents>
    <us-gaap:InterestReceivable
      contextRef="C_5cba9a1a-7684-4b5b-9e26-eb24c2aeb651"
      decimals="-5"
      id="F_7993b6af-1aa9-4d95-8a20-945d6a216bfe"
      unitRef="U_USD">600000</us-gaap:InterestReceivable>
    <us-gaap:InterestReceivable
      contextRef="C_d42ac1db-ea33-4759-bbf7-4fa64295c694"
      decimals="-5"
      id="F_9cd5ecac-21aa-487b-893e-3dc20c4f7c0f"
      unitRef="U_USD">800000</us-gaap:InterestReceivable>
    <us-gaap:FinancingReceivableAccruedInterestWriteoff
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_d8dc962a-f70d-4e80-a052-5ba848d2f6ac"
      unitRef="U_USD">0</us-gaap:FinancingReceivableAccruedInterestWriteoff>
    <us-gaap:FinancingReceivableAccruedInterestWriteoff
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_c1e03ab9-d79c-4c1e-b165-52c11a44c65d"
      unitRef="U_USD">0</us-gaap:FinancingReceivableAccruedInterestWriteoff>
    <us-gaap:DebtSecuritiesAvailableForSaleTerm
      contextRef="C_7073499b-8aca-4a83-ae2c-8686d7874fe9"
      id="F_ad680609-2c31-4ffc-be09-d73962caf992">P2Y</us-gaap:DebtSecuritiesAvailableForSaleTerm>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="C_2aa1b8d8-ce49-419f-80ad-d249064f51e3"
      id="F_44606458-4835-4e14-83e1-afd53b9a1399">&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;June&#160;30, 2021, the Company calculated the estimated fair value of the clinical and regulatory milestones using the following significant unobservable inputs: &lt;/span&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.062%;"/&gt;
        &lt;td style="width:2.562%;"/&gt;
        &lt;td style="width:32.377%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unobservable input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Range&lt;br/&gt;(Weighted-Average)&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);top:-3.752pt;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Discount rates&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% (&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%)&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Probability of achievement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% (&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;62&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%)&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:5.000000000000004E-4in;display:flex;margin-top:0.0pt;line-height:1.2620833333333334;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.1875in;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.1875in;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;Unobservable inputs were weighted based on the relative fair value of the clinical and regulatory milestone payments.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_f7017d66-420f-462d-adcf-f3fb86e73c23"
      decimals="2"
      id="F_eedf6555-c570-477d-8f16-8cdd93f9b39b"
      unitRef="U_pure">0.04</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_8a64e883-900d-492a-b0a8-528b6645aa64"
      decimals="2"
      id="F_dfeb5c11-f6ec-465e-a911-219ce65c2da1"
      unitRef="U_pure">0.08</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_d0832ce6-8218-4bd2-a0a0-9ac172d5777a"
      decimals="2"
      id="F_9c009c67-e6f6-4098-8951-601312e1939e"
      unitRef="U_pure">0.05</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_943aaa7d-bd8e-4ac3-a401-aaa53e6c2044"
      decimals="2"
      id="F_a0a30f24-aca0-4941-9090-570e22369935"
      unitRef="U_pure">0.21</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_6a378198-8973-420d-8130-5f606a6b57c5"
      decimals="2"
      id="F_00c871dd-ddfa-4fa3-8f32-e1ee2e31543e"
      unitRef="U_pure">0.76</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_7fcc913c-909b-4375-aabd-561f445a0b0f"
      decimals="2"
      id="F_bb4b78ac-feb8-4c7b-915d-f82d5be6e70c"
      unitRef="U_pure">0.62</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="C_ea616198-c6e1-442a-bb05-ddf05a1b5bc8"
      id="F_09359b81-1c1a-4cdd-80fc-b3b1ae55f730">&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;June&#160;30, 2021, the Monte Carlo simulation assumed a commercial product launch and associated discrete revenue forecast, as well as the following significant unobservable inputs: &lt;/span&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.062%;"/&gt;
        &lt;td style="width:2.562%;"/&gt;
        &lt;td style="width:32.377%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unobservable input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Value or Range&lt;br/&gt;(Weighted-Average)&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);top:-3.752pt;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Volatility&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Discount rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Probability of achievement&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% (&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;66&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%)&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;Unobservable inputs were weighted based on the relative fair value of the commercial milestone payments.&lt;/span&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_8482726a-4650-4001-aa57-337a908bb4ee"
      decimals="2"
      id="F_3fc0effe-077a-457b-be78-cd81563ae0e9"
      unitRef="U_pure">0.60</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_ec0ee7d1-1e16-4d9f-82e9-4d32b4f67282"
      decimals="2"
      id="F_daff6193-bbf4-476a-9d8a-157d74ee8503"
      unitRef="U_pure">0.11</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_4e1a0849-5b76-49b5-9f9a-4c78c1961b02"
      decimals="2"
      id="F_860b67b2-83e8-45e4-a820-8df4f2b81016"
      unitRef="U_pure">0.21</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_c6864edf-79da-4827-8feb-994154b4369a"
      decimals="2"
      id="F_a9ff057e-0024-4020-9739-bf0e4099abee"
      unitRef="U_pure">0.76</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput
      contextRef="C_b3b3b775-48e3-4d0e-8077-eeeff976fb8e"
      decimals="2"
      id="F_3584cc21-6d37-4ef6-87ac-6540b38c433d"
      unitRef="U_pure">0.66</us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_f54bf625-9153-4033-9112-6b27a3bd3803"
      decimals="-5"
      id="F_6486320d-6edc-411e-a7a2-563a87e28f02"
      unitRef="U_USD">62500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_7a088139-2add-4c37-8158-c3dc9538d2fe"
      decimals="-5"
      id="F_7b7437be-3789-4096-b51b-64190a6309fa"
      unitRef="U_USD">29200000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_782d1920-e03d-4185-85d4-a0abdc3fe2bc"
      decimals="-5"
      id="F_869a7a0a-f8c4-4221-b67e-f7b09cd64920"
      unitRef="U_USD">10000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock
      contextRef="C_f678eb79-9e2a-44ae-9e54-e1a433974f29"
      id="F_215deb6b-ad56-4b6d-834a-89e4dec3baba">&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;June&#160;30, 2021, the fair value of the remaining contingent consideration was estimated using the following significant unobservable inputs:&lt;/span&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.062%;"/&gt;
        &lt;td style="width:2.562%;"/&gt;
        &lt;td style="width:32.377%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unobservable input&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Value or Range&lt;br/&gt;(Weighted-Average)&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);top:-3.752pt;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;95&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Discount rates&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% (&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%)&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:5.000000000000004E-4in;display:flex;margin-top:0.0pt;line-height:1.2620833333333334;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.1875in;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.1875in;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;Unobservable inputs were weighted based on the relative fair value of the underlying milestones. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock>
    <us-gaap:EmbeddedDerivativeLiabilityMeasurementInput
      contextRef="C_f8e1feaf-38cf-4eb8-be71-a6d9ca4cc72d"
      decimals="2"
      id="F_27fda7ed-591d-4518-af47-9f573ab1e5ce"
      unitRef="U_pure">0.95</us-gaap:EmbeddedDerivativeLiabilityMeasurementInput>
    <us-gaap:EmbeddedDerivativeLiabilityMeasurementInput
      contextRef="C_1f8aa1e7-f35e-48bb-afdc-73dd30c26626"
      decimals="2"
      id="F_18a16493-faf3-428a-b4fb-7c6f1cc4f093"
      unitRef="U_pure">0</us-gaap:EmbeddedDerivativeLiabilityMeasurementInput>
    <us-gaap:EmbeddedDerivativeLiabilityMeasurementInput
      contextRef="C_61e10aad-3a2a-4489-b640-a9768ebb4c27"
      decimals="3"
      id="F_e80ccab1-add9-4c97-91bd-79f96dd448ef"
      unitRef="U_pure">0.001</us-gaap:EmbeddedDerivativeLiabilityMeasurementInput>
    <us-gaap:EmbeddedDerivativeLiabilityMeasurementInput
      contextRef="C_20e142d1-b753-47f7-9ab1-dd536e70a74d"
      decimals="3"
      id="F_0e373577-f4ac-45f8-9fe7-66848eeef012"
      unitRef="U_pure">0.001</us-gaap:EmbeddedDerivativeLiabilityMeasurementInput>
    <vir:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_d67bc640-0ce6-494e-ad6f-32b76b35dc04"
      decimals="-5"
      id="F_71c9ff3f-ae7f-4497-8539-7eb4cf98d9b0"
      unitRef="U_USD">6400000</vir:AssetAcquisitionContingentConsiderationLiability>
    <vir:AssetAcquisitionContingentConsiderationLiability
      contextRef="C_492c3181-e320-4bbf-9047-04048449d863"
      decimals="-5"
      id="F_aa13f9bf-0bf3-4c69-bf16-a589d5a8769a"
      unitRef="U_USD">6800000</vir:AssetAcquisitionContingentConsiderationLiability>
    <us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_399c5229-84c2-45c6-8cfd-234d2841c2fc">&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table sets forth the changes in the estimated fair value of the Company&#x2019;s Level&#160;3 financial liabilities (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:76.563%;"/&gt;
        &lt;td style="width:1.25%;"/&gt;
        &lt;td style="width:1.25%;"/&gt;
        &lt;td style="width:19.942%;"/&gt;
        &lt;td style="width:0.995%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Contingent&lt;br/&gt;Consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35,974&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Changes in fair value recognized in research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;33,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Changes in fair value recognized in other income (expense), net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,618&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Reclassification of contingent consideration to accrued liabilities upon &lt;br/&gt;&#160;&#160;achievement of milestone&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at June 30, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;68,892&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_8d26edc6-7745-4758-988b-eb4ba800efed"
      decimals="-3"
      id="F_0b1d2899-3aab-4bff-bdc6-4447c22c82b4"
      unitRef="U_USD">35974000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="C_53ccc202-bb29-4485-bc6c-689015df256e"
      decimals="-3"
      id="F_94dfd76e-01a4-4902-9a37-7c808931c835"
      unitRef="U_USD">33300000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease
      contextRef="C_6d69c128-4e88-4988-9333-0cfb938c1233"
      decimals="-3"
      id="F_175db0b0-ebc8-4a9b-bc68-1ed998518903"
      unitRef="U_USD">9618000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease>
    <vir:FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone
      contextRef="C_95a77a5d-c658-44c7-bb81-77f5350143bd"
      decimals="-3"
      id="F_5eceb5bd-b911-428d-a9d4-83add358890f"
      unitRef="U_USD">-10000000</vir:FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue
      contextRef="C_50d30b84-60dd-41c6-9dc3-a2fcb990166c"
      decimals="-3"
      id="F_9def618c-b995-4e1a-b3a4-a8c3ab02a5f9"
      unitRef="U_USD">68892000</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_2535cd7d-9993-4cb7-9c26-2658f3e26700">&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;4.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;	&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Acquisitions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Acquisition of TomegaVax&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In September 2016, the Company entered into an agreement and plan of merger (&#x201c;TomegaVax Merger Agreement&#x201d;) to acquire all of the equity interests of TomegaVax. The primary asset purchased in the acquisition was an in-process cytomegalovirus vector-based vaccine platform for use in HBV, HIV, and tuberculosis. The acquisition was accounted for as an asset purchase.  &#160;&#160;&#160;&#160;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the entry into the TomegaVax Merger Agreement, the Company also entered into a letter agreement with TomegaVax (the &#x201c;TomegaVax Letter Agreement&#x201d;), which provides for certain payments to TomegaVax&#x2019;s former stockholders before September 2024, in each case so long as the Company is continuing to pursue the development of the TomegaVax technology. Under the terms of the TomegaVax Letter Agreement, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;the Company will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million if the per-share price of the Company&#x2019;s publicly traded common stock, or implied price per share of the Company&#x2019;s Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and/or the stage of the Company&#x2019;s clinical development at the time of the relevant event triggering the payment.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The share price of the Company&#x2019;s publicly traded common stock will be determined using the average of the daily volume-weighted average trading price of the Company&#x2019;s common stock for each trading day during a consecutive 90-day period. The foregoing payments are payable (i) during any date after the completion of an initial public offering by the Company or any successor or affiliate controlling the TomegaVax technology, provided that no payment will be due before the first anniversary of the initial public offering, (ii) upon the sale of all assets related to the TomegaVax technology or (iii) upon a merger or stock sale of the Company or any successor or affiliate controlling the TomegaVax technology, in each case subject to certain conditions with respect to the timing of the payments. The payments under the TomegaVax Letter Agreement can be made in cash or shares of the Company&#x2019;s common stock, at the discretion of the Company&#x2019;s board of directors.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In February 2021, the Company achieved &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; of the milestones related to the specified per-share price of its common stock, which resulted in a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million payable to TomegaVax&#x2019;s former stockholders. In July 2021, the Company made the milestone payment to the former TomegaVax stockholders through a combination of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.1&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million cash payment and issuance of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;42,737&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock with a total fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.9&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. The remaining milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in the aggregate will be triggered if (i) the per-share price of the Company&#x2019;s publicly traded common stock is at least $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (as adjusted in the case of any stock dividend, stock split or other similar recapitalization) and upon the achievement of a certain milestone related to the stage of the Company&#x2019;s clinical development at the time of the relevant event triggering the payment&#160;and/or (ii) the per-share price of the Company&#x2019;s publicly traded common stock is at least $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;90&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (as adjusted in the case of any stock dividend, stock split or other similar recapitalization).&#160;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company determined that the future milestone payments contain net settlement provisions and therefore, they were required to be accounted for as embedded derivatives under the relevant accounting guidance. As of June&#160;30, 2021&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the estimated fair value of the embedded derivative was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.4&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Acquisition of Humabs&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2017, the Company acquired all of the outstanding equity of Humabs, a private Swiss company which discovers and develops monoclonal antibodies (&#x201c;mAbs&#x201d;) derived from individuals whose immune systems have successfully responded to major diseases. The Company acquired all of Humabs&#x2019; rights, title and interest in and to substantially all of the assets of Humabs except for rights under certain license agreements with third parties. The Company is obligated to pass-through to the former Humabs shareholders any amounts received by Humabs under such license agreements, net of any program expenses. The transaction was accounted for as an acquisition of a business. In addition to the cash payment and issuance of common stock to the former Humabs shareholders at the acquisition date, the Company also agreed to pay additional amounts in cash upon the achievement of specified milestone events: (i) up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;135.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;upon the achievement of clinical, regulatory and commercial milestones for an HBV&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;product; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and (ii) up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;105.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upon the achievement of clinical, regulatory and commercial milestones for another product, which the Company elected as a SARS-CoV-2 product.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In May 2020, the Company achieved &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; of the specified clinical milestones for the HBV product. As such, the Company paid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million related to this milestone event in June 2020. In October 2020, the Company achieved another specified clinical milestone for the SARS-CoV-2 product and paid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million related to this milestone event. The estimated fair value of the remaining contingent consideration was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;62.5&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;June&#160;30, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Acquisition of Agenovir&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In January 2018, the Company entered into an agreement and plan of merger with Agenovir Corporation (&#x201c;Agenovir&#x201d;), under which the Company purchased all equity interests of Agenovir. The primary assets purchased in the acquisition were in-process research and development programs in human papillomavirus and HBV using CRISPR/Cas9. The acquisition was accounted for as an asset purchase.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At the acquisition date, the Company paid cash and issued shares of Series A-2 convertible preferred stock to the former Agenovir stockholders. During a specified period following the closing of the Agenovir acquisition, the Company will be required to pay Agenovir&#x2019;s former stockholders up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;135.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in the aggregate for the achievement of specified development, regulatory and commercial milestones for the first HBV product.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;None&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; of the milestones have been achieved as of &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;June&#160;30, 2021&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, therefore &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; amounts were recognized relating to the contingent consideration.&lt;/span&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <vir:MilestonePaymentsRelatedTermsDescription
      contextRef="C_4ba8283a-0045-486b-80d8-2e80d28e4574"
      id="F_18d07983-c2e5-4383-821e-304c16eb2629">the Company will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $30.0 million if the per-share price of the Company&#x2019;s publicly traded common stock, or implied price per share of the Company&#x2019;s Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $45 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and/or the stage of the Company&#x2019;s clinical development at the time of the relevant event triggering the payment.</vir:MilestonePaymentsRelatedTermsDescription>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="C_28568052-9082-41a4-83b2-60aaae0ee1be"
      decimals="-5"
      id="F_97f10471-4c79-4715-9e00-93ed1d122bb4"
      unitRef="U_USD">30000000.0</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <vir:MinimumCommonStockConversionPriceForMilestonePaymentsConsideration
      contextRef="C_6fc26d34-68e7-4c09-8e67-4e2b004cdc10"
      decimals="INF"
      id="F_60ee73e1-9533-4913-aa3a-bbc044ba52bb"
      unitRef="U_USDollarShare">45</vir:MinimumCommonStockConversionPriceForMilestonePaymentsConsideration>
    <vir:BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration
      contextRef="C_ec6ee7cb-4c4f-4392-b06d-b2cc4c6ba486"
      decimals="INF"
      id="F_bbf42b0c-284c-4d28-96da-0b36982a78c0"
      unitRef="U_Milestone">1</vir:BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_bc5714bf-f943-475e-bcd8-0aa08e910f85"
      decimals="INF"
      id="F_099dbb82-775d-425b-9a71-3a5df69fb6ca"
      unitRef="U_USD">10000000.0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <vir:PaymentMadeForBusinessCombinationMilestone
      contextRef="C_93f053bf-00d2-4957-b2e8-a0580ba1a1ee"
      decimals="-5"
      id="F_6d27e7e9-b2a1-4d1d-96b0-b31ed82c04de"
      unitRef="U_USD">8100000</vir:PaymentMadeForBusinessCombinationMilestone>
    <vir:CommonStockSharesIssuedForMilestonePaymentShares
      contextRef="C_93f053bf-00d2-4957-b2e8-a0580ba1a1ee"
      decimals="0"
      id="F_f24f3fc3-474c-4041-9b81-58d522f17a8b"
      unitRef="U_shares">42737</vir:CommonStockSharesIssuedForMilestonePaymentShares>
    <vir:ValueOfCommonStockSharesIssuedForMilestonePayment
      contextRef="C_93f053bf-00d2-4957-b2e8-a0580ba1a1ee"
      decimals="-5"
      id="F_33839bb7-d9a6-4b38-9c34-57a75e20c4cc"
      unitRef="U_USD">1900000</vir:ValueOfCommonStockSharesIssuedForMilestonePayment>
    <vir:RemainingPaymentMadeForBusinessCombinationMilestone
      contextRef="C_4e33744e-999f-4346-9f7e-415731786c7b"
      decimals="-5"
      id="F_be8c14b3-be88-46b6-b8b4-4f302e478eb1"
      unitRef="U_USD">20000000.0</vir:RemainingPaymentMadeForBusinessCombinationMilestone>
    <vir:MinimumCommonStockConversionPriceForMilestonePaymentsConsideration
      contextRef="C_59766912-8729-44fa-8223-2711163a2f37"
      decimals="INF"
      id="F_3947ba33-0dd1-465a-932d-66196d87bf88"
      unitRef="U_USDollarShare">45</vir:MinimumCommonStockConversionPriceForMilestonePaymentsConsideration>
    <vir:MinimumCommonStockConversionPriceForMilestonePaymentsConsideration
      contextRef="C_31d70583-f863-4f52-9c17-5d19f672cbae"
      decimals="INF"
      id="F_74e40ae1-cc0b-4121-98be-0e33c841adba"
      unitRef="U_USDollarShare">90</vir:MinimumCommonStockConversionPriceForMilestonePaymentsConsideration>
    <us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability
      contextRef="C_75ead0cb-5540-4c8d-9421-64e16f11ecda"
      decimals="-5"
      id="F_12c1c551-5b4b-4fc5-8bc4-b0755c70461e"
      unitRef="U_USD">6400000</us-gaap:EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability>
    <vir:BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents
      contextRef="C_d8c8927a-29a9-44cd-b032-581051ff30bf"
      decimals="-5"
      id="F_ad07700c-2792-46b2-b91f-ce1ddfa24bf5"
      unitRef="U_USD">135000000.0</vir:BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents>
    <vir:BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents
      contextRef="C_d2c8c218-592c-4345-a42f-8c7f3cefb5aa"
      decimals="-5"
      id="F_d7db4be3-4ccf-4355-998e-cc9b6ca07027"
      unitRef="U_USD">105000000.0</vir:BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents>
    <vir:BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved
      contextRef="C_ff3535ee-1915-4fab-bcf7-801568ea00ac"
      decimals="INF"
      id="F_88845b70-bb12-48a3-ad1a-12f80cfc341b"
      unitRef="U_Milestone">1</vir:BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved>
    <vir:BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved
      contextRef="C_bbedea33-e0d1-40dc-8d3b-acfc0f01d81c"
      decimals="INF"
      id="F_82d27fb1-8aec-4c22-9473-aef36afa7435"
      unitRef="U_Milestone">1</vir:BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved>
    <vir:SpecifiedClinicalDevelopmentMilestonesPayment
      contextRef="C_ff3535ee-1915-4fab-bcf7-801568ea00ac"
      decimals="INF"
      id="F_679867e0-f37b-42ab-8b29-fa63787b94d0"
      unitRef="U_USD">10000000.0</vir:SpecifiedClinicalDevelopmentMilestonesPayment>
    <vir:SpecifiedClinicalDevelopmentMilestonesPayment
      contextRef="C_bbedea33-e0d1-40dc-8d3b-acfc0f01d81c"
      decimals="INF"
      id="F_c17fae5f-d3b0-4bd5-9263-7383a90b6711"
      unitRef="U_USD">10000000.0</vir:SpecifiedClinicalDevelopmentMilestonesPayment>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_1e5484c7-876b-4630-8566-d2b6146b4e47"
      decimals="-5"
      id="F_a1b82652-4df9-4395-ae9a-49d6bf1ec792"
      unitRef="U_USD">62500000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh
      contextRef="C_4df49172-31b6-455e-a6d9-ebce7871f7da"
      decimals="-5"
      id="F_8323c232-05cb-43df-9f15-8b943a3df663"
      unitRef="U_USD">135000000.0</us-gaap:BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh>
    <vir:BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration
      contextRef="C_a7eab319-293e-4b73-85e4-92da414f023c"
      decimals="INF"
      id="F_37be6e1f-c919-4bf3-b891-fbb035643a1c"
      unitRef="U_Milestone">0</vir:BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_20097cda-ecaf-4c10-976d-a846aa4a6d9b"
      decimals="INF"
      id="F_e903d186-e854-4f09-a1a8-a3a27e26fc6c"
      unitRef="U_USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <vir:GrantAgreementsDisclosureTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_eb3772a6-b070-4eba-8770-b0d4a284dbd9">&lt;p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;5.	Grant Agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Bill&#160;&amp;amp; Melinda Gates Foundation Grants&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Human Immunodeficiency Virus (&#x201c;HIV&#x201d;) Grant&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On January&#160;26, 2018, the Company entered into a grant agreement with the Bill&#160;&amp;amp; Melinda Gates Foundation under which it was awarded a grant totaling up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12.2&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;million for its HIV program (the &#x201c;HIV Grant&#x201d;). In February 2020, the parties amended the HIV Grant under which the Company was awarded a supplemental grant of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.6&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. In June 2021, the parties further amended the agreement under which the grant term was extended from December 31, 2021 to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;October 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, unless earlier terminated by the Bill&#160;&amp;amp; Melinda Gates Foundation for the Company&#x2019;s breach, failure to progress the funded project, in the event of the Company&#x2019;s change of control, change in the Company&#x2019;s tax status, or significant changes in the Company&#x2019;s leadership that the Bill&#160;&amp;amp; Melinda Gates Foundation reasonably believes may threaten the success of the project.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Payments received in advance that are related to future research activities are deferred and recognized as revenue when the donor-imposed conditions are met, which is as the research and development activities are performed. The Company recognized grant revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three months ended June&#160;30, 2021 and 2020&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.6&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.4&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;six months ended June&#160;30, 2021 and 2020&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, respectively. As of June 30, 2021 and December 31, 2020, the Company has deferred revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.7&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.8&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, under this grant agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Tuberculosis (&#x201c;TB&#x201d;) Grant&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On March&#160;16, 2018, the Company entered into a grant agreement with the Bill&#160;&amp;amp; Melinda Gates Foundation under which it was awarded a grant totaling up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14.9&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;million for its TB program (the &#x201c;TB Grant&#x201d;). The parties amended the agreement in June 2021 under which the grant term was extended from February 28, 2021 to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;January 31, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, unless earlier terminated by the Bill&#160;&amp;amp; Melinda Gates Foundation for the Company&#x2019;s breach, failure to progress the funded project, in the event of the Company&#x2019;s change of control, change in the Company&#x2019;s tax status, or significant changes in the Company&#x2019;s leadership that the Bill&#160;&amp;amp; Melinda Gates Foundation reasonably believes may threaten the success of the project. As of June&#160;30, 2021&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company had $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of unused funds received in advance and previously recorded as deferred revenue within accrued and other liabilities. &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of June 30, 2021 and December 31, 2020, the Company has deferred revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.3&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.6&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, under this grant agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Payments received in advance that are related to future research activities are deferred and recognized as revenue when the donor-imposed conditions are met, which is as the research and development activities are performed. The Company recognized grant revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.1&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;nil&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; for the &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three months ended June&#160;30, 2021 and 2020&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.8&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;six months ended June&#160;30, 2021 and 2020&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, respectively.&lt;/span&gt;</vir:GrantAgreementsDisclosureTextBlock>
    <vir:GrantAwardedAmountMaximum
      contextRef="C_b64fcbdc-5a21-4b8c-8ac7-983b9bfe2eb4"
      decimals="INF"
      id="F_c321077a-0bf1-4daa-a853-d70387396225"
      unitRef="U_USD">12200000</vir:GrantAwardedAmountMaximum>
    <vir:GrantAwardedAmount
      contextRef="C_cd7a1755-2831-46df-a378-33b1c1bbe888"
      decimals="-5"
      id="F_794938aa-ad4b-4dea-9406-302e29374f0c"
      unitRef="U_USD">8600000</vir:GrantAwardedAmount>
    <vir:GrantAgreementAmendedExpirationDate
      contextRef="C_325ad0aa-a95c-4661-a917-fc337e70902e"
      id="F_6a95122c-cf5d-4298-a66e-d68e2d2c74d4">2022-10-31</vir:GrantAgreementAmendedExpirationDate>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_a077a0ad-b848-485c-96a1-3489ae549b2f"
      decimals="-5"
      id="F_a8c729d7-b5a4-495e-a020-a8a4a5eab26a"
      unitRef="U_USD">900000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_cd460f41-06b3-4477-9de5-9e78e41bc13e"
      decimals="-5"
      id="F_fce8a32b-f128-44ea-841c-c0400b0607d0"
      unitRef="U_USD">500000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_66892b6e-71bf-4e32-a6ae-3770380bc675"
      decimals="-5"
      id="F_87c5bdfc-d629-4ef3-8729-4fdd2dbb7b57"
      unitRef="U_USD">1600000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_69fd0161-00a7-47b8-8f7e-c649aad213a7"
      decimals="-5"
      id="F_7e1e6168-bfdd-472b-8a39-94595d833799"
      unitRef="U_USD">5400000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_3943c51c-7e55-4e41-b9e4-df3e298c1f39"
      decimals="-5"
      id="F_c887b3f5-6009-488e-8280-11a6b78d22e7"
      unitRef="U_USD">3700000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_3b639fc9-2f14-4483-9c0f-de032ca38766"
      decimals="-5"
      id="F_d7a77758-6df0-4b5d-add7-546b46c16ca5"
      unitRef="U_USD">3800000</us-gaap:ContractWithCustomerLiability>
    <vir:GrantAwardedAmountMaximum
      contextRef="C_6d87011b-3e4c-46db-bad8-0f23e0dcc637"
      decimals="INF"
      id="F_0f0dbfdd-68d8-4fbc-be9c-ff12b467ee04"
      unitRef="U_USD">14900000</vir:GrantAwardedAmountMaximum>
    <vir:GrantAgreementAmendedExpirationDate
      contextRef="C_c37af972-2bf8-4eff-9bc7-4763e2ab45d0"
      id="F_27d03d85-2d7b-4da1-884c-c908a06fd897">2022-01-31</vir:GrantAgreementAmendedExpirationDate>
    <vir:UnusedFundsReceivedInAdvance
      contextRef="C_fd53f66c-e257-4732-8340-be571f9ac325"
      decimals="-5"
      id="F_85788bc8-60cc-47c5-bed1-94cff3f7e0d2"
      unitRef="U_USD">2000000.0</vir:UnusedFundsReceivedInAdvance>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_26c131f2-0874-4ae2-9e57-8f39b5db6f09"
      decimals="-5"
      id="F_0a7db4f1-8865-46df-88da-315ca31ed1bb"
      unitRef="U_USD">1300000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="C_eca11749-bb55-4f33-bd21-2d25c913415b"
      decimals="-5"
      id="F_3f5379bb-042c-4983-8a5b-bbefadcdc76a"
      unitRef="U_USD">2600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_42a0066f-bcc3-4b1a-a379-4a993e12dcb9"
      decimals="-5"
      id="F_3522ec94-8df5-489f-bfc0-5e13c34541b5"
      unitRef="U_USD">2100000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_33d141a8-0bd8-4ec8-aaaf-e21290176a35"
      decimals="-3"
      id="F_20277aea-3c6b-459b-8e35-572945b17e43"
      unitRef="U_USD">0</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_abdc6453-b0c7-4eaa-a85e-f7e083980647"
      decimals="-5"
      id="F_1f888f8f-fb65-42f7-b5c6-8c6910ddd3f4"
      unitRef="U_USD">2800000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:RevenueNotFromContractWithCustomer
      contextRef="C_237f8a0b-7ccb-4bfe-9900-7d13c307285b"
      decimals="-5"
      id="F_cd72c77f-e24b-4429-b267-bcf89d80a948"
      unitRef="U_USD">100000</us-gaap:RevenueNotFromContractWithCustomer>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_ed42266b-b426-4410-ab53-79bc1cfa6d4d">&lt;p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;6.	Collaboration and License Agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Collaboration Agreements with GSK&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2020 GSK Collaboration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On June 9, 2020, the Company, Glaxo Wellcome UK Limited and Beecham S.A. (referred to&#160;&lt;/span&gt;&lt;span style="color:rgba(35,31,32,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;individually and&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; together, as &#x201c;GSK&#x201d;) entered into a definitive collaboration agreement under the terms set forth in the preliminary collaboration agreement entered into by the Company and certain GSK entities in April 2020 (the &#x201c;2020 Preliminary Agreement&#x201d;) (such definitive collaboration agreement, the &#x201c;2020 GSK Agreement&#x201d;). Concurrently with the execution of the 2020 Preliminary Agreement, the Company entered into a stock purchase agreement (the &#x201c;2020 Stock Purchase Agreement&#x201d;) with Glaxo Group Limited (&#x201c;GGL&#x201d;), an affiliate of GSK, under which GGL purchased &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,626,027&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s common stock on April 29, 2020, at a price per share of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37.73&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, for an aggregate purchase price of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;250.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. After receipt of antitrust clearance on April 22, 2020, the Preliminary Agreement became effective as of April 29, 2020, which was also the closing date for the associated 2020 Stock Purchase Agreement between the parties (&#x201c;Effective Date&#x201d;). Under the terms of the 2020 GSK Agreement, the Company and GSK agreed to collaborate to research, develop and commercialize products for the prevention, treatment and prophylaxis of diseases caused by SARS-CoV-2, the virus that causes COVID-19, and potentially other coronaviruses. The collaboration is focused on the development and commercialization of three types of collaboration products under three programs: (1) antibodies targeting SARS-CoV-2, and potentially other coronaviruses (the &#x201c;Antibody Program&#x201d;); (2) vaccines targeting SARS-CoV-2, and potentially other coronaviruses (the &#x201c;Vaccine Program&#x201d;), and (3) products based on genome-wide CRISPR screening of host targets expressed in connection with exposure to SARS-CoV-2, and potentially other coronaviruses (the &#x201c;Functional Genomics Program&#x201d;).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;four years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; following the Effective Date, the parties will conduct certain research and development activities under mutually agreed development plans and associated budgets for each of the three programs, and under the oversight of a joint steering committee (&#x201c;JSC&#x201d;). The Company will be primarily responsible for the development and clinical manufacturing activities for the Antibody Program, and for conducting the initial development activities directed to a vaccine in the Vaccine Program. GSK will be primarily responsible for the commercialization activities for the Antibody Program (except in connection with sales of antibody products licensed to WuXi Biologics (Hong Kong) Limited in greater China), the later-stage development, manufacturing and commercialization activities for the Vaccine Program and the development, manufacturing and commercialization activities for the Functional Genomics Program. Subject to an opt-out mechanism, the parties will share all development costs, manufacturing costs and costs and expenses for the commercialization of the collaboration products, with the Company bearing &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;72.5&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of such costs for the antibody products, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27.5&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of such costs for the vaccine products, and equal sharing of such costs for the functional genomics products.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On a collaboration product-by-collaboration product basis, each party will have the one-time right, at specified points in development, to opt-out of its co-funding obligations, and the other party may, at its election, either pursue such program unilaterally, or also cease research and development activities and funding of such collaboration product. If the opt-out provisions are not exercised by either party subject to the terms of the 2020 GSK Agreement, the parties would share all profits and losses arising from any collaboration product in the same ratios in which the parties bore development costs for such collaboration program. For each collaboration product as to which a party exercises its opt-out right, the commercializing party will pay to the opt-out party royalties on net sales of the applicable collaboration product at rates based on factors such as the stage of development of such collaboration product at the time the opt-out party exercises such right, and whether the opt-out party is the lead party, or a portion of the sublicense revenue if the commercializing party chooses to sublicense or otherwise divest rights to such collaboration product. On an antibody product-by-antibody product basis, the Company has a co-promotion right for such antibody product in the United States, under which the Company will have the right to perform up to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of details in connection with such antibody product.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The 2020 GSK Agreement will remain in effect with respect to each collaboration program for as long as there is a collaboration product being developed or commercialized by the lead party, or the non-opt-out party, in such program. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Either party has the right to terminate the 2020 GSK Agreement in the case of the insolvency of the other party, an uncured material breach of the other party with respect to a collaboration program or collaboration product, or as mutually agreed by the parties.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The 2020 GSK Agreement superseded and replaced the 2020 Preliminary Agreement between the parties.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considered the ASC 606 criteria for combining contracts and determined that the 2020 GSK Agreement and 2020 Stock Purchase Agreement should be combined into a single contract because they were negotiated and entered into in contemplation of one another. The fair market value of the common stock issued to GGL was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;206.7&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, based on the closing stock price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36.70&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; on the date of execution of the 2020 Preliminary Agreement and 2020 Stock Purchase Agreement and taking into account a discount for the lack of marketability due to the restrictions in place on the underlying shares, resulting in a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;43.3&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million premium received by the Company.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company accounted for the common stock issued to GGL based on its fair market value on the transaction date and determined that the premium paid by GSK should be attributed to the transaction price of the 2020 GSK Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company concluded that the 2020 GSK Agreement contained &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;four&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; units of account: (i) the license granted to GSK under the Antibody Program (the &#x201c;Antibody License&#x201d;); (ii) the research and development activities (including clinical manufacturing) under the Antibody Program; (iii) the research and development activities under the Vaccine Program; and (iv) the research and development activities under the Functional Genomics Program. The Company considered the guidance in ASC 606 to determine which of these elements of the 2020 GSK Agreement are performance obligations with a customer. The Company determined that the Antibody License is within the scope of ASC 606 and accordingly, accounted for the Antibody License as a distinct performance obligation under ASC 606. The Antibody License is a functional intellectual property and is distinct from the associated research and development activities to be performed under the program due to its significant standalone functionality. All other elements of the 2020 GSK Agreement including the research and development activities, and participation in the JSC and subcommittees for each collaboration program were not determined to be distinct performance obligations with a customer.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The transaction price for the Antibody License at inception was determined to be $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;43.3&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, representing the premium on the sale of common stock to GSK. The Company determined that GSK can benefit from the Antibody License at the time of grant and therefore, the related performance obligation is satisfied at a point in time. As such, the Company recognized the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;43.3&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as contract revenue during the second quarter of 2020. Additionally, the Company is entitled to consideration from GSK related to profit and loss sharing arrangements (including royalties) contingent upon future sales of collaboration products under the Antibody Program.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The remaining units of account of the 2020 GSK Agreement were determined to be within the scope of ASC 808 as the Company and GSK are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on the commercial success of the activities of the arrangement. Furthermore, the Company and GSK participate in the commercial profit and loss sharing arrangement for each program commensurate with each party&#x2019;s cost-sharing responsibilities during research and development. Because ASC 808 does not provide recognition and measurement guidance, the Company determined that the guidance in ASC 730, Research and Development, was appropriate to analogize to, based on the nature of the cost-sharing provisions of the agreement. The Company has concluded that payments to or reimbursements from GSK related to these services will be accounted for as an increase to or reduction of research and development expenses, respectively. The Company also concluded that any payments from GSK related to the profit and loss sharing arrangement (including royalties) contingent upon the commercialization of the products under the Vaccine and Functional Genomics Programs will be analogized to ASC 606 and therefore, will be recognized when the related sales occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In May 2021, the Company and GSK received an EUA for sotrovimab, the first collaboration product under the Antibody Program. As the lead party for all commercialization activities, GSK incurs all of the sales and marketing expenses and is the principal on sales transactions with third parties. As the Company is the agent under the agreement, the Company recognizes its contractual share of the profit sharing amounts or royalties (in case of an opt-out) as revenue, net of any cost of sales and allowable expenses (including distribution, selling and marketing expenses) in the period the sale occurs. During the three months ended June 30, 2021, the Company recorded its share of net profit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.3&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as collaboration revenue in the condensed consolidated statement of operations.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Costs associated with co-development activities performed under the agreement are included in research and development expenses on the condensed consolidated statements of operations, with any reimbursement of costs by GSK reflected as a reduction of such expenses. Under the 2020 GSK Agreement, the Company recognized additional research and development expense of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.9&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36.4&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million during the &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three and six months ended June&#160;30, 2021&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, respectively. The Company recognized a reduction of research and development expense of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.8&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million during the &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three and six months ended June&#160;30, 2020&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The Company has a payable to GSK of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12.7&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million included in accrued and other liabilities as of &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;June&#160;30, 2021 and December 31, 2020, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2021 Expanded GSK Collaboration&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On February&#160;14, 2021, the Company and GSK entered into a binding preliminary collaboration agreement (the &#x201c;2021 Preliminary Agreement&#x201d;), under which the parties agreed to expand the 2020 GSK Agreement to collaborate on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; separate programs: (1)&#160;a program to research, develop and commercialize mAbs for the prevention, treatment or prophylaxis of the influenza virus (the &#x201c;Influenza Program&#x201d;), excluding VIR-2482 unless GSK exercises its option as described below; (2) an expansion of the parties&#x2019; current Functional Genomics Program to focus on functional genomics screens directed to targets associated with respiratory viruses (the &#x201c;Expanded Functional Genomics Program&#x201d;); and (3)&#160;additional programs to develop neutralizing mAbs directed to up to three&#160;non-influenza&#160;target pathogens selected by GSK (the &#x201c;Selected Pathogens&#x201d; and such programs, the &#x201c;Additional Programs&#x201d;).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Concurrently with the execution of the 2021 Preliminary Agreement, the Company entered into a stock purchase agreement (the &#x201c;2021 Stock Purchase Agreement&#x201d;) with GGL under which GGL agreed to purchase shares of the Company&#x2019;s common stock for an aggregate purchase price of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;120.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. The consummation of the transactions under each of the 2021 Preliminary Agreement and the 2021 Stock Purchase Agreement were subject to the satisfaction of customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, which expiration was effective on March 24, 2021. The 2021 Preliminary Agreement and 2021 Stock Purchase Agreement consummated on March 25, 2021, which the Company used as the measurement date for accounting purposes. On March 31, 2021, the Company closed the sale of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,924,927&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock to GGL.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The 2021 Preliminary Agreement was superseded on May 18, 2021 upon execution of the definitive collaboration agreement (the &#x201c;2021 GSK Agreement&#x201d;, or collectively with the 2021 Preliminary Agreement, the &#x201c;2021 GSK Collaboration&#x201d;). The material terms of the 2021 GSK Agreement, including the promised goods and services, are discussed below and is consistent with those of the 2021 Preliminary Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the 2021 GSK Collaboration, the parties will conduct certain research and development activities under mutually agreed development plans and associated budgets for the programs within the expanded collaboration for a period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; following the effective date. Under the Influenza Program, the parties will collaborate to research, develop and commercialize mAbs for the prevention, treatment or prophylaxis of influenza, including the Company&#x2019;s influenza mAbs (with respect to VIR-2482, only if GSK exercises its option). The Company may conduct the development and clinical manufacturing activities for&#160;VIR-2482&#160;up to completion of a Phase 2 clinical trial. Provided that the Company conducts and completes a Phase 2 clinical trial for VIR-2482, GSK will have the exclusive option to obtain exclusive rights to&#160;co-develop&#160;and commercialize&#160;VIR-2482&#160;under the Influenza Program (the &#x201c;VIR-2482 Option&#x201d;). GSK will be the lead party for development, clinical and commercial manufacturing and commercialization activities for products under the Influenza Program (other than&#160;VIR-2482&#160;unless and until GSK exercises the VIR-2482 Option, if applicable). The parties will mutually agree upon the allocation of responsibility for development of products under the Expanded Functional Genomics Program, and for development and early-stage manufacturing of products under the Additional Programs if and when GSK decides which Selected Pathogens to pursue. GSK will be primarily responsible for commercial manufacturing and commercialization activities for products under the Expanded Functional Genomics Program and Additional Programs, if and when selected by GSK. For each collaboration program, upon execution of the definitive agreement, the Company will grant GSK certain license rights related to the development, manufacturing and commercialization of products arising from the program.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The parties will share &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;of all development costs in accordance with the budget for each of the collaboration programs (other than for&#160;the Selected Pathogens and VIR-2482 unless GSK exercises the VIR-2482 Option), with each party having the right to&#160;opt-out&#160;of its&#160;co-funding&#160;obligations at specified points in development. In such case, the party continuing with the program will pay to&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;the&#160;opt-out&#160;party &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;a royalty on net sales of products arising from such program at specified rates based on the stage of development at which the&#160;opt-out&#160;is exercised. Following the exercise of an&#160;opt-out&#160;right by a party, the other party may, at its election, either pursue development and commercialization of such product or program unilaterally, or also cease the conduct and funding of such collaboration product or program. In the absence of any&#160;opt-out,&#160;the parties will also share &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of all profits and losses arising from any collaboration product.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;GSK was obligated to make an upfront payment to the Company of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;225.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;million, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of which became payable at the effective date of the 2021 Preliminary Agreement and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of which became payable following execution of the 2021 GSK Agreement. If GSK exercises the VIR-2482 Option, GSK will pay the Company an option exercise fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;300.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;million unless certain agreed product criteria for&#160;VIR-2482&#160;are not met, in which case the parties will negotiate an alternative option exercise fee. Upon achievement of a&#160;pre-defined&#160;regulatory milestone for the first product in the Influenza Program, which may be (i) VIR-2482 (if GSK exercised the VIR-2482 Option), (ii) a next-generation mAb, or (iii) any other influenza mAb approved by the JSC to be included in the collaboration, arising from the Influenza Program, GSK will make a milestone payment to the Company of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;200.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company concluded that the 2021 GSK Agreement is a collaboration arrangement as defined in ASC 808, Collaborative Agreements, under which certain elements are required to be accounted for under ASC 606 where the counterparty is a customer for a good or service that is a distinct unit of account. In addition, the 2021 GSK Agreement is considered a contract modification to the 2021 Preliminary Agreement and will be accounted for prospectively, as a termination of the 2021 Preliminary Agreement and commencement of a new contract. There was no impact to the accounting assessment of the original contract as no goods or services had been delivered to GSK, no performance obligations were satisfied, and accordingly,&#160;no contract revenue was recognized under ASC 606 prior to the execution of the 2021 GSK Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considered the ASC 606 criteria for combining contracts and determined that the 2021 GSK Collaboration and 2021 Stock Purchase Agreement should be combined into a single contract because they were negotiated and entered into in contemplation of one another. The fair market value of the common stock issued to GGL was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;85.2&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, based on the closing stock price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;52.70&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; on March 25, 2021 and taking into account a discount for the lack of marketability due to the restrictions in place on the underlying shares, resulting in a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;34.8&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million premium received by the Company. The Company accounted for the common stock issued to GGL based on its fair market value on the transaction date and determined that the premium paid by GSK should be attributed to the transaction price of the 2021 GSK Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company concluded that the 2021 GSK Agreement contained the following units of account: (i) the VIR-2482 Option; (ii) three distinct rights granted to GSK related to the Selected Pathogens (each, a &#x201c;Selected Pathogens Right&#x201d;); (iii) the license and know-how to the next-generation mAbs under the Influenza Program (the &#x201c;Next Gen License&#x201d;); (iv) the research and development activities for next-generation mAbs under the Influenza Program; and (v) the research and development activities, including license rights and know-how, under the Expanded Functional Genomics Program. The Company considered the guidance in ASC 606 to determine which of these elements of the 2021 GSK Agreement are performance obligations with a customer. The Company determined that the distinct performance obligations under ASC 606 consisted of: (i) the Next Gen License and (ii) the three Selected Pathogens Rights, each representing a material right. All other elements of the 2021 GSK Agreement including the VIR-2482 Option, research and development activities, and participation in the JSC and subcommittees for each collaboration program were not determined to be distinct performance obligations with a customer.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The transaction price for the 2021 GSK Agreement included fixed consideration consisting of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;225.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upfront fee paid by GSK and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;34.8&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, representing the premium on the sale of common stock to GSK for a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;259.8&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. All potential future milestones and other payments under the 2021 GSK Agreement are constrained since the Company could not conclude it was probable that a significant reversal in the amount recognized would not occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The respective estimated SSP for each of the performance obligations was determined to allocate the transaction price. The estimated SSP of each performance obligation was determined considering relevant market conditions, entity-specific factors and information about the customer, while maximizing the use of available observable inputs. For the Next Gen License, the Company determined that GSK can benefit from the license at the time the license is granted and therefore, the related performance obligation is satisfied at a point in time. If any of the Selected Pathogens Rights are exercised, the Company will evaluate the related promises to identify the performance obligations to be transferred and the timing of revenue recognition. If any of the Selected Pathogens Rights expire prior to being exercised, the Company will recognize any deferred revenue allocated to that right as revenue at the time of expiration.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The research and development activities for the next generation mAbs under the Influenza Program and the Expanded Functional Genomics Program were determined to be within the scope of ASC 808 as the Company and GSK are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;the commercial success of the activities of the arrangement. Furthermore, the Company and GSK participate in the commercial profit and loss sharing arrangement for each program commensurate with each party&#x2019;s cost-sharing responsibilities during research and development. Because ASC 808 does not provide recognition and measurement guidance, the Company determined that the guidance in ASC 730, Research and Development, was appropriate to analogize to based on the nature of the cost-sharing provisions of the agreement. The Company has concluded that payments to or reimbursements from GSK related to these services will be accounted for as an increase to or reduction of research and development expenses, respectively. The Company also concluded that any payments from GSK related to the profit and loss sharing arrangement (including royalties) contingent upon the commercialization of the related products will be analogized to ASC 606 and therefore, will be recognized when the related sales occur.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upon execution of the 2021 GSK Agreement, the Company granted the Next Gen License to GSK and therefore, recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;168.3&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as contract revenue during the three months ended June 30, 2021. As of June 30, 2021, of the total unrecognized transaction price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;91.5&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;39.8&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;51.7&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million is classified as current and noncurrent deferred revenue, respectively, on the Company's condensed consolidated balance sheet related to the remaining performance obligations, being the material rights resulting from the Selected Pathogens Rights.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Costs associated with co-development activities performed under the agreement are included in research and development expenses in the condensed consolidated statements of operations, with any reimbursement of costs by GSK reflected as a reduction of such expenses. During the three and six months ended June 30, 2021, the Company recognized a &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;reduction of research and development expense of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;under the 2021 GSK Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Brii Biosciences&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In May 2018, the Company entered into a collaboration, option and license agreement (the &#x201c;Brii Agreement&#x201d;) with Brii Biosciences Limited (previously named BiiG Therapeutics Limited) (&#x201c;Brii Bio Parent&#x201d;) and Brii Biosciences Offshore Limited (&#x201c;Brii Bio&#x201d;), pursuant to which the Company granted to Brii Bio, with respect to up to four of the Company&#x2019;s programs, an exclusive option to obtain exclusive rights to develop and commercialize compounds and products arising from such programs in China, Taiwan, Hong Kong and Macau (collectively, the &#x201c;China Territory&#x201d;) for the treatment, palliation, diagnosis, prevention or cure of acute and chronic diseases of infectious pathogen origin or hosted by pathogen infection (the &#x201c;Field of Use&#x201d;). The Company&#x2019;s HBV siRNA program being developed under the Alnylam Agreement (described below) is included within the Brii Agreement as a program for which Brii Bio may exercise one of its options. In partial consideration for the options granted by the Company to Brii Bio, Brii Bio Parent and Brii Bio granted the Company, with respect to up to four of Brii Bio Parent&#x2019;s or Brii Bio&#x2019;s programs, an exclusive option to be granted exclusive rights to develop and commercialize compounds and products arising from such Brii Bio programs in the United States for the Field of Use. The number of options that the Company may exercise for a Brii Bio program is limited to the corresponding number of options that Brii Bio exercises for a Vir program.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As partial consideration for the Company&#x2019;s entry into the Brii Agreement, upon closing of Brii Bio Parent&#x2019;s Series A preferred stock financing, the Company received ordinary shares equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.9&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the outstanding shares in Brii Bio Parent. As a result of Brii Bio&#x2019;s right to exercise one of its options for the Company&#x2019;s HBV siRNA program, under the terms of the Alnylam Agreement, as amended, the Company transferred to Alnylam a specified percentage of such equity consideration allocable to such program under a share transfer agreement in February 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;With respect to programs for which Brii Bio exercises its options, Brii Bio will be required to pay the Company an option exercise fee for each such Vir program ranging from the mid-single-digit millions up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, determined based on the commercial potential of the licensed program. Brii Bio will also be required to pay regulatory milestone payments on a licensed product-by-licensed product basis ranging from the mid-single-digit millions up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, also determined based on the commercial potential of such program. Following commercialization, Brii Bio will be required to make sales milestone payments based on certain specified levels of aggregate annual net sales of products arising from each licensed program in the China Territory, up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;175.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million per licensed program. Brii Bio also will pay royalties to the Company that range from the mid-teens to the high-twenties, as described below.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upon exercise of each option for a Brii Bio program, the Company will be required to pay to Brii Bio an option exercise fee ranging from the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;low tens of millions&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, determined based on the commercial potential of the licensed program. The Company will be required to make regulatory milestone payments to Brii Bio on a licensed product-by-licensed product basis ranging from the low tens of millions up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, also determined based on the commercial potential of such program. The Company will also be required to make sales milestone payments based on certain specified levels of aggregate annual net sales of products in the United States arising from each licensed program, up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;175.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million per licensed program.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In addition, the Company is obligated under the Brii Agreement to pay Brii Bio tiered royalties based on net sales of products arising from the licensed programs in the United States, and Brii Bio is obligated to pay the Company tiered royalties based on net sales of products arising from the licensed programs in the China Territory. The rates of royalties payable by the Company to Brii Bio, and by Brii Bio to the Company, on net sales range from mid-teens to high-twenties. Each party&#x2019;s obligations to pay royalties expires, on a product-by-product and territory-by-territory basis, on the latest of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years after the first commercial sale of such licensed product in the United States or China Territory, as applicable; the expiration or abandonment of licensed patent rights that cover such product in the United States or China Territory, as applicable; and the expiration of regulatory exclusivity in the United States or the China Territory, as applicable. Royalty rates are subject to specified reductions and offsets.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Brii Agreement will remain in force until the expiration of all options or, if any option is exercised, expiration of all royalty payment obligations for all licensed products within such licensed program, unless terminated in its entirety or on a program-by-program basis by either party. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Each party may terminate for convenience all rights and obligations with respect to any program for which it has an option, with &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30 days&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2019; written notice (if the terminating party has not exercised an option for such program) or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;180 days&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2019; notice (following the exercise of an option for such program). The Brii Agreement may also be terminated by either party for insolvency of the other party, and either party may terminate the Brii Agreement in its entirety or on a program-by-program basis for the other party&#x2019;s uncured material breach on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60 days&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2019; written notice (or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; days&#x2019; notice following failure to make payment).&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has determined that Brii Bio Parent and its wholly-owned subsidiary Brii Bio are variable interest entities due to their reliance on future financing and having insufficient equity at risk. However, the Company does not have the power to direct activities that most significantly impact the economic success of these entities and is not considered the primary beneficiary of these entities. Therefore, the Company does not consolidate Brii Bio Parent or Brii Bio. The Company also determined that it does not exercise significant influence over Brii Bio Parent or Brii Bio. As of June 30, 2021 and December 31, 2020, the investment in Brii Bio Parent has a carrying value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.7&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, which is included in other assets on the condensed consolidated balance sheets. The Company also has a contract liability of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.8&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million within deferred revenue which represents deferred consideration for the remaining three options that the Company granted to Brii Bio. The deferred consideration will be recognized when Brii Bio exercises its options or the options expire. The Company accounts for its investment in Brii Bio Parent&#x2019;s ordinary shares at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment in Brii Bio Parent.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s maximum exposure to loss under the Brii Agreement is represented by options to acquire licenses to develop and commercialize potential products and future milestone payments. The ultimate expense that the Company incurs under the Brii Agreement cannot be quantified at this time as the amount will vary based on the timing and outcome of research activities.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Option Exercise by Brii Bio&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In June 2020, Brii Bio exercised its option to obtain exclusive rights to develop and commercialize compounds and products arising from VIR-2218 in the China Territory. In consideration of the Company&#x2019;s grant to Brii Bio of an exclusive license related to VIR-2218 in the China Territory, the Company received a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million option exercise fee in connection with the option exercise. Also, the Company is eligible to receive the following payments related to VIR-2218 in the China Territory: a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million regulatory milestone payment, up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;175.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in sales-based milestone payments, and royalties on net sales ranging from high-teens to high-twenties.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company evaluated the transaction under ASC 606 and identified one performance obligation consisting of the license granted to Brii Bio. Under the Brii Agreement, Brii Bio is responsible for performing all research and development activities and the Company does not have any other performance obligations within the context of ASC 606 under the arrangement after the option exercise. The transaction price is determined to be $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22.7&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million which consists of the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million option exercise fee and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.7&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of the deferred revenue allocated to the VIR-2218 option at the inception of the Brii Agreement. The Company determined that the license is considered a functional intellectual property that is a distinct performance obligation under ASC 606. Specifically, the Company believes the license is capable of being distinct, as Brii Bio has the capabilities to develop the license either on its own or by contracting other third parties. Brii Bio can benefit from the license at the time of grant and therefore, the related performance obligation is satisfied at a point in time. Additionally, all potential future milestones and other payments are constrained because the Company cannot conclude it is probable that a significant reversal in the amount recognized would not occur. The Company will re-evaluate the transaction price in each reporting period.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;During the three and six months ended June 30, 2021, the Company recognized &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;zero&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively, as contract revenue from the supply of biological materials to Brii Bio. During the three and six months ended June 30, 2020, the Company recognized the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22.7&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as license revenue from a related party. The Company separately paid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, half of the option exercise proceeds, to Alnylam in connection with the Alnylam Agreement that was recognized as research and development expense during the same period.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Alnylam&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;October 2017 Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In October 2017, the Company entered into the Alnylam Agreement for the development of siRNA products for the treatment of HBV and following the exercise of certain program options, the development and commercialization of siRNA therapeutic products directed to up to four other infectious disease targets selected by the Company. The technology licensed under the Alnylam Agreement forms the basis of the Company&#x2019;s siRNA technology platform.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the Alnylam Agreement, the Company obtained a worldwide, exclusive license to develop, manufacture and commercialize the HBV siRNA product candidates, including VIR-2218, for all uses and purposes other than agricultural, horticultural, forestry, aquaculture and other residential applications, such excluded fields, the Excluded Fields. In addition, Alnylam granted the Company an exclusive option, for each of the infectious disease siRNA programs directed to the Company&#x2019;s selected targets, to obtain a worldwide, exclusive license to develop, manufacture and commercialize siRNA products directed to the target of each such program for all uses and purposes other than the Excluded Fields. On a product-by-product basis for each product arising from the HBV and, following the Company&#x2019;s option exercise, the infectious disease programs, Alnylam has an exclusive option, exercisable during a specified period prior to the initiation of a Phase 3 clinical trial for each such product, to negotiate and enter into a profit-sharing agreement for such product.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company and Alnylam are jointly responsible for funding the initial research and development activities for VIR-2218 through the completion of proof of concept trials. Prior to the exercise of the Company&#x2019;s option for each siRNA program directed to one of the Company&#x2019;s selected infectious disease targets, Alnylam is responsible for conducting all development activities, at the Company&#x2019;s expense, in accordance with an agreed upon development plan. Following the Company&#x2019;s exercise of an option for a program and payment of the program option exercise fee and any outstanding program costs due to Alnylam, the Company is solely responsible, at the Company&#x2019;s expense (subject to Alnylam&#x2019;s exercise of a profit-sharing option), for conducting all development, manufacture and commercialization activities for products arising from each such program. If Alnylam exercises a profit-sharing option for a product, the Company will negotiate the terms of such profit-sharing agreement, which will include sharing equally with Alnylam all subsequent costs associated with the development of such product, as well as the profits and losses in connection with such product, subject to reimbursement by Alnylam of a portion of specified development costs in certain circumstances.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the Alnylam Agreement, the Company paid Alnylam an upfront fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and issued to Alnylam &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,111,111&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s common stock. Additionally, the receipt of consideration from Brii Bio as discussed above triggered a requirement under the Alnylam Agreement to transfer a portion of the consideration, consisting of equity in Brii Bio Parent valued at $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, to Alnylam &lt;/span&gt;&lt;span style="color:rgba(33,37,41,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upon the achievement of a certain development milestone, as further discussed below, the Company was obligated to issue shares of the Company&#x2019;s common stock equal to the lesser of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,111,111&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares or (ii) a certain number of shares based on the Company&#x2019;s stock price at the time such milestone is achieved (the &#x201c;Milestone Shares&#x201d;). The Company will be required to pay Alnylam up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;190.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in the aggregate for the achievement of specified development and regulatory milestones by the first siRNA product directed to HBV, and up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;115.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the achievement of specified development and regulatory milestones by the first product directed to the target of each infectious disease siRNA program for which the Company exercised its option. Following commercialization, the Company will be required to pay to Alnylam up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;250.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in the aggregate for the achievement of specified levels of net sales by siRNA products directed to HBV and up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the achievement of specified levels of net sales by products directed to the target of each infectious disease siRNA program for which the Company exercised its option. The Company may also be required to pay Alnylam tiered royalties at percentages ranging from the low double-digits to mid-teens on annual net sales of HBV products, and tiered royalties at percentages ranging from the high single-digits to the sub-teen double-digits on annual net sales of licensed infectious disease products, in each case subject to specified reductions and offsets. The royalties are payable on a product-by-product and country-by-country basis until the later of the expiration of all valid claims of specified patents covering such product in such country and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; after the first commercial sale of such product in such country.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The term of the Alnylam Agreement will continue, on a product-by-product and country-by-country basis, until the expiration of all royalty payment obligations under the Alnylam Agreement. If the Company does not exercise its option for an infectious disease program directed to one of its selected targets, the Alnylam Agreement will expire upon the expiration of the applicable option period with respect to such program. However, if Alnylam exercises its profit-sharing option for any product, the term of the Alnylam Agreement will continue until the expiration of the profit-sharing arrangement for such product. The Company may terminate the Alnylam Agreement on a program-by-program basis or in its entirety for any reason on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;90 days&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2019; written notice. Either party may terminate the agreement for cause for the other party&#x2019;s uncured material breach on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60 days&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2019; written notice (or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30 days&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2019; notice for payment breach), or if the other party challenges the validity or enforceability of any patent licensed to it under the Alnylam Agreement on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30 days&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2019; notice.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March 2020, the Company achieved the specified development milestone relating to the Milestone Shares, which was accounted for as an embedded derivative. Consequently, the Company remeasured and reclassified the derivative liability to additional paid-in capital based on the estimated fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29.2&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. The Company issued Alnylam &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,111,111&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock and paid Alnylam $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in the second quarter of 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Second and Third Amendments&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March and April 2020, the Company and Alnylam entered into the second and third amendments to the Alnylam Agreement (as amended, the &#x201c;Amended Alnylam Agreement&#x201d;) to expand the parties&#x2019; existing collaboration to include the development and commercialization of siRNA products targeting SARS-CoV-2, and potentially other related coronaviruses, and up to three targeting human host factors for SARS-CoV-2 (collectively, the &#x201c;COVID Collaboration Targets&#x201d;).&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2020, the Company and Alnylam entered into a letter amendment (the &#x201c;Letter Agreement&#x201d;), amending the Amended Alnylam Agreement, to modify certain funding and governance provisions in connection with the siRNA products directed to the COVID Collaboration Targets, including VIR-2703 (the &#x201c;COV Target&#x201d;), and to modify certain rights of each party with respect to products arising from such programs. Pursuant to the Letter Agreement, Alnylam were responsible for conducting pre-clinical research activities set forth in the existing workplan for the COV Target (the &#x201c;COV Workplan&#x201d;) at its discretion and sole expense, and the Company was no longer obligated to reimburse Alnylam for any share of costs incurred by Alnylam in conducting activities under the COV Workplan after July 1, 2020. In July 2021, Alnylam elected to discontinue the development of the COV Target, and all other related research and development activities in accordance with their rights under the Letter Agreement. As a result, the COV Target and related siRNA program is no longer included within the Amended Alnylam Agreement and all rights to the siRNA program directed to the COV Target reverted to Alnylam.&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development Expenses Recognized for the Period&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company incurred expenses under the Alnylam Agreement of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.7&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million during the &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three and six months ended June&#160;30, 2021&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, respectively. In addition to the Milestone Shares and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;million milestone payable to Alnylam in the first quarter of 2020, and the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;million payment resulting from Brii Bio&#x2019;s option exercise in the second quarter of 2020, the Company incurred expenses of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.5&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.8&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million under the Alnylam Agreement during the &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;three and six months ended June&#160;30, 2020, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;WuXi Biologics&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In February 2020, the Company entered into a development and manufacturing collaboration agreement with WuXi Biologics (Hong Kong) Limited (&#x201c;WuXi Biologics&#x201d;) (the &#x201c;WuXi Biologics Collaboration Agreement&#x201d;), for the clinical development, manufacturing, and commercialization of the Company&#x2019;s proprietary antibodies developed for SARS-CoV-2. Under the WuXi Biologics Collaboration Agreement, WuXi Biologics will conduct cell-line development, process and formulation development, and initial manufacturing for clinical development. WuXi Biologics will have the right to commercialize products incorporating such antibodies in greater China under an exclusive license granted for the selected antibodies that have been developed. The Company will have the right to commercialize such products in all other markets worldwide.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;WuXi &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Biologics will perform mutually agreed development and manufacturing activities, under individual statements of work. In addition, the parties agreed that WuXi Biologics will pay the Company tiered royalties at percentages ranging from the high single-digits to mid-teens on annual net sales of all products sold by WuXi Biologics in greater China. The royalties are payable for a specified, standard royalty term. In addition, if WuXi Biologics sublicenses its commercialization rights to a third party, WuXi Biologics will pay the Company a percentage of the sublicense revenue received from such third party. The WuXi Biologics Collaboration Agreement will continue until the expiration of WuXi Biologics&#x2019; payment obligations to the Company, unless&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;terminated &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;earlier. If terminated earlier, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;the WuXi Biologics Collaboration Agreement may be terminated by (i) the written agreement of both parties, (ii) WuXi Biologics following the one year anniversary of the WuXi Biologics Collaboration Agreement effective date with respect to the entire agreement or on a product by product basis with 90 days&#x2019; prior written notice or (iii) by either party if the other party materially breaches the WuXi Biologics Collaboration Agreement and fails to cure such breach within sixty days.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Rockefeller University&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In July 2018, the Company entered into an exclusive license agreement with The Rockefeller University (&#x201c;Rockefeller&#x201d;), which was amended in May 2019, in September 2020, and in March 2021 (the &#x201c;Rockefeller Agreement&#x201d;). Under the Rockefeller Agreement, Rockefeller granted the Company a worldwide exclusive license under certain patent rights, and a worldwide non-exclusive license under certain materials and know-how covering certain antibody variants relating to a specified mutation leading to enhanced antibody function and utility, to develop, manufacture and commercialize infectious disease products covered by the licensed patents, or that involve the use or incorporation of the licensed materials and know-how, in each case for all uses and purposes for infectious diseases. The Company uses technology licensed under the Rockefeller Agreement in the Company&#x2019;s antibody platform and in the Company&#x2019;s product candidates VIR-3434 and VIR-7832.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company paid Rockefeller an upfront fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;million for entry into the Rockefeller Agreement, and is required to pay annual license maintenance fees of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;million. In addition, for the achievement of specified development, regulatory and commercial success milestone events, the Company will be required to pay up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;80.3&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;million, in the aggregate, for up to six infectious disease products. Any follow-on products beyond six products may result in additional milestone event payments. The Company will also be required to pay to Rockefeller a royalty at a low single-digit percentage rate on net sales of licensed products, subject to certain adjustments. The Company&#x2019;s obligation to pay royalties to Rockefeller will terminate, on a product-by-product and jurisdiction-by-jurisdiction basis, upon the latest of the expiration of the last valid claim of a licensed patent in such jurisdiction, the expiration of all regulatory exclusivity in such jurisdiction or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; following the first commercial sale of the applicable licensed product in such jurisdiction.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under the Rockefeller Agreement, the Company recognized a total of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.3&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million during the three and six months ended June 30, 2021 and 2020, respectively, as research and development expenses related to certain development milestone payments, annual license maintenance fees, and estimated sublicense fees.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Rockefeller Agreement will remain in force, absent earlier termination, until the expiration of all of the Company&#x2019;s obligations to pay royalties to Rockefeller in all jurisdictions. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has the right to terminate the Rockefeller Agreement in its entirety, or in part, for any reason on 60 days&#x2019; written notice to Rockefeller. Rockefeller may terminate the Rockefeller Agreement on 90 days&#x2019; written notice for the Company&#x2019;s uncured material breach, or if the Company challenges the validity or enforceability of any of the licensed patents, or immediately in the event of the Company&#x2019;s insolvency. Rockefeller may also terminate the Rockefeller Agreement if the Company ceases to carry on business with respect to the rights granted to the Company under the agreement. &lt;/span&gt;&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"/&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;MedImmune&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In September 2018, the Company entered into a license agreement, which was amended in September 2020 (the &#x201c;MedImmune Agreement&#x201d;), with MedImmune, LLC  (&#x201c;MedImmune&#x201d;), under which the Company obtained a worldwide, exclusive license to develop and commercialize half-life extended versions of two specified antibodies under development by MedImmune that target influenza A and influenza B, respectively, for all uses in humans and animals. The Company is developing VIR-2482 using technology licensed under the MedImmune Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In consideration for the grant of the licenses under the MedImmune Agreement, the Company made an upfront payment to MedImmune of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company will be obligated to make development, regulatory, and commercial milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;331.5&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;million, of which $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million was paid in the third quarter of 2019, in the aggregate relating to influenza A and influenza B products. MedImmune will also be entitled to receive tiered royalties based on net sales of products containing half-life extended versions of antibodies directed to influenza A and/or influenza B at percentages ranging from the mid-single-digits to sub-teen double-digits.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The MedImmune Agreement will remain in force until the expiration on a country-by-country and product-by-product basis of all of the Company&#x2019;s obligations to pay royalties to MedImmune. &lt;/span&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Company may terminate the MedImmune Agreement in its entirety or on a product-by-product basis, for convenience, upon 120 days&#x2019; notice. Either party may terminate the MedImmune Agreement for cause for the other party&#x2019;s uncured material breach on 60 days&#x2019; notice or immediately in the event of bankruptcy of the other party. &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Additionally, &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;MedImmune may terminate the MedImmune Agreement for cause on 30 days&#x2019; written notice if the Company challenges the validity or enforceability of the patents to which the Company has obtained a license under the MedImmune Agreement.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Xencor&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;August 2019 License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2019, the Company entered into a patent license agreement, which was amended in February 2021 (the &#x201c;2019 Xencor Agreement&#x201d;) with Xencor, Inc., (&#x201c;Xencor&#x201d;). Under the 2019 Xencor Agreement, as amended, the Company obtained a non-exclusive, sublicensable (only to its affiliates and subcontractors) license to incorporate Xencor&#x2019;s licensed technologies into, and to evaluate, antibodies that target influenza A and HBV, and a worldwide, non-exclusive, sublicensable license to develop and commercialize products containing such antibodies incorporating such technologies for all uses, including the treatment, palliation, diagnosis and prevention of human or animal diseases, disorders or conditions. The Company is obligated to use commercially reasonable efforts to develop and commercialize an antibody product that incorporates Xencor&#x2019;s licensed technologies, for each of the influenza A and HBV research programs. These technologies are used in the Company&#x2019;s VIR-2482, incorporating Xencor&#x2019;s Xtend technology, and VIR-3434, incorporating Xencor&#x2019;s Xtend and other Fc technologies, product candidates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In consideration for the grant of the license, the Company paid Xencor an upfront fee. For each of the influenza A and HBV research programs, the Company will be required to pay Xencor development and regulatory milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.8&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;million in the aggregate, and commercial sales milestone payments of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;million in the aggregate, for a total of up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;77.8&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;million in aggregate milestones for each program and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;155.5&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;million in aggregate milestones for both programs. On a product-by-product basis, the Company will also be obligated to pay tiered royalties based on net sales of licensed products ranging from low- to mid-single-digits. The royalties are payable, on a product-by-product and country-by-country basis, until the expiration of the last to expire valid claim in the licensed patents covering such product in such country.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2019, the Company achieved one of the specified development milestones related to the influenza A program. As such, the Company paid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;million related to the upfront fee and this milestone event in September 2019. In May 2020, the Company achieved one of the specified development milestones related to the HBV program. As such, the Company paid $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million related to this milestone event in June 2020. The milestone payments are expensed to research and development.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;March 2020 License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March 2020, the Company entered into a patent license agreement, which was amended in February 2021 (the &#x201c;2020 Xencor Agreement&#x201d;) with Xencor under which the Company obtained a non-exclusive, sublicensable (only to the Company&#x2019;s affiliates and subcontractors) license to incorporate Xencor&#x2019;s licensed technologies into, and to evaluate, antibodies that target any component of a coronavirus, including SARS-CoV-2, SARS-CoV and MERS-CoV, and a worldwide, non-exclusive, sublicensable license to develop and commercialize products containing such antibodies incorporating such technologies for all uses, including the treatment, palliation, diagnosis and prevention of human or animal diseases, disorders or conditions. The Company is obligated to use commercially reasonable efforts to develop and commercialize an antibody product that incorporates Xencor&#x2019;s licensed technologies, for each of the coronavirus research programs. These technologies are used in the Company&#x2019;s sotrovimab, incorporating Xencor&#x2019;s Xtend technology, and VIR-7832, incorporating Xencor&#x2019;s Xtend and other Fc technologies, product candidates.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In consideration for the grant of the license, the Company will be obligated to pay royalties based on net sales of licensed products at the mid-single-digits. The royalties are payable, on a product-by-product and country-by-country basis, until the later of the expiration of the last to expire valid claim in the licensed patents covering such product in such country or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12 years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. During the three months ended June 30, 2021, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of royalties due to Xencor from the sale of sotrovimab.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The amended 2020 Xencor Agreement and 2019 Xencor Agreement will remain in force, on a product-by-product and country-by-country basis, until the expiration of all royalty payment obligations under each of the respective agreements. The Company may terminate each agreement in its entirety, or on a target-by-target basis, for convenience upon &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60 days&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2019; written notice. Either party may terminate each agreement for the other party&#x2019;s uncured material breach upon &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60 days&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2019; written notice (or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30 days&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; in the case of non-payment) or in the event of bankruptcy of the other party immediately upon written notice. Xencor may terminate each agreement immediately upon written notice if the Company challenges, or upon &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30 days&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2019; written notice if any of the Company&#x2019;s sublicensees challenge, the validity or enforceability of any patent licensed to the Company under each respective agreement.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9fb0d2a0-3667-49a0-9e2e-0eb6e51eb0f2"
      decimals="INF"
      id="F_e9776ca1-436b-42c1-ac54-75771e60539e"
      unitRef="U_shares">6626027</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="C_99cf4f8f-4dae-413b-b3e0-c9a5646a7659"
      decimals="INF"
      id="F_290671cc-02df-4c49-8f0f-8fb5037cedb0"
      unitRef="U_USDollarShare">37.73</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_9fb0d2a0-3667-49a0-9e2e-0eb6e51eb0f2"
      decimals="-5"
      id="F_8410b32c-bd05-49f9-951f-c2f9abf3ee90"
      unitRef="U_USD">250000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <vir:NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans
      contextRef="C_de475ddf-8c37-4d7a-ad85-a7698299ec12"
      id="F_9213d111-f718-46ef-90f0-409fca6fb819">P4Y</vir:NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans>
    <vir:PercentageOfDevelopmentCosts
      contextRef="C_3b26811f-118d-4a95-ad64-0f8108301f7e"
      decimals="3"
      id="F_d4ab55f0-6335-4118-871f-61b2dea051f6"
      unitRef="U_pure">0.725</vir:PercentageOfDevelopmentCosts>
    <vir:PercentageOfDevelopmentCosts
      contextRef="C_f9ac6857-461c-4a04-bd24-2ecc9ae4c36c"
      decimals="3"
      id="F_3e42d848-ea5f-4e87-8ee9-bc3a15f17919"
      unitRef="U_pure">0.275</vir:PercentageOfDevelopmentCosts>
    <vir:MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct
      contextRef="C_de475ddf-8c37-4d7a-ad85-a7698299ec12"
      decimals="2"
      id="F_74eef57c-9d17-44f3-801e-9e2fe39bfe2b"
      unitRef="U_pure">0.20</vir:MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct>
    <vir:CollaborationAgreementTerminationDescription
      contextRef="C_da489d47-65d8-4ebf-bb93-4ab4e0d479cc"
      id="F_7ca59415-87d8-42aa-92f1-fb7194ef45c5">Either party has the right to terminate the 2020 GSK Agreement in the case of the insolvency of the other party, an uncured material breach of the other party with respect to a collaboration program or collaboration product, or as mutually agreed by the parties.</vir:CollaborationAgreementTerminationDescription>
    <vir:FairMarketValueOfCommonStockIssued
      contextRef="C_0e63f2d6-4f5f-4686-b5df-65f256ff2672"
      decimals="-5"
      id="F_0a745543-af22-4e11-a2fb-db062e0e8cba"
      unitRef="U_USD">206700000</vir:FairMarketValueOfCommonStockIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_65199b01-efc8-4ecd-92f0-3fdb4dbb14b2"
      decimals="2"
      id="F_cfbcb13c-ff44-4ad5-b545-ca88246e70f0"
      unitRef="U_USDollarShare">36.70</us-gaap:SaleOfStockPricePerShare>
    <vir:PremiumReceivedOnSalePriceOfCommonStock
      contextRef="C_0e63f2d6-4f5f-4686-b5df-65f256ff2672"
      decimals="-5"
      id="F_be655130-e588-4682-b5a2-1e26d72491bc"
      unitRef="U_USD">43300000</vir:PremiumReceivedOnSalePriceOfCommonStock>
    <vir:CollaborationAgreementNumberOfUnitsOfAccount
      contextRef="C_8f037847-06a9-43f3-aee1-9f0d4957157f"
      decimals="INF"
      id="F_c8160f87-7ae2-454e-8cc7-9fd6c2170257"
      unitRef="U_Unit">4</vir:CollaborationAgreementNumberOfUnitsOfAccount>
    <vir:AntibodyLicenseTransactionPrice
      contextRef="C_3b26811f-118d-4a95-ad64-0f8108301f7e"
      decimals="-5"
      id="F_8ad2b990-e882-4aa3-9eb7-4ce49a7abf20"
      unitRef="U_USD">43300000</vir:AntibodyLicenseTransactionPrice>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_2063058a-a5a7-4574-92c4-5fad668297f8"
      decimals="-5"
      id="F_b6abee3a-96d3-44c5-a432-95c92d9d8aa3"
      unitRef="U_USD">43300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b4f1dc34-56da-4847-88c1-d9bfde49f709"
      decimals="-5"
      id="F_15c94fd0-d358-42a1-bbfd-36b4e7eced9c"
      unitRef="U_USD">5300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <vir:IncreaseDecreaseInResearchAndDevelopmentExpense
      contextRef="C_eae8bb82-8872-4a24-ae26-c2e4d2dfb653"
      decimals="-5"
      id="F_d8cf98fc-b1e6-4ee4-a647-98f35f7d21ce"
      unitRef="U_USD">17900000</vir:IncreaseDecreaseInResearchAndDevelopmentExpense>
    <vir:IncreaseDecreaseInResearchAndDevelopmentExpense
      contextRef="C_da489d47-65d8-4ebf-bb93-4ab4e0d479cc"
      decimals="-5"
      id="F_bd08179e-3f90-4f21-841e-b3d52fc33bca"
      unitRef="U_USD">36400000</vir:IncreaseDecreaseInResearchAndDevelopmentExpense>
    <vir:ReductionOfResearchAndDevelopmentExpense
      contextRef="C_0f91c4ca-040c-431f-8606-3532fe5467a6"
      decimals="-5"
      id="F_c3cbc28d-00e3-4bca-8797-4217d559e5cb"
      unitRef="U_USD">3800000</vir:ReductionOfResearchAndDevelopmentExpense>
    <vir:ReductionOfResearchAndDevelopmentExpense
      contextRef="C_b649d3cd-def2-4c81-bc48-8799c56de0c7"
      decimals="-5"
      id="F_6aebb1f4-b94e-4e54-8769-fb83e738b560"
      unitRef="U_USD">3800000</vir:ReductionOfResearchAndDevelopmentExpense>
    <vir:PayableUnderAgreementCurrent
      contextRef="C_9ae22d18-4ca6-4836-bd15-1b10932c9c7f"
      decimals="-5"
      id="F_d29271a7-00de-45ce-abbe-9288020da2e9"
      unitRef="U_USD">12700000</vir:PayableUnderAgreementCurrent>
    <vir:PayableUnderAgreementCurrent
      contextRef="C_89d302b2-5e08-4283-8a49-1c1dc6be912e"
      decimals="-5"
      id="F_8566e0be-5f46-42c3-968e-779e28786155"
      unitRef="U_USD">28000000.0</vir:PayableUnderAgreementCurrent>
    <vir:CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate
      contextRef="C_02f60d12-f390-4dfe-ac4c-a065441e738a"
      decimals="INF"
      id="F_bb626b74-2a01-4a1d-9a42-efb1b9658533"
      unitRef="U_Program">3</vir:CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_502695ad-a686-4d7f-9e55-303eb9e384b6"
      decimals="-5"
      id="F_30c224e7-f95e-4d5c-a53b-19b284cfddc2"
      unitRef="U_USD">120000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_e5e16aa4-a601-484e-b470-db2c156ea530"
      decimals="INF"
      id="F_415c8348-887d-445a-9be7-5c3e41f89093"
      unitRef="U_shares">1924927</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <vir:NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans
      contextRef="C_8078c547-b260-434d-8ab2-1b0f12cd0d5f"
      id="F_6fe4a76a-adef-4f34-a1f5-5cae2d67e86a">P3Y</vir:NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans>
    <vir:PercentageOfShareDevelopmentCosts
      contextRef="C_a83f3768-0952-4ecd-91fb-ac4523a646de"
      decimals="INF"
      id="F_90965b46-c62d-43e6-b8e5-3c74eedffc02"
      unitRef="U_pure">0.50</vir:PercentageOfShareDevelopmentCosts>
    <vir:ProfitsAndLossesSharingPercentage
      contextRef="C_a83f3768-0952-4ecd-91fb-ac4523a646de"
      decimals="INF"
      id="F_a6a71e06-a562-44c4-ad4b-a08766f069ad"
      unitRef="U_pure">0.50</vir:ProfitsAndLossesSharingPercentage>
    <vir:UpfrontPaymentReceivable
      contextRef="C_cff84f6a-b57e-47a0-a02b-dcac6185a725"
      decimals="-5"
      id="F_02aec6ea-265e-4c2d-b25d-2af5ca3d9a90"
      unitRef="U_USD">225000000.0</vir:UpfrontPaymentReceivable>
    <vir:PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement
      contextRef="C_cff84f6a-b57e-47a0-a02b-dcac6185a725"
      decimals="INF"
      id="F_5dc4f0ba-e17e-4956-8eaf-ff65bf35f0d5"
      unitRef="U_pure">0.50</vir:PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement>
    <vir:PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement
      contextRef="C_8f7f9c58-f98b-4a8f-95b9-e5182870c64d"
      decimals="2"
      id="F_e3adeeb9-85fe-4431-8d5a-bb8274d56be3"
      unitRef="U_pure">0.50</vir:PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement>
    <vir:OptionExerciseFeeConsiderationToBeReceived
      contextRef="C_cff84f6a-b57e-47a0-a02b-dcac6185a725"
      decimals="-5"
      id="F_29155f18-3655-4243-8693-72e115d36e91"
      unitRef="U_USD">300000000.0</vir:OptionExerciseFeeConsiderationToBeReceived>
    <vir:PreDefinedRegulatoryMilestoneConsiderationReceivable
      contextRef="C_33123595-07a6-4f85-a3a1-bc8546d832b5"
      decimals="-5"
      id="F_17e6aa47-cdd2-4f83-99cf-96c4f24f8b29"
      unitRef="U_USD">200000000.0</vir:PreDefinedRegulatoryMilestoneConsiderationReceivable>
    <vir:FairMarketValueOfCommonStockIssued
      contextRef="C_c50def4f-f04d-4b74-a20a-53c116d0b11f"
      decimals="-5"
      id="F_fc7e4de1-9d08-442f-8217-4d55f285cad1"
      unitRef="U_USD">85200000</vir:FairMarketValueOfCommonStockIssued>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_52d2443e-0fd8-42f6-9e80-a3310414715c"
      decimals="INF"
      id="F_8bec148c-d86e-4e73-8f7d-e70908c0d868"
      unitRef="U_USDollarShare">52.70</us-gaap:SaleOfStockPricePerShare>
    <vir:PremiumReceivedOnSalePriceOfCommonStock
      contextRef="C_c50def4f-f04d-4b74-a20a-53c116d0b11f"
      decimals="-5"
      id="F_5c2a5540-ae32-4f74-b749-e56f607b302f"
      unitRef="U_USD">34800000</vir:PremiumReceivedOnSalePriceOfCommonStock>
    <vir:CollaborationAgreementTransactionPriceFixedConsideration
      contextRef="C_3b171620-e654-43aa-be16-06e50f0a2698"
      decimals="-5"
      id="F_e96eae6d-bb0c-4bce-8d93-03e4be96b948"
      unitRef="U_USD">225000000.0</vir:CollaborationAgreementTransactionPriceFixedConsideration>
    <vir:PremiumPaidOnSalePriceOfCommonStock
      contextRef="C_d0b20436-58e4-46d4-92e4-fe201bcf47c2"
      decimals="-5"
      id="F_867461b7-6f07-4d68-a7da-02c1a91293d3"
      unitRef="U_USD">34800000</vir:PremiumPaidOnSalePriceOfCommonStock>
    <vir:CollaborationAgreementTransactionPriceConsideration
      contextRef="C_3b171620-e654-43aa-be16-06e50f0a2698"
      decimals="-5"
      id="F_5270cb65-02e3-46c1-aaa6-8fbba0ed9d7a"
      unitRef="U_USD">259800000</vir:CollaborationAgreementTransactionPriceConsideration>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_9f0a8c2d-23ab-4ba5-9c8d-ca28574c8b2c"
      decimals="-5"
      id="F_cf0ca705-82ea-43e9-8542-22211ccf8ac0"
      unitRef="U_USD">168300000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:DeferredRevenue
      contextRef="C_51cc81ca-5eda-4a6a-a5dd-56c6a7083323"
      decimals="-5"
      id="F_c861ab76-20e9-4575-840e-893f4f81a979"
      unitRef="U_USD">91500000</us-gaap:DeferredRevenue>
    <us-gaap:DeferredRevenueCurrent
      contextRef="C_51cc81ca-5eda-4a6a-a5dd-56c6a7083323"
      decimals="-5"
      id="F_32ea01f2-0938-4709-a590-ecbf4d37621b"
      unitRef="U_USD">39800000</us-gaap:DeferredRevenueCurrent>
    <us-gaap:DeferredRevenueNoncurrent
      contextRef="C_51cc81ca-5eda-4a6a-a5dd-56c6a7083323"
      decimals="-5"
      id="F_208ae8d8-2f98-419a-9bc1-2a7f3ad3a773"
      unitRef="U_USD">51700000</us-gaap:DeferredRevenueNoncurrent>
    <vir:ReductionOfResearchAndDevelopmentExpense
      contextRef="C_8d5790db-7c09-460a-9153-c6331074affd"
      decimals="-5"
      id="F_1841b788-2750-47bf-8c07-f3c7977058f8"
      unitRef="U_USD">100000</vir:ReductionOfResearchAndDevelopmentExpense>
    <vir:ReductionOfResearchAndDevelopmentExpense
      contextRef="C_cc499f93-896e-4bdf-be24-28ce2921af3f"
      decimals="-5"
      id="F_6cb891bd-da9f-4969-b64a-d42cc11ed4bb"
      unitRef="U_USD">100000</vir:ReductionOfResearchAndDevelopmentExpense>
    <vir:PercentageOfOrdinaryShareEqualToOutstandingShare
      contextRef="C_c99a0b18-718d-4edc-baf8-ddcb6d2b2cee"
      decimals="INF"
      id="F_e240a742-cd59-4d12-8fd3-e02a42cd471a"
      unitRef="U_pure">0.099</vir:PercentageOfOrdinaryShareEqualToOutstandingShare>
    <vir:OptionExerciseFeeConsiderationReceivable
      contextRef="C_ac8bcb94-38bb-498a-a74f-16bc3f88cf85"
      decimals="-5"
      id="F_ca4366e3-d51c-48ee-82c4-de012c4e1c1c"
      unitRef="U_USD">20000000.0</vir:OptionExerciseFeeConsiderationReceivable>
    <vir:RegulatoryMilestoneConsiderationReceivable
      contextRef="C_4b592749-62ec-4fae-9b15-04061affca47"
      decimals="-5"
      id="F_6c0607c2-fdd3-4740-8dbf-b00efee7b451"
      unitRef="U_USD">30000000.0</vir:RegulatoryMilestoneConsiderationReceivable>
    <vir:SalesMilestoneConsiderationReceivable
      contextRef="C_ac8bcb94-38bb-498a-a74f-16bc3f88cf85"
      decimals="-5"
      id="F_001862ba-9eca-40f8-b87b-6f7cfb530e8b"
      unitRef="U_USD">175000000.0</vir:SalesMilestoneConsiderationReceivable>
    <vir:OptionExerciseFeeConsiderationPayableDescription
      contextRef="C_dc5358a1-e8cd-4f63-a453-32242603a269"
      id="F_cf886abf-d491-495e-a408-18569468e9fa">low tens of millions</vir:OptionExerciseFeeConsiderationPayableDescription>
    <vir:OptionExerciseFeeConsiderationPayable
      contextRef="C_4830ca2a-0ad5-4a32-b98f-bae2d1970486"
      decimals="-5"
      id="F_fec1634c-b5b3-46fe-9350-ad16a5e20c60"
      unitRef="U_USD">50000000.0</vir:OptionExerciseFeeConsiderationPayable>
    <vir:RegulatoryMilestonePaymentConsiderationPayable
      contextRef="C_8ae3adcd-4938-4c7c-921a-6d25c5205981"
      decimals="-5"
      id="F_3aa52cc6-795d-4c38-815d-47c7e27973e1"
      unitRef="U_USD">100000000.0</vir:RegulatoryMilestonePaymentConsiderationPayable>
    <vir:SalesMilestoneConsiderationPayable
      contextRef="C_1f9878a0-4b15-4465-8e06-ac38077a8fcc"
      decimals="-5"
      id="F_78a898b8-da9b-400c-8136-584f3474613e"
      unitRef="U_USD">175000000.0</vir:SalesMilestoneConsiderationPayable>
    <vir:RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales
      contextRef="C_0593f237-da08-4238-8805-6911cc8c2af4"
      id="F_1d9bc0c5-e556-4055-9c53-b2e209c6c30a">P10Y</vir:RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales>
    <vir:CollaborationAgreementTerminationDescription
      contextRef="C_2780ba97-f35b-4286-8d16-f6c692bbc074"
      id="F_74b84ad8-2634-4c15-9517-c5985d08032b">Each party may terminate for convenience all rights and obligations with respect to any program for which it has an option, with 30 days&#x2019; written notice (if the terminating party has not exercised an option for such program) or 180 days&#x2019; notice (following the exercise of an option for such program). The Brii Agreement may also be terminated by either party for insolvency of the other party, and either party may terminate the Brii Agreement in its entirety or on a program-by-program basis for the other party&#x2019;s uncured material breach on 60 days&#x2019; written notice (or 30 days&#x2019; notice following failure to make payment).</vir:CollaborationAgreementTerminationDescription>
    <vir:WrittenNoticePeriodForLicensedProgramNotExercisedAnOption
      contextRef="C_69fba054-c419-4e8e-b49f-667d17bf850d"
      id="F_c5dbc2e5-7397-4daa-b134-a8589ee6e8e3">P30D</vir:WrittenNoticePeriodForLicensedProgramNotExercisedAnOption>
    <vir:WrittenNoticePeriodForLicensedProgramExerciseAnOption
      contextRef="C_69fba054-c419-4e8e-b49f-667d17bf850d"
      id="F_7e0c512f-7a5f-462b-b97d-75c37c2396ba">P180D</vir:WrittenNoticePeriodForLicensedProgramExerciseAnOption>
    <vir:WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach
      contextRef="C_69fba054-c419-4e8e-b49f-667d17bf850d"
      id="F_0cae3f18-2d8f-4025-964c-ee5fb6cf1d7d">P60D</vir:WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach>
    <vir:WrittenNoticePeriodForLicensedProgramFailureToMakePayment
      contextRef="C_69fba054-c419-4e8e-b49f-667d17bf850d"
      id="F_1d4f351b-277c-4570-8db6-0ba35073207a">P30D</vir:WrittenNoticePeriodForLicensedProgramFailureToMakePayment>
    <us-gaap:Investments
      contextRef="C_f57d1eff-a8c4-4b5c-8802-9f372ef5f371"
      decimals="-5"
      id="F_a697e222-9295-4bbc-96fb-0fe984920474"
      unitRef="U_USD">5700000</us-gaap:Investments>
    <us-gaap:Investments
      contextRef="C_66bfb7f9-fc0b-4e62-b6fc-4e629327a410"
      decimals="-5"
      id="F_7347d1d8-82dd-48a0-8271-dee8457106ee"
      unitRef="U_USD">5700000</us-gaap:Investments>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_8bc5a624-6688-41fd-9d8d-c6c0f2147de0"
      decimals="-5"
      id="F_ab17a35f-28bf-4f2a-bfdb-504d2be8f7b0"
      unitRef="U_USD">3800000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <vir:OptionExerciseFeeReceived
      contextRef="C_a4c9273d-ad95-4c98-a7c8-805e95b768b3"
      decimals="-5"
      id="F_466bc407-020d-47d6-80e7-85c23a54c7c8"
      unitRef="U_USD">20000000.0</vir:OptionExerciseFeeReceived>
    <vir:RegulatoryMilestoneConsiderationReceivable
      contextRef="C_4b592749-62ec-4fae-9b15-04061affca47"
      decimals="-5"
      id="F_03e8de45-f5be-4bec-893a-5e6bc87db38c"
      unitRef="U_USD">30000000.0</vir:RegulatoryMilestoneConsiderationReceivable>
    <vir:SalesMilestoneConsiderationReceivable
      contextRef="C_ac8bcb94-38bb-498a-a74f-16bc3f88cf85"
      decimals="-5"
      id="F_48845bc4-fc62-42a1-b5c4-ad94d21b57b5"
      unitRef="U_USD">175000000.0</vir:SalesMilestoneConsiderationReceivable>
    <vir:DeterminedTransactionPrice
      contextRef="C_393392b3-d188-48ce-8ebf-843e5e51a678"
      decimals="-5"
      id="F_0accbfdf-cc8d-4853-a838-63a8f3b5785a"
      unitRef="U_USD">22700000</vir:DeterminedTransactionPrice>
    <vir:RegulatoryMilestoneConsiderationReceivable
      contextRef="C_ac8bcb94-38bb-498a-a74f-16bc3f88cf85"
      decimals="-5"
      id="F_b72a70c3-208f-4039-b054-8bb36f345573"
      unitRef="U_USD">20000000.0</vir:RegulatoryMilestoneConsiderationReceivable>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent
      contextRef="C_ac8bcb94-38bb-498a-a74f-16bc3f88cf85"
      decimals="-5"
      id="F_a91cb0c7-0b6e-4dde-a141-a9aa5bb388ef"
      unitRef="U_USD">2700000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_2aa44c95-3aa8-4eec-9de8-8fa66be5bfc1"
      decimals="-6"
      id="F_0a49f986-3295-4066-82df-b583a608a474"
      unitRef="U_USD">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_b213ca27-309b-4229-b799-81e86bb50576"
      decimals="-5"
      id="F_f5ffc929-15af-4dfa-8b61-64847ad5977a"
      unitRef="U_USD">400000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="C_10f77595-19f0-40f3-8510-ff21caa1970b"
      decimals="-5"
      id="F_1e863df7-24f6-4bfb-848a-5e696133e5d4"
      unitRef="U_USD">22700000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <vir:PaymentToPartnerResultingFromProgramOptionExercise
      contextRef="C_c3b4e715-3396-4fc0-a8e8-1b7c2ed5260b"
      decimals="-5"
      id="F_528026f0-2cca-4646-aece-fd209e33500e"
      unitRef="U_USD">10000000.0</vir:PaymentToPartnerResultingFromProgramOptionExercise>
    <vir:UpfrontFeePaid
      contextRef="C_b68e43f8-fa5f-4941-a772-ac4ca77f6039"
      decimals="-5"
      id="F_59e3318a-6ebf-4c95-b922-ac1469505e56"
      unitRef="U_USD">10000000.0</vir:UpfrontFeePaid>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_b68e43f8-fa5f-4941-a772-ac4ca77f6039"
      decimals="INF"
      id="F_6ba58c55-5f53-4fc4-9d72-c1b7265791b5"
      unitRef="U_shares">1111111</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <vir:SharePayableToCollaborator
      contextRef="C_267658dc-f7db-4ab6-94bc-b9662b0d993d"
      decimals="-5"
      id="F_69a7284a-7438-40a8-88f6-94927aee376f"
      unitRef="U_USD">800000</vir:SharePayableToCollaborator>
    <vir:MaximumSharesToBeIssued
      contextRef="C_267658dc-f7db-4ab6-94bc-b9662b0d993d"
      decimals="INF"
      id="F_71b7aae8-ed03-4323-bcd3-acc15d15b44c"
      unitRef="U_shares">1111111</vir:MaximumSharesToBeIssued>
    <vir:MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory
      contextRef="C_11d39f80-330e-4128-989f-4084388ad346"
      decimals="-5"
      id="F_1f3395f2-40ba-43ee-b4f9-5ab82cd256a6"
      unitRef="U_USD">190000000.0</vir:MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory>
    <vir:MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory
      contextRef="C_d9b5a18c-ba78-4c5f-bb0f-40e2ed6661d1"
      decimals="-5"
      id="F_c1519893-3d0a-4655-9b6d-c3952076da97"
      unitRef="U_USD">115000000.0</vir:MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory>
    <vir:MaximumAggregateSalesMilestonePayment
      contextRef="C_e2de7da2-b046-4ec0-ad5e-5f3b001ed026"
      decimals="-5"
      id="F_888effdc-7b58-4d91-a9d0-3c54ed05a48c"
      unitRef="U_USD">250000000.0</vir:MaximumAggregateSalesMilestonePayment>
    <vir:MaximumSalesMilestonePayment
      contextRef="C_e2de7da2-b046-4ec0-ad5e-5f3b001ed026"
      decimals="-5"
      id="F_82a67608-a379-49a6-8868-d9bc1600c1c2"
      unitRef="U_USD">100000000.0</vir:MaximumSalesMilestonePayment>
    <vir:RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales
      contextRef="C_580342cb-5db5-408f-ae9b-48fd57cdb017"
      id="F_379deb3a-5683-44f6-ab21-912f99b01d28">P10Y</vir:RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales>
    <vir:WrittenNoticePeriodForLicensedProgramExerciseAnOption
      contextRef="C_b68e43f8-fa5f-4941-a772-ac4ca77f6039"
      id="F_3d5d1c09-55ee-4d93-bb9d-05599f6be94f">P90D</vir:WrittenNoticePeriodForLicensedProgramExerciseAnOption>
    <vir:WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach
      contextRef="C_b68e43f8-fa5f-4941-a772-ac4ca77f6039"
      id="F_6f2bb8a7-25e6-4cc1-b740-86ba0ba8ff3d">P60D</vir:WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach>
    <vir:WrittenNoticePeriodForLicensedProgramFailureToMakePayment
      contextRef="C_b68e43f8-fa5f-4941-a772-ac4ca77f6039"
      id="F_fe2c5b9e-49fa-4cda-b4ed-b947d2e2b4ec">P30D</vir:WrittenNoticePeriodForLicensedProgramFailureToMakePayment>
    <vir:WrittenNoticePeriodForLicensedProgramOtherPartyChallengesValidityOrEnforceabilityOfPatentLicense
      contextRef="C_b68e43f8-fa5f-4941-a772-ac4ca77f6039"
      id="F_ece8a9b7-a4f9-419e-b9c6-454d904cabec">P30D</vir:WrittenNoticePeriodForLicensedProgramOtherPartyChallengesValidityOrEnforceabilityOfPatentLicense>
    <us-gaap:DerivativeFairValueOfDerivativeLiability
      contextRef="C_17da886f-2297-41d5-a984-97218fc86f75"
      decimals="-5"
      id="F_a009c562-0a34-4709-b02e-c87048a20037"
      unitRef="U_USD">29200000</us-gaap:DerivativeFairValueOfDerivativeLiability>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_cca64f01-43cb-4521-a7c0-b8c072d00e2a"
      decimals="INF"
      id="F_55eeb7ae-0a64-4d34-a208-06a54a9d391f"
      unitRef="U_shares">1111111</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <vir:ContractualPayments
      contextRef="C_33c31548-53fa-4da7-9d3c-4b3f3239fd4a"
      decimals="-5"
      id="F_57e3fcd7-f959-46b0-b022-1d677e33197f"
      unitRef="U_USD">15000000.0</vir:ContractualPayments>
    <vir:CollaborationAgreementRelatedCostsAndExpenses
      contextRef="C_97110788-5408-406c-be78-a9a445a7d443"
      decimals="-5"
      id="F_dcabc38a-e08c-45a9-89f4-7a3cd5ac2040"
      unitRef="U_USD">800000</vir:CollaborationAgreementRelatedCostsAndExpenses>
    <vir:CollaborationAgreementRelatedCostsAndExpenses
      contextRef="C_580342cb-5db5-408f-ae9b-48fd57cdb017"
      decimals="-5"
      id="F_89c118cd-4ec5-40ed-ba3c-888e59af53d3"
      unitRef="U_USD">1700000</vir:CollaborationAgreementRelatedCostsAndExpenses>
    <vir:MilestonePaymentsPaid
      contextRef="C_b435674c-7a19-45d9-b704-d50d4dea4823"
      decimals="-5"
      id="F_f510a42c-d984-4126-afe1-6bcab5c0bf8b"
      unitRef="U_USD">15000000.0</vir:MilestonePaymentsPaid>
    <vir:MilestonePaymentsPaid
      contextRef="C_44f8d63c-2efc-4376-972c-8a2d8299bc16"
      decimals="-5"
      id="F_4b71bf9b-21ae-47c3-b9d9-0083b8f3a5fc"
      unitRef="U_USD">10000000.0</vir:MilestonePaymentsPaid>
    <vir:CollaborationAgreementRelatedCostsAndExpenses
      contextRef="C_33c31548-53fa-4da7-9d3c-4b3f3239fd4a"
      decimals="-5"
      id="F_add6c9f9-c011-41f4-b3b0-ed5f077fee43"
      unitRef="U_USD">2500000</vir:CollaborationAgreementRelatedCostsAndExpenses>
    <vir:CollaborationAgreementRelatedCostsAndExpenses
      contextRef="C_f34e6246-fbef-4861-a312-c896b3da8b57"
      decimals="-5"
      id="F_0bada294-e048-4ed0-9099-3c0126c3d256"
      unitRef="U_USD">4800000</vir:CollaborationAgreementRelatedCostsAndExpenses>
    <vir:CollaborationAgreementTerminationDescription
      contextRef="C_416eb633-0ce4-467f-ad2a-37987bfe677b"
      id="F_f633d4c5-f61c-46a9-9400-ed49a37d150e">the WuXi Biologics Collaboration Agreement may be terminated by (i) the written agreement of both parties, (ii) WuXi Biologics following the one year anniversary of the WuXi Biologics Collaboration Agreement effective date with respect to the entire agreement or on a product by product basis with 90 days&#x2019; prior written notice or (iii) by either party if the other party materially breaches the WuXi Biologics Collaboration Agreement and fails to cure such breach within sixty days.</vir:CollaborationAgreementTerminationDescription>
    <vir:UpfrontFeePaid
      contextRef="C_9e18bb3c-4c77-45f7-a376-3d3aa6ea7b8b"
      decimals="-5"
      id="F_3131d972-217d-4f92-b462-bd5460898080"
      unitRef="U_USD">300000</vir:UpfrontFeePaid>
    <vir:PaymentOfAnnualLicenseMaintenanceFees
      contextRef="C_cc967922-0ffb-4e42-9643-902ddc2a4a56"
      decimals="-5"
      id="F_220a8d1f-2cda-4467-aa61-9ec9d9ebc11d"
      unitRef="U_USD">1000000.0</vir:PaymentOfAnnualLicenseMaintenanceFees>
    <vir:MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory
      contextRef="C_8e7bbb2c-772e-4f93-ba28-8ef8fd39ba8a"
      decimals="-5"
      id="F_658000be-bd4c-4d75-b3b0-d843608661a2"
      unitRef="U_USD">80300000</vir:MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory>
    <vir:RoyaltyObligationPeriodFromDateOfFirstCommercialSale
      contextRef="C_656e7f8d-dcdb-4596-bc50-c6a3693b2cf4"
      id="F_d3951307-0ebb-4c29-9827-100c43529db7">P12Y</vir:RoyaltyObligationPeriodFromDateOfFirstCommercialSale>
    <vir:SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees
      contextRef="C_9e86b99a-0581-4171-849d-e82b23f80034"
      decimals="-2"
      id="F_b6bff92d-5721-40df-81fc-a0987d715d10"
      unitRef="U_USD">4000.0</vir:SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees>
    <vir:SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees
      contextRef="C_8780a7ad-2026-45bc-835f-43e7a4f6e155"
      decimals="-2"
      id="F_618794d9-82f6-44ee-8df7-4e49dc788c93"
      unitRef="U_USD">4000.0</vir:SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees>
    <vir:SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees
      contextRef="C_30c20ac0-452b-41d8-aabf-b6962ca7e754"
      decimals="-5"
      id="F_692bb654-0e4e-4ee4-8c7c-e4b7e9362fe6"
      unitRef="U_USD">1300000</vir:SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees>
    <vir:SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees
      contextRef="C_222e97e5-5f11-45bd-9409-870b0ab08dec"
      decimals="-5"
      id="F_72c38f0a-3f6e-4333-bdd3-e3bce25983bf"
      unitRef="U_USD">1300000</vir:SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees>
    <vir:CollaborationAgreementTerminationDescription
      contextRef="C_656e7f8d-dcdb-4596-bc50-c6a3693b2cf4"
      id="F_6c7d993f-6d91-4b7d-bdec-58fed1927a65">The Company has the right to terminate the Rockefeller Agreement in its entirety, or in part, for any reason on 60 days&#x2019; written notice to Rockefeller. Rockefeller may terminate the Rockefeller Agreement on 90 days&#x2019; written notice for the Company&#x2019;s uncured material breach, or if the Company challenges the validity or enforceability of any of the licensed patents, or immediately in the event of the Company&#x2019;s insolvency. Rockefeller may also terminate the Rockefeller Agreement if the Company ceases to carry on business with respect to the rights granted to the Company under the agreement. </vir:CollaborationAgreementTerminationDescription>
    <vir:LicenseAgreementUpfrontPayment
      contextRef="C_d18e2209-527e-424f-914a-da611d338ba7"
      decimals="-5"
      id="F_c95f9d3f-ad04-4dac-881a-8df45095e0cc"
      unitRef="U_USD">10000000.0</vir:LicenseAgreementUpfrontPayment>
    <vir:DevelopmentRegulatoryAndCommercialMilestonePaymentsMaximumAmount
      contextRef="C_7ac0807c-bde4-490e-afcd-dd874265ab98"
      decimals="INF"
      id="F_2547185c-ee74-4f06-8a03-89fad20a120a"
      unitRef="U_USD">331500000</vir:DevelopmentRegulatoryAndCommercialMilestonePaymentsMaximumAmount>
    <vir:DevelopmentRegulatoryAndCommercialMilestonePayments
      contextRef="C_7ac0807c-bde4-490e-afcd-dd874265ab98"
      decimals="-5"
      id="F_4ad5bb28-3e21-4f5c-9f95-06937bb4685c"
      unitRef="U_USD">5000000.0</vir:DevelopmentRegulatoryAndCommercialMilestonePayments>
    <vir:CollaborationAgreementTerminationDescription
      contextRef="C_17fb449e-4cf8-4a5c-b8a6-4e7113c7b17e"
      id="F_68808e86-161f-4c00-af97-3785ef71e150">The Company may terminate the MedImmune Agreement in its entirety or on a product-by-product basis, for convenience, upon 120 days&#x2019; notice. Either party may terminate the MedImmune Agreement for cause for the other party&#x2019;s uncured material breach on 60 days&#x2019; notice or immediately in the event of bankruptcy of the other party. Additionally, MedImmune may terminate the MedImmune Agreement for cause on 30 days&#x2019; written notice if the Company challenges the validity or enforceability of the patents to which the Company has obtained a license under the MedImmune Agreement.</vir:CollaborationAgreementTerminationDescription>
    <vir:MaximumAggregateDevelopmentAndRegulatoryMilestonePayments
      contextRef="C_6b3098b0-fc6d-48cf-bf55-bfa1dcc811a9"
      decimals="INF"
      id="F_876c4b0b-d241-448f-bc6c-38dc41da6822"
      unitRef="U_USD">17800000</vir:MaximumAggregateDevelopmentAndRegulatoryMilestonePayments>
    <vir:MaximumAggregateCommercialSalesMilestonePayments
      contextRef="C_6b3098b0-fc6d-48cf-bf55-bfa1dcc811a9"
      decimals="INF"
      id="F_9dfcc7eb-a627-435f-a79a-78232527b276"
      unitRef="U_USD">60000000.0</vir:MaximumAggregateCommercialSalesMilestonePayments>
    <vir:MaximumAggregateMilestonePayments
      contextRef="C_6b3098b0-fc6d-48cf-bf55-bfa1dcc811a9"
      decimals="INF"
      id="F_f16fabbf-d370-4ea6-b506-d775a4a14704"
      unitRef="U_USD">77800000</vir:MaximumAggregateMilestonePayments>
    <vir:MaximumAggregateMilestonePayments
      contextRef="C_ab45b547-9dd6-4076-8bde-04eaac698732"
      decimals="INF"
      id="F_51524ee7-c126-4d91-adff-886c09e013b9"
      unitRef="U_USD">77800000</vir:MaximumAggregateMilestonePayments>
    <vir:MaximumAggregateMilestonePayments
      contextRef="C_19b8ac7c-1cc1-4683-98aa-a394a77dd75f"
      decimals="INF"
      id="F_5177f989-387d-4964-90b6-9db544fd2fdd"
      unitRef="U_USD">155500000</vir:MaximumAggregateMilestonePayments>
    <vir:SpecifiedDevelopmentMilestonesPayment
      contextRef="C_eb7ebaf7-00e9-4b11-8346-81d73478b9fa"
      decimals="-5"
      id="F_e6b95902-e1a6-44fd-8906-c0c4d436cb06"
      unitRef="U_USD">800000</vir:SpecifiedDevelopmentMilestonesPayment>
    <vir:SpecifiedDevelopmentMilestonesPayment
      contextRef="C_be6f5270-fc80-45c9-a95c-b5ef6403279b"
      decimals="-5"
      id="F_4c6ed125-a08d-419f-99c0-04d174318a4b"
      unitRef="U_USD">300000</vir:SpecifiedDevelopmentMilestonesPayment>
    <vir:LicensedPatentsExpirationPeriod
      contextRef="C_0967f1dd-e649-43d3-b4d5-8e34df7fb432"
      id="F_8735c857-c865-4f76-8203-82c26ac64993">P12Y</vir:LicensedPatentsExpirationPeriod>
    <us-gaap:PaymentsForRoyalties
      contextRef="C_436fb49f-f2d5-49a1-83a3-3a3e54fd290d"
      decimals="-5"
      id="F_c2c6b921-fdd8-4e6c-b7ea-5c1ed177e821"
      unitRef="U_USD">900000</us-gaap:PaymentsForRoyalties>
    <vir:WrittenNoticePeriodForTerminationOfLicensedProgram
      contextRef="C_c55af785-6145-4ede-ac28-0f3933e1634e"
      id="F_f4cda960-abe4-4fa4-b6a4-5e8fdb8e0e73">P60D</vir:WrittenNoticePeriodForTerminationOfLicensedProgram>
    <vir:WrittenNoticePeriodForTerminationOfLicensedProgram
      contextRef="C_0967f1dd-e649-43d3-b4d5-8e34df7fb432"
      id="F_ff525600-173a-482b-9ac3-5890f5f30df0">P60D</vir:WrittenNoticePeriodForTerminationOfLicensedProgram>
    <vir:WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach
      contextRef="C_c55af785-6145-4ede-ac28-0f3933e1634e"
      id="F_448fd184-2ea8-4e1a-84a4-b1e9d2c6de5f">P60D</vir:WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach>
    <vir:WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach
      contextRef="C_0967f1dd-e649-43d3-b4d5-8e34df7fb432"
      id="F_8bbd6c61-681b-426c-80f9-c5fac58bf973">P60D</vir:WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach>
    <vir:WrittenNoticePeriodForLicensedProgramFailureToMakePayment
      contextRef="C_c55af785-6145-4ede-ac28-0f3933e1634e"
      id="F_9d3efc31-6f53-414c-a8e0-e735df9a7082">P30D</vir:WrittenNoticePeriodForLicensedProgramFailureToMakePayment>
    <vir:WrittenNoticePeriodForLicensedProgramFailureToMakePayment
      contextRef="C_0967f1dd-e649-43d3-b4d5-8e34df7fb432"
      id="F_341b6b60-a8d0-4401-8551-8096a632ca3c">P30D</vir:WrittenNoticePeriodForLicensedProgramFailureToMakePayment>
    <vir:WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge
      contextRef="C_c55af785-6145-4ede-ac28-0f3933e1634e"
      id="F_0964e134-e494-40fe-b755-1605c816e491">P30D</vir:WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge>
    <vir:WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge
      contextRef="C_0967f1dd-e649-43d3-b4d5-8e34df7fb432"
      id="F_1e9126fe-0bfe-4c13-b745-62c285c0b1b5">P30D</vir:WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge>
    <us-gaap:SupplementalBalanceSheetDisclosuresTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_6ab4f3ed-9a52-4293-8c20-a195c2582789">&lt;p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;7.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;	&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance Sheet Components&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and Equipment, net&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:69.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.143%;"/&gt;
        &lt;td style="width:1.651%;"/&gt;
        &lt;td style="width:1.449%;"/&gt;
        &lt;td style="width:11.634%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
        &lt;td style="width:1.651%;"/&gt;
        &lt;td style="width:1.449%;"/&gt;
        &lt;td style="width:11.554%;"/&gt;
        &lt;td style="width:1.449%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;June&#160;30,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation and amortization expenses was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.3&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.5&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; for the three and six months ended June&#160;30, 2021&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.1&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.1&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; for the three and six months ended June&#160;30, 2020, respectively. &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Accrued and Other Liabilities&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued and other liabilities consist of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:69.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.384%;"/&gt;
        &lt;td style="width:1.664%;"/&gt;
        &lt;td style="width:1.463%;"/&gt;
        &lt;td style="width:11.661%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
        &lt;td style="width:1.664%;"/&gt;
        &lt;td style="width:1.463%;"/&gt;
        &lt;td style="width:11.661%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;June&#160;30,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;49,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Milestone payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Payroll and related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,060&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Excess funds payable under grant agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other professional and consulting expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total accrued and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;64,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:SupplementalBalanceSheetDisclosuresTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_da9fcc2f-d80a-4378-b9b1-558dc7ef0743">&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net consists of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:69.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.143%;"/&gt;
        &lt;td style="width:1.651%;"/&gt;
        &lt;td style="width:1.449%;"/&gt;
        &lt;td style="width:11.634%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
        &lt;td style="width:1.651%;"/&gt;
        &lt;td style="width:1.449%;"/&gt;
        &lt;td style="width:11.554%;"/&gt;
        &lt;td style="width:1.449%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;June&#160;30,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18,168&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16,769&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;580&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,444&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,281&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,274&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,544&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, gross&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32,017&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,178&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less accumulated depreciation and amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,766&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,232&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20,251&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,946&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_60e33361-8e0c-4167-99a3-8c9f96e030ef"
      decimals="-3"
      id="F_6b865e9e-41d0-48cf-a302-05c115da3f41"
      unitRef="U_USD">18168000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a445d18b-0608-4e5b-93b9-215040fa78ac"
      decimals="-3"
      id="F_003f2107-1a04-4c5a-8bd3-57f046273054"
      unitRef="U_USD">16769000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_669328e0-ec12-4a46-9f8e-7642c8e0853a"
      decimals="-3"
      id="F_25f3d4c0-b9a7-4278-9e17-55bb3f206b3b"
      unitRef="U_USD">580000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_7d59a58f-5636-44a9-b169-b1a6c7e3176b"
      decimals="-3"
      id="F_55ac52c5-5143-46ed-886c-f8dd8774c7c3"
      unitRef="U_USD">556000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a6dafe0c-9e29-491e-9182-9ea032ca7de7"
      decimals="-3"
      id="F_346aa29a-2231-4f38-b31a-44cb524f1eb6"
      unitRef="U_USD">1444000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_b2be4dcd-5221-4917-9b4b-42643238614b"
      decimals="-3"
      id="F_67b0418a-b55f-4811-b126-201361eec166"
      unitRef="U_USD">1444000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8e671199-2ede-4d79-bb43-b621397a4811"
      decimals="-3"
      id="F_7f40e704-fafb-4788-b551-fe72116b7358"
      unitRef="U_USD">7281000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_565a5874-4857-48d4-82b7-a9f3af6c43c8"
      decimals="-3"
      id="F_33798bf7-34de-4bd0-a184-e1bc044ce446"
      unitRef="U_USD">7274000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_78a42173-a11f-4d19-985c-306f3564ed73"
      decimals="-3"
      id="F_3bdf7915-fa2e-43cb-bb45-2395e72c2cd6"
      unitRef="U_USD">4544000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_522751c2-1d6d-4f23-b1b2-c7eaa1905197"
      decimals="-3"
      id="F_8049cabe-f931-4a66-8bb4-ea7f43aff81d"
      unitRef="U_USD">1135000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_7a5344ff-78c3-4951-bae6-211f9df9b852"
      unitRef="U_USD">32017000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_0c2c3b71-655d-4652-b4d6-afdc86c53d51"
      unitRef="U_USD">27178000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_62cd2b04-f65a-4bfd-8c4b-55ee3eda390e"
      unitRef="U_USD">11766000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_a994f32f-d41b-40a8-93a5-1ac7ba712bc2"
      unitRef="U_USD">9232000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_f14afc41-701c-4677-96a7-84f01a8bd84f"
      unitRef="U_USD">20251000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_b545bb1f-1864-46a1-a833-8e223efce5a4"
      unitRef="U_USD">17946000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="-5"
      id="F_9b6f9e8c-7f3b-4f4a-96b4-29849ff45c3e"
      unitRef="U_USD">1300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-5"
      id="F_7ee431fd-2ba3-4db3-8544-20c0a492a968"
      unitRef="U_USD">2500000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-5"
      id="F_0306dd44-f570-40b0-928a-865d7a572ac8"
      unitRef="U_USD">1100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-5"
      id="F_5f9fce8c-40a6-4bf0-a16e-14485a843b9f"
      unitRef="U_USD">2100000</us-gaap:DepreciationDepletionAndAmortization>
    <vir:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_4ab2962d-aa5b-483c-b910-671a5c53ea00">&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued and other liabilities consist of the following:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:69.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:68.384%;"/&gt;
        &lt;td style="width:1.664%;"/&gt;
        &lt;td style="width:1.463%;"/&gt;
        &lt;td style="width:11.661%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
        &lt;td style="width:1.664%;"/&gt;
        &lt;td style="width:1.463%;"/&gt;
        &lt;td style="width:11.661%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;June&#160;30,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,952&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;49,384&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Milestone payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Payroll and related expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,353&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,060&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Excess funds payable under grant agreements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,046&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,467&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease liabilities, current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other professional and consulting expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,595&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,334&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total accrued and other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;64,074&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;76,936&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</vir:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock>
    <vir:ResearchAndDevelopmentExpensesCurrent
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_a9677b4e-48e4-4b6b-8a65-cd61af98cb43"
      unitRef="U_USD">30952000</vir:ResearchAndDevelopmentExpensesCurrent>
    <vir:ResearchAndDevelopmentExpensesCurrent
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_cc5e6174-3bdc-4fbd-a2cf-5ac7d967d621"
      unitRef="U_USD">49384000</vir:ResearchAndDevelopmentExpensesCurrent>
    <vir:MilestonePayable
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_e0ca81d0-41b3-4aa6-a0b6-242f25734f2e"
      unitRef="U_USD">10000000</vir:MilestonePayable>
    <vir:PayrollAndRelatedExpensesCurrent
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_3e525123-f0ca-4ff3-b20c-85f84c0ffc59"
      unitRef="U_USD">10353000</vir:PayrollAndRelatedExpensesCurrent>
    <vir:PayrollAndRelatedExpensesCurrent
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_41d1e4a8-7642-4ddf-b7c5-a6581c38044e"
      unitRef="U_USD">17060000</vir:PayrollAndRelatedExpensesCurrent>
    <vir:ExcessFundsPayableUnderGrantAgreementsCurrent
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_bf2fff1b-875b-4475-9ea0-9eb14b6776b4"
      unitRef="U_USD">2046000</vir:ExcessFundsPayableUnderGrantAgreementsCurrent>
    <vir:ExcessFundsPayableUnderGrantAgreementsCurrent
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_73f8dbc3-0dd9-4d69-9272-322e466a6d67"
      unitRef="U_USD">3467000</vir:ExcessFundsPayableUnderGrantAgreementsCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_f325ea35-0699-4e1f-93ea-537453528df9"
      unitRef="U_USD">3522000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_f74f8e93-b2f2-4c85-aeea-c01da2121d76"
      unitRef="U_USD">3625000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_3e648c8f-3f4e-4eab-b369-f9c53effe429"
      unitRef="U_USD">3867000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_d97a6a8c-4476-43c5-82e0-ac187a9b2b3e"
      unitRef="U_USD">2595000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_c321a475-fbb0-4149-a078-e53cbbe6c291"
      unitRef="U_USD">3334000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_0635bfc1-1c44-42a4-8951-61602576eda7"
      unitRef="U_USD">805000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_c534ab75-8672-4396-86e8-4ff4dfeb9db7"
      unitRef="U_USD">64074000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_9d2dcdd0-0114-4dd2-8f0a-0b4eeb682c48"
      unitRef="U_USD">76936000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_74af05ef-1201-4b82-ace6-938717f02c6b">&lt;p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;8.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;	&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Commitments and Contingencies&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Lease Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has various lease arrangements for office and laboratory spaces located in California, Oregon, Missouri and Switzerland with contractual lease periods expiring between &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2033&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain lease agreements also provide the Company with the option to renew for additional periods ranging from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_68e96f79-a508-48f1-bc17-ed7aec35b970;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. &lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Most of these renewal options are not considered in the remaining lease term unless it is reasonably certain that the Company will exercise such options. In February 2021, the Company entered into a new lease arrangement for office and laboratory spaces in Oregon. The lease is expected to commence in the fourth quarter of 2021 when the Company obtains access to the leased space. In addition to the operating lease agreements, the Company entered into a sale-leaseback transaction in August 2019.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Throughout the term of the lease agreements, the Company is responsible for paying certain operating costs, in addition to rent, such as common area maintenance, taxes, utilities and insurance. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred. &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The maturity of the Company&#x2019;s operating lease liabilities as of &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;June&#160;30, 2021 was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:59.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:73.525%;"/&gt;
        &lt;td style="width:1.915%;"/&gt;
        &lt;td style="width:1.679%;"/&gt;
        &lt;td style="width:21.861%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amounts&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2021 (excluding the six months ended June 30, 2021)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;67,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;110,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;38,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: net tenant improvement allowance yet to be received&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;62,173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following amounts were recorded in the condensed consolidated balance sheets for the periods ended:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:59.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.954%;"/&gt;
        &lt;td style="width:1.601%;"/&gt;
        &lt;td style="width:1.695%;"/&gt;
        &lt;td style="width:15.207%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
        &lt;td style="width:1.601%;"/&gt;
        &lt;td style="width:1.695%;"/&gt;
        &lt;td style="width:15.207%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;June&#160;30,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Current operating lease liabilities, net of tenant&lt;br/&gt;&#160;&#160;&#160;improvement allowances&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);top:-4.6899999999999995pt;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;&#160;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;58,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;61,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_89b36744-6825-4405-8082-31787f74cb3c;"&gt;&lt;span style="-sec-ix-hidden:F_580369ee-3852-4e0f-9dd1-a3ca48903cb6;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued and other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease liabilities, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;68,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;66,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;72,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;70,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:2.777777777777657E-4in;display:flex;margin-top:0.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.19027777777777777in;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.19027777777777777in;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;Current portion of lease liabilities recorded in prepaid expenses and other current assets for which the lease incentives to be received exceed the minimum lease payments to be paid over the next twelve months.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Manufacturing and Supply Letter Agreements&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In April 2020, the Company and Samsung Biologics Co., Ltd. (&#x201c;Samsung&#x201d;) entered into a binding letter agreement (the &#x201c;Samsung Letter Agreement&#x201d;), pursuant to which Samsung will perform development and manufacturing services for the Company&#x2019;s SARS-CoV-2 antibody program.&#160;In August 2020, the Company, GlaxoSmithKline Trading Services Limited (&#x201c;GSKTSL&#x201d;) and Samsung entered into an Assignment and Novation Agreement effective as of July 31, 2020 pursuant to which the Company assigned and transferred to GSKTSL all of the Company&#x2019;s right, title, and interest in, to and under the Samsung Letter Agreement, and GSKTSL became the Company&#x2019;s successor in interest in and to all of the Company&#x2019;s rights, duties, and obligations in, to and under the Samsung Letter Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In June 2020, the Company and WuXi Biologics entered into a binding letter of intent (the &#x201c;WuXi Biologics Letter Agreement&#x201d;), pursuant to which WuXi Biologics will perform certain development and manufacturing services for the Company&#x2019;s SARS-CoV-2 antibody program. In August 2020, the Company, GSKTSL and WuXi Biologics entered into an Assignment and Novation Agreement effective as of July 29, 2020 pursuant to which the Company assigned and transferred to GSKTSL all of the Company&#x2019;s right, title, and interest in, to and under the WuXi Biologics Letter Agreement, and GSKTSL became the Company&#x2019;s successor in interest in and to all of the Company&#x2019;s rights, duties, and obligations in, to and under the WuXi Biologics Letter Agreement.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2020, GSKTSL entered into a Master Services Agreement with Samsung (the &#x201c;Samsung MSA&#x201d;) and a non-exclusive Master Services Agreement for Commercial Manufacture of Drug Substance with WuXi Biologics (the &#x201c;WuXi Biologics MSA&#x201d;) in connection with the performance of the obligations of the Company and GSK, pursuant to the 2020 GSK Agreement. In accordance with the terms of the 2020 GSK Agreement, the Company will continue to be responsible for &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;72.5&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the costs under each of the Samsung MSA and the WuXi Biologics MSA, and GSK will bear &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27.5&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of such costs under each of the Samsung MSA and the WuXi Biologics MSA, subject to certain conditions and exceptions.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Indemnification&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. In some cases, the indemnification obligation will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. In addition, the Company has entered into indemnification agreements with its directors and certain officers that may require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no demands have been made upon the Company to provide indemnification under these agreements, and thus, there are no indemnification claims that the Company is aware of that could have a material effect on the Company&#x2019;s condensed consolidated balance sheets, condensed consolidated statements of operations, or condensed consolidated statements of cash flows.&lt;/span&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <vir:LeaseArrangementContractualExpirationBeginningYear
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_6fa7de1f-719c-4e55-b44c-ccaf56f837c2">2021</vir:LeaseArrangementContractualExpirationBeginningYear>
    <vir:LeaseArrangementContractualExpirationEndingYear
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_41270209-41e8-46e3-b731-dadbbd7ce211">2033</vir:LeaseArrangementContractualExpirationEndingYear>
    <us-gaap:LesseeOperatingLeaseOptionToExtend
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_050a889c-0633-4de5-9583-0834e8a7c631">These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain lease agreements also provide the Company with the option to renew for additional periods ranging from one to five years. </us-gaap:LesseeOperatingLeaseOptionToExtend>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="C_7073499b-8aca-4a83-ae2c-8686d7874fe9"
      id="F_594685a3-15ce-49c2-b342-3b85ce39311e">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_9aa2c0d0-7e99-4fe7-82f2-3da31e7ed05c">&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The maturity of the Company&#x2019;s operating lease liabilities as of &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;June&#160;30, 2021 was as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:59.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:73.525%;"/&gt;
        &lt;td style="width:1.915%;"/&gt;
        &lt;td style="width:1.679%;"/&gt;
        &lt;td style="width:21.861%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amounts&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2021 (excluding the six months ended June 30, 2021)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,713&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,387&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,564&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;67,466&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;110,600&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;38,140&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: net tenant improvement allowance yet to be received&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Present value of operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;62,173&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_58fc6d2c-d8f0-44f5-958b-9b30aefdf98c"
      unitRef="U_USD">3428000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_1e65600c-d552-4474-9819-158046df6bd6"
      unitRef="U_USD">9713000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_b83491b9-a066-4490-a01e-9bfb1ffb3e30"
      unitRef="U_USD">11387000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_4ae9af29-ad3a-472f-8c65-9f73269792c9"
      unitRef="U_USD">10564000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_8f347820-64cd-481d-a6d7-66b4151dbfed"
      unitRef="U_USD">8042000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <vir:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_e88fc6a7-c7cd-4fc3-8a82-9dc9372228ad"
      unitRef="U_USD">67466000</vir:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_e155b8e4-7d6b-404d-add6-854819d92448"
      unitRef="U_USD">110600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_63374e32-a37f-4931-ba98-61e3c7674866"
      unitRef="U_USD">38140000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <vir:LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_6ea59b13-f866-4100-aa63-3d90fa056f63"
      unitRef="U_USD">10287000</vir:LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived>
    <vir:PresentValueOfOperatingLeaseLiabilities
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_b994cab5-1477-48d8-8e24-418c0d878583"
      unitRef="U_USD">62173000</vir:PresentValueOfOperatingLeaseLiabilities>
    <vir:ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_e78239e1-99d0-447c-98d5-2be8124a34e2">&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following amounts were recorded in the condensed consolidated balance sheets for the periods ended:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:59.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:60.954%;"/&gt;
        &lt;td style="width:1.601%;"/&gt;
        &lt;td style="width:1.695%;"/&gt;
        &lt;td style="width:15.207%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
        &lt;td style="width:1.601%;"/&gt;
        &lt;td style="width:1.695%;"/&gt;
        &lt;td style="width:15.207%;"/&gt;
        &lt;td style="width:1.02%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;June&#160;30,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December&#160;31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Current operating lease liabilities, net of tenant&lt;br/&gt;&#160;&#160;&#160;improvement allowances&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);top:-4.6899999999999995pt;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;"&gt;&#160;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,287&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,913&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating right-of-use assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;58,972&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;61,947&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_89b36744-6825-4405-8082-31787f74cb3c;"&gt;&lt;span style="-sec-ix-hidden:F_580369ee-3852-4e0f-9dd1-a3ca48903cb6;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued and other liabilities&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease liabilities, noncurrent&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;68,938&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;66,556&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total operating lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;72,460&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;70,181&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"&gt;&lt;span style="font-size:6.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:2.777777777777657E-4in;display:flex;margin-top:0.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.19027777777777777in;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.19027777777777777in;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;Current portion of lease liabilities recorded in prepaid expenses and other current assets for which the lease incentives to be received exceed the minimum lease payments to be paid over the next twelve months.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</vir:ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock>
    <vir:OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_621ac5dc-b959-41b4-a949-bfa6ead3db85"
      unitRef="U_USD">10287000</vir:OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid>
    <vir:OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_3d6a3aee-cb76-466b-916d-4d85ca0061f4"
      unitRef="U_USD">7913000</vir:OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_e73f8073-3d09-4d00-83a7-27c97b615ac9"
      unitRef="U_USD">58972000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_f21be78f-3be9-49bd-bcac-2619d2a62130"
      unitRef="U_USD">61947000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_a18daa7a-80d9-44ac-b9ac-c00c241e4c63"
      unitRef="U_USD">3522000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_e2414089-5a97-4911-9fbe-6f456942ab5d"
      unitRef="U_USD">3625000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_1e636a02-a02a-4970-b2bd-eef18f4ca9ed"
      unitRef="U_USD">68938000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_8b5607c8-878b-441b-b833-9e0587e3bbed"
      unitRef="U_USD">66556000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f"
      decimals="-3"
      id="F_74ff2349-4169-4890-a579-9d5233a499cb"
      unitRef="U_USD">72460000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_e403ff64-40f3-494a-998d-769d7e8bb228"
      decimals="-3"
      id="F_5b959f8c-2c52-4c59-b46b-52d7746d6573"
      unitRef="U_USD">70181000</us-gaap:OperatingLeaseLiability>
    <vir:PercentageOfDevelopmentCosts
      contextRef="C_2a630976-9689-4329-bdef-af492a67b7b2"
      decimals="3"
      id="F_6a91cc0c-4236-42f7-8c1f-d2784ba66bde"
      unitRef="U_pure">0.725</vir:PercentageOfDevelopmentCosts>
    <vir:PercentageOfDevelopmentCosts
      contextRef="C_e7b02693-c6da-4de6-a120-f9ea9345d4d8"
      decimals="3"
      id="F_fdf0a045-e7a0-406c-8074-f747f1e75cd4"
      unitRef="U_pure">0.275</vir:PercentageOfDevelopmentCosts>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_b49c23cc-55fe-4df2-ad9c-c9c6120a86d9">&lt;p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;9.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;	&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Related Party Transaction&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As a result of the Brii Agreement in May 2018, the Company holds a minority equity interest in Brii Bio through its parent company, Brii Bio Parent. Additionally, a member of the Company&#x2019;s board of directors serves on Brii Bio Parent&#x2019;s board of directors.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Effective June 22, 2021, the Company's Chief Executive Officer is no longer a member of Brii Bio Parent's board of directors.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_64c8a998-4341-4896-8c64-4b32d43bc43d">&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-Based Awards &lt;/span&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock Option Activity&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Activity under the Company&#x2019;s stock option plans is set forth below:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.681%;"/&gt;
        &lt;td style="width:1.307%;"/&gt;
        &lt;td style="width:1.008%;"/&gt;
        &lt;td style="width:12.973%;"/&gt;
        &lt;td style="width:1.019%;"/&gt;
        &lt;td style="width:1.317%;"/&gt;
        &lt;td style="width:1.06%;"/&gt;
        &lt;td style="width:12.942%;"/&gt;
        &lt;td style="width:1.019%;"/&gt;
        &lt;td style="width:1.317%;"/&gt;
        &lt;td style="width:1.019%;"/&gt;
        &lt;td style="width:12.984%;"/&gt;
        &lt;td style="width:1.019%;"/&gt;
        &lt;td style="width:1.317%;"/&gt;
        &lt;td style="width:1.06%;"/&gt;
        &lt;td style="width:12.942%;"/&gt;
        &lt;td style="width:1.019%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,798,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,583,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;61.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,050,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;628,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding at June 30, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,702,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;223,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested and expected to vest at June 30, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,702,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;223,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested and exercisable at June 30, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,262,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;110,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of June&#160;30, 2021&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, the Company expects to recognize the remaining unamortized stock-based compensation expense of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;203.1&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;million related to stock options, over an estimated weighted average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.7&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock Options Granted to Employees&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;T&lt;/span&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;he fair value of stock options granted to employees was estimated on the date of grant using the Black-Scholes option-pricing model using the following assumptions: &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.787%;"/&gt;
        &lt;td style="width:1.296%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.296%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.009%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.296%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.009%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.296%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.009%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Three Months Ended June&#160;30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Six Months Ended June&#160;30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term of options (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected stock price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;106.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;110.2&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;95.7&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100.6&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;103.1&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;110.2&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;88.8&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100.6&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.1&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The valuation assumptions were determined as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.45pt;text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Expected Term&#x2014;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.45pt;text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Expected Volatility&#x2014;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The expected volatility was determined by examining the historical volatilities for industry peers and using an average of historical volatilities of the Company&#x2019;s industry peers as the Company does not have a sufficient historical trading history for its own stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.45pt;text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Risk-Free Interest Rate&#x2014;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="margin-left:24.45pt;text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Expected Dividend Rate&#x2014;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its profit interest units in the foreseeable future.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Restricted Stock Awards and Restricted Stock Units Activities&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s restricted stock awards (RSAs&#x201d;) and restricted stock units (&#x201c;RSUs&#x201d;) were summarized as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:68.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.746%;"/&gt;
        &lt;td style="width:1.471%;"/&gt;
        &lt;td style="width:1.471%;"/&gt;
        &lt;td style="width:14.597%;"/&gt;
        &lt;td style="width:1.471%;"/&gt;
        &lt;td style="width:1.471%;"/&gt;
        &lt;td style="width:10.226%;"/&gt;
        &lt;td style="width:1.035%;"/&gt;
        &lt;td style="width:1.416%;"/&gt;
        &lt;td style="width:1.471%;"/&gt;
        &lt;td style="width:7.339%;"/&gt;
        &lt;td style="width:1.035%;"/&gt;
        &lt;td style="width:1.471%;"/&gt;
        &lt;td style="width:7.312%;"/&gt;
        &lt;td style="width:1.471%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;RSU&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;RSA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;RSU&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;RSA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;89,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,050,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;64.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;87,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;67.38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested as of June 30, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,022,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;64.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The unvested shares of RSA and RSU have not been included in the shares issued and outstanding.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of June&#160;30, 2021&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, there was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;59.7&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;million of total unrecognized compensation cost related to unvested RSUs, all of which is expected to be recognized over a remaining weighted-average period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.6&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; years.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-Based Compensation Expense&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table sets forth the total stock-based compensation expense for all awards granted to employees and non-employees and the Company's Employee Stock Purchase Plan ("ESPP") in the condensed consolidated statements of operations:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.195%;"/&gt;
        &lt;td style="width:1.245%;"/&gt;
        &lt;td style="width:1.049%;"/&gt;
        &lt;td style="width:9.146%;"/&gt;
        &lt;td style="width:1.019%;"/&gt;
        &lt;td style="width:1.235%;"/&gt;
        &lt;td style="width:1.049%;"/&gt;
        &lt;td style="width:9.146%;"/&gt;
        &lt;td style="width:1.019%;"/&gt;
        &lt;td style="width:1.235%;"/&gt;
        &lt;td style="width:1.049%;"/&gt;
        &lt;td style="width:9.146%;"/&gt;
        &lt;td style="width:1.019%;"/&gt;
        &lt;td style="width:1.235%;"/&gt;
        &lt;td style="width:1.049%;"/&gt;
        &lt;td style="width:9.146%;"/&gt;
        &lt;td style="width:1.019%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Three Months Ended June&#160;30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Six Months Ended June&#160;30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_6439d11b-8e14-4bf3-bed3-dc4e32ee9794">&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Activity under the Company&#x2019;s stock option plans is set forth below:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.681%;"/&gt;
        &lt;td style="width:1.307%;"/&gt;
        &lt;td style="width:1.008%;"/&gt;
        &lt;td style="width:12.973%;"/&gt;
        &lt;td style="width:1.019%;"/&gt;
        &lt;td style="width:1.317%;"/&gt;
        &lt;td style="width:1.06%;"/&gt;
        &lt;td style="width:12.942%;"/&gt;
        &lt;td style="width:1.019%;"/&gt;
        &lt;td style="width:1.317%;"/&gt;
        &lt;td style="width:1.019%;"/&gt;
        &lt;td style="width:12.984%;"/&gt;
        &lt;td style="width:1.019%;"/&gt;
        &lt;td style="width:1.317%;"/&gt;
        &lt;td style="width:1.06%;"/&gt;
        &lt;td style="width:12.942%;"/&gt;
        &lt;td style="width:1.019%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;Options&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding at December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,798,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,583,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;61.99&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,050,899&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.66&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;628,801&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28.19&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Outstanding at June 30, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,702,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;223,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested and expected to vest at June 30, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,702,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30.24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;223,581&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested and exercisable at June 30, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,262,612&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.40&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;110,878&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_06a67e5e-7cd4-4262-8c8f-9cc28e2a7ddf"
      decimals="INF"
      id="F_db244228-85d7-4de7-b453-8cece1e12cf4"
      unitRef="U_shares">9798282</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_06a67e5e-7cd4-4262-8c8f-9cc28e2a7ddf"
      decimals="2"
      id="F_a96d2248-c9e5-4630-b0af-279a630beeaf"
      unitRef="U_USDollarShare">5.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_eda1b75d-a4eb-47cf-a94a-90d8ad6a84c9"
      id="F_9d7a853e-d8bb-4790-8b25-49317bf76567">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_e877910e-22cc-4649-a193-5d784dba152c"
      decimals="INF"
      id="F_7b29cdcf-b4be-46ea-a456-e09bad4ac66a"
      unitRef="U_shares">2583490</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_e877910e-22cc-4649-a193-5d784dba152c"
      decimals="2"
      id="F_b139d420-52d9-456c-a1fe-08f2868bf2d5"
      unitRef="U_USDollarShare">61.99</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_e877910e-22cc-4649-a193-5d784dba152c"
      decimals="INF"
      id="F_5b305e1f-bc50-4ac0-8ad4-c490d03ff743"
      unitRef="U_shares">1050899</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_e877910e-22cc-4649-a193-5d784dba152c"
      decimals="2"
      id="F_4732432a-0758-4702-b15c-e7bc69c2f951"
      unitRef="U_USDollarShare">5.66</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="C_e877910e-22cc-4649-a193-5d784dba152c"
      decimals="INF"
      id="F_77f2d7ea-6740-473c-a9c2-d2ac2d8e62ec"
      unitRef="U_shares">628801</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="C_e877910e-22cc-4649-a193-5d784dba152c"
      decimals="2"
      id="F_4d737a15-8a27-4e8a-911e-6f65602d74f3"
      unitRef="U_USDollarShare">28.19</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_7828555d-b746-4f30-8bb5-ef260d0b147b"
      decimals="INF"
      id="F_88e4cd46-60f2-497f-8964-a0ae8ee93506"
      unitRef="U_shares">10702072</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_7828555d-b746-4f30-8bb5-ef260d0b147b"
      decimals="2"
      id="F_8297d5b5-b26d-4fe7-b666-e69d1732c496"
      unitRef="U_USDollarShare">30.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_e877910e-22cc-4649-a193-5d784dba152c"
      id="F_05869e98-4af3-44b6-a9ad-d24549c196cd">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_7828555d-b746-4f30-8bb5-ef260d0b147b"
      decimals="-3"
      id="F_c19cfe2f-b80c-4a5e-bac2-491fffa1dea1"
      unitRef="U_USD">223581000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_7828555d-b746-4f30-8bb5-ef260d0b147b"
      decimals="INF"
      id="F_3a5c7edf-02bf-40e3-a82d-11c8fad7feda"
      unitRef="U_shares">10702072</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_7828555d-b746-4f30-8bb5-ef260d0b147b"
      decimals="2"
      id="F_dca5a681-ac33-47c9-8f3a-14ae8b15c04c"
      unitRef="U_USDollarShare">30.24</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_e877910e-22cc-4649-a193-5d784dba152c"
      id="F_ad2ab348-d3a3-460a-af8e-13c23d894ac8">P8Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_7828555d-b746-4f30-8bb5-ef260d0b147b"
      decimals="-3"
      id="F_74c00c0f-15b9-45cb-85df-85c88587f330"
      unitRef="U_USD">223581000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="C_7828555d-b746-4f30-8bb5-ef260d0b147b"
      decimals="INF"
      id="F_19da3803-acc6-4c96-89b6-e0afa4ad5b1a"
      unitRef="U_shares">3262612</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="C_7828555d-b746-4f30-8bb5-ef260d0b147b"
      decimals="2"
      id="F_f49303b3-1dd8-476d-919c-583d8f2c6819"
      unitRef="U_USDollarShare">13.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_e877910e-22cc-4649-a193-5d784dba152c"
      id="F_8447db98-e078-407b-8676-42d82f876a0b">P7Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="C_7828555d-b746-4f30-8bb5-ef260d0b147b"
      decimals="-3"
      id="F_28c87811-31c1-45fe-ab32-a47a8ddf643d"
      unitRef="U_USD">110878000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_7828555d-b746-4f30-8bb5-ef260d0b147b"
      decimals="-5"
      id="F_37bee8f9-8033-4ba1-9aef-f41f59b51335"
      unitRef="U_USD">203100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_e877910e-22cc-4649-a193-5d784dba152c"
      id="F_c3dbdc57-86cf-4c51-898b-b91054b6cf01">P2Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_9139662a-d5ff-4c5c-a2e7-8433ad6eb786">&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;he fair value of stock options granted to employees was estimated on the date of grant using the Black-Scholes option-pricing model using the following assumptions: &lt;/span&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:34.787%;"/&gt;
        &lt;td style="width:1.296%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.0%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.296%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.009%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.296%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.009%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.296%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:13.009%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Three Months Ended June&#160;30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Six Months Ended June&#160;30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term of options (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.5&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected stock price volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;106.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;110.2&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;95.7&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100.6&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;103.1&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;110.2&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;88.8&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100.6&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.0&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.1&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_33a88677-9ecc-4f3d-aca3-76408bf827c3"
      id="F_484ff5e6-26ad-41b1-8927-e4f7daa90ab6">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_27542471-f913-4a68-8616-f01ea8e68d78"
      id="F_f73737db-d0ba-41ff-abb8-c5bebc96ce08">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_e9e35c31-e697-4c7a-a5b4-23131aea2dca"
      id="F_d567248c-3805-466e-9371-8c5c162a8762">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_24a7634d-6a60-4a00-b501-5473727d2f4a"
      id="F_0976a599-e897-4209-95df-bd255081916d">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_3dda4289-3d1f-4bc7-9199-58bb203939aa"
      id="F_272ad4da-33fb-4012-b0c9-1461da708aa6">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_a548882f-b462-4623-9763-e036f6ae6cce"
      id="F_fdc44c48-9bba-4422-99d1-3d413f30f1ce">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_e8581c5a-3e43-44a2-8670-9db42cd8f49a"
      id="F_d480baa1-0435-4e9b-883d-924b5da0ee08">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_51eb1ee6-e4e4-42a9-b6e3-135a3e77a4ef"
      id="F_9bb3ef06-4a6a-40c5-9d78-87b475f1ef52">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="3"
      id="F_2ac88208-ee24-4219-814c-f0490a91da35"
      unitRef="U_pure">1.060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="3"
      id="F_bc030479-9c30-4d40-b1c1-88a585291876"
      unitRef="U_pure">1.102</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="3"
      id="F_f788772b-79f8-40eb-be0f-599a48dba6bf"
      unitRef="U_pure">0.957</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="3"
      id="F_1ac12bb4-3b03-4293-bf04-cf032d84e9ef"
      unitRef="U_pure">1.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="3"
      id="F_0a8d78d7-0f86-4fbb-98fe-a9daf50f7edd"
      unitRef="U_pure">1.031</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="3"
      id="F_fec336b4-af2e-4a7a-8785-1c9993ee66f0"
      unitRef="U_pure">1.102</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="3"
      id="F_7ddc94e7-39d9-4ab0-8166-b56bd9d78049"
      unitRef="U_pure">0.888</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="3"
      id="F_1ba6d173-a1b6-4dd5-91e8-54bdb3a9c4cb"
      unitRef="U_pure">1.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="3"
      id="F_f63269e4-0f6b-492f-ae15-d3a3ebb8998d"
      unitRef="U_pure">0.010</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="3"
      id="F_9d6e978d-d864-4e16-8b7c-fb8315c770b5"
      unitRef="U_pure">0.011</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="3"
      id="F_17a29e5c-cf1b-432c-835c-c8a9a7f48665"
      unitRef="U_pure">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="3"
      id="F_e7b5f795-3413-43e8-940f-e56535e8c591"
      unitRef="U_pure">0.005</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="3"
      id="F_5eca9e73-83cd-4051-880a-43f06c8fd90c"
      unitRef="U_pure">0.006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="3"
      id="F_e33d1665-f6ab-44d8-91ab-2a9c0f179637"
      unitRef="U_pure">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="3"
      id="F_5a892188-44f0-4334-9d84-23ce184830ee"
      unitRef="U_pure">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="3"
      id="F_69f81614-1c2f-4db9-b6dd-0cb56501217e"
      unitRef="U_pure">0.012</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="2"
      id="F_0f50243f-9b38-415f-ad73-01f892fb6ea8"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="2"
      id="F_db7ad2e7-2e41-42fe-b23f-fc3830edcf3a"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="2"
      id="F_a6e51d93-ebf6-4e8d-92a0-da28f34c3cc3"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="2"
      id="F_0661c670-ff67-4ec4-b7b0-c0602ec54b78"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_5e64bafd-4422-40c4-b917-3107a57974ad">&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s restricted stock awards (RSAs&#x201d;) and restricted stock units (&#x201c;RSUs&#x201d;) were summarized as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:68.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.746%;"/&gt;
        &lt;td style="width:1.471%;"/&gt;
        &lt;td style="width:1.471%;"/&gt;
        &lt;td style="width:14.597%;"/&gt;
        &lt;td style="width:1.471%;"/&gt;
        &lt;td style="width:1.471%;"/&gt;
        &lt;td style="width:10.226%;"/&gt;
        &lt;td style="width:1.035%;"/&gt;
        &lt;td style="width:1.416%;"/&gt;
        &lt;td style="width:1.471%;"/&gt;
        &lt;td style="width:7.339%;"/&gt;
        &lt;td style="width:1.035%;"/&gt;
        &lt;td style="width:1.471%;"/&gt;
        &lt;td style="width:7.312%;"/&gt;
        &lt;td style="width:1.471%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Shares&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted Average Grant Date Fair Value&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;RSU&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;RSA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;RSU&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;RSA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;89,261&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,050,995&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;64.25&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;87,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;28,550&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;67.38&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested as of June 30, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,022,445&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,852&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;64.16&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.53&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_0edc973f-cc4f-4eea-b393-2ad3dc16ecf5"
      decimals="INF"
      id="F_5be7b76b-1c3a-48f9-985d-1212f2f1f8ea"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_61924055-2acd-43c4-9155-681af2ed1b88"
      decimals="INF"
      id="F_5388b78d-0b04-45d7-8373-1a766c2e94cf"
      unitRef="U_shares">89261</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_0edc973f-cc4f-4eea-b393-2ad3dc16ecf5"
      decimals="0"
      id="F_df0d912f-fc6b-4365-adee-d9d839e650cc"
      unitRef="U_USDollarShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_61924055-2acd-43c4-9155-681af2ed1b88"
      decimals="2"
      id="F_1de30fc9-c0fc-4da0-b9cf-25d264e5f84b"
      unitRef="U_USDollarShare">1.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_704b0f66-c02a-4e7b-91c5-906e38831293"
      decimals="INF"
      id="F_c3612538-146b-424c-8900-08baa6af2bb3"
      unitRef="U_shares">1050995</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="C_6ed8a63f-0dfd-42e1-84e0-c0de8453fb41"
      decimals="INF"
      id="F_158a7cd8-3077-4a9a-936c-1f31946dbd1b"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_704b0f66-c02a-4e7b-91c5-906e38831293"
      decimals="2"
      id="F_fcc162a8-9daf-4184-9bb6-66ffb7e16dda"
      unitRef="U_USDollarShare">64.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_6ed8a63f-0dfd-42e1-84e0-c0de8453fb41"
      decimals="0"
      id="F_41ecb537-f584-47ab-8d5e-799e58fcef1e"
      unitRef="U_USDollarShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_704b0f66-c02a-4e7b-91c5-906e38831293"
      decimals="INF"
      id="F_0a971b8c-0eaa-4f33-a4c4-8186426bda2d"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="C_6ed8a63f-0dfd-42e1-84e0-c0de8453fb41"
      decimals="INF"
      id="F_fd4f9e24-fb09-4b58-96b7-b965f5321e36"
      unitRef="U_shares">87409</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_704b0f66-c02a-4e7b-91c5-906e38831293"
      decimals="0"
      id="F_5ca9656c-d7ee-4551-9364-8a0bb031fd84"
      unitRef="U_USDollarShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_6ed8a63f-0dfd-42e1-84e0-c0de8453fb41"
      decimals="2"
      id="F_f5041b77-6588-42cf-962e-5e4d8e48736c"
      unitRef="U_USDollarShare">1.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_704b0f66-c02a-4e7b-91c5-906e38831293"
      decimals="INF"
      id="F_a0d9adfd-bef3-4db8-a2f7-b202b5d598ff"
      unitRef="U_shares">28550</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="C_6ed8a63f-0dfd-42e1-84e0-c0de8453fb41"
      decimals="INF"
      id="F_ca8aee2a-39fe-48a4-8ced-7deb196f7235"
      unitRef="U_shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_704b0f66-c02a-4e7b-91c5-906e38831293"
      decimals="2"
      id="F_b8c78a4d-e7c7-43ed-b2bc-ad6ebbe719a5"
      unitRef="U_USDollarShare">67.38</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="C_6ed8a63f-0dfd-42e1-84e0-c0de8453fb41"
      decimals="0"
      id="F_e9ea366c-1566-430d-82cb-dcf275f205c5"
      unitRef="U_USDollarShare">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_8f01da11-0303-4186-9f77-73befdf1a6bc"
      decimals="INF"
      id="F_829d11e9-6896-45fa-86dd-18c885027477"
      unitRef="U_shares">1022445</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="C_6ef0ac41-102d-42f3-9751-1d32659fb4a7"
      decimals="INF"
      id="F_f5244eb2-15e5-4056-b78e-8eabd71c51b3"
      unitRef="U_shares">1852</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_8f01da11-0303-4186-9f77-73befdf1a6bc"
      decimals="2"
      id="F_09c751fe-ab57-4a88-ba66-c5f563bc88d9"
      unitRef="U_USDollarShare">64.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_6ef0ac41-102d-42f3-9751-1d32659fb4a7"
      decimals="2"
      id="F_2b4aecda-4740-48d4-96bf-7d77c2ca369b"
      unitRef="U_USDollarShare">1.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="C_8f01da11-0303-4186-9f77-73befdf1a6bc"
      decimals="-5"
      id="F_360c4443-36b0-4ca6-90db-27ef029e2575"
      unitRef="U_USD">59700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_704b0f66-c02a-4e7b-91c5-906e38831293"
      id="F_bdf46915-8a51-4020-a1d1-eacec344a0c5">P3Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_24441ab4-990e-4fbc-a957-be7b24da3b87">&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table sets forth the total stock-based compensation expense for all awards granted to employees and non-employees and the Company's Employee Stock Purchase Plan ("ESPP") in the condensed consolidated statements of operations:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.195%;"/&gt;
        &lt;td style="width:1.245%;"/&gt;
        &lt;td style="width:1.049%;"/&gt;
        &lt;td style="width:9.146%;"/&gt;
        &lt;td style="width:1.019%;"/&gt;
        &lt;td style="width:1.235%;"/&gt;
        &lt;td style="width:1.049%;"/&gt;
        &lt;td style="width:9.146%;"/&gt;
        &lt;td style="width:1.019%;"/&gt;
        &lt;td style="width:1.235%;"/&gt;
        &lt;td style="width:1.049%;"/&gt;
        &lt;td style="width:9.146%;"/&gt;
        &lt;td style="width:1.019%;"/&gt;
        &lt;td style="width:1.235%;"/&gt;
        &lt;td style="width:1.049%;"/&gt;
        &lt;td style="width:9.146%;"/&gt;
        &lt;td style="width:1.019%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Three Months Ended June&#160;30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Six Months Ended June&#160;30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,860&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,700&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19,290&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,188&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Selling, general and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,138&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,050&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,179&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,529&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20,998&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,469&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,717&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ce595069-e39b-49ee-a1e2-8dcfaf1fc58f"
      decimals="-3"
      id="F_883be59c-f87f-49ea-96d0-6dbf3f8f4f27"
      unitRef="U_USD">10860000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d09734ea-ce01-4393-81cd-a61fc90f7e98"
      decimals="-3"
      id="F_f0bbef1d-0797-474d-86fa-582bae15fff1"
      unitRef="U_USD">2700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e39462a8-8050-424d-a953-9a65943f5705"
      decimals="-3"
      id="F_ca2624d0-3942-4911-ae60-d79b2698b04f"
      unitRef="U_USD">19290000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3c73e700-bcbb-487f-bdf6-77164c1deeaf"
      decimals="-3"
      id="F_55cf98df-02b8-44be-9cad-e8ccab174f8f"
      unitRef="U_USD">4188000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ad365c4d-bc8d-4cfb-9e07-53dd946f68e3"
      decimals="-3"
      id="F_b12c3b79-873d-438b-b1a0-bae7bc594f22"
      unitRef="U_USD">10138000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_ee4e07f2-7234-48ee-b89e-21a8a39c2507"
      decimals="-3"
      id="F_bf89bbd0-c5ea-405f-904e-9522fa9f7905"
      unitRef="U_USD">3050000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_991c9783-f1f0-4095-b9b0-9d1076bde40f"
      decimals="-3"
      id="F_2048143e-e729-4d23-99ff-11b15c658692"
      unitRef="U_USD">17179000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_f7225c3a-02c3-4844-a759-8800e4846129"
      decimals="-3"
      id="F_0e9c60f5-aa97-409d-b47d-28fd083e9c15"
      unitRef="U_USD">4529000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="-3"
      id="F_73f1d69d-7cc8-4eb9-8471-31a35baa358e"
      unitRef="U_USD">20998000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_ded514e8-7072-49d3-8632-cbc084c13af5"
      unitRef="U_USD">5750000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_951bef6d-de73-4b91-b578-71b27dde2194"
      unitRef="U_USD">36469000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_ed6b87e8-7d52-46c8-9466-e2a5918cd00a"
      unitRef="U_USD">8717000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_2aaa8b3c-f3e1-444d-93ec-40d691b4a359">&lt;p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;11.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;	&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Net Income (Loss) Per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net income (loss) per common share is computed by dividing the net income (loss) by the sum of the weighted average number of common shares outstanding during the period plus any potential dilutive effects of common stock equivalents outstanding during the period calculated in accordance with the treasury stock method. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following is a calculation of the basic and diluted net income (loss) per share (in thousands, except share and per share data):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.704%;"/&gt;
        &lt;td style="width:1.046%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.991%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.056%;"/&gt;
        &lt;td style="width:1.037%;"/&gt;
        &lt;td style="width:12.361%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.056%;"/&gt;
        &lt;td style="width:1.037%;"/&gt;
        &lt;td style="width:10.407%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.056%;"/&gt;
        &lt;td style="width:1.037%;"/&gt;
        &lt;td style="width:11.213%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Three Months Ended June&#160;30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Six Months Ended June&#160;30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net income (loss), basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;61,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;107,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;108,407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average shares outstanding, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;130,121,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;114,980,652&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;128,938,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;111,684,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average effect of dilutive securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,635,656&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted shares subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Contingently issuable shares&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average shares outstanding, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;133,789,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;114,980,652&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;128,938,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;111,684,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net income (loss) per share, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net income (loss) per share, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.909%;"/&gt;
        &lt;td style="width:1.08%;"/&gt;
        &lt;td style="width:1.008%;"/&gt;
        &lt;td style="width:9.887%;"/&gt;
        &lt;td style="width:1.008%;"/&gt;
        &lt;td style="width:1.07%;"/&gt;
        &lt;td style="width:0.998%;"/&gt;
        &lt;td style="width:12.459%;"/&gt;
        &lt;td style="width:0.998%;"/&gt;
        &lt;td style="width:1.07%;"/&gt;
        &lt;td style="width:1.111%;"/&gt;
        &lt;td style="width:10.031%;"/&gt;
        &lt;td style="width:0.998%;"/&gt;
        &lt;td style="width:1.07%;"/&gt;
        &lt;td style="width:0.998%;"/&gt;
        &lt;td style="width:11.307%;"/&gt;
        &lt;td style="width:0.998%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Three Months Ended June&#160;30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Six Months Ended June&#160;30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,164,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,932,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,702,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,932,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Estimated shares issuable under the ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;71,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;71,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted shares subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;933,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;844,886&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,024,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;844,886&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Contingently issuable shares&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;39,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,169,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,777,731&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,837,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,777,731&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_a1edddb2-2637-496c-9b54-5ba32a04d967">&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following is a calculation of the basic and diluted net income (loss) per share (in thousands, except share and per share data):&lt;/span&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.704%;"/&gt;
        &lt;td style="width:1.046%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:9.991%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.056%;"/&gt;
        &lt;td style="width:1.037%;"/&gt;
        &lt;td style="width:12.361%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.056%;"/&gt;
        &lt;td style="width:1.037%;"/&gt;
        &lt;td style="width:10.407%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
        &lt;td style="width:1.056%;"/&gt;
        &lt;td style="width:1.037%;"/&gt;
        &lt;td style="width:11.213%;"/&gt;
        &lt;td style="width:1.0%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Three Months Ended June&#160;30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Six Months Ended June&#160;30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:11.0pt;font-family:Calibri;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net income (loss), basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;61,813&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31,167&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;107,098&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;108,407&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average shares outstanding, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;130,121,943&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;114,980,652&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;128,938,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;111,684,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average effect of dilutive securities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,635,656&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted shares subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19,409&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Contingently issuable shares&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average shares outstanding, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;133,789,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;114,980,652&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;128,938,851&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;111,684,283&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net income (loss) per share, basic&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.48&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net income (loss) per share, diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.46&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.27&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.83&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.97&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="-3"
      id="F_4f9b8af4-1844-43fa-a5e0-6a429148df79"
      unitRef="U_USD">61813000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="-3"
      id="F_4c66319b-f86d-4b9e-8341-91cd90488483"
      unitRef="U_USD">-31167000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="-3"
      id="F_a6713aea-8871-4dbb-8adc-d06ff3faac87"
      unitRef="U_USD">-107098000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="-3"
      id="F_ab1807b0-9a8e-48fb-8851-247614774a58"
      unitRef="U_USD">-108407000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="0"
      id="F_03e1fb52-472f-4f05-a11c-901224c6ddd0"
      unitRef="U_shares">130121943</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="0"
      id="F_6dcafd54-ec67-4aa8-9b75-48eb8250b51e"
      unitRef="U_shares">114980652</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="0"
      id="F_f24ade01-54f6-492d-8af2-a981551aea87"
      unitRef="U_shares">128938851</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="0"
      id="F_6c7e1377-f6e7-4c09-a6c6-097c42192523"
      unitRef="U_shares">111684283</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="0"
      id="F_732bf63f-54b3-48d8-b9e1-47feffa47adc"
      unitRef="U_shares">3635656</us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements>
    <vir:IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="0"
      id="F_fc56bd7b-d7bd-4252-b221-6aedcba0ceac"
      unitRef="U_shares">19409</vir:IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting>
    <us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="0"
      id="F_37204caf-d0c5-43b4-bc57-b169730a947c"
      unitRef="U_shares">12969</us-gaap:IncrementalCommonSharesAttributableToContingentlyIssuableShares>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="0"
      id="F_d5311527-2649-4308-a51e-a44dcc3f867d"
      unitRef="U_shares">133789977</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="0"
      id="F_9e350c78-e8aa-4324-9cde-93edea97f73a"
      unitRef="U_shares">114980652</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="0"
      id="F_ae1c2028-3239-4677-a09f-822cfcded63f"
      unitRef="U_shares">128938851</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="0"
      id="F_c5b248f0-c9b0-4db5-bb7f-51ac7762cd96"
      unitRef="U_shares">111684283</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="2"
      id="F_6fb506e2-2899-4748-918e-858bc7f296fa"
      unitRef="U_USDollarShare">0.48</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="2"
      id="F_2ccb2c67-599d-4c77-bb53-245606506213"
      unitRef="U_USDollarShare">-0.27</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="2"
      id="F_5ce77d44-05b2-4591-a8bd-39bd4dc85dfd"
      unitRef="U_USDollarShare">-0.83</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="2"
      id="F_31ee118e-96da-466e-b63e-09c709fe14d3"
      unitRef="U_USDollarShare">-0.97</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="2"
      id="F_c017e2fd-6790-412a-922a-5b67457c5b2a"
      unitRef="U_USDollarShare">0.46</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="2"
      id="F_44237d65-d3c3-47ba-9c37-83ece647d22a"
      unitRef="U_USDollarShare">-0.27</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="2"
      id="F_9cd3ef3b-fd37-4c5a-aa4c-5a97aab1ff9a"
      unitRef="U_USDollarShare">-0.83</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="2"
      id="F_8c7d0215-1375-44ec-af99-2d593396ffc3"
      unitRef="U_USDollarShare">-0.97</us-gaap:EarningsPerShareDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_a7d87c36-b630-453a-bb7a-2e9da6554145">&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:43.909%;"/&gt;
        &lt;td style="width:1.08%;"/&gt;
        &lt;td style="width:1.008%;"/&gt;
        &lt;td style="width:9.887%;"/&gt;
        &lt;td style="width:1.008%;"/&gt;
        &lt;td style="width:1.07%;"/&gt;
        &lt;td style="width:0.998%;"/&gt;
        &lt;td style="width:12.459%;"/&gt;
        &lt;td style="width:0.998%;"/&gt;
        &lt;td style="width:1.07%;"/&gt;
        &lt;td style="width:1.111%;"/&gt;
        &lt;td style="width:10.031%;"/&gt;
        &lt;td style="width:0.998%;"/&gt;
        &lt;td style="width:1.07%;"/&gt;
        &lt;td style="width:0.998%;"/&gt;
        &lt;td style="width:11.307%;"/&gt;
        &lt;td style="width:0.998%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Three Months Ended June&#160;30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Six Months Ended June&#160;30,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,164,036&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,932,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,702,072&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8,932,845&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Estimated shares issuable under the ESPP&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;71,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;71,582&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted shares subject to future vesting&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;933,870&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;844,886&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,024,297&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;844,886&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Contingently issuable shares&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;39,340&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,169,488&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,777,731&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,837,291&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,777,731&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_23d80066-9c6a-4bf0-aa4b-f95964ef06dc"
      decimals="INF"
      id="F_375318a8-08e1-4a1b-b38c-9c1d8cebad74"
      unitRef="U_shares">6164036</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_bd77d5c8-3f48-412e-8a01-2400a5a99d89"
      decimals="INF"
      id="F_7df1b0eb-069c-4c20-ab7f-0061cd7ef166"
      unitRef="U_shares">8932845</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f1864eb6-8023-4cef-ad5b-04b72b08c0df"
      decimals="INF"
      id="F_caa15d88-2dc2-487c-9c4f-89e7c394c646"
      unitRef="U_shares">10702072</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b863aacc-f9e9-437e-93af-f43803e428c1"
      decimals="INF"
      id="F_7f8e0763-62b1-4e7b-b41e-f4d80a2e77ab"
      unitRef="U_shares">8932845</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c85ee215-3e1c-44fb-b984-1097930c5e13"
      decimals="INF"
      id="F_ef4e0d8f-d89f-4f2a-a7fa-54b645d27b9f"
      unitRef="U_shares">71582</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_63fb600b-266b-4936-b5f6-f0acd37a0f30"
      decimals="INF"
      id="F_cdd199cf-8752-4917-ac39-c0fd12e7251a"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_0546abb1-16aa-4fcd-a7d6-0e80f088c135"
      decimals="INF"
      id="F_58bc2415-97d7-4650-befd-f2dfded164e5"
      unitRef="U_shares">71582</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a2ea91d2-7c4a-4260-9f6d-7c6a185c065b"
      decimals="INF"
      id="F_3f71e725-bbd3-4a4a-90f1-f7f7ea292b7c"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_cc9ec168-d4bd-41fa-97ec-80d1e7eac7e4"
      decimals="INF"
      id="F_f68449e0-c533-4f29-b969-9c00e9b95cae"
      unitRef="U_shares">933870</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7b946c14-81b3-4ee4-9cc6-59aca5e74078"
      decimals="INF"
      id="F_cf7ef683-5bda-4164-8754-07d28bb31767"
      unitRef="U_shares">844886</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_64416581-7d0b-4707-ab43-2587ae9cbcd4"
      decimals="INF"
      id="F_d1428778-06bf-4df4-a0b6-0d60ee3f83bf"
      unitRef="U_shares">1024297</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_7b508c4b-45d1-41c3-816a-cd29050692e2"
      decimals="INF"
      id="F_498a05c2-09ca-469a-9e7c-c381aed6e78b"
      unitRef="U_shares">844886</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_04fdbfd3-0666-4745-bebd-01d2061c67e4"
      decimals="0"
      id="F_c90ea2e7-cd85-4492-8284-477b156d3223"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_a4e86e58-4404-4536-961e-ac48e8ff6e70"
      decimals="0"
      id="F_af94b75c-aba6-4eef-8a7e-e944dae44b68"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_324b7022-f782-4c4b-a128-564a104bd122"
      decimals="0"
      id="F_f441d205-d9e9-4270-9a0b-4759a09a5dbe"
      unitRef="U_shares">39340</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_eeb1528b-b730-41f5-8477-0b25922ee91b"
      decimals="0"
      id="F_5ba48e56-8305-45dc-a188-94220133d0ba"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7"
      decimals="INF"
      id="F_098b0914-4a80-4fe1-8aa8-a61f2ebe6431"
      unitRef="U_shares">7169488</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d82c1375-fe52-423c-8c26-277c32efef51"
      decimals="INF"
      id="F_f0878af0-2e6b-442e-b5ae-4e32930d4dff"
      unitRef="U_shares">9777731</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      decimals="INF"
      id="F_e81c7dee-c7c4-423d-a5f0-63ef4ce60c69"
      unitRef="U_shares">11837291</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_4f13f3d6-dd12-44ba-9d6c-334087ac8241"
      decimals="INF"
      id="F_c9877ba2-4eda-4dda-9da5-9dba69987874"
      unitRef="U_shares">9777731</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_52d977a7-74c8-43be-9bfc-01aba0a3d398"
      id="F_4728eeb5-1646-49f9-a73d-f37c402c49be">&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;12. Subsequent Event&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Investment in Brii Bio Parent&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On July 13, 2021, Brii Bio Parent became a publicly traded company on the Stock Exchange of Hong Kong Limited. As such, the Company's investment in shares of Brii Bio Parent became a marketable equity investment with readily determinable price, which will then be measured at fair value at each reporting period going forward.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_56109b05-5ebc-4f11-b821-ed99759c2371"
          xlink:label="F_56109b05-5ebc-4f11-b821-ed99759c2371"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_6773aded-723c-495c-83b9-6854a1396b26"
          xlink:label="F_6773aded-723c-495c-83b9-6854a1396b26"
          xlink:type="locator"/>
        <link:footnote id="FNT_d3053df8-07d3-47e7-a42a-fa71bc831f41" xlink:label="FNT_d3053df8-07d3-47e7-a42a-fa71bc831f41" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Includes </xhtml:span><xhtml:span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</xhtml:span><xhtml:span style="font-size:8.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">14.0</xhtml:span><xhtml:span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> million</xhtml:span><xhtml:span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> of restricted cash equivalents.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_56109b05-5ebc-4f11-b821-ed99759c2371"
          xlink:to="FNT_d3053df8-07d3-47e7-a42a-fa71bc831f41"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_6773aded-723c-495c-83b9-6854a1396b26"
          xlink:to="FNT_d3053df8-07d3-47e7-a42a-fa71bc831f41"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_bbaff870-ba24-4b6f-84f4-7aa037d1f56c"
          xlink:label="F_bbaff870-ba24-4b6f-84f4-7aa037d1f56c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e1d45d63-d79c-4ab1-8c89-4be796dbbcd7"
          xlink:label="F_e1d45d63-d79c-4ab1-8c89-4be796dbbcd7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_bd6a27fd-8bca-4f9b-b2b4-7aca9663363e"
          xlink:label="F_bd6a27fd-8bca-4f9b-b2b4-7aca9663363e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_27166cde-7091-4715-bef5-9da941265164"
          xlink:label="F_27166cde-7091-4715-bef5-9da941265164"
          xlink:type="locator"/>
        <link:footnote id="FNT_d9b30841-09a6-45ce-abe3-d841782efe16" xlink:label="FNT_d9b30841-09a6-45ce-abe3-d841782efe16" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Includes $</xhtml:span><xhtml:span style="font-size:8.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">50.7</xhtml:span><xhtml:span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> million classified as long-term investments.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_bbaff870-ba24-4b6f-84f4-7aa037d1f56c"
          xlink:to="FNT_d9b30841-09a6-45ce-abe3-d841782efe16"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e1d45d63-d79c-4ab1-8c89-4be796dbbcd7"
          xlink:to="FNT_d9b30841-09a6-45ce-abe3-d841782efe16"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_bd6a27fd-8bca-4f9b-b2b4-7aca9663363e"
          xlink:to="FNT_d9b30841-09a6-45ce-abe3-d841782efe16"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_27166cde-7091-4715-bef5-9da941265164"
          xlink:to="FNT_d9b30841-09a6-45ce-abe3-d841782efe16"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_a30731d5-b26d-4d84-aaf8-d60f6fae99ba"
          xlink:label="F_a30731d5-b26d-4d84-aaf8-d60f6fae99ba"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_5b0ce1b2-dad8-4280-9da4-923155a0d87d"
          xlink:label="F_5b0ce1b2-dad8-4280-9da4-923155a0d87d"
          xlink:type="locator"/>
        <link:footnote id="FNT_e1cbc8b4-2fd4-49ea-849b-b5db014aa101" xlink:label="FNT_e1cbc8b4-2fd4-49ea-849b-b5db014aa101" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Includes $</xhtml:span><xhtml:span style="font-size:8.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">14.9</xhtml:span><xhtml:span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;million of restricted cash equivalents.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_a30731d5-b26d-4d84-aaf8-d60f6fae99ba"
          xlink:to="FNT_e1cbc8b4-2fd4-49ea-849b-b5db014aa101"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_5b0ce1b2-dad8-4280-9da4-923155a0d87d"
          xlink:to="FNT_e1cbc8b4-2fd4-49ea-849b-b5db014aa101"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_9c009c67-e6f6-4098-8951-601312e1939e"
          xlink:label="F_9c009c67-e6f6-4098-8951-601312e1939e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_bb4b78ac-feb8-4c7b-915d-f82d5be6e70c"
          xlink:label="F_bb4b78ac-feb8-4c7b-915d-f82d5be6e70c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_dfeb5c11-f6ec-465e-a911-219ce65c2da1"
          xlink:label="F_dfeb5c11-f6ec-465e-a911-219ce65c2da1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_a0a30f24-aca0-4941-9090-570e22369935"
          xlink:label="F_a0a30f24-aca0-4941-9090-570e22369935"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_00c871dd-ddfa-4fa3-8f32-e1ee2e31543e"
          xlink:label="F_00c871dd-ddfa-4fa3-8f32-e1ee2e31543e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_eedf6555-c570-477d-8f16-8cdd93f9b39b"
          xlink:label="F_eedf6555-c570-477d-8f16-8cdd93f9b39b"
          xlink:type="locator"/>
        <link:footnote id="FNT_29cb2c38-3c6e-43b9-9519-fa69c33f0bf5" xlink:label="FNT_29cb2c38-3c6e-43b9-9519-fa69c33f0bf5" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Unobservable inputs were weighted based on the relative fair value of the clinical and regulatory milestone payments.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_9c009c67-e6f6-4098-8951-601312e1939e"
          xlink:to="FNT_29cb2c38-3c6e-43b9-9519-fa69c33f0bf5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_bb4b78ac-feb8-4c7b-915d-f82d5be6e70c"
          xlink:to="FNT_29cb2c38-3c6e-43b9-9519-fa69c33f0bf5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_dfeb5c11-f6ec-465e-a911-219ce65c2da1"
          xlink:to="FNT_29cb2c38-3c6e-43b9-9519-fa69c33f0bf5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_a0a30f24-aca0-4941-9090-570e22369935"
          xlink:to="FNT_29cb2c38-3c6e-43b9-9519-fa69c33f0bf5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_00c871dd-ddfa-4fa3-8f32-e1ee2e31543e"
          xlink:to="FNT_29cb2c38-3c6e-43b9-9519-fa69c33f0bf5"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_eedf6555-c570-477d-8f16-8cdd93f9b39b"
          xlink:to="FNT_29cb2c38-3c6e-43b9-9519-fa69c33f0bf5"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_a9ff057e-0024-4020-9739-bf0e4099abee"
          xlink:label="F_a9ff057e-0024-4020-9739-bf0e4099abee"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_3fc0effe-077a-457b-be78-cd81563ae0e9"
          xlink:label="F_3fc0effe-077a-457b-be78-cd81563ae0e9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_daff6193-bbf4-476a-9d8a-157d74ee8503"
          xlink:label="F_daff6193-bbf4-476a-9d8a-157d74ee8503"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_860b67b2-83e8-45e4-a820-8df4f2b81016"
          xlink:label="F_860b67b2-83e8-45e4-a820-8df4f2b81016"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_3584cc21-6d37-4ef6-87ac-6540b38c433d"
          xlink:label="F_3584cc21-6d37-4ef6-87ac-6540b38c433d"
          xlink:type="locator"/>
        <link:footnote id="FNT_58e4891f-39b5-45d1-8dc4-f916fec2ed20" xlink:label="FNT_58e4891f-39b5-45d1-8dc4-f916fec2ed20" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Unobservable inputs were weighted based on the relative fair value of the commercial milestone payments.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_a9ff057e-0024-4020-9739-bf0e4099abee"
          xlink:to="FNT_58e4891f-39b5-45d1-8dc4-f916fec2ed20"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_3fc0effe-077a-457b-be78-cd81563ae0e9"
          xlink:to="FNT_58e4891f-39b5-45d1-8dc4-f916fec2ed20"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_daff6193-bbf4-476a-9d8a-157d74ee8503"
          xlink:to="FNT_58e4891f-39b5-45d1-8dc4-f916fec2ed20"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_860b67b2-83e8-45e4-a820-8df4f2b81016"
          xlink:to="FNT_58e4891f-39b5-45d1-8dc4-f916fec2ed20"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_3584cc21-6d37-4ef6-87ac-6540b38c433d"
          xlink:to="FNT_58e4891f-39b5-45d1-8dc4-f916fec2ed20"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_18a16493-faf3-428a-b4fb-7c6f1cc4f093"
          xlink:label="F_18a16493-faf3-428a-b4fb-7c6f1cc4f093"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_0e373577-f4ac-45f8-9fe7-66848eeef012"
          xlink:label="F_0e373577-f4ac-45f8-9fe7-66848eeef012"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_27fda7ed-591d-4518-af47-9f573ab1e5ce"
          xlink:label="F_27fda7ed-591d-4518-af47-9f573ab1e5ce"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e80ccab1-add9-4c97-91bd-79f96dd448ef"
          xlink:label="F_e80ccab1-add9-4c97-91bd-79f96dd448ef"
          xlink:type="locator"/>
        <link:footnote id="FNT_975f8be1-254b-40dd-96db-8cb78836fecf" xlink:label="FNT_975f8be1-254b-40dd-96db-8cb78836fecf" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Unobservable inputs were weighted based on the relative fair value of the underlying milestones. </xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_18a16493-faf3-428a-b4fb-7c6f1cc4f093"
          xlink:to="FNT_975f8be1-254b-40dd-96db-8cb78836fecf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_0e373577-f4ac-45f8-9fe7-66848eeef012"
          xlink:to="FNT_975f8be1-254b-40dd-96db-8cb78836fecf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_27fda7ed-591d-4518-af47-9f573ab1e5ce"
          xlink:to="FNT_975f8be1-254b-40dd-96db-8cb78836fecf"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e80ccab1-add9-4c97-91bd-79f96dd448ef"
          xlink:to="FNT_975f8be1-254b-40dd-96db-8cb78836fecf"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_621ac5dc-b959-41b4-a949-bfa6ead3db85"
          xlink:label="F_621ac5dc-b959-41b4-a949-bfa6ead3db85"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_3d6a3aee-cb76-466b-916d-4d85ca0061f4"
          xlink:label="F_3d6a3aee-cb76-466b-916d-4d85ca0061f4"
          xlink:type="locator"/>
        <link:footnote id="FNT_af2a8f75-e140-4119-9483-1f845d2145ab" xlink:label="FNT_af2a8f75-e140-4119-9483-1f845d2145ab" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Current portion of lease liabilities recorded in prepaid expenses and other current assets for which the lease incentives to be received exceed the minimum lease payments to be paid over the next twelve months.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_621ac5dc-b959-41b4-a949-bfa6ead3db85"
          xlink:to="FNT_af2a8f75-e140-4119-9483-1f845d2145ab"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_3d6a3aee-cb76-466b-916d-4d85ca0061f4"
          xlink:to="FNT_af2a8f75-e140-4119-9483-1f845d2145ab"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196273088008">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - shares<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Aug. 02, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-Q<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">VIR<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Vir Biotechnology, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001706431<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130,611,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentQuarterlyReport', window );">Document Quarterly Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-39083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-2730369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">499 Illinois Street, Suite 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">San Francisco<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">94158<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">415<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">906-4324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentQuarterlyReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an quarterly report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-Q<br> -Number 240<br> -Section 308<br> -Subsection a<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentQuarterlyReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196196336360">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 741,951<span></span>
</td>
<td class="nump">$ 436,575<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Short-term investments</a></td>
<td class="nump">84,107<span></span>
</td>
<td class="nump">300,286<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash and cash equivalents, current</a></td>
<td class="nump">7,004<span></span>
</td>
<td class="nump">7,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">29,233<span></span>
</td>
<td class="nump">27,511<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">862,295<span></span>
</td>
<td class="nump">772,365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Intangible assets, net</a></td>
<td class="nump">33,554<span></span>
</td>
<td class="nump">33,820<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">16,937<span></span>
</td>
<td class="nump">16,937<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term Investments</a></td>
<td class="nump">50,680<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">20,251<span></span>
</td>
<td class="nump">17,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating right-of-use assets</a></td>
<td class="nump">58,972<span></span>
</td>
<td class="nump">61,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash and cash equivalents, noncurrent</a></td>
<td class="nump">7,002<span></span>
</td>
<td class="nump">6,919<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">7,890<span></span>
</td>
<td class="nump">8,827<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">1,057,581<span></span>
</td>
<td class="nump">918,761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">11,032<span></span>
</td>
<td class="nump">5,077<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued and other liabilities</a></td>
<td class="nump">64,074<span></span>
</td>
<td class="nump">76,936<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenue, current portion</a></td>
<td class="nump">44,718<span></span>
</td>
<td class="nump">6,451<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration, current portion</a></td>
<td class="nump">26,200<span></span>
</td>
<td class="nump">10,600<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">146,024<span></span>
</td>
<td class="nump">99,064<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="nump">55,496<span></span>
</td>
<td class="nump">3,815<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="nump">68,938<span></span>
</td>
<td class="nump">66,556<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration, noncurrent</a></td>
<td class="nump">42,692<span></span>
</td>
<td class="nump">25,374<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="nump">3,253<span></span>
</td>
<td class="nump">3,253<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">3,853<span></span>
</td>
<td class="nump">3,847<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">320,256<span></span>
</td>
<td class="nump">201,909<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 8)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>STOCKHOLDERS&#8217; EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of June 30, 2021 and December 31, 2020; no shares issued and outstanding as of June 30, 2021 and December 31, 2020</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 300,000,000 shares authorized as of June 30, 2021 and December 31, 2020; 130,479,975 and 127,416,740 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">13<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">1,512,928<span></span>
</td>
<td class="nump">1,385,301<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,334)<span></span>
</td>
<td class="num">(1,278)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(774,282)<span></span>
</td>
<td class="num">(667,184)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">TOTAL STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">737,325<span></span>
</td>
<td class="nump">716,852<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">TOTAL LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</a></td>
<td class="nump">$ 1,057,581<span></span>
</td>
<td class="nump">$ 918,761<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=120406818&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559654&amp;loc=d3e5710-111685<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196272617080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">300,000,000<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">130,479,975<span></span>
</td>
<td class="nump">127,416,740<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">130,479,975<span></span>
</td>
<td class="nump">127,416,740<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196196258056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Operations (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenue</a></td>
<td class="nump">$ 177,068<span></span>
</td>
<td class="nump">$ 66,988<span></span>
</td>
<td class="nump">$ 179,052<span></span>
</td>
<td class="nump">$ 72,706<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfRevenue', window );">Cost of revenue</a></td>
<td class="nump">1,144<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,152<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">86,126<span></span>
</td>
<td class="nump">79,653<span></span>
</td>
<td class="nump">220,996<span></span>
</td>
<td class="nump">144,632<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative</a></td>
<td class="nump">28,781<span></span>
</td>
<td class="nump">16,386<span></span>
</td>
<td class="nump">54,520<span></span>
</td>
<td class="nump">29,035<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">116,051<span></span>
</td>
<td class="nump">96,039<span></span>
</td>
<td class="nump">276,668<span></span>
</td>
<td class="nump">173,667<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Income (loss) from operations</a></td>
<td class="nump">61,017<span></span>
</td>
<td class="num">(29,051)<span></span>
</td>
<td class="num">(97,616)<span></span>
</td>
<td class="num">(100,961)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium', window );">Interest income</a></td>
<td class="nump">97<span></span>
</td>
<td class="nump">825<span></span>
</td>
<td class="nump">261<span></span>
</td>
<td class="nump">2,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="nump">752<span></span>
</td>
<td class="num">(2,895)<span></span>
</td>
<td class="num">(9,494)<span></span>
</td>
<td class="num">(9,964)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income (expense)</a></td>
<td class="nump">849<span></span>
</td>
<td class="num">(2,070)<span></span>
</td>
<td class="num">(9,233)<span></span>
</td>
<td class="num">(7,384)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income (loss) before provision for income taxes</a></td>
<td class="nump">61,866<span></span>
</td>
<td class="num">(31,121)<span></span>
</td>
<td class="num">(106,849)<span></span>
</td>
<td class="num">(108,345)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for income taxes</a></td>
<td class="num">(53)<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
<td class="num">(62)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 61,813<span></span>
</td>
<td class="num">$ (31,167)<span></span>
</td>
<td class="num">$ (107,098)<span></span>
</td>
<td class="num">$ (108,407)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic</a></td>
<td class="nump">$ 0.48<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (0.97)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted</a></td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (0.97)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted Average Number of Shares Outstanding, Basic</a></td>
<td class="nump">130,121,943<span></span>
</td>
<td class="nump">114,980,652<span></span>
</td>
<td class="nump">128,938,851<span></span>
</td>
<td class="nump">111,684,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted Average Number of Shares Outstanding, Diluted</a></td>
<td class="nump">133,789,977<span></span>
</td>
<td class="nump">114,980,652<span></span>
</td>
<td class="nump">128,938,851<span></span>
</td>
<td class="nump">111,684,283<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vir_CollaborationRevenueMember', window );">Collaboration Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">$ 5,333<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,333<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vir_ContractRevenueMember', window );">Contract Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="nump">168,653<span></span>
</td>
<td class="nump">43,522<span></span>
</td>
<td class="nump">169,266<span></span>
</td>
<td class="nump">44,009<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Total revenue</a></td>
<td class="nump">$ 3,082<span></span>
</td>
<td class="nump">719<span></span>
</td>
<td class="nump">4,453<span></span>
</td>
<td class="nump">5,950<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,747<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 22,747<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate cost of goods produced and sold and services rendered during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120385591&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_ContractRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_ContractRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196196857336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Comprehensive Income (Loss )(Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 61,813<span></span>
</td>
<td class="num">$ (31,167)<span></span>
</td>
<td class="num">$ (107,098)<span></span>
</td>
<td class="num">$ (108,407)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on investments</a></td>
<td class="num">(44)<span></span>
</td>
<td class="num">(549)<span></span>
</td>
<td class="num">(84)<span></span>
</td>
<td class="nump">295<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax', window );">Amortization of actuarial loss</a></td>
<td class="nump">14<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">28<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(543)<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income ( loss)</a></td>
<td class="nump">$ 61,783<span></span>
</td>
<td class="num">$ (31,710)<span></span>
</td>
<td class="num">$ (107,154)<span></span>
</td>
<td class="num">$ (108,101)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL34724391-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e689-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196190557944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Stockholders' Equity (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2019</a></td>
<td class="nump">$ 423,942<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">$ 793,051<span></span>
</td>
<td class="num">$ (601)<span></span>
</td>
<td class="num">$ (368,519)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">107,648,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital', window );">Reclassification of derivative liability to additional paid-in capital</a></td>
<td class="nump">29,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodSharesAchievementOfMilestone', window );">Issuance of common stock in connection with the achievement of a milestone (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodValueCollaborationAgreement', window );">Issuance of common stock in connection with a collaboration agreement</a></td>
<td class="nump">206,699<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">206,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodSharesCollaborationAgreement', window );">Issuance of common stock in connection with a collaboration agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,626,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant', window );">Issuance of common stock for cashless exercise of warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="nump">889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">889<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,230,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">2,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,388<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock option (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">898,624<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">8,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,717<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="nump">306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">306<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(108,407)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(108,407)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">563,779<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">1,040,988<span></span>
</td>
<td class="num">(295)<span></span>
</td>
<td class="num">(476,926)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,727,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2020</a></td>
<td class="nump">380,333<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
<td class="nump">825,833<span></span>
</td>
<td class="nump">248<span></span>
</td>
<td class="num">(445,759)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,350,368<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodSharesAchievementOfMilestone', window );">Issuance of common stock in connection with the achievement of a milestone (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodValueCollaborationAgreement', window );">Issuance of common stock in connection with a collaboration agreement</a></td>
<td class="nump">206,699<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">206,698<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodSharesCollaborationAgreement', window );">Issuance of common stock in connection with a collaboration agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,626,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant', window );">Issuance of common stock for cashless exercise of warrant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">211,774<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted common stock</a></td>
<td class="nump">462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">612,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">2,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock option (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">815,260<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">5,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(543)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(543)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(31,167)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31,167)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2020</a></td>
<td class="nump">563,779<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">1,040,988<span></span>
</td>
<td class="num">(295)<span></span>
</td>
<td class="num">(476,926)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117,727,086<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2020</a></td>
<td class="nump">$ 716,852<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">1,385,301<span></span>
</td>
<td class="num">(1,278)<span></span>
</td>
<td class="num">(667,184)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">127,416,740<span></span>
</td>
<td class="nump">127,416,740<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodValueCollaborationAgreement', window );">Issuance of common stock in connection with a collaboration agreement</a></td>
<td class="nump">$ 85,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_StockIssuedDuringPeriodSharesCollaborationAgreement', window );">Issuance of common stock in connection with a collaboration agreement (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,924,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">5,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock option (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,050,899<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">36,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="num">(107,098)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(107,098)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 737,325<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">1,512,928<span></span>
</td>
<td class="num">(1,334)<span></span>
</td>
<td class="num">(774,282)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="nump">130,479,975<span></span>
</td>
<td class="nump">130,479,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Mar. 31, 2021</a></td>
<td class="nump">$ 650,951<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">1,488,337<span></span>
</td>
<td class="num">(1,304)<span></span>
</td>
<td class="num">(836,095)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Mar. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129,891,856<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted common stock (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34,446<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">3,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock option (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">553,673<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">20,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,998<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income (loss)</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">61,813<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">61,813<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Jun. 30, 2021</a></td>
<td class="nump">$ 737,325<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="nump">$ 1,512,928<span></span>
</td>
<td class="num">$ (1,334)<span></span>
</td>
<td class="num">$ (774,282)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Jun. 30, 2021</a></td>
<td class="nump">130,479,975<span></span>
</td>
<td class="nump">130,479,975<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=120383193&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326096&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification of derivative liability to additional paid In capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_StockIssuedDuringPeriodSharesAchievementOfMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares achievement of milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_StockIssuedDuringPeriodSharesAchievementOfMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares cashless exercise of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_StockIssuedDuringPeriodSharesCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_StockIssuedDuringPeriodSharesCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_StockIssuedDuringPeriodValueCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_StockIssuedDuringPeriodValueCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196195987368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>CASH FLOWS FROM OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (107,098)<span></span>
</td>
<td class="num">$ (108,407)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,538<span></span>
</td>
<td class="nump">2,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization of intangible assets</a></td>
<td class="nump">266<span></span>
</td>
<td class="nump">612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums on investments, net</a></td>
<td class="num">(238)<span></span>
</td>
<td class="nump">818<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_NoncashLeaseExpense', window );">Noncash lease expense</a></td>
<td class="nump">2,973<span></span>
</td>
<td class="nump">1,646<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ChangeInEstimatedFairValueOfContingentConsideration', window );">Change in estimated fair value of contingent consideration</a></td>
<td class="nump">42,918<span></span>
</td>
<td class="nump">27,790<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue', window );">Payment of contingent consideration in excess of acquisition date fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(6,453)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Change in estimated fair value of derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">16,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">36,469<span></span>
</td>
<td class="nump">8,717<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">521<span></span>
</td>
<td class="num">(2,159)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="num">(857)<span></span>
</td>
<td class="num">(361)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">4,933<span></span>
</td>
<td class="num">(1,342)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued liabilities and other long-term liabilities</a></td>
<td class="num">(22,287)<span></span>
</td>
<td class="nump">6,791<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(93)<span></span>
</td>
<td class="num">(1,557)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenue</a></td>
<td class="nump">90,452<span></span>
</td>
<td class="num">(4,011)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">50,529<span></span>
</td>
<td class="num">(59,048)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>CASH FLOWS FROM INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,744)<span></span>
</td>
<td class="num">(2,645)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireInvestments', window );">Purchases of investments</a></td>
<td class="num">(55,729)<span></span>
</td>
<td class="num">(129,899)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments', window );">Maturities of investments</a></td>
<td class="nump">221,382<span></span>
</td>
<td class="nump">247,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyHeldForSale', window );">Proceeds from disposal of an asset held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">162,909<span></span>
</td>
<td class="nump">114,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PaymentOfContingentConsideration', window );">Payment of contingent consideration</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(3,547)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinanceLeasePrincipalPayments', window );">Payment of principal on financing lease obligation</a></td>
<td class="num">(126)<span></span>
</td>
<td class="num">(115)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">5,945<span></span>
</td>
<td class="nump">2,388<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">91,032<span></span>
</td>
<td class="nump">205,425<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash, cash equivalents and restricted cash and cash equivalents</a></td>
<td class="nump">304,470<span></span>
</td>
<td class="nump">261,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash and cash equivalents at beginning of period</a></td>
<td class="nump">451,487<span></span>
</td>
<td class="nump">122,816<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash and cash equivalents at end of period</a></td>
<td class="nump">755,957<span></span>
</td>
<td class="nump">383,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>NONCASH INVESTING AND FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment purchases included in accounts payable and accrued liabilities</a></td>
<td class="nump">2,485<span></span>
</td>
<td class="nump">312<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone', window );">Reclassification of derivative liability to additional paid-in capital</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">29,245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities', window );">Deferred offering costs in accounts payable and accrued liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">690<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH TO THE CONDENSED CONSOLIDATED BALANCE SHEETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">741,951<span></span>
</td>
<td class="nump">371,781<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash and cash equivalents, current</a></td>
<td class="nump">7,004<span></span>
</td>
<td class="nump">11,024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent', window );">Restricted cash and cash equivalents, noncurrent</a></td>
<td class="nump">7,002<span></span>
</td>
<td class="nump">1,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash and cash equivalents at end of period</a></td>
<td class="nump">755,957<span></span>
</td>
<td class="nump">383,997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_CollaborationAgreementMember', window );">Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>CASH FLOWS FROM FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 85,213<span></span>
</td>
<td class="nump">$ 206,699<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinanceLeasePrincipalPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for principal payment on finance lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinanceLeasePrincipalPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the purchase of all investments (debt, security, other) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyHeldForSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of formerly productive land held for sale, anything permanently fixed to it, including buildings, structures on it, and so forth.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyHeldForSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3000-108585<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3044-108585<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ChangeInEstimatedFairValueOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in estimated fair value of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ChangeInEstimatedFairValueOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred offering costs in accounts payable and accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in payment of contingent consideration in excess of acquisition date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_NoncashLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_NoncashLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PaymentOfContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PaymentOfContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassification&#8203; of derivative liability&#8203; to additional paid-&#8203;in capital upon achievement of development milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196195907752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Organization</a></td>
<td class="text"><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Organization</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vir Biotechnology, Inc. (&#8220;Vir&#8221; or the &#8220;Company&#8221;) is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Its development pipeline consists of product candidates targeting the current coronavirus disease 2019 (&#8220;COVID-19&#8221;), hepatitis B virus (&#8220;HBV&#8221;), influenza A virus, and human immunodeficiency virus (&#8220;HIV&#8221;). Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. In May 2021, the Company received an Emergency Use Authorization (&#8220;EUA&#8221;) from the U.S. Food and Drug Administration for sotrovimab (previously VIR-7831) for the treatment of&#160;mild-to-moderate&#160;COVID-19&#160;in adults and pediatric patients (12 years of age and older weighing at least 40 kg) with positive results of direct&#160;SARS-CoV-2&#160;viral testing, and who are at high risk for progression to severe&#160;COVID-19,&#160;including hospitalization or death.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Follow-On Offering</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 10, 2020, the Company issued and sold </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,214,285</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s common stock pursuant to a registration statement on Form S-1 (File No. 333-239689) and a registration statement on Form S-1 filed pursuant to Rule 462(b) under the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;) (File No. 333-239747) (collectively, the &#8220;Registration Statements&#8221;). The Registration Statements became effective on July 7, 2020. The price of the shares sold in the follow-on offering was $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42.00</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share and the Company received total gross proceeds from the offering of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">345.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. After deducting underwriting discounts and commissions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.7</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and offering expenses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, the net proceeds were $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">323.2</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sales Agreement</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2020, the Company entered into a sales agreement (the &#8220;Sales Agreement&#8221;) with Cowen and Company, LLC (&#8220;Cowen&#8221;), under which the Company may from time to time offer and sell shares of its common stock, par value $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0001</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, having an aggregate offering price of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">300.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, through or to Cowen, acting as sales agent or principal. The shares will be offered and sold under the Company&#8217;s shelf registration statement on Form S-3 and a related prospectus filed with the Securities and Exchange Commission (the &#8220;SEC&#8221;) on November 10, 2020. The Company will pay Cowen a commission of up to </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the aggregate gross proceeds from each sale of shares, reimburse legal fees and disbursements and provide Cowen with customary indemnification and contribution rights. As of June 30, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares have been issued under the Sales Agreement.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Need for Additional Capital</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has incurred net losses since inception and expects such losses to continue over the next several years. As of June&#160;30, 2021, the Company had an accumulated deficit of </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">774.3</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Management expects to incur additional losses in the future to conduct research and development and recognizes the need to raise additional capital to fully implement its business plan. The Company had, excluding restricted cash, </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">876.7</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;of cash, cash equivalents, and investments at June&#160;30, 2021. Based on the Company&#8217;s business plans, management believes that its cash, cash equivalents, and investments as of June&#160;30, 2021</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> will be sufficient to fund its operations for at least the next 12 months from the issuance date of these condensed consolidated financial statements.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196195886088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Summary of Significant Accounting Policies</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and applicable rules and regulations of the SEC regarding interim financial reporting. The condensed consolidated financial statements include the accounts of Vir and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company&#8217;s financial information. The condensed consolidated results of operations for the six months ended June&#160;30, 2021 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2021 or for any other future annual or interim period.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain information and footnote disclosures typically included in the Company&#8217;s annual consolidated financial statements have been condensed or omitted. As such, these interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and related notes included in the Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on February 25, 2021.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p></div><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expense during the reporting periods. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">With the global spread of the ongoing COVID-19 pandemic, the Company has implemented a number of plans and policies designed to address and mitigate the impact of the COVID-19 pandemic on its business. The Company anticipates that the COVID-19 pandemic will continue to have an impact on the clinical development timelines for some of its clinical programs. The extent to which the COVID-19 pandemic impacts the Company&#8217;s business, clinical development and regulatory efforts, corporate development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States, Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the Company is subject to a number of other challenges and risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#8217;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investments. Cash and cash equivalents are deposited in checking and sweep accounts at a financial institution. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments, and issuers of the investments to the extent recorded on the condensed consolidated balance sheets. As of June&#160;30, 2021, the Company has no off-balance sheet concentrations of credit risk.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is exposed to credit losses primarily through receivables from customers and collaborators and through its available-for-sale debt securities. The Company&#8217;s expected loss allowance methodology for the receivables is developed using historical collection experience, current and future economic market conditions, a review of the current aging status and financial condition of the entities. Specific allowance amounts are established to record the appropriate allowance for customers that have a higher probability of default. Balances are written off when determined to be uncollectible. The Company&#8217;s expected loss allowance methodology for the debt securities is developed by reviewing the extent of the unrealized loss, the size, term, geographical location, and industry of the issuer, the issuers&#8217; credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers&#8217; current status and financial condition. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted. During the six months ended June 30, 2021 and 2020, there was </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> allowance for losses on available-for-sale debt securities attributable to credit risk.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investments</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investments include available-for-sale debt securities and are carried at estimated fair value. The Company&#8217;s valuations of marketable securities are generally derived from independent pricing services based on quoted prices in active markets for similar securities at period end. Generally, investments with original maturities beyond three months at the date of purchase and which mature at, or less than 12 months from, the condensed consolidated balance sheet date are considered short-term investments, with all others considered to be long-term investments. Unrealized gains and losses deemed temporary in nature are reported as a component of accumulated comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the condensed consolidated statements of operations. The Company&#8217;s policy is not to measure an allowance for credit losses for interest receivable and to write off any uncollectible interest receivable as a reversal of interest income in the period in which it determines the interest will not be collected.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company, through its investment in Brii Biosciences Limited, holds privately held equity securities in which the Company does not have a controlling interest or significant influence. The Company&#8217;s investment in Brii Biosciences Limited is recorded at cost and adjusted for impairments and observable price changes with the same or similar security from the same issuer. The valuation of the Company&#8217;s investment in Brii Biosciences Limited utilizes significant unobservable inputs or data in an inactive market and the valuation requires the Company&#8217;s judgment due to the absence of market prices and inherent lack of liquidity. Additionally, the determination of whether an orderly transaction is for the same or similar investment requires significant management judgment including the nature of the rights and obligations of its investments, the extent to which differences in those rights and obligations would affect the fair values of those investments, and the impact of any differences based on the stage of operational development of the investee. See Note 6&#8212;Collaboration and License Agreements for additional information on the Company&#8217;s investment in Brii Biosciences Limited.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Cash and Cash Equivalents</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash and cash equivalents represent money market funds to secure standby letters of credit and security deposits with financial institutions, both under office and laboratory space lease agreements. Additionally, funds received from certain grants are restricted as to their use and are therefore classified as restricted cash and cash equivalents.</span></p></div><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaboration, License and Contract Revenue</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), the Company recognizes revenue when the Company&#8217;s customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as the Company satisfies a performance obligation.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For collaborative arrangements that fall within the scope of ASC 808, Collaborative Arrangements (&#8220;ASC 808&#8221;), the Company first determines which elements of the collaboration are deemed to be a performance obligation with a customer within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808 and are not subject to the guidance in ASC 606, the Company applies the revenue recognition model under ASC 606 or other guidance, as deemed appropriate. The Company has entered into a number of license and collaboration agreements that fall within the scope of ASC 606. The Company evaluates the promised goods or services in these agreements to determine which ones represent distinct performance obligations. These agreements may include the following types of promised goods or services: (i) grants of licenses, (ii) performance of research and development services, and (iii) participation on joint research and/or development committees. They also may include options to obtain licenses to the Company&#8217;s intellectual property.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period as required. These agreements may include the following types of consideration: non-refundable upfront payments, reimbursement for research services, research, development or regulatory milestone payments, profit-sharing arrangements and royalty and commercial sales milestone payments.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on their estimated standalone selling prices (&#8220;SSP&#8221;). For performance obligations satisfied over time, the Company estimates the efforts needed to complete the performance obligation and recognizes revenue by measuring the progress towards complete satisfaction of the performance obligation using an input measure.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For arrangements that include sales-based royalties, including commercial milestone payments based on pre-specified level of sales, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon performance of the licensee.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Grant Revenue</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grants received, including cost reimbursement agreements, are assessed to determine if the agreement should be accounted for as an exchange transaction or a contribution. An agreement is accounted for as a contribution if the resource provider does not receive commensurate value in return for the assets transferred. Contributions are recognized as grant revenue when all donor-imposed conditions have been met.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Acquisitions</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process research and development (&#8220;IPR&amp;D&#8221;) projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date. Any excess fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with the business combination are recorded at their fair values on the acquisition date and are remeasured each subsequent reporting period until the related contingencies are resolved and are classified as contingent consideration on the condensed consolidated balance sheets. The changes in fair values of contingent consideration related to the achievement of various development milestones related to product candidates are recorded within research and development expense.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">When the Company determines that entities acquired do not meet the definition of a business, the transaction is accounted for as an acquisition of assets. Therefore, the consideration paid to acquire IPR&amp;D is expensed, and no goodwill is recorded. Any contingent consideration is generally recognized only when it becomes payable or is paid.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Embedded Derivatives</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluates its acquisitions, collaborative arrangements and other business development transactions to determine if embedded components of these contracts meet the definition of a derivative under ASC 815, Derivatives and Hedging. In general, embedded derivatives are required to be bifurcated from the host instrument if (i) the embedded feature is not clearly and closely related to the host contract and (ii) the embedded feature, if considered a freestanding instrument, meets the definition of a derivative. Embedded derivatives are reported on the condensed consolidated balance sheets at their estimated fair values. Contingent consideration related to asset acquisitions that meet the definition of an embedded derivative is classified as contingent consideration on the condensed consolidated balance sheets. Any change in estimated fair values, as determined at each measurement period, are recorded in the condensed consolidated statements of operations based on the nature of the related contingencies.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair values of embedded derivatives related to the achievement of various development milestones for product candidates are recorded within research and development expense. Otherwise, changes in fair values are recorded within other income (expense), net.</span><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196195400568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:8.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Fair Value Measurements</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy, which establishes three levels of inputs that may be used to measure fair value, as follows:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:24.5pt;text-indent:-18.0pt;padding-left:18.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#61623;	</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level&#160;1: Inputs which include quoted prices in active markets for identical assets and liabilities.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:24.5pt;text-indent:-18.0pt;padding-left:18.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#61623;	</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level&#160;2: Inputs other than Level&#160;1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:24.5pt;text-indent:-18.0pt;padding-left:18.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Symbol;">&#61623;	</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level&#160;3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The carrying amounts of the Company&#8217;s financial instruments, including accounts payable and accrued liabilities approximate fair value due to their relatively short maturities.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables summarize the Company&#8217;s Level 1 and Level 2 financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.806%;"/>
        <td style="width:1.083%;"/>
        <td style="width:9.963%;"/>
        <td style="width:1.083%;"/>
        <td style="width:1.037%;"/>
        <td style="width:7.917%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.083%;"/>
        <td style="width:1.037%;"/>
        <td style="width:7.917%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.083%;"/>
        <td style="width:1.037%;"/>
        <td style="width:7.917%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.083%;"/>
        <td style="width:1.037%;"/>
        <td style="width:7.917%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">June&#160;30, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Valuation<br/>Hierarchy</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br/>Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span><span style="color:rgba(0,0,0,1);top:-4.6899999999999995pt;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">739,286</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">739,286</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Bank time deposits</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government treasuries</span><span style="color:rgba(0,0,0,1);top:-4.6899999999999995pt;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">129,786</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">129,787</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total financial assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">874,072</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">874,073</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:5.5in;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:-13.5pt;padding-left:13.5pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(1)	</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Includes </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span><span style="font-size:8.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">14.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> million</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> of restricted cash equivalents.</span></p><p style="text-indent:-13.5pt;padding-left:13.5pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(2)	</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Includes $</span><span style="font-size:8.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">50.7</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> million classified as long-term investments.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.769%;"/>
        <td style="width:1.083%;"/>
        <td style="width:9.954%;"/>
        <td style="width:1.083%;"/>
        <td style="width:1.037%;"/>
        <td style="width:7.907%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.083%;"/>
        <td style="width:1.037%;"/>
        <td style="width:7.907%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.083%;"/>
        <td style="width:1.037%;"/>
        <td style="width:7.907%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.083%;"/>
        <td style="width:1.037%;"/>
        <td style="width:7.991%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Valuation<br/>Hierarchy</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br/>Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span><span style="color:rgba(0,0,0,1);top:-4.6899999999999995pt;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Level 1</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">421,835</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">421,835</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government treasuries</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Level 2</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">300,201</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">300,286</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total financial assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">722,036</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">722,121</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></div><p style="text-indent:-13.5pt;padding-left:13.5pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(1)	</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Includes $</span><span style="font-size:8.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">14.9</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;million of restricted cash equivalents.</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:-13.5pt;padding-left:13.5pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">	 </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued interest receivable excluded from both the fair value and amortized cost basis of the available-for-sale securities is presented within prepaid expenses and other current assets, and other assets in the condensed consolidated balance sheets, and amounted to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June&#160;30, 2021</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and December 31, 2020, respectively. The Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t write off any accrued interest receivable during the six months ended June 30, 2021 and 2020.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of June&#160;30, 2021, there were no investments that have been in a continuous unrealized loss position for longer than 12 months. Total net unrealized gains recorded in accumulated other comprehensive income (loss) were immaterial at June&#160;30, 2021. All investments with gross unrealized losses as of June 30, 2021 have been in a loss position for less than 12 months and were temporary in nature. The Company currently does not intend, and it is highly unlikely that it will be required to sell these securities before recovery of their amortized cost basis. As of June&#160;30, 2021</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, no securities have contractual maturities of longer than</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> two years</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3 liabilities consist of contingent consideration as of June&#160;30, 2021 and December 31, 2020.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingent Consideration</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contingent consideration includes potential milestone payments in connection with the acquisitions of Humabs Biomed SA (&#8220;Humabs&#8221;) and TomegaVax, Inc. (&#8220;TomegaVax&#8221;). See further discussion in Note 4&#8212;Acquisitions.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">estimated fair value of the contingent consideration related to the Humabs acquisition was determined by calculating the probability-weighted clinical, regulatory and commercial milestone payments based on the assessment of the likelihood and estimated</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">timing </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">that certain milestones would be achieved. </span><span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June&#160;30, 2021, the Company calculated the estimated fair value of the clinical and regulatory milestones using the following significant unobservable inputs: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.062%;"/>
        <td style="width:2.562%;"/>
        <td style="width:32.377%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unobservable input</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Range<br/>(Weighted-Average)</span><span style="color:rgba(0,0,0,1);top:-3.752pt;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;">1</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discount rates</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% (</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Probability of achievement</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% (</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
       </tr>
      </table><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="margin-left:5.000000000000004E-4in;display:flex;margin-top:0.0pt;line-height:1.2620833333333334;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.1875in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.1875in;">(1)</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Unobservable inputs were weighted based on the relative fair value of the clinical and regulatory milestone payments.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></div></div></div><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the commercial milestones, the Company used a Monte Carlo simulation because of the availability of a discrete revenue forecast and the increased likelihood that the clinical trials would commence. </span><span style="font-size:12.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June&#160;30, 2021, the Monte Carlo simulation assumed a commercial product launch and associated discrete revenue forecast, as well as the following significant unobservable inputs: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.062%;"/>
        <td style="width:2.562%;"/>
        <td style="width:32.377%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unobservable input</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value or Range<br/>(Weighted-Average)</span><span style="color:rgba(0,0,0,1);top:-3.752pt;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;">1</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Volatility</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discount rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Probability of achievement</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% (</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
       </tr>
      </table><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></div><div style="margin-left:5.000000000000004E-4in;display:flex;margin-top:0.0pt;line-height:1.2620833333333334;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.1875in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.1875in;">(1)</span><div style="display:inline;"><span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Unobservable inputs were weighted based on the relative fair value of the commercial milestone payments.</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></div></div><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The discount rate captures the credit risk associated with the payment of the contingent consideration when earned and due. As of June&#160;30, 2021 and December&#160;31, 2020</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the estimated fair value of the contingent consideration related to the Humabs acquisition was $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62.5</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.2</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, with changes in the estimated fair value recorded in research and development expense in the condensed consolidated statements of operations.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated fair value of the contingent consideration related to the TomegaVax acquisition was determined by using a Monte Carlo simulation model which included estimates of both the probability and timing to achieve the required per-share price of the Company&#8217;s common stock, and incorporates assumptions as to expected volatility and discount rate. The discount rate captures the credit risk associated with the payment of the contingent consideration when earned and due. Although the TomegaVax acquisition was accounted for as an asset acquisition, such contingent consideration met the definition of an embedded derivative financial instrument. In February 2021, the Company achieved one of the milestones related to a specified per-share price of its common stock resulting in a $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million payable to the former TomegaVax&#8217;s stockholders which was paid out in July 2021. </span><span style="font-size:12.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June&#160;30, 2021, the fair value of the remaining contingent consideration was estimated using the following significant unobservable inputs:</span></span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.062%;"/>
        <td style="width:2.562%;"/>
        <td style="width:32.377%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unobservable input</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value or Range<br/>(Weighted-Average)</span><span style="color:rgba(0,0,0,1);top:-3.752pt;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;">1</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discount rates</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% (</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
       </tr>
      </table><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="margin-left:5.000000000000004E-4in;display:flex;margin-top:0.0pt;line-height:1.2620833333333334;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.1875in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.1875in;">(1)</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Unobservable inputs were weighted based on the relative fair value of the underlying milestones. </span></div></div></div><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of June&#160;30, 2021 and December&#160;31, 2020</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the estimated fair value of the contingent consideration related to the TomegaVax acquisition was $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.4</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.8</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, with changes in the estimated fair value recorded in other income (expense), net in the condensed consolidated statements of operations.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated fair value of the contingent consideration related to the Humabs and TomegaVax acquisitions involves significant estimates and assumptions which give rise to measurement uncertainty.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the changes in the estimated fair value of the Company&#8217;s Level&#160;3 financial liabilities (in thousands):</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.563%;"/>
        <td style="width:1.25%;"/>
        <td style="width:1.25%;"/>
        <td style="width:19.942%;"/>
        <td style="width:0.995%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Contingent<br/>Consideration</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,974</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair value recognized in research and development expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,300</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair value recognized in other income (expense), net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,618</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reclassification of contingent consideration to accrued liabilities upon <br/>&#160;&#160;achievement of milestone</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at June 30, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68,892</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196195816296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisitions</a></td>
<td class="text"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Acquisitions</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Acquisition of TomegaVax</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2016, the Company entered into an agreement and plan of merger (&#8220;TomegaVax Merger Agreement&#8221;) to acquire all of the equity interests of TomegaVax. The primary asset purchased in the acquisition was an in-process cytomegalovirus vector-based vaccine platform for use in HBV, HIV, and tuberculosis. The acquisition was accounted for as an asset purchase.  &#160;&#160;&#160;&#160;</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the entry into the TomegaVax Merger Agreement, the Company also entered into a letter agreement with TomegaVax (the &#8220;TomegaVax Letter Agreement&#8221;), which provides for certain payments to TomegaVax&#8217;s former stockholders before September 2024, in each case so long as the Company is continuing to pursue the development of the TomegaVax technology. Under the terms of the TomegaVax Letter Agreement, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Company will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million if the per-share price of the Company&#8217;s publicly traded common stock, or implied price per share of the Company&#8217;s Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and/or the stage of the Company&#8217;s clinical development at the time of the relevant event triggering the payment.</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The share price of the Company&#8217;s publicly traded common stock will be determined using the average of the daily volume-weighted average trading price of the Company&#8217;s common stock for each trading day during a consecutive 90-day period. The foregoing payments are payable (i) during any date after the completion of an initial public offering by the Company or any successor or affiliate controlling the TomegaVax technology, provided that no payment will be due before the first anniversary of the initial public offering, (ii) upon the sale of all assets related to the TomegaVax technology or (iii) upon a merger or stock sale of the Company or any successor or affiliate controlling the TomegaVax technology, in each case subject to certain conditions with respect to the timing of the payments. The payments under the TomegaVax Letter Agreement can be made in cash or shares of the Company&#8217;s common stock, at the discretion of the Company&#8217;s board of directors.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2021, the Company achieved </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the milestones related to the specified per-share price of its common stock, which resulted in a $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million payable to TomegaVax&#8217;s former stockholders. In July 2021, the Company made the milestone payment to the former TomegaVax stockholders through a combination of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.1</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million cash payment and issuance of </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42,737</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock with a total fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.9</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The remaining milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate will be triggered if (i) the per-share price of the Company&#8217;s publicly traded common stock is at least $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (as adjusted in the case of any stock dividend, stock split or other similar recapitalization) and upon the achievement of a certain milestone related to the stage of the Company&#8217;s clinical development at the time of the relevant event triggering the payment&#160;and/or (ii) the per-share price of the Company&#8217;s publicly traded common stock is at least $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (as adjusted in the case of any stock dividend, stock split or other similar recapitalization).&#160;</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determined that the future milestone payments contain net settlement provisions and therefore, they were required to be accounted for as embedded derivatives under the relevant accounting guidance. As of June&#160;30, 2021</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the estimated fair value of the embedded derivative was $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.4</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Acquisition of Humabs</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2017, the Company acquired all of the outstanding equity of Humabs, a private Swiss company which discovers and develops monoclonal antibodies (&#8220;mAbs&#8221;) derived from individuals whose immune systems have successfully responded to major diseases. The Company acquired all of Humabs&#8217; rights, title and interest in and to substantially all of the assets of Humabs except for rights under certain license agreements with third parties. The Company is obligated to pass-through to the former Humabs shareholders any amounts received by Humabs under such license agreements, net of any program expenses. The transaction was accounted for as an acquisition of a business. In addition to the cash payment and issuance of common stock to the former Humabs shareholders at the acquisition date, the Company also agreed to pay additional amounts in cash upon the achievement of specified milestone events: (i) up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">135.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">upon the achievement of clinical, regulatory and commercial milestones for an HBV</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product; </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and (ii) up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the achievement of clinical, regulatory and commercial milestones for another product, which the Company elected as a SARS-CoV-2 product.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2020, the Company achieved </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the specified clinical milestones for the HBV product. As such, the Company paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to this milestone event in June 2020. In October 2020, the Company achieved another specified clinical milestone for the SARS-CoV-2 product and paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to this milestone event. The estimated fair value of the remaining contingent consideration was $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62.5</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June&#160;30, 2021.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Acquisition of Agenovir</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2018, the Company entered into an agreement and plan of merger with Agenovir Corporation (&#8220;Agenovir&#8221;), under which the Company purchased all equity interests of Agenovir. The primary assets purchased in the acquisition were in-process research and development programs in human papillomavirus and HBV using CRISPR/Cas9. The acquisition was accounted for as an asset purchase.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the acquisition date, the Company paid cash and issued shares of Series A-2 convertible preferred stock to the former Agenovir stockholders. During a specified period following the closing of the Agenovir acquisition, the Company will be required to pay Agenovir&#8217;s former stockholders up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">135.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate for the achievement of specified development, regulatory and commercial milestones for the first HBV product.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the milestones have been achieved as of </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June&#160;30, 2021</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, therefore </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> amounts were recognized relating to the contingent consideration.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196195260584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_GrantAgreementsDisclosureTextBlock', window );">Grant Agreements</a></td>
<td class="text"><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5.	Grant Agreements</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Bill&#160;&amp; Melinda Gates Foundation Grants</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Human Immunodeficiency Virus (&#8220;HIV&#8221;) Grant</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On January&#160;26, 2018, the Company entered into a grant agreement with the Bill&#160;&amp; Melinda Gates Foundation under which it was awarded a grant totaling up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.2</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million for its HIV program (the &#8220;HIV Grant&#8221;). In February 2020, the parties amended the HIV Grant under which the Company was awarded a supplemental grant of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.6</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. In June 2021, the parties further amended the agreement under which the grant term was extended from December 31, 2021 to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">October 31, 2022</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, unless earlier terminated by the Bill&#160;&amp; Melinda Gates Foundation for the Company&#8217;s breach, failure to progress the funded project, in the event of the Company&#8217;s change of control, change in the Company&#8217;s tax status, or significant changes in the Company&#8217;s leadership that the Bill&#160;&amp; Melinda Gates Foundation reasonably believes may threaten the success of the project.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments received in advance that are related to future research activities are deferred and recognized as revenue when the donor-imposed conditions are met, which is as the research and development activities are performed. The Company recognized grant revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three months ended June&#160;30, 2021 and 2020</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.4</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">six months ended June&#160;30, 2021 and 2020</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively. As of June 30, 2021 and December 31, 2020, the Company has deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.7</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.8</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, under this grant agreement.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Tuberculosis (&#8220;TB&#8221;) Grant</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March&#160;16, 2018, the Company entered into a grant agreement with the Bill&#160;&amp; Melinda Gates Foundation under which it was awarded a grant totaling up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.9</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million for its TB program (the &#8220;TB Grant&#8221;). The parties amended the agreement in June 2021 under which the grant term was extended from February 28, 2021 to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">January 31, 2022</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, unless earlier terminated by the Bill&#160;&amp; Melinda Gates Foundation for the Company&#8217;s breach, failure to progress the funded project, in the event of the Company&#8217;s change of control, change in the Company&#8217;s tax status, or significant changes in the Company&#8217;s leadership that the Bill&#160;&amp; Melinda Gates Foundation reasonably believes may threaten the success of the project. As of June&#160;30, 2021</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company had $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of unused funds received in advance and previously recorded as deferred revenue within accrued and other liabilities. </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of June 30, 2021 and December 31, 2020, the Company has deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.6</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, under this grant agreement.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments received in advance that are related to future research activities are deferred and recognized as revenue when the donor-imposed conditions are met, which is as the research and development activities are performed. The Company recognized grant revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.1</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">nil</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for the </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three months ended June&#160;30, 2021 and 2020</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.8</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">six months ended June&#160;30, 2021 and 2020</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_GrantAgreementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant agreements disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_GrantAgreementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196195478904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Collaboration and License Agreements</a></td>
<td class="text"><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6.	Collaboration and License Agreements</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaboration Agreements with GSK</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2020 GSK Collaboration</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On June 9, 2020, the Company, Glaxo Wellcome UK Limited and Beecham S.A. (referred to&#160;</span><span style="color:rgba(35,31,32,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">individually and</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> together, as &#8220;GSK&#8221;) entered into a definitive collaboration agreement under the terms set forth in the preliminary collaboration agreement entered into by the Company and certain GSK entities in April 2020 (the &#8220;2020 Preliminary Agreement&#8221;) (such definitive collaboration agreement, the &#8220;2020 GSK Agreement&#8221;). Concurrently with the execution of the 2020 Preliminary Agreement, the Company entered into a stock purchase agreement (the &#8220;2020 Stock Purchase Agreement&#8221;) with Glaxo Group Limited (&#8220;GGL&#8221;), an affiliate of GSK, under which GGL purchased </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,626,027</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s common stock on April 29, 2020, at a price per share of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37.73</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, for an aggregate purchase price of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">250.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. After receipt of antitrust clearance on April 22, 2020, the Preliminary Agreement became effective as of April 29, 2020, which was also the closing date for the associated 2020 Stock Purchase Agreement between the parties (&#8220;Effective Date&#8221;). Under the terms of the 2020 GSK Agreement, the Company and GSK agreed to collaborate to research, develop and commercialize products for the prevention, treatment and prophylaxis of diseases caused by SARS-CoV-2, the virus that causes COVID-19, and potentially other coronaviruses. The collaboration is focused on the development and commercialization of three types of collaboration products under three programs: (1) antibodies targeting SARS-CoV-2, and potentially other coronaviruses (the &#8220;Antibody Program&#8221;); (2) vaccines targeting SARS-CoV-2, and potentially other coronaviruses (the &#8220;Vaccine Program&#8221;), and (3) products based on genome-wide CRISPR screening of host targets expressed in connection with exposure to SARS-CoV-2, and potentially other coronaviruses (the &#8220;Functional Genomics Program&#8221;).</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four years</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> following the Effective Date, the parties will conduct certain research and development activities under mutually agreed development plans and associated budgets for each of the three programs, and under the oversight of a joint steering committee (&#8220;JSC&#8221;). The Company will be primarily responsible for the development and clinical manufacturing activities for the Antibody Program, and for conducting the initial development activities directed to a vaccine in the Vaccine Program. GSK will be primarily responsible for the commercialization activities for the Antibody Program (except in connection with sales of antibody products licensed to WuXi Biologics (Hong Kong) Limited in greater China), the later-stage development, manufacturing and commercialization activities for the Vaccine Program and the development, manufacturing and commercialization activities for the Functional Genomics Program. Subject to an opt-out mechanism, the parties will share all development costs, manufacturing costs and costs and expenses for the commercialization of the collaboration products, with the Company bearing </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72.5</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of such costs for the antibody products, </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27.5</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of such costs for the vaccine products, and equal sharing of such costs for the functional genomics products.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On a collaboration product-by-collaboration product basis, each party will have the one-time right, at specified points in development, to opt-out of its co-funding obligations, and the other party may, at its election, either pursue such program unilaterally, or also cease research and development activities and funding of such collaboration product. If the opt-out provisions are not exercised by either party subject to the terms of the 2020 GSK Agreement, the parties would share all profits and losses arising from any collaboration product in the same ratios in which the parties bore development costs for such collaboration program. For each collaboration product as to which a party exercises its opt-out right, the commercializing party will pay to the opt-out party royalties on net sales of the applicable collaboration product at rates based on factors such as the stage of development of such collaboration product at the time the opt-out party exercises such right, and whether the opt-out party is the lead party, or a portion of the sublicense revenue if the commercializing party chooses to sublicense or otherwise divest rights to such collaboration product. On an antibody product-by-antibody product basis, the Company has a co-promotion right for such antibody product in the United States, under which the Company will have the right to perform up to </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of details in connection with such antibody product.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2020 GSK Agreement will remain in effect with respect to each collaboration program for as long as there is a collaboration product being developed or commercialized by the lead party, or the non-opt-out party, in such program. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Either party has the right to terminate the 2020 GSK Agreement in the case of the insolvency of the other party, an uncured material breach of the other party with respect to a collaboration program or collaboration product, or as mutually agreed by the parties.</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The 2020 GSK Agreement superseded and replaced the 2020 Preliminary Agreement between the parties.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considered the ASC 606 criteria for combining contracts and determined that the 2020 GSK Agreement and 2020 Stock Purchase Agreement should be combined into a single contract because they were negotiated and entered into in contemplation of one another. The fair market value of the common stock issued to GGL was $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">206.7</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, based on the closing stock price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36.70</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on the date of execution of the 2020 Preliminary Agreement and 2020 Stock Purchase Agreement and taking into account a discount for the lack of marketability due to the restrictions in place on the underlying shares, resulting in a $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43.3</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million premium received by the Company.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounted for the common stock issued to GGL based on its fair market value on the transaction date and determined that the premium paid by GSK should be attributed to the transaction price of the 2020 GSK Agreement.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company concluded that the 2020 GSK Agreement contained </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">four</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> units of account: (i) the license granted to GSK under the Antibody Program (the &#8220;Antibody License&#8221;); (ii) the research and development activities (including clinical manufacturing) under the Antibody Program; (iii) the research and development activities under the Vaccine Program; and (iv) the research and development activities under the Functional Genomics Program. The Company considered the guidance in ASC 606 to determine which of these elements of the 2020 GSK Agreement are performance obligations with a customer. The Company determined that the Antibody License is within the scope of ASC 606 and accordingly, accounted for the Antibody License as a distinct performance obligation under ASC 606. The Antibody License is a functional intellectual property and is distinct from the associated research and development activities to be performed under the program due to its significant standalone functionality. All other elements of the 2020 GSK Agreement including the research and development activities, and participation in the JSC and subcommittees for each collaboration program were not determined to be distinct performance obligations with a customer.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The transaction price for the Antibody License at inception was determined to be $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43.3</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, representing the premium on the sale of common stock to GSK. The Company determined that GSK can benefit from the Antibody License at the time of grant and therefore, the related performance obligation is satisfied at a point in time. As such, the Company recognized the $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43.3</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as contract revenue during the second quarter of 2020. Additionally, the Company is entitled to consideration from GSK related to profit and loss sharing arrangements (including royalties) contingent upon future sales of collaboration products under the Antibody Program.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The remaining units of account of the 2020 GSK Agreement were determined to be within the scope of ASC 808 as the Company and GSK are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on the commercial success of the activities of the arrangement. Furthermore, the Company and GSK participate in the commercial profit and loss sharing arrangement for each program commensurate with each party&#8217;s cost-sharing responsibilities during research and development. Because ASC 808 does not provide recognition and measurement guidance, the Company determined that the guidance in ASC 730, Research and Development, was appropriate to analogize to, based on the nature of the cost-sharing provisions of the agreement. The Company has concluded that payments to or reimbursements from GSK related to these services will be accounted for as an increase to or reduction of research and development expenses, respectively. The Company also concluded that any payments from GSK related to the profit and loss sharing arrangement (including royalties) contingent upon the commercialization of the products under the Vaccine and Functional Genomics Programs will be analogized to ASC 606 and therefore, will be recognized when the related sales occur.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2021, the Company and GSK received an EUA for sotrovimab, the first collaboration product under the Antibody Program. As the lead party for all commercialization activities, GSK incurs all of the sales and marketing expenses and is the principal on sales transactions with third parties. As the Company is the agent under the agreement, the Company recognizes its contractual share of the profit sharing amounts or royalties (in case of an opt-out) as revenue, net of any cost of sales and allowable expenses (including distribution, selling and marketing expenses) in the period the sale occurs. During the three months ended June 30, 2021, the Company recorded its share of net profit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.3</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as collaboration revenue in the condensed consolidated statement of operations.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs associated with co-development activities performed under the agreement are included in research and development expenses on the condensed consolidated statements of operations, with any reimbursement of costs by GSK reflected as a reduction of such expenses. Under the 2020 GSK Agreement, the Company recognized additional research and development expense of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.9</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36.4</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during the </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three and six months ended June&#160;30, 2021</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively. The Company recognized a reduction of research and development expense of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.8</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during the </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three and six months ended June&#160;30, 2020</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company has a payable to GSK of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.7</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million included in accrued and other liabilities as of </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June&#160;30, 2021 and December 31, 2020, respectively.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2021 Expanded GSK Collaboration</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On February&#160;14, 2021, the Company and GSK entered into a binding preliminary collaboration agreement (the &#8220;2021 Preliminary Agreement&#8221;), under which the parties agreed to expand the 2020 GSK Agreement to collaborate on </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> separate programs: (1)&#160;a program to research, develop and commercialize mAbs for the prevention, treatment or prophylaxis of the influenza virus (the &#8220;Influenza Program&#8221;), excluding VIR-2482 unless GSK exercises its option as described below; (2) an expansion of the parties&#8217; current Functional Genomics Program to focus on functional genomics screens directed to targets associated with respiratory viruses (the &#8220;Expanded Functional Genomics Program&#8221;); and (3)&#160;additional programs to develop neutralizing mAbs directed to up to three&#160;non-influenza&#160;target pathogens selected by GSK (the &#8220;Selected Pathogens&#8221; and such programs, the &#8220;Additional Programs&#8221;).</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Concurrently with the execution of the 2021 Preliminary Agreement, the Company entered into a stock purchase agreement (the &#8220;2021 Stock Purchase Agreement&#8221;) with GGL under which GGL agreed to purchase shares of the Company&#8217;s common stock for an aggregate purchase price of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">120.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The consummation of the transactions under each of the 2021 Preliminary Agreement and the 2021 Stock Purchase Agreement were subject to the satisfaction of customary closing conditions, including the expiration or termination of the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, which expiration was effective on March 24, 2021. The 2021 Preliminary Agreement and 2021 Stock Purchase Agreement consummated on March 25, 2021, which the Company used as the measurement date for accounting purposes. On March 31, 2021, the Company closed the sale of </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,924,927</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock to GGL.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2021 Preliminary Agreement was superseded on May 18, 2021 upon execution of the definitive collaboration agreement (the &#8220;2021 GSK Agreement&#8221;, or collectively with the 2021 Preliminary Agreement, the &#8220;2021 GSK Collaboration&#8221;). The material terms of the 2021 GSK Agreement, including the promised goods and services, are discussed below and is consistent with those of the 2021 Preliminary Agreement.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the 2021 GSK Collaboration, the parties will conduct certain research and development activities under mutually agreed development plans and associated budgets for the programs within the expanded collaboration for a period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three years</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> following the effective date. Under the Influenza Program, the parties will collaborate to research, develop and commercialize mAbs for the prevention, treatment or prophylaxis of influenza, including the Company&#8217;s influenza mAbs (with respect to VIR-2482, only if GSK exercises its option). The Company may conduct the development and clinical manufacturing activities for&#160;VIR-2482&#160;up to completion of a Phase 2 clinical trial. Provided that the Company conducts and completes a Phase 2 clinical trial for VIR-2482, GSK will have the exclusive option to obtain exclusive rights to&#160;co-develop&#160;and commercialize&#160;VIR-2482&#160;under the Influenza Program (the &#8220;VIR-2482 Option&#8221;). GSK will be the lead party for development, clinical and commercial manufacturing and commercialization activities for products under the Influenza Program (other than&#160;VIR-2482&#160;unless and until GSK exercises the VIR-2482 Option, if applicable). The parties will mutually agree upon the allocation of responsibility for development of products under the Expanded Functional Genomics Program, and for development and early-stage manufacturing of products under the Additional Programs if and when GSK decides which Selected Pathogens to pursue. GSK will be primarily responsible for commercial manufacturing and commercialization activities for products under the Expanded Functional Genomics Program and Additional Programs, if and when selected by GSK. For each collaboration program, upon execution of the definitive agreement, the Company will grant GSK certain license rights related to the development, manufacturing and commercialization of products arising from the program.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The parties will share </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of all development costs in accordance with the budget for each of the collaboration programs (other than for&#160;the Selected Pathogens and VIR-2482 unless GSK exercises the VIR-2482 Option), with each party having the right to&#160;opt-out&#160;of its&#160;co-funding&#160;obligations at specified points in development. In such case, the party continuing with the program will pay to</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the&#160;opt-out&#160;party </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a royalty on net sales of products arising from such program at specified rates based on the stage of development at which the&#160;opt-out&#160;is exercised. Following the exercise of an&#160;opt-out&#160;right by a party, the other party may, at its election, either pursue development and commercialization of such product or program unilaterally, or also cease the conduct and funding of such collaboration product or program. In the absence of any&#160;opt-out,&#160;the parties will also share </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of all profits and losses arising from any collaboration product.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GSK was obligated to make an upfront payment to the Company of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">225.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million, </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of which became payable at the effective date of the 2021 Preliminary Agreement and </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of which became payable following execution of the 2021 GSK Agreement. If GSK exercises the VIR-2482 Option, GSK will pay the Company an option exercise fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">300.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million unless certain agreed product criteria for&#160;VIR-2482&#160;are not met, in which case the parties will negotiate an alternative option exercise fee. Upon achievement of a&#160;pre-defined&#160;regulatory milestone for the first product in the Influenza Program, which may be (i) VIR-2482 (if GSK exercised the VIR-2482 Option), (ii) a next-generation mAb, or (iii) any other influenza mAb approved by the JSC to be included in the collaboration, arising from the Influenza Program, GSK will make a milestone payment to the Company of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">200.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company concluded that the 2021 GSK Agreement is a collaboration arrangement as defined in ASC 808, Collaborative Agreements, under which certain elements are required to be accounted for under ASC 606 where the counterparty is a customer for a good or service that is a distinct unit of account. In addition, the 2021 GSK Agreement is considered a contract modification to the 2021 Preliminary Agreement and will be accounted for prospectively, as a termination of the 2021 Preliminary Agreement and commencement of a new contract. There was no impact to the accounting assessment of the original contract as no goods or services had been delivered to GSK, no performance obligations were satisfied, and accordingly,&#160;no contract revenue was recognized under ASC 606 prior to the execution of the 2021 GSK Agreement.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considered the ASC 606 criteria for combining contracts and determined that the 2021 GSK Collaboration and 2021 Stock Purchase Agreement should be combined into a single contract because they were negotiated and entered into in contemplation of one another. The fair market value of the common stock issued to GGL was $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85.2</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, based on the closing stock price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52.70</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> on March 25, 2021 and taking into account a discount for the lack of marketability due to the restrictions in place on the underlying shares, resulting in a $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34.8</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million premium received by the Company. The Company accounted for the common stock issued to GGL based on its fair market value on the transaction date and determined that the premium paid by GSK should be attributed to the transaction price of the 2021 GSK Agreement.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company concluded that the 2021 GSK Agreement contained the following units of account: (i) the VIR-2482 Option; (ii) three distinct rights granted to GSK related to the Selected Pathogens (each, a &#8220;Selected Pathogens Right&#8221;); (iii) the license and know-how to the next-generation mAbs under the Influenza Program (the &#8220;Next Gen License&#8221;); (iv) the research and development activities for next-generation mAbs under the Influenza Program; and (v) the research and development activities, including license rights and know-how, under the Expanded Functional Genomics Program. The Company considered the guidance in ASC 606 to determine which of these elements of the 2021 GSK Agreement are performance obligations with a customer. The Company determined that the distinct performance obligations under ASC 606 consisted of: (i) the Next Gen License and (ii) the three Selected Pathogens Rights, each representing a material right. All other elements of the 2021 GSK Agreement including the VIR-2482 Option, research and development activities, and participation in the JSC and subcommittees for each collaboration program were not determined to be distinct performance obligations with a customer.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The transaction price for the 2021 GSK Agreement included fixed consideration consisting of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">225.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upfront fee paid by GSK and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34.8</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, representing the premium on the sale of common stock to GSK for a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">259.8</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. All potential future milestones and other payments under the 2021 GSK Agreement are constrained since the Company could not conclude it was probable that a significant reversal in the amount recognized would not occur.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The respective estimated SSP for each of the performance obligations was determined to allocate the transaction price. The estimated SSP of each performance obligation was determined considering relevant market conditions, entity-specific factors and information about the customer, while maximizing the use of available observable inputs. For the Next Gen License, the Company determined that GSK can benefit from the license at the time the license is granted and therefore, the related performance obligation is satisfied at a point in time. If any of the Selected Pathogens Rights are exercised, the Company will evaluate the related promises to identify the performance obligations to be transferred and the timing of revenue recognition. If any of the Selected Pathogens Rights expire prior to being exercised, the Company will recognize any deferred revenue allocated to that right as revenue at the time of expiration.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The research and development activities for the next generation mAbs under the Influenza Program and the Expanded Functional Genomics Program were determined to be within the scope of ASC 808 as the Company and GSK are both active participants in the development, manufacturing and commercialization activities and are exposed to significant risks and rewards that are dependent on</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the commercial success of the activities of the arrangement. Furthermore, the Company and GSK participate in the commercial profit and loss sharing arrangement for each program commensurate with each party&#8217;s cost-sharing responsibilities during research and development. Because ASC 808 does not provide recognition and measurement guidance, the Company determined that the guidance in ASC 730, Research and Development, was appropriate to analogize to based on the nature of the cost-sharing provisions of the agreement. The Company has concluded that payments to or reimbursements from GSK related to these services will be accounted for as an increase to or reduction of research and development expenses, respectively. The Company also concluded that any payments from GSK related to the profit and loss sharing arrangement (including royalties) contingent upon the commercialization of the related products will be analogized to ASC 606 and therefore, will be recognized when the related sales occur.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon execution of the 2021 GSK Agreement, the Company granted the Next Gen License to GSK and therefore, recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">168.3</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as contract revenue during the three months ended June 30, 2021. As of June 30, 2021, of the total unrecognized transaction price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91.5</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39.8</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51.7</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million is classified as current and noncurrent deferred revenue, respectively, on the Company's condensed consolidated balance sheet related to the remaining performance obligations, being the material rights resulting from the Selected Pathogens Rights.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs associated with co-development activities performed under the agreement are included in research and development expenses in the condensed consolidated statements of operations, with any reimbursement of costs by GSK reflected as a reduction of such expenses. During the three and six months ended June 30, 2021, the Company recognized a </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reduction of research and development expense of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">under the 2021 GSK Agreement.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Brii Biosciences</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2018, the Company entered into a collaboration, option and license agreement (the &#8220;Brii Agreement&#8221;) with Brii Biosciences Limited (previously named BiiG Therapeutics Limited) (&#8220;Brii Bio Parent&#8221;) and Brii Biosciences Offshore Limited (&#8220;Brii Bio&#8221;), pursuant to which the Company granted to Brii Bio, with respect to up to four of the Company&#8217;s programs, an exclusive option to obtain exclusive rights to develop and commercialize compounds and products arising from such programs in China, Taiwan, Hong Kong and Macau (collectively, the &#8220;China Territory&#8221;) for the treatment, palliation, diagnosis, prevention or cure of acute and chronic diseases of infectious pathogen origin or hosted by pathogen infection (the &#8220;Field of Use&#8221;). The Company&#8217;s HBV siRNA program being developed under the Alnylam Agreement (described below) is included within the Brii Agreement as a program for which Brii Bio may exercise one of its options. In partial consideration for the options granted by the Company to Brii Bio, Brii Bio Parent and Brii Bio granted the Company, with respect to up to four of Brii Bio Parent&#8217;s or Brii Bio&#8217;s programs, an exclusive option to be granted exclusive rights to develop and commercialize compounds and products arising from such Brii Bio programs in the United States for the Field of Use. The number of options that the Company may exercise for a Brii Bio program is limited to the corresponding number of options that Brii Bio exercises for a Vir program.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As partial consideration for the Company&#8217;s entry into the Brii Agreement, upon closing of Brii Bio Parent&#8217;s Series A preferred stock financing, the Company received ordinary shares equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.9</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding shares in Brii Bio Parent. As a result of Brii Bio&#8217;s right to exercise one of its options for the Company&#8217;s HBV siRNA program, under the terms of the Alnylam Agreement, as amended, the Company transferred to Alnylam a specified percentage of such equity consideration allocable to such program under a share transfer agreement in February 2020.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">With respect to programs for which Brii Bio exercises its options, Brii Bio will be required to pay the Company an option exercise fee for each such Vir program ranging from the mid-single-digit millions up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, determined based on the commercial potential of the licensed program. Brii Bio will also be required to pay regulatory milestone payments on a licensed product-by-licensed product basis ranging from the mid-single-digit millions up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, also determined based on the commercial potential of such program. Following commercialization, Brii Bio will be required to make sales milestone payments based on certain specified levels of aggregate annual net sales of products arising from each licensed program in the China Territory, up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">175.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million per licensed program. Brii Bio also will pay royalties to the Company that range from the mid-teens to the high-twenties, as described below.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon exercise of each option for a Brii Bio program, the Company will be required to pay to Brii Bio an option exercise fee ranging from the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">low tens of millions</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, determined based on the commercial potential of the licensed program. The Company will be required to make regulatory milestone payments to Brii Bio on a licensed product-by-licensed product basis ranging from the low tens of millions up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, also determined based on the commercial potential of such program. The Company will also be required to make sales milestone payments based on certain specified levels of aggregate annual net sales of products in the United States arising from each licensed program, up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">175.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million per licensed program.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the Company is obligated under the Brii Agreement to pay Brii Bio tiered royalties based on net sales of products arising from the licensed programs in the United States, and Brii Bio is obligated to pay the Company tiered royalties based on net sales of products arising from the licensed programs in the China Territory. The rates of royalties payable by the Company to Brii Bio, and by Brii Bio to the Company, on net sales range from mid-teens to high-twenties. Each party&#8217;s obligations to pay royalties expires, on a product-by-product and territory-by-territory basis, on the latest of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years after the first commercial sale of such licensed product in the United States or China Territory, as applicable; the expiration or abandonment of licensed patent rights that cover such product in the United States or China Territory, as applicable; and the expiration of regulatory exclusivity in the United States or the China Territory, as applicable. Royalty rates are subject to specified reductions and offsets.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Brii Agreement will remain in force until the expiration of all options or, if any option is exercised, expiration of all royalty payment obligations for all licensed products within such licensed program, unless terminated in its entirety or on a program-by-program basis by either party. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each party may terminate for convenience all rights and obligations with respect to any program for which it has an option, with </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30 days</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8217; written notice (if the terminating party has not exercised an option for such program) or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">180 days</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8217; notice (following the exercise of an option for such program). The Brii Agreement may also be terminated by either party for insolvency of the other party, and either party may terminate the Brii Agreement in its entirety or on a program-by-program basis for the other party&#8217;s uncured material breach on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60 days</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8217; written notice (or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days&#8217; notice following failure to make payment).</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has determined that Brii Bio Parent and its wholly-owned subsidiary Brii Bio are variable interest entities due to their reliance on future financing and having insufficient equity at risk. However, the Company does not have the power to direct activities that most significantly impact the economic success of these entities and is not considered the primary beneficiary of these entities. Therefore, the Company does not consolidate Brii Bio Parent or Brii Bio. The Company also determined that it does not exercise significant influence over Brii Bio Parent or Brii Bio. As of June 30, 2021 and December 31, 2020, the investment in Brii Bio Parent has a carrying value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.7</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which is included in other assets on the condensed consolidated balance sheets. The Company also has a contract liability of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.8</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million within deferred revenue which represents deferred consideration for the remaining three options that the Company granted to Brii Bio. The deferred consideration will be recognized when Brii Bio exercises its options or the options expire. The Company accounts for its investment in Brii Bio Parent&#8217;s ordinary shares at cost minus impairment, if any, plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment in Brii Bio Parent.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s maximum exposure to loss under the Brii Agreement is represented by options to acquire licenses to develop and commercialize potential products and future milestone payments. The ultimate expense that the Company incurs under the Brii Agreement cannot be quantified at this time as the amount will vary based on the timing and outcome of research activities.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Option Exercise by Brii Bio</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2020, Brii Bio exercised its option to obtain exclusive rights to develop and commercialize compounds and products arising from VIR-2218 in the China Territory. In consideration of the Company&#8217;s grant to Brii Bio of an exclusive license related to VIR-2218 in the China Territory, the Company received a $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million option exercise fee in connection with the option exercise. Also, the Company is eligible to receive the following payments related to VIR-2218 in the China Territory: a $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million regulatory milestone payment, up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">175.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in sales-based milestone payments, and royalties on net sales ranging from high-teens to high-twenties.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluated the transaction under ASC 606 and identified one performance obligation consisting of the license granted to Brii Bio. Under the Brii Agreement, Brii Bio is responsible for performing all research and development activities and the Company does not have any other performance obligations within the context of ASC 606 under the arrangement after the option exercise. The transaction price is determined to be $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22.7</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million which consists of the $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million option exercise fee and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.7</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the deferred revenue allocated to the VIR-2218 option at the inception of the Brii Agreement. The Company determined that the license is considered a functional intellectual property that is a distinct performance obligation under ASC 606. Specifically, the Company believes the license is capable of being distinct, as Brii Bio has the capabilities to develop the license either on its own or by contracting other third parties. Brii Bio can benefit from the license at the time of grant and therefore, the related performance obligation is satisfied at a point in time. Additionally, all potential future milestones and other payments are constrained because the Company cannot conclude it is probable that a significant reversal in the amount recognized would not occur. The Company will re-evaluate the transaction price in each reporting period.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the three and six months ended June 30, 2021, the Company recognized </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">zero</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively, as contract revenue from the supply of biological materials to Brii Bio. During the three and six months ended June 30, 2020, the Company recognized the $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22.7</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as license revenue from a related party. The Company separately paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, half of the option exercise proceeds, to Alnylam in connection with the Alnylam Agreement that was recognized as research and development expense during the same period.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Alnylam</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">October 2017 Agreement</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2017, the Company entered into the Alnylam Agreement for the development of siRNA products for the treatment of HBV and following the exercise of certain program options, the development and commercialization of siRNA therapeutic products directed to up to four other infectious disease targets selected by the Company. The technology licensed under the Alnylam Agreement forms the basis of the Company&#8217;s siRNA technology platform.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Alnylam Agreement, the Company obtained a worldwide, exclusive license to develop, manufacture and commercialize the HBV siRNA product candidates, including VIR-2218, for all uses and purposes other than agricultural, horticultural, forestry, aquaculture and other residential applications, such excluded fields, the Excluded Fields. In addition, Alnylam granted the Company an exclusive option, for each of the infectious disease siRNA programs directed to the Company&#8217;s selected targets, to obtain a worldwide, exclusive license to develop, manufacture and commercialize siRNA products directed to the target of each such program for all uses and purposes other than the Excluded Fields. On a product-by-product basis for each product arising from the HBV and, following the Company&#8217;s option exercise, the infectious disease programs, Alnylam has an exclusive option, exercisable during a specified period prior to the initiation of a Phase 3 clinical trial for each such product, to negotiate and enter into a profit-sharing agreement for such product.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company and Alnylam are jointly responsible for funding the initial research and development activities for VIR-2218 through the completion of proof of concept trials. Prior to the exercise of the Company&#8217;s option for each siRNA program directed to one of the Company&#8217;s selected infectious disease targets, Alnylam is responsible for conducting all development activities, at the Company&#8217;s expense, in accordance with an agreed upon development plan. Following the Company&#8217;s exercise of an option for a program and payment of the program option exercise fee and any outstanding program costs due to Alnylam, the Company is solely responsible, at the Company&#8217;s expense (subject to Alnylam&#8217;s exercise of a profit-sharing option), for conducting all development, manufacture and commercialization activities for products arising from each such program. If Alnylam exercises a profit-sharing option for a product, the Company will negotiate the terms of such profit-sharing agreement, which will include sharing equally with Alnylam all subsequent costs associated with the development of such product, as well as the profits and losses in connection with such product, subject to reimbursement by Alnylam of a portion of specified development costs in certain circumstances.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Alnylam Agreement, the Company paid Alnylam an upfront fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and issued to Alnylam </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,111,111</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s common stock. Additionally, the receipt of consideration from Brii Bio as discussed above triggered a requirement under the Alnylam Agreement to transfer a portion of the consideration, consisting of equity in Brii Bio Parent valued at $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, to Alnylam </span><span style="color:rgba(33,37,41,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon the achievement of a certain development milestone, as further discussed below, the Company was obligated to issue shares of the Company&#8217;s common stock equal to the lesser of (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,111,111</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares or (ii) a certain number of shares based on the Company&#8217;s stock price at the time such milestone is achieved (the &#8220;Milestone Shares&#8221;). The Company will be required to pay Alnylam up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">190.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate for the achievement of specified development and regulatory milestones by the first siRNA product directed to HBV, and up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">115.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the achievement of specified development and regulatory milestones by the first product directed to the target of each infectious disease siRNA program for which the Company exercised its option. Following commercialization, the Company will be required to pay to Alnylam up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">250.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate for the achievement of specified levels of net sales by siRNA products directed to HBV and up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the achievement of specified levels of net sales by products directed to the target of each infectious disease siRNA program for which the Company exercised its option. The Company may also be required to pay Alnylam tiered royalties at percentages ranging from the low double-digits to mid-teens on annual net sales of HBV products, and tiered royalties at percentages ranging from the high single-digits to the sub-teen double-digits on annual net sales of licensed infectious disease products, in each case subject to specified reductions and offsets. The royalties are payable on a product-by-product and country-by-country basis until the later of the expiration of all valid claims of specified patents covering such product in such country and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10 years</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> after the first commercial sale of such product in such country.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term of the Alnylam Agreement will continue, on a product-by-product and country-by-country basis, until the expiration of all royalty payment obligations under the Alnylam Agreement. If the Company does not exercise its option for an infectious disease program directed to one of its selected targets, the Alnylam Agreement will expire upon the expiration of the applicable option period with respect to such program. However, if Alnylam exercises its profit-sharing option for any product, the term of the Alnylam Agreement will continue until the expiration of the profit-sharing arrangement for such product. The Company may terminate the Alnylam Agreement on a program-by-program basis or in its entirety for any reason on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90 days</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8217; written notice. Either party may terminate the agreement for cause for the other party&#8217;s uncured material breach on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60 days</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8217; written notice (or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30 days</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8217; notice for payment breach), or if the other party challenges the validity or enforceability of any patent licensed to it under the Alnylam Agreement on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30 days</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8217; notice.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, the Company achieved the specified development milestone relating to the Milestone Shares, which was accounted for as an embedded derivative. Consequently, the Company remeasured and reclassified the derivative liability to additional paid-in capital based on the estimated fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29.2</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company issued Alnylam </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,111,111</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock and paid Alnylam $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the second quarter of 2020.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Second and Third Amendments</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March and April 2020, the Company and Alnylam entered into the second and third amendments to the Alnylam Agreement (as amended, the &#8220;Amended Alnylam Agreement&#8221;) to expand the parties&#8217; existing collaboration to include the development and commercialization of siRNA products targeting SARS-CoV-2, and potentially other related coronaviruses, and up to three targeting human host factors for SARS-CoV-2 (collectively, the &#8220;COVID Collaboration Targets&#8221;).</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2020, the Company and Alnylam entered into a letter amendment (the &#8220;Letter Agreement&#8221;), amending the Amended Alnylam Agreement, to modify certain funding and governance provisions in connection with the siRNA products directed to the COVID Collaboration Targets, including VIR-2703 (the &#8220;COV Target&#8221;), and to modify certain rights of each party with respect to products arising from such programs. Pursuant to the Letter Agreement, Alnylam were responsible for conducting pre-clinical research activities set forth in the existing workplan for the COV Target (the &#8220;COV Workplan&#8221;) at its discretion and sole expense, and the Company was no longer obligated to reimburse Alnylam for any share of costs incurred by Alnylam in conducting activities under the COV Workplan after July 1, 2020. In July 2021, Alnylam elected to discontinue the development of the COV Target, and all other related research and development activities in accordance with their rights under the Letter Agreement. As a result, the COV Target and related siRNA program is no longer included within the Amended Alnylam Agreement and all rights to the siRNA program directed to the COV Target reverted to Alnylam.&#160;&#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses Recognized for the Period</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company incurred expenses under the Alnylam Agreement of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during the </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three and six months ended June&#160;30, 2021</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, respectively. In addition to the Milestone Shares and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million milestone payable to Alnylam in the first quarter of 2020, and the $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million payment resulting from Brii Bio&#8217;s option exercise in the second quarter of 2020, the Company incurred expenses of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.8</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million under the Alnylam Agreement during the </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">three and six months ended June&#160;30, 2020, respectively.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">WuXi Biologics</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2020, the Company entered into a development and manufacturing collaboration agreement with WuXi Biologics (Hong Kong) Limited (&#8220;WuXi Biologics&#8221;) (the &#8220;WuXi Biologics Collaboration Agreement&#8221;), for the clinical development, manufacturing, and commercialization of the Company&#8217;s proprietary antibodies developed for SARS-CoV-2. Under the WuXi Biologics Collaboration Agreement, WuXi Biologics will conduct cell-line development, process and formulation development, and initial manufacturing for clinical development. WuXi Biologics will have the right to commercialize products incorporating such antibodies in greater China under an exclusive license granted for the selected antibodies that have been developed. The Company will have the right to commercialize such products in all other markets worldwide.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">WuXi </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Biologics will perform mutually agreed development and manufacturing activities, under individual statements of work. In addition, the parties agreed that WuXi Biologics will pay the Company tiered royalties at percentages ranging from the high single-digits to mid-teens on annual net sales of all products sold by WuXi Biologics in greater China. The royalties are payable for a specified, standard royalty term. In addition, if WuXi Biologics sublicenses its commercialization rights to a third party, WuXi Biologics will pay the Company a percentage of the sublicense revenue received from such third party. The WuXi Biologics Collaboration Agreement will continue until the expiration of WuXi Biologics&#8217; payment obligations to the Company, unless</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">terminated </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">earlier. If terminated earlier, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the WuXi Biologics Collaboration Agreement may be terminated by (i) the written agreement of both parties, (ii) WuXi Biologics following the one year anniversary of the WuXi Biologics Collaboration Agreement effective date with respect to the entire agreement or on a product by product basis with 90 days&#8217; prior written notice or (iii) by either party if the other party materially breaches the WuXi Biologics Collaboration Agreement and fails to cure such breach within sixty days.</span></span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Rockefeller University</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2018, the Company entered into an exclusive license agreement with The Rockefeller University (&#8220;Rockefeller&#8221;), which was amended in May 2019, in September 2020, and in March 2021 (the &#8220;Rockefeller Agreement&#8221;). Under the Rockefeller Agreement, Rockefeller granted the Company a worldwide exclusive license under certain patent rights, and a worldwide non-exclusive license under certain materials and know-how covering certain antibody variants relating to a specified mutation leading to enhanced antibody function and utility, to develop, manufacture and commercialize infectious disease products covered by the licensed patents, or that involve the use or incorporation of the licensed materials and know-how, in each case for all uses and purposes for infectious diseases. The Company uses technology licensed under the Rockefeller Agreement in the Company&#8217;s antibody platform and in the Company&#8217;s product candidates VIR-3434 and VIR-7832.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company paid Rockefeller an upfront fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million for entry into the Rockefeller Agreement, and is required to pay annual license maintenance fees of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million. In addition, for the achievement of specified development, regulatory and commercial success milestone events, the Company will be required to pay up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80.3</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million, in the aggregate, for up to six infectious disease products. Any follow-on products beyond six products may result in additional milestone event payments. The Company will also be required to pay to Rockefeller a royalty at a low single-digit percentage rate on net sales of licensed products, subject to certain adjustments. The Company&#8217;s obligation to pay royalties to Rockefeller will terminate, on a product-by-product and jurisdiction-by-jurisdiction basis, upon the latest of the expiration of the last valid claim of a licensed patent in such jurisdiction, the expiration of all regulatory exclusivity in such jurisdiction or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12 years</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> following the first commercial sale of the applicable licensed product in such jurisdiction.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Rockefeller Agreement, the Company recognized a total of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during the three and six months ended June 30, 2021 and 2020, respectively, as research and development expenses related to certain development milestone payments, annual license maintenance fees, and estimated sublicense fees.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Rockefeller Agreement will remain in force, absent earlier termination, until the expiration of all of the Company&#8217;s obligations to pay royalties to Rockefeller in all jurisdictions. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has the right to terminate the Rockefeller Agreement in its entirety, or in part, for any reason on 60 days&#8217; written notice to Rockefeller. Rockefeller may terminate the Rockefeller Agreement on 90 days&#8217; written notice for the Company&#8217;s uncured material breach, or if the Company challenges the validity or enforceability of any of the licensed patents, or immediately in the event of the Company&#8217;s insolvency. Rockefeller may also terminate the Rockefeller Agreement if the Company ceases to carry on business with respect to the rights granted to the Company under the agreement. </span></span><span style="font-size:10.0pt;font-family:Times New Roman;"/></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">MedImmune</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In September 2018, the Company entered into a license agreement, which was amended in September 2020 (the &#8220;MedImmune Agreement&#8221;), with MedImmune, LLC  (&#8220;MedImmune&#8221;), under which the Company obtained a worldwide, exclusive license to develop and commercialize half-life extended versions of two specified antibodies under development by MedImmune that target influenza A and influenza B, respectively, for all uses in humans and animals. The Company is developing VIR-2482 using technology licensed under the MedImmune Agreement.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In consideration for the grant of the licenses under the MedImmune Agreement, the Company made an upfront payment to MedImmune of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company will be obligated to make development, regulatory, and commercial milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">331.5</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million, of which $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was paid in the third quarter of 2019, in the aggregate relating to influenza A and influenza B products. MedImmune will also be entitled to receive tiered royalties based on net sales of products containing half-life extended versions of antibodies directed to influenza A and/or influenza B at percentages ranging from the mid-single-digits to sub-teen double-digits.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The MedImmune Agreement will remain in force until the expiration on a country-by-country and product-by-product basis of all of the Company&#8217;s obligations to pay royalties to MedImmune. </span><span style="font-size:12.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company may terminate the MedImmune Agreement in its entirety or on a product-by-product basis, for convenience, upon 120 days&#8217; notice. Either party may terminate the MedImmune Agreement for cause for the other party&#8217;s uncured material breach on 60 days&#8217; notice or immediately in the event of bankruptcy of the other party. </span></span><span style=""/></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">MedImmune may terminate the MedImmune Agreement for cause on 30 days&#8217; written notice if the Company challenges the validity or enforceability of the patents to which the Company has obtained a license under the MedImmune Agreement.</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Xencor</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">August 2019 License Agreement</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2019, the Company entered into a patent license agreement, which was amended in February 2021 (the &#8220;2019 Xencor Agreement&#8221;) with Xencor, Inc., (&#8220;Xencor&#8221;). Under the 2019 Xencor Agreement, as amended, the Company obtained a non-exclusive, sublicensable (only to its affiliates and subcontractors) license to incorporate Xencor&#8217;s licensed technologies into, and to evaluate, antibodies that target influenza A and HBV, and a worldwide, non-exclusive, sublicensable license to develop and commercialize products containing such antibodies incorporating such technologies for all uses, including the treatment, palliation, diagnosis and prevention of human or animal diseases, disorders or conditions. The Company is obligated to use commercially reasonable efforts to develop and commercialize an antibody product that incorporates Xencor&#8217;s licensed technologies, for each of the influenza A and HBV research programs. These technologies are used in the Company&#8217;s VIR-2482, incorporating Xencor&#8217;s Xtend technology, and VIR-3434, incorporating Xencor&#8217;s Xtend and other Fc technologies, product candidates.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In consideration for the grant of the license, the Company paid Xencor an upfront fee. For each of the influenza A and HBV research programs, the Company will be required to pay Xencor development and regulatory milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.8</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million in the aggregate, and commercial sales milestone payments of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million in the aggregate, for a total of up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77.8</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million in aggregate milestones for each program and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">155.5</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million in aggregate milestones for both programs. On a product-by-product basis, the Company will also be obligated to pay tiered royalties based on net sales of licensed products ranging from low- to mid-single-digits. The royalties are payable, on a product-by-product and country-by-country basis, until the expiration of the last to expire valid claim in the licensed patents covering such product in such country.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2019, the Company achieved one of the specified development milestones related to the influenza A program. As such, the Company paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million related to the upfront fee and this milestone event in September 2019. In May 2020, the Company achieved one of the specified development milestones related to the HBV program. As such, the Company paid $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to this milestone event in June 2020. The milestone payments are expensed to research and development.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">March 2020 License Agreement</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, the Company entered into a patent license agreement, which was amended in February 2021 (the &#8220;2020 Xencor Agreement&#8221;) with Xencor under which the Company obtained a non-exclusive, sublicensable (only to the Company&#8217;s affiliates and subcontractors) license to incorporate Xencor&#8217;s licensed technologies into, and to evaluate, antibodies that target any component of a coronavirus, including SARS-CoV-2, SARS-CoV and MERS-CoV, and a worldwide, non-exclusive, sublicensable license to develop and commercialize products containing such antibodies incorporating such technologies for all uses, including the treatment, palliation, diagnosis and prevention of human or animal diseases, disorders or conditions. The Company is obligated to use commercially reasonable efforts to develop and commercialize an antibody product that incorporates Xencor&#8217;s licensed technologies, for each of the coronavirus research programs. These technologies are used in the Company&#8217;s sotrovimab, incorporating Xencor&#8217;s Xtend technology, and VIR-7832, incorporating Xencor&#8217;s Xtend and other Fc technologies, product candidates.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In consideration for the grant of the license, the Company will be obligated to pay royalties based on net sales of licensed products at the mid-single-digits. The royalties are payable, on a product-by-product and country-by-country basis, until the later of the expiration of the last to expire valid claim in the licensed patents covering such product in such country or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12 years</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. During the three months ended June 30, 2021, the Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of royalties due to Xencor from the sale of sotrovimab.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The amended 2020 Xencor Agreement and 2019 Xencor Agreement will remain in force, on a product-by-product and country-by-country basis, until the expiration of all royalty payment obligations under each of the respective agreements. The Company may terminate each agreement in its entirety, or on a target-by-target basis, for convenience upon </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60 days</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8217; written notice. Either party may terminate each agreement for the other party&#8217;s uncured material breach upon </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60 days</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8217; written notice (or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30 days</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in the case of non-payment) or in the event of bankruptcy of the other party immediately upon written notice. Xencor may terminate each agreement immediately upon written notice if the Company challenges, or upon </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30 days</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8217; written notice if any of the Company&#8217;s sublicensees challenge, the validity or enforceability of any patent licensed to the Company under each respective agreement.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196189685544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock', window );">Balance Sheet Components</a></td>
<td class="text"><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Balance Sheet Components</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, net</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net consists of the following:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:69.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.143%;"/>
        <td style="width:1.651%;"/>
        <td style="width:1.449%;"/>
        <td style="width:11.634%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1.651%;"/>
        <td style="width:1.449%;"/>
        <td style="width:11.554%;"/>
        <td style="width:1.449%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">June&#160;30,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December&#160;31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,168</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,769</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">580</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">556</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,444</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,444</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,281</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,274</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,544</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,135</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, gross</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32,017</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,178</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,766</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,232</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,251</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,946</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization expenses was $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for the three and six months ended June&#160;30, 2021</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.1</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> for the three and six months ended June&#160;30, 2020, respectively. </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#160;&#160;</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued and Other Liabilities</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued and other liabilities consist of the following:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:69.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.384%;"/>
        <td style="width:1.664%;"/>
        <td style="width:1.463%;"/>
        <td style="width:11.661%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1.664%;"/>
        <td style="width:1.463%;"/>
        <td style="width:11.661%;"/>
        <td style="width:1.02%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">June&#160;30,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December&#160;31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,952</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49,384</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Milestone payable</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payroll and related expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,353</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,060</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Excess funds payable under grant agreements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,046</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,467</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,522</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,625</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other professional and consulting expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,867</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,595</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,334</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">805</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total accrued and other liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64,074</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76,936</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalBalanceSheetDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -URI http://asc.fasb.org/topic&amp;trid=2122208<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalBalanceSheetDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196195899784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Commitments and Contingencies</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Lease Agreements</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has various lease arrangements for office and laboratory spaces located in California, Oregon, Missouri and Switzerland with contractual lease periods expiring between </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2033</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain lease agreements also provide the Company with the option to renew for additional periods ranging from </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_68e96f79-a508-48f1-bc17-ed7aec35b970;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span></span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. </span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Most of these renewal options are not considered in the remaining lease term unless it is reasonably certain that the Company will exercise such options. In February 2021, the Company entered into a new lease arrangement for office and laboratory spaces in Oregon. The lease is expected to commence in the fourth quarter of 2021 when the Company obtains access to the leased space. In addition to the operating lease agreements, the Company entered into a sale-leaseback transaction in August 2019.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Throughout the term of the lease agreements, the Company is responsible for paying certain operating costs, in addition to rent, such as common area maintenance, taxes, utilities and insurance. These additional charges are considered variable lease costs and are recognized in the period in which the costs are incurred. </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#160;&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The maturity of the Company&#8217;s operating lease liabilities as of </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June&#160;30, 2021 was as follows (in thousands):</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:59.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:73.525%;"/>
        <td style="width:1.915%;"/>
        <td style="width:1.679%;"/>
        <td style="width:21.861%;"/>
        <td style="width:1.02%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amounts</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 (excluding the six months ended June 30, 2021)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,428</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,713</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,387</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,564</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,042</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67,466</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110,600</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38,140</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: net tenant improvement allowance yet to be received</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,287</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62,173</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following amounts were recorded in the condensed consolidated balance sheets for the periods ended:</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:59.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.954%;"/>
        <td style="width:1.601%;"/>
        <td style="width:1.695%;"/>
        <td style="width:15.207%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1.601%;"/>
        <td style="width:1.695%;"/>
        <td style="width:15.207%;"/>
        <td style="width:1.02%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">June&#160;30,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December&#160;31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Operating Leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current operating lease liabilities, net of tenant<br/>&#160;&#160;&#160;improvement allowances</span><span style="color:rgba(0,0,0,1);top:-4.6899999999999995pt;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">&#160;(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,287</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,913</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58,972</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61,947</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_89b36744-6825-4405-8082-31787f74cb3c;"><span style="-sec-ix-hidden:F_580369ee-3852-4e0f-9dd1-a3ca48903cb6;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued and other liabilities</span></span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,522</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,625</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, noncurrent</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68,938</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66,556</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72,460</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70,181</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="margin-left:2.777777777777657E-4in;display:flex;margin-top:0.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.19027777777777777in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.19027777777777777in;">(1)</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Current portion of lease liabilities recorded in prepaid expenses and other current assets for which the lease incentives to be received exceed the minimum lease payments to be paid over the next twelve months.</span></div></div></div><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Manufacturing and Supply Letter Agreements</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2020, the Company and Samsung Biologics Co., Ltd. (&#8220;Samsung&#8221;) entered into a binding letter agreement (the &#8220;Samsung Letter Agreement&#8221;), pursuant to which Samsung will perform development and manufacturing services for the Company&#8217;s SARS-CoV-2 antibody program.&#160;In August 2020, the Company, GlaxoSmithKline Trading Services Limited (&#8220;GSKTSL&#8221;) and Samsung entered into an Assignment and Novation Agreement effective as of July 31, 2020 pursuant to which the Company assigned and transferred to GSKTSL all of the Company&#8217;s right, title, and interest in, to and under the Samsung Letter Agreement, and GSKTSL became the Company&#8217;s successor in interest in and to all of the Company&#8217;s rights, duties, and obligations in, to and under the Samsung Letter Agreement.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2020, the Company and WuXi Biologics entered into a binding letter of intent (the &#8220;WuXi Biologics Letter Agreement&#8221;), pursuant to which WuXi Biologics will perform certain development and manufacturing services for the Company&#8217;s SARS-CoV-2 antibody program. In August 2020, the Company, GSKTSL and WuXi Biologics entered into an Assignment and Novation Agreement effective as of July 29, 2020 pursuant to which the Company assigned and transferred to GSKTSL all of the Company&#8217;s right, title, and interest in, to and under the WuXi Biologics Letter Agreement, and GSKTSL became the Company&#8217;s successor in interest in and to all of the Company&#8217;s rights, duties, and obligations in, to and under the WuXi Biologics Letter Agreement.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2020, GSKTSL entered into a Master Services Agreement with Samsung (the &#8220;Samsung MSA&#8221;) and a non-exclusive Master Services Agreement for Commercial Manufacture of Drug Substance with WuXi Biologics (the &#8220;WuXi Biologics MSA&#8221;) in connection with the performance of the obligations of the Company and GSK, pursuant to the 2020 GSK Agreement. In accordance with the terms of the 2020 GSK Agreement, the Company will continue to be responsible for </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72.5</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the costs under each of the Samsung MSA and the WuXi Biologics MSA, and GSK will bear </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27.5</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of such costs under each of the Samsung MSA and the WuXi Biologics MSA, subject to certain conditions and exceptions.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Indemnification</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. In some cases, the indemnification obligation will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. In addition, the Company has entered into indemnification agreements with its directors and certain officers that may require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers. To date, no demands have been made upon the Company to provide indemnification under these agreements, and thus, there are no indemnification claims that the Company is aware of that could have a material effect on the Company&#8217;s condensed consolidated balance sheets, condensed consolidated statements of operations, or condensed consolidated statements of cash flows.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121559207&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196195400568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transaction<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transaction</a></td>
<td class="text"><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Related Party Transaction</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a result of the Brii Agreement in May 2018, the Company holds a minority equity interest in Brii Bio through its parent company, Brii Bio Parent. Additionally, a member of the Company&#8217;s board of directors serves on Brii Bio Parent&#8217;s board of directors.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective June 22, 2021, the Company's Chief Executive Officer is no longer a member of Brii Bio Parent's board of directors.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196195816584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Awards</a></td>
<td class="text"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Stock-Based Awards </span><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Option Activity</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Activity under the Company&#8217;s stock option plans is set forth below:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.681%;"/>
        <td style="width:1.307%;"/>
        <td style="width:1.008%;"/>
        <td style="width:12.973%;"/>
        <td style="width:1.019%;"/>
        <td style="width:1.317%;"/>
        <td style="width:1.06%;"/>
        <td style="width:12.942%;"/>
        <td style="width:1.019%;"/>
        <td style="width:1.317%;"/>
        <td style="width:1.019%;"/>
        <td style="width:12.984%;"/>
        <td style="width:1.019%;"/>
        <td style="width:1.317%;"/>
        <td style="width:1.06%;"/>
        <td style="width:12.942%;"/>
        <td style="width:1.019%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br/>Options</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Exercise<br/>Price</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br/>Intrinsic<br/>Value</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,798,282</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.25</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.5</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,583,490</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61.99</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,050,899</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.66</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">628,801</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28.19</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at June 30, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,702,072</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.24</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.5</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">223,581</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested and expected to vest at June 30, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,702,072</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.24</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.5</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">223,581</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested and exercisable at June 30, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,262,612</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.40</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.7</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110,878</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of June&#160;30, 2021</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, the Company expects to recognize the remaining unamortized stock-based compensation expense of $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">203.1</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million related to stock options, over an estimated weighted average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.7</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Options Granted to Employees</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">T</span><span style="font-size:12.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">he fair value of stock options granted to employees was estimated on the date of grant using the Black-Scholes option-pricing model using the following assumptions: </span></span><span style=""/></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:34.787%;"/>
        <td style="width:1.296%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.296%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.009%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.296%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.009%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.296%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.009%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended June&#160;30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Six Months Ended June&#160;30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term of options (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected stock price volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110.2</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95.7</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100.6</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103.1</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110.2</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88.8</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100.6</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The valuation assumptions were determined as follows:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:24.45pt;text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Term&#8212;</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected term represents the period that the options granted are expected to be outstanding and is determined using the simplified method (based on the mid-point between the vesting date and the end of the contractual term) as the Company has concluded that its stock option exercise history does not provide a reasonable basis upon which to estimate expected term.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:24.45pt;text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Volatility&#8212;</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected volatility was determined by examining the historical volatilities for industry peers and using an average of historical volatilities of the Company&#8217;s industry peers as the Company does not have a sufficient historical trading history for its own stock. The Company will continue to apply this process until a sufficient amount of historical information regarding the volatility of its own stock price becomes available.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:24.45pt;text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risk-Free Interest Rate&#8212;</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company based the risk-free interest rate over the expected term of the options based on the constant maturity rate of U.S. Treasury securities with similar maturities as of the date of the grant.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="margin-left:24.45pt;text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected Dividend Rate&#8212;</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected dividend is zero as the Company has not paid nor does it anticipate paying any dividends on its profit interest units in the foreseeable future.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Stock Awards and Restricted Stock Units Activities</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s restricted stock awards (RSAs&#8221;) and restricted stock units (&#8220;RSUs&#8221;) were summarized as follows:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:68.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.746%;"/>
        <td style="width:1.471%;"/>
        <td style="width:1.471%;"/>
        <td style="width:14.597%;"/>
        <td style="width:1.471%;"/>
        <td style="width:1.471%;"/>
        <td style="width:10.226%;"/>
        <td style="width:1.035%;"/>
        <td style="width:1.416%;"/>
        <td style="width:1.471%;"/>
        <td style="width:7.339%;"/>
        <td style="width:1.035%;"/>
        <td style="width:1.471%;"/>
        <td style="width:7.312%;"/>
        <td style="width:1.471%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted Average Grant Date Fair Value</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RSU</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RSA</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RSU</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RSA</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89,261</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.48</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,050,995</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64.25</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87,409</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.48</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,550</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67.38</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested as of June 30, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,022,445</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,852</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64.16</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.53</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The unvested shares of RSA and RSU have not been included in the shares issued and outstanding.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of June&#160;30, 2021</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, there was $</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59.7</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;million of total unrecognized compensation cost related to unvested RSUs, all of which is expected to be recognized over a remaining weighted-average period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.6</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> years.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation Expense</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the total stock-based compensation expense for all awards granted to employees and non-employees and the Company's Employee Stock Purchase Plan ("ESPP") in the condensed consolidated statements of operations:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.195%;"/>
        <td style="width:1.245%;"/>
        <td style="width:1.049%;"/>
        <td style="width:9.146%;"/>
        <td style="width:1.019%;"/>
        <td style="width:1.235%;"/>
        <td style="width:1.049%;"/>
        <td style="width:9.146%;"/>
        <td style="width:1.019%;"/>
        <td style="width:1.235%;"/>
        <td style="width:1.049%;"/>
        <td style="width:9.146%;"/>
        <td style="width:1.019%;"/>
        <td style="width:1.235%;"/>
        <td style="width:1.049%;"/>
        <td style="width:9.146%;"/>
        <td style="width:1.019%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended June&#160;30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Six Months Ended June&#160;30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,860</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,700</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,290</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,188</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Selling, general and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,138</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,050</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,179</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,529</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,998</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,750</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,469</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,717</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196195886088">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Income (Loss) Per Share</a></td>
<td class="text"><p style="text-indent:-24.5pt;padding-left:24.5pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Net Income (Loss) Per Share</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic net income (loss) per common share is computed by dividing the net income (loss) by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted net income (loss) per common share is computed by dividing the net income (loss) by the sum of the weighted average number of common shares outstanding during the period plus any potential dilutive effects of common stock equivalents outstanding during the period calculated in accordance with the treasury stock method. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following is a calculation of the basic and diluted net income (loss) per share (in thousands, except share and per share data):</span></span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:43.704%;"/>
        <td style="width:1.046%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.991%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.056%;"/>
        <td style="width:1.037%;"/>
        <td style="width:12.361%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.056%;"/>
        <td style="width:1.037%;"/>
        <td style="width:10.407%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.056%;"/>
        <td style="width:1.037%;"/>
        <td style="width:11.213%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended June&#160;30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Six Months Ended June&#160;30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss), basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61,813</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,167</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">107,098</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108,407</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares outstanding, basic</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">130,121,943</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114,980,652</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">128,938,851</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">111,684,283</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average effect of dilutive securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,635,656</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted shares subject to future vesting</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,409</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contingently issuable shares</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,969</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares outstanding, diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133,789,977</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114,980,652</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">128,938,851</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">111,684,283</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss) per share, basic</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.48</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.27</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.83</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.97</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss) per share, diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.46</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.27</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.83</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.97</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></div><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.909%;"/>
        <td style="width:1.08%;"/>
        <td style="width:1.008%;"/>
        <td style="width:9.887%;"/>
        <td style="width:1.008%;"/>
        <td style="width:1.07%;"/>
        <td style="width:0.998%;"/>
        <td style="width:12.459%;"/>
        <td style="width:0.998%;"/>
        <td style="width:1.07%;"/>
        <td style="width:1.111%;"/>
        <td style="width:10.031%;"/>
        <td style="width:0.998%;"/>
        <td style="width:1.07%;"/>
        <td style="width:0.998%;"/>
        <td style="width:11.307%;"/>
        <td style="width:0.998%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"><br/></span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended June&#160;30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Six Months Ended June&#160;30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options issued and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,164,036</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,932,845</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,702,072</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,932,845</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Estimated shares issuable under the ESPP</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71,582</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71,582</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted shares subject to future vesting</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">933,870</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">844,886</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,024,297</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">844,886</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contingently issuable shares</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39,340</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,169,488</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,777,731</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,837,291</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,777,731</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196197566040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12. Subsequent Event</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investment in Brii Bio Parent</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 13, 2021, Brii Bio Parent became a publicly traded company on the Stock Exchange of Hong Kong Limited. As such, the Company's investment in shares of Brii Bio Parent became a marketable equity investment with readily determinable price, which will then be measured at fair value at each reporting period going forward.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196189478232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2241666666666668;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (&#8220;GAAP&#8221;) and applicable rules and regulations of the SEC regarding interim financial reporting. The condensed consolidated financial statements include the accounts of Vir and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated upon consolidation.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The unaudited interim condensed consolidated financial statements have been prepared on the same basis as the annual consolidated financial statements and reflect, in the opinion of management, all adjustments of a normal and recurring nature that are necessary for the fair presentation of the Company&#8217;s financial information. The condensed consolidated results of operations for the six months ended June&#160;30, 2021 are not necessarily indicative of the results to be expected for the year ending December&#160;31, 2021 or for any other future annual or interim period.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Certain information and footnote disclosures typically included in the Company&#8217;s annual consolidated financial statements have been condensed or omitted. As such, these interim condensed consolidated financial statements should be read in conjunction with the Company&#8217;s audited consolidated financial statements and related notes included in the Annual Report on Form 10-K for the year ended December 31, 2020, filed with the SEC on February 25, 2021.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the condensed consolidated financial statements and the reported amounts of revenue and expense during the reporting periods. The Company evaluates its estimates and assumptions on an ongoing basis using historical experience and other factors and adjusts those estimates and assumptions when facts and circumstances dictate. Actual results could materially differ from those estimates.</span><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock', window );">Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties</a></td>
<td class="text"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">With the global spread of the ongoing COVID-19 pandemic, the Company has implemented a number of plans and policies designed to address and mitigate the impact of the COVID-19 pandemic on its business. The Company anticipates that the COVID-19 pandemic will continue to have an impact on the clinical development timelines for some of its clinical programs. The extent to which the COVID-19 pandemic impacts the Company&#8217;s business, clinical development and regulatory efforts, corporate development objectives and the value of and market for its common stock, will depend on future developments that are highly uncertain and cannot be predicted with confidence at this time, such as the ultimate duration of the pandemic, travel restrictions, quarantines, social distancing and business closure requirements in the United States, Europe and other countries, and the effectiveness of actions taken globally to contain and treat the disease.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the Company is subject to a number of other challenges and risks similar to other biopharmaceutical companies in the early stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, the need to successfully commercialize and gain market acceptance of the Company&#8217;s products and protection of proprietary technology. If the Company does not successfully obtain regulatory approval, commercialize or partner any of its product candidates, it will be unable to generate revenue from product sales or achieve profitability. In addition, to the extent the ongoing COVID-19 pandemic adversely affects the Company&#8217;s business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties discussed above.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents and investments. Cash and cash equivalents are deposited in checking and sweep accounts at a financial institution. Such deposits may, at times, exceed federally insured limits. The Company has not experienced any losses on its deposits of cash and cash equivalents.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents and investments, and issuers of the investments to the extent recorded on the condensed consolidated balance sheets. As of June&#160;30, 2021, the Company has no off-balance sheet concentrations of credit risk.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is exposed to credit losses primarily through receivables from customers and collaborators and through its available-for-sale debt securities. The Company&#8217;s expected loss allowance methodology for the receivables is developed using historical collection experience, current and future economic market conditions, a review of the current aging status and financial condition of the entities. Specific allowance amounts are established to record the appropriate allowance for customers that have a higher probability of default. Balances are written off when determined to be uncollectible. The Company&#8217;s expected loss allowance methodology for the debt securities is developed by reviewing the extent of the unrealized loss, the size, term, geographical location, and industry of the issuer, the issuers&#8217; credit ratings and any changes in those ratings, as well as reviewing current and future economic market conditions and the issuers&#8217; current status and financial condition. The Company considered the current and expected future economic and market conditions surrounding the COVID-19 pandemic and determined that the estimate of credit losses was not significantly impacted. During the six months ended June 30, 2021 and 2020, there was </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> allowance for losses on available-for-sale debt securities attributable to credit risk.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investments</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investments include available-for-sale debt securities and are carried at estimated fair value. The Company&#8217;s valuations of marketable securities are generally derived from independent pricing services based on quoted prices in active markets for similar securities at period end. Generally, investments with original maturities beyond three months at the date of purchase and which mature at, or less than 12 months from, the condensed consolidated balance sheet date are considered short-term investments, with all others considered to be long-term investments. Unrealized gains and losses deemed temporary in nature are reported as a component of accumulated comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the condensed consolidated statements of operations. The Company&#8217;s policy is not to measure an allowance for credit losses for interest receivable and to write off any uncollectible interest receivable as a reversal of interest income in the period in which it determines the interest will not be collected.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company, through its investment in Brii Biosciences Limited, holds privately held equity securities in which the Company does not have a controlling interest or significant influence. The Company&#8217;s investment in Brii Biosciences Limited is recorded at cost and adjusted for impairments and observable price changes with the same or similar security from the same issuer. The valuation of the Company&#8217;s investment in Brii Biosciences Limited utilizes significant unobservable inputs or data in an inactive market and the valuation requires the Company&#8217;s judgment due to the absence of market prices and inherent lack of liquidity. Additionally, the determination of whether an orderly transaction is for the same or similar investment requires significant management judgment including the nature of the rights and obligations of its investments, the extent to which differences in those rights and obligations would affect the fair values of those investments, and the impact of any differences based on the stage of operational development of the investee. See Note 6&#8212;Collaboration and License Agreements for additional information on the Company&#8217;s investment in Brii Biosciences Limited.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Cash and Cash Equivalents</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash and cash equivalents represent money market funds to secure standby letters of credit and security deposits with financial institutions, both under office and laboratory space lease agreements. Additionally, funds received from certain grants are restricted as to their use and are therefore classified as restricted cash and cash equivalents.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaboration, License and Contract Revenue</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In accordance with Accounting Standards Codification (&#8220;ASC&#8221;) Topic 606, Revenue from Contracts with Customers (&#8220;ASC 606&#8221;), the Company recognizes revenue when the Company&#8217;s customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive in exchange for those goods and services. To determine revenue recognition for arrangements within the scope of ASC 606, the Company performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when or as the Company satisfies a performance obligation.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For collaborative arrangements that fall within the scope of ASC 808, Collaborative Arrangements (&#8220;ASC 808&#8221;), the Company first determines which elements of the collaboration are deemed to be a performance obligation with a customer within the scope of ASC 606. For elements of collaboration arrangements that are accounted for pursuant to ASC 808 and are not subject to the guidance in ASC 606, the Company applies the revenue recognition model under ASC 606 or other guidance, as deemed appropriate. The Company has entered into a number of license and collaboration agreements that fall within the scope of ASC 606. The Company evaluates the promised goods or services in these agreements to determine which ones represent distinct performance obligations. These agreements may include the following types of promised goods or services: (i) grants of licenses, (ii) performance of research and development services, and (iii) participation on joint research and/or development committees. They also may include options to obtain licenses to the Company&#8217;s intellectual property.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to recognizing revenue, the Company makes estimates of the transaction price, including variable consideration that is subject to a constraint. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur and when the uncertainty associated with the variable consideration is subsequently resolved. These estimates are re-assessed each reporting period as required. These agreements may include the following types of consideration: non-refundable upfront payments, reimbursement for research services, research, development or regulatory milestone payments, profit-sharing arrangements and royalty and commercial sales milestone payments.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If there are multiple distinct performance obligations, the Company allocates the transaction price to each distinct performance obligation based on their estimated standalone selling prices (&#8220;SSP&#8221;). For performance obligations satisfied over time, the Company estimates the efforts needed to complete the performance obligation and recognizes revenue by measuring the progress towards complete satisfaction of the performance obligation using an input measure.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For arrangements that include sales-based royalties, including commercial milestone payments based on pre-specified level of sales, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). Achievement of these royalties and commercial milestones may solely depend upon performance of the licensee.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Grant Revenue</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2729166666666667;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grants received, including cost reimbursement agreements, are assessed to determine if the agreement should be accounted for as an exchange transaction or a contribution. An agreement is accounted for as a contribution if the resource provider does not receive commensurate value in return for the assets transferred. Contributions are recognized as grant revenue when all donor-imposed conditions have been met.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Acquisitions</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Business combinations are accounted for using the acquisition method of accounting. Under the acquisition method, assets acquired, including in-process research and development (&#8220;IPR&amp;D&#8221;) projects, and liabilities assumed are recorded at their respective fair values as of the acquisition date. Any excess fair value of consideration transferred over the fair value of the net assets acquired is recorded as goodwill. Contingent consideration obligations incurred in connection with the business combination are recorded at their fair values on the acquisition date and are remeasured each subsequent reporting period until the related contingencies are resolved and are classified as contingent consideration on the condensed consolidated balance sheets. The changes in fair values of contingent consideration related to the achievement of various development milestones related to product candidates are recorded within research and development expense.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">When the Company determines that entities acquired do not meet the definition of a business, the transaction is accounted for as an acquisition of assets. Therefore, the consideration paid to acquire IPR&amp;D is expensed, and no goodwill is recorded. Any contingent consideration is generally recognized only when it becomes payable or is paid.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesEmbeddedDerivatives', window );">Embedded Derivatives</a></td>
<td class="text"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:18.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Embedded Derivatives</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company evaluates its acquisitions, collaborative arrangements and other business development transactions to determine if embedded components of these contracts meet the definition of a derivative under ASC 815, Derivatives and Hedging. In general, embedded derivatives are required to be bifurcated from the host instrument if (i) the embedded feature is not clearly and closely related to the host contract and (ii) the embedded feature, if considered a freestanding instrument, meets the definition of a derivative. Embedded derivatives are reported on the condensed consolidated balance sheets at their estimated fair values. Contingent consideration related to asset acquisitions that meet the definition of an embedded derivative is classified as contingent consideration on the condensed consolidated balance sheets. Any change in estimated fair values, as determined at each measurement period, are recorded in the condensed consolidated statements of operations based on the nature of the related contingencies.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair values of embedded derivatives related to the achievement of various development milestones for product candidates are recorded within research and development expense. Otherwise, changes in fair values are recorded within other income (expense), net.</span><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesEmbeddedDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for embedded derivatives, including how such derivatives are identified and analyzed for possible separation from their host contracts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 25<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=107671284&amp;loc=SL5844817-113951<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77984636&amp;loc=d3e40733-113955<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -Section 35<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=56949186&amp;loc=d3e50579-113967<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 15<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121596415&amp;loc=d3e48542-113965<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesEmbeddedDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(3)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration of credit risk credit loss and other risks and uncertainties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196196611128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock', window );">Summary of Financial Assets Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables summarize the Company&#8217;s Level 1 and Level 2 financial assets measured at fair value on a recurring basis by level within the fair value hierarchy:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.806%;"/>
        <td style="width:1.083%;"/>
        <td style="width:9.963%;"/>
        <td style="width:1.083%;"/>
        <td style="width:1.037%;"/>
        <td style="width:7.917%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.083%;"/>
        <td style="width:1.037%;"/>
        <td style="width:7.917%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.083%;"/>
        <td style="width:1.037%;"/>
        <td style="width:7.917%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.083%;"/>
        <td style="width:1.037%;"/>
        <td style="width:7.917%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">June&#160;30, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Valuation<br/>Hierarchy</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br/>Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span><span style="color:rgba(0,0,0,1);top:-4.6899999999999995pt;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">739,286</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">739,286</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Bank time deposits</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government treasuries</span><span style="color:rgba(0,0,0,1);top:-4.6899999999999995pt;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">129,786</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">129,787</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total financial assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">874,072</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">874,073</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:5.5in;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:-13.5pt;padding-left:13.5pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(1)	</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Includes </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span><span style="font-size:8.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">14.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> million</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> of restricted cash equivalents.</span></p><p style="text-indent:-13.5pt;padding-left:13.5pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(2)	</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Includes $</span><span style="font-size:8.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">50.7</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> million classified as long-term investments.</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:44.769%;"/>
        <td style="width:1.083%;"/>
        <td style="width:9.954%;"/>
        <td style="width:1.083%;"/>
        <td style="width:1.037%;"/>
        <td style="width:7.907%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.083%;"/>
        <td style="width:1.037%;"/>
        <td style="width:7.907%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.083%;"/>
        <td style="width:1.037%;"/>
        <td style="width:7.907%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.083%;"/>
        <td style="width:1.037%;"/>
        <td style="width:7.991%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Valuation<br/>Hierarchy</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Holding<br/>Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Gross<br/>Unrealized<br/>Holding<br/>Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br/>Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds</span><span style="color:rgba(0,0,0,1);top:-4.6899999999999995pt;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Level 1</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">421,835</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">421,835</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">U.S. government treasuries</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;Level 2</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">300,201</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">300,286</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:28.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:28.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total financial assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">722,036</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">722,121</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(1)	</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Includes $</span><span style="font-size:8.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">14.9</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;million of restricted cash equivalents.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock', window );">Summary of Changes in Estimated Fair Value of Financial Liabilities</a></td>
<td class="text"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the changes in the estimated fair value of the Company&#8217;s Level&#160;3 financial liabilities (in thousands):</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.1700000000000002;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:76.563%;"/>
        <td style="width:1.25%;"/>
        <td style="width:1.25%;"/>
        <td style="width:19.942%;"/>
        <td style="width:0.995%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Contingent<br/>Consideration</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35,974</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair value recognized in research and development expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33,300</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in fair value recognized in other income (expense), net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,618</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Reclassification of contingent consideration to accrued liabilities upon <br/>&#160;&#160;achievement of milestone</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at June 30, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68,892</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Clinical and Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Estimated Fair Value of Significant Unobservable Inputs</a></td>
<td class="text"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June&#160;30, 2021, the Company calculated the estimated fair value of the clinical and regulatory milestones using the following significant unobservable inputs: </span><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.062%;"/>
        <td style="width:2.562%;"/>
        <td style="width:32.377%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unobservable input</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Range<br/>(Weighted-Average)</span><span style="color:rgba(0,0,0,1);top:-3.752pt;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;">1</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discount rates</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% (</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Probability of achievement</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% (</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
       </tr>
      </table><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="margin-left:5.000000000000004E-4in;display:flex;margin-top:0.0pt;line-height:1.2620833333333334;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.1875in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.1875in;">(1)</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Unobservable inputs were weighted based on the relative fair value of the clinical and regulatory milestone payments.</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></div></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Estimated Fair Value of Significant Unobservable Inputs</a></td>
<td class="text"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June&#160;30, 2021, the Monte Carlo simulation assumed a commercial product launch and associated discrete revenue forecast, as well as the following significant unobservable inputs: </span><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.062%;"/>
        <td style="width:2.562%;"/>
        <td style="width:32.377%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unobservable input</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value or Range<br/>(Weighted-Average)</span><span style="color:rgba(0,0,0,1);top:-3.752pt;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;">1</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Volatility</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discount rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Probability of achievement</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% (</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
       </tr>
      </table><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Unobservable inputs were weighted based on the relative fair value of the commercial milestone payments.</span><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock', window );">Estimated Fair Value of Significant Unobservable Inputs</a></td>
<td class="text"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June&#160;30, 2021, the fair value of the remaining contingent consideration was estimated using the following significant unobservable inputs:</span><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.062%;"/>
        <td style="width:2.562%;"/>
        <td style="width:32.377%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unobservable input</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Value or Range<br/>(Weighted-Average)</span><span style="color:rgba(0,0,0,1);top:-3.752pt;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;">1</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Discount rates</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% (</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%)</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
       </tr>
      </table><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="margin-left:5.000000000000004E-4in;display:flex;margin-top:0.0pt;line-height:1.2620833333333334;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.1875in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.1875in;">(1)</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Unobservable inputs were weighted based on the relative fair value of the underlying milestones. </span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19279-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=vir_ClinicalAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=vir_ClinicalAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=vir_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=vir_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196195885048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment Net</a></td>
<td class="text"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net consists of the following:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:69.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.143%;"/>
        <td style="width:1.651%;"/>
        <td style="width:1.449%;"/>
        <td style="width:11.634%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1.651%;"/>
        <td style="width:1.449%;"/>
        <td style="width:11.554%;"/>
        <td style="width:1.449%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">June&#160;30,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December&#160;31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18,168</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16,769</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">580</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">556</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,444</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,444</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,281</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,274</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in progress</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,544</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,135</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, gross</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32,017</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,178</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less accumulated depreciation and amortization</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,766</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,232</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total property and equipment, net</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,251</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,946</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock', window );">Schedule of Accrued and Other Liabilities</a></td>
<td class="text"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued and other liabilities consist of the following:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:69.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:68.384%;"/>
        <td style="width:1.664%;"/>
        <td style="width:1.463%;"/>
        <td style="width:11.661%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1.664%;"/>
        <td style="width:1.463%;"/>
        <td style="width:11.661%;"/>
        <td style="width:1.02%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">June&#160;30,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December&#160;31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,952</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49,384</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Milestone payable</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payroll and related expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,353</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,060</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Excess funds payable under grant agreements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,046</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,467</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,522</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,625</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other professional and consulting expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,867</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,595</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other expenses</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,334</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">805</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total accrued and other liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64,074</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76,936</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of accrued liabilities and other liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196195453400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The maturity of the Company&#8217;s operating lease liabilities as of </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June&#160;30, 2021 was as follows (in thousands):</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:59.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:73.525%;"/>
        <td style="width:1.915%;"/>
        <td style="width:1.679%;"/>
        <td style="width:21.861%;"/>
        <td style="width:1.02%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amounts</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2021 (excluding the six months ended June 30, 2021)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,428</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,713</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,387</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,564</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,042</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67,466</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110,600</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38,140</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: net tenant improvement allowance yet to be received</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,287</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Present value of operating lease liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62,173</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock', window );">Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheets</a></td>
<td class="text"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following amounts were recorded in the condensed consolidated balance sheets for the periods ended:</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:59.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:60.954%;"/>
        <td style="width:1.601%;"/>
        <td style="width:1.695%;"/>
        <td style="width:15.207%;"/>
        <td style="width:1.02%;"/>
        <td style="width:1.601%;"/>
        <td style="width:1.695%;"/>
        <td style="width:15.207%;"/>
        <td style="width:1.02%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">June&#160;30,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December&#160;31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Operating Leases</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current operating lease liabilities, net of tenant<br/>&#160;&#160;&#160;improvement allowances</span><span style="color:rgba(0,0,0,1);top:-4.6899999999999995pt;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">&#160;(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,287</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,913</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating right-of-use assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58,972</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61,947</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_89b36744-6825-4405-8082-31787f74cb3c;"><span style="-sec-ix-hidden:F_580369ee-3852-4e0f-9dd1-a3ca48903cb6;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued and other liabilities</span></span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,522</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,625</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liabilities, noncurrent</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68,938</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66,556</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72,460</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70,181</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2620833333333334;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:5.5in;text-align:left;"><span style="font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p><div style="margin-left:2.777777777777657E-4in;display:flex;margin-top:0.0pt;line-height:1.3;justify-content:flex-start;margin-bottom:0.0pt;min-width:0.19027777777777777in;"><span style="color:rgba(0,0,0,1);font-weight:normal;display:inline-block;font-size:8.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:0.19027777777777777in;">(1)</span><div style="display:inline;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Current portion of lease liabilities recorded in prepaid expenses and other current assets for which the lease incentives to be received exceed the minimum lease payments to be paid over the next twelve months.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of operating lease amounts recorded in condensed consolidated balance sheet.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196189685016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Plans Activity</a></td>
<td class="text"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Activity under the Company&#8217;s stock option plans is set forth below:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:34.681%;"/>
        <td style="width:1.307%;"/>
        <td style="width:1.008%;"/>
        <td style="width:12.973%;"/>
        <td style="width:1.019%;"/>
        <td style="width:1.317%;"/>
        <td style="width:1.06%;"/>
        <td style="width:12.942%;"/>
        <td style="width:1.019%;"/>
        <td style="width:1.317%;"/>
        <td style="width:1.019%;"/>
        <td style="width:12.984%;"/>
        <td style="width:1.019%;"/>
        <td style="width:1.317%;"/>
        <td style="width:1.06%;"/>
        <td style="width:12.942%;"/>
        <td style="width:1.019%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of<br/>Options</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Exercise<br/>Price</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Aggregate<br/>Intrinsic<br/>Value</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,798,282</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.25</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.5</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,583,490</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61.99</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,050,899</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.66</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">628,801</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28.19</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Outstanding at June 30, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,702,072</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.24</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.5</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">223,581</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested and expected to vest at June 30, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,702,072</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.24</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.5</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">223,581</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested and exercisable at June 30, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,262,612</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.40</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.7</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110,878</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted</a></td>
<td class="text"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">he fair value of stock options granted to employees was estimated on the date of grant using the Black-Scholes option-pricing model using the following assumptions: </span><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:34.787%;"/>
        <td style="width:1.296%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.0%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.296%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.009%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.296%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.009%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.296%;"/>
        <td style="width:1.0%;"/>
        <td style="width:13.009%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended June&#160;30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Six Months Ended June&#160;30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term of options (in years)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span></span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected stock price volatility</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110.2</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95.7</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100.6</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103.1</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">110.2</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88.8</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100.6</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected dividend yield</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Summary of Restricted Stock Activity and Restricted Stock Units</a></td>
<td class="text"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s restricted stock awards (RSAs&#8221;) and restricted stock units (&#8220;RSUs&#8221;) were summarized as follows:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:68.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.746%;"/>
        <td style="width:1.471%;"/>
        <td style="width:1.471%;"/>
        <td style="width:14.597%;"/>
        <td style="width:1.471%;"/>
        <td style="width:1.471%;"/>
        <td style="width:10.226%;"/>
        <td style="width:1.035%;"/>
        <td style="width:1.416%;"/>
        <td style="width:1.471%;"/>
        <td style="width:7.339%;"/>
        <td style="width:1.035%;"/>
        <td style="width:1.471%;"/>
        <td style="width:7.312%;"/>
        <td style="width:1.471%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Shares</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted Average Grant Date Fair Value</span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RSU</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RSA</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RSU</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">RSA</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89,261</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.48</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Granted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,050,995</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64.25</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87,409</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.48</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cancelled</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28,550</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67.38</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested as of June 30, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,022,445</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,852</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64.16</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.53</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Stock-based Compensation Expense</a></td>
<td class="text"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the total stock-based compensation expense for all awards granted to employees and non-employees and the Company's Employee Stock Purchase Plan ("ESPP") in the condensed consolidated statements of operations:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.2458333333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.195%;"/>
        <td style="width:1.245%;"/>
        <td style="width:1.049%;"/>
        <td style="width:9.146%;"/>
        <td style="width:1.019%;"/>
        <td style="width:1.235%;"/>
        <td style="width:1.049%;"/>
        <td style="width:9.146%;"/>
        <td style="width:1.019%;"/>
        <td style="width:1.235%;"/>
        <td style="width:1.049%;"/>
        <td style="width:9.146%;"/>
        <td style="width:1.019%;"/>
        <td style="width:1.235%;"/>
        <td style="width:1.049%;"/>
        <td style="width:9.146%;"/>
        <td style="width:1.019%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended June&#160;30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Six Months Ended June&#160;30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,860</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,700</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,290</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,188</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Selling, general and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,138</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,050</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,179</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,529</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:14.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:14.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,998</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,750</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,469</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,717</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196305497560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Income (loss) Per Share</a></td>
<td class="text"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following is a calculation of the basic and diluted net income (loss) per share (in thousands, except share and per share data):</span><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:6.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
       <tr style="visibility:collapse;">
        <td style="width:43.704%;"/>
        <td style="width:1.046%;"/>
        <td style="width:1.0%;"/>
        <td style="width:9.991%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.056%;"/>
        <td style="width:1.037%;"/>
        <td style="width:12.361%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.056%;"/>
        <td style="width:1.037%;"/>
        <td style="width:10.407%;"/>
        <td style="width:1.0%;"/>
        <td style="width:1.056%;"/>
        <td style="width:1.037%;"/>
        <td style="width:11.213%;"/>
        <td style="width:1.0%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended June&#160;30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Six Months Ended June&#160;30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:11.0pt;font-family:Calibri;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss), basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61,813</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31,167</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">107,098</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108,407</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares outstanding, basic</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">130,121,943</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114,980,652</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">128,938,851</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">111,684,283</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average effect of dilutive securities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,635,656</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted shares subject to future vesting</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,409</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contingently issuable shares</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,969</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares outstanding, diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">133,789,977</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">114,980,652</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">128,938,851</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">111,684,283</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss) per share, basic</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.48</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.27</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.83</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.97</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net income (loss) per share, diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.46</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.27</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.83</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.97</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Not Included in the Diluted Per Share Calculations</a></td>
<td class="text"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:12.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Potentially dilutive securities that were not included in the diluted per share calculations because they would be anti-dilutive were as follows:</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:43.909%;"/>
        <td style="width:1.08%;"/>
        <td style="width:1.008%;"/>
        <td style="width:9.887%;"/>
        <td style="width:1.008%;"/>
        <td style="width:1.07%;"/>
        <td style="width:0.998%;"/>
        <td style="width:12.459%;"/>
        <td style="width:0.998%;"/>
        <td style="width:1.07%;"/>
        <td style="width:1.111%;"/>
        <td style="width:10.031%;"/>
        <td style="width:0.998%;"/>
        <td style="width:1.07%;"/>
        <td style="width:0.998%;"/>
        <td style="width:11.307%;"/>
        <td style="width:0.998%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"><br/></span><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Three Months Ended June&#160;30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Six Months Ended June&#160;30,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options issued and outstanding</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,164,036</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,932,845</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,702,072</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,932,845</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Estimated shares issuable under the ESPP</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71,582</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71,582</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted shares subject to future vesting</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">933,870</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">844,886</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,024,297</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">844,886</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contingently issuable shares</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39,340</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,169,488</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,777,731</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,837,291</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,777,731</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.3;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196272757400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 10, 2020</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (774,282)<span></span>
</td>
<td class="num">$ (667,184)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndShortTermInvestments', window );">Cash, cash equivalents and investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 876,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Sales Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock | Sales Agreement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PercentageOfAggregateGrossProceedsFromSaleOfShares', window );">Percentage of aggregate gross proceeds from sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_SaleOfStockConsiderationAggregateOfferingPrice', window );">Aggregate offering price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=vir_FollowOnOfferingMember', window );">Follow-on Offering | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares</a></td>
<td class="nump">8,214,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price per share</a></td>
<td class="nump">$ 42.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Gross proceeds from the offering</a></td>
<td class="nump">$ 345,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PaymentsOfUnderwritingDiscountsAndCommissions', window );">Payments of underwriting discounts and commissions</a></td>
<td class="nump">20,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ProceedsFromIssuanceSecondaryPublicOffering', window );">Net proceeds after deducting underwriting discounts, commissions and offering expenses</a></td>
<td class="nump">$ 323,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121370832&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization consolidation and presentation of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PaymentsOfUnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments of underwriting discounts and commissions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PaymentsOfUnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PercentageOfAggregateGrossProceedsFromSaleOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of aggregate gross proceeds from sale of shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PercentageOfAggregateGrossProceedsFromSaleOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ProceedsFromIssuanceSecondaryPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's follow on offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ProceedsFromIssuanceSecondaryPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_SaleOfStockConsiderationAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale of stock consideration aggregate offering price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_SaleOfStockConsiderationAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=vir_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis=vir_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=vir_FollowOnOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=vir_FollowOnOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196195908008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss', window );">Allowance for losses on available-for-sale debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922900-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=121582814&amp;loc=SL82922900-210455<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -URI http://asc.fasb.org/extlink&amp;oid=121645371&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121558606&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196196461064">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2"><div>Jun. 30, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FinancialAssetsAmortizedCostBasis', window );">Financial Assets, Amortized Cost</a></td>
<td class="nump">$ 874,072<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">$ 722,036<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FinancialAssetsGrossUnrealizedHoldingGains', window );">Financial Assets, Gross Unrealized Holding Gains</a></td>
<td class="nump">8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">91<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FinancialAssetsGrossUnrealizedHoldingLosses', window );">Financial Assets, Gross Unrealized Holding Losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="num">(6)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FinancialAssetsFairValue', window );">Financial Assets, Aggregate Fair Value</a></td>
<td class="nump">874,073<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="nump">722,121<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FinancialAssetsAmortizedCostBasis', window );">Financial Assets, Amortized Cost</a></td>
<td class="nump">739,286<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">421,835<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FinancialAssetsFairValue', window );">Financial Assets, Aggregate Fair Value</a></td>
<td class="nump">739,286<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">421,835<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | Bank Time Deposits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FinancialAssetsAmortizedCostBasis', window );">Financial Assets, Amortized Cost</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FinancialAssetsFairValue', window );">Financial Assets, Aggregate Fair Value</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Government Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FinancialAssetsAmortizedCostBasis', window );">Financial Assets, Amortized Cost</a></td>
<td class="nump">129,786<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">300,201<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FinancialAssetsGrossUnrealizedHoldingGains', window );">Financial Assets, Gross Unrealized Holding Gains</a></td>
<td class="nump">8<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">91<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FinancialAssetsGrossUnrealizedHoldingLosses', window );">Financial Assets, Gross Unrealized Holding Losses</a></td>
<td class="num">(7)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="num">(6)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FinancialAssetsFairValue', window );">Financial Assets, Aggregate Fair Value</a></td>
<td class="nump">$ 129,787<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
<td class="nump">$ 300,286<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="5"></td></tr>
<tr><td colspan="5"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Includes </span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span><span style="font-size:8.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">14.0</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> million</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> of restricted cash equivalents.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Includes $</span><span style="font-size:8.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">14.9</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#160;million of restricted cash equivalents.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Includes $</span><span style="font-size:8.0pt;font-family:Times New Roman;color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">50.7</span><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> million classified as long-term investments.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_FinancialAssetsAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial assets amortized cost basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_FinancialAssetsAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_FinancialAssetsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial assets fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_FinancialAssetsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_FinancialAssetsGrossUnrealizedHoldingGains">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial assets gross unrealized holding gains.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_FinancialAssetsGrossUnrealizedHoldingGains</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_FinancialAssetsGrossUnrealizedHoldingLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial assets gross unrealized holding losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_FinancialAssetsGrossUnrealizedHoldingLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196272745608">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Parenthetical) (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term Investments</a></td>
<td class="nump">$ 50,680<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 | Money Market Funds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashEquivalents', window );">Restricted cash equivalents</a></td>
<td class="nump">14,000<span></span>
</td>
<td class="nump">$ 14,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 | U.S. Government Treasuries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term Investments</a></td>
<td class="nump">$ 50,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash equivalents restricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121583591&amp;loc=SL98516268-108586<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByAssetClassAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196272896856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancingReceivableAccruedInterestWriteoff', window );">Write off of accrued interest receivable</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Estimated fair value of contingent consideration</a></td>
<td class="nump">62,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_AssetAcquisitionContingentConsiderationLiability', window );">Estimated fair value of contingent consideration</a></td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax | TomegaVax Letter Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Estimated fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTerm', window );">Securities contractual term</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivable', window );">Accrued interest receivable excluded from fair value and amortized cost basis of available for sale securities</a></td>
<td class="nump">$ 600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=vir_ContingentConsiderationLiabilityMember', window );">Contingent Consideration Liability | TomegaVax | TomegaVax Letter Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Estimated fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancingReceivableAccruedInterestWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of writeoff of accrued interest on financing receivable recognized by reversing interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3D<br> -URI http://asc.fasb.org/extlink&amp;oid=121599337&amp;loc=SL120267969-210447<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancingReceivableAccruedInterestWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_AssetAcquisitionContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in an asset acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_AssetAcquisitionContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_LetterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_LetterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=vir_ContingentConsiderationLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=vir_ContingentConsiderationLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196196388296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Estimated Fair Value of Significant Unobservable Inputs (Details)<br></strong></div></th>
<th class="th" colspan="2"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Clinical and Regulatory Milestones | Discount Rates | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.04<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Clinical and Regulatory Milestones | Discount Rates | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.08<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Clinical and Regulatory Milestones | Discount Rates | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.05<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Clinical and Regulatory Milestones | Probability of Achievement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Clinical and Regulatory Milestones | Probability of Achievement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.76<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Clinical and Regulatory Milestones | Probability of Achievement | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.62<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Commercial Milestones | Discount Rates</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.11<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Commercial Milestones | Probability of Achievement | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.21<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Commercial Milestones | Probability of Achievement | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.76<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Commercial Milestones | Probability of Achievement | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.66<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Commercial Milestones | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.60<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[2]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax | Discount Rates | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax | Discount Rates | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax | Discount Rates | Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.001<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax | Volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeLiabilityMeasurementInput', window );">Fair value contingent consideration measurement input</a></td>
<td class="nump">0.95<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[3]</sup></td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Unobservable inputs were weighted based on the relative fair value of the clinical and regulatory milestone payments.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Unobservable inputs were weighted based on the relative fair value of the commercial milestone payments.</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[3]</td>
<td style="vertical-align: top;" valign="top"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Unobservable inputs were weighted based on the relative fair value of the underlying milestones. </span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure contingent consideration liability from business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeLiabilityMeasurementInput">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of input used to measure embedded derivative liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeLiabilityMeasurementInput</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=vir_ClinicalAndRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=vir_ClinicalAndRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=us-gaap_MeasurementInputDiscountRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=vir_MeasurementInputProbabilityRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=vir_MeasurementInputProbabilityRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContingentConsiderationByTypeAxis=vir_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContingentConsiderationByTypeAxis=vir_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MeasurementInputTypeAxis=vir_MeasurementInputExpectedRevenueVolatilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MeasurementInputTypeAxis=vir_MeasurementInputExpectedRevenueVolatilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196272616952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details) - Level 3 - Contingent Consideration Liability<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at December 31, 2020</a></td>
<td class="nump">$ 35,974<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone', window );">Reclassification of contingent consideration to accrued liabilities upon achievement of milestone</a></td>
<td class="num">(10,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue', window );">Balance at March 31, 2021</a></td>
<td class="nump">68,892<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Changes in fair value recognized</a></td>
<td class="nump">33,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Other Expense</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems', window );"><strong>Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease', window );">Changes in fair value recognized</a></td>
<td class="nump">$ 9,618<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, reclassification of contingent consideration to accrued liabilities upon achievement of milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByLiabilityClassAxis=vir_ContingentConsiderationLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByLiabilityClassAxis=vir_ContingentConsiderationLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196190364584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($) </div>
<div>Milestone</div>
</th>
<th class="th">
<div>Oct. 31, 2020 </div>
<div>USD ($) </div>
<div>Milestone</div>
</th>
<th class="th">
<div>May 31, 2020 </div>
<div>USD ($) </div>
<div>Milestone</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>Milestone</div>
</th>
<th class="th">
<div>Jul. 01, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration', window );">Minimum common stock conversion price for milestone payments consideration | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PaymentMadeForBusinessCombinationMilestone', window );">Payment made for business combination milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CommonStockSharesIssuedForMilestonePaymentShares', window );">Common stock shares Issued for milestone payment| shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,737<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ValueOfCommonStockSharesIssuedForMilestonePayment', window );">Value of common stock shares Issued for milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax | Clinical Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration', window );">Minimum common stock conversion price for milestone payments consideration | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax | TomegaVax Letter Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Milestone payments aggregate amount payable, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration', window );">Minimum common stock conversion price for milestone payments consideration | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MilestonePaymentsRelatedTermsDescription', window );">Milestone payments related terms</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company will be required to pay to the former stockholders of TomegaVax milestone payments of up to an aggregate of $30.0 million if the per-share price of the Company&#8217;s publicly traded common stock, or implied price per share of the Company&#8217;s Series A-1 convertible preferred stock (or common stock upon conversion) upon a certain asset sale, merger or stock sale, is at least $45 (as adjusted in the case of any stock dividend, stock split or other similar recapitalization), with the amount of such payments determined by the share price and/or the stage of the Company&#8217;s clinical development at the time of the relevant event triggering the payment.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration', window );">Number of milestones achieved | Milestone</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability', window );">Estimated fair value of embedded derivative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember', window );">TomegaVax | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RemainingPaymentMadeForBusinessCombinationMilestone', window );">Remaining payment made for business combination milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | HBV Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 62,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents', window );">Additional consideration payable upon achievement of specified milestone events, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved', window );">Number of specified clinical milestones achieved | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_SpecifiedClinicalDevelopmentMilestonesPayment', window );">Specified clinical development milestones payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | Another Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents', window );">Additional consideration payable upon achievement of specified milestone events, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 105,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember', window );">Humabs | SARS-CoV-2 Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved', window );">Number of specified clinical milestones achieved | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_SpecifiedClinicalDevelopmentMilestonesPayment', window );">Specified clinical development milestones payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_AgenovirCorporationMember', window );">Agenovir</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration', window );">Number of milestones achieved | Milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=vir_AgenovirCorporationMember', window );">Agenovir | HBV Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh', window );">Milestone payments aggregate amount payable, maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 135,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition number of milestones achieved related to contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition number of specified clinical milestones achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combinations additional consideration payable upon achievement of specified events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CommonStockSharesIssuedForMilestonePaymentShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares issued for milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CommonStockSharesIssuedForMilestonePaymentShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MilestonePaymentsRelatedTermsDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments related terms description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MilestonePaymentsRelatedTermsDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum common stock conversion price for milestone payments consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PaymentMadeForBusinessCombinationMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment made for business combination milestone.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PaymentMadeForBusinessCombinationMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RemainingPaymentMadeForBusinessCombinationMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Remaining Payment Made For Business Combination Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RemainingPaymentMadeForBusinessCombinationMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_SpecifiedClinicalDevelopmentMilestonesPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specified clinical development milestones payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_SpecifiedClinicalDevelopmentMilestonesPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ValueOfCommonStockSharesIssuedForMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of common shares issued for milestone payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ValueOfCommonStockSharesIssuedForMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_TomegaVaxIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vir_ClinicalDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=vir_ClinicalDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_LetterAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_LetterAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_HumabsBiomedSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_HepatitisBVirusProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_HepatitisBVirusProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_AnotherProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_AnotherProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_SARSCoV2ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_SARSCoV2ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_AgenovirCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_AgenovirCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196197435656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Grant Agreements - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Feb. 29, 2020</div></th>
<th class="th"><div>Mar. 16, 2018</div></th>
<th class="th"><div>Jan. 26, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_GrantMember', window );">Grant Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue from grants</a></td>
<td class="nump">$ 3,082,000<span></span>
</td>
<td class="nump">$ 719,000<span></span>
</td>
<td class="nump">$ 4,453,000<span></span>
</td>
<td class="nump">$ 5,950,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_HumanImmunodeficiencyVirusGrantMember', window );">Human Immunodeficiency Virus ('HIV') Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_GrantAwardedAmount', window );">Grant awarded amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_GrantAgreementAmendedExpirationDate', window );">Grant agreement amended expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Oct. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_HumanImmunodeficiencyVirusGrantMember', window );">Human Immunodeficiency Virus ('HIV') Grant | Bill And Melinda Gates Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_HumanImmunodeficiencyVirusGrantMember', window );">Human Immunodeficiency Virus ('HIV') Grant | Grant Revenue | Bill And Melinda Gates Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue from grants</a></td>
<td class="nump">900,000<span></span>
</td>
<td class="nump">500,000<span></span>
</td>
<td class="nump">1,600,000<span></span>
</td>
<td class="nump">5,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_HumanImmunodeficiencyVirusGrantMember', window );">Human Immunodeficiency Virus ('HIV') Grant | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_GrantAwardedAmountMaximum', window );">Grant awarded amount. maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,200,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TuberculosisTBGrantMember', window );">Tuberculosis ('TB') Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_UnusedFundsReceivedInAdvance', window );">Unused funds received in advance</a></td>
<td class="nump">2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_GrantAgreementAmendedExpirationDate', window );">Grant agreement amended expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TuberculosisTBGrantMember', window );">Tuberculosis ('TB') Grant | Bill And Melinda Gates Foundation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TuberculosisTBGrantMember', window );">Tuberculosis ('TB') Grant | Grant Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueNotFromContractWithCustomer', window );">Revenue from grants</a></td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,800,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TuberculosisTBGrantMember', window );">Tuberculosis ('TB') Grant | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_GrantAwardedAmountMaximum', window );">Grant awarded amount. maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueNotFromContractWithCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue that is not accounted for under Topic 606.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueNotFromContractWithCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_GrantAgreementAmendedExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant agreement amended expiration date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_GrantAgreementAmendedExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_GrantAwardedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant awarded amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_GrantAwardedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_GrantAwardedAmountMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum grant awarded amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_GrantAwardedAmountMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_UnusedFundsReceivedInAdvance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unused funds received in advance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_UnusedFundsReceivedInAdvance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_GrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_GrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_HumanImmunodeficiencyVirusGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_HumanImmunodeficiencyVirusGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_BillAndMelindaGatesFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_BillAndMelindaGatesFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TuberculosisTBGrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TuberculosisTBGrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196101771752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Collaboration and License Agreements - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="9">1 Months Ended</th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Mar. 25, 2021 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Feb. 14, 2021 </div>
<div>USD ($) </div>
<div>Program</div>
</th>
<th class="th">
<div>Feb. 14, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Apr. 29, 2020 </div>
<div>Unit </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Apr. 29, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,718,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44,718,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,451,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,496,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,496,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,815,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,126,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 79,653,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220,996,000<span></span>
</td>
<td class="nump">$ 144,632,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vir_ContractRevenueMember', window );">Contract Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,653,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,522,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,266,000<span></span>
</td>
<td class="nump">44,009,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=vir_CollaborationRevenueMember', window );">Collaboration Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,333,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,333,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember', window );">License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,747,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">22,747,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember', window );">2020 GSK | Collaboration Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember', window );">2021 GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Current deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenue, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyStockPurchaseAgreementMember', window );">2020 Stock Purchase Agreement | GGL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,626,027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share purchase price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.73<span></span>
</td>
<td class="nump">$ 37.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember', window );">Preliminary Collaboration Agreement | 2020 GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans', window );">Number of years conduct certain research and development activities under mutually agreed development plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct', window );">Maximum percentage of right to perform details in connection with antibody product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CollaborationAgreementTerminationDescription', window );">Termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Either party has the right to terminate the 2020 GSK Agreement in the case of the insolvency of the other party, an uncured material breach of the other party with respect to a collaboration program or collaboration product, or as mutually agreed by the parties.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CollaborationAgreementNumberOfUnitsOfAccount', window );">Number of units of account | Unit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_IncreaseDecreaseInResearchAndDevelopmentExpense', window );">Additional research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ReductionOfResearchAndDevelopmentExpense', window );">Reduction of research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember', window );">Preliminary Collaboration Agreement | 2020 GSK | Accrued and Other Liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PayableUnderAgreementCurrent', window );">Payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember', window );">Preliminary Collaboration Agreement | 2020 GSK | Antibody Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PercentageOfDevelopmentCosts', window );">Percentage of development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">72.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_AntibodyLicenseTransactionPrice', window );">Antibody license transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember', window );">Preliminary Collaboration Agreement | 2020 GSK | Vaccine Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PercentageOfDevelopmentCosts', window );">Percentage of development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember', window );">Preliminary Collaboration Agreement | 2021 GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate', window );">Number of separate programs | Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_UpfrontPaymentReceivable', window );">Upfront payment receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000,000.0<span></span>
</td>
<td class="nump">$ 225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement', window );">Percentage of upfront payment receivable at effective date of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OptionExerciseFeeConsiderationToBeReceived', window );">Option exercise fee to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td class="nump">$ 300,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember', window );">Preliminary Collaboration Agreement | 2021 GSK | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PreDefinedRegulatoryMilestoneConsiderationReceivable', window );">Pre-defined regulatory milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="nump">$ 200,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember', window );">2020 Preliminary Collaboration Agreement and Stock Purchase Agreement | GGL | ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FairMarketValueOfCommonStockIssued', window );">Fair market value of the common stock issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 206,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.70<span></span>
</td>
<td class="nump">$ 36.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PremiumReceivedOnSalePriceOfCommonStock', window );">Premium received on sale price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 43,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_DefinitiveCollaborationAgreementMember', window );">Definitive Collaboration Agreement | 2021 GSK</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement', window );">Percentage of upfront payment receivable at effective date of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyOneStockPurchaseAgreementMember', window );">2021 Stock Purchase Agreement | GGL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 120,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyOneStockPurchaseAgreementMember', window );">2021 Stock Purchase Agreement | GGL</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,924,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember', window );">2021 Preliminary Collaboration Agreement and Stock Purchase Agreement | GGL | ASC 606</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_FairMarketValueOfCommonStockIssued', window );">Fair market value of the common stock issued</a></td>
<td class="nump">$ 85,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Common stock price per share | $ / shares</a></td>
<td class="nump">$ 52.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PremiumReceivedOnSalePriceOfCommonStock', window );">Premium received on sale price of common stock</a></td>
<td class="nump">$ 34,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKCollaborationMember', window );">2021 GSK Collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans', window );">Number of years conduct certain research and development activities under mutually agreed development plans</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PercentageOfShareDevelopmentCosts', window );">Percentage of share development costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ProfitsAndLossesSharingPercentage', window );">Percentage of share Profit and loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKAgreementMember', window );">2021 GSK Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ReductionOfResearchAndDevelopmentExpense', window );">Reduction of research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CollaborationAgreementTransactionPriceFixedConsideration', window );">Fixed consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PremiumPaidOnSalePriceOfCommonStock', window );">Premium paid on sale price of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CollaborationAgreementTransactionPriceConsideration', window );">Consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 259,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKAgreementMember', window );">2021 GSK Agreement | Contract Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">168,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CollaborationAgreementTerminationDescription', window );">Termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Each party may terminate for convenience all rights and obligations with respect to any program for which it has an option, with 30 days&#8217; written notice (if the terminating party has not exercised an option for such program) or 180 days&#8217; notice (following the exercise of an option for such program). The Brii Agreement may also be terminated by either party for insolvency of the other party, and either party may terminate the Brii Agreement in its entirety or on a program-by-program basis for the other party&#8217;s uncured material breach on 60 days&#8217; written notice (or 30 days&#8217; notice following failure to make payment).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodForLicensedProgramNotExercisedAnOption', window );">Written notice period for not exercising an option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodForLicensedProgramExerciseAnOption', window );">Written notice period for exercise an option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">180 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach', window );">Written notice period for uncured material breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodForLicensedProgramFailureToMakePayment', window );">Written notice period for failure to make payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Licensed Product-By-Licensed Product | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RegulatoryMilestonePaymentConsiderationPayable', window );">Milestone payment on basis of ranging from low tens</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Brii Bio Parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PercentageOfOrdinaryShareEqualToOutstandingShare', window );">Percentage of ordinary share equal to outstanding share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OptionExerciseFeeConsiderationReceivable', window );">Option exercise fee ranging from mid-single-digit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RegulatoryMilestoneConsiderationReceivable', window );">Milestone payment on basis ranging from mid-single-digit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_SalesMilestoneConsiderationReceivable', window );">Sales milestone receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000,000.0<span></span>
</td>
<td class="nump">175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OptionExerciseFeeReceived', window );">Option exercise fee received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_DeterminedTransactionPrice', window );">Determined transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MilestonePaymentsPaid', window );">Milestone payments paid.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Brii Bio Parent | Licensed Product-By-Licensed Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RegulatoryMilestoneConsiderationReceivable', window );">Milestone payment on basis ranging from mid-single-digit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Brii Bio Parent | Biological Materials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Brii Bio Parent | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Brii Bio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OptionExerciseFeeConsiderationPayableDescription', window );">Option exercise fee of ranging from low tens description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">low tens of millions<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales', window );">Royalty payment obligation expiration period after first commercial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Brii Bio | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OptionExerciseFeeConsiderationPayable', window );">Option exercise fee of ranging from low tens</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Brii Bio | United States | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_SalesMilestoneConsiderationPayable', window );">Sale milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Brii Bio | Other Assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Investments', window );">Carrying value of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,700,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember', window );">Brii Agreement | Alnylam Pharmaceuticals Inc | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PaymentToPartnerResultingFromProgramOptionExercise', window );">Proceeds from options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_AlnylamAgreementMember', window );">Alnylam Agreement | Alnylam Pharmaceuticals Inc</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, shares | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales', window );">Royalty payment obligation expiration period after first commercial sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodForLicensedProgramExerciseAnOption', window );">Written notice period for exercise an option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach', window );">Written notice period for uncured material breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodForLicensedProgramFailureToMakePayment', window );">Written notice period for failure to make payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_UpfrontFeePaid', window );">Upfront fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_SharePayableToCollaborator', window );">Recognized liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumSharesToBeIssued', window );">Maximum shares to be issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,111,111<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodForLicensedProgramOtherPartyChallengesValidityOrEnforceabilityOfPatentLicense', window );">Written notice period for licensed program other party challenges validity or enforceability of patent license.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeFairValueOfDerivativeLiability', window );">Estimated fair value of the derivative liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ContractualPayments', window );">Contractual payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MilestonePaymentsPaid', window );">Milestone payments paid.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CollaborationAgreementRelatedCostsAndExpenses', window );">Expenses incurred under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700,000<span></span>
</td>
<td class="nump">4,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_AlnylamAgreementMember', window );">Alnylam Agreement | Alnylam Pharmaceuticals Inc | First siRNA product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory', window );">Maximum milestone payment for achievement of specified development and regulatory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 190,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_AlnylamAgreementMember', window );">Alnylam Agreement | Alnylam Pharmaceuticals Inc | Each Infectious Disease siRNA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory', window );">Maximum milestone payment for achievement of specified development and regulatory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_AlnylamAgreementMember', window );">Alnylam Agreement | Alnylam Pharmaceuticals Inc | Commercialization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumSalesMilestonePayment', window );">Maximum sales milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumAggregateSalesMilestonePayment', window );">Maximum aggregate sales milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_DevelopmentAndManufacturingCollaborationAgreementMember', window );">Development and Manufacturing Collaboration Agreement | WuXi Biologics</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CollaborationAgreementTerminationDescription', window );">Termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the WuXi Biologics Collaboration Agreement may be terminated by (i) the written agreement of both parties, (ii) WuXi Biologics following the one year anniversary of the WuXi Biologics Collaboration Agreement effective date with respect to the entire agreement or on a product by product basis with 90 days&#8217; prior written notice or (iii) by either party if the other party materially breaches the WuXi Biologics Collaboration Agreement and fails to cure such breach within sixty days.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_RockefellerAgreementMember', window );">Rockefeller Agreement | Rockefeller</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CollaborationAgreementTerminationDescription', window );">Termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company has the right to terminate the Rockefeller Agreement in its entirety, or in part, for any reason on 60 days&#8217; written notice to Rockefeller. Rockefeller may terminate the Rockefeller Agreement on 90 days&#8217; written notice for the Company&#8217;s uncured material breach, or if the Company challenges the validity or enforceability of any of the licensed patents, or immediately in the event of the Company&#8217;s insolvency. Rockefeller may also terminate the Rockefeller Agreement if the Company ceases to carry on business with respect to the rights granted to the Company under the agreement. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_UpfrontFeePaid', window );">Upfront fee paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale', window );">Royalty obligation period from date of first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_RockefellerAgreementMember', window );">Rockefeller Agreement | Rockefeller | Commercialization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PaymentOfAnnualLicenseMaintenanceFees', window );">Payment of annual license maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_RockefellerAgreementMember', window );">Rockefeller Agreement | Rockefeller | First Infectious Disease Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory', window );">Maximum milestone payment for achievement of specified development and regulatory</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_RockefellerAgreementMember', window );">Rockefeller Agreement | Rockefeller | HBV Program | Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees', window );">Specified development milestones and annual license maintenance fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000.0<span></span>
</td>
<td class="nump">$ 1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_MedImmuneAgreementMember', window );">MedImmune Agreement | MedImmune</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CollaborationAgreementTerminationDescription', window );">Termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The Company may terminate the MedImmune Agreement in its entirety or on a product-by-product basis, for convenience, upon 120 days&#8217; notice. Either party may terminate the MedImmune Agreement for cause for the other party&#8217;s uncured material breach on 60 days&#8217; notice or immediately in the event of bankruptcy of the other party. Additionally, MedImmune may terminate the MedImmune Agreement for cause on 30 days&#8217; written notice if the Company challenges the validity or enforceability of the patents to which the Company has obtained a license under the MedImmune Agreement.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_LicenseAgreementUpfrontPayment', window );">License agreement upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_MedImmuneAgreementMember', window );">MedImmune Agreement | MedImmune | Influenza A and Influenza B</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_DevelopmentRegulatoryAndCommercialMilestonePaymentsMaximumAmount', window );">Development, regulatory, and commercial milestone payments maximum amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">331,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_DevelopmentRegulatoryAndCommercialMilestonePayments', window );">Development, regulatory, and commercial milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenXencorAgreementMember', window );">2019 Xencor Agreement | Xencor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach', window );">Written notice period for uncured material breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodForLicensedProgramFailureToMakePayment', window );">Written notice period for failure to make payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodForTerminationOfLicensedProgram', window );">Written notice period for termination of licensed program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge', window );">Written notice period for termination of licensed program based on challenge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenXencorAgreementMember', window );">2019 Xencor Agreement | Xencor | Influenza A Research Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments', window );">Maximum aggregate development and regulatory milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumAggregateCommercialSalesMilestonePayments', window );">Maximum aggregate commercial sales milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumAggregateMilestonePayments', window );">Maximum aggregate milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_SpecifiedDevelopmentMilestonesPayment', window );">Specified development milestones payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenXencorAgreementMember', window );">2019 Xencor Agreement | Xencor | HBV Research Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumAggregateMilestonePayments', window );">Maximum aggregate milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_SpecifiedDevelopmentMilestonesPayment', window );">Specified development milestones payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenXencorAgreementMember', window );">2019 Xencor Agreement | Xencor | Influenza A and HBV Research Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MaximumAggregateMilestonePayments', window );">Maximum aggregate milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 155,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyXencorAgreementMember', window );">2020 Xencor Agreement | Xencor</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach', window );">Written notice period for uncured material breach</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodForLicensedProgramFailureToMakePayment', window );">Written notice period for failure to make payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_LicensedPatentsExpirationPeriod', window );">Licensed patents expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodForTerminationOfLicensedProgram', window );">Written notice period for termination of licensed program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge', window );">Written notice period for termination of licensed program based on challenge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130532-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556615&amp;loc=SL49130531-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeFairValueOfDerivativeLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4D<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121570589&amp;loc=SL51823488-111719<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121590274&amp;loc=SL5624163-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226000-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeFairValueOfDerivativeLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Investments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.1(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Investments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9031-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130543-203045<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 42<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e9054-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=121604090&amp;loc=SL49130545-203045<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 924<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -URI http://asc.fasb.org/extlink&amp;oid=6472922&amp;loc=d3e499488-122856<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_AntibodyLicenseTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Transaction price for the Antibody License under the collaboration agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_AntibodyLicenseTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement, number of separate programs agreed to collaborate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CollaborationAgreementNumberOfUnitsOfAccount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement, number of units of account.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CollaborationAgreementNumberOfUnitsOfAccount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CollaborationAgreementRelatedCostsAndExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs and expenses for the period incurred under the collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CollaborationAgreementRelatedCostsAndExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CollaborationAgreementTerminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement termination description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CollaborationAgreementTerminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CollaborationAgreementTransactionPriceConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement transaction price consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CollaborationAgreementTransactionPriceConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CollaborationAgreementTransactionPriceFixedConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration agreement, transaction price fixed consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CollaborationAgreementTransactionPriceFixedConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ContractualPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ContractualPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_DeterminedTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Determined transaction price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_DeterminedTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_DevelopmentRegulatoryAndCommercialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development regulatory and commercial milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_DevelopmentRegulatoryAndCommercialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_DevelopmentRegulatoryAndCommercialMilestonePaymentsMaximumAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development, regulatory, and commercial milestone payments maximum amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_DevelopmentRegulatoryAndCommercialMilestonePaymentsMaximumAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_FairMarketValueOfCommonStockIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair market value of common stock issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_FairMarketValueOfCommonStockIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_IncreaseDecreaseInResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase (decrease) in research And development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_IncreaseDecreaseInResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_LicenseAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_LicenseAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_LicensedPatentsExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensed patents expiration period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_LicensedPatentsExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumAggregateCommercialSalesMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate commercial sales milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumAggregateCommercialSalesMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate development and regulatory milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumAggregateMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumAggregateMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumAggregateSalesMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate milestone payment for achievement of specified annual net sales</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumAggregateSalesMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum milestone payment for achievement of specified development and regulatory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of right to perform details in connection with antibody product.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumSalesMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum milestone payment for achievement of specified annual net sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumSalesMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MaximumSharesToBeIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum shares to be issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MaximumSharesToBeIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MilestonePaymentsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MilestonePaymentsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of years conduct certain research and development activities under mutually agreed development plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OptionExerciseFeeConsiderationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option exercise fee consideration payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OptionExerciseFeeConsiderationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OptionExerciseFeeConsiderationPayableDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option Exercise Fee Consideration Payable Description</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OptionExerciseFeeConsiderationPayableDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OptionExerciseFeeConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option exercise fee consideration receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OptionExerciseFeeConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OptionExerciseFeeConsiderationToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option exercise fee consideration to be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OptionExerciseFeeConsiderationToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OptionExerciseFeeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Option exercise fee received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OptionExerciseFeeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PayableUnderAgreementCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payable under agreement, current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PayableUnderAgreementCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PaymentOfAnnualLicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment of annual license maintenance fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PaymentOfAnnualLicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PaymentToPartnerResultingFromProgramOptionExercise">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to a collaborator due to a program option exercise under a separate agreement .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PaymentToPartnerResultingFromProgramOptionExercise</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PercentageOfDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PercentageOfDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PercentageOfOrdinaryShareEqualToOutstandingShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of ordinary share equal to outstanding share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PercentageOfOrdinaryShareEqualToOutstandingShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PercentageOfShareDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of share development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PercentageOfShareDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of upfront payment receivable at effective date of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PreDefinedRegulatoryMilestoneConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre-defined regulatory milestone consideration receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PreDefinedRegulatoryMilestoneConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PremiumPaidOnSalePriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium paid on sale price of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PremiumPaidOnSalePriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PremiumReceivedOnSalePriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Premium received on sale price of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PremiumReceivedOnSalePriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ProfitsAndLossesSharingPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Profits and losses sharing percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ProfitsAndLossesSharingPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ReductionOfResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduction of research and development expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ReductionOfResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RegulatoryMilestoneConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regulatory milestone consideration receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RegulatoryMilestoneConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RegulatoryMilestonePaymentConsiderationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Regulatory milestone payment consideration payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RegulatoryMilestonePaymentConsiderationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty obligation period from date of first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty payment obligation expiration period after first commercial sales.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_SalesMilestoneConsiderationPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sales milestone consideration payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_SalesMilestoneConsiderationPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_SalesMilestoneConsiderationReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sale milestone consideration receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_SalesMilestoneConsiderationReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_SharePayableToCollaborator">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Portion of the carrying value of the equity investment due to a third party that is payable within one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_SharePayableToCollaborator</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specified development milestones and annual license maintenance fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_SpecifiedDevelopmentMilestonesPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specified development milestones payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_SpecifiedDevelopmentMilestonesPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_UpfrontFeePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront fee paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_UpfrontFeePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_UpfrontPaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_UpfrontPaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticePeriodForLicensedProgramExerciseAnOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Written notice period for licensed program, exercise an option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticePeriodForLicensedProgramExerciseAnOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticePeriodForLicensedProgramFailureToMakePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Written notice period for licensed program, failure to make payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticePeriodForLicensedProgramFailureToMakePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticePeriodForLicensedProgramNotExercisedAnOption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Written notice for period for licensed program not exercised an option.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticePeriodForLicensedProgramNotExercisedAnOption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticePeriodForLicensedProgramOtherPartyChallengesValidityOrEnforceabilityOfPatentLicense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Written notice period for licensed program other party challenges validity or enforceability of patent license.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticePeriodForLicensedProgramOtherPartyChallengesValidityOrEnforceabilityOfPatentLicense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Written notice period for licensed program, uncured material breach.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticePeriodForTerminationOfLicensedProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Written notice period for termination of licensed program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticePeriodForTerminationOfLicensedProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Written notice period for termination of licensed program based on challenge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_ContractRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_ContractRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_CollaborationRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_CollaborationRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=vir_GlaxoGroupLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=vir_GlaxoGroupLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_PreliminaryCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=vir_AccruedLiabilitiesAndOtherLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=vir_AccruedLiabilitiesAndOtherLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_AntibodyProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_AntibodyProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_VaccineProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_VaccineProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_DefinitiveCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_DefinitiveCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyOneStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyOneStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_GlaxoGroupLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_GlaxoGroupLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKCollaborationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKCollaborationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandAndTwentyOneGSKAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_BriiAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_LicensedProductByLicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_LicensedProductByLicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_BriiBioParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_BriiBioParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_BiologicalMaterialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_BiologicalMaterialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_BriiBiosciencesOffshoreLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_BriiBiosciencesOffshoreLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_AlnylamPharmaceuticalsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_AlnylamPharmaceuticalsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_AlnylamAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_AlnylamAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_FirstSiRNAProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_FirstSiRNAProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_EachInfectiousDiseaseSiRNAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_EachInfectiousDiseaseSiRNAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_CommercializationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_CommercializationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_DevelopmentAndManufacturingCollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_DevelopmentAndManufacturingCollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_WuXiBiologicsLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_WuXiBiologicsLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_RockefellerAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_RockefellerAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_RockefellerUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_RockefellerUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_FirstInfectiousDiseaseProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_FirstInfectiousDiseaseProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_HBVProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_HBVProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_MedImmuneAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_MedImmuneAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_MedImmuneLimitedLiabilityCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_MedImmuneLimitedLiabilityCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_InfluenzaAAndInfluenzaBMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_InfluenzaAAndInfluenzaBMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenXencorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandNineteenXencorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_XencorIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_XencorIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_InfluenzaAResearchProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_InfluenzaAResearchProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_HBVResearchProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_HBVResearchProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_InfluenzaAAndHBVResearchProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_InfluenzaAAndHBVResearchProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyXencorAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_TwoThousandTwentyXencorAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196196817208">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Property and Equipment Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 32,017<span></span>
</td>
<td class="nump">$ 27,178<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(11,766)<span></span>
</td>
<td class="num">(9,232)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Total property and equipment, net</a></td>
<td class="nump">20,251<span></span>
</td>
<td class="nump">17,946<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vir_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">18,168<span></span>
</td>
<td class="nump">16,769<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">580<span></span>
</td>
<td class="nump">556<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">1,444<span></span>
</td>
<td class="nump">1,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">7,281<span></span>
</td>
<td class="nump">7,274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 4,544<span></span>
</td>
<td class="nump">$ 1,135<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=vir_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=vir_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196188212680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Balance Sheet Components - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expenses</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="nump">$ 2,538<span></span>
</td>
<td class="nump">$ 2,061<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196196105576">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Balance Sheet Components - Schedule of Accrued and Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract', window );"><strong>Balance Sheet Related Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ResearchAndDevelopmentExpensesCurrent', window );">Research and development expenses</a></td>
<td class="nump">$ 30,952<span></span>
</td>
<td class="nump">$ 49,384<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_MilestonePayable', window );">Milestone payable</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PayrollAndRelatedExpensesCurrent', window );">Payroll and related expenses</a></td>
<td class="nump">10,353<span></span>
</td>
<td class="nump">17,060<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_ExcessFundsPayableUnderGrantAgreementsCurrent', window );">Excess funds payable under grant agreements</a></td>
<td class="nump">2,046<span></span>
</td>
<td class="nump">3,467<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="nump">3,522<span></span>
</td>
<td class="nump">3,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Other professional and consulting expenses</a></td>
<td class="nump">3,867<span></span>
</td>
<td class="nump">2,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Other expenses</a></td>
<td class="nump">3,334<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total accrued and other liabilities</a></td>
<td class="nump">$ 64,074<span></span>
</td>
<td class="nump">$ 76,936<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetRelatedDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetRelatedDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121566466&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ExcessFundsPayableUnderGrantAgreementsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess funds payable under grant agreements current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ExcessFundsPayableUnderGrantAgreementsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_MilestonePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_MilestonePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PayrollAndRelatedExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payroll and related expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PayrollAndRelatedExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_ResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of current obligations incurred and payable to vendors for goods and services attributable to the entity's research and development activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_ResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196196971544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_LeaseArrangementContractualExpirationBeginningYear', window );">Lease arrangement, contractual expiration period, beginning year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_LeaseArrangementContractualExpirationEndingYear', window );">Lease arrangement, contractual expiration period, ending year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2033<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, operating lease, existence of option to extend [true false]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseOptionToExtend', window );">Lessee, operating lease, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">These leases require monthly lease payments that may be subject to annual increases throughout the lease term. Certain lease agreements also provide the Company with the option to renew for additional periods ranging from one to five years. <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vir_GlaxoSmithKlineTradingServiceLimitedMember', window );">GSKTSL | WuXi Biologics MSA and Samsung MSA | Antibody Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PercentageOfDevelopmentCosts', window );">Percentage of development costs</a></td>
<td class="nump">72.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember', window );">GSK | WuXi Biologics MSA and Samsung MSA | Antibody Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PercentageOfDevelopmentCosts', window );">Percentage of development costs</a></td>
<td class="nump">27.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lessee, operating lease, renewal term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_LeaseArrangementContractualExpirationBeginningYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease arrangement, contractual expiration beginning year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_LeaseArrangementContractualExpirationBeginningYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_LeaseArrangementContractualExpirationEndingYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease arrangement, contractual expiration ending year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_LeaseArrangementContractualExpirationEndingYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PercentageOfDevelopmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of development costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PercentageOfDevelopmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_GlaxoSmithKlineTradingServiceLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_GlaxoSmithKlineTradingServiceLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=vir_AntibodyProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=vir_AntibodyProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196273086648">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear', window );">2021 (excluding the six months ended June 30, 2021)</a></td>
<td class="nump">$ 3,428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2022</a></td>
<td class="nump">9,713<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2023</a></td>
<td class="nump">11,387<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2024</a></td>
<td class="nump">10,564<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2025</a></td>
<td class="nump">8,042<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour', window );">Thereafter</a></td>
<td class="nump">67,466<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">110,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(38,140)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived', window );">Less: net tenant improvement allowance yet to be received</a></td>
<td class="num">(10,287)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_PresentValueOfOperatingLeaseLiabilities', window );">Present Value Of Operating Lease Liabilities</a></td>
<td class="nump">$ 62,173<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121609121&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability net tenant improvement allowance yet to be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee operating lease liability payments due after year four.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_PresentValueOfOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, net of tenant improvement allowance yet to be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_PresentValueOfOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196195344600">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Operating Leases</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid', window );">Current operating lease liabilities, net of tenant improvement allowances</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 10,287<span></span>
</td>
<td class="nump">$ 7,913<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating right-of-use assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">58,972<span></span>
</td>
<td class="nump">61,947<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liabilities, current</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,522<span></span>
</td>
<td class="nump">$ 3,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">Accrued and other liabilities<span></span>
</td>
<td class="text">Accrued and other liabilities<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liabilities, noncurrent</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 68,938<span></span>
</td>
<td class="nump">$ 66,556<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 72,460<span></span>
</td>
<td class="nump">$ 70,181<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="color:rgba(0,0,0,1);font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Current portion of lease liabilities recorded in prepaid expenses and other current assets for which the lease incentives to be received exceed the minimum lease payments to be paid over the next twelve months.</span></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>srt-types:extensibleListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121603541&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Current portion of lease liabilities recorded in prepaid expenses and other current assets for which the lease incentives to be received exceed the minimum lease payments to be paid over the next twelve months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196295164504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Summary of Stock Option Plans Activity (Details) - Stock Option<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options,Outstanding, Beginning Balance | shares</a></td>
<td class="nump">9,798,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Options,Granted | shares</a></td>
<td class="nump">2,583,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Options,Exercised | shares</a></td>
<td class="num">(1,050,899)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Number of Options,Forfeited | shares</a></td>
<td class="num">(628,801)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Options,Outstanding, Ending Balance | shares</a></td>
<td class="nump">10,702,072<span></span>
</td>
<td class="nump">9,798,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Options,Vested and expected to vest | shares</a></td>
<td class="nump">10,702,072<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Number of Options,Vested and exercisable | shares</a></td>
<td class="nump">3,262,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 5.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted | $ / shares</a></td>
<td class="nump">61.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised | $ / shares</a></td>
<td class="nump">5.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited | $ / shares</a></td>
<td class="nump">28.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Ending Balance | $ / shares</a></td>
<td class="nump">30.24<span></span>
</td>
<td class="nump">$ 5.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price,Vested and expected to vest | $ / shares</a></td>
<td class="nump">30.24<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price,Vested and exercisable | $ / shares</a></td>
<td class="nump">$ 13.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">8 years 6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term,Vested and expected to vest</a></td>
<td class="text">8 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term,Vested and exercisable</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Balance | $</a></td>
<td class="nump">$ 223,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest | $</a></td>
<td class="nump">223,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and exercisable | $</a></td>
<td class="nump">$ 110,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196195440712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unamortized stock-based compensation expense related to stock option</a></td>
<td class="nump">$ 203.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted average period</a></td>
<td class="text">2 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Estimated weighted average period</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Unrecognized compensation cost related to unvested restricted stock</a></td>
<td class="nump">$ 59.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196197548200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected stock price volatility, minimum</a></td>
<td class="nump">106.00%<span></span>
</td>
<td class="nump">95.70%<span></span>
</td>
<td class="nump">103.10%<span></span>
</td>
<td class="nump">88.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected stock price volatility, maximum</a></td>
<td class="nump">110.20%<span></span>
</td>
<td class="nump">100.60%<span></span>
</td>
<td class="nump">110.20%<span></span>
</td>
<td class="nump">100.60%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.10%<span></span>
</td>
<td class="nump">0.50%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (in years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term of options (in years)</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196196669048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Summary of Restricted Stock Activity and Restricted Stock Units (Details)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, Beginning Balance | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted | shares</a></td>
<td class="nump">1,050,995<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Cancelled | shares</a></td>
<td class="num">(28,550)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, Ending Balance | shares</a></td>
<td class="nump">1,022,445<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">64.25<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Cancelled | $ / shares</a></td>
<td class="nump">67.38<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending Balance | $ / shares</a></td>
<td class="nump">$ 64.16<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=vir_RestrictedStockAwardsRSAMember', window );">Restricted Stock Awards (RSAs)</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, Beginning Balance | shares</a></td>
<td class="nump">89,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Number of Shares, Granted | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Number of Shares, Vested | shares</a></td>
<td class="num">(87,409)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Number of Shares, Cancelled | shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Number of Shares, Unvested, Ending Balance | shares</a></td>
<td class="nump">1,852<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 1.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Granted | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Vested | $ / shares</a></td>
<td class="nump">1.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Cancelled | $ / shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, Ending Balance | $ / shares</a></td>
<td class="nump">$ 1.53<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=vir_RestrictedStockAwardsRSAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=vir_RestrictedStockAwardsRSAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196196722872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Awards - Summary of Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 20,998<span></span>
</td>
<td class="nump">$ 5,750<span></span>
</td>
<td class="nump">$ 36,469<span></span>
</td>
<td class="nump">$ 8,717<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">10,860<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">19,290<span></span>
</td>
<td class="nump">4,188<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation</a></td>
<td class="nump">$ 10,138<span></span>
</td>
<td class="nump">$ 3,050<span></span>
</td>
<td class="nump">$ 17,179<span></span>
</td>
<td class="nump">$ 4,529<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196275533944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (loss) Per Share (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income (loss)</a></td>
<td class="nump">$ 61,813<span></span>
</td>
<td class="num">$ (31,167)<span></span>
</td>
<td class="num">$ (107,098)<span></span>
</td>
<td class="num">$ (108,407)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares outstanding, basic</a></td>
<td class="nump">130,121,943<span></span>
</td>
<td class="nump">114,980,652<span></span>
</td>
<td class="nump">128,938,851<span></span>
</td>
<td class="nump">111,684,283<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract', window );"><strong>Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements', window );">Options to purchase common stock</a></td>
<td class="nump">3,635,656<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting', window );">Restricted shares subject to future vesting</a></td>
<td class="nump">19,409<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares', window );">Contingently issuable shares</a></td>
<td class="nump">12,969<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares outstanding, diluted</a></td>
<td class="nump">133,789,977<span></span>
</td>
<td class="nump">114,980,652<span></span>
</td>
<td class="nump">128,938,851<span></span>
</td>
<td class="nump">111,684,283<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income (loss) per share, basic</a></td>
<td class="nump">$ 0.48<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (0.97)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income (loss) per share, diluted</a></td>
<td class="nump">$ 0.46<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.83)<span></span>
</td>
<td class="num">$ (0.97)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=120380238&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1337-109256<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares.  Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 54<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2603-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 44<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2062-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1828-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2600-109256<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2597-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 48<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2538-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 48<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2538-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 51<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e2574-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1707-109256<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28A<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1500-109256<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1757-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8924-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22595-107794<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121641772&amp;loc=SL7669625-108580<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8736-108599<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395209&amp;loc=SL114868664-224227<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=121586364&amp;loc=d3e3602-108585<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8906-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=SL5780133-109256<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120311839&amp;loc=d3e8933-108599<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121326447&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of restricted shares subject to future vesting using the treasury stock method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>vir_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.21.2</span><table class="report" border="0" cellspacing="2" id="idm140196272886552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Income (Loss) Per Share - Schedule of Potentially Dilutive Securities Not Included in Diluted Per Share Calculations (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">7,169,488<span></span>
</td>
<td class="nump">9,777,731<span></span>
</td>
<td class="nump">11,837,291<span></span>
</td>
<td class="nump">9,777,731<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">6,164,036<span></span>
</td>
<td class="nump">8,932,845<span></span>
</td>
<td class="nump">10,702,072<span></span>
</td>
<td class="nump">8,932,845<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vir_EstimatedSharesIssuableUnderTheESPPMember', window );">Estimated shares issuable under the ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">71,582<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">71,582<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares Subject to Future Vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">933,870<span></span>
</td>
<td class="nump">844,886<span></span>
</td>
<td class="nump">1,024,297<span></span>
</td>
<td class="nump">844,886<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vir_ContingentlyIssuableSharesMember', window );">Contingently issuable shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive shares excluded from calculation of diluted net loss per share (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">39,340<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vir_EstimatedSharesIssuableUnderTheESPPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vir_EstimatedSharesIssuableUnderTheESPPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vir_ContingentlyIssuableSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=vir_ContingentlyIssuableSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>62
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=:#@6AU(IS72Z?]"JK*V%PI7NZ<(TKA&&J,BCXK%(E^3Q6NVE&D;!![_=/V
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M*VA+S#"'UI0(#8#O2\[5\T0[:)O=R6]02P,$%     @ [X$%4];&*7@!"
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MCB4].Y9V=BP;L&,7R*2;G'":,7&(^O$J B([ O^1&TMW?":^QLB/J*\E]>H
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MHUJX"'IT54 ]"E7] FR4I?A:%2U!=!VV*0?G2);@PN"(^ZHO0&?1:O#.DW%
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MIV05$9$)'$TE=DAB@ZT2IU?LN6+4!)MA6R"PF"!QIIX.HF0#ZV'@;)JKXE<
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M; Y'\2U8Q,29$0]'8Q2ML:W.'3*UQA&3]<<,C8F9;DK-LGRH<\2<U  Y3J:
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M(J%<3![:U"2C-,(#TVS+%7RI<WJ&YLP1;\;FS"TQ7I=UP0J*6H:DK)I3N_5
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MP313QQW$O$_" ]EE4"@/)TLU2GABH@/C4X1=>B2U=!XN.;\0CZFP\D]@LRT
M<-Y =8I1V)QK2M<Z'R5A,->3;(/U.$'#K](BD)ELM)>E_H7AG/(]U:2LJ)I)
MK&NI E+$<D6Y ]#(Q6+#*_L! 51,3$@QY]&)'/-H!O#6F2P'N0M+.3?1J:1]
M%CW'O<0[+,.GMWH%+W$)%%T:!3SZ@WG197?/0&*\<))$"'OFY%)#RKTIVTJ=
MKKE=P?*TB*33Q@=U&9Q-L,(0D+;F**N\94,E99!364L]EW@Q/:5W2%EM\F X
M8<K*\($I2.P)N9&4I8_UDTX4$B2G I-+'X$ :C3 S,B13!V = 0F^ H/E\'?
M,=@)"PCB*=W:C%C&<.+*Y5*7FN035%F#THWN.P1'HX2JP)$"H:]-TG\;"@!<
MQ$P&&&T=D7"MJ:"($:-OC^@\@NTZ%AUG)$J*K81T+CU'^25]0+)C>I)ED*.[
MZCU4J3M1_E/<,Z2%=O$)M$F*)O2 E#RV.ERU:!^:N"26$<F/BJ74B!U%2I2V
M8X3C)  %:HI&A9HAI:!/P=93P;FOR>]1*NU<N\QVV79HV\)(F]/+' Q#G8KC
MKN%[M; M19R:V9TN("LTT &;ZBX,'=/L19A<I)>,_?M<HOVNWH'^828FDP"X
M$C@\ZU-3JK.O[0+8GA_:\I M[.*! 5U-#$EV&ZT!W?K"FG95,&9T37J@T^?C
M6:<R1S )INY..]?*.CCA?#YZ=O:L%]T=E/0DWANPAEA*;=%#EFVD[-GX13HC
MY)E5-,Q2&C[$_8_@B3[7Q[:V:P<2'$3TIS@L&=;^I);@KV99=GF'2C%_4_>V
M[0ZV+MO-X;^,61.?,XY^&V^_F'YC;X=,3!768W=F':ZIUK?V0,V%EIM"45.;
M!E@L0YB8N!PC+\]&.)]9BHL9?3*^#IKDA=J?CF@ R,DW*%Q]+XG<^W#<A2=N
MI,"L6IU3E6+.Y>K!A*^Z"5\$)($%&!;YG$%Q\KO](WER>R2>CL^WA;LS-[]I
M*[EP!%K7[0HQHHGYV2X$1UM[<ZUI/?*TYFXFSKB=,/ !Y<\]%??=6CM&W3!B
M,-X231CB>'9O3&0GD$(FPW"$Y(9G],+DU)6G";RZ7KANUF8+R0G65$@ISIT6
M\R(.,#3>5A7YSFV0<IB#"G1NB:N7;8F\)2XU=1["5\E/B!F40LHJ-\RG7=.#
M@;$0A*7.$.9ZC=0)2!OG?*:2FL6#VLE3U,&4F[X+8X^RC8'ZDF%TY P*DF/"
M),1 S2FTBMOIUZ5^7H-4&XFY95=_%*-!K:X2OC0X]#31R)!SHA)<_HEPV 4\
M*1#39HJ=CE8QK@WJ\0"QK]N(RRK6.$IJ964%$QM:%K4$?-1.9@_?,0S358I%
MO*ABHI5YZ)&2+0]2WP"FOL)XOW?_0MWU@4L*-KJ;EY-.E,?1=ZFM.L8*V[9E
MBU(,W.XE,V$BTMG918])CTE+'#%"S%8MN,70[5(=<%K9C'KI7@O%ON8+(0I3
MWF;^%:^.W74\>?K-3@X 'X]./=G@QHXNIJD&$1-Q=_WA[O36?#R=IRV<".\D
M-US37V\>M[[NN'1')5K5\P;C,27Y4'8C=;[;+ Z8'+6W$TW* T9UTI35_C=Z
MX'A3=$SUY*"'].[4WO=.N-7\[;J&"GV(;[;=7[BZ6O$P =8$CUO9%37H9SZ^
MZ(Z5^]RVQTG7$$7WF=Q*RSI.!K/G?^ BEX&RDWMK;&.BCHE@TLOMY6" M_U\
MW%[1$IH?NN%-L@Y<\+I?N>&EYJ)WOPN12F)]GRI3DT*(RMA2 +UH4FG@8U/)
M<!-,&RB+PRW'[8>W=^\_3&ZE>_'[[W>OOP81.=<8[1+^T@U:-VYTEVWS!R_;
MAO#<!6XX:7V7KE &8Y\V9 ,\L4[M;D;WVMMAN9/6,^3KKD+[.7+T&O@P6.^-
M/:EDCU)!+]J_ 4^W-RD#"/O7X?&96Z.%4G4/;XXUGZ$)IHN<1&NQ$\[,JM:_
M8"M#2KS #K=/AW%A?.C'I$GOISDN6OH!DEI''!5^I>N>=K]Q7H>?]K;+PP^D
M[Z1=:73OI5IBZW3\[.(D=%3IBS<-_]"W,-Z;BO\M%$892POP?FF,3U_H@.Z7
MWZO_ U!+ P04    " #O@053K]3!7# %  #($   &0   'AL+W=O<FMS:&5E
M=',O<VAE970Q,BYX;6SM6-MNW#80_97!M@A28*N5M+YLX@O@3>K$ 0(;B>L^
M%'W@2MP5&XI4>?%Z\_6=(27M);;A("V0A[QXQ1'G\,QPYE#T\5*;3[;BW,%=
M+94]&53.-2]'(UM4O&8VT0U7^&:N3<T<#LUB9!O#61F<:CG*T_1@5#.A!J?'
MP79E3H^U=U(H?F7 ^KIF9C7E4B]/!MF@,WP0B\J1871ZW+ %_\C=[\V5P=&H
M1RE%S9456H'A\Y/!6?9RND?SPX0;P9=VXQDHDIG6GVAP49X,4B+$)2\<(3#\
MN>6ON)0$A#3^:3$'_9+DN/G<H9^'V#&6&;/\E99_B-)5)X/) $H^9UZZ#WKY
MEK?Q[!->H:4-?V$9YQZ^&$#AK=-UZXP,:J'B+[MK\[#A,$D?<,A;ASSPC@L%
MEJ^98Z?'1B_!T&Q$HX<0:O!&<D+1IGQT!M\*]'.G;PQ3#LX6AG-,M;/'(X>H
M]&Y4M C3B) _@'  [[5RE87?5,G+;?\1LNDIY1VE:?XHX#NO$ABG0\C3/'L$
M;]R'. YXXP?P+LV"*?&9A2IXI9754I1Q=*9*N#+<8N31<#F'<Z&8*@23\!&-
M,2OPY]G,.H,E]-<CA/9Z0GN!T-XWY/QQA/T$=D%@*J2$9ZQNCN ]1X>2P1OD
M;^%<>]7&&YPLO/4U4W!1UUYIK&!1"*Z*%=P(XRT\?_;3),_3H[<7-^$I._JE
M7>Q2P3NF//8NY >T/=ED"*[BF-2Z86H%R(,;7H)03@.#1?!B'46L;%>%^4^A
MB@_<P+(2104"?9D%MF0&2ZQ'=MHQ]%Z ;_ 9?H8L3W)L$BD)  4+'3'8BQMH
MC$:7&I[3ZNOX8EQ=E E<*#CG,Q,C3/,T1M<PXP228Q@$+4^VWGF+YV8NM@E;
MWS0R9 'K*K+7<V0\20XZPF%YK'T>ZGY[Z;DW.#1;%-9YW:709H>;.K#@=RYZ
MS8VNX34O>#W#^>,L=ABE[K)P>L.6PQ!!);?HS(P4^(;0L#$<PLQ63]Y$VH.-
MI%"FL\,C"S,\/XIJ"',FI#><*(0MHA5I_MP'PFC[&]5[B 45S/R6Q\3=AUE4
M3"TXO2U0CXR6P\[4>N\Z.'8'%EO<VR$@3RL62F O4.ZBHWW(4^+IQXVM!-9=
MQ=R3TX%16ZW83*Y@AG,P'(M:3NG$-[A) <CZHJ \M&&V.4C@BJUBHQO<03S)
MJ,V E;<H5CS28)A)PV78),SHW#L?+!8W$4LC'( BEC+:L?&YH6YE*(*(J3'\
MSS2D%3#1GF-)M9Q*K;3Y5=2-MC@#\UL*"B@"U1QWJ&U42^[DL5X5T4O$D[H)
MQ;K#HN&&OBQXF<#U1O=L\(G5W%$*79,F+_HV)WRR[&\U/E&@K"*[>#C%#@CM
MU1TMP97:'*L]HF3K;FPM^\G>%[A6W#T1%9/0\/#9(5<)G(4]_7+R;D>FVZ):
M84;[O=I*PS@YW*$[3B:=97OU82L2KL(MVM%ES+S'Y0LOM15K_;^>?BG_[\.6
M9M^G^.]M5$4G_M?3>[4?S3O2?_V T*\#$!OJ_'62NSY3)FO)[4[2'Y+[_4KN
M?1V[VYS4=GF2]I6'#EYYDDG*Z/UJ3<V*5ZA;H;V54>QB;=_3Z=0WY%H4QK=B
MK<.W@!1L)F10TO]!6[)DO*,M^5H<OT9;?AQ;?4[S)-O*J1+R&PZK'+6^._RR
M_^J0NN]V,]JX7=;<+,(=&IL?F\S%BV9O[:_I9_%VNIX>[_AX?BR$HFZ>HVN:
M'.X/P,1[<QPXW82[ZDP[O/F&QRIT/DW ]W.M73>@!?I_7IS^"U!+ P04
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M49;@]C[79#_S<.E</-#I_3//@;DPG%W)&MS;.01N('!O7U^_>5OH$OA2(RW
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M&=R@ FG2%%?!/L42B"F)^4;:&2J8B0LF5.*FKW=D%Z@*[7@CL#=.U6['FT#
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M=W"YT4V$_@;=0+98INJ>SN:1=S)I?@K+C3:4RW7IM"@ZE;%A)@8HFY;S&PI
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MT?>XONE WLREHZ-+ (.!=@0D[%?L!BH+'02UT QB,Z@O S\E>;P1'/K[Y-L
M]BCDZ;NR8?";;_,Z<STUT.GB6VNYPO3GM?E):S8X QE?A+>]_9'=0\)YSRZ?
MC*9\K^M$3T<:H'R;0%0P6<;-'?^S5@[Q<&#VD1Z!2(JWV1)4YC>?O)UPCR)(
M6C?#Z]<AEE6F=&ZFY<S.12RN1G+\:K[D0T8AX?NJ3Q-?&XHJ'<I<C'O.8CE4
M&(X51WY8+:I*<3H]DER'%M2B8 UF-<#=Q"<=*+9@0*PBE1F#Q"8(^J *D?<;
M[T>T>A*52=*K/LS<I*_5GNM.$PCF>(#FSP[O.WC@@2T=8JH:_PL? 7 F/(#K
M*@<#Z7RWSN#0Z1<XAK_9, OO(S6G<YG+KA-UA-Z8BTR#H?RM(GLAPM++OP67
M=":2LC\V84:*M_#P<9L ,1X=U#WX:R69$\+'_4+*M0'>#W^;80ZF =:O!X2)
M+>/JEQ9)8&:D*H834OM3:_2XQ:X&1CP<U61[YJ @9#+H]^<[%^V1[G1\@TET
M(;:;[6A<?N-_4>/9O>[YLWM*PW]*^%_;W,)_*?[\1G3B^3/P+ROY$IBM^<3V
MUR>7)\&G"+OZ^N3J\LNKV<D]>-,__OS95JSDCZ(%^Z.+2B[AU8OIXX<G[,OL
M/[IFBT,BSKIK-O3G6@K8'7P OE\V$#^8?^ $MTW[@<A[_C]02P,$%     @
M[X$%4YF)A\,8!   (PD  !D   !X;"]W;W)K<VAE971S+W-H965T,30N>&UL
MK599;^,V$'[7KR#4H-@ A*U;=FH;R+&+MDBP0=+CH>@#+8UM8BE22U*QW5_?
M(64K#MH8Q:(O%(^9;[ZY2,VV2G\Q&P!+=HV09AYNK&VOQF-3;:!A9J1:D'BR
M4KIA%I=Z/3:M!E9[I4:,DR@JQ@WC,ES,_-ZC7LQ49P67\*B)Z9J&Z?T-"+6=
MAW%XW'CBZXUU&^/%K&5K> ;[:_NH<34>4&K>@#1<2:)A-0^OXZN;S,E[@=\X
M;,W)G#A/EDI]<8N?ZGD8.4(@H+(.@>'G!6Y!" >$-+X>,,/!I%,\G1_1/WG?
MT9<E,W"KQ.^\MIMY. E)#2O6"?NDMC_"P9_<X55*&#^2;2^;Y2&I.F-5<U!&
M!@V7_9?M#G$X49A$[R@D!X7$\^X->99WS++%3*LMT4X:T=S$N^JUD1R7+BG/
M5N,I1SV[N&&"R0K(LZ^ 6]6T2H*T9C:VB.YDQM4!Z:9'2MY!*LB#DG9CR$=9
M0_U6?XRL!FK)D=I-<A;PYTZ.2!I1DD1)? 8O'5Q-/5[ZGUQ] L$LU.2.FTHH
MTVDPY(_KI;$:"^7/,^:RP5SFS67_0V3/(KF^O#(MJV >8N,9T"\0+LH1><\"
M>=38M-KN"9,U^?BUXRVVD:5$HMB;,WA[5BEL-H, :D7L!LA*"6Q:+M=7 28#
M?#+NH()F"9JD,0T^<(F"JC,(9BZ#>[94FEFE]Z_(Y(+$$QH7$S<I:%E, \>T
MLPCQ*I1/(I+G1?"ITY);3(:GM^([ZQ,3TRS+^C&X!VS"C1(UX4VKU0LTWN>2
M)I/8C66&!B3FL>O['BFBV!IA#,EH[G'B- _>"\1:*Y1,$QK%)4E*&I<3M(E;
MK*JZINNKI@;,1,59?[,@ &N4MORO?N,#B6/TM""7.)W2)$W(9?"+LDPX*N^&
M_P(KG29Y[")5TFE68+#/F8$=7LT&P[-EQNF,4KPAA#C*(MPH'W;P_O8YM1L-
M?70-WY&F;UEP+4N&'+N&(_0 $H_B?\#&WPJ+(R:B!7\7B_V(7%>5[E#(:7Y&
M($WN.5MRP2U'QTY/E3\5)Z>'<OW6:GW"5F*ZVGCT&I"/ZHMQB.N%PYCF"4ZR
M*4TG6?# !>"=C.@MV[.E !)'-(HB\OUWDR1.?@@>V5XC#X^I#U?,@(>R:9ZZ
MY$9%%'S<5:ZL5AVR&>!P@6S7FB$/AD5[J&ZL1BR'E&9%&7S& L("D&LB7"N<
MAH3BDZ&U\R&E>9+@6"1YT,<5*V^%]C!IK*?GPH=OEP,:&*9T4F#5TWQZ5#LY
M2M.,3*+\4,GL;&XN2)'1J,QP4A9TFA;DWZ[4\<G#U8!>^^?9);:3MG_#AMWA
M#^"Z?_A>Q?O?AP>FUUP:C,D*5:-1B0^N[I_D?F%5ZY_!I;+XJ/KI!O]B0#L!
M/%\I98\+9V#X+UK\#5!+ P04    " #O@053]>D\@^D)  !^&P  &0   'AL
M+W=O<FMS:&5E=',O<VAE970Q-2YX;6S-66USV[@1_NY?@7'3CC-#VQ)E2W+B
M>,9Q[J[IV3U/G-YUIM,/( E):$B" 4#+OE_?9Q=\$>6W7-N9WA>;HK"+W6>?
M?0%TNC;VBULIY<5=D9?NW>[*^^K-X:%+5ZJ0[L!4JL0W"V,+Z?'1+@]=997,
M6*C(#^/1:'I82%WNGIWRNVM[=FIJG^M275OAZJ*0]OZ]RLWZW>YXMWWQ22]7
MGEX<GIU6<JENE/];=6WQZ;#3DNE"E4Z;4EBU>+=[/G[S_HC6\X*?M5J[C6=!
MGB3&?*$/'[-WNR,R2.4J]:1!XM^MNE!Y3HI@QM=&YVZW)0EN/K?:OV??X4LB
MG;HP^2\Z\ZMWN_-=D:F%K'/_R:S_K!I_CDE?:G+'?\4ZK#V.=T5:.V^*1A@6
M%+H,_^5=@\.&P'STA$#<",1L=]B(K?P@O3P[M68M+*V&-GI@5UD:QNF2@G+C
M+;[5D/-G%Z8HM ?*W@E99N+"E%Z72U6F6KG30X\M:.%AVJA[']3%3ZB;BBLH
M6#GQ79FI;"A_"-,Z^^+6OO?QLPK_4I<'8C**1#R*Q\_HFW3^3EC?Y!O\/=_V
M5WS0+LV-JZT2_SA/G+<@S3^?V?6HV_6(=SWZ7Z'\O+KY@7A6H[A4(*HX7UJE
MPI+/*T4BE2SOQ4HZ<2NM-K43.2^4UDK(AJ5(=&$6"YTJ5IS+Q%CIC;T7KI(I
ME.<FE5YE0I?B0N8:ZTLM(_&354M31N)*.V=JJUGZ9JW]K\KF](S'E4AA)Z%:
MR[S9O%(P)7-"W57:P@61*+]6JN2(LY)X-)F( _(!RUG(H1Y\K37"5!#=\OM6
ME[P/3OB5]$B3>RA#O4G^A1H@O(&VDC;696J#&K^RIEZN4*WPV"@77MD"""OK
M4=1:B'HL9>Z,J*RYU9EBJ198=I!>F(HK#C:TJD1A(DAEEFEZB^U;CPET<GAA
M32%,J4A@@1HE[I6T#AY?&><1"]()$U@7Q(-VV 'W2^,)4@=3; @)[6\5E6-2
MW3LDZC)7S@GMA2;XI(,M"9!+&S\9LJ$[>8ZH*)MJ1RBFJW;K _&Q%-^KQ-:H
MXQRG:" )F!IS"'-!$#P@VLL\@TV!4QSZ1H-FHB"<4 _E*=( G%>MYPLP#T'X
M"L-@ F''+%JO5#FPT"3D,S!,4P(%FKKP9V%_]K$-6KL O1 V]L#VK'@6 "=S
MM<\2B4R_""1 Z63H2K#[O%ZBSL/0\0EY.B D1RXPX(4M.:BN(BXDN6)TD0UD
M:AO@WO@4O(*X'CH(?ODHQ!D5@I"EK@FF"&*35Z4$T-A4WBD(UU[G$%6A_ #+
MVM+W;9INT#U=2;M4@:\;7*42),G4X!?;Q+IHG56I69;ZUY[3(6GHTWJETY!G
MC8RE\*>UA=9 %31K%"!_WR+78/2G/\SC\>RM>Q#&'(9TWCB20MM17=L1:\GO
M%R;'#./$'IN$\@EKW>LW.^>%J1&/'5Z[I^[2O,Y(.6WM]%VH4> MM<2AYM?B
ME9A$1_&<9&-Q$LW&$WJ<B/$XFLQG]'PDQJ/H>'I$S\=B'HV.XATXB;@LB.+3
M670TG>Y\-KZOJ&T5'$-R.AKM7(+C;X0NJCK4;2(G&+<G)O-H?#02KYL5)89
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M<VAE971S+W-H965T,3<N>&ULK5A9;^,X$G[WKR"\5P(HLB1?<CH)D*2[=V>
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M6YEL;8PV47EL7O_@AF\=/%]U1@^]%.0]"ZXH"?+<Y3K2S DI$VC<44E!KM=
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M-><28(&OK.W!K"XJX\O:>E !3W<=N*V9;S:"9,G;HKVWCHR*-XH<;%J "M;
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M*AM69H.!JPUVT/!/(5!A1/#()VH$'%@A3RV-[38*$6"IAYYU3/(3H]/Q$:"
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M'<EX0/S0VX[_,LO2]KUM^,>-5A _/8#OZ2W]^($V2'^KY]7_ E!+ P04
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M[00:GTEIUA]V@?+%\_@?4$L#!!0    ( .^!!5-#=L.X]0,  +4(   9
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M9(#_K[1V^PT%Z+[)YO\#4$L#!!0    ( .^!!5.R8IC1Q04  $D.   9
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M>ER1 8[/I31MAQ;H7H]7_P!02P,$%     @ [X$%4Z\P']9E!   ]@H  !D
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M"&&)F38(G/Z>\ K+T@ 1C;];3*<S:13WUUOT'^W;Z2USKO!*E%^+7"_'3N)
MC@O>E/I.K'_"]CV68"9*97]AW<JZ#F2-TJ)JE8E!5=2;?_[<^N$]"GZKX%O>
M&T.6Y377?#*28@W22!.:6=BG6FTB5]0F*#,MZ;8@/3VYI;A_KC-1(7S\12AU
M!E.4,%MR20?W?%ZB.AL--%DR\H.L1;W<H/IOH$;P1=1ZJ>"FSC$_U!\0PXZF
MOZ5YZ9\$_+FI^Q"X#'S7]T[@!=VS XL7O(%WPV5=U ]J[[5_7,R5EI0E?Y[
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M <#*!_+(LCSKR3MNO'[P2Q$#KOLN]GHSL*4R,%YC*P@20^PQ>$.Q%$I!:41
M::A0)$6&%*3'[.H4ROH99SX4[8<^VG5OQOW->541%5%$)>-Q(:-64OY)\_!=
M\^E03]US<7_3O1$I_/F\M.4J27Q#34GUA5KW3#Q^,;*I&R?N[YS_H8M<ER:;
M;63F87C[C#L*47=9//V>[>2Z--=4Q,CK(%'W5=S?6']L.3$ZJ07:2F1V*LW1
MN%N:=7_%_0UV2[X6E8?ZY#RD\BCASRX(-&0J$/G36]>4CBES$VJOV-5)Q3RW
M\ZWKU6W7ZV^[U7&ACW +5.UR*6TTG6/<Z;ONPA[N]?T1;J15D4BD02<A#?/
M9J<]51?-/-F\B;,"P*?%]7SO) 2G<:4Q-]8/1,8,'*4T J [G$(*9'$)+"9:
M[.TMYUYHN#/980(79RK-!G@>":&?)N;B5%W%EW\!4$L#!!0    ( .^!!5,2
MI-0]( (  *8$   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;(U446^;
M,!#^*Q;:0RLM,8&VFRJ"E"::UDF3HJ)N#],>#!Q@U=C,-J'[]SL;@C(IJ?H"
M/ON^[^X^WSD9E'XQ#8 EKZV09ATTUG;WE)JB@9:9I>I XDFE=,LLFKJFIM/
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M? Y&6%$%'I[ !5D1!GY1O: \._Z,$HFEOW@"7R9$8\K45S/;W<T$?-G["O:
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M51[M0&48M]UF-V'L,ZP4G5%;FE" "3[?UT0&@/*5<22HI.UDRB8!D?.H7J6
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M<8>O+ @K%X&[A&GK+[@T('!.N*AV2$[K[<6V[5BU]'?#5%FZ:7PSI7\!U"Z
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M+(OUD]A^@B*AMK$7BEC9;[(M9/T&"3.E15(H8P0)3_-?MBL*45- .\<5:*%
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M"XW=I!VN@&%^1@#?+X30^P?CH/PGQ? '4$L#!!0    ( .^!!5,(3P 8=@4
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M?JS<J5*>"+K1FSWF5 B:Z<,U1G)(U VR?$FI>#Y1'=3[A:;_ 5!+ P04
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M'%'Z=7/:-Q.K*G_"+I2E\]H/"[HAH78+Z/M2*;N=. ?=G6OV&U!+ P04
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M'66:+RN442O*5N9ZU5KU-*S? ?M[&M,EN2>?+5A^A>5K+*\#ZRP7<$4(5!,
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M-<$A8<I OE]2*IYOE(/RWQ6C'U!+ P04    " #O@053P1&$W2$7  #BF@
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MU2.:<WK+-,[+_UMW=5O[R%KN\B+=U"\#!YLHJ?X-?]0S(;W@D($7:/T"[;Q
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M7IFU[4R(=&_6UL;Q5=0<U[73>_5$*! 55)7"%\8M%\8MKTQ:=B9 NM-KXVZ
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M2Y/(EA+834:)'Z TD$'*Y+5ZU^+]$:K/74N ,,35Y>&U6G6L!RV!OA!W8A5
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MD"^K*_3ZU1OT"C&./F]%I2!>35T-3,UY;M:PNJQ9^2=8?:SX!0J\M\CW?#P
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M9<JD9 0B2J(+DT:BYD%Z!37M4--)U-^?,M":'&M<$"\^$1S@:CHIBB^7GA2
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M4F1ZU197$ZN:KA7-E*7&U@TK^I1 [3;0^EPI^SIQW:W_.)G^ 5!+ P04
M" #O@053DQ<ZCM<#   ;"P  &0   'AL+W=O<FMS:&5E=',O<VAE970T,2YX
M;6RM5M]OXC@0_E>L:!]VI;;Y10)4@%3@5G>KGJXJNW</JWLPR4"L=>R<[0#]
M[V_LI"F%E*M6]P*Q,]_XFV\FXYGLI?JA"P!##B47>NH5QE2WOJ^S DJJ;V0%
M M]LI"JIP:7:^KI20','*KD?!4'JEY0);S9Q>P]J-I&UX4S @R*Z+DNJGN;
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M,BYX;6REF%UOHS@4AO^*%<W%C-0&;,)'1FFD).WNSFIG)FJGG8O57KC@)*B
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MD"POC16"/*7%/_Y6%J)F,&PS0*4!,KB+0 ;E1RSQ;,+9 7 ]6WG3%R958ZW
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MEB1)EH41P,(*D@1#X&W$$4P!:,"0)''[X,%^%&_VJ7C[+]CX-U!+ P04
M" #O@053EXJ[',     3 @  "P   %]R96QS+RYR96QSG9*Y;L,P#$!_Q=">
M, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_:I7&0"QEY/3P2W!YI0.TXI+:+J1C]
M$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$VV-#L%HL/D N&6:WO606IW.D5XA<
MUYVE/=LO3T%O@*\Z3'%":4A+,P[PS=)_,O?S##5%Y4HCE5L:>-/E_G;@2=&A
M(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH^7%H5 J.W&,EC'%BM/XU@LD/['X
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M;%!+ 0(4 Q0    ( .^!!5-&Q0P.[@   "L"   1              "  :\
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M2P$"% ,4    " #O@053[2S )M8"  !E"0  &               @(&O%
M>&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#%     @ [X$%4R?\\BA4
M!@  8!P  !@              ("!NQ<  'AL+W=O<FMS:&5E=',O<VAE970T
M+GAM;%!+ 0(4 Q0    ( .^!!5.!GX:V7 ,  /@*   8              "
M@44>  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q02P$"% ,4    " #O@053
MUL8I> $(   J+0  &               @('7(0  >&PO=V]R:W-H965T<R]S
M:&5E=#8N>&UL4$L! A0#%     @ [X$%4Z2IO4&&"   GR,  !@
M     ("!#BH  'AL+W=O<FMS:&5E=',O<VAE970W+GAM;%!+ 0(4 Q0    (
M .^!!5."^NN\/@@  (H2   8              " @<HR  !X;"]W;W)K<VAE
M971S+W-H965T."YX;6Q02P$"% ,4    " #O@053*C^81R06  #30P  &
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M970Q,RYX;6Q02P$"% ,4    " #O@053F8F'PQ@$   C"0  &0
M    @($KC@  >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;%!+ 0(4 Q0    (
M .^!!5/UZ3R#Z0D  'X;   9              " @7J2  !X;"]W;W)K<VAE
M971S+W-H965T,34N>&UL4$L! A0#%     @ [X$%4X[RC?2F @  % 8  !D
M             ("!FIP  'AL+W=O<FMS:&5E=',O<VAE970Q-BYX;6Q02P$"
M% ,4    " #O@053PV+TH6<(  !&%   &0              @(%WGP  >&PO
M=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0    ( .^!!5-\]T)"MP0
M #\,   9              " @16H  !X;"]W;W)K<VAE971S+W-H965T,3@N
M>&UL4$L! A0#%     @ [X$%4V&+=Q6J @  S@4  !D              ("!
M ZT  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q02P$"% ,4    " #O@053
M@&S<5ZP6  "W1P  &0              @('DKP  >&PO=V]R:W-H965T<R]S
M:&5E=#(P+GAM;%!+ 0(4 Q0    ( .^!!5,8F%LF808  /T4   9
M      " @<?&  !X;"]W;W)K<VAE971S+W-H965T,C$N>&UL4$L! A0#%
M  @ [X$%4T-VP[CU P  M0@  !D              ("!7\T  'AL+W=O<FMS
M:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " #O@053Z^+&K#H$  "?"0
M&0              @(&+T0  >&PO=V]R:W-H965T<R]S:&5E=#(S+GAM;%!+
M 0(4 Q0    ( .^!!5.R8IC1Q04  $D.   9              " @?S5  !X
M;"]W;W)K<VAE971S+W-H965T,C0N>&UL4$L! A0#%     @ [X$%4Z\P']9E
M!   ]@H  !D              ("!^-L  'AL+W=O<FMS:&5E=',O<VAE970R
M-2YX;6Q02P$"% ,4    " #O@0535 ']$C$$  "6#P  &0
M@(&4X   >&PO=V]R:W-H965T<R]S:&5E=#(V+GAM;%!+ 0(4 Q0    ( .^!
M!5,2I-0]( (  *8$   9              " @?SD  !X;"]W;W)K<VAE971S
M+W-H965T,C<N>&UL4$L! A0#%     @ [X$%4P$S5-S!!   M10  !D
M         ("!4^<  'AL+W=O<FMS:&5E=',O<VAE970R."YX;6Q02P$"% ,4
M    " #O@053>['$%O4"  !I"   &0              @(%+[   >&PO=V]R
M:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    ( .^!!5-U;N 7# 0  + 0
M   9              " @7?O  !X;"]W;W)K<VAE971S+W-H965T,S N>&UL
M4$L! A0#%     @ [X$%4PA/ !AV!0  .R0  !D              ("!NO,
M 'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"% ,4    " #O@053S<TP
MZTT#  !_"0  &0              @(%G^0  >&PO=V]R:W-H965T<R]S:&5E
M=#,R+GAM;%!+ 0(4 Q0    ( .^!!5,II"^90 <  +L@   9
M  " @>O\  !X;"]W;W)K<VAE971S+W-H965T,S,N>&UL4$L! A0#%     @
M[X$%4]O_KXWH!   NA@  !D              ("!8@0! 'AL+W=O<FMS:&5E
M=',O<VAE970S-"YX;6Q02P$"% ,4    " #O@053P1&$W2$7  #BF@  &0
M            @(&!"0$ >&PO=V]R:W-H965T<R]S:&5E=#,U+GAM;%!+ 0(4
M Q0    ( .^!!5/:<U>N@@,  %T-   9              " @=D@ 0!X;"]W
M;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%     @ [X$%4]'6HU"' @
MR08  !D              ("!DB0! 'AL+W=O<FMS:&5E=',O<VAE970S-RYX
M;6Q02P$"% ,4    " #O@053"I8&6T(#  !)"0  &0              @(%0
M)P$ >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+ 0(4 Q0    ( .^!!5/^
M11:'#00  %,.   9              " @<DJ 0!X;"]W;W)K<VAE971S+W-H
M965T,SDN>&UL4$L! A0#%     @ [X$%4R+3&-T7 P  J @  !D
M     ("!#2\! 'AL+W=O<FMS:&5E=',O<VAE970T,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .^!!5,^:%;+ @0  /X1   9              "
M@5-" 0!X;"]W;W)K<VAE971S+W-H965T-#4N>&UL4$L! A0#%     @ [X$%
M4RV;+Z\N P  RPH  !D              ("!C$8! 'AL+W=O<FMS:&5E=',O
M<VAE970T-BYX;6Q02P$"% ,4    " #O@053*9*,UP $  !7#0  &0
M        @('Q20$ >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;%!+ 0(4 Q0
M   ( .^!!5.>*;VH^0,  #@0   9              " @2A. 0!X;"]W;W)K
M<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @ [X$%4Y71'.XM P  $A,
M  T              ( !6%(! 'AL+W-T>6QE<RYX;6Q02P$"% ,4    " #O
M@053EXJ[',     3 @  "P              @ &P50$ 7W)E;',O+G)E;'-0
M2P$"% ,4    " #O@053I^+3!?X#  !F(   #P              @ &95@$
M>&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ [X$%4Y(LH):X 0  YQP  !H
M             ( !Q%H! 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QS4$L!
M A0#%     @ [X$%4XQ/ZH^Z 0  [AP  !,              ( !M%P! %M#
G;VYT96YT7U1Y<&5S72YX;6Q02P4&     #@ .  _#P  GUX!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.21.2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>284</ContextCount>
  <ElementCount>407</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>100</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical</Role>
      <ShortName>Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Operations (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss )(Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Comprehensive Income (Loss )(Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Stockholders' Equity (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows (Unaudited)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Organization</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganization</Role>
      <ShortName>Organization</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Acquisitions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitions</Role>
      <ShortName>Acquisitions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Grant Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreements</Role>
      <ShortName>Grant Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements</Role>
      <ShortName>Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Balance Sheet Components</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponents</Role>
      <ShortName>Balance Sheet Components</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Related Party Transaction</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureRelatedPartyTransaction</Role>
      <ShortName>Related Party Transaction</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Stock-Based Awards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwards</Role>
      <ShortName>Stock-Based Awards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Net Income (Loss) Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShare1</Role>
      <ShortName>Net Income (Loss) Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Balance Sheet Components (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables</Role>
      <ShortName>Balance Sheet Components (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponents</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Stock-Based Awards (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsTables</Role>
      <ShortName>Stock-Based Awards (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwards</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Net Income (Loss) Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareTables</Role>
      <ShortName>Net Income (Loss) Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShare1</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Organization - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails</Role>
      <ShortName>Organization - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails</Role>
      <ShortName>Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Fair Value Measurements - Estimated Fair Value of Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails</Role>
      <ShortName>Fair Value Measurements - Estimated Fair Value of Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails</Role>
      <ShortName>Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Acquisitions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails</Role>
      <ShortName>Acquisitions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Grant Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails</Role>
      <ShortName>Grant Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Collaboration and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Collaboration and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Property and Equipment Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Balance Sheet Components - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails</Role>
      <ShortName>Balance Sheet Components - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Balance Sheet Components - Schedule of Accrued and Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails</Role>
      <ShortName>Balance Sheet Components - Schedule of Accrued and Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Commitments and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Stock-Based Awards - Summary of Stock Option Plans Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails</Role>
      <ShortName>Stock-Based Awards - Summary of Stock Option Plans Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Stock-Based Awards - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Awards - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails</Role>
      <ShortName>Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Stock-Based Awards - Summary of Restricted Stock Activity and Restricted Stock Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityAndRestrictedStockUnitsDetails</Role>
      <ShortName>Stock-Based Awards - Summary of Restricted Stock Activity and Restricted Stock Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Stock-Based Awards - Summary of Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Awards - Summary of Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (loss) Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails</Role>
      <ShortName>Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (loss) Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="vir-20210630.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Net Income (Loss) Per Share - Schedule of Potentially Dilutive Securities Not Included in Diluted Per Share Calculations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails</Role>
      <ShortName>Net Income (Loss) Per Share - Schedule of Potentially Dilutive Securities Not Included in Diluted Per Share Calculations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareTables</ParentRole>
      <Position>48</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-Q" original="vir-20210630.htm">vir-20210630.htm</File>
    <File>vir-20210630.xsd</File>
    <File>vir-20210630_cal.xml</File>
    <File>vir-20210630_def.xml</File>
    <File>vir-20210630_lab.xml</File>
    <File>vir-20210630_pre.xml</File>
    <File>vir-20210630ex10_2.htm</File>
    <File>vir-20210630ex10_3.htm</File>
    <File>vir-20210630ex10_4.htm</File>
    <File>vir-20210630ex31_1.htm</File>
    <File>vir-20210630ex31_2.htm</File>
    <File>vir-20210630ex32_1.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2020-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2020-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>68
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "vir-20210630.htm": {
   "axisCustom": 0,
   "axisStandard": 21,
   "contextCount": 284,
   "dts": {
    "calculationLink": {
     "local": [
      "vir-20210630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "vir-20210630_def.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml",
      "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml"
     ]
    },
    "inline": {
     "local": [
      "vir-20210630.htm"
     ]
    },
    "labelLink": {
     "local": [
      "vir-20210630_lab.xml"
     ],
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-doc-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-doc-2020-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "vir-20210630_pre.xml"
     ]
    },
    "referenceLink": {
     "remote": [
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-ref-2020-01-31.xml",
      "https://xbrl.sec.gov/dei/2020/dei-ref-2020-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "vir-20210630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd",
      "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd",
      "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd",
      "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd",
      "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd",
      "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "http://xbrl.fasb.org/us-gaap/2020/elts/us-parts-codification-2020-01-31.xsd",
      "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 556,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2020-01-31": 9,
    "http://xbrl.sec.gov/dei/2020-01-31": 4,
    "total": 13
   },
   "keyCustom": 111,
   "keyStandard": 296,
   "memberCustom": 67,
   "memberStandard": 30,
   "nsprefix": "vir",
   "nsuri": "http://www.vir.bio/20210630",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Fair Value Measurements",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Acquisitions",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitions",
     "shortName": "Acquisitions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vir:GrantAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Grant Agreements",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreements",
     "shortName": "Grant Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vir:GrantAgreementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Collaboration and License Agreements",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements",
     "shortName": "Collaboration and License Agreements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Balance Sheet Components",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponents",
     "shortName": "Balance Sheet Components",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Commitments and Contingencies",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Related Party Transaction",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureRelatedPartyTransaction",
     "shortName": "Related Party Transaction",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Stock-Based Awards",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwards",
     "shortName": "Stock-Based Awards",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - Net Income (Loss) Per Share",
     "role": "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShare1",
     "shortName": "Net Income (Loss) Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Subsequent Events",
     "role": "http://www.vir.bio/20210630/taxonomy/role/DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Condensed Consolidated Balance Sheets (Unaudited)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_e403ff64-40f3-494a-998d-769d7e8bb228",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Balance Sheet Components (Tables)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables",
     "shortName": "Balance Sheet Components (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Commitments and Contingencies (Tables)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables",
     "shortName": "Commitments and Contingencies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Stock-Based Awards (Tables)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsTables",
     "shortName": "Stock-Based Awards (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Net Income (Loss) Per Share (Tables)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareTables",
     "shortName": "Net Income (Loss) Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Organization - Additional Information (Details)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
     "shortName": "Organization - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "ix:continuation",
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:CashCashEquivalentsAndShortTermInvestments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "vir:ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "vir:ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vir:FinancialAssetsAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Details)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
     "shortName": "Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vir:FinancialAssetsAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermInvestments",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Parenthetical) (Details)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails",
     "shortName": "Fair Value Measurements - Financial Assets Measured at Fair Value on a Recurring Basis by Level Within Fair Value Hierarchy (Parenthetical) (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "link:footnote",
       "p",
       "us-gaap:FairValueAssetsMeasuredOnRecurringBasisTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_93449051-f049-49fc-bbdb-95aeef0d2e9a",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RestrictedCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical",
     "shortName": "Condensed Consolidated Balance Sheets (Unaudited) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinancingReceivableAccruedInterestWriteoff",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FinancingReceivableAccruedInterestWriteoff",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_f7017d66-420f-462d-adcf-f3fb86e73c23",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Fair Value Measurements - Estimated Fair Value of Significant Unobservable Inputs (Details)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
     "shortName": "Fair Value Measurements - Estimated Fair Value of Significant Unobservable Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_f7017d66-420f-462d-adcf-f3fb86e73c23",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_8d26edc6-7745-4758-988b-eb4ba800efed",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails",
     "shortName": "Fair Value Measurements - Summary of Changes in Estimated Fair Value of Financial Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_8d26edc6-7745-4758-988b-eb4ba800efed",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_31d70583-f863-4f52-9c17-5d19f672cbae",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "vir:MinimumCommonStockConversionPriceForMilestonePaymentsConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Acquisitions - Additional Information (Details)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
     "shortName": "Acquisitions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_31d70583-f863-4f52-9c17-5d19f672cbae",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "vir:MinimumCommonStockConversionPriceForMilestonePaymentsConsideration",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_9b221d24-b45a-4cc0-b6cb-8320c56dc6fc",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueNotFromContractWithCustomer",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Grant Agreements - Additional Information (Details)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
     "shortName": "Grant Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "vir:GrantAgreementsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_cd7a1755-2831-46df-a378-33b1c1bbe888",
      "decimals": "-5",
      "lang": null,
      "name": "vir:GrantAwardedAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredRevenueCurrent",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Collaboration and License Agreements - Additional Information (Details)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
     "shortName": "Collaboration and License Agreements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_b4f1dc34-56da-4847-88c1-d9bfde49f709",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Balance Sheet Components - Schedule of Property and Equipment Net (Details)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
     "shortName": "Balance Sheet Components - Schedule of Property and Equipment Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Balance Sheet Components - Additional Information (Details)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails",
     "shortName": "Balance Sheet Components - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "vir:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vir:ResearchAndDevelopmentExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Balance Sheet Components - Schedule of Accrued and Other Liabilities (Details)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails",
     "shortName": "Balance Sheet Components - Schedule of Accrued and Other Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "vir:ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock",
       "div",
       "us-gaap:SupplementalBalanceSheetDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vir:ResearchAndDevelopmentExpensesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vir:LeaseArrangementContractualExpirationBeginningYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Commitments and Contingencies - Additional Information (Details)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitments and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "vir:LeaseArrangementContractualExpirationBeginningYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Condensed Consolidated Statements of Operations (Unaudited)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited",
     "shortName": "Condensed Consolidated Statements of Operations (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Revenues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails",
     "shortName": "Commitments and Contingencies - Schedule of Maturities of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "vir:ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vir:OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Commitments and Contingencies - Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheets (Details)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetsDetails",
     "shortName": "Commitments and Contingencies - Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "vir:ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_a655ae38-8b11-45c7-83f7-3fcbcc2a343f",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "vir:OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_06a67e5e-7cd4-4262-8c8f-9cc28e2a7ddf",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Stock-Based Awards - Summary of Stock Option Plans Activity (Details)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails",
     "shortName": "Stock-Based Awards - Summary of Stock Option Plans Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_e877910e-22cc-4649-a193-5d784dba152c",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_7828555d-b746-4f30-8bb5-ef260d0b147b",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Stock-Based Awards - Additional Information (Details)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
     "shortName": "Stock-Based Awards - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_7828555d-b746-4f30-8bb5-ef260d0b147b",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails",
     "shortName": "Stock-Based Awards - Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_0edc973f-cc4f-4eea-b393-2ad3dc16ecf5",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Stock-Based Awards - Summary of Restricted Stock Activity and Restricted Stock Units (Details)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityAndRestrictedStockUnitsDetails",
     "shortName": "Stock-Based Awards - Summary of Restricted Stock Activity and Restricted Stock Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_0edc973f-cc4f-4eea-b393-2ad3dc16ecf5",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Stock-Based Awards - Summary of Stock-based Compensation Expense (Details)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Awards - Summary of Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (loss) Per Share (Details)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails",
     "shortName": "Net Income (Loss) Per Share - Schedule of Basic and Diluted Net Income (loss) Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Net Income (Loss) Per Share - Schedule of Potentially Dilutive Securities Not Included in Diluted Per Share Calculations (Details)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails",
     "shortName": "Net Income (Loss) Per Share - Schedule of Potentially Dilutive Securities Not Included in Diluted Per Share Calculations (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Condensed Consolidated Statements of Comprehensive Income (Loss )(Unaudited)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited",
     "shortName": "Condensed Consolidated Statements of Comprehensive Income (Loss )(Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_5f3f72f9-95a5-41aa-84c7-afba8cb647f7",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_2961edff-bc89-457f-97d0-23460c2e7059",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
     "shortName": "Condensed Consolidated Statements of Stockholders' Equity (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_2961edff-bc89-457f-97d0-23460c2e7059",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
     "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Organization",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganization",
     "shortName": "Organization",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "vir-20210630.htm",
      "contextRef": "C_52d977a7-74c8-43be-9bfc-01aba0a3d398",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 100,
   "tag": {
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "CHINA",
        "terseLabel": "China Territory"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "verboseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "verboseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report",
        "terseLabel": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r419"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "verboseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address Address Line1",
        "verboseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address City Or Town",
        "verboseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address State Or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock Shares Outstanding",
        "verboseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation State Country Code",
        "verboseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r420"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "verboseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r416"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Security12b Title",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r40",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r216",
      "r218",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r350",
      "r387",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r216",
      "r218",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r350",
      "r387",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]",
        "verboseLabel": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r156",
      "r200",
      "r202",
      "r351",
      "r386",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Product Or Service [Axis]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [
      "r156",
      "r200",
      "r202",
      "r351",
      "r386",
      "r388"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products And Services [Domain]",
        "terseLabel": "Product and Service"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r205",
      "r216",
      "r218",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r350",
      "r387",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r205",
      "r216",
      "r218",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r350",
      "r387",
      "r390"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Member]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Repurchase Agreement Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [
      "r157",
      "r158",
      "r200",
      "r203",
      "r389",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Geographical [Domain]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r157",
      "r158",
      "r200",
      "r203",
      "r389",
      "r404",
      "r406",
      "r407",
      "r408",
      "r409",
      "r410",
      "r411",
      "r412",
      "r413",
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Geographical [Axis]",
        "terseLabel": "Geographical"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_WeightedAverageMember": {
     "auth_ref": [
      "r343",
      "r345",
      "r348"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted Average [Member]",
        "terseLabel": "Weighted Average"
       }
      }
     },
     "localname": "WeightedAverageMember",
     "nsuri": "http://fasb.org/srt/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update201409 [Member]",
        "terseLabel": "ASC 606"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r80"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion Amortization Of Discounts And Premiums Investments",
        "negatedLabel": "Amortization of premiums on investments, net"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities And Other Liabilities",
        "terseLabel": "Accrued and other liabilities",
        "totalLabel": "Total accrued and other liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r32"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Professional Fees Current",
        "terseLabel": "Other professional and consulting expenses"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r28",
      "r186"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation Depletion And Amortization Property Plant And Equipment",
        "negatedLabel": "Less accumulated depreciation and amortization",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r18",
      "r45",
      "r46",
      "r47",
      "r374",
      "r398",
      "r402"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income Loss Net Of Tax",
        "terseLabel": "Accumulated other comprehensive loss",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r44",
      "r47",
      "r50",
      "r94",
      "r95",
      "r96",
      "r293",
      "r393",
      "r394"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income [Member]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r16",
      "r256"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid In Capital",
        "periodEndLabel": "Additional Paid in Capital, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Beginning Balance",
        "terseLabel": "Additional paid-in capital",
        "totalLabel": "Additional Paid in Capital, Total"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r253",
      "r254",
      "r255"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid In Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r100",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r266",
      "r267",
      "r268",
      "r269",
      "r353",
      "r354",
      "r355",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Adjustments For New Accounting Pronouncements [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r219",
      "r221",
      "r259",
      "r260"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash provided by (used in) operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r221",
      "r245",
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share Based Compensation Expense",
        "terseLabel": "Total stock-based compensation"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r79",
      "r177",
      "r183"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization Of Intangible Assets",
        "terseLabel": "Amortization of intangible assets",
        "totalLabel": "Amortization of Intangible Assets, Total"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount",
        "terseLabel": "Antidilutive shares excluded from calculation of diluted net loss per share (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Arrangements And Nonarrangement Transactions [Member]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r90",
      "r145",
      "r148",
      "r154",
      "r163",
      "r288",
      "r294",
      "r318",
      "r361",
      "r372"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "ASSETS"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r38",
      "r90",
      "r163",
      "r288",
      "r294",
      "r318"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets Current [Abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r222",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityAndRestrictedStockUnitsDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r301",
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BalanceSheetRelatedDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Balance Sheet Related Disclosures [Abstract]"
       }
      }
     },
     "localname": "BalanceSheetRelatedDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Bank Time Deposits"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis Of Accounting Policy Policy [Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r215",
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r215",
      "r217",
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For contingent consideration arrangements recognized in connection with a business combination, this element represents an estimate of the high-end of the potential range (undiscounted) of the consideration which may be paid.",
        "label": "Business Combination Contingent Consideration Arrangements Range Of Outcomes Value High",
        "terseLabel": "Milestone payments aggregate amount payable, maximum"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsRangeOfOutcomesValueHigh",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r275",
      "r276",
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination Contingent Consideration Liability",
        "terseLabel": "Contingent consideration payable",
        "totalLabel": "Business Combination, Contingent Consideration, Liability, Total",
        "verboseLabel": "Estimated fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r275",
      "r277"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination Contingent Consideration Liability Current",
        "terseLabel": "Contingent consideration, current portion"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityMeasurementInput": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure contingent consideration liability from business combination.",
        "label": "Business Combination Contingent Consideration Liability Measurement Input",
        "terseLabel": "Fair value contingent consideration measurement input"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r275",
      "r277"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination Contingent Consideration Liability Noncurrent",
        "terseLabel": "Contingent consideration, noncurrent"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r280"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r87",
      "r272"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r83",
      "r84",
      "r85"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred But Not Yet Paid",
        "terseLabel": "Property and equipment purchases included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r25",
      "r81"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash And Cash Equivalents At Carrying Value",
        "periodEndLabel": "Cash and Cash Equivalents, at Carrying Value, Ending Balance",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r10",
      "r82",
      "r87",
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash And Cash Equivalents Restricted Cash And Cash Equivalents Policy",
        "terseLabel": "Restricted Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r25"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash Cash Equivalents And Short Term Investments",
        "terseLabel": "Cash, cash equivalents and investments",
        "totalLabel": "Cash, Cash Equivalents, and Short-term Investments, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r75",
      "r81",
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash and cash equivalents at end of period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash and cash equivalents at beginning of period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents [Abstract]",
        "terseLabel": "RECONCILIATION OF CASH, CASH EQUIVALENTS AND RESTRICTED CASH TO THE CONDENSED CONSOLIDATED BALANCE SHEETS:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r75",
      "r319"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect",
        "totalLabel": "Net increase in cash, cash equivalents and restricted cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r281",
      "r282",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Collaboration and License Agreements"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r35",
      "r192",
      "r363",
      "r378"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments And Contingencies",
        "terseLabel": "Commitments and contingencies (Note 8)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments And Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r189",
      "r190",
      "r191",
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments And Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r94",
      "r95"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock Par Or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "verboseLabel": "Common stock price per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock Shares Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock Shares Outstanding",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock Value",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.0001 par value; 300,000,000 shares authorized as of June 30, 2021 and December 31, 2020; 130,479,975 and 127,416,740 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r53",
      "r55",
      "r56",
      "r60",
      "r366",
      "r381"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income Net Of Tax",
        "totalLabel": "Comprehensive income ( loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction In Progress [Member]",
        "terseLabel": "Construction in Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContingentConsiderationByTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of contingent consideration.",
        "label": "Contingent Consideration By Type [Axis]",
        "terseLabel": "Contingent Consideration by Type"
       }
      }
     },
     "localname": "ContingentConsiderationByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ContingentConsiderationTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of contingent payment arrangement.",
        "label": "Contingent Consideration Type [Domain]",
        "terseLabel": "Contingent Consideration Type"
       }
      }
     },
     "localname": "ContingentConsiderationTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetNetCurrent": {
     "auth_ref": [
      "r196",
      "r198",
      "r201"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time, classified as current.",
        "label": "Contract With Customer Asset Net Current",
        "terseLabel": "Contract asset",
        "totalLabel": "Contract with Customer, Asset, after Allowance for Credit Loss, Current, Total"
       }
      }
     },
     "localname": "ContractWithCustomerAssetNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiability": {
     "auth_ref": [
      "r196",
      "r197",
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Contract with Customer, Liability",
        "terseLabel": "Deferred revenue",
        "totalLabel": "Contract with Customer, Liability, Total"
       }
      }
     },
     "localname": "ContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r196",
      "r197",
      "r201"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract With Customer Liability Noncurrent",
        "terseLabel": "Contract liability"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfRevenue": {
     "auth_ref": [
      "r63",
      "r90",
      "r163",
      "r318"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate cost of goods produced and sold and services rendered during the reporting period.",
        "label": "Cost of revenue",
        "totalLabel": "Cost of Revenue, Total"
       }
      }
     },
     "localname": "CostOfRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAllowanceForCreditLoss": {
     "auth_ref": [
      "r161",
      "r171",
      "r172",
      "r173"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of allowance for credit loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities Available For Sale Allowance For Credit Loss",
        "periodEndLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Ending Balance",
        "periodStartLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Beginning Balance",
        "terseLabel": "Allowance for losses on available-for-sale debt securities",
        "totalLabel": "Debt Securities, Available-for-sale, Allowance for Credit Loss, Total"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTerm": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and maturity of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Debt Securities Available For Sale Term",
        "terseLabel": "Securities contractual term"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r263",
      "r264"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities Net",
        "terseLabel": "Deferred tax liability",
        "totalLabel": "Deferred Income Tax Liabilities, Net, Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r22"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred revenue",
        "totalLabel": "Deferred Revenue, Total"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueCurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Deferred Revenue Current",
        "terseLabel": "Deferred revenue, current portion",
        "totalLabel": "Deferred Revenue, Current, Total",
        "verboseLabel": "Current deferred revenue"
       }
      }
     },
     "localname": "DeferredRevenueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenueNoncurrent": {
     "auth_ref": [
      "r22"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Deferred Revenue Noncurrent",
        "terseLabel": "Deferred revenue, noncurrent",
        "totalLabel": "Deferred Revenue, Noncurrent, Total"
       }
      }
     },
     "localname": "DeferredRevenueNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r79",
      "r143"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation Depletion And Amortization",
        "terseLabel": "Depreciation and amortization",
        "totalLabel": "Depreciation, Depletion and Amortization, Total",
        "verboseLabel": "Depreciation and amortization expenses"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeFairValueOfDerivativeLiability": {
     "auth_ref": [
      "r39",
      "r41",
      "r303",
      "r349"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, before effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities elected not to be offset. Excludes liabilities not subject to a master netting arrangement.",
        "label": "Derivative Fair Value Of Derivative Liability",
        "terseLabel": "Estimated fair value of the derivative liability",
        "totalLabel": "Derivative Liability, Fair Value, Gross Liability, Total"
       }
      }
     },
     "localname": "DerivativeFairValueOfDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r302"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative Gain Loss On Derivative Net",
        "negatedLabel": "Change in estimated fair value of derivative liability",
        "totalLabel": "Derivative, Gain (Loss) on Derivative, Net, Total"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativesEmbeddedDerivatives": {
     "auth_ref": [
      "r87",
      "r299",
      "r300",
      "r308",
      "r309"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for embedded derivatives, including how such derivatives are identified and analyzed for possible separation from their host contracts.",
        "label": "Derivatives Embedded Derivatives",
        "terseLabel": "Embedded Derivatives"
       }
      }
     },
     "localname": "DerivativesEmbeddedDerivatives",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r261"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure Of Compensation Related Costs Share Based Payments [Text Block]",
        "terseLabel": "Stock-Based Awards"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwards"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r61",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r109",
      "r111",
      "r124",
      "r125",
      "r126",
      "r130",
      "r131",
      "r367",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "terseLabel": "Net income (loss) per share, basic",
        "totalLabel": "Earnings Per Share, Basic, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r125"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share Basic And Diluted",
        "terseLabel": "Net loss per share, basic and diluted",
        "totalLabel": "Earnings Per Share, Basic and Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r61",
      "r101",
      "r102",
      "r103",
      "r104",
      "r105",
      "r111",
      "r124",
      "r125",
      "r126",
      "r130",
      "r131",
      "r367",
      "r382"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "terseLabel": "Net income (loss) per share, diluted",
        "totalLabel": "Earnings Per Share, Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r127",
      "r128",
      "r129",
      "r132"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Income (Loss) Per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShare1"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability": {
     "auth_ref": [
      "r304"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value as of the balance sheet date of the embedded derivative or group of embedded derivatives classified as a liability.",
        "label": "Embedded Derivative Fair Value Of Embedded Derivative Liability",
        "verboseLabel": "Estimated fair value of embedded derivative"
       }
      }
     },
     "localname": "EmbeddedDerivativeFairValueOfEmbeddedDerivativeLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmbeddedDerivativeLiabilityMeasurementInput": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of input used to measure embedded derivative liability.",
        "label": "Embedded Derivative Liability Measurement Input",
        "terseLabel": "Fair value contingent consideration measurement input"
       }
      }
     },
     "localname": "EmbeddedDerivativeLiabilityMeasurementInput",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "decimalItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1",
        "terseLabel": "Estimated weighted average period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options",
        "terseLabel": "Unrecognized compensation cost related to unvested restricted stock"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r246"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options",
        "terseLabel": "Unamortized stock-based compensation expense related to stock option"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Employee Stock Option [Member]",
        "terseLabel": "Stock Option",
        "verboseLabel": "Options Issued and Outstanding"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r98",
      "r106",
      "r108",
      "r133",
      "r167",
      "r194",
      "r195",
      "r253",
      "r254",
      "r255",
      "r268",
      "r269",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r393",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r310",
      "r311",
      "r312",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Valuation Techniques Table [Text Block]",
        "terseLabel": "Estimated Fair Value of Significant Unobservable Inputs"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisTextBlock": {
     "auth_ref": [
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, by class that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Fair Value Assets Measured On Recurring Basis [Text Block]",
        "terseLabel": "Summary of Financial Assets Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class of asset.",
        "label": "Fair Value Assets Measured On Recurring Basis Unobservable Input Reconciliation By Asset Class [Domain]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueAssetsMeasuredOnRecurringBasisUnobservableInputReconciliationByAssetClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueByAssetClassAxis": {
     "auth_ref": [
      "r310",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of asset.",
        "label": "Fair Value By Asset Class [Axis]",
        "terseLabel": "Asset Class"
       }
      }
     },
     "localname": "FairValueByAssetClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r311",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value By Fair Value Hierarchy Level [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByLiabilityClassAxis": {
     "auth_ref": [
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by class of liability.",
        "label": "Fair Value By Liability Class [Axis]",
        "terseLabel": "Derivative Liability"
       }
      }
     },
     "localname": "FairValueByLiabilityClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r316"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r206",
      "r207",
      "r212",
      "r214",
      "r311",
      "r340"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value Inputs Level1 [Member]",
        "terseLabel": "Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r206",
      "r207",
      "r212",
      "r214",
      "r311",
      "r341"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value Inputs Level2 [Member]",
        "terseLabel": "Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r311",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Inputs Level3 [Member]",
        "terseLabel": "Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents classes of liabilities measured and disclosed at fair value.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation By Liability Class [Domain]",
        "terseLabel": "Fair Value by Liability Class"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Line Items]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable": {
     "auth_ref": [
      "r315",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of information required and determined to be provided for purposes of reconciling beginning and ending balances of fair value measurements of liabilities using significant unobservable inputs (level 3). Separately presenting changes during the period, attributable to: (1) total gains or losses for the period (realized and unrealized) and location reported in the statement of income (or activities); (2) purchases, sales, issuances, and settlements (net); (3) transfers in and/or out of Level 3.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]",
        "terseLabel": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Table]"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock": {
     "auth_ref": [
      "r315",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value measurement of liabilities using significant unobservable inputs (Level 3), a reconciliation of the beginning and ending balances, separately presenting changes attributable to the following: (1) total gains or losses for the period (realized and unrealized), segregating those gains or losses included in earnings (or changes in net assets), and gains or losses recognized in other comprehensive income (loss) and a description of where those gains or losses included in earnings (or changes in net assets) are reported in the statement of income (or activities); (2) purchases, sales, issues, and settlements (each type disclosed separately); and (3) transfers in and transfers out of Level 3 (for example, transfers due to changes in the observability of significant inputs) by class of liability.",
        "label": "Fair Value Liabilities Measured On Recurring Basis Unobservable Input Reconciliation [Text Block]",
        "terseLabel": "Summary of Changes in Estimated Fair Value of Financial Liabilities"
       }
      }
     },
     "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease": {
     "auth_ref": [
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Period Increase Decrease",
        "terseLabel": "Changes in fair value recognized",
        "totalLabel": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Period Increase (Decrease), Total"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPeriodIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": {
     "auth_ref": [
      "r315"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value Measurement With Unobservable Inputs Reconciliations Recurring Basis Liability Value",
        "periodEndLabel": "Balance at March 31, 2021",
        "periodStartLabel": "Balance at December 31, 2020"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r212",
      "r214",
      "r340",
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Measurements Fair Value Hierarchy [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinanceLeasePrincipalPayments": {
     "auth_ref": [
      "r329",
      "r331"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for principal payment on finance lease.",
        "label": "Finance Lease Principal Payments",
        "negatedLabel": "Payment of principal on financing lease obligation"
       }
      }
     },
     "localname": "FinanceLeasePrincipalPayments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialSupportToNonconsolidatedLegalEntityAxis": {
     "auth_ref": [
      "r285",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.",
        "label": "Financial Support To Nonconsolidated Legal Entity [Axis]",
        "terseLabel": "Financial Support to Nonconsolidated Legal Entity"
       }
      }
     },
     "localname": "FinancialSupportToNonconsolidatedLegalEntityAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialSupportToNonconsolidatedLegalEntityDomain": {
     "auth_ref": [
      "r285",
      "r403"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial support arrangement provided to a nonconsolidated legal entity that is required to comply with or operate in accordance with requirements that are similar to those included in Rule 2a-7 of the Investment Company Act of 1940 for registered money market funds.",
        "label": "Financial Support To Nonconsolidated Legal Entity [Domain]",
        "terseLabel": "Financial Support to Nonconsolidated Legal Entity"
       }
      }
     },
     "localname": "FinancialSupportToNonconsolidatedLegalEntityDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancingReceivableAccruedInterestWriteoff": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of writeoff of accrued interest on financing receivable recognized by reversing interest income.",
        "label": "Financing Receivable Accrued Interest Writeoff",
        "terseLabel": "Write off of accrued interest receivable"
       }
      }
     },
     "localname": "FinancingReceivableAccruedInterestWriteoff",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r178",
      "r179",
      "r182",
      "r184",
      "r352",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r178",
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture And Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r62"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General And Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r174",
      "r175",
      "r359"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, Ending Balance",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "terseLabel": "Goodwill",
        "totalLabel": "Goodwill, Total"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantMember": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award of money not required to be repaid.",
        "label": "Grant [Member]",
        "terseLabel": "Grant Revenue"
       }
      }
     },
     "localname": "GrantMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r58",
      "r145",
      "r147",
      "r150",
      "r153",
      "r155",
      "r357",
      "r364",
      "r369",
      "r384"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest",
        "totalLabel": "Income (loss) before provision for income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r91",
      "r107",
      "r108",
      "r144",
      "r265",
      "r270",
      "r271",
      "r385"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense Benefit",
        "negatedLabel": "Provision for income taxes",
        "totalLabel": "Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase Decrease In Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase Decrease In Accrued Liabilities And Other Operating Liabilities",
        "terseLabel": "Accrued liabilities and other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredRevenue": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Increase Decrease In Deferred Revenue",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase Decrease In Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase Decrease In Other Operating Assets",
        "negatedLabel": "Other assets",
        "totalLabel": "Increase (Decrease) in Other Operating Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase Decrease In Prepaid Deferred Expense And Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToContingentlyIssuableShares": {
     "auth_ref": [
      "r113",
      "r114",
      "r116",
      "r117",
      "r118",
      "r119",
      "r120",
      "r121",
      "r122",
      "r126"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of contingently issuable shares.  Contingently issuable shares are those shares that are issuable for little or no cash contingent on certain conditions being met.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Contingently Issuable Shares",
        "terseLabel": "Contingently issuable shares"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToContingentlyIssuableShares",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IncrementalCommonSharesAttributableToShareBasedPaymentArrangements": {
     "auth_ref": [
      "r112",
      "r113",
      "r115",
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of share based payment arrangements using the treasury stock method.",
        "label": "Incremental Common Shares Attributable to Dilutive Effect of Share-based Payment Arrangements",
        "terseLabel": "Options to purchase common stock",
        "totalLabel": "Incremental Common Shares Attributable to Share-based Payment Arrangements, Total"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToShareBasedPaymentArrangements",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r176",
      "r180"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets Net Excluding Goodwill",
        "terseLabel": "Intangible assets, net",
        "totalLabel": "Intangible Assets, Net (Excluding Goodwill), Total"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivable": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of interest earned but not received. Also called accrued interest or accrued interest receivable.",
        "label": "Interest Receivable",
        "terseLabel": "Accrued interest receivable excluded from fair value and amortized cost basis of available for sale securities"
       }
      }
     },
     "localname": "InterestReceivable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeNetAmortizationOfDiscountAndPremium": {
     "auth_ref": [
      "r66"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accretion (amortization) of purchase discount (premium) on nonoperating securities.",
        "label": "Investment Income Net Amortization Of Discount And Premium",
        "terseLabel": "Interest income",
        "totalLabel": "Investment Income, Net, Amortization of Discount and Premium, Total"
       }
      }
     },
     "localname": "InvestmentIncomeNetAmortizationOfDiscountAndPremium",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r162",
      "r383"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment Policy [Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Investments": {
     "auth_ref": [
      "r379"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all investments.",
        "label": "Investments",
        "terseLabel": "Carrying value of investment",
        "totalLabel": "Investments, Total"
       }
      }
     },
     "localname": "Investments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesOperatingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases Operating [Abstract]",
        "terseLabel": "Operating Leases"
       }
      }
     },
     "localname": "LeasesOperatingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee Operating Lease Existence Of Option To Extend",
        "terseLabel": "Lessee, operating lease, existence of option to extend [true false]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee Operating Lease Liability Maturity Table [Text Block]",
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r332"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee Operating Lease Liability Payments Due",
        "totalLabel": "Total lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r332"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Next Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r332"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r332"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r332"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee Operating Lease Liability Payments Due Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear": {
     "auth_ref": [
      "r332"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease having initial or remaining lease term in excess of one year to be paid in remainder of current fiscal year.",
        "label": "Lessee Operating Lease Liability Payments Remainder Of Fiscal Year",
        "terseLabel": "2021 (excluding the six months ended June 30, 2021)"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r332"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee Operating Lease Liability Undiscounted Excess Amount",
        "negatedLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseOptionToExtend": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of terms and conditions of option to extend lessee's operating lease. Includes, but is not limited to, information about option recognized as part of right-of-use asset and lease liability.",
        "label": "Lessee Operating Lease Option To Extend",
        "terseLabel": "Lessee, operating lease, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r330"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee Operating Lease Renewal Term",
        "terseLabel": "Lessee, operating lease, renewal term"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r30",
      "r90",
      "r149",
      "r163",
      "r289",
      "r294",
      "r295",
      "r318"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "TOTAL LIABILITIES"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r21",
      "r90",
      "r163",
      "r318",
      "r362",
      "r376"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities And Stockholders Equity",
        "totalLabel": "TOTAL LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities And Stockholders Equity [Abstract]",
        "terseLabel": "LIABILITIES AND STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r33",
      "r90",
      "r163",
      "r289",
      "r294",
      "r295",
      "r318"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities Current [Abstract]",
        "terseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LicenseMember": {
     "auth_ref": [
      "r202"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark.",
        "label": "License [Member]",
        "terseLabel": "License"
       }
      }
     },
     "localname": "LicenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r26"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "totalLabel": "Long-term Investments, Total"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "auth_ref": [
      "r3",
      "r31"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security, classified as current.",
        "label": "Marketable Securities Current",
        "terseLabel": "Short-term investments",
        "totalLabel": "Marketable Securities, Current, Total"
       }
      }
     },
     "localname": "MarketableSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MeasurementInputDiscountRateMember": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using interest rate to determine present value of future cash flows.",
        "label": "Measurement Input Discount Rate [Member]",
        "terseLabel": "Discount Rates"
       }
      }
     },
     "localname": "MeasurementInputDiscountRateMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputPriceVolatilityMember": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.",
        "label": "Measurement Input Price Volatility [Member]",
        "terseLabel": "Measurement Input, Price Volatility"
       }
      }
     },
     "localname": "MeasurementInputPriceVolatilityMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MeasurementInputTypeAxis": {
     "auth_ref": [
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Axis]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MeasurementInputTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input used to determine value of asset and liability.",
        "label": "Measurement Input Type [Domain]",
        "terseLabel": "Measurement Input Type"
       }
      }
     },
     "localname": "MeasurementInputTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided By Used In Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Financing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided By Used In Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Investing Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM INVESTING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r75",
      "r77",
      "r80"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided By Used In Operating Activities",
        "totalLabel": "Net cash provided by (used in) operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided By Used In Operating Activities [Abstract]",
        "terseLabel": "CASH FLOWS FROM OPERATING ACTIVITIES:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r0",
      "r51",
      "r54",
      "r59",
      "r80",
      "r90",
      "r97",
      "r101",
      "r102",
      "r103",
      "r104",
      "r107",
      "r108",
      "r123",
      "r145",
      "r147",
      "r150",
      "r153",
      "r155",
      "r163",
      "r318",
      "r365",
      "r380"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vir.bio/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net income (loss)",
        "verboseLabel": "Net income (loss)"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://www.vir.bio/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing And Financing Items [Abstract]",
        "terseLabel": "NONCASH INVESTING AND FINANCING ACTIVITIES:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "auth_ref": [
      "r65"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).",
        "label": "Nonoperating Income Expense",
        "totalLabel": "Total other income (expense)"
       }
      }
     },
     "localname": "NonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nonoperating Income Expense [Abstract]",
        "terseLabel": "Other income (expense):"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r145",
      "r147",
      "r150",
      "r153",
      "r155"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income Loss",
        "totalLabel": "Income (loss) from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease Liability",
        "totalLabel": "Total operating lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      },
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease Liability Current",
        "terseLabel": "Operating lease liabilities, current",
        "verboseLabel": "Operating lease liabilities, current"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease Liability Current Statement Of Financial Position Extensible List",
        "terseLabel": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible List]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "extensibleListItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r327"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease Liability Noncurrent",
        "terseLabel": "Operating lease liabilities, noncurrent"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetsDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease Right Of Use Asset",
        "terseLabel": "Operating right-of-use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetsDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization Consolidation And Presentation Of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r1",
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization Consolidation And Presentation Of Financial Statements Disclosure [Text Block]",
        "terseLabel": "Organization"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganization"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r7",
      "r8",
      "r9",
      "r32"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities Current",
        "terseLabel": "Other expenses"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssets": {
     "auth_ref": [
      "r13",
      "r360",
      "r371"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets classified as other.",
        "label": "Other Assets",
        "terseLabel": "Other assets",
        "totalLabel": "Other Assets, Total"
       }
      }
     },
     "localname": "OtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsMember": {
     "auth_ref": [
      "r301",
      "r307"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other assets.",
        "label": "Other Assets [Member]",
        "terseLabel": "Other Assets"
       }
      }
     },
     "localname": "OtherAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r52",
      "r55",
      "r286",
      "r287",
      "r292"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent",
        "terseLabel": "Other comprehensive income (loss)",
        "totalLabel": "Other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited",
      "http://www.vir.bio/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax": {
     "auth_ref": [
      "r45",
      "r48",
      "r49",
      "r213"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income Loss Reclassification Adjustment From A O C I Pension And Other Postretirement Benefit Plans For Net Gain Loss Net Of Tax",
        "negatedLabel": "Amortization of actuarial loss"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r43",
      "r45"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax",
        "terseLabel": "Unrealized gain (loss) on investments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/StatementCondensedConsolidatedStatementsOfComprehensiveIncomeLossUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherExpenseMember": {
     "auth_ref": [
      "r306"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other expense.",
        "label": "Other Expense [Member]",
        "terseLabel": "Other Expense"
       }
      }
     },
     "localname": "OtherExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r34"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities Noncurrent",
        "terseLabel": "Other long-term liabilities",
        "totalLabel": "Other Liabilities, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income Expense",
        "terseLabel": "Other income (expense), net",
        "totalLabel": "Other Nonoperating Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example,  cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).",
        "label": "Other Operating Activities Cash Flow Statement",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRoyalties": {
     "auth_ref": [
      "r76"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid for royalties during the current period.",
        "label": "Payments for Royalties",
        "terseLabel": "Royalties"
       }
      }
     },
     "localname": "PaymentsForRoyalties",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments Of Stock Issuance Costs",
        "terseLabel": "Offering expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireInvestments": {
     "auth_ref": [
      "r71"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the purchase of all investments (debt, security, other) during the period.",
        "label": "Payments To Acquire Investments",
        "negatedLabel": "Purchases of investments",
        "totalLabel": "Payments to Acquire Investments, Total"
       }
      }
     },
     "localname": "PaymentsToAcquireInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r70"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments To Acquire Property Plant And Equipment",
        "negatedLabel": "Purchases of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock Par Or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock Shares Issued",
        "terseLabel": "Preferred stock, shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnauditedParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r14"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock Value",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock, $0.0001 par value; 10,000,000 shares authorized as of June 30, 2021 and December 31, 2020; no shares issued and outstanding as of June 30, 2021 and December 31, 2020",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r4",
      "r23",
      "r24"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense And Other Assets Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpensesAndOtherCurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing prepaid expenses and other current assets.",
        "label": "Prepaid Expenses And Other Current Assets [Member]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r72"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds From Issuance Of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionsOfInvestments": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the sale, maturity and collection of all investments such as debt, security and so forth during the period.",
        "label": "Proceeds From Sale Maturity And Collections Of Investments",
        "terseLabel": "Maturities of investments",
        "totalLabel": "Proceeds from Sale, Maturity and Collection of Investments, Total"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionsOfInvestments",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyHeldForSale": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of formerly productive land held for sale, anything permanently fixed to it, including buildings, structures on it, and so forth.",
        "label": "Proceeds From Sale Of Property Held For Sale",
        "terseLabel": "Proceeds from disposal of an asset held for sale"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyHeldForSale",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r72",
      "r248"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds From Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r0",
      "r51",
      "r54",
      "r74",
      "r90",
      "r97",
      "r107",
      "r108",
      "r145",
      "r147",
      "r150",
      "r153",
      "r155",
      "r163",
      "r286",
      "r290",
      "r291",
      "r296",
      "r297",
      "r318",
      "r369"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Profit Loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r28",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property Plant And Equipment By Type [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r27",
      "r185"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Property and equipment, gross",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property Plant And Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r11",
      "r12",
      "r187",
      "r377"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property Plant And Equipment Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Total property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r11",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property Plant And Equipment [Text Block]",
        "terseLabel": "Schedule of Property and Equipment Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r11",
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property Plant And Equipment Type [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r333",
      "r334",
      "r335",
      "r336",
      "r337"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureRelatedPartyTransaction"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r262",
      "r415"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research And Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research And Development Expense [Member]",
        "terseLabel": "Research and Development Expense"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r2",
      "r10",
      "r81",
      "r86"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents At Carrying Value",
        "terseLabel": "Restricted cash and cash equivalents, current",
        "totalLabel": "Restricted Cash and Cash Equivalents, Current, Total"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsNoncurrent": {
     "auth_ref": [
      "r6",
      "r13",
      "r81",
      "r86",
      "r405"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash And Cash Equivalents Noncurrent",
        "terseLabel": "Restricted cash and cash equivalents, noncurrent",
        "totalLabel": "Restricted Cash and Cash Equivalents, Noncurrent, Total"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedCashEquivalents": {
     "auth_ref": [
      "r86",
      "r358",
      "r373"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash equivalents restricted as to withdrawal or usage. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Restricted Cash Equivalents",
        "terseLabel": "Restricted cash equivalents",
        "totalLabel": "Restricted Cash Equivalents, Total"
       }
      }
     },
     "localname": "RestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "verboseLabel": "Restricted Shares Subject to Future Vesting"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units R S U [Member]",
        "terseLabel": "Restricted Stock Units (RSUs)",
        "verboseLabel": "RSUs"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r195",
      "r256",
      "r375",
      "r397",
      "r402"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings Accumulated Deficit",
        "negatedLabel": "Accumulated deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r98",
      "r106",
      "r108",
      "r167",
      "r253",
      "r254",
      "r255",
      "r268",
      "r269",
      "r393",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r141",
      "r142",
      "r146",
      "r151",
      "r152",
      "r156",
      "r157",
      "r159",
      "r199",
      "r200",
      "r351"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue From Contract With Customer Excluding Assessed Tax",
        "terseLabel": "Total revenue",
        "totalLabel": "Revenue from Contract with Customer, Excluding Assessed Tax, Total"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueNotFromContractWithCustomer": {
     "auth_ref": [
      "r57"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_Revenues",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue that is not accounted for under Topic 606.",
        "label": "Revenue Not From Contract With Customer",
        "terseLabel": "Total revenue",
        "verboseLabel": "Revenue from grants"
       }
      }
     },
     "localname": "RevenueNotFromContractWithCustomer",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r88",
      "r89"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue Recognition Policy [Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Revenues": {
     "auth_ref": [
      "r57",
      "r90",
      "r141",
      "r142",
      "r146",
      "r151",
      "r152",
      "r156",
      "r157",
      "r159",
      "r163",
      "r318",
      "r369"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).",
        "label": "Revenues",
        "totalLabel": "Total revenue"
       }
      }
     },
     "localname": "Revenues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenuesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenues [Abstract]",
        "terseLabel": "Revenues:"
       }
      }
     },
     "localname": "RevenuesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SalariesWagesAndOfficersCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Salaries Wages And Officers Compensation [Abstract]"
       }
      }
     },
     "localname": "SalariesWagesAndOfficersCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale Of Stock Name Of Transaction [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale Of Stock Price Per Share",
        "terseLabel": "Common stock price per share"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r127"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Not Included in the Diluted Per Share Calculations"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r273",
      "r274"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule Of Business Acquisitions By Acquisition [Table]",
        "terseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block]",
        "terseLabel": "Summary of Stock-based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r126"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Net Income (loss) Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r229"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule Of Nonvested Restricted Stock Units Activity Table [Text Block]",
        "terseLabel": "Summary of Restricted Stock Activity and Restricted Stock Units"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r28",
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Schedule Of Property Plant And Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r222",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityAndRestrictedStockUnitsDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r224",
      "r234",
      "r235"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]",
        "terseLabel": "Summary of Stock Option Plans Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]",
        "terseLabel": "Summary of Assumptions Used for Estimating the Fair Value of Stock Options Granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r64"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "terseLabel": "Selling, general and administrative",
        "totalLabel": "Selling, General and Administrative Expense, Total"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share Based Compensation",
        "terseLabel": "Stock-based compensation",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period",
        "negatedLabel": "Number of Shares, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period",
        "terseLabel": "Number of Shares, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r231"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number",
        "periodEndLabel": "Number of Shares, Unvested, Ending Balance",
        "periodStartLabel": "Number of Shares, Unvested, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Weighted Average Grant Date Fair Value, Ending Balance",
        "periodStartLabel": "Weighted Average Grant Date Fair Value, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period",
        "negatedLabel": "Number of Shares, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r232"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, Vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r240"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum",
        "terseLabel": "Expected stock price volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum",
        "terseLabel": "Expected stock price volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityAndRestrictedStockUnitsDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockBasedCompensationExpenseDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r228"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period",
        "negatedLabel": "Number of Options,Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross",
        "terseLabel": "Number of Options,Granted",
        "verboseLabel": "Options to purchase common stock"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r247"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r226",
      "r247"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number",
        "periodEndLabel": "Number of Options,Outstanding, Ending Balance",
        "periodStartLabel": "Number of Options,Outstanding, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r225"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price",
        "periodEndLabel": "Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Weighted Average Exercise Price, Beginning Balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Number",
        "terseLabel": "Number of Options,Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price,Vested and exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r235"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number",
        "terseLabel": "Number of Options,Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price,Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r220",
      "r223"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityAndRestrictedStockUnitsDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Forfeited"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted Average Exercise Price, Granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share purchase price per share"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r239",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1",
        "terseLabel": "Expected term of options (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfAssumptionsUsedForEstimatingFairValueOfStockOptionsGrantedDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2",
        "terseLabel": "Weighted Average Remaining Contractual Term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r237"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Remaining Contractual Term,Vested and exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1",
        "terseLabel": "Weighted Average Remaining Contractual Term,Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r93"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r36",
      "r94",
      "r95",
      "r96",
      "r98",
      "r106",
      "r108",
      "r133",
      "r167",
      "r194",
      "r195",
      "r253",
      "r254",
      "r255",
      "r268",
      "r269",
      "r320",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r393",
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Statement Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsTables",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement Of Stockholders Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r94",
      "r95",
      "r96",
      "r133",
      "r351"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsTables",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r194",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period Shares New Issues",
        "verboseLabel": "Issuance of common stock, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r194",
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Stock Issued During Period Shares Restricted Stock Award Gross",
        "verboseLabel": "Vesting of restricted common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r194",
      "r195",
      "r227"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Stock Issued During Period Shares Stock Options Exercised",
        "negatedLabel": "Number of Options,Exercised",
        "terseLabel": "Exercise of stock option (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfStockOptionPlansActivityDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r194",
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period Value New Issues",
        "terseLabel": "Gross proceeds from the offering",
        "verboseLabel": "Issuance of common stock, value"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r14",
      "r15",
      "r194",
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Stock Issued During Period Value Restricted Stock Award Gross",
        "terseLabel": "Vesting of restricted common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r36",
      "r194",
      "r195"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period Value Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r19",
      "r20",
      "r90",
      "r160",
      "r163",
      "r318"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders Equity",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "TOTAL STOCKHOLDERS\u2019 EQUITY"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders Equity [Abstract]",
        "terseLabel": "STOCKHOLDERS\u2019 EQUITY:"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedBalanceSheetsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r338",
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Subsidiary Sale Of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalBalanceSheetDisclosuresTextBlock": {
     "auth_ref": [
      "r42"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for supplemental balance sheet disclosures, including descriptions and amounts for assets, liabilities, and equity.",
        "label": "Supplemental Balance Sheet Disclosures [Text Block]",
        "terseLabel": "Balance Sheet Components"
       }
      }
     },
     "localname": "SupplementalBalanceSheetDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r97",
      "r98",
      "r99",
      "r100",
      "r164",
      "r165",
      "r166",
      "r167",
      "r168",
      "r169",
      "r249",
      "r250",
      "r251",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r266",
      "r267",
      "r268",
      "r269",
      "r353",
      "r354",
      "r355",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Type Of Adoption [Member]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Type Of Arrangement [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r206",
      "r214",
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "U S Treasury Securities [Member]",
        "terseLabel": "U.S. Government Treasuries"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use Of Estimates",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Incremental Weighted Average Shares Attributable to Dilutive Effect [Abstract]"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r110",
      "r126"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average share outstanding, diluted",
        "totalLabel": "Weighted-average shares outstanding, diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number Of Share Outstanding Basic And Diluted",
        "terseLabel": "Weighted-average shares outstanding, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r109",
      "r126"
     ],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average shares outstanding, basic",
        "totalLabel": "Weighted Average Number of Shares Outstanding, Basic, Total"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2020-01-31",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_AccruedLiabilitiesAndOtherLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued Liabilities And Other Liabilities.",
        "label": "Accrued Liabilities And Other Liabilities [Member]",
        "terseLabel": "Accrued and Other Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilitiesMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_AgenovirCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agenovir Corporation.",
        "label": "Agenovir Corporation [Member]",
        "terseLabel": "Agenovir"
       }
      }
     },
     "localname": "AgenovirCorporationMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_AggregateValueOfCommonStockToBeIssued": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of common stock to be issued under the Stock Purchase Agreement.",
        "label": "Aggregate Value Of Common Stock To Be Issued",
        "verboseLabel": "Common stock to be issued, value"
       }
      }
     },
     "localname": "AggregateValueOfCommonStockToBeIssued",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_AlnylamAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alnylam agreement.",
        "label": "Alnylam Agreement [Member]",
        "terseLabel": "Alnylam Agreement"
       }
      }
     },
     "localname": "AlnylamAgreementMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_AlnylamPharmaceuticalsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Alnylam Pharmaceuticals, Inc.",
        "label": "Alnylam Pharmaceuticals Inc [Member]",
        "terseLabel": "Alnylam Pharmaceuticals Inc"
       }
      }
     },
     "localname": "AlnylamPharmaceuticalsIncMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_AnotherProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Another product.",
        "label": "Another Product [Member]",
        "terseLabel": "Another Product"
       }
      }
     },
     "localname": "AnotherProductMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_AntibodyLicenseTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction price for the Antibody License under the collaboration agreement",
        "label": "Antibody License Transaction Price",
        "terseLabel": "Antibody license transaction price"
       }
      }
     },
     "localname": "AntibodyLicenseTransactionPrice",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_AntibodyProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Antibody Program.",
        "label": "Antibody Program [Member]",
        "terseLabel": "Antibody Program"
       }
      }
     },
     "localname": "AntibodyProgramMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_AssetAcquisitionContingentConsiderationLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in an asset acquisition.",
        "label": "Asset Acquisition Contingent Consideration Liability",
        "terseLabel": "Estimated fair value of contingent consideration"
       }
      }
     },
     "localname": "AssetAcquisitionContingentConsiderationLiability",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_BillAndMelindaGatesFoundationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Bill &amp; Melinda Gates Foundation.",
        "label": "Bill And Melinda Gates Foundation [Member]",
        "terseLabel": "Bill And Melinda Gates Foundation"
       }
      }
     },
     "localname": "BillAndMelindaGatesFoundationMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_BiologicalMaterialsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Biological materials.",
        "label": "Biological Materials [Member]",
        "terseLabel": "Biological Materials"
       }
      }
     },
     "localname": "BiologicalMaterialsMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_BriiAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Brii Agreement.",
        "label": "Brii Agreement [Member]",
        "terseLabel": "Brii Agreement"
       }
      }
     },
     "localname": "BriiAgreementMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_BriiBioParentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Brii Bio Parent.",
        "label": "Brii Bio Parent [Member]",
        "terseLabel": "Brii Bio Parent"
       }
      }
     },
     "localname": "BriiBioParentMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_BriiBiosciencesOffshoreLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Brii Biosciences Offshore Limited.",
        "label": "Brii Biosciences Offshore Limited [Member]",
        "terseLabel": "Brii Bio"
       }
      }
     },
     "localname": "BriiBiosciencesOffshoreLimitedMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition number of milestones achieved related to contingent consideration.",
        "label": "Business Acquisition Number Of Milestones Achieved Related To Contingent Consideration",
        "terseLabel": "Number of milestones achieved"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfMilestonesAchievedRelatedToContingentConsideration",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vir_BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business acquisition number of specified clinical milestones achieved.",
        "label": "Business Acquisition Number Of Specified Clinical Milestones Achieved",
        "terseLabel": "Number of specified clinical milestones achieved"
       }
      }
     },
     "localname": "BusinessAcquisitionNumberOfSpecifiedClinicalMilestonesAchieved",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vir_BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combinations additional consideration payable upon achievement of specified events.",
        "label": "Business Combinations Additional Consideration Payable Upon Achievement Of Specified Events",
        "terseLabel": "Additional consideration payable upon achievement of specified milestone events, maximum"
       }
      }
     },
     "localname": "BusinessCombinationsAdditionalConsiderationPayableUponAchievementOfSpecifiedEvents",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ChangeInEstimatedFairValueOfContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in estimated fair value of contingent consideration.",
        "label": "Change In Estimated Fair Value Of Contingent Consideration",
        "terseLabel": "Change in estimated fair value of contingent consideration"
       }
      }
     },
     "localname": "ChangeInEstimatedFairValueOfContingentConsideration",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ChangeInFairValueOfMilestoneShares": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value of milestone shares.",
        "label": "Change In Fair Value Of Milestone Shares",
        "terseLabel": "Change in fair value of Milestone Shares"
       }
      }
     },
     "localname": "ChangeInFairValueOfMilestoneShares",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ClinicalAndRegulatoryMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical and regulatory milestones [Member]",
        "label": "Clinical And Regulatory Milestones [Member]",
        "terseLabel": "Clinical and Regulatory Milestones"
       }
      }
     },
     "localname": "ClinicalAndRegulatoryMilestonesMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_ClinicalDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Clinical Development [Member]",
        "label": "Clinical Development"
       }
      }
     },
     "localname": "ClinicalDevelopmentMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_CollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement.",
        "label": "Collaboration Agreement [Member]",
        "terseLabel": "Collaboration Agreement"
       }
      }
     },
     "localname": "CollaborationAgreementMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement, number of separate programs agreed to collaborate.",
        "label": "Collaboration Agreement Number Of Separate Programs Agreed To Collaborate",
        "terseLabel": "Number of separate programs"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfSeparateProgramsAgreedToCollaborate",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vir_CollaborationAgreementNumberOfUnitsOfAccount": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement, number of units of account.",
        "label": "Collaboration Agreement Number Of Units Of Account",
        "terseLabel": "Number of units of account"
       }
      }
     },
     "localname": "CollaborationAgreementNumberOfUnitsOfAccount",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "vir_CollaborationAgreementPercentageOfUpfrontFee": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement, percentage of upfront fee.",
        "label": "Collaboration Agreement Percentage Of Upfront Fee",
        "terseLabel": "Percentage of upfront fee"
       }
      }
     },
     "localname": "CollaborationAgreementPercentageOfUpfrontFee",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_CollaborationAgreementRelatedCostsAndExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Costs and expenses for the period incurred under the collaboration agreements.",
        "label": "Collaboration Agreement Related Costs And Expenses",
        "terseLabel": "Expenses incurred under agreement"
       }
      }
     },
     "localname": "CollaborationAgreementRelatedCostsAndExpenses",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_CollaborationAgreementRemainingUpfrontFee": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement, remaining upfront fee.",
        "label": "Collaboration Agreement Remaining Upfront Fee",
        "terseLabel": "Remaining upfront fee"
       }
      }
     },
     "localname": "CollaborationAgreementRemainingUpfrontFee",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_CollaborationAgreementTerminationDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement termination description.",
        "label": "Collaboration Agreement Termination Description",
        "terseLabel": "Termination description"
       }
      }
     },
     "localname": "CollaborationAgreementTerminationDescription",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_CollaborationAgreementTransactionPriceConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement transaction price consideration.",
        "label": "Collaboration Agreement Transaction Price Consideration",
        "terseLabel": "Consideration"
       }
      }
     },
     "localname": "CollaborationAgreementTransactionPriceConsideration",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_CollaborationAgreementTransactionPriceFixedConsideration": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration agreement, transaction price fixed consideration.",
        "label": "Collaboration Agreement Transaction Price Fixed Consideration",
        "terseLabel": "Fixed consideration"
       }
      }
     },
     "localname": "CollaborationAgreementTransactionPriceFixedConsideration",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_CollaborationRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaboration revenue.",
        "label": "Collaboration Revenue [Member]",
        "terseLabel": "Collaboration Revenue"
       }
      }
     },
     "localname": "CollaborationRevenueMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_CommercialMilestonesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial milestones.",
        "label": "Commercial Milestones [Member]",
        "terseLabel": "Commercial Milestones"
       }
      }
     },
     "localname": "CommercialMilestonesMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_CommercializationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercialization.",
        "label": "Commercialization [Member]",
        "terseLabel": "Commercialization"
       }
      }
     },
     "localname": "CommercializationMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_CommitmentsAndContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Line Items]",
        "terseLabel": "Commitments And Contingencies [Line Items]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesLineItems",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_CommitmentsAndContingenciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commitments and contingencies.",
        "label": "Commitments And Contingencies [Table]",
        "terseLabel": "Commitments And Contingencies [Table]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesTable",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_CommonStockSharesIssuedForMilestonePaymentShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares issued for milestone payment.",
        "label": "Common stock shares Issued for milestone payment| shares"
       }
      }
     },
     "localname": "CommonStockSharesIssuedForMilestonePaymentShares",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Concentration of credit risk credit loss and other risks and uncertainties.",
        "label": "Concentration Of Credit Risk Credit Loss And Other Risks And Uncertainties Policy [Text Block]",
        "terseLabel": "Concentration of Credit Risk, Credit Loss and Other Risks and Uncertainties"
       }
      }
     },
     "localname": "ConcentrationOfCreditRiskCreditLossAndOtherRisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vir_ContingentConsiderationLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent consideration liability",
        "label": "Contingent Consideration Liability [Member]",
        "terseLabel": "Contingent Consideration Liability"
       }
      }
     },
     "localname": "ContingentConsiderationLiabilityMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_ContingentlyIssuableSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingently issuable shares member.",
        "label": "Contingently Issuable Shares [Member]",
        "terseLabel": "Contingently issuable shares"
       }
      }
     },
     "localname": "ContingentlyIssuableSharesMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_ContractRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract revenue.",
        "label": "Contract Revenue [Member]",
        "terseLabel": "Contract Revenue [Member]",
        "verboseLabel": "Contract Revenue"
       }
      }
     },
     "localname": "ContractRevenueMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfOperationsUnaudited"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_ContractualPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual payments.",
        "label": "Contractual Payments",
        "terseLabel": "Contractual payments"
       }
      }
     },
     "localname": "ContractualPayments",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred offering costs in accounts payable and accrued liabilities.",
        "label": "Deferred Offering Costs In Accounts Payable And Accrued Liabilities",
        "terseLabel": "Deferred offering costs in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "DeferredOfferingCostsInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_DefinitiveCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Definitive collaboration agreement.",
        "label": "Definitive Collaboration Agreement [Member]",
        "terseLabel": "Definitive Collaboration Agreement"
       }
      }
     },
     "localname": "DefinitiveCollaborationAgreementMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_DeterminedTransactionPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Determined transaction price.",
        "label": "Determined Transaction Price",
        "terseLabel": "Determined transaction price"
       }
      }
     },
     "localname": "DeterminedTransactionPrice",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_DevelopmentAndManufacturingCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development and manufacturing collaboration agreement.",
        "label": "Development And Manufacturing Collaboration Agreement [Member]",
        "terseLabel": "Development and Manufacturing Collaboration Agreement"
       }
      }
     },
     "localname": "DevelopmentAndManufacturingCollaborationAgreementMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_DevelopmentRegulatoryAndCommercialMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development regulatory and commercial milestone payments.",
        "label": "Development Regulatory And Commercial Milestone Payments",
        "terseLabel": "Development, regulatory, and commercial milestone payments"
       }
      }
     },
     "localname": "DevelopmentRegulatoryAndCommercialMilestonePayments",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_DevelopmentRegulatoryAndCommercialMilestonePaymentsMaximumAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Development, regulatory, and commercial milestone payments maximum amount.",
        "label": "Development Regulatory And Commercial Milestone Payments Maximum Amount",
        "terseLabel": "Development, regulatory, and commercial milestone payments maximum amount"
       }
      }
     },
     "localname": "DevelopmentRegulatoryAndCommercialMilestonePaymentsMaximumAmount",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_EachInfectiousDiseaseSiRNAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Each infectious disease siRNA.",
        "label": "Each Infectious Disease Si R N A [Member]",
        "terseLabel": "Each Infectious Disease siRNA"
       }
      }
     },
     "localname": "EachInfectiousDiseaseSiRNAMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_EstimatedSharesIssuableUnderTheESPPMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated Shares Issuable Under the E S P P [Member]",
        "label": "Estimated Shares Issuable Under the E S P P [Member]",
        "terseLabel": "Estimated shares issuable under the ESPP"
       }
      }
     },
     "localname": "EstimatedSharesIssuableUnderTheESPPMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_ExcessFundsPayableUnderGrantAgreementsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess funds payable under grant agreements current.",
        "label": "Excess Funds Payable Under Grant Agreements Current",
        "terseLabel": "Excess funds payable under grant agreements"
       }
      }
     },
     "localname": "ExcessFundsPayableUnderGrantAgreementsCurrent",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FairMarketValueOfCommonStockIssued": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair market value of common stock issued.",
        "label": "Fair Market Value Of Common Stock Issued",
        "terseLabel": "Fair market value of the common stock issued"
       }
      }
     },
     "localname": "FairMarketValueOfCommonStockIssued",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value, reclassification of contingent consideration to accrued liabilities upon achievement of milestone.",
        "label": "Fair Value Reclassification Of Contingent Consideration To Accrued Liabilities Upon Achievement Of Milestone",
        "terseLabel": "Reclassification of contingent consideration to accrued liabilities upon achievement of milestone"
       }
      }
     },
     "localname": "FairValueReclassificationOfContingentConsiderationToAccruedLiabilitiesUponAchievementOfMilestone",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsSummaryOfChangesInEstimatedFairValueOfFinancialLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FinancialAssetsAmortizedCostBasis": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial assets amortized cost basis.",
        "label": "Financial Assets Amortized Cost Basis",
        "terseLabel": "Financial Assets, Amortized Cost",
        "totalLabel": "Financial Assets, Amortized Cost"
       }
      }
     },
     "localname": "FinancialAssetsAmortizedCostBasis",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FinancialAssetsFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial assets fair value.",
        "label": "Financial Assets Fair Value",
        "terseLabel": "Financial Assets, Aggregate Fair Value"
       }
      }
     },
     "localname": "FinancialAssetsFairValue",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FinancialAssetsGrossUnrealizedHoldingGains": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial assets gross unrealized holding gains.",
        "label": "Financial Assets Gross Unrealized Holding Gains",
        "terseLabel": "Financial Assets, Gross Unrealized Holding Gains"
       }
      }
     },
     "localname": "FinancialAssetsGrossUnrealizedHoldingGains",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FinancialAssetsGrossUnrealizedHoldingLosses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial assets gross unrealized holding losses.",
        "label": "Financial Assets Gross Unrealized Holding Losses",
        "negatedLabel": "Financial Assets, Gross Unrealized Holding Losses"
       }
      }
     },
     "localname": "FinancialAssetsGrossUnrealizedHoldingLosses",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsFinancialAssetsMeasuredAtFairValueOnRecurringBasisByLevelWithinFairValueHierarchyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_FirstInfectiousDiseaseProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First infectious disease product.",
        "label": "First Infectious Disease Product [Member]",
        "terseLabel": "First Infectious Disease Product"
       }
      }
     },
     "localname": "FirstInfectiousDiseaseProductMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_FirstSiRNAProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First siRNA product member.",
        "label": "First Si R N A Product [Member]",
        "terseLabel": "First siRNA product"
       }
      }
     },
     "localname": "FirstSiRNAProductMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_FollowOnOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Follow-on offering.",
        "label": "Follow On Offering [Member]",
        "terseLabel": "Follow-on Offering"
       }
      }
     },
     "localname": "FollowOnOfferingMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_GlaxoGroupLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glaxo Group Limited.",
        "label": "Glaxo Group Limited [Member]",
        "terseLabel": "GGL"
       }
      }
     },
     "localname": "GlaxoGroupLimitedMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "GlaxoSmithKline Intellectual Property Development Limited and GlaxoSmithKline Biologicals SA.",
        "label": "Glaxo Smith Kline Intellectual Property Development Limited And Glaxo Smith Kline Biologicals S A [Member]",
        "terseLabel": "GSK"
       }
      }
     },
     "localname": "GlaxoSmithKlineIntellectualPropertyDevelopmentLimitedAndGlaxoSmithKlineBiologicalsSAMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_GlaxoSmithKlineTradingServiceLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Glaxo SmithKline Trading Service Limited.",
        "label": "Glaxo Smith Kline Trading Service Limited [Member]",
        "terseLabel": "GSKTSL"
       }
      }
     },
     "localname": "GlaxoSmithKlineTradingServiceLimitedMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_GrantAgreementAmendedExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant agreement amended expiration date.",
        "label": "Grant Agreement Expiration Date",
        "terseLabel": "Grant agreement amended expiration date"
       }
      }
     },
     "localname": "GrantAgreementAmendedExpirationDate",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "vir_GrantAgreementsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant agreements disclosure.",
        "label": "Grant Agreements Disclosure [Text Block]",
        "terseLabel": "Grant Agreements"
       }
      }
     },
     "localname": "GrantAgreementsDisclosureTextBlock",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vir_GrantAwardedAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant awarded amount.",
        "label": "Grant Awarded Amount",
        "terseLabel": "Grant awarded amount"
       }
      }
     },
     "localname": "GrantAwardedAmount",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_GrantAwardedAmountMaximum": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum grant awarded amount.",
        "label": "Grant Awarded Amount Maximum",
        "terseLabel": "Grant awarded amount. maximum"
       }
      }
     },
     "localname": "GrantAwardedAmountMaximum",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_HBVProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HBV program.",
        "label": "H B V Program [Member]",
        "terseLabel": "HBV Program"
       }
      }
     },
     "localname": "HBVProgramMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_HBVResearchProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "HBV research programs.",
        "label": "H B V Research Programs [Member]",
        "terseLabel": "HBV Research Programs"
       }
      }
     },
     "localname": "HBVResearchProgramsMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_HepatitisBVirusProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Hepatitis B Virus Product Member.",
        "label": "Hepatitis B Virus Product [Member]",
        "terseLabel": "HBV Product"
       }
      }
     },
     "localname": "HepatitisBVirusProductMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_HumabsBiomedSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Humabs Biomed SA.",
        "label": "Humabs Biomed S A [Member]",
        "terseLabel": "Humabs"
       }
      }
     },
     "localname": "HumabsBiomedSAMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_HumanImmunodeficiencyVirusGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Human immunodeficiency virus grant.",
        "label": "Human Immunodeficiency Virus Grant [Member]",
        "terseLabel": "Human Immunodeficiency Virus ('HIV') Grant"
       }
      }
     },
     "localname": "HumanImmunodeficiencyVirusGrantMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liabilities.",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in payment of contingent consideration in excess of acquisition date fair value.",
        "label": "Increase Decrease In Payment Of Contingent Consideration In Excess Of Acquisition Date Fair Value",
        "terseLabel": "Payment of contingent consideration in excess of acquisition date fair value"
       }
      }
     },
     "localname": "IncreaseDecreaseInPaymentOfContingentConsiderationInExcessOfAcquisitionDateFairValue",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_IncreaseDecreaseInResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase (decrease) in research And development expense.",
        "label": "Increase Decrease In Research And Development Expense",
        "terseLabel": "Additional research and development expense"
       }
      }
     },
     "localname": "IncreaseDecreaseInResearchAndDevelopmentExpense",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional shares included in the calculation of diluted EPS as a result of the potentially dilutive effect of restricted shares subject to future vesting using the treasury stock method.",
        "label": "Incremental Common Shares Attributable To Dilutive Effect Of Restricted Share Subject To Future Vesting",
        "terseLabel": "Restricted shares subject to future vesting"
       }
      }
     },
     "localname": "IncrementalCommonSharesAttributableToDilutiveEffectOfRestrictedShareSubjectToFutureVesting",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_InfluenzaAAndHBVResearchProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Influenza A and HBV research programs member.",
        "label": "Influenza A And H B V Research Programs [Member]",
        "terseLabel": "Influenza A and HBV Research Programs"
       }
      }
     },
     "localname": "InfluenzaAAndHBVResearchProgramsMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_InfluenzaAAndInfluenzaBMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Influenza A and Influenza B member.",
        "label": "Influenza A And Influenza B [Member]",
        "terseLabel": "Influenza A and Influenza B"
       }
      }
     },
     "localname": "InfluenzaAAndInfluenzaBMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_InfluenzaAResearchProgramsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Influenza A research programs.",
        "label": "Influenza A Research Programs [Member]",
        "terseLabel": "Influenza A Research Programs"
       }
      }
     },
     "localname": "InfluenzaAResearchProgramsMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory equipment.",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_LeaseArrangementContractualExpirationBeginningYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease arrangement, contractual expiration beginning year.",
        "label": "Lease Arrangement Contractual Expiration Beginning Year",
        "terseLabel": "Lease arrangement, contractual expiration period, beginning year"
       }
      }
     },
     "localname": "LeaseArrangementContractualExpirationBeginningYear",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "vir_LeaseArrangementContractualExpirationEndingYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease arrangement, contractual expiration ending year.",
        "label": "Lease Arrangement Contractual Expiration Ending Year",
        "terseLabel": "Lease arrangement, contractual expiration period, ending year"
       }
      }
     },
     "localname": "LeaseArrangementContractualExpirationEndingYear",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "gYearItemType"
    },
    "vir_LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability net tenant improvement allowance yet to be received.",
        "label": "Lessee Operating Lease Liability Net Tenant Improvement Allowance Yet To Be Received",
        "negatedLabel": "Less: net tenant improvement allowance yet to be received"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityNetTenantImprovementAllowanceYetToBeReceived",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lessee operating lease liability payments due after year four.",
        "label": "Lessee Operating Lease Liability Payments Due After Year Four",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_LetterAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Letter agreement.",
        "label": "Letter Agreement [Member]",
        "terseLabel": "TomegaVax Letter Agreement"
       }
      }
     },
     "localname": "LetterAgreementMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_LicenseAgreementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement upfront payment.",
        "label": "License Agreement Upfront Payment",
        "terseLabel": "License agreement upfront payment"
       }
      }
     },
     "localname": "LicenseAgreementUpfrontPayment",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_LicenseMaintenanceFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License maintenance fees.",
        "label": "License Maintenance Fees",
        "terseLabel": "License maintenance fees"
       }
      }
     },
     "localname": "LicenseMaintenanceFees",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_LicensedPatentsExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensed patents expiration period.",
        "label": "Licensed Patents Expiration Period",
        "terseLabel": "Licensed patents expiration period"
       }
      }
     },
     "localname": "LicensedPatentsExpirationPeriod",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_LicensedProductByLicensedProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licensed product-by-licensed product.",
        "label": "Licensed Product By Licensed Product [Member]",
        "terseLabel": "Licensed Product-By-Licensed Product"
       }
      }
     },
     "localname": "LicensedProductByLicensedProductMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_MaximumAggregateCommercialSalesMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate commercial sales milestone payments.",
        "label": "Maximum Aggregate Commercial Sales Milestone Payments",
        "terseLabel": "Maximum aggregate commercial sales milestone payments"
       }
      }
     },
     "localname": "MaximumAggregateCommercialSalesMilestonePayments",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumAggregateDevelopmentAndRegulatoryMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate development and regulatory milestone payments.",
        "label": "Maximum Aggregate Development And Regulatory Milestone Payments",
        "terseLabel": "Maximum aggregate development and regulatory milestone payments"
       }
      }
     },
     "localname": "MaximumAggregateDevelopmentAndRegulatoryMilestonePayments",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumAggregateMilestonePayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate milestone payments.",
        "label": "Maximum Aggregate Milestone Payments",
        "terseLabel": "Maximum aggregate milestone payments"
       }
      }
     },
     "localname": "MaximumAggregateMilestonePayments",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumAggregateSalesMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate milestone payment for achievement of specified annual net sales",
        "label": "Maximum Aggregate Sales Milestone Payment",
        "terseLabel": "Maximum aggregate sales milestone payment"
       }
      }
     },
     "localname": "MaximumAggregateSalesMilestonePayment",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum milestone payment for achievement of specified development and regulatory.",
        "label": "Maximum Milestone Payment For Achievement Of Specified Development And Regulatory",
        "terseLabel": "Maximum milestone payment for achievement of specified development and regulatory"
       }
      }
     },
     "localname": "MaximumMilestonePaymentForAchievementOfSpecifiedDevelopmentAndRegulatory",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of right to perform details in connection with antibody product.",
        "label": "Maximum Percentage Of Right To Perform Details In Connection With Antibody Product",
        "terseLabel": "Maximum percentage of right to perform details in connection with antibody product"
       }
      }
     },
     "localname": "MaximumPercentageOfRightToPerformDetailsInConnectionWithAntibodyProduct",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_MaximumSalesMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum milestone payment for achievement of specified annual net sales.",
        "label": "Maximum Sales Milestone Payment",
        "terseLabel": "Maximum sales milestone payment"
       }
      }
     },
     "localname": "MaximumSalesMilestonePayment",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MaximumSharesToBeIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum shares to be issued.",
        "label": "Maximum Shares To Be Issued",
        "terseLabel": "Maximum shares to be issued"
       }
      }
     },
     "localname": "MaximumSharesToBeIssued",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_MeasurementInputExpectedRevenueVolatilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input expected revenue volatility.",
        "label": "Measurement Input Expected Revenue Volatility [Member]",
        "terseLabel": "Volatility"
       }
      }
     },
     "localname": "MeasurementInputExpectedRevenueVolatilityMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_MeasurementInputProbabilityRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement input, probability rate.",
        "label": "Measurement Input Probability Rate [Member]",
        "terseLabel": "Probability of Achievement"
       }
      }
     },
     "localname": "MeasurementInputProbabilityRateMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_MedImmuneAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MedImmune agreement.",
        "label": "Med Immune Agreement [Member]",
        "terseLabel": "MedImmune Agreement"
       }
      }
     },
     "localname": "MedImmuneAgreementMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_MedImmuneLimitedLiabilityCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "MedImmune, limited liability company.",
        "label": "Med Immune Limited Liability Company [Member]",
        "terseLabel": "MedImmune"
       }
      }
     },
     "localname": "MedImmuneLimitedLiabilityCompanyMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_MilestonePayable": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payable.",
        "label": "Milestone Payable",
        "terseLabel": "Milestone payable"
       }
      }
     },
     "localname": "MilestonePayable",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MilestonePaymentsPaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments paid.",
        "label": "Milestone Payments Paid",
        "terseLabel": "Milestone payments paid."
       }
      }
     },
     "localname": "MilestonePaymentsPaid",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_MilestonePaymentsRelatedTermsDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone payments related terms description.",
        "label": "Milestone Payments Related Terms Description",
        "terseLabel": "Milestone payments related terms"
       }
      }
     },
     "localname": "MilestonePaymentsRelatedTermsDescription",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_MinimumCommonStockConversionPriceForMilestonePaymentsConsideration": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Minimum common stock conversion price for milestone payments consideration.",
        "label": "Minimum Common Stock Conversion Price For Milestone Payments Consideration",
        "terseLabel": "Minimum common stock conversion price for milestone payments consideration"
       }
      }
     },
     "localname": "MinimumCommonStockConversionPriceForMilestonePaymentsConsideration",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "vir_NoncashLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Noncash lease expense.",
        "label": "Noncash Lease Expense",
        "terseLabel": "Noncash lease expense"
       }
      }
     },
     "localname": "NoncashLeaseExpense",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of years conduct certain research and development activities under mutually agreed development plans.",
        "label": "Number Of Years Conduct Certain Research And Development Activities Under Mutually Agreed Development Plans",
        "terseLabel": "Number of years conduct certain research and development activities under mutually agreed development plans"
       }
      }
     },
     "localname": "NumberOfYearsConductCertainResearchAndDevelopmentActivitiesUnderMutuallyAgreedDevelopmentPlans",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Current portion of lease liabilities recorded in prepaid expenses and other current assets for which the lease incentives to be received exceed the minimum lease payments to be paid over the next twelve months.",
        "label": "Operating Lease Liability Current Net Of Tenant Improvement Allowances Included In Prepaid",
        "terseLabel": "Current operating lease liabilities, net of tenant improvement allowances"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentNetOfTenantImprovementAllowancesIncludedInPrepaid",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_OptionExerciseFeeConsiderationPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option exercise fee consideration payable.",
        "label": "Option Exercise Fee Consideration Payable",
        "terseLabel": "Option exercise fee of ranging from low tens"
       }
      }
     },
     "localname": "OptionExerciseFeeConsiderationPayable",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_OptionExerciseFeeConsiderationPayableDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option Exercise Fee Consideration Payable Description",
        "label": "Option Exercise Fee Consideration Payable Description",
        "terseLabel": "Option exercise fee of ranging from low tens description"
       }
      }
     },
     "localname": "OptionExerciseFeeConsiderationPayableDescription",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_OptionExerciseFeeConsiderationReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option exercise fee consideration receivable.",
        "label": "Option Exercise Fee Consideration Receivable",
        "terseLabel": "Option exercise fee ranging from mid-single-digit"
       }
      }
     },
     "localname": "OptionExerciseFeeConsiderationReceivable",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_OptionExerciseFeeConsiderationToBeReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option exercise fee consideration to be received.",
        "label": "Option Exercise Fee Consideration To Be Received",
        "terseLabel": "Option exercise fee to be received"
       }
      }
     },
     "localname": "OptionExerciseFeeConsiderationToBeReceived",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_OptionExerciseFeeReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option exercise fee received.",
        "label": "Option Exercise Fee Received",
        "terseLabel": "Option exercise fee received"
       }
      }
     },
     "localname": "OptionExerciseFeeReceived",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Line Items]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Line Items]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsLineItems",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_OrganizationConsolidationAndPresentationOfFinancialStatementsTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization consolidation and presentation of financial statements.",
        "label": "Organization Consolidation And Presentation Of Financial Statements [Table]",
        "terseLabel": "Organization Consolidation And Presentation Of Financial Statements [Table]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsTable",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "vir_PayableUnderAgreementCurrent": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payable under agreement, current.",
        "label": "Payable Under Agreement Current",
        "terseLabel": "Payable"
       }
      }
     },
     "localname": "PayableUnderAgreementCurrent",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PaymentMadeForBusinessCombinationMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment made for business combination milestone.",
        "label": "Payment made for business combination milestone"
       }
      }
     },
     "localname": "PaymentMadeForBusinessCombinationMilestone",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PaymentOfAnnualLicenseMaintenanceFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of annual license maintenance fees.",
        "label": "Payment Of Annual License Maintenance Fees",
        "terseLabel": "Payment of annual license maintenance fees"
       }
      }
     },
     "localname": "PaymentOfAnnualLicenseMaintenanceFees",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PaymentOfContingentConsideration": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payment of contingent consideration.",
        "label": "Payment Of Contingent Consideration",
        "negatedLabel": "Payment of contingent consideration"
       }
      }
     },
     "localname": "PaymentOfContingentConsideration",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PaymentToPartnerResultingFromProgramOptionExercise": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of payment to a collaborator due to a program option exercise under a separate agreement .",
        "label": "Payment To Partner Resulting From Program Option Exercise",
        "terseLabel": "Proceeds from options exercised"
       }
      }
     },
     "localname": "PaymentToPartnerResultingFromProgramOptionExercise",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PaymentsOfUnderwritingDiscountsAndCommissions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payments of underwriting discounts and commissions.",
        "label": "Payments Of Underwriting Discounts And Commissions",
        "terseLabel": "Payments of underwriting discounts and commissions"
       }
      }
     },
     "localname": "PaymentsOfUnderwritingDiscountsAndCommissions",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PayrollAndRelatedExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Payroll and related expenses current.",
        "label": "Payroll And Related Expenses Current",
        "terseLabel": "Payroll and related expenses"
       }
      }
     },
     "localname": "PayrollAndRelatedExpensesCurrent",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PercentageOfAggregateGrossProceedsFromSaleOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of aggregate gross proceeds from sale of shares.",
        "label": "Percentage Of Aggregate Gross Proceeds From Sale Of Shares",
        "terseLabel": "Percentage of aggregate gross proceeds from sale of shares"
       }
      }
     },
     "localname": "PercentageOfAggregateGrossProceedsFromSaleOfShares",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_PercentageOfDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of development costs.",
        "label": "Percentage Of Development Costs",
        "terseLabel": "Percentage of development costs"
       }
      }
     },
     "localname": "PercentageOfDevelopmentCosts",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_PercentageOfOrdinaryShareEqualToOutstandingShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of ordinary share equal to outstanding share.",
        "label": "Percentage Of Ordinary Share Equal To Outstanding Share",
        "terseLabel": "Percentage of ordinary share equal to outstanding share"
       }
      }
     },
     "localname": "PercentageOfOrdinaryShareEqualToOutstandingShare",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_PercentageOfShareDevelopmentCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of share development costs.",
        "label": "Percentage Of Share Development Costs",
        "terseLabel": "Percentage of share development costs"
       }
      }
     },
     "localname": "PercentageOfShareDevelopmentCosts",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of upfront payment receivable at effective date of agreement.",
        "label": "Percentage Of Upfront Payment Receivable At Effective Date Of Agreement",
        "terseLabel": "Percentage of upfront payment receivable at effective date of agreement"
       }
      }
     },
     "localname": "PercentageOfUpfrontPaymentReceivableAtEffectiveDateOfAgreement",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_PreDefinedRegulatoryMilestoneConsiderationReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pre-defined regulatory milestone consideration receivable.",
        "label": "Pre Defined Regulatory Milestone Consideration Receivable",
        "terseLabel": "Pre-defined regulatory milestone payment"
       }
      }
     },
     "localname": "PreDefinedRegulatoryMilestoneConsiderationReceivable",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PreliminaryCollaborationAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Preliminary Collaboration Agreement.",
        "label": "Preliminary Collaboration Agreement [Member]",
        "terseLabel": "Preliminary Collaboration Agreement"
       }
      }
     },
     "localname": "PreliminaryCollaborationAgreementMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_PremiumPaidOnSalePriceOfCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premium paid on sale price of common stock.",
        "label": "Premium Paid On Sale Price Of Common Stock",
        "terseLabel": "Premium paid on sale price of common stock"
       }
      }
     },
     "localname": "PremiumPaidOnSalePriceOfCommonStock",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PremiumReceivedOnSalePriceOfCommonStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Premium received on sale price of common stock.",
        "label": "Premium Received On Sale Price Of Common Stock",
        "terseLabel": "Premium received on sale price of common stock"
       }
      }
     },
     "localname": "PremiumReceivedOnSalePriceOfCommonStock",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_PresentValueOfOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, net of tenant improvement allowance yet to be received.",
        "label": "Present Value Of Operating Lease Liabilities"
       }
      }
     },
     "localname": "PresentValueOfOperatingLeaseLiabilities",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ProceedsFromIssuanceSecondaryPublicOffering": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's follow on offering of stock to the public.",
        "label": "Proceeds From Issuance Secondary Public Offering",
        "terseLabel": "Net proceeds after deducting underwriting discounts, commissions and offering expenses"
       }
      }
     },
     "localname": "ProceedsFromIssuanceSecondaryPublicOffering",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ProfitShareRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profit Share Revenue.",
        "label": "Profit Share Revenue [Member]",
        "terseLabel": "Profit Share Revenue"
       }
      }
     },
     "localname": "ProfitShareRevenueMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_ProfitsAndLossesSharingPercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Profits and losses sharing percentage.",
        "label": "Profits And Losses Sharing Percentage",
        "terseLabel": "Percentage of share Profit and loss"
       }
      }
     },
     "localname": "ProfitsAndLossesSharingPercentage",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "vir_ReceivableFromCollaboration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount due from collaboration partner under the collaboration agreement.",
        "label": "Receivable From Collaboration",
        "verboseLabel": "Receivable from collaboration"
       }
      }
     },
     "localname": "ReceivableFromCollaboration",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification of derivative liability to additional paid In capital.",
        "label": "Reclassification Of Derivative Liability To Additional Paid In Capital",
        "terseLabel": "Reclassification of derivative liability to additional paid-in capital"
       }
      }
     },
     "localname": "ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapital",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reclassification\u200b of derivative liability\u200b to additional paid-\u200bin capital upon achievement of development milestone.",
        "label": "Reclassification Of Derivative Liability To Additional Paid In Capital Upon Achievement Of Development Milestone",
        "terseLabel": "Reclassification of derivative liability to additional paid-in capital"
       }
      }
     },
     "localname": "ReclassificationOfDerivativeLiabilityToAdditionalPaidInCapitalUponAchievementOfDevelopmentMilestone",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfCashFlowsUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ReductionOfResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Reduction of research and development expense.",
        "label": "Reduction of Research and Development Expense",
        "terseLabel": "Reduction of research and development expense"
       }
      }
     },
     "localname": "ReductionOfResearchAndDevelopmentExpense",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_RegulatoryMilestoneConsiderationReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestone consideration receivable.",
        "label": "Regulatory Milestone Consideration Receivable",
        "terseLabel": "Milestone payment on basis ranging from mid-single-digit"
       }
      }
     },
     "localname": "RegulatoryMilestoneConsiderationReceivable",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_RegulatoryMilestonePaymentConsiderationPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regulatory milestone payment consideration payable",
        "label": "Regulatory Milestone Payment Consideration Payable",
        "terseLabel": "Milestone payment on basis of ranging from low tens"
       }
      }
     },
     "localname": "RegulatoryMilestonePaymentConsiderationPayable",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_RemainingPaymentMadeForBusinessCombinationMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Remaining Payment Made For Business Combination Milestone",
        "label": "Remaining payment made for business combination milestone"
       }
      }
     },
     "localname": "RemainingPaymentMadeForBusinessCombinationMilestone",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of current obligations incurred and payable to vendors for goods and services attributable to the entity's research and development activities.",
        "label": "Research And Development Expenses Current",
        "terseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsScheduleOfAccruedAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_RestrictedSharesSubjectToFutureVesting": {
     "auth_ref": [],
     "calculation": {
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted shares subject to future vesting.",
        "label": "Restricted Shares Subject To Future Vesting",
        "terseLabel": "Restricted shares subject to future vesting"
       }
      }
     },
     "localname": "RestrictedSharesSubjectToFutureVesting",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfBasicAndDilutedNetIncomeLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_RestrictedStockAwardsRSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Restricted stock awards (RSA).",
        "label": "Restricted Stock Awards R S A [Member]",
        "terseLabel": "Restricted Stock Awards (RSAs)"
       }
      }
     },
     "localname": "RestrictedStockAwardsRSAMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureStockBasedAwardsSummaryOfRestrictedStockActivityAndRestrictedStockUnitsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_RockefellerAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rockefeller agreement.",
        "label": "Rockefeller Agreement [Member]",
        "terseLabel": "Rockefeller Agreement"
       }
      }
     },
     "localname": "RockefellerAgreementMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_RockefellerUniversityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rockefeller University.",
        "label": "Rockefeller University [Member]",
        "terseLabel": "Rockefeller"
       }
      }
     },
     "localname": "RockefellerUniversityMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_RoyaltyObligationPeriodFromDateOfFirstCommercialSale": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty obligation period from date of first commercial sale.",
        "label": "Royalty Obligation Period From Date Of First Commercial Sale",
        "terseLabel": "Royalty obligation period from date of first commercial sale"
       }
      }
     },
     "localname": "RoyaltyObligationPeriodFromDateOfFirstCommercialSale",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Royalty payment obligation expiration period after first commercial sales.",
        "label": "Royalty Payment Obligation Expiration Period After First Commercial Sales",
        "terseLabel": "Royalty payment obligation expiration period after first commercial sales"
       }
      }
     },
     "localname": "RoyaltyPaymentObligationExpirationPeriodAfterFirstCommercialSales",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_SARSCoV2ProductMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "SARS-CoV-2 product.",
        "label": "S A R S Co V2 Product [Member]",
        "terseLabel": "SARS-CoV-2 Product"
       }
      }
     },
     "localname": "SARSCoV2ProductMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_SaleOfStockConsiderationAggregateOfferingPrice": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of stock consideration aggregate offering price.",
        "label": "Sale Of Stock Consideration Aggregate Offering Price",
        "terseLabel": "Aggregate offering price"
       }
      }
     },
     "localname": "SaleOfStockConsiderationAggregateOfferingPrice",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales agreement.",
        "label": "Sales Agreement [Member]",
        "terseLabel": "Sales Agreement"
       }
      }
     },
     "localname": "SalesAgreementMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureOrganizationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_SalesMilestoneConsiderationPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales milestone consideration payable.",
        "label": "Sales Milestone Consideration Payable",
        "terseLabel": "Sale milestone payments"
       }
      }
     },
     "localname": "SalesMilestoneConsiderationPayable",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_SalesMilestoneConsiderationReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale milestone consideration receivable.",
        "label": "Sales Milestone Consideration Receivable",
        "terseLabel": "Sales milestone receivable"
       }
      }
     },
     "localname": "SalesMilestoneConsiderationReceivable",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of accrued liabilities and other liabilities.",
        "label": "Schedule Of Accrued Liabilities And Other Liabilities Table [Text Block]",
        "terseLabel": "Schedule of Accrued and Other Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesAndOtherLiabilitiesTableTextBlock",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureBalanceSheetComponentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vir_ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of operating lease amounts recorded in condensed consolidated balance sheet.",
        "label": "Schedule Of Operating Lease Amounts Recorded In Condensed Consolidated Balance Sheet Table [Text Block]",
        "terseLabel": "Schedule of Operating Lease Amounts Recorded in Condensed Consolidated Balance Sheets"
       }
      }
     },
     "localname": "ScheduleOfOperatingLeaseAmountsRecordedInCondensedConsolidatedBalanceSheetTableTextBlock",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "vir_SharePayableToCollaborator": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Portion of the carrying value of the equity investment due to a third party that is payable within one year.",
        "label": "Share Payable To Collaborator",
        "terseLabel": "Recognized liability"
       }
      }
     },
     "localname": "SharePayableToCollaborator",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_SpecifiedClinicalDevelopmentMilestonesPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specified clinical development milestones payment.",
        "label": "Specified Clinical Development Milestones Payment",
        "terseLabel": "Specified clinical development milestones payment"
       }
      }
     },
     "localname": "SpecifiedClinicalDevelopmentMilestonesPayment",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specified development milestones and annual license maintenance fees.",
        "label": "Specified Development Milestones And Annual License Maintenance Fees",
        "terseLabel": "Specified development milestones and annual license maintenance fees"
       }
      }
     },
     "localname": "SpecifiedDevelopmentMilestonesAndAnnualLicenseMaintenanceFees",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_SpecifiedDevelopmentMilestonesPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Specified development milestones payment.",
        "label": "Specified Development Milestones Payment",
        "terseLabel": "Specified development milestones payment"
       }
      }
     },
     "localname": "SpecifiedDevelopmentMilestonesPayment",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vested shares related to repayment of promissory notes.",
        "label": "Stock Issued During Period Repayment Of Promissory Notes Net Of Unvested Common Stock Shares",
        "terseLabel": "Repayment of promissory notes, net of unvested shares (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockShares",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of promissory notes related to vested shares.",
        "label": "Stock Issued During Period Repayment Of Promissory Notes Net Of Unvested Common Stock Value",
        "terseLabel": "Repayment of promissory notes, net of unvested shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodRepaymentOfPromissoryNotesNetOfUnvestedCommonStockValue",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_StockIssuedDuringPeriodSharesAchievementOfMilestone": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares achievement of milestone.",
        "label": "Stock Issued During Period Shares Achievement Of Milestone",
        "terseLabel": "Issuance of common stock in connection with the achievement of a milestone (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesAchievementOfMilestone",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares cashless exercise of warrant.",
        "label": "Stock Issued During Period Shares Cashless Exercise Of Warrant",
        "terseLabel": "Issuance of common stock for cashless exercise of warrant (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCashlessExerciseOfWarrant",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_StockIssuedDuringPeriodSharesCollaborationAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares collaboration agreement.",
        "label": "Stock Issued During Period Shares Collaboration Agreement",
        "terseLabel": "Issuance of common stock in connection with a collaboration agreement (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesCollaborationAgreement",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_StockIssuedDuringPeriodSharesLicenseAgreement": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of common stock issued in connection with a license agreement.",
        "label": "Stock Issued During Period Shares License Agreement",
        "terseLabel": "Issuance of common stock in connection with a license agreement (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesLicenseAgreement",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "sharesItemType"
    },
    "vir_StockIssuedDuringPeriodValueCollaborationAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value collaboration agreement.",
        "label": "Stock Issued During Period Value Collaboration Agreement",
        "terseLabel": "Issuance of common stock in connection with a collaboration agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueCollaborationAgreement",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_StockIssuedDuringPeriodValueLicenseAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of common stock issued in connection with a license agreement.",
        "label": "Stock Issued During Period Value License Agreement",
        "terseLabel": "Issuance of common stock in connection with a license agreement"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueLicenseAgreement",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_StatementCondensedConsolidatedStatementsOfStockholdersEquityUnaudited"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_TomegaVaxIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TomegaVax, Inc.",
        "label": "Tomega Vax Inc [Member]",
        "terseLabel": "TomegaVax"
       }
      }
     },
     "localname": "TomegaVaxIncMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsEstimatedFairValueOfSignificantUnobservableInputsDetails",
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TuberculosisTBGrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tuberculosis (\u201cTB\u201d) grant.",
        "label": "Tuberculosis T B Grant [Member]",
        "terseLabel": "Tuberculosis ('TB') Grant"
       }
      }
     },
     "localname": "TuberculosisTBGrantMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandAndTwentyOneGSKAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 GSK Agreement [Member]",
        "label": "Two Thousand And Twenty One G S K Agreement [Member]",
        "terseLabel": "2021 GSK Agreement"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneGSKAgreementMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandAndTwentyOneGSKCollaborationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "2021 GSK Collaboration [Member]",
        "label": "Two Thousand And Twenty One G S K Collaboration [Member]",
        "terseLabel": "2021 GSK Collaboration"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOneGSKCollaborationMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty one preliminary collaboration agreement and stock purchase agreement.",
        "label": "Two Thousand And Twenty One Preliminary Collaboration Agreement And Stock Purchase Agreement [Member]",
        "terseLabel": "2021 Preliminary Collaboration Agreement and Stock Purchase Agreement"
       }
      }
     },
     "localname": "TwoThousandAndTwentyOnePreliminaryCollaborationAgreementAndStockPurchaseAgreementMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand and twenty preliminary collaboration agreement and stock purchase agreement.",
        "label": "Two Thousand And Twenty Preliminary Collaboration Agreement And Stock Purchase Agreement [Member]",
        "terseLabel": "2020 Preliminary Collaboration Agreement and Stock Purchase Agreement"
       }
      }
     },
     "localname": "TwoThousandAndTwentyPreliminaryCollaborationAgreementAndStockPurchaseAgreementMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandNineteenXencorAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand nineteen xencor agreement.",
        "label": "Two Thousand Nineteen Xencor Agreement [Member]",
        "terseLabel": "2019 Xencor Agreement"
       }
      }
     },
     "localname": "TwoThousandNineteenXencorAgreementMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand wenty Glaxo Wellcome UK Limited and Beecham S.A.",
        "label": "Two Thousand Twenty Glaxo Wellcome U K Limited And Beecham S A [Member]",
        "terseLabel": "2020 GSK"
       }
      }
     },
     "localname": "TwoThousandTwentyGlaxoWellcomeUKLimitedAndBeechamSAMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one Glaxo Wellcome UK Limited and Beecham S.A.",
        "label": "Two Thousand Twenty One Glaxo Wellcome U K Limited And Beecham S A [Member]",
        "terseLabel": "2021 GSK"
       }
      }
     },
     "localname": "TwoThousandTwentyOneGlaxoWellcomeUKLimitedAndBeechamSAMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandTwentyOneStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty one stock purchase agreement.",
        "label": "Two Thousand Twenty One Stock Purchase Agreement [Member]",
        "terseLabel": "2021 Stock Purchase Agreement"
       }
      }
     },
     "localname": "TwoThousandTwentyOneStockPurchaseAgreementMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandTwentyStockPurchaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty stock purchase agreement.",
        "label": "Two Thousand Twenty Stock Purchase Agreement [Member]",
        "terseLabel": "2020 Stock Purchase Agreement"
       }
      }
     },
     "localname": "TwoThousandTwentyStockPurchaseAgreementMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_TwoThousandTwentyXencorAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand twenty xencor agreement.",
        "label": "Two Thousand Twenty Xencor Agreement [Member]",
        "terseLabel": "2020 Xencor Agreement"
       }
      }
     },
     "localname": "TwoThousandTwentyXencorAgreementMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_UnusedFundsReceivedInAdvance": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unused funds received in advance.",
        "label": "Unused Funds Received In Advance",
        "terseLabel": "Unused funds received in advance"
       }
      }
     },
     "localname": "UnusedFundsReceivedInAdvance",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureGrantAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_UpfrontFeePaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront fee paid.",
        "label": "Upfront Fee Paid",
        "terseLabel": "Upfront fee paid"
       }
      }
     },
     "localname": "UpfrontFeePaid",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_UpfrontPaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment receivable.",
        "label": "Upfront Payment Receivable",
        "terseLabel": "Upfront payment receivable"
       }
      }
     },
     "localname": "UpfrontPaymentReceivable",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_VaccineProgramMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vaccine Program.",
        "label": "Vaccine Program [Member]",
        "terseLabel": "Vaccine Program"
       }
      }
     },
     "localname": "VaccineProgramMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_ValueOfCommonStockSharesIssuedForMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of common shares issued for milestone payment.",
        "label": "Value of common stock shares Issued for milestone payment"
       }
      }
     },
     "localname": "ValueOfCommonStockSharesIssuedForMilestonePayment",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureAcquisitionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "vir_WarrantsToPurchaseCommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Warrants to purchase common stock.",
        "label": "Warrants To Purchase Common Stock [Member]",
        "terseLabel": "Warrants to Purchase Common Stock"
       }
      }
     },
     "localname": "WarrantsToPurchaseCommonStockMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/DisclosureNetIncomeLossPerShareScheduleOfPotentiallyDilutiveSecuritiesNotIncludedInDilutedPerShareCalculationsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_WrittenNoticePeriodForLicensedProgramExerciseAnOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice period for licensed program, exercise an option.",
        "label": "Written Notice Period For Licensed Program Exercise An Option",
        "terseLabel": "Written notice period for exercise an option"
       }
      }
     },
     "localname": "WrittenNoticePeriodForLicensedProgramExerciseAnOption",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticePeriodForLicensedProgramFailureToMakePayment": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice period for licensed program, failure to make payment",
        "label": "Written Notice Period For Licensed Program Failure To Make Payment",
        "terseLabel": "Written notice period for failure to make payment"
       }
      }
     },
     "localname": "WrittenNoticePeriodForLicensedProgramFailureToMakePayment",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticePeriodForLicensedProgramNotExercisedAnOption": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice for period for licensed program not exercised an option.",
        "label": "Written Notice Period For Licensed Program Not Exercised An Option",
        "terseLabel": "Written notice period for not exercising an option"
       }
      }
     },
     "localname": "WrittenNoticePeriodForLicensedProgramNotExercisedAnOption",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticePeriodForLicensedProgramOtherPartyChallengesValidityOrEnforceabilityOfPatentLicense": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice period for licensed program other party challenges validity or enforceability of patent license.",
        "label": "Written Notice Period For Licensed Program Other Party Challenges Validity Or Enforceability Of Patent License",
        "terseLabel": "Written notice period for licensed program other party challenges validity or enforceability of patent license."
       }
      }
     },
     "localname": "WrittenNoticePeriodForLicensedProgramOtherPartyChallengesValidityOrEnforceabilityOfPatentLicense",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice period for licensed program, uncured material breach.",
        "label": "Written Notice Period For Licensed Program Uncured Material Breach",
        "terseLabel": "Written notice period for uncured material breach"
       }
      }
     },
     "localname": "WrittenNoticePeriodForLicensedProgramUncuredMaterialBreach",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticePeriodForTerminationOfLicensedProgram": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice period for termination of licensed program.",
        "label": "Written Notice Period For Termination Of Licensed Program",
        "terseLabel": "Written notice period for termination of licensed program"
       }
      }
     },
     "localname": "WrittenNoticePeriodForTerminationOfLicensedProgram",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Written notice period for termination of licensed program based on challenge.",
        "label": "Written Notice Period For Termination Of Licensed Program Based On Challenge",
        "terseLabel": "Written notice period for termination of licensed program based on challenge"
       }
      }
     },
     "localname": "WrittenNoticePeriodForTerminationOfLicensedProgramBasedOnChallenge",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "vir_WuXiBiologicsLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WuXi Biologics Limited.",
        "label": "Wu Xi Biologics Limited [Member]",
        "terseLabel": "WuXi Biologics"
       }
      }
     },
     "localname": "WuXiBiologicsLimitedMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "WuXi biologics and Samsung letter agreement assignments and master services agreements.",
        "label": "Wuxi Biologics And Samsung Letter Agreement Assignments And Master Services Agreements [Member]",
        "terseLabel": "WuXi Biologics MSA and Samsung MSA"
       }
      }
     },
     "localname": "WuxiBiologicsAndSamsungLetterAgreementAssignmentsAndMasterServicesAgreementsMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "vir_XencorIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Xencor, incorporation member.",
        "label": "Xencor Incorporation [Member]",
        "terseLabel": "Xencor"
       }
      }
     },
     "localname": "XencorIncorporationMember",
     "nsuri": "http://www.vir.bio/20210630",
     "presentation": [
      "http://www.vir.bio/20210630/taxonomy/role/Role_DisclosureCollaborationAndLicenseAgreementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    }
   },
   "unitCount": 7
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "http://asc.fasb.org/topic&trid=2122149"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22595-107794"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22644-107794"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22658-107794"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1448-109256"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1505-109256"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1252-109256"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1707-109256"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1757-109256"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "26",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1828-109256"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1500-109256"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2062-109256"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "48",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2538-109256"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "48",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2538-109256"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "51",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2574-109256"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2597-109256"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2600-109256"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "54",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e2603-109256"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=SL5780133-109256"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=121326447&loc=d3e1337-109256"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3630-109257"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e3842-109258"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=120380238&loc=d3e4984-109258"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6828210&loc=d3e70191-108054"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8736-108599"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8906-108599"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8924-108599"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e8933-108599"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9031-108599"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9038-108599"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=120311839&loc=d3e9054-108599"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aaa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=121645371&loc=d3e27161-111563"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121646688&loc=SL121648383-210437"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121599337&loc=SL120267969-210447"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121558606&loc=SL82898722-210454"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(i)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121582814&loc=SL82922900-210455"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=121559207&loc=d3e25336-109308"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130531-203044"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130532-203044"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121556615&loc=SL49130533-203044"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130543-203045"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130545-203045"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121604090&loc=SL49130549-203045"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=121551570&loc=SL49130690-203046-203046"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121326096&loc=d3e4534-113899"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11149-113907"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120383193&loc=d3e11178-113907"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31917-109318"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120406818&loc=d3e31931-109318"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32672-109319"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=120385591&loc=d3e38679-109324"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116873149&loc=d3e923-111674"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=121559654&loc=d3e5710-111685"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "http://asc.fasb.org/topic&trid=2197479"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=107671284&loc=SL5844817-113951"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=77984636&loc=d3e40733-113955"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5618551-113959"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624163-113959"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121590274&loc=SL5624177-113959"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121582272&loc=SL5629052-113961"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "15",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=121596415&loc=d3e48542-113965"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "15",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=56949186&loc=d3e50579-113967"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.2)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918627-209977"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918631-209977"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121603541&loc=SL77918643-209977"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918673-209980"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918686-209980"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=121609121&loc=SL77918701-209980"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=SL51823488-111719"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=119991564&loc=SL119991595-234733"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=121551529&loc=d3e60009-112784"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120252992&loc=d3e62557-112803"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(h))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(3)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121643868&loc=SL117782755-158439"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117783719-158441"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121639165&loc=SL117819544-158441"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=121370832&loc=SL117420844-207641"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=66023616&loc=SL35737432-115832"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=120402547&loc=d3e617274-123014"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226000-175313"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=120402810&loc=d3e638233-123024"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r416": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r417": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r418": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a"
  },
  "r419": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "210",
   "URI": "http://asc.fasb.org/topic&trid=2122208"
  },
  "r420": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r421": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669646-108580"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e637-108580"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e681-108580"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669686-108580"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e689-108580"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724391-108580"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL34724394-108580"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669619-108580"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=SL7669625-108580"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=121641772&loc=d3e557-108580"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6812-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.8)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=120395209&loc=SL114868664-224227"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6911-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3213-108585"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3255-108585"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3291-108585"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3000-108585"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3521-108585"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3536-108585"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e6935-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3602-108585"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121586364&loc=d3e3044-108585"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4273-108586"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4304-108586"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4313-108586"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=d3e4332-108586"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=121583591&loc=SL98516268-108586"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=121566466&loc=d3e7018-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21914-107793"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21930-107793"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=115929471&loc=d3e21711-107793"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>69
<FILENAME>0000950170-21-000935-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-21-000935-xbrl.zip
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M^O>'_0$*$WP]% OW+C_R]62T'H*M+K!H4.%I7P5+63@&Q47(RJ3@/GP#F$P
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M)F@&ORU+R J'"DX'8#I7SW0TF='\)*;!"8$2.(EVW1J[876;]7-F/+]6",?
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M47"=BI#-0K&5UVR^=WL-3LX*-N?EF[<2EB>PJ"8<I6Y[SK3) 64.S=PR4%$
M*>G::P;26.KVM]N\9E%%&9:G*!TU-->\X EP:$9ZD"P)49E0M<1BA8NV65?5
M]M@=RW(L0HY".$WN1&,0D%)_W((WD$4:&@R$]D=STF5SR4&?*#'N#ZBBZ'<8
M](<E_H:L,7F,B\N*,A%7X[OD D&L3)IQDR7-6DTL\"19K)"J,L$4UVSIUY8<
MW24..^8E"0\H"2IU-]?6>18@1A9T2"4C):/:=FHM7CZY^)UG:8+P,HY/#N(
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M,BF8B0^"-K,H/D-[\U^:F<2R 6>DB]Q[H0*3L=  7N68[VI?5,G!*%]D;;;
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M!8UTQ9WTNW$!NPAVC=)G%5 ;9<A,9X$H.=?$JK*!&P_!VVUO2;366MH-)(V
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MT71H$1HDBHR><P4U^)OGG%ZB80>NGH]?H*V'8*()4_ ARC]\BF$_;IC,O1V
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M+IE3K_5\X[2L,U7[Z!1Z=>60'Z3R$##[JBR>KSO#S^*DQ'_U?AN,4AST#F
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MAY9\!XV=%I111*U1B-,@D!..(T=)Q%I;DMV)-@+1&UI[Q KJ$&,.V>I]L'?
M$##L H:@.RWICO>1):(XPDQJQ#DCR!(?4""4!*LY3W1#=[:)69]&=XQAH#M]
MBV6A2MJ>T;^9Q2L[6AW_LMP5NSG:]?JLKZJ*4#CM3;;VX7NI ,Z/OF<-^"+?
MXXOP9'&,RB/F??8K?(C(8(:1X)'':#%-E+81 R])\67#B=D7.2V$>%3S8)MY
M=&J&E+7E@,"N5WO!&@ XR.%^XPQRV)(<$D])(B2@9(1 //"$M+$*X>B2#9Q8
ME3;D<)O0_-'D4 T%:6L=#;!S-X/W+Q2B:4LA/#VL$/YL.B^'LK80K4,."_+^
M/<<0G(NV&I^%2EJZ[%<P:?,_ B,;-$?,6NMC< E3UT:LW;X;H24=4@.KG_;"
MG@%#P+ +&(*NM*0K+C%-$L^B0#'.&A$LLC0FY*,W@6>)"'%C_X=M@M;V=44I
M.F02=*5W(2?LU?F0@3B9S.WD?%0.S&IBR.%@$K=L7(:R+RQQZA5Z(.]MR7L,
MGO&LYQHSE>7=DBSO*B!L&>$N1B'CQF8:VX2--VS5"/WK.'_YT8\7830Y_^MT
M&LJ9V.VL=6)#(=IJ3@;+!EX$] X&/5"5EE2%*B6EYP+9'"$B[BA!FDN,% LL
MB&BM#;B-H/$Q5467T[I 5?H21![HR5M;&?'*5" STL-,)V (V>+."']0,EIB
M< XGL4 \"HJL)A2)A%GT3@2<6ME^J55Q)W)H6%M[+8$E QL"A@>/(2A*6_LH
M&*E=S &D4"[FL#!E10G)(658E(KK9+EL(Y0$1>FO)4/E\5'#Q5?3R3ELU-L!
M?0+T($7<5UT/ D?EO45*"XVX3QYIJ0GR02GJF2?*FS8BQ4)69YFK3FZHJA6)
M%W@H-62$>VO(@!Z@!R*RFU,F;WT45=&CT4=T,0KYD5[\\EY&9JC)S"^9%H@K
MS9!.PB!#%!52YYC.X$?Q8__]WSY23/C-R-_^#UA1U\(SJ.E]RT9!TZN,Q*=Z
M@Z"RQ>U5\7V^HT<4TA"0E.TYAONMNX\8O%E"<OQ&;([;BH0'JY!A1B!,=5+4
M8FT3;V=CGX;$WHSM9'XT"2]7//8ZMK2%09E'<!3H7E@W8 @8=@%#4)FVNDA#
ML"9XB8B,$G'->7/T-/-84X*3$+R5@SYWKC)$#0UOZ_@5L&XH!W8JTCS-QF/G
MH\GYH"87-$UH4478AK9?.4E #S*Z'=!\8YB4N(@\(QAQ:PQR,<0<8WKCM;22
M"=9&9'E-6J^BK>+;\ABGZ=>J64?23H%0#XVB4"#LJTD#>H >R$G/Y43D"!#+
MY)!DW",NB<LB(0+"QDM.LZ80N;$KVC8AY.[E1)(<0\*!T#V*'J%:^?#A>-CA
MG'GBP_F<_4V, H:07.Z.9T"ITP9C%&G*X67$$3F;0TYF4]2,"JUU*RL5OW9.
MVNMK3FOM:,ZV@DXP=:!+P/#@,03):6N+;H>C)"D'EIRG'%TZBDR(''DA8U:.
MQ+QO92GC(TN.'!IB0'+Z%IY"<?-!Q<WZ:$VH9?8J?0IGB'4-9_ AV@I;C0O,
MY3A56*JR4Q 9LN5<395#5JF$T(2TLFQR[<BPEN+2'&S#46% #@#XT[,QX RJ
MURO54\H;PX1%05&'N*(2Y9C39^ECRB:6 G&BE3)NRZJGAYH^:<T62!C*O!V*
MIL].SXY>#8[>O7MY]@X21#W,!=_F$_J<BL(G8;HHQ]#TRLG8R?S^0Y<'!+R1
MEKP13K,7PK)3(3P)V;VP.;+F2J 8<WQMA!)>M!*#M^B(D"$6:BAT!Y:Z?GW&
M'JQ/ K@?).X@F5T=$)#,MG;QQ3GLUEP@$666/YUR,*Z9081:&[DW*NC0WBFB
MK4BF(7JH) AFEXD;BN';<K6;CL,W6O:KDZ.?3EZ=G)V\?#<X>OWSX-W9Z?%_
M_^WTU<\OW[YKME(S/PY>_L^O)V?_@DKY3ER4C%7YRU^>T6>PZ*C[A0( %&P=
M;/TPIN;A @J%E">(FH]_??OVY>NSP9I/]@(**EV@8VBT[UH"#F %ZP?K/]1I
M>KBPMI\<6T=KB<Y67MH2E6*VJ^MTD$%VXK@=>9_AG5>#*_O)NG&$Z+DG 5['
MT>M2;0X"Z"==(4*H\ (GQ*,O_^B$+%8&65>V;-=.ZN!;Z4Y9,MF;ALB.6UQ1
M2L@0,]@Z#[@2T.L>>J TH#3+/DCC,)/.(AR80SR(K!]2^"PBC)*4)$ZXE549
M.U0:,<0*-M7K4:/&G4P 1*1M1*2S10SUEGO3>K>#\<BZT7@T'\4MMSR K")D
M9GN.(3@)+3D)/F"N>:3(>YV=!!($LA1KE%CB6!*A+-[H_-PR'"TT]NJ&NXXF
MH5[/N?92._L=\>PT\*?O"^W0A.RMF0.&@&$7, 2Y:>O\$!RQBC'KB\,4<:XC
M<D0+E )6S%%'K&MEC[W'DQLEAX;!X6&]BU2A:MJ>K?\<4YS-<I ZBQ_B9!&'
M@^4&EH.KZ:R8 V1L(+E] .B!F]"2FR"%B]%1CJS'*D>EPB-G>$1:4<RXD5C[
M5HJD*^)ZV_!6FZEKSH>*:,A=]]66 3U #W2DYSKBF;>)6HV(SW+ @R!(XT"1
M-QX'KB06=&,KF&W"S1WJB!QRT=8J=S!E*('V,+P\SG\=3<Y+/)E-M1J%^C"_
MZ:2E,!.2+AW:@ ?VQ>T*VN"$M+4[+L98^4019<[GP%1CI /&*&!"5,#"B[21
M\]XFF/UI466 J^IX>NE&DYHA;YCS>)TX5SGP3VTZ*E0.*6YK#_E=SO"#W8X'
M8#] V$$]03W[K)X2:Z.2$(@FHQ$O^]-9ZR1B5C%O,"/1ZC9"^"=63X*'$M2S
MR\2RV\HS;2DU0 \K-7 VG=OQ=1K@NSNC(4$&E8)>H0=N1DMNAJ,B1]I,(*>%
M1-S*LBPW)B2(\RD0(FFD;03I:^UGK;H/7 XQ;:OK&0P9:!#0.QCT0$3:.D%<
M!<YDL$AP)Q!W#N>XTV/$28Y(5?3$\%:V4=^1B!@SQ!(TI$>A).S)^3U-RGF2
M+R-'*!SW,!D+&,+"ILY(OY-1Z!(_,NUS+&@=JW=T0M0)C6U01@BW@X[EU]<4
MULY^&V+(#2QFV@O3!@P!PRY@"!+3DL1$B9FA02/*0RHQI4<NJPK*82(+TD>G
M--]!,W/+$L.&F@A0F+Y%FM\6SA]JC'EZ5?<(3,X'XVBKN%Z0_/YP$S(JD%?N
M%7J@_&WM&8P-22J'AT$1C;B3%FGL. K>9 V/@5J\T0.U37!Y35^O"GM=]SFU
M[ %(/30,5L;VUJP!/4 /)*7GDF)2X@X'A11.- >&-@>305+$</22T.19LFT$
MDX\D*7(H1%MY2S!KJ%QV*JK\_/I7J& ^O8X!AI!>W@>/(%D67)(:22T#XEQ)
MY')LB3SV,G(F/58;>V4\TC+5EKT%3H?2M'5^#9@_4"A@>/ 8@@RUU4.+N6&"
ME+-JG,R2DL--+;% @I%$G?1$B%9.K7EZ&:)BR&"C^OZ%KE *_:9VV[G]>%T'
M_009F9XD6@$]2%-WP!N(-GDC+$=*BQQ@!IJ0ID0BGTC2)#D90FJSK?9DXJ>7
M\<Q^7%MB\SJVU?E$!8,<=5]M&M #]$!/>JXGEL;@%),H$(W+$=P26:UHK1):
M.>VI)FWVT(*>]-^FH>;Y%)VTS5&GT\DYRG1W"8>>=D&[8)_"O4,;/(NVCAK(
M8:I5E" B><B>!=7(\/P/T8QKH8WW<2-OO56/[IU#[-I?GM.:4P';$.X=;P#L
M((Z'@S:(8UMI7.IM=($CGZ)&/&2U<SZF_(\/*F@G0FIEZ>KNQ9$K$,?N\@;4
M>!]W]]W3LZ-7@U<G1S^=O#HY.WGY#I)//4DH@\?1-9S!UVCKP  K#,'8(XE+
M("Z\S.&U$"@83$GT+BK2RG$[;1\DSVAQ!IYT$1,X%EVC!P <=&^_<0;=:TGW
M*$V6R>21"=HCKH- 5B2)J.4!<ZZB91L[V'_GYL/MM$%C,C38@.YUD1Z@]OTD
MZWTO+T?SR_R8U<!.0FVS];H$GVUN\,/KZ3P.])^@#+Y#1<R(E;_\Y5FF3%@R
MU*OT/L *U@_6?ZC3]'!AA=K'HSII[\Y.C__[;Z>O?G[Y]MV__]O'',68'P<O
M_^?7D[-_O8 RR-/2,O38=R$'!(""K8.M'\;4/%Q (4/V!,[7F]EJ=X%J/O6_
M#0=_6 U-#Q+U.A&*C8\(L_JHV<B1#8$B+(3#B7MEXD8SW#8%ZFN0WA6,WMC9
MZ>S=W,YC^(<=+^*;.'MW86?Q;@Y_.A[;U5]N<O@GKW_Y;..[QY1HS9#"Y>2C
M0"BRU K$O#;$*B>B9FW4'5I_G#Q],2;WU!T^4XC8^:QN2.;*S@8?RB/]..C1
MI*;.2&6D1]);5\Y/IGFJ2H%(C%HKR42BK71=W)X%]<!61XOYQ726[S_<&OVJ
M_N/=8?]2*>HS:T8)-I8)BAPNIWH:[9$5 B/.A<3">8LU;G^"M_QH) \_KO_?
MN0G?/,S 7C_JP%:#:1K\UV(2!PP/!S033%T(^0\W&_QY^:GU?W^./EZZ.!LP
M4K\;]\MT=+3*.(6,4+SL>&6R'FB.O$O2!<&(<1L$VI;IG%35XIOG%JJB+_.K
M>"15G'QV)Z^4@I1<(,M90)RQ_(34"$2MU5+3H$AJI2#]V,]E@C#2D8B(+.<P
M.2:0(5PC+%F@41&MW 8?M#5>IXMY-<^F,)J<[^;A8E F>&H0UY85BO-(*TH1
M"Y8+%S@C80=JWOK#3:8/H;EN$N&HGKLUX4UO$/E^4H2240_K&8 AU(2^ZE:L
M?[10(1I]1!>CD!_I18G/K.314I1"<5HCED@G7@@>A\2C)L*Y1PG:FRH)OQG_
MV_\!B^J/10&&@&$7,#QL9B?>&$EC1):8S.Q2!&0M5D@&)JFQWB:-@=GWSJ*@
MT>/1NW&GDSX6&D02DHI$$.:.(,Z<0\:55(R40B8E?#"MY&0;A'9;9=!<8HP]
M1@8+CGC2!%FO*3)1<AT8YX*VDDQJ]UF@Q-#B=&8\N.2$0IBJ/)RR+C2%HGF2
M4B.Q5BFT/)T?I;Z@\T0.R464HS*5[U$89"A)R%'E%8G$1][*YAB[>RZ&H;K0
M5:LA6&(KLL'$/&?R=,D^I'8X3Q>K!/8E^-<;Q-F*U6R5@G^8Q3#O)$VIK'++
M3\(-T<@JPY$/&BLM$R&B;6'[W@SU1CTN3SVNS- HT3F3J8VA1S/<*<I%I"B/
M8LJZH RR#@<D:"0AVJ0,;F5/WQW.AL\4!I5RCG&#!"^=%3AIY'1^.HJ]"-Q+
MY38%KY4':\5T"55#3N10\<Z*PN<K+9_3@GN%8T,@AH-\]:N8'^U#',.9)WUI
M8@3TH 6T"WI&'-$F>S>415OB 8H<4QP14TX\"3H'.ZIE[Z:.;UM9S4]@1_K>
M6C"@!^B!>O1</1)W+G&14#FP&7&K%;*".Q2UI7F\L"/2M1PT@'KTRH)AQ<H3
M5)&.0AB5^6S'@RL["OF1!]Y>C>9V#&72'C8> (;0O-$9R<^C1TG$#!%.*.)1
M$F24MT@:[;&-A ;<2HK_AL/>9 H[F1PW!-:.\@\%H4-#]=-OK]ZA6=A;VP8,
M <,N8 @:TU98*:W&0O"L%RDASJU$3N/\CZ/)L\@-\1L',6\35NY68Y@60W9O
M0P[8=J=#36A5?%"0Z?WB<C$N'6N#:7V II]>7LWB19Q4HP]Q,)Y66YZ>"?D4
MR"?W"KW^"?].&.&''O7QX!APTCD&I9SY["Y07E:.8R1]B"*['3KP5M95K[%D
M?5[8\3I'-@=VO\I$^3K.3].9_?APUZ/*8YM_^IH/PC@DN1]7%[?<*WL?\>TX
M;0-Z('H')7HR!1R3X8@Q)A!/1B 7N$.!$&&8-((DW4I<_;2B1U5;B=U]I)7'
M$SVH_3YQ6!YB&OG1'!)./4PFP^%AW40;W)[>N3W"8\MT((@)$\L*+H%TRC\1
MK8TJAX+K=K:+?!OG-H]E>&EGD]'DO%JCXI\;)FZELJ 4'U)-G[ZNL'\GF74I
M(0 #L[\B FB#9(-D?T&R+:;&2N=0.6@4<>(8*HJ,"*<F!*&,E*UD*AY)LJ54
M0Z+;2L6#,O0[G0']!0\9@[/3LZ-7@R^<? 4IO9Y4"L OZAK._?.(.NJG$!P<
MMD&@0*A'W,<\6-K*?)F@%.&EI:"5U$*]].UB.L[C6[W\O\5H_JF=5 )30T;O
MVQ2F.Y.V=QY)WUD"  ?YVV^<0?Y:DC_NHB\[NZ-R9A'BO/3H!Y=_U=1)$C&-
MMI7=!'<E?T0.M6@KDPYLW,UV?N@>^-:@^]7)T4\GKT[.3EZ^&QR]_KG](!QZ
M"SJ4.J?/J2BD$Z8+-X[]<DEV8@1_Z/* @._25C.DMMSE\4*2LNR,Z)B0=<*A
MB(,W2D8?J&\C='\ULFXT'LU'L3J:A!UY,F2(A1H*W8'5AE^?RP?KT@#N!XD[
MB&E7!P3$M"4Q#9YI9K5!5N3PGS,7\D\TJZ,VE&NAE?2M) (>14P-T4,E04J[
M3.FK[$#^K\UHU#]^[KG_V*7')G2;Y^[0X]T0Y7=I!\%?Q:%Y<[G^B[(MQ\B7
M!,5%'%A?=AJPDT]E__3)=)X_9&?YY4Q&^=;.9_6V=[-Y.7AC?A&K6'@G@U7%
M4'ZJ<VOU\H@TFMB)'^6W5^7@G<O\8-7S5D!?#G(O47_VG_P.!A?7^;<K>QX;
M\D(VY?MY8<>_VT_5C\\&?^[_%'592+X5JG^<O!W\=')Z]O+X;Z]/7YW^]5_#
MP<GKXW8FT<Y@J37[VB;>K]O$^QM+>#^]BC,[?P00CZ_-\WC=/-]M<T[#-M]_
M_<B%,4[KI\YR7W5[$'</R[W]HNU_T7TL/YIDYIXN*CL)U7 0/_I8BB(7#<N'
M01ZBY6]YIMC'FB9_.NP)<=\X_;"8V$4896OM*#B[\L5JIW-UP>4]E.]Z81?S
MZ<IOSY_PV45Y@7^LWX[&]M-T,7^11A]C^/'W49A?9 AJ3)8?\.5TOZLJOJAB
M=F R*ZT>KPX%FVL_NUL3^S"J1G5,].G%ZO/WE,::K^/B.<;FCP61^P*8Y3T]
M9XQ]]3WX:^_ SQGEWW^9YU+)[MP,XQU"YLENYHDZH3<WGEB9=U<BWONY^.86
M=!?[9CJ$WY?IN@7T,E;E+W]Y)I]UI0.I'W/X&_V)!_4:7,QB'/P]O^>B&KS,
MSQOJX\Z:$61XV.TNG-Z-8-^[]WJ<Z@3BVBOB>C?Z"+35-]H"GQ5\UIY3/P7J
M?VKJ+\?P L%WDN"[,P0=@GSG755 3ITB)]QMR^C=* $Y@><$Y 2>4R='"<@)
MR G("3RG3HY2Y_)VL SXX</Q-GZ(DT5\ :M[NQ ZPY&475OS!;""]8/U'^HT
M!5C!^L'Z#W6: JQ@_6#]ASI-#Q?6]ANHUM$BO+[&5EF9]?4WR^MTD$%VDJ@Y
M+BM^W+19L3B8-6D;Z,/J286DX^AU:3^8[^VZW$.R?LP3U$R0/"F-M&<*\> %
MLE93A%.D$O-@?8AWMW?11-*H'4=,8H.X"QXY2R02D00EG6->NLWC6&H"^V4V
MO3S.%RLW\<_1_.)X464(X^SE1S]>A-'D_*BJ8OY?^*;#8[^PXXL8,L;@S%C@
M44"O<^B!"H$*-2H4G1>$8XZ$5EE11+T/IXLH>*PHCIXY8^ZJ$#9*9_$BR(80
M$"_R99UA2$HLA%'EL [\9"KT_^)L&FQU48R^[*K,?P0- A8%]#J''F@0:- R
M$@K2"<89\BQ)Q(F(R#E,$+914((IDVXC$E)2*B6\02'I'#U)ZY&5WB)LC+#*
M2Q&T@DBH'TP / KH@0J!"CVM"CDN% [4(!J\RXJB"3(&6Q1L_CFHB .A&_DX
MF;#@5"*L4CFK*7_&*:P1#DI:XSBGD4$DU <>Z%Q%[TX]%>IZ+=3U&FO[OI(>
MM&- 2TO/,027H267 5-E"'<."6X"XL$2I*W7B'LB!'-8FK!QW!%F2G,2/7+"
M$<0U-LC&I!"Q3#G"0TC)="5P)5(/I6@K= 6K!^8$# \>0U"?MM*FSG'I; Y8
MJ3.(JQRK:JLBDMIAY[QU1&T$K($S'2,MY3Y'\V>2S@%K5JS$=(YUB4G*="9M
MRME0T+8.$@:C!^($# \>0Q"?EL3'TCQ^A,4<QN1_N- 2&>8D2MY1$6)4F.*[
MXB-B(I)JD\7'>,1-2L@9E<>.V!"UYT&7 ^VZ(3Y$FB&5$M1G'ZP>, 0,NX A
MJ$]+ZJ.CUEHQE^,6D95$D(1L"A)YJHP+G*8@Y%WUX0)S3RA&CKK\&8P-TLDQ
MI)G"AB2'*=\X&O7)0A\^S/<'XM.WHATLPVO/\O\ZLY/OK-5!H1K:?7J%'C@(
M+3D(RBGEA."(:&X0U\8BC8U#F >O35""X(VSTXVCE 3*D>/"(NY]=A6D=]E!
MH-@+&;Q,_C,.PNOI_',^0BO^ !MBW58F%,P:2!'0.QCT0%):DA2?:!*..$02
M=HA'(Y!UP:(<5DF"B??,;I3;,FMC10A&$H>$..,::8(EBIKF"T3.K?M<S+EK
M25&DK?@2C!HH$= [&/1 4%H2%,(Y<5Y0A*WF)8F9AR ICX22AF),;0Y'[@I*
M=-R&)#UBDGO$G3+(T!00U=8:*W"6%/)$@L*'O+5603!K($5 [V#0 TEIJRM#
M1,(LH2BHK!&<,)HEQ2L4!/8)6YP,T7<EA203B*8.89I(_@S'R&B6?R54&A*T
MCTP\D:2(H1$8)*4_]2]8M-:VG;\:94:LXJH.-DC9W@8V_SJV\Q@&5W8V_P1E
MX1[V@CS\,"E ^S'1!E^DK>4)V:\(WN5X-GF)N"T[73J6D(@<QQ2-I<QN+$^(
M+&@F+>+:)\0#3T@KDH-CCA4QS%!'X_ZMI]_EO.[Q>8!]IA. '33S<- &S6QK
M#QJF/#:8(RVTR)II,=):1^1%9,9CS+#:V(U3&D,49A*QK*QE'^FLLT9)A"77
M&#NI<7<6E%,Z5%R!; *C .P=@AUD$V2SS[(9:&219>$3.I:PD5%D.7<HFF1\
M$I$RMK&!*(2:0-Y[02< .VCFX: -FMF29O*H<J0I$I)!D*Q_(2*##4.8,<PT
M#RJYL%DJ3D*43;>]HUDX1<B:*1E!B@?*-*&)T,X</P2A9M<99;>K+JENI]Z\
MO$X'QV$G9'$VG=LQK+KL60,5H ?M9QWP*1S!6#K*D;1EBP4M#'*4>(0=IYY:
M[R-1&YL")9843089807BQ%JDN5?()F>U=Y*K]+D=Z:IV=OI1:HBEAC:SOIHO
MH ?H@73T7#J"#SHPGF6 E*VTF9?(61ZR# AC'*&4QLUN(4T]84J@% 5%G#*/
MM*<24:4\HS'%)#ZW&*8=Z9!R:#0H1V^M%] #]$ Y>JX<#IL0RS:BQ/-2OHM9
M!4B6 J^B\$)C8^W&FA=!@U'**J1X.:Z!N8B,2SE0(=99;%E@YG/K\ML*.LP0
M"]C2I;?F"^@!>B =/9<.HD(0RFG$&+&(AR(=6"@D7(RI'-^GV<8*?)X(2RQ(
M% +)00=W%IE0%N0SCK6R7M//KL!O1SH4'2K<UL;48+V/ORIRJY)4!W'>B:&>
M7L69G8\FYX/X\:JL?*Q>P/+&':I31JS\Y2_/Z+.=X;G?>@6[B>\7K!T"$:P?
MIBG "M8/U@_3%& %ZP?KAVEZV+#"22T=S-D<3ZOY8)KN=@WO_'L'D//L2<4"
MT(-Z3P?J/2HQG9*,R"2!$<?4(N,L02HF)JEBQAO61G]R(<33M*SZM-,O,"2<
M0\VGKQ8,Z %ZH!X]5X_(L+,A"40B,XA'JI&3*2%-2+1<FB#D1J/9-BW*+:C'
MSO:/ /L%]@/T#@8]T(ZV-N9W*DC#&=(JAQ]<I_P3CP0EKH+V*4C'-W9;V*9)
M>2>1!_0I]]>" 3U #]2CY^JA-944<XVR5DC$4]GBE02)7#"46"-BP!OJL4V?
M,D0>_;1?.+^EL[6QM[&*=N8O!G82LME\B./IU65^:&AMZ&'='3"$WH7N. 6!
M&ZJ-1XEFSX"'H)!V6B."@S5).I<CS78VVVD8[&@2?K[AKY?-ZHQ60DPMAX2V
MM:()S!LH$C \> Q!9MI:(YM2$EYY9(7+DB$Q1<XG6C:+]4HGK#RA[6S,LVN9
M468H6SNA&LP;*!(P/'@,06;:VH[<*"FH2BAH:1!G(2(7$D&.>ATPP5C%S6AF
MJUU\=BTSE.*A,1#.[(5] X: 81<P!)UI26=,5!Q+DE",V"ZWJ&98(::QCBK)
M$)1O9\N?7>L,X7PH65NM&6#?L/2LA^6U=W&<;_M\.#B/DSBSX[K,9L/E:#*J
MYF4CH0]PB$5?VD7@R*VNX0Q>1UL+SR(CP7N'K/(8<4\QTH23<D9S<#X['H3*
M-FIU2SK\:T.&V?<XND6%K8:Y>J@T><KF'CA9JVO$ 8"#(NXWSJ"(+2FB#T%$
MGA)R/$G$J8W(4AP12T%%S&RXIWMEF[+B(RHBD4.FGW1C7B#HKA$'  Z*N-\X
M@R*VM420!Z:TX\@IZA /.>AS+@=]V,?$HM#$<M-&!?01%5'PH: 8%!&( P!_
M>J8&G$$1>Z6(FAF%/0^(&980]\X@HP)&4;O$)0O>L=1&K?8QLZ9FB)D 1>PB
M<3S&*DJJVRGS+J_3P='8"3^<3>=V/)ANG T#O0X][&4"CZ6;:(/?TI+?(HUA
MVCJ*(M8A1_).(ALP08F8P)7!WJG-$TFWJ/9>GY6U]%!:.IJ4R"$6;55V=SES
M#]93 =@/$'9015#%/JMB-#))%BER-!"4XW>+G! "1>9UR"$[HVDCFM^FXKL;
M5319%)D!402^ -@[!#N((HABGT71!^6"XPX%Q[(H1I8C/I=P%D6>C(_1NKAY
M(L461=_=B")5<BBE!E4$P@#8.P0[J"*H8I]54?H0I14<28[K9&A$&DN-&-=>
MJ"25(!L)U&T*OSM*H"J655&!*G:7,-I?R[M51;>#"._$RD\F?GH9!S^,IU7U
MIT&:32]7M=SI9,L:+JS/A<WP>X4>. =MA<PD1BDQ1D(+AKAC NE$./(B26D5
MC5GQ6ZVN-NSU*G-7*^Z!)$-,VO(.P)"!!@&]@T&O?R*R$V'XX;XCQCLJ5]%Q
M$U.(B%M<-C94#AEO."(*8\\2#IAO;#CU767/;>2JRN.7?_IJZW)K;4'[R!T[
MF51_ GQ[PLV 'BC;02D;D]C:(#@*PGC$I;,EG@H(>\>X$5YP2UJM7>Y*V8P:
M2O*D&S=T:*Z#L@$W WJ@;(>L;%@&[V7@2#M!$!<L(ALX02XPZY+)"B9:67BZ
M<V4C& ^-A*"M"]*VJ^6E4'G\PDB<SB_B;#!:UA^7RT;_] +6C>Y00C-BY2]_
M>4:?[0S/_HEJ+WJ= %:P?K#^0YVF "M8/UC_H4Y3@!6L'ZS_4*?IX<(*YSIU
M,&]S4J9@K.;+U WD*WM2[ #T#JM4U-$"CN:.<6\)DB(IQ"T)2!OM4?)$<JDX
MD<:UT2-^,OF02:J<[-A4<%['^='E- _M_ZO7MIRFGT>5SU-C?C0);V;Q<K2X
M;&<W$N@?[ZV1 WJ '@A,SP6&FD@,8Q01ZAGBF!!D*&?(,$XM4TX(NM'[MDU7
M]U,)C*9/NDEUAV9E#ZT<T /T0&%ZKC".V62(34A0IA%7PB+G8U88B:6PW*@L
M.FUT5S^5PE!H2^NOE0-Z@!XH3,\5QCC#HQ(1::EC.91<(2.\18RD**/71AC5
M1I?SDRG,4.@G/7RN0_.R%YLI?>'<'"BCM=C^/!Q,XAP:(7I8I8>='[N)-O@D
M+?DD(M#L7BB,F @*<2H\<HH;I+RV!$N'C1*M;.Y4B/'U=#*]O0*KS:/^E*"P
M!20P!\#>(=A!'D$>'R2/![\$6C.5C.46.1-Y#O0E1MHR@RSU&/.@D]6TE6VK
M6A+B!^U@-=2FK;(FB$-']P>!@=E?'0&T0;5!M;^T<4E(G$3/4?(RJS9-&)F
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M;;/7HEGV=**TR%&)$\[^3C ;S9G;= /<X^2TNLV0),/LF'6G:_*^^7NX/@Q
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M7SJ!7?Y3G-T\DL#Y)@?5=#P*@]OS X!^)*#!X7FR12U?'20JQ'#U__P,8!:
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M +K#2,E\+,Y2V0Z?1Q 1Q&& .#[U&>+:%%HQ4@&"B" BGR*?;H,5(X@(XC!
M'!^?#K8Z8J2@1K@$VAL'@A@"-IERHYRENAUT[I*]6AV)AH5V8!'DU(XL8#R
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MTZWP>@0101P&B./3GR&F76C%2 4((H(X1CX=;#P?/ _&.P-2\-3N(I-@#0E
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MF >.-(KD4.[.N$32>1H%H0&\% :$M^T8,)<AAF"HUS2QG*Z*)/$T&\I4T=1
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MOG^K" KM$_$<,IX#PF\XGKY+>O2=!=^;W(:]$%8GJVF[?(+Q /+#]O$#*M<
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M>HC>&- ;'V<.M*9!#:%<!0F:F@R"9 4N<@K12QZX%ISF:V-01*8\\Z@@1LI
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MHQY7[5T^=N7N-$TZ*2E?R4_FJ\4%F!^KTZE;M@E]N=3C%M"2\\14[L*LO+;
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MP9%0)@?SM3.<L?,=HB$\=KU.$@ZZP$ECL &8NP!T6.&0\[X)W$+J51LPW%P
MBN$^[FDHRR5L--:LK!K,Q?9[.&A#BY2$U3@WR+7"\P_W7D/3?G" W<)2/62
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MATVN!0?&MHIE![ZNYZ[BR?!=QIO(8EL4X^J4QTKFONO_XZ[HIY5:Q;@3D/'
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M$<8KI^3KD)/Y:?X+=C[# I*O9%7L##JV([O-U>JAR_Y'] DIZS,_3[W27C^
MK%K?X@"U_[/;CY6S  ,_HLC_G0:C0%,+HG)]&SKK;>ZZ)=?;B/FCHG+6H;M/
MK[?#MG#4T2-&SU"CU"6V_UDWFA_[5W*]*E\IUT:68*= V+:7X2MW.9G)^W*]
M>ID7?UCSZEUA5C= !I=JJ7_@\OB+RKZL[$*B2]J\HNOAZN_]15?FNVI-QKNB
M*OR MY?-/7H7PI6FN=(_EK%+'J9_1NK\967><V%T&?+X =>)2Y$^Y+J'W@^N
MB[,'7)==BN@AUT5(Y6EUG\GJX!_+;<>DEBL^M+']?"BI_W7M!MV1D:@,OWR%
M<[Z\;_;2>VCXP:L[NW1AU5KP>(&T312=BFC<[JA\'&1@B[6]8Z/V2-,3HN'[
MU<O)4G#BRHFF[Z7I:_BA6A8/HR50#K_]KR\B]L43$+:VB]J72T)8;>""&\'0
MACV[+?C(J-!#>'\\5OO Y^"#VT63Y*+Y?Z#3.>[;/L719*<<?0LF.^5$*3B)
M_H_9HM^;T3K_J9;!7_[ZMR8&=&J;-E8 )[1;!SDIK<5$)X/IV*?FJAG\YT_-
MZ[):G?Z!.;N->P[*9I);D]PZ';GUW;*L*B^SNO&IM>:'NQ7S:_^/[W!@Q.D?
MI;/;TDFB31)MDFC'D&C?NZ'$IW^6SFY/)Y$VB;1)I.W5N;R^7MIKN;)><G5%
M@:=_;,YN^Z:@_+/:@BDH?Z(4G+ARXLJ]V2A/ QDX.Q9] M/CA4,%E^M*SDWU
MY20C3L9XJ-_Q8ZP'&F87E(5@G5'DC ?M!!#OE,A^J&8BOO[AY>/Y_3&T/C<I
M_MBN0H<BY!F+CU,G[0F1\C \^N!PR'[XM>./4R&SJQLY7X:=:#L)@TD83 P[
MT782!I,PF!AVHNTD#"9A,#'L1-NGC3FV<=\^[2+F[O.H &2_0T)]GQ.4+$_3
M&^.'<F[OFQ9N.5#ZP8V \<4)NTRYZ/^7-$_<M:KT,OO HA:E[]?_LFG"@SF#
MZ-")@A,ZI"<0,OT\<BU/V&0Q.'2UZPD1^USY]\1)^#3<^A_'$Q+/T3QZFDVJ
M.[I]NVS&O[F6;DD:A4*%"4FLTH3E4404IQ&Q1H@L$9K&6;39TDW$C(DPB4@>
M,D&8R#51RB@B$FEM'AIJA6Q:NMT5RY=MPT:?SFQKU+ ZS35R^R)8SPM_]]_^
M\=O;K\%I@3V'7\=?!,;J MZV^J\O"/S+32Y?_=<7Q1] AO6M*5?U]U_\-8O%
M!>5I,Q>D><^_3@)@DJ$3"4^+A),:.HX:>AJZ^\Z0;.+Q24Q,)#PQ$DZ2=I*T
MSYW')S$QD?#X))PD[11:&816TBR+I;&&9#36A(E$$QXK05*>,!G%(E4TW7-H
MI6V</T54SE-T/GFUQ93__/3C_I6<_RM8P<=PE%SB\5&#4/<PEV "T)PQL&-*
M;]*)E\^9ER="3FBO4[.Y#==1(C+8F="BS2TE$3*V8$YK%7*>9"%GFS9W:/+(
M,!.3.,[!YJ9PN9)4D"0R.4MX$JOD".G,Y"(,PSV:WM-!/_Y!GP@Y$?*T"'E^
MJN=4 ^L3-Q^?FR="3H0\+4).\G62K\^'FR="3H0\+4*>GWP]V= )3=(D@2T@
MBFI)F&$A459D)-$VCIG-P]SR/8=.]INNG"(FSR1E.15K[O&P_W;Y]C*X+H%"
M\UMXV6"U=(/9"WNB19MT*MH\.V36E-7<3U9SXM\3G</0,LE$[./,7)B,^T\S
M[BV8Z8E)8V(RH0F3*B)<<S#9E<U$:I32)MLT[K5(<LE53I)<@$-@K29"<T8R
MJL-8T8BG47[XO&A$Q45V?%#B<Q[=<L:R8Z+ZI!X_%V)/ZG%_L:\L2E-M+,E"
M$1&610E1-D^(,%*PB*9)E(Y@0Y^H'MU\N&XR7#T3SLVWW(N>Y).&G,3'1/43
MH?JD(2<->;SL^XMMH=Z35<;*I))FN2%<82(J%XHHJD"Q2BU%FL9Q&MN#*&,_
MFG4_I723-CZ/=,FALP_/;U^>EPJ9B#WIZW/T:)62><ZS$/$8C#"5YH2S')6H
M#./,1'F2ZCTKT?VB.7R<=]*;IRTR#EJO3OE^("#U?4YP;YY&0OQ:KN0LR)O3
M&DAW7"=@U-'5Z>=42'X^I#TA4IXWCPYU)[VD">I.4Z[5S)Z7F7URO9T.LRN3
M/;Z_PO20L31,*.%9;@F+PYA(:K$9%$:[.&5Y/.JS+=,DD3;FA*LH(BS1&>%Q
MGI$XUTIK*F,6'P& P3-V$6;T-(#6'V;FS]L^GXC_^1)_4JXGO2N3<MV;<I4B
MSE+-%1&"<L)4E! I,D6TB9B(I1;2CC)&GZA<SPF^,8GXYRKB)^*?@B0_<9I/
M^O5,].L$_@ _.:*<\U02QCB%/ZPA/&*@RJ5,8B,R'HW!'T^BRD\4_#&IDY/&
M@$S;,VG[YW@D)FW_^7C3AB9I+A4E*DW!F[:Y)LK&,1%,QRDSQF;):&[!)ZK@
M_4)'?(0ZGK3N.8CU/H($_BZ!+.]]^X4T:)XU"XX.1)+WX(":Z]TI?YE<)L7\
MX11,'T7 K?0A47R9]"CDVYWXSX[.,Q\MP/A#7)OHRS\U9(&SGI?E:EZNK)=C
M/_[Z#Q.'X#3DG(29B0G+;$8DHQ)NF$5*\SC*6?1%\,?M[.5,SJ__ZPL[)[^]
M/<3"W\SU;&W@P[T,CGC($__C_5[@AV_Q)*O:KH!B%N4R#$/"90B.8"(I$6F6
MPM[)6*@DA<W[I)G$ZXI<2[EX^8NM5LM"KZQY+:N;;_Z]+NY U\Q7N[V^=*"%
MDO<#&-GE[FY43[[? 7P^@R<>[H%E'BQ;@@8:*!K8CJ27K?CJ'=1)F/6%&?V
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MZIO[4]NT,TZ%[MM@HI.]=.Q3TQ;0^5.#972G?V#.;N.>@[*9Y-8DMTY';CE
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M%<'W7GI;OK+P&5"O&O@;RL)2K2/WG875>"<%G)EM+@Q0;0?C'.[H7B!?]E[
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M@(KA_[(L <:P.,4RM(2'64:LM7DNLC17_(0#&T?EC@FP^3P F[M@:!.0\WA
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MZ\:5M[ZV!S69\YK6HU3.P)31A'*F"?:"Q+$'X#VJ.!6<RHSK47K#ZA0L*:W
M'F(YN*6"$A6FABBJ-=.IDN!U]HVBQH_HA4-!+X)KWP-_534FS#3N9[G#U1C8
M1SWLV- VZOL0!-0%^A&8=JPL.+(.+GP\PZD^ZJU_.I*[*+B*W+D#8_^B6&T*
M$Q]^ >&SGM6FF#PSRSP4PB@%?FF6)88PFB@B)/BWL4Q,GHI<I7K4DUWI)(N8
MRDDN&,X*2BQ1VG "_FS(K8C"G">/=V@_LC7[)LN-P8BGX;8V5M"#HW&7 0B]
M_U[/M@D\IP$'G-R:+,,83:=,!]&:U<VR7%_?.).NW8_SB\:DAF8VLP+$GXQ
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M:=C3%4]C7;BY<Q7);M/E<M#VJ>Z9TN7)06G<%=X.6.(,@3JQBDFA7@Q,XA.
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MY7--I0_WHI]UE">4V.8O1_6<)AZXQ+F1)(X2<-8C.#-JU)J+@NL?1SDE(<_
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M&WD;O+V\N@Q>M%V#5^50W>UXB3BYB*.+F.[G/;HQTC/7<_6 9L2JO+:8<;_
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M^]W?;_0T?ZL7\9<=%92LJ8N#3FXM>5<86T_. 3D#M)G7<U1N2CBA?GU8I;+
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M\TW?:=*WC29MKC*8H[@,YHC+8,YE,.<RF/.\@SDGHVJ>M8M S7N*2']$L[^
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MITM_,)TWXK:\41];Q3":C[T_BV7*7C7/D/Z5\EUAD6Y7KC&^8<UC"$"ZR^[
MK%W#7L"09V]0LP=BE,;T\IK#Y2"I?^!2<0^ZU6A)+ELBA9@ K6-(D]*;,/>H
MHT+L?M422*1WZ;IO<R)PO/VS"W!8Y$;4STTB]O7MR/3W*3IGYD,&L\SM,@P?
M[E-8*6<F(V=>(95<PWZMY]\^)I43)^MNN1K)8YRV'+[W%4AM%^MF.1V<RZ$=
MZF8\893#M#'S8/9XLE+PB9D7O$]>N.-E'9^2H!Y6'S/?Z'#!Y^\VDX"-;[_.
MHZ&P6! 367CS& 9/D[TYYQ:"KOMRN3ZZ5-QGT>+%9][W:O#"HT3W,=:>M!-W
M>O8'1I#B*B78EHCZDGVAEH@F'?S11/*#00/ZNSY@0>HY0Q>$]UGFVK/*O<A"
M<J8I1X83&QQ"QY$6CJ'2 ->-]=X4D_RN$J4O*RY0(1G)4-38:RB\,E(J3KD]
MR!(;DRV?R@9Z5^Z%O2Q;S?/="SR1.7[DW%04/.B($-&&\BF:F?"/SVJFNF\8
M.]\(/C^CPD%['*_#SAC*+Z_&(!S@W;3@?)D,)-TWCT7F?\2$5NO29(*Y_+L>
M8M[=A'K7P2'(W%K!">L\Z(\9@F$/3].N7POBU_&CO5"BX"1GG)\33J'KY;W
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M]K!],>J6L >2[I%G2H7W# [S6[=N(/!O7ND8"2=JJ.BAQG![T+*1IAAZ5(3
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MKYBCUFT,_[+NMQNHA=^OXZ*H5>R^B/CR^Y3P#=9WEQ&AEE @M-&5,+M#WL;
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M_?P+^F;S#T12*TJ+);_ZV**J)+1 L]D&)S5H0P#ZZ#?R)@S+[I+O]F$_%N^
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M=R[TC%W]P:Z?@PNG-LR6^$4N\0OW?^(,;@"[G$K9?,WFZ_#-5[$+"A@<+NP
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MKG;LP%D.[)=C_+PY'(W-^70Q/X[5E^"?M]M =!.$7AX/8S,V9W4XK@.8Y$"
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MKI'!XO!@D0694;=WJ,N4LJEA/;:8(UYZB123#!$CA7 T:.[B==051,/ E27
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MP S*O6%6;214E-1K*0TP'G<*<: ]I&UT",.%##;,,[W9W-N=!+\8AW?Q.EP
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MH-?#*-^D-9T,)ZV)W^G(R70R\(7<B/+Y$^EWA^-6T)\&K7XW!%5D)/W6N!.
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MQ#E!]'L 1+(N5?L^;-=O#WJ]+]]7WM#KC'OE__K'(%RW:2+_FQ8@WM(B#DA
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M:&@JTF91.9MI$<6(1[B1"I5GRY9%W5R*N=YO,T#"0,J%(Z_1TX2 N(I4[C:
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M96Y5AW&JL']-*4-W@@WG;L=MTX;QA(Z$/Y+M^F^Y%@9>U8BW[&!CYF!PW?!
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M9FEA.UJ:Q^LS171RT<>W;\SNAG]%AIV4JNZ]I@Y()$CT."*'!!ULI+-G":"
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M(3.11\F%(Z\7V/]&O>0F-X^)S4 R_.;OS[QGCT;0XT/K/<H_IFOCZ-H@*C(
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M/;P4WYS(H.V\2S.9TM# FH2)4-ZA#U8FSB6(0('Q<33P4%@STD6TIN2#'2?
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MX3"3EQ'<>@_AS<QQ6LRAH4CS!RS_IHE4U0[70<BRR$J<S34^">T?TKE^Z(#
M'! 3F7++ N2WOY^53]&9MLM; GYX5YG>:#*LJK?IG*U+( /SZ>GQ:27A;+2F
M3+$C9VC%LZMISW4.H[2_)7,6<]9=" C6PT)H-,,LTC* FV(L6:>/" J+ V>
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M B:(X.F"*!S-%W 5W2T!*M-YY,,4?:"-I9R2U3PHWI%)>BN]D+3G)<!P(G'
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M?%$UV.M-4_7&S\0%ND*\,=,YHH1G%]45FI;9D#'-W'D(/J8H!.E'D+8*56U
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M@FXSV],#MB><B"D;98"#60@4E;%0@R!NN%4G6E5,%*>&*$?R55;3%M?,=O6
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M(21U-G;Y,!&F3SD0:?0I,_A^R1L??\5+[C19B6JZA)$Z0_ZG?HVB+Q\]EO>
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MY&!P$XH__B/;',4X3C=O'('*09$]F(IJ8J(Y"K1)2+M.,DJ@@FF--3(%)QO
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M7M-V&[&HWNL$%SQD#8S=3>^U8^L6KV'E4IZ0E*-/R*)R?&WP631@:+Z#AW'
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M#3H3VH*;9.OQ6A>5%<PL'=6Z*13?$P*,0&)^JF)W"P]U)#P(42 Y;!<.><L
M:V"[YH49&TX*[LLQ(PJMBM-/R$%.>!%H=*.'@_]QZ4P['."[@4@>9DWAL_^E
MDQ8BJL=7"%B\DTHA&62+Q!:=- O&!7?'7(?['CH HGPE-9R@F2Q^,<.P&H[
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ME6N:VL\3C"/4MPWD-B^PWXTQ #8D1&_!8E>&8IY-\ GQ35)#39N==^8C8J:
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MH%RYJEM&D_OM'JA3385MG'/)AY0P@^(]DAN-S?Q8?D+<2^O]58>J.1W%7(P
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M/1Y @Q[ER[%L$++I;+#);0YV/#/FO[:,0)0E\R-"OTOR%?:P""UKO#Y'#A'
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M9Q:*B,5(%]VX_Z6>9V)-3:=8<-%P417NW'R>6K[S:J*),\FG%:3_"^B$@*I
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M!- IRLM"OH7:45!&:[Q#NQC\*-IR83,R'-D'6R? ?B?.JHQQ(3U4,1$X6($
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M7OU3<.W9K.N]F[+H </;RJ>SNAF@D['-N0=O>\5(YL*>IO++>^XCA.5D$@*
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MZ<N.@;F,@E(?)OS 6P$_S8J!,XZ,&574G2_1P-2#?_,GW@6+R[YFV^,"A6\
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MORHAJS\'8(-MZUZ#*\G+1^Y3\*#$(0N16AJE\?'%3THQD,G [L@:TW8RE[4
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MA6+%WM@+7&3C[%K&1]4L'1W]%06GF9@*VZ<>MB0O*<&G\-$H(0"'MQ@/EJW
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MH@LN"+@"X&X\560)H:GSD]'UF'9A8%ZO0+R<<!N)Q%WAEM[,,=C76[!3FGD
M^;.QA@4(/@M6XVL4(;8Y[["RHR@+0G;8=B7P']/!E1?^W\@?108G9#DHC"<
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M50G;,V](N@)K<)=8;G@-QKVB!P]D+M183^K<P446:: <\=]M6'A0D$1;0T7
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MW\W)>H7LBI)!MB>-*_'H2A<X6,2QI6(@5<2QPH%#M%>,VB2R(#.B+I_]Y?#
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M0T(6Y-:LF;W!F@GJ=M&N,7(TH6(YLF&2BB6A13H ^!6M*6Q^1B5S$$<&3%<
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M)H163]-L,[640[1MKZ6N.OM<_/<(KO['_P-02P,$%     @ [X$%4VD%X+E
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MDR*6%%A]ULX:;+0*;4Q!K:3V49<,BB@CHVW$A06*2TV:9?2QR.7REK>>'V8
MX4;)<HKF48SR<G#AH>3B!>A%%,-%Z,1KHLN @^CB>RDBY.4J3%$,W#*3E>ZO
M1[THPEB+G7<*%';N\Q'8+:V-[M:UC"Q:VRBC:Z073AS">E>J4.Q,Y#)&3"]K
MRL@+A:S@V,O2ND;_&\(/4) W>88S^H1N,DRSIG,RMF2:I?AMA5<X=['60ZX-
MPV9:+,#.8.7FRFS%E%U)L,?2G=3NW*YEV-J1,6YOL-9)=FRL,?>-S602-U$
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MR?U1K5'637HOIJ#-N*46C0\&;0&J2<RZZ78BA*+V-6O1Z'04QG0*.EP-R@7
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M^$M,UO0AC!X3%#_C=;P*5UE:RG]^L=*"VTIE5Q9&HQE*Y&HX-O8JEICY2%5
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M.\M]$8K^F=9S7AU5$:17\QB8IR([52Z04AZ*<XOVL(BLOB;IQ9RPM<\(!VH
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MPW>;#;4MDUCCRDVJ5?80K:TOE,DS*L($,&90+]'7_2RC+52M'#Q'*7']19Z
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MA,!\P#HOY)7!RDYCY+@+Y8B.1)@10O32\0. ]#[ZXGPK[WGE@(Y MN%IQZI
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M([^$K8#/1Y:2P4[G%TZ,<_Q58+0)E<J:UR]:[CD5,?E222?:V/_]!G^ZIC?
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M1G-Z3UWJO]36P] '6U?98%#@ (W(IZTGK+[F<=^1M@*W06!QP[F\_W?;&3P
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MFDV1T#S@)7(!,X3Y2_!<+8K7H]950_-18/1F_7<+UJPD!?1\B8NG5+-"VS%
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MG2SC7N2RX"\&116 0$D0)P&D1&(E"EKRV:P M*W9"IMU:Y?\PD'_O^9.L"O
MFH)6]8*G4@I ?%2BX8F")='^&L7G@9,HD0U'+F*.Y1U#0PH\A",Z(PP58;@(
M(B._<'3C,#[?%:QC>(H1IO'05=G^!3$9Y%>J+T(!F[8FU/U4$K8AQ7 ZA"..
MBU"!C*PH)=&*8+PJ'CSPU-S ]?E*4AHFQ"MPGB;G08EIB8< (E+"1 0J<G'J
M'%?.V@EQ7JZH,8/_\5A1$%%4 &T8PQ]=CH1/'(X 5KK$0+!R\LGP5IG(GNQ]
M;X8_9OEEU 3"\< *&\_2-/:?X)'.^D-<B.<\-TLM5DK8'7[]D#W]%7Z_C*XR
MC&K'] ,X<0:*9>9YK/$?:!,)(PD4>VY"@!](^DQ!_P]<K+>)$H*#CMD<X*^7
M=P_$28@#)SMV_, _X=?;"$L@^NA0)-(\02ACB!V3.4L27<*YPM?&BO%%7CAC
M!#6V-0.:HK4\BW<D07<-V=#T.?*^^IE2-^=]?[E][6(15Y)"$.$4$4X246DB
MRXA(J@@GBRQ61!$G&T0$:?@Y)XY\,25-J67UDNA^[DN1&7.PLKFOQK!'_E8$
MT.+;$,7(-ME7Q;=BU^JY;$ L[-?O6/?/_#FI4F'< &9?4(=MK71_:\$)WR4V
M<_+:R[J@;^D\@+4\9)_<TI1P"QWY%FUTWQ$ SYF<[@-,6>_Y TS ,KYJ!](>
MU),]XEO"UF/1W)24C,R'LO-"XZ>HM!U\L1W02/S=1*E6MX!%F@N"N0,."Y9E
M,-/"A@^K:TY744SY=TOG#3UV:>Q$L<>:MS!WY6T$?PU3+/X(0V7?TX&77L$]
M>6(D<),^%C5D!F(AH!1),B>?W)>A9V;+?+'=%.62-NF92IAR.^2 0QC\0638
M0UC)?981.A?\&<?O]466)M@?Z9A'BC(=$M4[A^.23Y6H '\FWX^GR[!RO-<S
M;(G?EZ*]CCF7TMT4'$G6_$<'<FO( K$?3\L7+8^J!0E4VW,<.;<,#YY!ZKM/
M[EF.C DAYU>Z%4^4[<ID[[$OS%\MC!N:\/XL\S\??>4<-LW_G_CH-)FNS#9[
M]9"070:C3[J\JFJ.LKS(;5IZBV@)2RI@ _NJ"V/+7SJF)EJ)%!9*T_ 0L1)4
M&Z%B U2^<EP5U_ML/<<Q"#"FS_"^]%_$LP/>0XL5O#V&L:& S5]7Q-#S2N\R
M"EI6D,$P"KU,5$-"2LR(1X7!DZMJ:Q/:]5!+6^F93N IQP]H"Z^&O1HD3N*[
MQMAY0N@C6XZ+VR#8X=V+OSWNJJV_8X(=NU:9J=BD(E%Q,B5?F?-M<*&TVGJ"
MG^+!IL#Q/$@-+_R]I_W@/=S+H&%H+YM;VL'>JA;>'8M.4'/<[86$]MZ[!J]+
MRP=RH,&/5SK()3EBO.6MW62Z*T+8CPV(KQ&4I( ($OJ*[!=)@\' 3,.FS:!\
MZN42N,U?S4(6"_7\NQC)H*OIN*^Q7_=DG.$S_H SROUQ,SXWJ[WJ>ELH,RM!
M%L[[?-T:GT!-[ 2=G$S]<=0Q'W:VDQ966N;"\-XH2I+6,H)E!/AB8"5'M43
M2)1X&C D!,X!N>:(&A\3V(J/L22%8%\ C5->$LHO2QY["(@)PVS(G,1+!3 R
MM!E6.4P1%FDT^D87]4$SX8;->;HXJ+HA:S@QYGKB";&#R"_;!?(<6Z.+IZU,
MJ3Z_0@[88$@,%D*_C<*H'!HC2L ,"CY#R+D-DG* WYUA4N\$S51Y+?X9O#4W
MW+:$0L"G^Y<(\P_0_77OI%04_!HB&@E8.$.W6+F(O.18SLB&XSAM.?FA>3EQ
M'#;W>+7B5,E/.M!T70 Z68YJO5LY*J+@(@P9^3K8;O6'%5E?J<(^7\TE3[A!
M$R HRCVK.PR-=3VP8(-1W[,,\6 GUK#-67@6SLC_?/_]^_?O/Y"M$Y,7!/T'
M\N/[]V?O^?])2Z^3I<]1C-U',%,-M/?_)PLI?'A&L%(3U]BIRU0&\N,']MOW
M?R ?X(/?_/9W9[_[[;^R3SY\_.W9;S[\V]EO?_.^$BZ"?U5< ?V1G&$>W):7
MG@H,U!RI%(N=R7JQBY!^>OB31FV)L0@@32I*1ID1IR7 )Q(! 0R$HR" @WPB
M#T1AT/"3PABGE0-R?^9&8ZQT5FM<DR6X)\A4[[59ONQ.>!J;UJ@M!N7%)3L%
M7T7Q?;1S@J-N936 0 *9-LG2D") L7!("Z2C6H3_AQW=X#*GO'GZ US=K.[Q
M-6LV-CCA%3&<<=V(%HC8_>P7& P^^"A+Y^EH&3;(4,LQG)$UQ\%X<TI83HX]
M1;7-V?NDL%?&0@0:XUX$,]P&!S-JYHR_3%)_D_=^2Z3SGQ577C[3RX>[N^'7
M=(Y$5:J9V3Q#/*SN V(Z,1:#*G</1: ]X^ZQX XN[SOX?V8O;&.<5B[KZ7#<
M'$>CPSQL,[PQ/VZ*HOH7F2@&[4<>>U3?TE?VET&7(PL'1)N!2ZF7\$Q*G+!H
MM:*QT;!&S>9OY;[@YF\5=.ZHO,QMX8;O"5&M/Q&IY*(@_1"N)$19=NJ,"*#&
M>;&1K*(P6E>P\4R)2BO;+6T6IBU""E&GA,N_HKQB_O;PB58"%Q$^4P+8#PJF
M,U+@LE".1&K)>1K); ,ZNFAUB&%H"5N;(!'1>&-8;K=$)[;M&<8:G!$5)YK;
M)%8F(('73FF64B.'RDX?7*(&HZF_E>"_PUI<^SO?].&5EP:[<WSO.CQWMCX@
M/)2U+;NK+D-/GF!%Q3&$BZP)R&?DDAM2YP[0[!I\K6AE[2%UXK0'<W.Z]L/P
ME/@K73PMG!G?;>6BJW .\#KW^ 2+(N_5#P:Q5E-E%OTHW^9(B,1B7F/@L1\Z
M2IZ4JA:=X3\%,W=X@*)3L!+17*X[0F3A$>,L,T6-"WZXOB<GT'1:I3F;E9IE
MR6Q6^[<^7G4,USN8H@U1L%EA?%_EF:7G3ASO8-D<Y>BK7A$M"H\#BI] 11@N
M>Y>&0=;5*^0PYBU>*D;XKR[W_IR/K.5KY+N?JF_KG7=!G]*BH<SLQ?$#O"&N
MHAB[Y\V"('K%=0;_/H^I=]Q=5=WPB),42$'+EVC?K:+X7>*@NINC9HX)CIP@
M=GM'@#W9J"?"4.E8/"-L"*A<WG"8:,QK<\RBAM7@4 "?G10IW>%Q FH6;T::
M+%::](6[D@'O@3$O4?)3)4>*3V>;>H,LZ)A7OI/V&I@UT%:UE+@4&B\ )PIT
M83>P6_92@Z5OOW*GK1O@'AOFAM23R0XSU\TV6 (<VP.O?-<_F*_J>2\Q%/D4
MWRI(B,#RG;V#W13+ZC'>FVF+Y[5^OLN*34^.31_#(J)A&<U<4*FP"3DZ!=(=
MMKA&>R4J6MMC:HJ53E\9-P%O:8&'2$1GA*'B3[<<FWD_=6V4^2 O?'MY9VZ1
M9KJK)5=\XU0><:M4CZG*[%4GC]TKMDXH_7RJ9U,?3BT>2YKT(9L*3MD74C59
M#K*\5CP>->;*$5HQ,M08U#Y<TVGJRLA0P)&Y2M&PUZS$V]*+\M2;SZP="3OP
M4"2/8?24T)@U%;X.MUF:R/Z.OBCTA3XZD:.?Y(Y*[L2ONI*&"!()E.81A48N
M5Y5*PLDD93K/2$XI2VI-2EY53BZI\4Y9...%+GQ\+L'^T2[5ZP>>4B#$QJ,L
M;![KFE@KG^;MS%D\R37P5W[AMG-F>"$>ZVW:GR()R>IDZ'"6%82;KUPY*'MH
MSZD@*B"-NMWU,%5R%[2Q9=,[,#39JUQ=M)DGJW>-6II8Z[FE!$F.Q-2 0E&=
MEVE=U:!Q;E1-O+;>KK4UDLSO/!.QKD&AD3<5?SNQZ-V]Q.#F %ZR81@,)@'?
M1.%:8WP @K,? J"!B:"%?C/+ZLH/81?Z3L"?S.)-C7:Q)&5OG2'ATSGP_$&>
MPR>(8/HE4/JESQLK0J./D?P JR]_8#@Y,@/8;A9$L)Z6<U9Q=WC*@0J4?/LO
MR_F_?$<8:#,\_)1MG/!ZL\G"R&/V>1JZNR]^G"6:^&$(2!4#82B OY^NOYAE
M\)YZF<NM=/<TH4[L8G3'!7VA0<3,G1I2\7(<HN<MP\*,JEZ!AU"325RFV QJ
M.+Q7.510F$U3,\7A7@7A ^;2T DI?<$+D8^#ETJR%W2.>8BN&\.#0G%_#UG&
MN0M:Y@$1%Q%C[*\CH]%%[Q">;,JQDZ! ?_+R""JBD"C9Q0X/N/W ?):D+Q"K
M@0@G+XK*QM"P.@QM%^&8Q&92M0E*O1G_'6<\I&MT6,OWGW![LBY"]1UU)LY6
M?8^WQ:HQO>HT^&GHYM8R3R9[R)?2@[I8O0XOWUR:)(L5BQQ(6*K%!2RZW.<T
MJ*9GMR1PUU)& G[E%$00#Z@@*_0LL4I+7Z_$Q';('5R2%CSC>^P1_(R3A%\I
M1!&DBA2^N:]7@I4-F$O2DY+T0]E53<M:-+1],7!RL6+&O9+ 9FMX1^)-(.]:
M5K9NR,;,(19W**M*9S#91B9#W^"$Y.[=([WXU8XP,M$Z8+,=J$&8(DW5T(S5
M)\ASNR&&T@>PF&2?[\7J9P<CE@Z/65!FCIDF,1JAVC\3HQ-<@;%H_ U?O7*D
MY%M?MATTU"G-CC#$:<F0R3:2')V,%!#F8HF12)1X/ JDIRR RF''!2$J WI<
M$-QW(*W+;:O"U$G6)HF9^^S#"Y;?$4>WT.VU*6#)PPD?BM!S%HZ"Y26<@@)V
MTBO--\?=)7I$TWN+*.AP<WPVVT[9 N<'[XW*2C#98CEW8\!6I+3A/I2QO/=T
MX_A8OV:QNO(3UPG^3)WAU0F_I7EF,6Z#Q'\CL%?29S@:0JS96BHA:F#]ZPS.
M*;4.D!:!YC*M'S15:0TC7<58]8O7H_Y?+D&U37<SSX-O$O&?&S^D'X\M*,7@
M$0'I3/Y $"99OD8&8\BSIX3^+4-[Z@L+HM?25"0'2CC4$Z _:""=_&*TT4<3
M'P-[GM6P8;"#F;9>$S7N?!8Z;*[EK3;2<]=DN3^&A7B*P:172Z!9HC]OVO2W
M#-^HT68+*D&87D1X*1][D#)8) =&?N'@IDY^J79BA0<;G984C_H+53)^L.X%
MJQQ2_V>ER'^R/*8RDCRN9!,F9H%3<*G91PESO52I4;]0^Q\DHD^3R3-[=/'5
M=O(Z+1EFVVT@NG.*6+J'9TI3+/P51)CCH.%*+U#(>#W"D! %B[5[WAR_ZFHH
M\YF?)08UL8(#W ]%/N(]9?F@S'.YU_1F\.066/FZ+_ 2@5BX<GF_K;F:VFAK
MSBU+IG0HX%/M'>>:-1@R7.E[OY)*5Z65NRCPW8-K24IM"W-19S4%54BUZDKM
M1QSWUR&1AI;VC25GS,67/25S/]I0[V&FY1' 01(.DSS,##T"=% N5F6%8C(S
M_ C007HUAN_)X$'Q^+",6?[BKJCM,DC@CR!D"5*I%V/A[:*/%74"'K]_^)Y\
MBEYH' J5C.$P%F74KX/7E?^&EY7Q-EYG-7V\5HC;2G2'+5GD]H*^G=P8RNGT
M<QLN@7*,_=[\VDUXSWT#Q]=WKEJ ?E;SW8M<:Z6J\\FQ6&LIDH$ !A6INYAN
M'=\3(;_XJF;U0$5< T_+&-A>F"&0(<W\F<QKC@HD(OG#1G\B8\Q6W#EECIT&
MCD?RT3V&GJC]33T>R33;X+^.349BN$@1Q,*P*;M2Q2<CO3C&4Q5 ;7@KHOP]
M\3=;ULK<%U6 #=<H>NKNA/M4[82[X,UOOP!U%)N1R6:URPA_)>([T#CU,_77
MS_@-J$O.FG*?+@N5YN=3Y@28S_;A6.M13EW9NJ":S.8[HGR6%TY"-HC@@W!&
MV+F2]]U=1NS71.&&2':(X(?D#!&%(\)8^C_3UG[&'2#+,S$_> K2@DI3N2WR
M?<[L,]PP<Z_IO:P\_GEXCL/ DV\!P7>&E&:]# 5[5@P>8L+!DGL+3^KK<!5D
M-/R[,Y/)1W=QM(Z=C9X\Y1P\,)(G'6T%!F-AZWI9$K.DLI)GBDG()S9+I6BW
M-K[,L/.9MZ7GH5K+:$Z/JTQ166L"J@RH22/R1$58C:&5IHD/L< D_2*:#N[,
M.17Q=I,F7UU,+7-@* H0;EU_Y5,U83*/]\,GQ2P,X>J[@8<\*/^?'50$0U:[
MF0[.',MQEU(H\Z __M)P&'YX.S("R*:@@*RHL=0QJV*1"F0N#C5WML#*$PJY
M. 1BHF FB/HKD$;)*Z5AA9R"(M/@DREI,ZB6F8B"SC5Y)W#0<OPSZ+_,EK!:
M@43CI*37#PPV$R@(P\%-)P)+^<UD,@:MU&]&+3^NI5\;-XR4ZX[;:\ZFMY)!
MN3=%:VJ_C59KO&"\0#BG(5T-*TNMU(D70,FW JSY6I87=!O#V<:6._P<4+:]
MX"15JKP.*QM?P#\C.0;>1%C!,4*//+9%<EO6\,*X#8WR^$XL['B6BN26G?:*
M'UUG:YA21QCK$R@LPC+Q7VP>:7XV-J$50[1BA[8TM1<T!JEC'%R>&KM8%;_4
MTN^T *<6W54K^O(FO?;ZG-;T.-L+3#&RZ)O:GM4%K8RY03X[\:^4M<\K7/L:
MRF$78$N=;6Q5N9:]&NYH+$/.?!?U"C] C\ 0SO(V$ ";O];/6*%IEVL7'('-
MPK*ZRGN6"Y9RJ/8JEE:[6^CJ)E33S\)NRR!Y(GZ"EQV6>E^$Q>\&-PV2@.!@
M!?"B3R;!<@W*GTRV#BK2Q/96Y(!ZI>+%)?+%U(594Z?T5)@JUQFHX:VN"*M1
MYOAA?$^WJ%&'ZX?42;-C[3^2'^%4SX$2#G7Z?)1R4\9CAG6LQ0"D%WKAI,Z1
M5W%Y4A286,?%D8Q-GX^:21F#F8=G&@1HXW'"8V.X!?4,$A&@IDIRC=0MT'TA
M[.O_E3DQ4!#L^+8[-F-"0",Y.+&-)TU\J7#A.!RP"$B?)V[HD'\![R3(KYT!
M2SSPO7;E!_0V&^"K%EL6X1 .:)KDUAPSEFA&XVF\%;&_>*?3<XPYBT'?\XY-
M[LRO)P4TTQ<H$< )0C\9MFK5U1*&,\$>MK*RQ.'2>;OV8$?Z*]]E-.C8*&A#
M+T.UL 0U<5([2Z,PM%\FY-A8Q,M2F9!2E1 #L8!:.:B=COIZ)PL3I9'VF#F'
M'Q?Q,GH]NM1 >3(0'EG$!"%.FOSVF6!L1-;88.?D(KZ+HQ<_/+S:8OU4\,,7
MYD*"G3XC-3=^/B7Y76*1G;LH29W@?_O;X?>^G!4.D@!,XY>A#B;:9L0**[@3
M9S%U!LP V\P(8Z)DEM*)+-!Z$[E.</<<A<.>$0P,87",J@]#R57%:X/F/.0(
M#RQ>8S#OG0-;QM<1:B1!8[6'HC&/A&XEPDCT&!K&B,PFLT&O]]=,>'66$9QA
M3%(P(X[O78?GSM:'LZP^W^.>\N+,]('&+[Y+>2E);"N[#AF4P;T 9W?7Y\*Z
MW]9V/ \=8-V!X?0E"A$68C]8*:RK.-K4Y55>RG*/.*?P_SUX90R+"N&5MU:
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MB,Q+SLWLBI8=<5:\V":Q&X8*XO"=D+_JIK )AK+?;P/L3_F(+#]BEACU/CM
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M,H^7L6GC58BLS)51!EOUO[,]-@VZ ++$#VF2G$>;)WC&X\'0;6$K"^18KX?
M3!34I(=Y<4]<7Y5P]FH@<O.6VV1+WE3/\$E)P^[2.&G6R]5V+I/4QQ \3[5Q
MLNID]>O '.N7<+QY'O4N:.R_.-CE7?=!(#&0 L4XV]T@JQ/<UJQH*99699VL
M$]_$HJZO_P7K.'>!H>$V6H?,:N_$/!-!U)=J$ WVM)#-=YV"=$/ZJ6D)B3W
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M2BH"2_9D7.B*7\RT2YN4$'G]@LO0$XM2IN4Y*3;!A*OEQP]GY./[CQ_^(>0
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ME7GG49X]D\)M7+S6)=*T'49*'K^AH&C0Q989AL/U#9SY1?>_STZ:Q?!?+6N
M8R(Y*L)P%<T/B<1F5>&RP'_3C OHN-+A7TUR,3+[Y55?YIX7:,9B7Q$66+[&
ME$X/L^J\(KV2>FKVF[&C,LIE$C"9\%K/K%P8HPUU E=2Q]K:2?+(DTB@2Y!
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MM73VL'T$G'JE0787JOC.B'RS8_<;H 22PK<$W#A "WKV<\13;DUZH1X]^Y^
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MU+#;,= KH]7B/T;-HP)]T;'!EGI0F+L#4N^[[8;17E 7\A%#V%)'FF%MOX3
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M"=2C^>M'66L[]%UT7X/%*5@._E#FA;8(",MAUJVN8(=<6/\<ZH9Q+[K#\I(
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M%,6UNHF\2,0^/FE:.JT>LDJU6XDC25H;/P5''AC+2==&2N8*241[/UVJ2&B
M7<>G:;N6J4^Z;<OB:C&79LCU&QGL9UL"H. :M/<S?B'TTJB;9JZW84CC[K,C
MP9.Q%#IWZ2!VV6$T7=M'>*N7SJ_.ZW7@<N\HH]%(X-;ZQ"KN44_?UF8:6J])
MI0O'ER'"_,;&-UJ,,07U*0B?8Q2]$""O@TV:%.G.< ZUY+[J_)1I(5):IB@T
MCFP>WW)M]1!" DNKL<=,6XYSBQ#1!E'CX%H.5N>4,;T<8LO!EA:L2LN,G*!S
MFK#M"T;U0*Q6K"V';2CI2T >)"24:1.T/OH2=\5RN[<R,\H22RW': 2DH2]I
MVO*=4V<A!+*YY5@9/>5:50F6.]0,_4CV?S"&V+!1I>8Y1DNXQ0EZBE*C=SZ)
M30D\XC&U(2X+;?I)B8Z:E,8/[@IY*:F+RB\L6?F34&M^^'BF26#W#$,R6VVY
MD*4.GH8#. 3S-+Y<34=(YT\G8],-B+T(L4MU;K\X24I.J93YL<M(VM^%^N=G
M:^*H&!,>&6Z>=TT2+WHDEZBWR\"(O"HI4'@R-'_*-$$\.(U5IY-D^2O3&=1^
M3[7%[U S!]$1/CYTXBT.7/4VQC(8,(L%5G+0QF?;O?PU=.J[^0<>X4)OG;78
M4;"73QG+KK+>^.$698=U3B\<T_>EO?WH,T2=0+:L,DVSR/>ZT<CX7/<TDKSY
MWAAW8=R]@VPB4+D5<5X34HYCU3#PF#"I$KWJU$NUXRR.TW7VM\[X'/ 1\UC=
MAC2P$E4J-],U/ 4XZ7ITNHQI'HGJ,2=T]2J,]O>X\KC.?#HM&NS+OBR4.I]1
ME9(B@D/.Q;1 P.3MVNLO'\I262YF]<F'UO+#\?DVRQ'6G_NRR359#B"?\:J!
MHH'5.14@N:;:!HT]%3R4#]8A_*+E;B#MAXP%^ZF (GG2.G';EKNMJ&(X*)\^
M1&Z9D623/D*U\+&GE-X=ZN;4B'.4"PSX!?93(!**XJ/::.97/PL2[)&YX1?T
M0/S#J*O Y:OKIW"ZKH!<D.N:%M7@5#-Q]_ ATT13)85WYU-F.9O8#4-]9]5B
MD^.\4MEQYGDX6\QUL BC-?WC!4H<[!M];>(HJ= J^*\FG8(_?;TG; 33$-7\
M51,5E9K5%^<5K],U=U[UWXT;5H@O7;+=>;D*C+CB/L:,D_7)"*VR[+::O'KF
MAU1,9=GB- UJLEX 4&,GVCXX5)(GPI3H>'';&UO!;AY$T3I?5*IEB:W_[1U-
MK>F@ S72^L[,ZW@5@FSY;0X?@R<:7GENM@Y.0V.9.DIHTLTFC)+'\#8$>7#G
M*76#EHY_"9Q.LA7<)N5ACF&]PDO782!=_IQPW>.RWCOWH#&;#<F:4):(<6;J
MOYDLQIJ;#(3>1?OMQO" [RG(=#WB-^8=6@C4UW&<(N\B)102Y"4<>E1DBF_1
M-_H3GVF4ZCPHAXX#,8=>^WT$S,==A%U4"*GM+$>]^<A.#0U*['AH&GTU7?O"
M^CM?/($$&WTC2H-@2>1EZK=,':'7:QS'Q+#$N-UJ_8V%RY6S+,$E_M94O<[9
M!6$77>!'H8N0%Q/=3/&!!Q(C[($<<)<^^]@M^#(6] J]1_"LW3G1/**4/3O*
M+5=:IJ>N;4 1J8_@+(D2;0DLRA(^]3DB%H@*Q#F-H:2;M1OJ@VADP/)36LL9
M4,ZB. 64-')8,X4!S!7K(04ID%<H+F>NFZ[3+!H0+;"+^=6Z6SN:+,34J'@
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M;6-]JJ-H>M XQ77W'C-V.U.0<ZK],(%EMQWR*<CYKGF4,X6<=XK9;$37=$^
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MGJ<@L:\%)7%;.YH3N_8GTQ8@+.ZCZ7 \!6F,O"NXH"1S+<K<"&;>"[ (K.P
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M&W^P'*OA1%"!!V6.[4^68:MT#D$T\L,EP:1(\MNT4]H&3[_4\?/#WVI4\43
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MJYABUWX_NMLO.GB_AK ;M,C8/>R*;O*@\&6+4<T??'/@%A.P&>/LBAK$.)^
M%1C?X_CWJP@1IS,$7'\R%&U@?M=:1 >D"Z+/VXOO<#1!]'DK\"V(W@5^P1X(
M^D-S"[7OFE*/<70.1,?%$/S[,%B,0I7.5"44(-3PZ0,"?QP:TCXTU U@+49O
M7!%)$JH RZV/)^?@8/8>M#TD=7V$[<:F4S3V64^'^U94V7XICG5G2J%V")/K
MM$$':,JT9K6<-DB;FJV/#)?3OFA3UDW9+4>Y/0VJ-F6",/[LU%6%?>2U'+L'
M5L/7=N8F $FRG0$F#"_<$7A=30'M4T"[M2&7%GNY3+YVX[&>[3VTEOG:=9GZ
MY1\IO'O7 9SZE.YYTT.[]/HNDI3KA4[Y^^H( \OPMF 7*&CPAR8AS-B#^X<9
MDWI*=+!OX^LIMP??]\;G[<,WRS!E#-_&Y^W#-\]U;1#B_1G8A_+(GH>O/]B,
M<2/M)B61%\#,EK*^.?C;IV;?O@B+4HQ@<U3G9]\.U1^Y\>V0ZOSLVZ%*18KQ
M;8_2Y.S;&RO>G:\_&[<,3+F5[$_+82O*)^=^."+L1V915)<%IVKGASI)GEBF
MI5/T-QT3_CT_J3**]U.'>&0TO6D%F+9G5-O3-"),M>E'MD$,*\14LWYD>[1O
M0YAJV8]XER2T47UX H]/\#BR#50VETP.PZ/:/V5CRA".Q=/^]61JR3=OJCHW
MCLU3,G@4FZ>U AV+?1F;6__NARK^).PAB-$Q>O$_.+X38;BPL-7Q+/#FBP5V
MX1;5CI?8#UIIB,GK>:Q>S]>!&Z[AY,-5)S.Z(5^"B0O#'<1]#,8M("#4*SB+
M%^@%^>&&3"Z_I&W1"ZT]1[8_@N@;48^C<R;8>Q;M\:V?^73P:C)SQNO""[&2
MZVQJ;9]1 &R$#Q=JYJUQ@,DSD. 7)',;Y?H:9_0ZO*"3N;H+TE(O5,.SHOTA
M.$W0>)Y"+1A;#E8_0ILL?;<=W#Z-[\)C;CFPRG11\E&VW10[.8,,IV#9Z59N
M49(=V)LPCN]01&'8[04 @EWR8&,_)18S5NMC5+1<.E& @V6YAA:E"K>Y*4:^
MMA&<2=?;F)II0X&9V5SSXT2QC.=I$B=.X ' ,^^?:9S0VR?>D$-'-:@VB"C!
MH;6TUF&037:6)!%^3A-"OQ[#?5)4H7U\[<*A VL*M9::"=TJ\L8M%LA-:@E:
M* %*G_\)?W\,KU)BP""F*-A'1IAVCQ\;U87)7\7JJ::D6>5Z<,?0'V-/OR.]
MB9(=1WUGS\. 3!):^=OK.$[)7[-VAUQ8P:@C.YX\VJMV0+FC&*M8WWCX19>.
MW78L,\^AE9Q[T=JT5-#&IU69_ 9/9&W6?\V<54-N/Y@]L5R\UXAZW]R2Y1H#
M%=J@R%1-R.D[[WVDGQY'TG;-I$"6?[8\G[>I9TW$P5N>H;L'R)7%A%Z2;9.:
MY=9"S)%-+$^+/0"0I:@TA$?ZZ%3^=V$"G\..[V\+OO,!N2FL'J/X-B1]_=0C
MGN$Y3L40YX[OICZ=YU&F4-Y!,(/U>WMKOWS-%GX%YY&8D=)L(?-%\_S(>29J
M^8@Q)ZG#)G^V90\@2E[=XQ?'HJ,Y-BO4@7MRT^)$J&WX(\5GM@[3@'<8](P]
M+F1:$[JW=C-VD]<;/]RB+%0AB^$0.E/RVVLRQER"L+@NO9SB0J!Y@@<V>ERA
MRX>[.V[N8_F^(\F%KY(#7R_,?*&1BVYK%TU3^\V): 3F8WB71N[*B5$N^W(1
MD^UE6@3HAU&K^0CVR=Y8KB!742[JWDG+H=7-;VD\\@6O,NW H7)/^Z:<4-9'
M63ZQIL[A\V+6VX1'_S3>G$QV-96CJ\BQ3\CM'4N.1-"'K6Q4%U[UE+4++);;
MNE0!DQ*CAJ@4RS44Y#^0_R%9>?_[_P-02P,$%     @ [X$%4V&P5SD+P@$
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M45_SJMF,8HQBC&(K03'./UK)0-^HWT%1 ]V,]3!&,$:P52(8)QZM)K.53.1
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M5/UJ.!=I&*F)=+@8*Z,7H]?*T(O9^A7I8BDB1R@CYE?4"6!+/5@,8&]4JA#
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MT@27/P-K]U%B^UBDH9TZ)0'<X& (\X'!7^86<Z$I^6?\Q\+1D9-.3/17+"S
M9D4!H16F4\<G,2T^BA'S ^$%_@AS5#_HF$(<3/B4S>%?& K,J1JS81<EG[*D
MM!2,1<VPW;T/4L\M/1P&Q5?*5:YQ#=.]:10&Z*FE9U%._\Q<;E+L1FJH,/.^
MBK.S-0A)"WMODG*G9(' ;+O%\+6*94Y.7SN8<P)B=M3''<J<YWF>7]*7*04Y
MA:@Y$FL_EE.+J#]2/<4HM62I"0&Z8;=PV]QO:2VY]>%=\T:9^0*4<T89WO)?
MW/*;3,+MD7+(?H*GCY4[.VWX__M\M%PCB6PR&V[>:%SK*3/+(0<[DJ--91R'
MMIXP\'1B:SV.0'[_S'>AB9H,,&</[2THRJ8[E&!')QE!#)X+"PGW.-<FT<'@
M8]RVX=^&KO^O7^5-9DOU'B@)X5I&*ZW9[O..LH]LZ"J32ZPG&[^Q 2Y''.#"
M 2YK,^R/&O 2J'* RX\9X/+U*DV3.::E,E7BFO+HL&+S//UN=V.P;DK-CR"$
M3>;#]AZ4D]("JXDU\2+-.X2M<#)H;/:#KU^.3:9]]M!+@LM@/O*M@T&$-=5$
M^/H%NB;*\8\@"TW.9I[+PJ.T;1BJ4%^M\BRLLY7_]:]_[2Y6KV$9J$P&&DWJ
MS&2@7.4JWPUJE8'"VZ^R1LJ\88:[7C0Z+^1"= &33W1I%'GI83D-X+K;$?-Z
M&KD'BHTH6).CBDWW(W!1\CFE<B!H-(%T&1#TK]=;,_QA4KA]]5H];C0MU*[5
M&G2A[]VULO1=RQG1&*\&L'YHZV#/Y/.>R6..N*@!:AI-1WLNK_8:Y(EZ,])Y
M4(MH5K@S_.@HT&@*W#,HT$ EI.^;& S"-7-LKLL0\#@N7UKM"&E_IGA,4:GD
M-846X&AO$O1CS86AH?Z;)V)JN"06G>%0>YKH@EGR@,=U8;/*"*6Z)J89IEI7
M]@*3A0X+Q]H+Y\GX-NZ!R(;&O$?A!7(::#<K@>,&Z2!I=NWJKP>;9C,17R[E
MP9K&<X[\.M*X50#_\'\L_T;^FTW;>7D38_E?-_G_T26RV1R>9R3R#J:AQCK8
MZ.@R31 F*^-0YU4*91P'CJ9B@*1%WX 6K2,3Y?D9_O#$J8X5:*(;\>:397E-
MQF1B$A:)M^:58;S$Z+VOT5WB/$OT0F4LY?*YO7K!;3+;Z>RTWJPHE)#@#*MW
MHG29E'LN1KW'219!S=E15K"&F\Q2.M/*JX.X7:SB, )\]LUR32(E37(-"KN,
M@G \\^2#)BZ%:W83"K,<8[:-<H9%>%00*^'(-#8;3,&Z@KTHQ50(M!DL;%(I
MI5B(Q&U6@C*K66ER)RQN<:_8JFV! /60-<R:9FP:_L)08[8T8ZFIG'SU5U3J
MJ8HH&-;*(DAXZ?5'[>U]WAU?BRQ-YGX5[(D;A=EA^%#YY*'2!$U1[.M.M575
MUS-*K[&!K\<<^,J!KVLS[(\:\!*L<N K![Z^3K%I,I?U,2VTUO-3G-&VUT^[
M*0CEQ\<5;K,R222^6A@C!['M::3D)*_9!G_20>Y1.I[,.'D?Z211?A$4D-/Y
M33P &Q,K1Y6=[2;3C@M8^2V(ON!QY6,4I"$?FUXX-NVU#]?LP/1#B&*3:;EG
M.HH3T0TF$ZR7B1N]K&^37\91FTO%:DJ;VEHLIH3JD#K@%!V(H0/D2,-,RUA]
M-/#C=$(%0+,-;Z1\A4Z[,!UXVC&)586,)C'HZOX(Z\-$T!KI9*GOB-J6-6%
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MR:S?LR "Y+B0OZLTJL]<05GAT=D+:L(L,&7' >YE#*AKJNS!UAQXV4E;4B$
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M5,./%(]=9["6GFM59%I%-8TH]R9,9JAH:0H%>[$3F^I'%/I-SAAS1Z:&)N/
MI4K688"Y)I%C H"C9(1AW+XKW)(:4G*O%I7U"%*RY\2PHN+AS+R96O='JB/:
MR6.6II>EJ=ELT$1Y'FQ$J:G)!SIE,A,W^+SZ7)8VS6T+25!8SXP20<98[BN<
M97\GD705+*$O\'>LHBF6/Q3V,_V&9<HB.,AE-^15PLP7N/%F*73A13*1 TSL
MFUU-^1<\S]ZBRZ,49J-D'X1Y6#5T3$;"E)M4":K6V:]#<0\"#@(;"5\F()R@
M08R5:8D:47TT12#A!TG+9L;(0SJ+2$^2[NP&O-P^'Q40N&IF00)_M^DNZ;.O
M[K$F)9+44*&/Z4FH\..+BD<XGM03K,!H8C'Q2-&R56LQ0P2,DX$QH\:DB<&8
M =;J1 ?S/1XCLI_O@\AK:L':E>)*L^F;:Y(@;IF^3J&D+;-)TM\%66FLI)<@
M'9.*T4Y _) ]U,KVSA8\*$P3&Y*-4I3HK0'R-$'B39G:*$H-_P@_&O@(L]1J
MI7S.6<[GA?>7=G.3QW:>I=3*"T]G*5P$@I'1E %]'.6": *X0<OI!L/&P.+3
MM@UEFH:I4NV:4&Y;:SJKG1@K;[@5%8':@\"=&3!#4""=A9HNH'D2AGH"0]!>
MDDTN3\]MZ5S/)1',,^F\D&R0#0YKA6-U\%)76UZ,U\;W6AM-9OC],P"]D')X
M(?L4!OY/HWCE6;UJV/- 2ZM\&+I=IG \2>$P;D  @5IH' R"ZP""329:&A"\
MD'XZ!-W5) ?^T0#P@@'P&0[;7KN.:#%&OG5 OB9360WRV4IY/QKD73/DO:SS
MK1]U]\>&HX-OHYI]BX!D FE XJ;LO"MSB&J&C<I'X^:4<>-956F7(6.](*/)
MK$8#3K< /S_DL>V6L>AE'89KT*\9(#69WFD J?X:IB:7MJ6 +"DV2NY/'8O?
ML;T8&7_O%T4Z+"MZ+LGV&@DVQA16FT!D/0.@&AM3N,\QA1Q3N#;#_J@!+^$P
MQQ1R3.%?5I*:3(#_5<WRG(B]:3WY30HM26$+'G'L4 _J+BWT;LN$//K19$Q$
MQ>H]94L$[<I5F*M+6]6*2/8%C3Z60X4<7,.T+]CT 8:V*971V^QE-@ GKT#B
M9"$E281A?=#B@1*NCJ#Y'A4JH4KR3W7$M)4R.>I-O&HLI_CP./7P-CC(N4HF
MXQ;\K#>-S Z4\H6GAVHK&0-\)0H/?W0!/,$2\O'.$%Z"W1L'<:B3@E."PR:0
M#*V'T&ZX((P"3-^45V=1#SHFMM_"G?B.Z>9<XT(8(:018R!?-/=05\=RH#VD
M !/=UY&A="CKV\;4=J3\((FDP1%T)<'H0!\6"260$@.-YUE783@B?MZ8ECM9
M?B$5 <05A+V @0PCLYZ@B;#B\"\]":6.)K:QKIS #G"29=$L-RFV+<IF=@RB
M!;.*0P+/H#B*P,9:A78M6H4=*^+898F43QD103-.8)9:>#97R$'/Z>-+B]=
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MUQ9'-0YF6BOY:3(5^!P=@K 482X4!36-@Q&L3M[@GM[@#IFLOVX2VF1N['F
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MTRJ.T\A4!, G9U_;0:[!G%9(9QV4?F,OH^A'2:4/4"PI#L:<%!9L;*7&"C>
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M.H%($^U!JXP28923*"O94G(U2J-OS:MON16B4 1*_&*R\4P#[:*"1PG0@G0
M%S\]O'#%([](J>>@C03>-%,W)L0'S1R>DR#+%1E+3SWKD^1M?ZV0I,EA$A<:
M3AM)X*,)8\91\R_8179JJA3+POFD<-815C!?W_S9Y<MES]=OR32:B![$6+C.
MCU4T-6R/3@C*AW3&M=K'I6T$JC]A$&M+;AJ2\:=DO0*)0=M4'[5&#)V[#CQ0
M%M%<9JU>2Y[3RDQ7<C1" QHFAM;Q5^2@9+[YROCFA\PW9[[YV@S[HP:\A%O,
M-V>^^5]6+QK--[^[J4&/J*'^9,XRR*SA2#<((I>/QTP;>#M0U&0&\.5IISYC
M-_UXBO;FCN$(D@!L@*1.@DB)88IIQUTUI/I((*:[.V;[[+;/VC=M6[YU9[]]
M($"88_5'._/*QZF#1+HB:3@\=[,(/)DHWT4KG3&>DR-=F<\4I)($&"H#KR13
MNRV?PX+RLJ TF8U["4OL5GKK%YQ.ZY.2[N-&>^N,E9MZ'-GQBN7:9'[G9>!O
MY3SGC^?7XC9)W3H]F\DXB+'B&+4B<T$"QAI.%+:0:J.AYTZ98D+H]/21V#TT
MA=J\%/V95 +-!O,5[DCXN*5\.?#(:Q@\:,<0BNS[6!I>E(:C)I,C41KJSW*_
MK##02$^5_U1<Q..L^.@UQV^+SO#2?GEI-YEQ!DL;HT"WKM($B:3:J2-(]LT<
MKM^U#]O[&W*3#]CK))]-)IF5Y9-IH"R>;U \F\S<,@D46":?ELG]]BY'O:^7
M0#8Y":P12-&S:4[$F6*%]GDRY2Z+S,LBTV2VVJ+(7*M(!^QCY3WM+0EHD_D>
MV?EO/OD6"^CS!\$]/@BNF8PVF0C!-M2OD4UF**V58#:9>)$))EMJUE4PO_^K
M.![K90QH,IN%'2AK#@$LET_)Y7&3>36Y7 9Z[6+>UT$L!<OEVLIEDTE!5Y'T
M1TI\"((OM08LGYUV1)@.<FI_HA/DU6?#04'54_B"8@!LVA:;!O]NK"(9JA2+
M&O2RF@Z.$CWX(Z6GQ>WLC;S:7USM=5!LOCG! \_CD_-8!Q>#YW'U\\@)5_B
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MP5!G. &YC.3R%M<J+A83F<+?)?Z== 4(;SDM4OQ"\^L<?YV(^,LXB!)!JB2
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MPZZ22/H!2YV[<1/[^OWCX$;&,@VG1$A#U#E@>C.9.O*R)#%G9R1QN*MKZ/9
M<>W0W%&F1DR_,.\-I@LNZ#D@>F8P#2'SW62<-W[(IQ*"X,'?NJ,G_>'G^62G
M(<=I<I.*17 MQ:)W\;(^*=KGQR?')X?+@7JS3ZKV9*=QP.9H3F]C*J3O#LU
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M:5D[U520CA68#.:?'%SX?\/\"<8DFQS5UF1J1OE2=IS=B;6>,IZ,RC+"//P
M:>0VD_#]@@QQL*[E5/J &VJL;',.D*KGYN9/6&L4,9(3!%:2YF@#1"%8-$ZX
M"JW"NM(5ZT8::\05.G>6LIGU(D;!C&@A<>GYGKJ6;5BWIRAALS%AN,W8F$(7
MF<$?UW0A<<2W+FPK262J;/)7=)OZN&%M;679DY_).IRXXRB@PE0I ;RZYO0Z
MS!QEA9V5S0G84GD"DX.V#+;TXX9K=>GX-4W8-'(,IT*CA\E>T$^OVD&Z*L?V
M"K0=+/7,^/:8[6E4XB/OD;X$<^'E@#KKII@/#@7)1K6SP 467$]'=JUGE8]=
MMGP=PDO#[$N M$3,0(1-Y^/,N@[@ 'C/Z$>KC/V!A+1IA ^0D $2,D!"!DA(
M5_7. PJV5$VK@WYGGSYF3J2IU$J@]Z&D%VV&DL;<,84L_86'^?6G31,9&P21
MFFP3\_S'^[,VH;9;9A7W8./_J22!;L"YH8'UX)4[A;&#""V5'#87Y:A D\I]
M/4E9NQ^N*-,GE=(8'Y?YT<<B#RX1U#)L8J<JLB;MY>:/N80BE4<F7'-)/7=T
M%%#E)-UXCA</JKO8]7=+":]Z*EC>/4Z_Z3ZHW,#+7SQ[T7:K]#[,07D*6C0]
MAC-LBR%)$>WJ?#S99L7:O_;VIZ)Z0G14F,S"J<$%.-D1XV4PX7BQQ!"^CIK#
M!58[EGBA^E:6MM_[:MGFOG+!PYJ&:6ZS:#DA0M8;8L$A_C:&![2-HG6CVQVC
M:<N9JTIJ:YTARTEJ11B7Q!+U\2)))=HOV$G$UG4X^+D>*>R $*4M"A'3Q=K9
M &-KJ6OV,J?- R;G=KJ"Z.GDSU^MZK4MJI@T)Z6(HI5)_9<RTO5532+SBIA*
M14Y.41-72UDV33>I7>IX7GK/4 [%D/+GJMZHRFS1;1W4%N,:"J V+&UM =19
MQ_5/-75/T\H:=U[PU(OCT&FE4YO[Q&EU.%EIQ(1CI3%U*46HW.*'ZB(YYMM0
MR-1KT;2FD*D#"07O',J8'EK&]"ARK4J1P69RK?$&<BU=I.0&E#V^T5)15"D$
MT\CIM4V1QMGEN")IJ@_<P+WK@&>_$SO9>IZT;8HGG#%N7@G.)?[P)1D<T/ZU
M=S#+ >OW9%B_%I=VP/H-6+\!ZS=@_3JK.=:Y*)? 7?<:4L9$C!1"Q,P((Z38
M'0S,L9<:3!+4Z1KG/A34;2PL=CN)LZD$4R[!R,R=JNXF6[BI&/A-&(,1A=;8
MOU0^Z"VVY1ARA%V63S:78YU5J[&,.;TVKJ&8(=@'>7OU3]Q1XV  H97J(-4\
MPP@P\!DG>:"J=DR//"\'Q?,W))JVF=UYFXFFX"DR36>UB29/50UYIW8C@"]4
M?N=2Y-V3[C4-9HL,4POC'$+&M&%JLUF7;<:*V\J]!"U&0'2R98LTW9)/1TUN
M[A]MS4S'(J/3A%R;6[T6*Z76'\Q4L%.Q%VDD&*:HX^@>$17H4L)"E76SH@N;
MR"BY'Z1H^U)T3>*M56&J$F^76R;>MH-T_(!V^4.M;[&F%9_3.5JM*9Y=G-W0
M[;JXU%T7%9D<[H&-='**PB.3TX)_PF:T(! P<X/D,7,99YRIES$\;"JUCM:.
M%HOM;$Q.Z[MPBM?/]%_I1NQV7_[!R8Z9#U."*,3W+(2F)Z$@R.M3^A+06[GJ
MJ(Y__IB*^$8&OR?)E[$1W)=@HT?\1R/7#^%>Y^(C^5<1WHD(WS:';Y (M0UF
MR;2@C\,W_1[",M^$TVQ$#D1,Q'RPP'%@[U6)L60^!&,Z"7P.;9:Z"WL.<]]Y
M$-+DZY=.&5ZI3\!<"2^6ND=DVYF.YL/R=1+"W/V8Y$,G9;ZA?89MF:W-"M.C
M1%D"WV:,6!*Q31''RSY VP>OJC6OZOG!:UV;]YYJ\[IQJEJ+4+6XQ=Y@555-
MS*')&<%3IMT1U;8HI].GSYU"&(,'VO3HC>[&>A]C"T]@K.&#;K]$<GU#K-\K
M%7H&HLAODQ3;)CKE[WV"R@6_M(F26[-TNI_5-[$#? ^C90#M/1EH[\4 VAM
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M>^O>@NK.2@N!'KD. !M1@$%M&JPO04S,5(U*";!I)+B,^_XVC&3]!F+C08W
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M75%IY6J5F!$:YU]5&V'^\Z&"W-_)43F!::NEU@^/6'RIV1M&]'7XG7($R;3
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M5Z!OJIJQ2I(R]IA4%D5>4-:73=2J86TY)5A3*PGPQDJ MV4)T/,,?,N$*5T
MJ-8NTP]#G_*@KV [4.,5#)_*N)9/95SF4PE.@SD<K^FMP^QTGZ1?8#[ Z%P\
M</_WN-@M>-GJ[A=Y+O#-%!?(DX'MEW7IR0$!2-;NIFL8,.RB*\I(MUK'XZC=
MDX,'C_.)%?00L?B6?=9J3/"-9Z+4Q?=\RV0CN5 )5*8#(!0IH%U'WG-(78X1
M-&U=<H51^"2S90BW)RD!=9$M*\PDPM*X0HJ!SL0(DF7=8)T;++E.E/)0 =3-
M(6TSK/AF.S\BM.>078-,<>?<8/LWCJ\IR:^*SG0(3E? Y?SK'<SHK$SE7!/!
M,_Z'B!]A_#E052>8MVX(MN9=?<9AVR=?O?>S'9TJ+NVF./T4F\?SD"3,6"$<
M.GC:!LHWG C8(%I.-^P?AH&Y:SQ+"%/'3$SN3J+>](U380+1TV0A2:!C5!D&
MQG>H9AV&(ZKY.92%B3)GF\RX82MLJZJ6J.XY]:55_BMG"_4-ZC:@A9X,+=0F
M@]Z %AK00@-:J(=HH1_'$'W<"> 245W"1P99I2$,&GN6=B,NIT\?9+69]B<]
M.^1[$(!Z?N!;;IT$E\J#Z$-J9_!(<7>T&C;Z5\FB)C2$LN15V-V)[#2'=,CG
M8$^!V7$T!@5\E48_MUP.B&TCTW!28,1*D:XY9#TJ>8#D+&./F@O%XC_CY/[H
M[\D]]D;+4W"S67HRKQJ#.XAR375Q4CPMS=]3#F>YGH;J%5]D5@HWN6)4 N*Z
M\]CW?;;&GU<#:_2EQI3@4^X37KU^.KPY7F ];T\I)$Z.?SH^:=.'6[O7QD1#
ME<!747'I4@,3_85O=GAUQBK3VP+F78?H.?WEA$4TD42]5VUKS,[,B/4NV2HA
MQL%6VHCJ!%GXZ+<\4A%O:=N$-A>Q/&EV"S=^P97EZOWP>508K1_C?6\-S1-R
M[^M)\'[UZ9_&SIH^Z',0(U<ZP-PQ--(TUXUR(O-[=CK-U\K?)3*/6TQ-V[B?
M1M@>*-DVP[ZGL"E*&PQV18;_H-:M3F#4-H-$M1-N$8XUJ$^+D"1Q4GJAFW/Q
M?QJWGG;Q>W!V90P[\5=7D/$9MNVF2R >:G%]*7)F)% M?,>5R"0A*L((OTIU
M"E[R/<I?8_@I:IPHH8W LB)<Z.3 NCD:,OE\BE\<F,0WSO(6F?(NZFP>-<ZA
MX&;#TG>87&^V^ZJM8(W+H!T <G1F,@KO5/I=DTRB54C$D]S->[U3L<'VK/$H
M="&"SA2J-!/<J0PYO$ UQJ(\T3:[%/-1<$6%'GDP8]HZ!=UEKS-7I(EXF_WB
M%,5L!,M>G2D*[BH9SX9WK:T=L6[]A(M%QELP=6RRO[AE#[@A4^4OT/G;8D+&
MMCZ%VYLAU'A:4 7<6I]#48GJ^3/525S -E,75D$Y6RT3LYN479,]/VAM$L4^
MY4$+#@4GX,%9MKS(N4P7Q#;9URZHSX]_;;/@:50;>%!.4U+D6:@8$K=SQ;CU
M;"]UXAZX!2\/+BRCDEZ4;BS_^J$,QOV&!6S5N$=Z>@68RD,".FDAJM(9VVI-
MU^H.*UF034^IV2AP6\^DQX!J>C)4T_,!U32@FGHS[94!K/^R =7TX-G92U23
M4.;TH3*NP2\)<W!HYM;;W\QP.7J$!<X>K)/^;^+IQ)QA&!?22?,_5$T[#)PE
MO %FE<W'96./8D/QV2M8UU4QL7_@L6(.LCI>Y9*P_Y\X'DM-KX)'?<U@@K()
MVF9D[<E,4,^'O07/?XL<.UXF8H<6!;?9-R$#VBPU')Q>WK _'93*,[IQ>*O#
M&)S=#0O7JK-[U4_X%TY#BPY125!B>-2@\2IU3F5^;G7K6IKN)3PWED0Y7K5G
MP!H22!<F6@=>E+],B>U.>OHXC7-] G/Y=2J7>9F,JP^[-7"W:ZO]KIJ#TVZH
MV=?R:AXQZ:OFN>8A30;F8?TJ]$YHO&@U1T#<?:N*@!@L9T^?M6DY?TAR%+!9
M#N($I6W?]F>+?"]CW>1"G?:>(KU;5_7(RFFJ#+);!;YG+M@-G6)9%E91/64!
M8%K^QM60PX1Z"Q-.D+ !LR3(DE<EG8>42<XX%10A<PF3[-A-R**$7& J7D17
M3^AISE#LS3S4FF"!T$1-]!EP 54.(+-?<(C#X^>.:C]08<RW]U,M(L/VR&6L
M:S*?L]VT7DNM,=>T+UI;+%Z[<F,5E++A)Q#RGCWG6&]E9WI[I3KH!]8/+??<
M%?XI?3"NFJBH<]X^&)WY/HD^JLHXQ'=AW(_9LG6?(3Q^/N?W]XQAVC>MB4 J
M$K<)=Z/;X$"9=^C39DY_&'.9A8HZ53470:/$B@0S3$J:K$2DFWCC0.&^#TB
M)2)I>#%J7H\(K<-LY,/N:P6"7I&^ F-:-GH'F<4RJ^5N:-H04!W1UBN\!F)M
MQ'BI,P%"JF=[N,7@9,5\(P^N 5RIY)H8E<4<*P_JFJGK :N0SWJ[L!,6T@8A
MV$FHAY28Y=!54W531+P IZI@L"9?!Z)?:P$WUR64(ECA]E89L9(B:!+NM'#@
M+J:YT0,Y-2Y.L]R!_=*#-CY'[1&"W"=!E!#">/TMH<W)7-A*7NH87JLX\::C
MR>JHZ7G$",5H:CTGJ<1?JFS_?1(!SYX=_]*F&TCGN&<3\&N;BEP=*"P_ Z>E
MK??RQ?C\W\(<%/<41K(H<IC##-FO,6C38IZJ6J9G[<E9(2LRA#Q@AV"E\4PK
M9_D,;HQG(@W^5P'R!7ME^%X^"H:]1Q_M+*"OS<,\ /H&0-\ Z!L ?:T#^F;&
MMAP;!K(;<$QOJ%+>AHW(!I6.68HZ%JQYTJ-:7SJJM:PZ;1GK%OK7> !T@U'A
MWT1Q-G2K>7RXY.<#+%C&VN#@6DYO8WC)S:H3.%+M2-8@DHB(=Z9N<6JR%R'5
M8>?Z&38YQ%L^B2.JL"LW9]L*-*<<7&HXGY>H_YS=;V">B"K-DDBZY%@.FD*5
MS=KTC4G3E/K".<]VT2G"Z?UF(K4]):K9[[Y@/V%?L%/+I7PI\MOD1L:FT*S2
M#^RG@]/7KR]4&[#+T^N_?WQ[_D&W ;L:^H#U6[+^U&D?L)_VM@_8]2W2XQ\^
M'VE2^Z4Z:)G7,M:VK_P<I@7HCY'A<^4:;EG+9]"GJ%2KL#;&078 @[S2JZ$%
M9@=1<<4E6#88?-HGD07KQ/MQ4(8_U33R,N3!W 89XU#*<NEMFZQ685/E-ED\
M.T_S_F?;9%A;%&1!0T=#GV(BJ)P/IH^\QPERK,9QF1Y6&[38,?Z[=D,DN5$=
MI>UIM.;4]%T$[T&'Q.K*_3!M$3</?=T&5?Q:6NZ:-/.KVD:)KVR3Q%><AY8=
MM)\?+&^RO$]\#K\: =.)2;YY6$-+P!YMHE9KO5XS')P@=#(-DYE!2XP;X83C
M8 (2$".XA+DP-:%$>JZ8 1441D,GHC#CUH%EWZC/!N;)[FO9=[ N3JQ<+TMG
MQ5ZJ.H%B]+5ER2&#8&<)/ =W8/UV:_@LC>NUCT=4M]KC<,1K@;/J#<628["-
M7KX+!F7.SH4(R=CL([RN52>^;Z;('NB0-NNKUL'.O?,I<LHI$'V!2W3O=Z*U
M>0K%?(ZW^*>M# +W4AD] V,32R$8Z;MYW(;SQN>MS7J5<U-V2X'E^S"3%D36
MUYH$?0P.PQ9/ I9E]7,2VIR%BB4_#]'YPS9#&8SJ:"&^$.]Q <(5K:S:1@5>
M^*\VRI&5;34GE?PY3-G2^_55AD7G49%A_>3*\1XR%9KKTWJ=(*GO'@.06_:!
MW$Y&:-Q3[YXL3T/3[*2\*W4O:^PRGV?<:1[W-@C <)+,5,499KD/D=>>S(DI
M=@-2[300B$:46G0 $.]0NE'=XU.-+<%13G5UF3H8NE]WY524 ;Y#<*X;'?W<
MCX*Y>8A.HG)KQK-GJ?,WC<'PQC;TR*=CNP08-R.619XB'S\>1YS):OE5->#.
M_8[H:I."=YL0M!V3Z69GNIWF=:L/+-E5,^L.2LM$%-;G7\,L5[-M*Y53]Y+3
MJ6J_=IIE3('<2\Z)#ORT4GD73A9: *A55*]+G>@GK]9T<(B3.QG5;'9-@<F5
MX;5KPVG4ZK)DJCMGFHA9M++/!L,/_B.,LX%G>H?+4EX.92E#64IOIKTR@$V:
M:RA+&<I2-L]$/33#:?RD#$9JMVC1=E$(FT;D14HD/Q-")U'$>;(R% QD[;@$
MU#Y$KQZ//RYC[=U8"#>&<YQ.SH]5S.&2B9"#N^SV#I::J6IEZM2K9D-=_ZPM
M0"RJE>_];:A(;S3%5:(1BX&UK'4=D"TG6 >_$IEG<-IF5FB53D6,P0$/ 58"
MISDW/[Q1U7[7"_R,]0+N4I\:JK-7P<?+ZZ./11Y\7/(N+9<._'SP^OSS^;N/
ME^_//UP'IV?7%Y\OKB_.K]2=?USC_U]\_#!4$?0\7/+S\;.#\GGO(DQ2.XY^
MH)5:+QCLB8VXX\D\V'&M K#JVDIS3/MU/=\D9TF82\*S,M9@EQVU6SE-NCM]
M!:/*HZFA.7+ J>&([4MU!>:U OO?[C_N['_K_RSGBVJAW&3E#-2(SNYL$]IQ
M;5#X&G%!FR*5=R%<1:R'1,PD>4.&,>Q1),JJM%?UZU?)?N,;9S:;PL6P<EK0
M=D8HR$@CMIP=J-!:Q601*L+%RMM*[8SU?R.72V7@A@.;XE]TZ?NSYL_$"]Z+
MN)C#B62L&G\?76.K'/Q+5!O92B%/9>"&]6ENFT'K#W@/BX#LJ4YI19TE7'.
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MH&5+N>>:EDZW#F7LGJF#GBG  ?KW:-"_+AM3#-"_ ?HW0/]Z"/W[?NS)A^V
M'RSQ72V5VTIES%E2R?=L@[>BL4>$ =BQOW!?\$N3PTXT.R6.="'!TC%7^!LA
M;"9 8/BD2V4L\0R>L%QBF MVPW],!XUUS[:]+Z9)EK\V$+E*]PONV8?1=MT8
MMV^F;J=1!2;=FJ@PK9;3V3#-O,B1D?JK:^UHG;#7RG4D66M=[%?Q1[@['U9?
MX7*V%#K=\]DL$G69*#W=\J2'MF,R-HQ,N$]@4N1/0,2INTJI)?0L0K+U]C%@
MOX+:IJNF138J+6YH T+OZ9_5&A-I^6OLQ(#:6DTCS<#.NQ?9YT4\]Q%-2KO*
M3*5H:I/M:</N-6B9]:' K2OQK;$/50KTW*1>8+*)XM37EYS4IEZ]K&7YZN_J
MY)<T_* AY3U>5V]8&]?8=/LT1T!][#"RJR29!?,0KAE++@W;MJ+(8&PYG$:+
M*"?0LR.W3Y;A9THZV@8+D[N>@B5V(4XUP836V&-J/$3K[1:&T[\O:-=GI4S+
M(QI2R *+IS/O?CS;%"\=)Q6"BZ3:R,+^E+:HV!.X[YJ>P:\6;T0%]MQ#!?;R
M^<%/KU[\V-LF&NVU6":V=QI3I*(Y\#%53R[#+SC/\RA'07Z79)EA(V]<\+Y2
M83U]>O"B\QIO%M^B$EAO."%UX4$#:I,Z^"Q86=#-P-Y)D[MPP;VE-7^$Y]2.
M86AY<!$N5&8V;-O&ZWG\'E;RYRY]FI(;VACC&;0,(U?;G 4WE\\&O=,JG,1R
MG3/6(K;C((M@8&&JW3![6BWN@G-K3H*[D*2Y])CT5=R!J#+<<M9X[.ABPKK;
ML^+^A87T027K$7:4+@B$?57$G"8'BS,/W ;SE5MI.(1T^]),UI6#N6^<;$.^
MZ-'R15URD@SYHB%?-.2+>I(O6F=+_.@YI/=A7.#IR(T+V_S.)GO@05&]1]["
M@T4HM2T-3LW8C9OWRL'HF#190K)NR#/,L@B+OZ8F^FG!5G5+$3-A1Z,@3\,X
MPW:C:)GBORDPI:W:^L_VX3J3%QE7:1&I)L.:XQA5EUA.O3;B%GPDMT+)4(E2
M7-DI_ZB7:+B15>&GQ8H!\RZ-HT_50MU@H 'K$? NZ$58ICW=GS7SE3<&^SA?
M&+7^C<)'>J YJA#;+WYN>Q4UA4ZT2S,S)1!( >J8YX%59DQ1\A!U1NX-S\Z@
M;=IKL[R$>N.FP,HX:'*_G.B8I!]PZ;0LS3TWC#+;Z<(XN#[_LD$\6LXZ#,BU
MR@859=7IG7=!2!Y-_>^#]'2G]BU3)_WKXMAD?TD$L%&*RDS6+%@D\15\1?"+
ML,BODY3:>=^H= /-H2.++<VCZ1KWP]^*&>8;3$W&'$>ANQXIRKC>+T0C+T=T
M2]4?3@D<  =!D>+N*1T?_BQO[^H$=B#W-AUR;]\B]V:3\+II';, /SY@94UL
MEA8 GXN&"CW:>90G*:"K=D6EO MOQVU)#$GLMYZTU9S_.N.8QD%OW3#N@^ >
M1/5#[/+18I==%E@,L<LA=CG$+GL2N]PUHV@V&$4/-8H0O;T&E#3V,I1:,V.3
MGV+@AQ'C$OHQ@$6,_6B+Z\XX-SK1FLSIL:[IE:0>__SA]ABU\/X:_*\X_AC,
MDI<U;!M"OG&\!?*-P6$2W: &W?!-=8-;?")"_^VW\]I(RT8[>NU=7&W7RTT>
M;+C/OY]DY4,)%%[L'<41S&'PIUK,P[1#7#]XM]6^CRCZF_20*K&L:[ZP* N.
M=)4*0Y.B^"992,E7P;LXI)?-W,0-/I0_AO>%C["5D<,M194O@C%>FJXW1!6B
MTB6!$GN1_YM>JUD!^Y(6M=-5?"L*.KQ)(HZP(/-T4DSR<3#CS!$1O\%T5:D:
M>U9LZH]HT 6<TX,I^K58K4#I@J9^_2WVY-'YY>GQNY/@Y_]_DO[WN;HJ%F&>
MI'?!D=T*E\?!__?_/'O^VERZ=W[R^Z=W1Y<?SO\*CHXO3_]Y>GEZ<D'7!/]G
M'AP'_V?!OWA*_^L3CD[?<2/=^_39P;-GSWY@[?OSP=,],!Y4BAC/#@\_+3ZE
MYWN$Y9 _@PUNKAJ72!,IO:*KE_ LSY3Z3&J<2!0I8"J9FS19I42WEUJ)SG(L
M7[KB3#5EM[W&6^^,_QT0S,.]]THA%C@S:=TBCJ:T+AUV!'5$M75$K<+[IGH"
MD:BYV8//2JUJM?(F9'\GZ RP/"29K=$9:! XHZ R!C+3EWJHMU*NAQ!NJ\E-
M!A1TK&[5K@WT2E*AP1@2V#DV0_$8/UB>6 *%I H>+4]I[3\JB!RRG3(I$;?[
M%1$RZ!.DXUJSF842+^E:A3,4>^Q $6JWR:!=CN$KF*Y%< &&EF@32<+ MQJQ
M\B8MKH(C5!HW<.D1?^_U*YOC"V-96YV!J2XOWNG78#\<5? S(;X7)6K S"SG
MAS(3N#'OXUU5NJITTU6*:R=, .!^)JM5DN8@.0Q_HKRX4+ N$V[$BTYUJFP+
MSAODL,OA;C-VTR:92F]T"Q&J:YI@5HE2S+9/)P^Y)(XTKK=OC@+AT^9)\;Z(
MM]#:74$419/X7^+PTBS85P=7!^/@^#V! N(D?C+5OXFRK%#9Z'6P/QF!($Z3
MU5UM3\V2:8%"#$8XO#_5.A!%JZYJ4&A?<HM:\><W?J'7['!.1Z5\W.P&3=89
M%8/#K?<;EVZD2XCU/.MY!5D3XWN&@RAB\^?XGE..)?$+(38T$X$_TU,Q4]DT
MC2;P(%[SZ2)$QX;FDSA.ZSU32WU\\P!WJI0QEZ *4:E1:[T%E%="]G6U.G>C
MHJXS8859.2SI4C(-1C4-%1JM2[5AF96'VQ07FGI\PQ;WZMQ[B/0&FI#NXO2/
M-0IVYY-3/VR^MT.6D2'?.^1[AWQO'_.]WT^H]V$[P,9&-\S.E**@-<(<UYA&
MLTH;VF6SCM%-<H17CFZQ,=P;";O*:0QF&2=[!'<5^BA5S-E?:N)><^_TR&!<
M$1>1\_5-EF;=OF CR6-0X/U<D\*??=HHVKD#485G>\X47AAC<SL!A:;!M,02
MAHP1+N+!4W?FWD8+=(&ZS#>\;0T7<E#AG0IGNE!(>^WOCC^.UO!K::PG.%>:
M0"\.E^"T)Q,,U$AM3A3S'Z!;ZC-!U[BJ0N(87(1T_^J)YL&6DEBG9V_@[[,W
M1_"_O[W#_VT<@[1D 9]MHA:47*;/EHDDM&WQ$44:2%=&N5K"KZ.%9AUP7*Y&
M=\N7A6XD:Q-'R_^ZW.BGPO[EZ3#TY/#YSX=4X?+[Q3_JS76HCTQ/*5Z>'W1<
MN(=Y^7&)H6Z,4Z@;&H$VO*(X ,RDS'6<F&.9'/$,1;!A%[BGHEX86-<X3V%M
M.8F+#PLS'2,T%VG41[EDPI5U0HF<O3% *J%E&O-0)?Y@-<"XN7D@;VM=VJ9W
M-OW]@,VM7V$X*/B@.-S[0*IA"V<$\?.Y(2B)B:+8ITEQQ0KLCX_':/M=A2G)
ME1/_ J%<A129<DLSG6!CZ-3+X=HOI(N(@(8^I&%\I8+?DN0S'$#.M2#WAT^#
MXX.W!^<' 3HGKUX?/GU^\.)9L#\;[1\R<=BS%\&G@XN#8WW%TQ<O@_V_A_GT
M^LF?X9<EMNB:YJ-*,_./1;I:\",U8R+%YU@].P-Z@F,!H<6WPRC])&2LCWX%
M?)W?(EB8JV@J3*$$24I2A2K!_CKCS8?8I')W+CEMJZR[%5I"IQ2,DH=-FY2.
M!+LV&",U6DBG).W3/#>08F!G%4Q>8@[CQX"R/A-UCL/VH/MT828#]_G'%(/$
M<%*O5!Z9>MW3. 8U0'\><17MX4\__1+L/S\L+V1P^!*6>+]K]DZSFCBZK1!W
MKI<AV;..X=:>%N;L\Y1/%%IBW>N+"3[':*UP=%Y:S[EN'9< T8@PX?,$B4-E
MDIR$E)6"T@S>*PUECZTKRJ+GMB.J3J$91_37GL)==\ W?;YW\F5Z33JR7 -/
M%?I;\5#;A]26\T98'9)X+:)E9.2-SP%2U)P:U)S?1Y;:672W#K#(CG)-*=2-
M&)!A0*U#N"M%P+8J^ P4O;.;*^G8I.JF249*P9$=ZW?4K27YW,2S#!ZGX$9S
MAXGPB3N\"NMZA$&G.):1>JE!,5#5H&$JD$+)3DON7>/<>%H]":/6BN7,<$*G
MU8E ?0+CR.9W/DM3GV&<&:33S<F/8P(9C5@5Z^%YC=56M_* ]# ;/80[YA3R
M+ I9([-,$JTPW806RIR]>,;/+-T'B@-H]I-J3*[*Q'\K$FL-<@,<PI>6U:[&
M'/6O'*]D%=XQ_E.T<JG]@5/$+==EV*@4-'FVN+,V#-EP[M(SRX:Q%L983*H$
M\X3I5S,/THQVL= 1Q;&3QG6\:<>F+(DX<9>6,!@@2^ "S3@.Z3P'D0ODS(/5
MEV0<UH07686&J$-RY+[@@#,4CX^C9;(!2A_%5>'VN^M=&3<=)@H)/C 952::
M[0SM+SC;,:OQMH1LW\,]O$2E-74<S^IA#D<(M)#M?!KMA\U,=\GZ.V2FA\ST
MD)D>,M.=9Z;O92+5\KW",%R![:E4 ()>@.S@])+3^V+/\3LZ;Y7KN+J^@;2"
MND^KGNGCM0SJ;8;HU<'+3IGC;96ZZ\=_XY8;X,"OYXIK#"\X^!3G.VRSE7(@
M1#]?MPNJYI"L(RMJI19++F/YV6>R65 '+K^N%'>EW>UJW'--(R%OY,,'.D<5
MF/'(60E6Z8X,324[K&;D6A^'58K+QI?W!2I,Z%['ULO9/_JJ'/;P!G1$"G4N
MA]>'.WU0=7;"4T*W<][!O)O7S:* _SR"#4$WPEHW?-\K?("B0@2X#'[9I^W?
M;0^02BBM!MBF^$3SI&?4+&L#$:PMK:XG\[2\XK(R08/5R\A @@PVHSJRDDBO
M 8%\3?C]!N.7TW AISG8"&4GY/EWX@[TNC3V%RR-K9\MU;+87_:./[Q_?W)^
M?'KT[O1_'UV>?C@;2F+[;9+^8DM2MV"'.D]O-3XOOH<NJG:S='AF(.K*6% Z
M+]^>QV75CC],4C+=C^884 65GE5S!6B2<<* ?F-,,VQ]R.EB#+"ZBD$C>=I#
MV9<J!?,0C@D/G;<.^=+1)/B%S* *6@E87 A4V_M7GCDXIZP)#COD,^9DG-4#
MAWOUE15.X>-PU5YO7.4T:5MZ@=VA]!.<P6FM2^@XQP0*P/:/$)JI'0#=B11<
M8;R67V&*&P(TAL/+BH9:A7A,6UQH^Q;L79BJ?:G9=\E[+"I0/_.(\\3$782#
ME]09(^^B&.0_]&T.XFK>]WN&/+UK ;JZFO'XN+=^^B^(D>X8R5DQHF7UW/:5
MV(3OWP4LBV9W%\>S='JQ$(59EDQ1 PO6=UURNVVA/1EXK@N99.C/8J  ['+,
MNC;<I5U:K'0/:I/5YC./ZL*)W(H]U328#8HL.ACG0 %& @-6;W>3?I_3L0&]
M,U-(O!7%!I.+90D,J8O2+&^ACV@_6USSE3/\JE39YAP](>$)RW*](IWG(G*[
M0D!L>\,;G.>ZP$II@BTOQQJ#80T.U%D6?:X1W(C&L>;6/!8VP!6#:G0;GXG]
MY]3^<S8J.09J9)Y9%>Q-+*%R28-S[+:;1^N*GW J^,U2=1/!0E'PC#:$TLO3
M>-9*@)7 0ZT7ZWF_.#:((?PW :6J3QTC;$RMG(ZA?[QO&2->4.X\9 T*9Y8F
M,B>R?@+<ZI#!L!^QNMU!PW28_QK0, ,:9D###&B8[M$P:XP&P]E49VO21W'M
M1 T7%C*!%TW#&--SI8!/DX5DF+8THOOX6"/A\0QWXT1,6Q5EJR)7I6HL).&=
M^3*Q?0K;/#OXI=L"W)XV$,5YZ+ !SE LRTYXE^%NOY\K-K_C3S4HDS'EX/'_
M8@PH3L(LRL859DRJ6\H<#]^G7:K8DF(UH[R/#*$Q!K_."<*6@V&N2STXJ)G,
MY2=8=C@+T^ O%:8-?ML6_#4=FD>=NN_KN^GQARI^3ZW(:+3&"Y3UT[/N]_XJ
M:_+@,Z9TL^%4&4Z5;\T \$G33X,T6D)=4'A8%1ECAV2KS\K":2" +LNH0RLU
METPU%MJE6'3&@0@J DH3J@SC1$>0<RL1_,$\PBM-19M'15'Y):=L*+%F^+-D
MT\YDA': \ 7G3MKUE@[/M)5LL3:J,*R8=)^KVM<J::IO7*/:-]"=6,'='ODS
MF$]*;AFZ$%T5Z*L@!%DH;1'*8E(;!RX2C[F0L#]='7C[L'<$>V@+=EE/?/X=
M2-T]]V3+3N8(1MT&15KK>!XY@?<@Q%R'D<=+AC*-T5P!S:^P #TU5#(5U!)\
M<U%,I(D2-9-A0'>5,WVJHE7>4*.]3O6)V;2.G[E>J_LOL!^S623@=RQ>MFN\
M0'2WP9O+2E.H ?LZK-)HJDM>4Q4M)T6:<6%\6&)!JB;L51N<HP&=W7"0R>M\
MBB,\."YRG.ZQ!BV( 2U?_@.&.DN6P3Y.(IRLG2?EWH?_@LEX'Z:?U38H5QJ:
M*[51YK52Z,#L&AR>^@(G>X9'+8/QM(20,P#VTG)%GPEGWJ9RTX\.(,-11$?1
MB[USO;2@RXAE)Z02CNJ^M&V)7@=OHBQ/HTF!7VSEP/KJ4;=WP3%1DS)[!3YN
M'VS*4:"?. Z<%GJ9.0OPPOI9<7D=I3.GIT[=]:\PCA#%?:HIC_"&;3!4&3AA
ML7SHV@E2E)'3'RZ81J(!+(MW$(> L(E--R2O?TK97M#KV!%"UTTUW!CG2"%%
M5_,EVN-B1P:>SGW2ITG!O"SX/;RE=?.J6&+[C?R*P9 18R?KR&/I0R!SC9BW
M.?5;W!!&#'_>F>#+7--:RG0PIZ)^Z$PAT2)Y0N;Y6 A'DT;3R.N.(9=_L3<P
MZ,/.]>%+CRE\SNP;6]%T+>/I@VG>X9S4(46A(1QG?A0WHBW]4] >,0&->W51
M;:DF*!F]%-F4;4Y*9%Y1,>.2DX"7S?1!E*29UK077,?&[.0EM-* >G7WYZL]
MG.OME;!71K"N=KW,3OP5#93[BH'?0JTZG^6:_[=G1^0  GLT$-BK 00V@,!Z
M,^VU :R+SPP@L $$MGXFSN ,U2:![FO30+QR3Y(53?P/;CK^')L9ZB0==@*X
MTM8RQS+2.\.&V0?S8BM%S;;\L5+4C/]N(:MQFE:Z'5Z;J&]L>29%E80,"UR$
MJ]"D),G9<0E*=GMEI%7%:L7\7[A073V>+\;[_QKEL/6F,*!E@?PB68#_A37O
MLN'!KIW-O>8G 5-IDO[WQ^L0YG>:W$17T8)B>+BAWZL9M<(]FL_#"/S\*FG)
MTY_V/O[]Z/S]T?&'?Y[^?OKNZ.SX)#@Z>Q.\/WES>GST+CAZ^_;H]/QB8#+I
M=T@"7N?I7ET$+M7TFGLA&S+"+40K-A]<:R"CO1&7IRR=MBC"II(J1I-!?M(^
MV+3I(%MGB=J=\505\BB$H&(*<95&]$O#U Y'I.YD8NF^$)<E*$?Z:U; X6S.
M\2D2DTE6'&8+['"A8,8?98;1CD-QPB1W-+M1:::"DQM?5\66K+=)I6PO/=TS
MT71:A;BD!3K6:6%:UOI)>D+/)KV^ ]Q4G0(<<?M-%R$"/<;],00-75VGT^'F
M'E=&87B:PP5%O##4_>!&+89.<9O:EKM^GB,I4+:5?)]]>.MY?$DEYU-N#H*]
M,/"HXGB <Q;K5#@W\*.-H+ZL, V%F>QID::,JG>[X1'M@K0*RW02C2_KT\[H
M6.>$.>?K-(%28].,*O'2IDN >&3X.?=*FV&:R-5)8;#1(5ZB;AKV,N_E9WO:
M$3N-T=B$1=G.OO8,9.T>K_1(:\H-:JQ2/ /QQ'\NY4G$(\PA);3&Y;'<8F:I
MEA,$J8C.T#]!NES%Q:;K.#ZP>S>A!,DJ#JM$Q8*LR;A>K'5$+7VD&%6#7^N?
MVE\:+F'G5VZ;4WPWC;[=UR\CK8%@K>9IN%2ZBZC;0I)+F2R9=$,+%P1/+M0-
M;M)5 OZ*]!RO#"C,G&(+'_6Q=#?'0A#\'OZ[T>;=\<C+4XR\O(VP_15".S[:
M;F>U0,O3O;>G9T=GR X;?#S_\,_3B],/9T-<I>^Z^^G!T[U/*]@<&&OG)E[;
MT-R>8;2#/K#E6$J%_9JC,72-,XGY7X$PY;8]LD %D9Z>C*.Q+M3=I'ZIVDW*
M04J%TGT9G&CUA'1,(>^B^Z?![__K\/!%\#Y:+'"8GR[>!/OXR?BGGW["_R>J
M?BYIR'XEYJ1HSO[7(@4E=@=WBC0(:AS\UU.8W^K=X+/Q"WTWDV&!$9!!Y:IL
MR\/ZE3=2KZLU;LT=NL85FZD#\1KVN.SQPSUQPD_$,P_>JBXQ/<X^]P[E/OS0
MF^Y/W;7>Y'EU5,()2DA-=+F4:&WK]-:=G_#;F8?-P<C9"HW=5E?<<M@Y:JT7
M!M?N(+M^'I!= [*K-]->&\ Z!3(@NQX#V?6#4_V@0=$IX>[IW+3UIN.^,=W1
M<R*5CK,>8VM578-%P!VY(\5AW--XOBA4_)_0Q-J.TXBJ2<;NC+J6C'5+_NO9
M3S]5_)=G[+N0__(@<^L;*N-=V(]=<F\-^_$Q]B,&&NZU)^-2.)>:;<3J*LD)
M.5+J-28Q]17\%#XR31%,@XQ"\PHY<!3/AN]=V.#P)9L3W\56?MA$[(>CO=-2
MLE/6K$DI2VB(,@"\S+SLCLBL<:[+R&!",&'Y%F-8B+S)Y.$0&1HBS7B2DK./
M"9 PSJ,\A3ERR! \M/?&.=?0;GD9I.[3:*FQ9O(L#X+YW R+%#Z RM<G"EZ0
M*1K4K&_XT5V0U4E=5CWM>-9(:)2S+IM@6P00,XYJ<M XY.K561K>QKK&T(WT
M.+U/K13'B7>CZ%BJCN=&6KPP;,H0>4R1F<J$*AUA8S=8O;U@,(LDAEO=1"$"
M^TRA+.?U*'@>JS2[CE::7,T2)]R-#>G7O$@IDV>!\Q)$KY";P08T+9),^R1;
MG.D2$'8>!1[,,C;+GG7= 6R 1\C</]L#!T5E.>Q(G=W:"C["/Y(-& YV>^MT
MV]+GHI^,HS0/G7HHMHU?/<NR-%)<RK#60@&'3BB 70T!BF\C(U/;>ELA,K/9
MJV7X69K#5 =&0)Y;,F4<MZRO"-[N19-2W,[,U,31"V8:+)\MJ>]N U(E:S>*
MLQQ!:()+J>VTBIHSG4KK"D[W:5,S)Z<Z#B8%T3Z"H\$(04TY#@*J?XG-HN!7
M5?7X:]\D<0>\U'"T=UFKXVJ*G+EQS<05JR!<,E7;O!HYLV(#DD2@G6AF(:;U
MH)YN0-JW:I>.-;KEVM<KX^OI8F>=9K.^15UHU!"PW%H0R(DX"+Y/FN,N[O 3
MQB:CFK7[87DT*:EM:R2QO5C5G1W2,G=)S#ST<-4F0Y?!DK+)H!F8C5VP>2QE
M%Q;F>8<+@T?U,OP2+8LEG 1P%%Q1830? ^48KIRDO3M$.^V<WKNW[]"$H*.F
M=Q/088\8IV;8XW ,L6#18,_WW$3.UDI@O0-IA6%_XDIOLIYN,9%%MK%I.:4-
M9UO0Y6'=Y%*LHPQI!X@1"^L]^1[Z2\PE(3DK$D'-HFR:JN\!OG%X\++;")3I
M6ZGG3=*0..]?08 *]SSYL@JI"]+;(J:7"Q?![RI.EM$T"RZY Q,?=F'/ @@#
M=OS1L.,=\HX-V/$!.SY@Q_N('?]^O,F'[8#:$8B M+%TQ0#Y0.$H$6B!F=(G
MH^,5&!T=&OC$!6YCS>,Z!!0\@%0%,%O4_&K_Q4__[]_@_T<$FJL9FV[30H8@
MV38!.BQ=BFU7^[&V4"?P0C;P":@O44;VJ7M#:85+"P_W/2!FB&FXF&(7,*>P
MN/X:!NO5\+B5+9I'LS?A? U^8POK#>M5F.<A_IMJE/-$FD76'^K2FJ"WE1E2
M!+'**=?M><']<A_)CYA2HIZ<'VY4"HJ1W-@3OB,]BC.9_BDV8#EO"76)6;5/
M^P:<GPY9S_N6\-T%)_O%'DCH/,K_]BX!.;X M00"OQTWVSN4/C25Z="=&$('
M?0H=5#@O5$3Y,)["";S8D@^',F%Z;\$_: 1UR5(6Q48NL7D<TY"@E=#0SVS#
MD$K-N)*,4)M)]3%53R[#+P$K&'P0Z9@UO4[I.&\;-9WLU29LC091PR >TRH:
M3M#N3]"778/%W3/SY=[1#%]7 SN/IGG!]%-S5/!M86JL!ZP='NV=6O^X."[#
M/5P@ %Y@Z4%<AGRZJI'3PHT>:'G9)=^:9F?83+R97NV=PXD'2@U+<$3^A#%[
M.T9IRX#Z8)H.6 >2FH.G>^>:(+UG!,6[ "8+1P\Z Q^RVF:9T2Q4*=IZ78(?
M/W@C/'A"/IG</?&;D9,PB[)Q"?(HN'B76%0W$97 D+7M_DS2S_2^:5*LX.G2
M6U3Z>H9\X+?$O>[1'L"$"4UG^S$8IB!HL?$TZ92/TBR7:TP])@\:O[#EEL%%
MN%#M7:&"9 KCS,:U%ZL8T*$V;+PV],/?<6M]$.P"LTAOI>6!6<.JXT$M8[EA
M-2[]!?85"M-9]GJK?8YT(6V7,0"JV2WOR',CJ!)/L4V^*U+;XG?B+>^SA1IQ
M"+1_.+ZLNU:@&7^$ECAE TYJ#-^3.]X"EJ)XP\UCL!1V!QT$)ZC*:K,CU15P
M4SB'.!809@D7F<]4'D8+OR._AN99^[[E%F?\2V%XGG%75N=EF1M9'QS\UDWM
MD?&+_:R8C&R+9*]C[E(H!J5"^8/@/D#4G[\;X^SA2/.N=.J9RFF_9,$VK,'@
M3Z$"6$1+CLVBW%VQF1+E)&M]B@>RX0S&6Y?JM,2'SGECRC3&5/A%5I%82(V&
MQS&L,)Y&P?\J8"=37Z='LD'J+=W;3#%A@[!F"W&I&Q'42GZ%:LEJJ;Z%Z'Y\
M!30=[?5RY@<0WF,]ZU678+ !A#> \ 807@]!>#_^23:KGF2['GA4W?D66 6[
M%:^BU-7(D*Q9YLZOJ&'H,5*AVQ"/&QYP.Y^;Z09OWP&"A)54?/\X =BQ>P(:
MH_.RMJ$K>A7Z(FR>P452Q>::AL5A[D2TL@U"V.SPXEU)7/+PL\H\1(<886M]
M=M^<HEU(5A[N(80X+>+.1-*W/8;PI,Y=GE1S<7&" Z!]FSB0/^%CU@D!I-"=
M1BN"Y=?S;[!'/2%XYIII",2W]53D[ZXBL )L .PO!?_CXL<J '=;$< <O)6!
M"M ]23V*@[\;:S4&ST5*D#6Q>?NU.\+!6K61\+<6((7S1((&2V0Z+#4&&WF5
M$:M;9,S6/@T+E*B$^9SI=M2#%]N)46/7FW!1( O#*LEAAO&6&)86;MHE7$=]
MZ$$B5ZENF:E);,V-X.X;BG8EFW,07"920Y(3>1=V\)TQ/Q"<R?(B:U\;H3>8
MTLK\VZ[,[H07JQ1IOV!&U562WMUC_&CB+:+/(.94F$]=L*@VW[3NY)H1PVT1
MQYB0YA%DP83V"UR^%;[$6G'*-OI7U74;3#0L^$2![,[KBV25G@ 9=$V3CIPW
M)@#K.D:;Y*:*AHIKKE7\A$83YTWE4??7@<QI[@CA5 N5::7LJ&22WIG)6M91
MP0WC,I+J?.\16I-D*-)5(NK /$0R4-7;$E(:O^RK^X>4"QV:I3"%U2E;F7S]
M0B#:?9^P%]U2*CB$YGTC1WSVT\'/SW]L0R*2."!U)QVFO_/IA_D?DKE;2^8*
M_^1F)N.@G;:AG=KM]'4F3ZMQ;@QS3@Q1856M-'N?C31^ZC8,<K<N? NV^' P
M;.U@X+8V6(H8)^L<;I)25U1LF579WZ^P'5?0CR%LGYFN "O[6/=U=:J\%0DX
M/_,%I3TJ6]H=]L$ >&S+TO9D _[X,Z_NDQ\?X%>/!K_JLJI\@%\-\*L!?C7
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M>\].7\@-.\W ;^!_M1[7QO_"@[9[_ZMM;%_C?_G/>N-]M3\6\QO"&WH:&_@
MDX@,IO)@*C^ZJ6S0*HYQ3#3G.)PZ?<9:$1ZHLR5V\&SO7"$L"*;6KY7$Z]A.
M7FC3T=VW,6REY2,K=</P5='J)1YD[B?I'4R]P?8L@7=#UOO;*+L6_XNT,A<
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M)QY1I'#="(<&N;!2ON:42>8I-'&*M?%7I>CU(HQ';N1/'\W-8S\@#"Z_*$V
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MB[8!V.+!._;4EGICCG3-I>/;>A.F:R/X=DFJ;^4(=/59ID/6*H'?& 8\/#G
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ME,0."B-HB&[S4,"6^;=RM5PQ(8@/,P?6ZP4SQNH;Z_XYQ@^RV%HF7$83&M.
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MH/(PO2NEARA;Y$2W5Q+=UC^/Z)+JX(1I $:>1KI]I!W?OLY+>>/FP3G=V>U
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MJ7&'B1JE>T.,R@+0DMNX-$A<#)G:^&IL7H_^H/>C<+UY0<>^IA-@OGY"_I7
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MV+V9]MH UJFQ 88]P+#7S\1MDBYFMQ@D**CT:%F@GX/$%U-TF,B=T6&$:5*
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M?JZ'$NR[-^YJ%?X>YM/K)W^&7^#/+<0*O_7K'6U-_<65LYY<X6("YUZF28A
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M,VY-8[QP%YO\!CG=9A4DZ.PU=Z9N**-R\H8]BRX/8*Y' W-UZ7(.8*X!S#6
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M*,,J-Z$2[TMV)?*4^D GGI1D.N:(,5#:F-IO!AVXB%-KV1IK[G>LD75>ZA(
MT)F'P;5O41=.=?M2N/,L3O SLET*$58YMR'3S:N+CYI[OR\1YXOQ_A\(LA#^
MQ4J.>RZPY@5M;C+9([R^6VIQ$9IHIA.E4^\"[,X4S<AX^6%$D0F^L/OKND@L
MLKRLTIAB4N4MIYOXL<"261KR?ZJ@N&21D1)*7DHV+2G/@(M<2AH1_7TM<E;"
M,*@UWT<:L6[(, ,9ES&N4I[92]2/4E!1<^O0J/1FN;"W"8^%9G[3LAD;@YC8
M^Z7/U+V#3#C(A(-,#! R\73:T#QL!X"W3 U .#7%'8:MTU%B) LO$1=PVMTT
M&=0>?'JZL),)_I+ASE&$#.,78%?,E@6,8&I/E15\H^UUPFQ8%;9+F3T3YO-D
MM*I*8N+/1$$\B^"SY=\%<9UH#\%^W@(M+'C+>NLKVQB<PS_![B],P^TR^"XH
M+1@4Y!%T&W ZJ5;+U-2M6@R,23"Q;-Y2Q 5]U=%<V$F8B3[?4\*PAP77F&A_
M$*0+W?FIN$L.5>:9*1'+MKP4*(%K&Q*M-#RM)+N]%TEJ.DCTO?(N&!"E44TN
MIEH+BBO962(K&+0.8*QY*FX*4"W@S:.##O^*L T!_@OW:96405KR'Q3@IF_$
M#]B_4C9@-2A)@<Y>6&N/@CG$5.#UDFY)%!AGF%I_+;M1G%Z!9J-GV1\'(2E*
M_%BK.1/DE]I4RGN7D'?H5W!KDRPN=4SKH+NW5\ A?C%?)(&%6ZA?7<LQ=#RK
MC5%HU0H3-L7 %?!K"4_H'($-56AN288ZP&29=D#(G6K::=6>V\Y V2"')0W"
MEOCFF#%#L8G)]"C 3L&F.BVZH5N?ND33&6[A!C3Q><77'X\;YMWNRP=UCW](
M\'J2_KM*>;>>BB06L_5$]U]NM0:R&KZFP5_$'!>T Z1!B#BI1$07@GO0$5"M
MX+T653HD5Z4QF&5>&I2$?L+0[?U31JJ'L-)E<'1&8.UA99/$#\-#$>"K(&+U
M;*2]QPQ+,@Z:VSX0%QY<+G^%3PD0*==^;U1(=0U;I;,@SA,Z1&2"SFBWYIOZ
MJ#3@#,$/L-E?G@LX%<A,N SR^;(P)J&N<NHAY&/$$^]/U#/U9CE*APP)--4W
M^XH-DB2)Y"6FCM?-=9:R4EZBR66 CYV18GU@H'"6B:S)$^([FNMYMLAC%$9"
MF]-RYK3';@\C9PN%=Q,QG=_;P8[);LRLG.^_JSPNHEB>G[0=Z&5:0P41@SW$
M-@'X9;A_]4D(SQF0='#\HF\14:TC9)TC1N@C[I[)Y92PD%=V%4%<>G-\(*<=
MI*)9XIH:R6(?02A+OJ5)+!'HU$XJ$5^E%E:8K  <6B)D=V8MTQN6;7],:^!5
M;]; J8!34-K5W<NU'O/@U=;M(UMI+XQ8SR$F'925#L4L2XJ#/IHO$*=B(=(;
M77$[P,]+\X:@-+$S+OTS# A>#:?^:(:!(MC-A3SJ19PKHQW-(#A[X2\,YN&?
MB$W:@<]H&I:E$V'O1=A5+KOA<B/P1;#+#)VZ4196W$-@.T9G;\%Y/MBJ(?P@
MC4/<TO,=3O!=WA2@?Q(P->"=8[P#]5Q&FZ"T(8^^C! M8C*MY F%CH^,1BQU
M.C0RCR!X2Y.CZ-3"@5:Q25)2\5-2%3@_RXTQ_*$]#^;5\1OV0^TWPVALZ85X
MS-(9I)+EMRJOI@_7)0%HK<&RR>;)RG\"=Q)/4NRON+T'DYZ'E]@.%Z?RQ@"@
MEJ//<2HH6(S11@S>,!L#MHJ@I/2R.$(D6(@%G=P@?KHGT%)#]".>TGP4,B5!
M;@-*;@.<U/I6JS"W%! ^\%>B:Z6[CE%1,"S%-,N^%S"@<,=[E+$$&Y\$>[Z)
MY3Z+(5QBV26676+9)99[3QVTD.Y%#?U7S]4Q83R>O(SCVHYV5I<A+C5J$,)/
MB$5R/"FTA$T,.:R&!JYL0VCQ^ZR.,RB+O-V^L%[^V6%VU_SE72S\;\6?I-FL
MS.,JM*V"NG4(/[N(<;[B4LP+O#[,XRDR%DTS[.]L!W"H!,Y^\ZDP-2-LSR\A
M%AU"D&,=A&G.V[_5VW_=F[=_@N6]&&W'8 U+_S%;R%QD<P:>)^VQ8CU>_^NM
MNX]PP^H 9/F^J3B?*J1)P;E9%3B@HB;5.YIRS$TXQZ!449\]>CGH@D43H<C)
M/Z=Z=Q6]+#R%]._*"XL?(JSL4^3L9*3".-X)1M?Q ,MO&BEGZ]A*94"=#]04
M*^?K02$Z7>;!=V$M,?PSA0.&X[:4;;='[!OHOD(AF<2[JIS3-0-PN8J'X45Y
MD!@R&T6:3;_Q90X''N7#FF3A]TO8'EB19V?0*>P#,YGRH=MDC#"T 3*L$\5:
M7*GT2R:ZP?) "\!.=M@Y>/Y<_4@>Q,J,P#)IL%+H;-;A"U_E43BU10\$FR2
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M(2 < L(A(-9R"/=9$7NO0UBQ#>-'J<)1MTYC@ICB(43P:9EX-8B%;?;BR\O
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M!UO5%%GM=;WSV@2S2=:BNS_*TA>'(H@4"SQ^9OZ6RRU;-W?\H*7(L8;H1;5
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M>FJ=&(&5EUK%SBM&Z<@X^%5W=U]Y7S"J'9?*Q[4[1O!$WJ\W'?UX@)9JA%9
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M<]\1WOSDI^;^2(W]D_\!4$L#!!0    ( .^!!5-ZN(3E]P<  +R@   6
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MCP=[/*A?,2&Y0[T,.K"?7%^&KD4TIBO/58*5'SH(.>Y6>1*>2YWSQZ4I./5
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M'FP%'W8_?/C73]V&&PLJ;M.=#2''"=/0-P%*;%GP/(0]K%@B6NK5AV#I$#*
M8[62*T9DJ6 "B+UCKFU$!RF6VWFP:YKE@OE\HIB@%M]5-3+#J%?E&OR00UX
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MU*()H#*@8D*GVE9JO3WWAVQZ>_9/X/P/4$L#!!0    ( .^!!5/,#0Y4I@@
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MKM*P-!JY.ZY0":5]/0IHS:WCK[==^)@4/@,EHOMA/A7%UF'_)N$!-Z3(]Q>
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M<BTR,#(Q,#8S,"YX<V102P$"% ,4    " #O@053<4*O)%,/   WS0  %
M            @ &Y?0, =FER+3(P,C$P-C,P7V-A;"YX;6Q02P$"% ,4
M" #O@053:07@N4!    GE00 %               @ $^C0, =FER+3(P,C$P
M-C,P7V1E9BYX;6Q02P$"% ,4    " #O@053?GN#E1"Z   UQ @ %
M        @ &PS0, =FER+3(P,C$P-C,P7VQA8BYX;6Q02P$"% ,4    " #O
M@053>THLATY4  !/8@8 %               @ 'RAP0 =FER+3(P,C$P-C,P
M7W!R92YX;6Q02P$"% ,4    " #O@0538;!7.0O" 0 5&!4 %@
M    @ %RW 0 =FER+3(P,C$P-C,P97@Q,%\R+FAT;5!+ 0(4 Q0    ( .^!
M!5/7T1:-R <  -F<   6              "  ;&>!@!V:7(M,C R,3 V,S!E
M>#$P7S,N:'1M4$L! A0#%     @ [X$%4WJXA.7W!P  O*   !8
M     ( !K:8& '9I<BTR,#(Q,#8S,&5X,3!?-"YH=&U02P$"% ,4    " #O
M@053L@<MM[<(   )1P  %@              @ '8K@8 =FER+3(P,C$P-C,P
M97@S,5\Q+FAT;5!+ 0(4 Q0    ( .^!!5/,#0Y4I@@  ,]&   6
M      "  <.W!@!V:7(M,C R,3 V,S!E>#,Q7S(N:'1M4$L! A0#%     @
M[X$%4^9 DVAK!@  D"P  !8              ( !G< & '9I<BTR,#(Q,#8S
A,&5X,S)?,2YH=&U02P4&      P #  < P  /,<&

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
